<SEC-DOCUMENT>0001213900-21-013722.txt : 20210305
<SEC-HEADER>0001213900-21-013722.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210305160148
ACCESSION NUMBER:		0001213900-21-013722
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210305
DATE AS OF CHANGE:		20210305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PolyPid Ltd.
		CENTRAL INDEX KEY:			0001611842
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38428
		FILM NUMBER:		21718438

	BUSINESS ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			495376
		BUSINESS PHONE:		972-74-7195700

	MAIL ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			495376
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2020_polypid.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 20-F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#9746; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the fiscal year ended December 31,
2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><B>OR</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission File No.: 001-38428</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>POLYPID LTD.</B><BR>
<I>(Exact name of registrant as specified in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Translation of registrant&rsquo;s
name into English: Not applicable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><B>State of
Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><I>(Jurisdiction
of incorporation or organization)</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>18 Hasivim Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Petach Tikva 495376, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><I>(Address
of principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Amir Weisberg</B><BR>
<B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PolyPid Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>The Atrium at 47 Maple Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Suite 302A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Summit, NJ 07901</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Telephone: (908) 378-9530</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><I>(Name, Telephone,
E-mail and/or Facsimile number and Address of Company Contact Person)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Securities registered or to be registered
pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><I>Title of each class</I></TD>
    <TD STYLE="width: 2%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><I>Trading Symbol(s)</I></TD>
    <TD STYLE="width: 2%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><I>Name of each exchange on
    which registered </I></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center; line-height: 107%"><B>Ordinary Shares, no par value</B></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><B>PYPD</B></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><B>Nasdaq Global Market</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered or to be registered pursuant to Section
12(g) of the Act: None&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities for which there is a reporting obligation pursuant
to Section 15(d) of the Act: None&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate the number of outstanding shares of each of the
issuer&rsquo;s classes of capital or common stock as of the close of the period covered by the annual report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">18,494,739 ordinary shares as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant
to Section 13 or 15(d) of the Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T during the preceding 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging
growth company. See definition of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and emerging growth
company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company &#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&dagger;
provided pursuant to Section 13(a) of the Exchange Act. o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;The
term &ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
GAAP &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
Financial Reporting Standards as issued by the International Accounting Standards Board o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&ldquo;Other&rdquo; has been checked in response to the previous question, indicate by check mark which financial statement item
the registrant has elected to follow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Item 17 &nbsp;&nbsp;&#9744; Item 18</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 8%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 82%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 7%; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INTRODUCTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">iii</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="3" STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">iv</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SUMMARY RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">v</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="4" STYLE="vertical-align: top; line-height: 107%; text-align: center"><A HREF="#aph010402a004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART I</B></FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 1.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 2.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OFFER STATISTICS AND EXPECTED TIMETABLE</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 3.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">KEY INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[Removed and reserved]</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capitalization and Indebtedness</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reasons for the Offer and Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 4.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INFORMATION ON THE COMPANY</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">48</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">History and Development of the Company</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">48</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Business Overview</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">49</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Organizational Structure</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">82</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property, Plants and Equipment</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">82</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 4.A</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">UNRESOLVED STAFF COMMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">82</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 5.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">83</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Operating Results</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">83</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liquidity and Capital Resources</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">91</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Off-Balance Sheet Arrangements</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">93</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tabular Disclosure of Contractual Obligations</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">94</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 6.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a023"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">94</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a024"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Directors and Senior Management</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">94</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a025"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Compensation</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">97</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a026"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Board Practices</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">98</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a027"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employees</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">105</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a028"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share Ownership</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">106</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 7.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a029"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">108</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a030"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Major Shareholders</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">108</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a031"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Related Party Transactions</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">111</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a032"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interests of Experts and Counsel</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">112</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 8.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a033"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a034"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements and Other Financial Information</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">112</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a035"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Significant Changes</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 9.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a036"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE OFFER AND LISTING</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a037"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer and Listing Details</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a038"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a039"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Markets</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a040"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Selling Shareholders</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a041"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dilution</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a042"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expenses of the Issue</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%; width: 8%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 10.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%; width: 82%"><A HREF="#aph010402a043"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 7%">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a044"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share Capital</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a045"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Memorandum and Articles of Association</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a046"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Material Contracts</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a047"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exchange Controls</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a048"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taxation</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">114</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a049"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
and Paying Agents</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">119</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">G.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a050"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement by Experts</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">119</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">H.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a051"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Documents on Display</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">119</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a052"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiary Information</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 11.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a053"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 12.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a054"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a055"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Debt Securities</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a056"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrants and rights</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a057"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other Securities</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">120</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">American Depositary Shares</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="4" STYLE="vertical-align: top; line-height: 107%; text-align: center"><A HREF="#aph010402a059"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART&nbsp;II</B></FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 13.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a060"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">121</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 14.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 10pt; text-indent: -10pt; line-height: 107%"><A HREF="#aph010402a061"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">121</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 15.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a062"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONTROLS AND PROCEDURES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">121</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a063"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AUDIT COMMITTEE FINANCIAL EXPERT</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">122</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a064"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CODE OF ETHICS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">122</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a065"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRINCIPAL ACCOUNTANT FEES AND SERVICES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">123</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a066"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">123</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a067"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">123</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a068"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHANGE IN REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">123</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">G</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a069"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CORPORATE GOVERNANCE</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">124</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 16.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">H</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a070"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MINE SAFETY DISCLOSURE</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">125</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="4" STYLE="vertical-align: top; line-height: 107%; text-align: center"><A HREF="#aph010402a071"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART&nbsp;III</B></FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 17.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a072"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">126</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 18.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a073"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">126</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 19.</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%"><A HREF="#aph010402a074"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBITS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">126</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="LOGO" STYLE="height: 87px; width: 171px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="aph010402a001"></A>INTRODUCTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a Phase&nbsp;3 clinical-stage
biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary
Polymer-Lipid Encapsulation matriX, or PLEX, technology. Our product candidates are designed to address diseases with high unmet
medical needs by pairing our PLEX technology with drugs already approved by the U.S. Food and Drug Administration, or FDA. Our
PLEX technology is designed to deliver drugs directly to precise sites in the body at predetermined release rates and over durations
ranging from several days to several months. We believe that our PLEX technology and product candidates have the potential to cause
a major shift in the management of a wide variety of localized medical conditions, including surgical site infections, or SSIs,
cancer, inflammation and pain. Our lead product candidate, D-PLEX<SUB>100</SUB>, is in a potentially pivotal Phase&nbsp;3 clinical
trial for abdominal (soft issue). We initiated the first of two potentially pivotal Phase&nbsp;3 trials of D-PLEX<SUB>100</SUB>,
which we refer to as SHIELD I and SHIELD II, respectively, for the prevention of abdominal (soft tissue) SSIs, that we initiated
in the third and fourth quarters of 2020, respectively. We expect to report topline results from the first abdominal surgery trial
at the end of 2021, and we initiated the second Phase&nbsp;3 trial in December 2020. The World Health Organization, or WHO, estimates
that SSIs result in up to $10&nbsp;billion of additional hospital costs per year in the United States alone, and a further &euro;11&nbsp;billion
per year in the European Union. We believe that D-PLEX<SUB>100</SUB>, if approved, would be a significant improvement over the
current standard of care, which includes systemic administration of drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an Israeli corporation based in
Israel near Tel Aviv, and were incorporated in 2008. Our Ordinary Shares are currently traded in the United States on the Nasdaq
Global Market under the symbol &ldquo;PYPD&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="aph010402a002"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain information included or incorporated
by reference in this annual report on Form 20-F may be deemed to be &ldquo;forward-looking statements&rdquo;. Forward-looking statements
are often characterized by the use of forward-looking terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;believe,&rdquo; &ldquo;should,&rdquo; &ldquo;intend,&rdquo;
&ldquo;project&rdquo; or other similar words, but are not the only way these statements are identified.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These forward-looking statements may
include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events
or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions
and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Important factors that could cause actual
results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include,
among other things:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&#9679;</TD>
    <TD>We depend on enrollment of patients in our clinical trials in
order to continue development of our product candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%">&#9679;</TD>
    <TD>our ability to raise capital through the issuance of&nbsp;&nbsp;securities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>our ability to advance the development our product candidates, including the anticipated starting
    and ending dates of our anticipated clinical trials;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">our assessment of the potential of our product candidates
        to treat certain indications;</P>
        </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully receive approvals
from the FDA, European Medicines Agency, or EMA, or other applicable regulatory bodies, including approval to conduct clinical
trials, the scope of those trials and the prospects for regulatory approval of, or other regulatory action with respect to our
product candidates, including the regulatory pathway to be designated to our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the regulatory environment and changes in the health policies and regimes in the countries in which we operate, including the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to commercialize our existing product candidates and future sales of our existing product candidates or any other future potential product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to meet our expectations regarding the commercial supply of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the overall global economic environment; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the impact of COVID-19 and resulting government actions on us;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the impact of competition and new technologies;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general market, political and economic conditions in the countries in which we operate;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">projected capital expenditures and liquidity;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes in our strategy;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">litigation; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">those factors referred to in &ldquo;Item 3. Key Information &ndash; D. Risk Factors,&rdquo; &ldquo;Item 4. Information on the Company,&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo;, as well as in this annual report on Form 20-F generally.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Readers are urged to carefully review
and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties
of the risks and factors that may affect our business, financial condition, results of operations and prospects.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should not put undue reliance on
any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date hereof,
and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the section of this annual
report on Form 20-F entitled &ldquo;Item 4. Information on the Company&rdquo; contains information obtained from independent industry
sources and other sources that we have not independently verified.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, all references
to &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;PolyPid&rdquo; refer to PolyPid Ltd., its wholly owned
subsidiaries, PolyPid Inc., a Delaware corporation with operations in New Jersey, and PolyPid Pharma SRL, a company organized and
existing under the laws of Romania. References to &ldquo;U.S. dollars&rdquo; and &ldquo;$&rdquo; are to currency of the United
States of America, and references to &ldquo;shekel,&rdquo; &ldquo;Israeli shekel&rdquo; and &ldquo;NIS&rdquo; are to New Israeli
Shekels. References to &ldquo;Ordinary Shares&rdquo; are to our Ordinary Shares, no par value. We report our financial statements
in accordance with generally accepted accounting principles in the United States, or U.S. GAAP.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless the context otherwise indicates
or requires, PolyPid and BonyPid are our proprietary trademarks. These trademarks are important to our business. Although we have
omitted the &ldquo;&reg;&rdquo; and &ldquo;<SUP>TM</SUP>&rdquo; trademark designations for such marks in this annual report on
Form 20-F, all rights to such trademarks and service marks are nevertheless reserved.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><A NAME="aph010402a003"></A>Summary Risk Factors&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The&nbsp;risk factors&nbsp;described below are a&nbsp;summary&nbsp;of
the principal&nbsp;risk factors&nbsp;associated with an investment in us. These are not the only&nbsp;risks&nbsp;we face. You should
carefully consider these&nbsp;risk factors, together with the&nbsp;risk factors&nbsp;set forth in Item 3D. of this annual report
on Form 20-F and the other reports and documents filed by us with U.S. Securities and Exchange Commission, or the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Our Financial Condition and Capital Requirements</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have never generated revenues, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We expect that we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to the Discovery, Development and Clinical Testing of Product Candidates</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We depend on enrollment of patients in our clinical trials in order to continue development of our product candidates.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We are heavily dependent on the success of D-PLEX<SUB>100</SUB>, including obtaining regulatory approval to market D-PLEX<SUB>100</SUB> in the United States and the European Union.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Regulatory approval processes of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time-consuming, costly and unpredictable, and if we are ultimately unable to obtain regulatory approval for D-PLEX<SUB>100</SUB> or any future product candidates, our business may fail.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLEX is a novel technology, which makes it difficult to accurately and reliably predict the time and cost of development and of subsequently obtaining regulatory approval of D-PLEX100 or any future PLEX product candidates.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Clinical drug development is difficult to design and implement and involves a lengthy and expensive process with uncertain outcomes; we have not previously conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop, including D-PLEX100. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Our Reliance on Third Parties</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We rely on third parties to conduct certain elements of our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We rely on third parties to manufacture the raw materials, including the active pharmaceutical ingredients, that we use to create our product candidates. Our business could be harmed if existing and prospective third parties fail to provide us with sufficient quantities of these materials and products or fail to do so at acceptable quality levels or prices.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our reliance on third parties requires us to share our trade secrets and intellectual property, which increases the possibility that a competitor will discover them or that our trade secrets and intellectual property will be misappropriated or disclosed. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Our Intellectual Property</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to effectively protect our products and business and compete effectively in our markets. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Our Business Operations</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our business and operations have been and are likely to further continue to be adversely affected by the COVID-19 global pandemic.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our future success depends in part on our ability to retain our senior management team and to attract, retain and motivate other qualified personnel.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Commercialization of Our Product Candidates</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have limited manufacturing experience and could experience production problems that result in delays in our development or commercialization programs or otherwise adversely affect our business.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities, or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We are subject to significant regulatory oversight with respect to manufacturing our product candidates. Delays in establishing and obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products, or the procedures in which they are used, is limited by government authorities and/or third-party payor policies. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Ownership of Our Ordinary Shares</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The market price of our Ordinary Shares may be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our executive officers, directors and principal shareholders have the ability to exert significant control over matters submitted to our shareholders for approval.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may be or may become classified as a passive foreign investment company. If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as a result.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risks Related to Israeli Law and Our Operations in Israel</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our headquarters and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We received Israeli government grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required to pay penalties and refund grants previously received.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="aph010402a004"></A>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a005"></A>ITEM 1.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a006"></A>ITEM 2.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>OFFER STATISTICS AND EXPECTED TIMETABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a007"></A>ITEM 3.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>KEY INFORMATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a008"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Selected Financial Data.</B> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">[Removed and reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%"><A NAME="aph010402a009"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Capitalization and Indebtedness.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%"><A NAME="aph010402a010"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reasons for the Offer and Use of Proceeds.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%"><A NAME="aph010402a011"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>D.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risk Factors.</B> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business faces significant risks. You should
carefully consider the risks described below, together with all of the other information in this annual report on Form 20-F. The
risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we
currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually
occurs, our business and financial condition could suffer and the price of our Ordinary Shares could decline. This report also
contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated
in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this
report and our other SEC filings. See &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risks Related to Our Financial Condition
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have incurred significant losses since our inception.
We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain
profitability. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a Phase&nbsp;3 clinical-stage
pharmaceutical company. We have incurred operating losses each year since our inception, including operating losses of $26.3&nbsp;million
and $18.6&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated
deficit of $132.3&nbsp;million. We have devoted substantially all of our financial resources to designing and developing our PLEX
product candidates, including conducting clinical trials and preclinical studies and providing general and administrative support
for these operations. We expect that our expenses and operating losses will increase for the foreseeable future as we continue
clinical development of D-PLEX<SUB>100</SUB> for the prevention of SSIs and develop other product candidates using our PLEX technology.
Our ability to ultimately achieve revenues and profitability is dependent upon our ability to successfully complete the development
of D-PLEX<SUB>100</SUB> and any future product candidates, obtain necessary regulatory approvals for and successfully manufacture,
market and commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We anticipate that our expenses will
increase substantially based on a number of factors, including to the extent that we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%">&#9679;</TD>
    <TD>continue our clinical development of D-PLEX<SUB>100</SUB>, including
our ongoing Phase&nbsp;3 trials of D-PLEX<SUB>100</SUB> for the prevention of SSIs in abdominal (soft tissue) surgeries, and our
ongoing Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention of SSIs in post-cardiac sternal (bone) surgeries;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>seek regulatory and marketing approvals for any product candidates that successfully complete
    clinical trials; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>advance our preclinical and research and development programs; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>identify, assess, acquire, license and/or develop other product candidates; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>manufacture current good manufacturing practices, or cGMP, material for clinical trials or potential
    commercial sales, either at our manufacturing facility or through third-party contract manufacturers; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>establish a sales, marketing and distribution infrastructure to commercialize any products for
    which we may obtain marketing approval; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>hire personnel and invest in additional infrastructure to support our operations as a public
    company and expand our product development; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>enter into agreements to license intellectual property from third parties; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>develop, maintain, protect and expand our intellectual property portfolio; and </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>experience any delays or encounter issues with respect to any of the above, including, but not
    limited to, failed trials, complex results, safety issues or other regulatory challenges that require longer follow-up of
    existing clinical trials, additional major clinical trials or additional supportive studies in order to pursue marketing approval.
    </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have financed our operations
primarily through the sale of equity securities, convertible loans made by certain of our shareholders, royalty-bearing and non-royalty
bearing grants that we received from the Israeli Innovation Authority, or the IIA, and non-royalty bearing grants under the European
Commission&rsquo;s Seventh Framework Programme for Research, or the FP7. The amount of any future operating losses will depend, in part,
on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations
or grants. Even if we obtain regulatory approval to market one or more product candidates, our future revenue will depend upon
the size of any markets in which such product candidates receive approval and our ability to achieve sufficient market acceptance,
pricing, reimbursement from third-party payors for such product candidates. Further, the operating losses that we incur may fluctuate
significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may
not be a good indication of our future performance. Other unanticipated costs may also arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have never generated any revenue from product sales
and may never be profitable. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have no products approved for marketing
in any jurisdiction and we have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability
depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain
the regulatory and marketing approvals necessary to commercialize, D-PLEX<SUB>100</SUB> or any future product candidates. We do
not anticipate generating revenue from product sales for at least the next several years. Our ability to generate future revenue
from product sales will depend heavily on our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">complete research and preclinical and clinical development of D-PLEX<SUB>100</SUB> and any future product candidates in a timely and successful manner, including our ability to resume enrollment in our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention of SSIs in sternal (bone) surgeries, which was paused in April 2020 in part due to the prioritization of SHIELD I and SHIELD II trials and in part due to the COVID-19 pandemic; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain regulatory and marketing approval for any product candidates for which we complete clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">maintain and enhance a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for D-PLEX<SUB>100</SUB> and any future product candidates that is compliant with cGMPs; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">establish and maintain supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support clinical development and the market demand for D-PLEX<SUB>100</SUB> and any future product candidates, if and when approved; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">launch and commercialize any product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution infrastructure, and/or with collaborators or distributors; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">expose and educate physicians and other medical professionals to use our products; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain market acceptance, if and when approved, of D-PLEX<SUB>100</SUB> and any future product candidates from the medical community and third-party payors; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ensure our product candidates are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">address any competing technological and market developments that impact D-PLEX<SUB>100</SUB> and any future product candidates or their prospective usage by medical professionals; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">identify, assess, acquire and/or develop new product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">avoid and defend against third-party interference or infringement claims; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">attract, hire and retain qualified personnel; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">locate and lease or acquire suitable facilities to support our clinical development, manufacturing facilities and commercial expansion. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if D-PLEX<SUB>100</SUB> or any future
product candidates are approved for marketing and sale, we anticipate incurring significant incremental costs associated with commercializing
such product candidates. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other regulatory
agencies, domestic or foreign, or ethical committees in medical centers, to change our manufacturing processes or assays or to
perform clinical, nonclinical or other types of studies in addition to those that we currently anticipate. Even if we are successful
in obtaining regulatory approvals to market D-PLEX<SUB>100</SUB> or any future product candidates, our revenue earned from such
product candidates will be dependent in part upon the breadth of the product label, the size of the markets in the territories
for which we gain regulatory approval for such products, the accepted price for such products, our ability to obtain reimbursement
for such products at any price, whether we own the commercial rights for that territory in which such products have been approved
and the expenses associated with manufacturing and marketing such products for such markets. Therefore, we may not generate significant
revenue from the sale of such products, even if approved. Further, if we are not able to generate significant revenue from the
sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties
involved in product development, it is difficult to predict the timing or amount of increased expenses, or when, or if, we will
be able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We expect that we will need to raise substantial additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely
basis may require us to curtail, delay or discontinue our product development efforts or other operations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are currently advancing D-PLEX<SUB>100</SUB>
through clinical development in multiple indications, in order to obtain regulatory approval. Developing product candidates is
expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities,
particularly as we advance product candidates through clinical trials and regulatory approval. Furthermore, we expect to incur
additional ongoing costs associated with operating as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have financed our operations
primarily through the sale of equity securities, convertible loans made by certain of our shareholders, royalty-bearing and non-royalty
bearing grants that we received from the IIA and FP7. As of March&nbsp;1, 2021, we had cash, cash equivalents, short-term and long-term
deposits of $63.4&nbsp;million. We will require significant additional financing to fund our operations. Our future funding requirements
will depend on many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the progress, results and costs of our ongoing and anticipated clinical trials of D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the cost, timing and outcomes of regulatory review of D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the costs of maintaining our own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or engaging third-party manufacturers therefor; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the scope, progress, results and costs of product development, laboratory testing, manufacturing, preclinical development and clinical trials for any other product candidates that we may develop or otherwise obtain in the future; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the cost of our future activities, including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we receive marketing approval for such product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the level of revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Identifying potential product candidates
and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to
complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales.
In addition, our product candidates, if and when approved, may not achieve commercial success. Our product revenues, if any, will
be derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts
may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We cannot guarantee that financing will
be available in sufficient amounts or on terms acceptable to us, if at all, and the terms of any financing may adversely affect
the interests or rights of our shareholders. Even if we believe that we have sufficient funds for our current or future operating
plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. The issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our
shares to decline. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic
conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide
resulting from the ongoing COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To the extent that we raise capital through
the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may
include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may
involve covenants restricting our operations or our ability to incur additional debt. If we raise funds through collaboration and
licensing arrangements with third parties, it may be necessary to relinquish certain rights to our technologies or our product
candidates, or to grant licenses on terms that are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are unable to obtain funding on
acceptable terms and on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research,
development or manufacturing programs or the commercialization of any approved product, or be unable to expand our operations or
otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Risks Related to the Discovery,
Development and Clinical Testing of Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>We depend on enrollment of
patients in our clinical trials in order to continue development of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white; text-indent: 0.5in">We initiated
SHIELD I and SHIELD II trials for the prevention of abdominal (soft tissue) SSIs. Our anticipated time to data in these trials
is subject to our ability to recruit sufficient eligible patients and the number and size of cohorts that will need to be enrolled
prior to observing activity, if achieved at all for the dose escalation and expansion arms of the relevant trials. There can be
no assurance that we will complete enrollment or have data from the trials when we anticipate or at all. The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number
of patients that are in line with our inclusions and exclusion criteria and our ability to monitor these patients as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white; text-indent: 0.5in">We may experience
difficulties in patient enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by many factors
including the size and nature of the patient population, the eligibility criteria for the trial, the design of the clinical trial,
the size of the patient population required for analysis of the trial&rsquo;s primary endpoints, the proximity of patients to study
sites, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the number of enrolling
clinical sites, our ability to obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop
out of the trials before completion, and competing clinical trials (including other clinical trials that we are conducting or will
conduct in the future) and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug being studied
in relation to other available therapies, or competing drugs against the same target as well as any new drugs that may be approved
for the indications we are investigating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white; text-indent: 0.5in">Additionally, we must compete for clinical sites, clinicians
and the limited number of patients who fulfill the stringent requirements for participation in clinical trials. Also, due to the
confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies and
who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability
to enroll enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or
termination of our trials, which could have a harmful effect on our ability to develop products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are heavily dependent on the success of D-PLEX<SUB>100</SUB>,
including obtaining regulatory approval to market D-PLEX<SUB>100</SUB> in the United States and the European Union. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have invested all of our efforts
and financial resources to: (i)&nbsp;research and develop our PLEX technology, our lead product candidate, D-PLEX<SUB>100</SUB>,
and our preclinical and research and development programs, including conducting preclinical studies and clinical trials, and providing
general and administrative support for these operations; (ii)&nbsp;develop and secure our intellectual property portfolio for
D-PLEX<SUB>100</SUB> and our PLEX technology and (iii) invest in our current manufacturing facility. Our future success is dependent
on our ability to successfully develop, obtain regulatory approval for and commercialize one or more of our current and future
product candidates. Our product candidates&rsquo; marketability is subject to significant risks associated with successfully completing
current and future clinical trials, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to complete our ongoing&nbsp;&nbsp;Phase&nbsp;3 clinical trials of D-PLEX<SUB>100</SUB> for the prevention of abdominal SSIs in a timely fashion, including our ability to resume enrollment in our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs, which was paused in April 2020 in part due to the prioritization of SHIELD I and SHIELD II trials and in part due to the COVID-19 pandemic, and that such Phase&nbsp;3 clinical trials, even if successfully completed, will be sufficient to support approval of a New Drug Application, or NDA; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">acceptance by the FDA, EMA or other regulatory agencies of our strategies for seeking regulatory approvals for D-PLEX<SUB>100</SUB> and any future product candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations and regulatory pathways; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the acceptance by the FDA, EMA or other regulatory agencies of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to successfully complete the clinical trials of D-PLEX<SUB>100</SUB> and any future product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the willingness of the FDA, EMA or other regulatory agencies to schedule an advisory committee meeting in a timely manner in connection with our regulatory submissions, if such advisory committee meetings are required; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the recommendation of the FDA&rsquo;s advisory committee to approve our applications to market D-PLEX<SUB>100</SUB> and any future product candidates in the United States, and the EMA&rsquo;s approval to market D-PLEX<SUB>100</SUB> in the European Union, if such advisory committee reviews are scheduled, without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the satisfaction of the FDA, EMA or other regulatory agencies with the safety and efficacy of D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the prevalence and severity of adverse events associated with D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the timely and satisfactory performance by third-party contractors, trial sites and principal investigators of their obligations in relation to our clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our success in educating medical professionals and patients about the benefits, administration and use of D-PLEX<SUB>100</SUB> and any future product candidates, if approved; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to scale, validate and maintain a commercially viable manufacturing process that is cGMP-compliant; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to obtain, protect and enforce our intellectual property rights with respect to D-PLEX<SUB>100</SUB>, any future product candidates and our PLEX technology; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes to regulatory guidelines. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many of these clinical, regulatory and
commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance D-PLEX<SUB>100</SUB>
and any future product candidates through clinical development, or to obtain regulatory approval of or commercialize any product
candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant
delays or an inability to successfully commercialize D-PLEX<SUB>100</SUB> and any future product candidates. Accordingly, we may
not be able to generate sufficient revenues through the sale of our product candidates to enable us to continue our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, approval of a product candidate
in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries
or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other
foreign countries or by the FDA. We may never obtain approval outside of the United States, which would limit our market opportunities
and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Regulatory approval processes of the FDA, EMA and comparable
foreign regulatory authorities are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory
approval for D-PLEX<SUB>100</SUB> or any future product candidates, our business may fail. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The research, development, testing, manufacturing,
labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring
and reporting and export and import of drug products are subject to extensive regulation by the FDA, the EMA and by foreign regulatory
authorities in other countries. These regulations differ from country to country. To gain approval to market D-PLEX<SUB>100</SUB>
and any future product candidates, we must provide data from well-controlled clinical trials that adequately demonstrate the safety
and efficacy of the product for the intended indication to the satisfaction of the FDA, EMA or other regulatory authority. We have
not yet obtained regulatory approval to market any product candidate in the United States or any other jurisdiction. The FDA, EMA
or other regulatory agencies can delay, limit or deny approval of D-PLEX<SUB>100</SUB> or any future product candidate for many
reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulatory requests for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our inability to demonstrate that a product candidate is safe and effective for the target indication to the satisfaction of the FDA, EMA or other regulatory agencies; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the FDA&rsquo;s, EMA&rsquo;s, or other regulatory agencies&rsquo; disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials, or adequacy of the conduct and control of clinical trials; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">clinical holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial in countries that require such approvals; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the patient population for which we seek approval; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding safety or efficacy of a product candidate observed in clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our inability to demonstrate that clinical or other benefits of a product candidate outweighs any safety or other perceived risks; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any determination that a clinical trial presents unacceptable health risks to subjects; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our inability to obtain approval from institutional review boards, or IRBs, to conduct clinical trials at their respective sites; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the FDA&rsquo;s determination that the 505(b)(2) regulatory pathway is not available for a product candidate; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the non-approval of the formulation, labeling or the specifications of a product candidate; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the failure to accept the manufacturing processes or facilities at our manufacturing facility or those of third-party manufacturers with which we contract; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the potential for approval policies or regulations of the FDA, EMA or other regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval; or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">resistance to approval from the advisory committees of the FDA, EMA or other regulatory agencies for any reason including safety or efficacy concerns. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the United States, we will be required
to submit an NDA to obtain FDA approval before marketing any product candidate. An NDA must include extensive preclinical and clinical
data and supporting information to establish the product candidate&rsquo;s safety and efficacy for each desired indication. In the case
of an NDA covered by Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FFDCA, we may rely in part on data
not developed by us and for which we have not obtained a right of reference or use, including published scientific literature or
the FDA&rsquo;s findings of safety and/or effectiveness for a previously approved drug. The NDA must also include significant information
regarding the chemistry, manufacturing and controls for the product. The FDA may further inspect our manufacturing facilities to
ensure that the facilities can manufacture any product candidate and any product, if and when approved, in compliance with the
applicable regulatory requirements, as well as inspect our clinical trial sites to ensure that our trials are properly conducted.
Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. Upon submission of
an NDA, the FDA must make an initial determination that the application is sufficiently complete to accept the submission for filing.
We cannot be certain that any submissions will be accepted for filing and review by the FDA, or ultimately be approved. If the
application is not accepted for review or approval, the FDA may require that we conduct additional clinical or preclinical trials,
or take other actions before it will reconsider our application. If the FDA requires additional trials or data, we would incur
increased costs and delays in the marketing approval process, which may require us to expend more resources than we have available.
Even if the FDA agrees that results from our ongoing Phase&nbsp;3 trial evaluating D-PLEX<SUB>100</SUB> for the prevention of post-cardiac
surgery sternal SSIs and our planned Phase&nbsp;3 trial for the prevention of SSIs following abdominal surgery are sufficient to
support the submission of one or more NDAs, the FDA may determine that the data from these trials support a narrower indication
than we may propose, if the FDA were to approve such NDAs at all. In addition, the FDA may not consider any additional information
to be complete or sufficient to support approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Regulatory authorities outside of the
United States, such as in the European Union, also have requirements for approval of drugs for commercial sale with which we must
comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of a product candidate. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in
any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability
to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate
testing and validation and additional administrative review periods. Seeking foreign regulatory approval could require additional
non-clinical studies or clinical trials, which could be costly and time consuming. Foreign regulatory approval may include all
of the risks associated with obtaining FDA approval. For all of these reasons, if we seek foreign regulatory approval for any product
candidate, we may not obtain such approvals on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if we eventually complete clinical
testing and receive approval of any regulatory filing for a product candidate, the FDA may grant approval contingent on the performance
of costly and potentially time-consuming additional post-approval clinical trials or subject to contraindications, black box warnings,
restrictive surveillance or Risk Evaluation and Mitigation Strategies, or REMS. Further, the FDA, EMA or other foreign regulatory
authorities may also approve a product candidate for a more limited indication or a narrower patient population than we originally
requested, and these regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of any product candidate. Following any approval for commercial sale of a product candidate, certain changes
to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, will
be subject to additional FDA notification, or review and approval. Also, regulatory approval for any product candidate may be withdrawn.
To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory
authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for D-PLEX<SUB>100</SUB>
or any future product candidate would delay or prevent commercialization of such product candidate and would thus negatively impact
our business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Clinical drug development is difficult to design and implement
and involves a lengthy and expensive process with uncertain outcomes. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Clinical testing is expensive and can
take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur
at any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need
to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be
delayed, suspended or terminated for a variety of reasons, including failure to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to support the initiation or continuation of clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain regulatory approval, or feedback on trial design, in order to commence a trial; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">identify, recruit and train suitable clinical investigators; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain and maintain IRB approval at each clinical trial site; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">identify, recruit and enroll suitable patients to participate in a trial; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">have a sufficient number of patients complete a trial or return for post-treatment follow-up; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">address any patient safety concerns that arise during the course of a trial; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">address any conflicts with new or existing laws or regulations; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">add a sufficient number of clinical trial sites; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">raise sufficient capital to fund a trial. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may also experience numerous unforeseen
events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize
any product candidate, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">clinical trials of a product candidate may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the number of patients required for clinical trials of a product candidate may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or amend a trial protocol; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and CROs; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we or our investigators might have to suspend or terminate clinical trials of a product candidate for various reasons, including non-compliance with regulatory requirements, a finding that a product candidate have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the cost of clinical trials of a product candidate may be greater than we anticipate; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the supply or quality of a product candidate or other materials necessary to conduct clinical trials of such product candidate may be insufficient or inadequate; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">there may be changes in government regulations or administrative actions; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a product candidate may have undesirable adverse effects or other unexpected characteristics; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may not be able to demonstrate that a produce candidate&rsquo;s clinical and other benefits outweigh its safety risks; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may not be able to demonstrate that a product candidate provides an advantage over current standards of care of future competitive therapies in development; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulators may revise the requirements for approving a product candidate, or such requirements may not be as we anticipate; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, disruptions caused by the
COVID-19 pandemic has caused and may continue to increase the likelihood that we encounter such difficulties in initiating, enrolling,
conducting or completing our planned and ongoing clinical trials. We may also encounter delays if a clinical trial is suspended
or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the trial&rsquo;s data safety monitoring
board, by the FDA, EMA or other regulatory agencies. Such authorities may suspend or terminate one or more of our clinical trials
due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements
or clinical protocols, inspection of the clinical trial operations or site by the FDA, EMA or other regulatory agencies resulting
in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using
a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, conducting clinical trials outside
of the United States, as we have done and continue to do and plan to expand for D-PLEX<SUB>100</SUB> and any future product candidates,
presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients
in the countries outside of the United States to adhere to clinical protocol as a result of differences in healthcare services
or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political
and economic risks relevant to such foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we experience delays in completing
any clinical trial of a product candidate or successfully obtaining regulatory approval, the commercial prospects of such product
candidate may be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition,
any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval
process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly
harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The results of earlier studies and trials may not be predictive
of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Results from preclinical studies or early-stage
clinical trials are not necessarily predictive of future clinical trial results. Preclinical tests and Phase&nbsp;1 and Phase&nbsp;2
clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side
effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials
does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates
may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or after
having successfully advanced through initial clinical trials. This failure might cause us to abandon further development of D-PLEX<SUB>100</SUB>
for the prevention of SSIs, which is currently our most advanced product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There is a high failure rate for product
candidates proceeding through clinical trials. Many companies in the pharmaceutical industry have suffered significant setbacks
in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials.
Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent
regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due
to changes in regulatory policy during the period of our product candidate development. Success in preclinical testing and early
clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to
demonstrate the efficacy and safety of a product candidate. Frequently, product candidates that have shown promising results in
early clinical trials have subsequently suffered significant setbacks in later clinical trials. Additionally, even if we are able
to complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Interim, &ldquo;top-line&rdquo; and preliminary data from
our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From time to time, we may publicly disclose
top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the
results and related findings and conclusions are subject to change following a more comprehensive review of the data related to
the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data,
and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary
results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify
such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to
audit and verification procedures that may result in the final data being materially different from the top-line or preliminary
data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are
available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From time to time, we may also disclose
interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject
to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further,
disclosure of interim data by us or by our competitors could result in volatility in the price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, others, including regulatory
agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh
the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree
with what we determine is material or otherwise appropriate information to include in our disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the interim, top-line or preliminary
data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached,
our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If the FDA does not conclude that D-PLEX<SUB>100</SUB>
satisfies the requirements under Section&nbsp;505(b)(2) of the FFDCA, or Section&nbsp;505(b)(2), or if we are unable to utilize
the hybrid application pathway in the European Union, or if the requirements are not as we expect, the approval pathway for D-PLEX<SUB>100</SUB>
will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated,
and in either case may not be successful. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We intend to utilize the FDA&rsquo;s Section&nbsp;505(b)(2)
regulatory pathway, and the hybrid application pathway in the European Union, which is analogous to the Section&nbsp;505(b)(2)
pathway, to seek approval of D-PLEX<SUB>100</SUB>. The Drug Price Competition and Patent Term Restoration Act of 1984, also known
as the Hatch-Waxman Act, added Section&nbsp;505(b)(2) to the FFDCA. Section&nbsp;505(b)(2) permits the filing of an NDA where at
least some of the information required for approval comes from trials or studies that were not conducted by or for the applicant,
and for which the applicant has not received a right of reference or use from the person by or for whom the investigations were
conducted, which we believe could expedite the development program for D-PLEX<SUB>100</SUB> by potentially decreasing the amount
of preclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that
D-PLEX<SUB>100</SUB> is a reformulation of an already-approved drug and, therefore, will be eligible for submission of an NDA under
Section&nbsp;505(b)(2), the FDA may disagree and determine that D-PLEX<SUB>100</SUB> is not eligible for review under such regulatory
pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are unable to pursue these regulatory
pathways as anticipated, we may need to conduct additional preclinical experiments and clinical trials, provide additional data
and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources
required to obtain FDA approval for D-PLEX<SUB>100</SUB>, and complications and risks associated with D-PLEX<SUB>100</SUB>, would
likely increase significantly. Moreover, inability to pursue the Section&nbsp;505(b)(2) or similar regulatory pathway could result
in new competitive products reaching the market more quickly than D-PLEX<SUB>100</SUB> or any future product candidates, which
would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section&nbsp;505(b)(2) or similar
regulatory pathway, D-PLEX<SUB>100</SUB> may not receive the requisite approvals for commercialization, and there is no guarantee
the 505(b)(2) or similar pathway would ultimately lead to faster product development or earlier approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, notwithstanding the approval
of a number of products by the FDA under Section&nbsp;505(b)(2) over the last few years, certain competitors and others have objected
to the FDA&rsquo;s interpretation of Section&nbsp;505(b)(2). If the FDA&rsquo;s interpretation of Section&nbsp;505(b)(2) is successfully challenged,
the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving
any NDA that we submit under Section&nbsp;505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2)
NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are
referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval
of our potential future NDAs for up to 30&nbsp;months depending on the outcome of any litigation. It is also not uncommon for a
manufacturer of an approved product to file&nbsp;a citizen petition with the FDA seeking to delay approval of, or impose additional
approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent,
the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval
while it considers and responds to the petition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Moreover, even if D-PLEX<SUB>100</SUB>
or any future product candidates are approved under the Section&nbsp;505(b)(2) pathway, as the case may be, the approval may be
subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may
contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PLEX is a novel technology, which makes it difficult to
accurately and reliably predict the time and cost of development and of subsequently obtaining regulatory approval of D-PLEX<SUB>100</SUB>
or any future PLEX product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have concentrated our efforts and
product research on our PLEX drug delivery technology, and our future success depends on the successful development of this technology
and products based on it. There can be no assurance that any development problems we experience in the future related to our product
candidates will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may be
unable to maintain and further develop sustainable, reproducible and scalable manufacturing processes, or transfer these processes
to collaborators, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable
basis, if at all. To our knowledge, no regulatory authority has granted approval to any person or entity, including us, to market
and commercialize therapeutics using our novel delivery system. We may never receive approval to market and commercialize any product
candidate that utilizes PLEX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>As an organization, we have not previously conducted pivotal
clinical trials, and we may be unable to do so for any product candidates we may develop, including D-PLEX<SUB>100</SUB>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will need to successfully complete
pivotal clinical trials in order to obtain the approval of the FDA, EMA or other regulatory agencies to market D-PLEX<SUB>100</SUB>
or any future product candidates. Carrying out later-stage clinical trials and the submission of a successful NDA is a complicated
process. As an organization, we have not previously conducted any later stage or pivotal clinical trials and have limited experience
in preparing, submitting and prosecuting regulatory filings. Consequently, we may be unable to successfully and efficiently execute
and complete necessary clinical trials, including our ongoing Phase&nbsp;3 trials, in a way that leads to marketing approval of
D-PLEX<SUB>100</SUB>. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory
approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could
prevent us from or delay us in commercializing D-PLEX<SUB>100</SUB>. See &ldquo;Risks Related to Our Reliance on Third Parties.&rdquo;
We rely on third parties to conduct certain elements of our preclinical and clinical trials and perform other tasks for us. If
these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements,
we may not be able to obtain regulatory approval for or commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may find it difficult to enroll patients in our clinical
trials due to various reasons, including possible disruption due to the COVID-19 pandemic, which could delay or prevent us from
proceeding with such trials. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Identifying and qualifying patients to
participate in our clinical trials is critical to our success. The timing of our clinical trials depends in part on the speed at
which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical trials
if we encounter difficulties in enrollment. Patient enrollment and retention in clinical trials depends on many factors, including
the size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with
the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the
number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity
of patients to clinical sites, clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any drugs that may be approved for the indications we are investigating,
the eligibility criteria for the trials, our ability to obtain and maintain patient consents and the risk that patients enrolled
in clinical trials will drop out of the trials before completion. We have experienced and may further continue to experience disruptions
in patient enrollment due to the COVID-19 pandemic, including difficulties in initiating clinical sites and enrolling and retaining
participants, the diversion of healthcare resources away from clinical trials and challenges related to travel or quarantine policies
that may be implemented. For example, we have paused enrollment in our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention
of sternal SSIs in April 2020 due to the COVID-19 pandemic, and we anticipate that enrollment may be further delayed if hospitals
and patients delay the rescheduling of sternal surgeries as a result of COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may not be able to identify, recruit and
enroll a sufficient number of patients to complete our clinical trials because of the perceived risks and benefits of the product
candidate under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability
of clinical trial sites for prospective patients and the patient referral practices of physicians. We may also face challenges
in identifying trial sites and enrolling patients in global trials such as our ongoing and planned Phase&nbsp;3 trials of D-PLEX<SUB>100</SUB>,
in which, to date, we have enrolled over a hundred patients. If patients are unwilling to participate in our trials for any reason,
the timeline for recruiting patients, conducting trials and obtaining regulatory approval of potential products will be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our product candidates and the administration of our product
candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit
the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Undesirable side effects, including toxicology,
caused by D-PLEX<SUB>100</SUB> or any future product candidates, or the drugs encapsulated by such product candidates, could cause
us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay
or denial of regulatory approval by the FDA, EMA or other regulatory agencies. Results of our trials could reveal a high and unacceptable
severity and prevalence of these or other side effects. In such an event, our clinical studies could be suspended or terminated,
and the FDA, EMA or other regulatory agencies could order us to cease further development of or deny or withdraw approval of our
product candidates for any or all targeted indications. Moreover, during the conduct of clinical trials, patients report changes
in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether
or not the product candidate being studied caused these conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Drug-related, drug-product related, formulation-related
and administration-related side effects could affect patient recruitment, the ability of enrolled patients to complete the clinical
trials or result in potential product liability claims, which could exceed our clinical trial insurance coverage. We do not currently
have product liability insurance and do not anticipate obtaining product liability insurance until such time as we have received
FDA, EMA or other comparable foreign authority marketing approval for one of our product candidates and such product is being provided
to patients outside of clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, if one or more of our product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number
of potentially significant negative consequences could result, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulatory authorities may suspend or withdraw approvals of such product; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulatory authorities may require additional warnings on the label, such as a &ldquo;black box&rdquo; warning or contraindication; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may be required to create a REMS, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we may be required to recall a product, change the way a product candidate is administered or conduct additional clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we could be sued and held liable for harm caused to patients; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the product may become less competitive; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our reputation may suffer. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any of these events could prevent us
from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm
our business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Even if we complete the necessary clinical trials, we
cannot predict when, or if, we will obtain regulatory approval to commercialize any of our product candidates, and the approval
may be for a more narrow indication than we seek or be subject to other limitations or restrictions that limit its commercial profile.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We cannot commercialize a product candidate
until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our current or future product
candidates meet safety and efficacy endpoints in pivotal clinical trials, the regulatory authorities may not complete their review
processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory
Committee or other regulatory authority recommends non-approval or restrictions on approval. This may include approval of a product
candidate for more limited indications than requested or they may impose significant limitations in the form of warnings. In addition,
we may experience delays or rejections based upon additional government regulation from future legislation or administrative action,
or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Regulatory authorities also may approve
a product candidate for more limited indications than requested or they may impose significant limitations in the form of warnings
or a REMS. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they
may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may
not approve the labeling claims that are necessary or desirable for the successful commercialization of any of our product candidates.
For example, the FDA may disagree that our ongoing and planned Phase&nbsp;3 trials evaluating D-PLEX<SUB>100</SUB> for the prevention
of post-cardiac surgery sternal SSIs and for the prevention of SSIs following abdominal surgery are sufficient to support either
NDA submissions seeking approval for the specific indications under evaluation in our ongoing and planned Phase&nbsp;3 trials or
NDA submissions seeking approval for broader indications covering the prevention of SSIs. Although we intend to pursue a broad
label for D-PLEX<SUB>100</SUB>, to date we have not had any discussions with, nor received any feedback from, the FDA with respect
to the possibility of pursuing a label broader than the prevention of post-cardiac surgery sternal SSIs or the prevention of SSIs
following abdominal surgery. Even if the FDA were to agree that these trials were sufficient to support one or more NDA submissions,
the FDA may determine that the data from these trials support more narrow indications than we may propose, if the FDA were to approve
such NDA submissions at all. If the FDA does not agree that our ongoing and planned Phase&nbsp;3 trials support the submission
of an NDA for any indication, we will be required to conduct additional clinical trials to support our proposed indications. Any
of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely
affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Although D-PLEX<SUB>100</SUB> has been granted Qualified
Infectious Disease Product designation by the FDA for the prevention of sternal wound infection after cardiac surgery and for the
prevention of post-abdominal surgery incisional infection, these designations do not guarantee a shorter FDA review process, or
that D-PLEX<SUB>100</SUB> will ultimately be approved by the FDA for any indication. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the Generating Antibiotic Incentives
Now Act, or GAIN Act, the FDA may designate a product as a &ldquo;qualified infectious disease product,&rdquo; or QIDP. In order
to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious
or life-threatening infections, including those caused by either (1)&nbsp;an antibacterial or antifungal resistant pathogen, including
novel or emerging infectious pathogens, or (2)&nbsp;a so-called &ldquo;qualifying pathogen&rdquo; found on a list of potentially
dangerous, drug-resistant organisms established and maintained by the FDA under the GAIN Act. A sponsor must request such designation
before submitting a marketing application. We requested and received QIDP designations for D-PLEX<SUB>100</SUB> for the prevention
of sternal wound infection after cardiac surgery and for the prevention of post-abdominal surgery incisional infection. We anticipate
that the QIDP designations will provide, among other benefits, an overall increased level of communication with the FDA during
the development process. The benefits of QIDP designation also include eligibility for priority review and an extension by an additional
five years of any non-patent market exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular
entity or a three-year market exclusivity period awarded to an applicant whose application relies on new clinical investigations
essential to the approval. This extension is in addition to any pediatric exclusivity extension that may be awarded. GAIN Act exclusivity
may not be awarded if the indication for which we obtain approval does not meet the definition of a qualified infectious disease
product. However, there is limited precedent for understanding the way in which the GAIN Act will be implemented. Receipt of QIDP
designation in practice may not result in a faster development process, review or approval compared to drugs considered for approval
under conventional FDA procedures, and does not assure ultimate approval by the FDA or related exclusivity benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Fast Track Designation from the FDA may not actually lead
to a faster development or regulatory review or approval process. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We received Fast Track Designation from
the FDA for D-PLEX<SUB>100</SUB> for topical use for the prevention of post-cardiac surgery sternal infection, as well as for the
prevention of post abdominal surgery incisional infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If a product candidate is intended for
the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet
medical needs for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether
or not to grant this designation, so even if we believe one of our product candidates is eligible for this designation, we cannot
assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, such as the Fast Track Designation
received for D-PLEX<SUB>100</SUB>, we may not experience a faster development process, review or approval compared to conventional
FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data
from our clinical development program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Breakthrough therapy designation by the FDA may not lead
to a faster development or regulatory review or approval process. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We received a breakthrough therapy designation
for D-PLEX<SUB>100</SUB> for the for the prevention of SSIs in patients undergoing elective colorectal surgery. A breakthrough
therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction
and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development
while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies
by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">However, the receipt of a breakthrough
therapy designation for a product candidate may not result in a faster development process, review or approval compared to product
candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition,
even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate
no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Even if we obtain regulatory approval for a product candidate,
our products and business will remain subject to ongoing regulatory obligations and review. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our product candidates are approved,
they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,
sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information,
including both federal and state requirements in the United States and comparable requirements outside of the United States. Accordingly,
we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any regulatory approvals that we receive
for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed
or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&nbsp;4
clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS
as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, EMA or other regulatory
agencies and to comply with requirements concerning advertising and promotion for our products. Promotional communications with
respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information
in the product&rsquo;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA,
EMA or other regulatory agency approval. The holder of an approved NDA must also submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to
conduct post-marketing clinical trials to verify the safety and efficacy of our product candidates in general or in specific patient
subsets. An unsuccessful post-marketing trial or failure to complete such a clinical trial could result in the withdrawal of marketing
approval. Furthermore, any new legislation addressing drug safety issues could result in delays in product development or commercialization
or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements. If a regulatory agency discovers
previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the
promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including
requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory
agency or enforcement authority may, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%; width: 0.5in">&nbsp;</TD>
    <TD STYLE="line-height: 107%; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">issue warning letters asserting that we are in violation of the law; </FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">seek an injunction or impose civil or criminal penalties or monetary fines; </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">suspend or withdraw regulatory approval; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">suspend any of our ongoing clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refuse to approve pending applications or supplements to approved applications submitted by us or our strategic partners; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">restrict the marketing or manufacturing of our products; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">seize or detain products, or require a product recall; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refuse to permit the import or export of our product candidates; or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refuse to allow us to enter into government contracts. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any government investigation of alleged
violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize
and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the
value of our company and our operating results will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA&rsquo;s and other regulatory authorities&rsquo;
policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained
and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Disruptions at the FDA and other government agencies caused
by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel,
or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which
could negatively impact our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The ability of the FDA to review and
approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&rsquo;s ability to hire and retain key personnel and accept the payment of user fees, and other events that
may otherwise affect the FDA&rsquo;s ability to perform routine functions. Average review times at the agency have fluctuated in recent
years as a result. In addition, government funding of other government agencies that fund research and development activities is
subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also
slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, including for 35&nbsp;days beginning
on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have
had to furlough critical FDA employees and stop critical activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Separately, in response to the COVID-19
pandemic, in March, 2020 the FDA announced the postponement of most foreign and routine surveillance inspections of domestic manufacturing
facilities, and only restarted domestic inspections on a risk-based basis in July 2020. Regulatory authorities outside the United
States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If a prolonged government shutdown occurs,
or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to
timely review and process our regulatory submissions, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be subject, directly or indirectly, to U.S. federal
and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy
and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our current and future operations may
be directly or indirectly through our relationships with U.S. healthcare providers, patients and other persons and entities, subject
to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business or financial arrangements
and relationships through which we research, market, sell and distribute our products in the United States. In addition, we may
be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws
that may affect our ability to operate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The U.S. Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other U.S. federal healthcare programs. The U.S. Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The U.S. federal false claims laws, including the False Claims Act, or FCA, and civil monetary penalties laws, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the U.S. federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government third-party payors if they are deemed to &ldquo;cause&rdquo; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &ldquo;whistleblower&rdquo; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties per false claim or statement. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &ldquo;off-label&rdquo; uses; and submitting inflated best price information to the Medicaid Rebate Program. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposes, among other things, annual reporting requirements for covered manufacturers for certain payments and &ldquo;transfers of value&rdquo; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists and certified nurse midwives. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates, which include individuals or entities that perform services for covered entities that involve the creation, use, maintenance or disclosure of, individually identifiable health information as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many states have analogous state laws
and regulations, such as state anti-kickback and false claims laws, that may apply to our business practices, including but not
limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed
by non-governmental third-party payors, including private insurers. In addition, certain states require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the U.S. federal government. Certain states and local jurisdictions require drug manufacturers to report information related to
payments and other transfers of value to physicians and other healthcare providers and register pharmaceutical sales representatives.
Additionally, certain states also require pharmaceutical companies to file reports relating to pricing information or marketing
expenditures and have laws governing the privacy and security of health information in certain circumstances, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because of the breadth of these laws
and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, the ACA has strengthened these laws. For example, health
care reform legislation, has among other things, amended the intent requirement of the U.S. Anti-Kickback statute and certain criminal
healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate
it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation
of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Ensuring that our internal operations
and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is
possible that governmental authorities will conclude that our business practices, including arrangements we may have with physicians
and other healthcare providers, some of whom may receive stock options as compensation for services provided, do not comply with
current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.
If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us,
we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible
exclusion from government funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings,
additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve
allegations of non-compliance with these laws, and curtailment of our operations, any of which could substantially disrupt our
operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Legislative or regulatory healthcare reforms in the United
States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to
produce, market and distribute our products after clearance or approval is obtained. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From time to time, legislation is drafted
and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval,
manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often
revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or
revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted
or adopted may have on our business in the future. Such changes could, among other things, require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes to manufacturing methods; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">change in protocol design; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additional treatment arm (control); </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">recall, replacement, or discontinuance of one or more of our products; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additional recordkeeping. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, in the United States, there
have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability
to sell our products profitably. The pharmaceutical industry in the United States, as an example, has been affected by the passage
of the ACA, which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs
and expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. There have
been executive, judicial and Congressional challenges to certain aspects of the ACA. Concurrently, Congress considered legislation
to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several
bills affecting the implementation of certain taxes under the ACA have been enacted. The Tax Cuts and Jobs Act of 2017 includes
a provision repealing, effective January&nbsp;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual
mandate&rdquo;. In addition, the 2020 federal spending package permanently eliminated, effective January&nbsp;1, 2020, the ACA-mandated
&ldquo;Cadillac&rdquo; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&nbsp;1,
2021, also eliminated the health insurer tax. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is
unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress as part of the Tax Act. Additionally,
on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th&nbsp;Circuit upheld the District Court ruling that the individual
mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of
the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, but it is unknown when a decision
will be reached. Although the Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President
Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes
of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining
Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers
to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other
such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other legislative changes have been proposed
and adopted in the United States since the ACA was enacted. For example, COVID-19 relief legislation suspended the 2% Medicare
sequester from May&nbsp;1, 2020 through March 31,&nbsp;2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, there has been particular and
increasing legislative and enforcement interest in the United States with respect to drug pricing practices in recent years, particularly
with respect to drugs that have been subject to relatively large price increases over relatively short time periods. There have
been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to
drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used
several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy
initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders
related to prescription drug pricing that attempt to implement several of the administration&rsquo;s proposals. The FDA also released
a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states
to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the U.S. Department of Health
and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers
to plan sponsors under Part&nbsp;D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in
response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as
well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation
of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued
an interim final rule implementing President Trump&rsquo;s Most Favored Nation executive order, which would tie Medicare Part B
payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective
January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary
injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse
these measures or pursue similar policy initiatives. Individual states in the United States have also become increasingly active
in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and in some cases, designed to encourage importation from other countries and bulk purchasing. In the future, there will likely
continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement
of drug products, including our product candidates. It is possible that additional governmental action is taken in response to
the COVID-19 pandemic, but there can be no certainty regarding what, if any, such action may be. Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors. Our results of operations
could be adversely affected by the ACA and by other health care reforms that may be enacted or adopted in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We face intense competition in an environment of rapid
technological change and the possibility that our competitors may develop products and drug delivery systems that are similar,
more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully market
or commercialize our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The pharmaceutical industry in which
we operate is intensely competitive and subject to rapid and significant technological change. We are currently aware of various
existing therapies in the market and in development that may in the future compete with our product candidates, including other
therapies that address the management of SSIs, as well as other drug delivery mechanisms that utilize polymer and/or lipid technology
to deliver APIs at the local level. Other approaches may also emerge for the prevention or treatment of any of the indications
on which we focus, and new technologies may emerge in localized drug delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have competitors both in the United
States and internationally, including major multinational pharmaceutical companies and specialty pharmaceutical companies. Our
competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective or less costly
than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization
and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. See &ldquo;Item
4. B. &mdash; Business Overview &mdash; Competition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Even if we obtain and maintain approval for D-PLEX<SUB>100</SUB>
or our other product candidates from the FDA, we may never obtain approval outside of the United States, which would limit our
market opportunities and adversely affect our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Approval of a product candidate in the
United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions,
and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries
or by the FDA. However, the failure to obtain approval from the FDA or other regulatory authorities may negatively impact our ability
to obtain approval in other foreign countries. Sales of D-PLEX<SUB>100</SUB> or our other product candidates outside of the United
States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants
marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing
and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical
studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement
before it can be approved for sale in that country. In some cases, the price that we intend to charge for our product candidates,
if approved, is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We intend to submit a marketing authorization
application to the EMA for approval of D-PLEX<SUB>100</SUB> in the European Union, but obtaining such approval from the European
Commission following the opinion of the EMA is a lengthy and expensive process. Even if a product candidate is approved, the applicable
regulatory agency may limit the indications for which the product may be marketed, require extensive warnings on the product labeling
or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities
in countries outside of the United States and the European Union also have requirements for approval of product candidates with
which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction
of our product candidates in certain countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, clinical trials conducted in
one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for a product candidate
may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize
the full market potential of D-PLEX<SUB>100</SUB> or our other product candidates will be harmed and our business, financial condition,
results of operations and prospects will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The misuse or off-label use of our products may harm our
reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines
or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prescription drugs may be promoted only
for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject
to significant liability. If the FDA does not agree that our data support the submission of an NDA seeking approval for the prevention
of SSIs generally or SSIs in bone and soft tissue, we intend to seek marketing approval for D-PLEX<SUB>100</SUB> for the prevention
of sternal SSIs after cardiac surgery and the prevention of SSIs in patients undergoing abdominal surgery. We will train our marketing
and sales personnel to not promote our products, if approved, for any off-label uses. We cannot, however, prevent a physician from
using our products off-label, when in the physician&rsquo;s independent professional medical judgment he or she deems it appropriate.
For example, if we obtain approval of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs after cardiac surgery and/or the
prevention of SSIs in patients undergoing abdominal surgery, physicians may nevertheless decide to use D-PLEX<SUB>100</SUB> in
an attempt to prevent infections in connection with other types of surgeries, and there may be increased risk of injury to patients
if physicians attempt to use our products for these uses for which they are not approved. While the FDA does not regulate the behavior
of physicians in their choice of treatments, the FDA does restrict manufacturer&rsquo;s communications on the subject of off-label use
of their products. Furthermore, the use of our products for indications other than those approved by the FDA or any foreign regulatory
body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the FDA, EMA or any foreign regulatory
body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify
our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or
criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other
regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties,
damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Risks Related to our Reliance
on Third Parties </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We rely on third parties to conduct certain elements of
our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out
their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have relied upon, and plan to continue
to rely upon, third-party vendors, including CROs, to monitor and manage data for our ongoing preclinical studies and clinical
trials. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need
to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our
clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and
we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. We rely on these CROs
for execution of our preclinical studies and clinical trials, and we control only certain aspects of their activities. Nevertheless,
we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory
and scientific standards, and our reliance on the vendors and CROs does not relieve us of our regulatory responsibilities. We and
our CROs and other vendors are required to comply with good clinical practice, cGMP, the Helsinki Declaration, the International
Conference on Harmonization Guideline for Good Clinical Practice, applicable European Commission Directives on Clinical Trials,
laws and regulations applicable to clinical trials conducted in other territories, and good laboratory practices, or GLP, which
are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area,
or EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, including Good Clinical Practice, or GCP, and cGMP
regulations, the clinical data generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign
regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Our failure
to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If any of our relationships with these
third-party CROs or vendors terminate, we may not be able to enter into arrangements with alternative CROs or vendors or do so
on commercially reasonable terms. In addition, our CROs are not our employees, and, except for remedies available to us under our
agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical,
nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.
CROs may also generate higher costs than anticipated, which could adversely affect our results of operations and the commercial
prospects for our product candidates, increase our costs and delay our ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Replacing or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences
work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though
we carefully manage our relationships with our CROs, we may encounter similar challenges or delays in the future, which could have
a material adverse impact on our business, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Independent clinical investigators and CROs that we engage
to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past
success. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expect to continue to depend on third
parties, including independent clinical investigators and CROs, to conduct our clinical trials. CROs may also assist us in the
collection and analysis of data. There is a limited number of third-party service providers and vendors that specialize or have
the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service
providers can be difficult, time consuming and cause delays in our development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These investigators and CROs will not
be our employees and we will not be able to control, other than through contract, the amount of resources, including time, which
they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources
to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects
for approval and commercialization of any product candidates that we develop. Further, the performance of our CROs may also be
interrupted by the ongoing COVID-19 pandemic, including due to travel or quarantine policies, heightened exposure of CRO staff
who are healthcare providers to COVID-19 patients or prioritization of resources toward the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Investigators for our clinical trials
may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities.
The FDA or other regulatory authorities may conclude that a financial relationship between us and an investigator has created a
conflict of interest or otherwise affected interpretation of the trial. The FDA or other regulatory authorities may therefore question
the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.
This could result in a delay in approval or rejection of our marketing applications by the FDA or other regulatory authorities,
as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the use of third-party service providers requires
us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.
Further, the FDA and other regulatory authorities require that we comply with standards, commonly referred to as GCP, for conducting,
recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations
to us or comply with GCP procedures could adversely affect the clinical data, the outcome of the clinical studies or the development
of our product candidates and harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We rely on third parties to manufacture the raw materials,
including the active pharmaceutical ingredients that we use to create our product candidates. Our business could be harmed if existing
and prospective third parties fail to provide us with sufficient quantities of these materials and products or fail to do so at
acceptable quality levels or prices. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely on third party suppliers for
certain raw materials necessary to manufacture our product candidates for our preclinical studies and clinical trials. Some of
these raw materials are difficult to source. Because there are a limited number of suppliers for these raw materials, we may need
to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product
candidates for our clinical trials, and if approved, ultimately for commercial sale. In several cases, we rely on a sole provider,
and there may be a need to identify additional providers in the future. We do not have any control over the availability of raw
materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels,
or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates,
would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for
our product candidates or generate revenues from the sale of any approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even following our establishment of our
own cGMP-compliant manufacturing capabilities, we intend to continue to rely on third party suppliers for these raw materials,
which will continue to expose us to manufacturing risks including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reduced control for certain aspects of manufacturing activities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain of our raw material suppliers
will be required to become cGMP-compliant and establish a drug master file for the applicable ingredient before we can submit our
NDA for D-PLEX<SUB>100</SUB>. If these suppliers do not successfully carry out their contractual duties or manufacture our raw
materials in accordance with regulatory requirements, we will not be able to submit our NDA as planned or complete, or may be delayed
in completing, the clinical trials required for approval of D-PLEX<SUB>100</SUB>. In such instances, we may need to locate an appropriate
replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay
or increased expense prior to the approval of D-PLEX<SUB>100</SUB> and would thereby have a material adverse effect on our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, we have not yet entered
into binding agreements with certain third-party manufacturers to produce the raw materials and products that we use to manufacture
our product candidates. Although we intend to rely on third-party manufacturers for the raw materials and products to support the
manufacturing of our product candidates for commercialization, we have not yet entered into agreements with certain manufacturers.
We may be unable to negotiate binding agreements with the manufacturers to support our commercialization activities at commercially
reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Although we have established our own manufacturing facility,
we may utilize third parties as needed to conduct our product manufacturing. Therefore, we are subject to the risk that these third
parties may not perform satisfactorily. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we expect that our manufacturing
facility will be the primary source of clinical and commercial supply for D-PLEX<SUB>100</SUB> for at least the first 30&nbsp;months
following a commercial launch, if approved, we intend to evaluate potential third-party manufacturing capabilities if necessary
to meet further commercial demand if and when required. In the event that we engage third-party manufacturers and they do not successfully
carry out their contractual duties, meet expected deadlines or manufacture D-PLEX<SUB>100</SUB> in accordance with regulatory requirements
or if there are disagreements between us and any third-party manufacturer, we may be delayed in producing sufficient clinical and
commercial supply of D-PLEX<SUB>100</SUB> or other product candidates. In such instances, we may need to locate an appropriate
replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay
or increased expense and would thereby have a material adverse effect on our business, financial condition, results of operations
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The manufacture of pharmaceutical products
is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques
and process controls. We and our contract manufacturers must comply with cGMP requirements. In the event that our contract manufacturers
fail to meet cGMP requirements, we may be delayed or unable to supply our products. In addition, manufacturers of pharmaceutical
products often encounter difficulties in production, particularly in scaling up and validating initial production and contamination
controls. These problems include difficulties with production costs and yields, quality control, including stability of the product,
quality assurance testing, operator error, and shortages of qualified personnel, as well as compliance with strictly enforced federal,
state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates
or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed
for an extended period of time to investigate and remedy the contamination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also rely on third party manufacturers
to conduct quality control reviews of and packaging and sterilization services for our product candidates or any approved products.
We cannot assure you that any stability, sterility or other issues relating to the manufacture of any of our product candidates
or any approved products will not occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, our third-party manufacturers
may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments.
If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any products to patients,
once approved, would be jeopardized. Any adverse developments affecting commercial manufacturing may result in shipment delays,
inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of an approved product.
We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced
at any level of our supply chain could materially adversely affect our business and delay and could have a material adverse effect
on our business, prospects, financial condition and results of operations. Some of these events could be the basis for FDA action,
including injunction, recall, seizure or total or partial suspension of product manufacture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our reliance on third parties requires us to share our
trade secrets and intellectual property, which increases the possibility that a competitor will discover them or that our trade
secrets and intellectual property will be misappropriated or disclosed. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because we rely on third parties to provide
us with the materials that we use to develop and, if appropriate in the future, manufacture our product candidates or approved
products, we may, at times, share trade secrets and intellectual property with such third parties. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants
prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties
to use or disclose our confidential information, such as trade secrets and intellectual property. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk
that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed
or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets,
a competitor&rsquo;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and
may have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Despite our efforts to protect our trade
secrets and knowhow, our competitors may discover our trade secrets, either through breach of these agreements, independent development
or publication of information including our trade secrets by third parties. A competitor&rsquo;s discovery of our trade secrets and knowhow
would impair our competitive position and have an adverse impact on our business, financial condition, results of operations and
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Risks Related to Our Intellectual
Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we are unable to obtain and maintain effective patent
rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. If
we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others
to compete against us. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely upon a combination of patents,
trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection
in the United States and in other countries with respect to our proprietary technology and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have sought to protect our proprietary
position by filing patent applications in the United States and in other countries, with respect to our novel technologies and
product candidates, which are important to our business. Patent prosecution is expensive and time consuming, and we may not be
able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also
possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain
patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 1, 2021, our portfolio of
owned patents and patent applications consists of seven families that protect our technology, including 96 issued patents, including
utility and composition of matter patents, two allowed patent applications and 29&nbsp;pending patent applications in jurisdictions
in the United States, the European Patent Office, Canada, Australia, China, Japan, Israel, Brazil, the Eurasian Patent Organization,
India, Mexico, New Zealand, the Philippines, Singapore, South Korea and Thailand. We cannot offer any assurances about which, if
any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or
will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us
after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that
we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, the patent position of pharmaceutical
companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved.
This renders the patent prosecution process particularly expensive and time-consuming. There is no assurance that all potentially
relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a patent from issuing
from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates,
third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable
or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately protect
our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims.
Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we cannot obtain and maintain effective
patent rights for our product candidates, we may not be able to compete effectively, and our business and results of operations
would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may not have sufficient patent lifespan to effectively
protect our products and business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Patents have a limited lifespan. In the
United States, the natural expiration of a patent is generally 20&nbsp;years after its priority date. Although various extensions
may be available, including pursuant to the QIDP designations we have received for D-PLEX<SUB>100</SUB>, the life of a patent,
and the protection it affords, is limited. Even if any of our patent applications mature into issued patents, if we do not have
sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Patent policy and rule changes could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Changes in either the patent laws or
interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue
from our patent applications, or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights
to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind
the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until
18&nbsp;months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were the first
to make the invention claimed in our owned and licensed patent or pending applications, or that we or our licensor were the first
to file for patent protection of such inventions. Assuming the other requirements for patentability are met, for United States
patent applications filed prior to March&nbsp;15, 2013, the first to conceive a claimed invention is entitled to the patent, while
outside the United States, the first to file&nbsp;a patent application is entitled to the patent. After March&nbsp;15, 2013, under
the Leahy-Smith America Invents Act, or the AIA, enacted on September&nbsp;16, 2011, the United States has moved to a first to
file system. The AIA also includes a number of significant changes that affect the way patent applications are prosecuted and may
also affect patent litigation. The courts have yet to address many of these provisions and the applicability of the AIA and new
regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the AIA and
its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of any issued patents, all of which could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If our trademarks and trade names are not adequately protected,
then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our registered or unregistered trademarks
or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We
may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential
partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our
trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other
entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our
use of our current trademarks throughout the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we are unable to maintain effective proprietary rights
for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to the protection afforded
by any patents that have been or may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other
elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining
the physical security of our premises and physical and electronic security of our information technology systems. While we have
confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have
adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently
discovered by competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we expect all of our employees
and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have
access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any
assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets and intellectual property
could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken
to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third
parties for misappropriating the trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Intellectual property rights of third parties could adversely
affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third
parties in order to develop or market our product candidate. Such litigation or licenses could be costly or not available on commercially
reasonable terms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is inherently difficult to conclusively
assess our freedom to operate without infringing on third party rights. Our competitive position may suffer if patents issued to
third parties or other third party intellectual property rights cover our product candidates or elements thereof, or our manufacturing
or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or our
product candidates unless we successfully pursue litigation to nullify or invalidate the third party intellectual property right
concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable
terms. There may also be pending patent applications that if they result in issued patents, could be alleged to be infringed by
our product candidates. If such an infringement claim should be brought and be successful, we may be required to pay substantial
damages, be forced to abandon our product candidates or seek a license from any patent holders. No assurances can be given that
a license will be available on commercially reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is also possible that we have failed
to identify relevant third party patents or applications. For example, U.S. applications filed before November&nbsp;29, 2000 and
certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue.
Patent applications in the U.S. and elsewhere are published approximately 18&nbsp;months after the earliest filing to which priority
is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering
our product candidates or platform technology could have been filed by others without our knowledge. Additionally, pending patent
applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform
technologies, our product candidates or the use of our product candidates. Third party intellectual property right holders may
also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise
resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required
to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial
delays in pursuing the development of and/or marketing of our product candidates. If we fail in any such dispute, in addition to
being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our product candidates that are
held to be infringing. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe the
third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert
substantial financial and management resources that we would otherwise be able to devote to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Third-party claims of intellectual property infringement
may prevent or delay our development and commercialization efforts. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our commercial success depends in part
on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement
lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous
U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which
we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that
our product candidates may be subject to claims of infringement of the patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Third parties may assert that we are
employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates.
Because patent applications can take many years to issue, there may be currently pending patent applications that may later result
in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction
to cover the manufacturing process of any of our product candidates, any materials formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates
unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Similarly, if any third-party patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use,
the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate
unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case,
such a license may not be available on commercially reasonable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Parties making claims against us may
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful infringement, pay
royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require
substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may not be successful in obtaining or maintaining necessary
rights to our product candidates through acquisitions and in-licenses. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because our programs may require the
use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire,
in-license, or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively
and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions,
methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for
our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights
that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources,
and greater clinical development and commercialization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For example, we sometimes collaborate
with academic institutions to accelerate our preclinical research or development under written agreements with these institutions.
Typically, these institutions provide us with an option to negotiate a license to any of the institution&rsquo;s rights in technology
resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe
or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights
to other parties, potentially blocking our ability to pursue our program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party
intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to
successfully obtain rights to required third-party intellectual property rights, we may have to abandon development of that program
and our business and financial condition could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be involved in lawsuits to protect or enforce our
intellectual property, which could be expensive, time consuming and unsuccessful. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Competitors may infringe our intellectual
property or that of our licensors that we may acquire in the future. If we or a future licensing partner were to initiate legal
proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim
that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged
failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information
from the USPTO, or made a misleading statement, during prosecution. Under the AIA, the validity of U.S. patents may also be challenged
in post-grant proceedings before the USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Interference proceedings provoked by
third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to
our patent or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related
technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party
does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and,
even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships
that would help us bring our product candidates to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the
results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be subject to claims that our employees, consultants,
or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have
wrongfully used or disclosed alleged trade secrets of their former employers. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We employ individuals who were previously
employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or
know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors
have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employees&rsquo; former employers or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be subject to claims challenging the inventorship
of our intellectual property. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may be subject to claims that former
employees, collaborators or other third parties have an interest in or right to compensation with respect to our current patent
and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse
effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. To the extent that our employees have not effectively waived the right
to compensation with respect to inventions that they helped create, they may be able to assert claims for compensation with respect
to our future revenue. As a result, we may receive less revenue from future products if such claims are successful which in turn
could impact our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Changes in United States and international patent law
could diminish the value of patents in general, thereby impairing our ability to protect our products. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our success is heavily dependent on intellectual
property. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity. Therefore,
obtaining and enforcing these patents is costly, time consuming and inherently uncertain. In addition, the United States has recently
enacted and is currently implementing wide-ranging patent reform legislation. Recent United States Supreme Court rulings have narrowed
the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once obtained. Depending on future actions by the United States Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken
our ability to obtain patents or to enforce patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may not be able to protect our intellectual property rights
throughout the world. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Filing, prosecuting and defending patents on
product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights
in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own product candidates and may also export otherwise infringing products
to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may
compete with our product candidates. Future patents or other intellectual property rights may not be effective or sufficient to
prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property
protection, particularly those relating to biotechnology products or methods of treatment, which could make it difficult for us
to stop the marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention
from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and our patent
applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts
to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from
the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Business Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our business and operations have been and are likely to further
continue to be adversely affected by the evolving and ongoing COVID-19 global pandemic. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business and operations have been and are
likely to further continue to be adversely affected by the effects of the recent and evolving COVID-19 virus, which was declared
by the World Health Organization as a global pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order
to reduce the spread of the disease, including public health directives and orders in Israel, the United States and the European
Union that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed
businesses and governmental agencies to cease non-essential operations at physical locations, prohibited certain non-essential
gatherings and events and ordered cessation of non-essential travel. Although our employees are no longer working remotely after
the expiration of such orders in Israel, future remote work policies and similar government orders or other restrictions on the
conduct of business operations related to the COVID-19 pandemic may negatively impact productivity and may disrupt our ongoing
research and development activities and our clinical programs and timelines, the magnitude of which will depend, in part, on the
length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Further,
such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts
and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have paused enrollment of our Phase&nbsp;3
trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs in April 2020 in part due to the prioritization of SHIELD I and
SHIELD II trials and in part due to the COVID-19 pandemic. Currently, we see a limited impact of the COVID-19 on our SHIELD I and
SHEILD II trials. We expect that approximately 70% of patients enrolling in these trials are colorectal cancer patients in an urgent
need of tumor removal and, therefore, in high priority to go into surgery. We remain in close contact with our principal investigators
and clinical sites in order to assess the impact of the COVID-19 pandemic on our clinical trials, expected timelines and costs
and to consider any appropriate mitigating measures. Future patient enrollment, when we deem it appropriate, and clinical site
initiation may be further delayed due to prioritization of hospital resources toward the COVID-19 pandemic or challenges in patient
enrollment or maintenance due to quarantines or other interruptions to healthcare services. Some patients may not be able to comply
with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, we may be unable
to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure
to COVID-19, which would adversely impact clinical trial operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The spread of COVID-19, which has caused a broad
impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19
may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets,
reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or
market correction resulting from the spread of COVID-19 could materially affect our business and the value of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The global COVID-19 pandemic continues to rapidly
evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory
efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this
annual report on Form 20-F, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and
effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social
distancing requirements and business closures in the United States, Israel and other countries to contain and treat the disease.
Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities,
healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition,
results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, to the extent the ongoing COVID-19
pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other
risks and uncertainties described in this &ldquo;Risk Factors&rdquo; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We will need to expand our organization, and we may experience
difficulties in managing this growth, which could disrupt our operations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our future financial performance and our ability
to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future
growth. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational,
sales, marketing, financial and legal personnel. Our management may need to divert a disproportionate amount of its attention away
from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional
product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected,
our ability to generate and/or grow revenue could be reduced, and we may not be able to implement our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Due to our limited resources and access to capital, we must,
and have in the past decided to, prioritize development of certain product candidates over other potential candidates. These decisions
may prove to have been wrong and may adversely affect our revenues. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because we have limited resources and access
to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to
each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular
product candidates may not lead to the development of viable commercial products and may divert resources away from better opportunities.
Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs
may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding
the market potential of our product candidates or misread trends in the pharmaceutical industry, in particular for our lead product
candidate, our business, financial condition and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may not be successful in our efforts to identify, discover
or license additional product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although a substantial amount of our effort
will focus on the continued clinical testing, potential approval and commercialization of D-PLEX<SUB>100</SUB>, the success of
our business also depends upon our ability to identify, discover or license additional product candidates. Our research programs
or licensing efforts may fail to yield additional product candidates for clinical development for a number of reasons, including:
lack of financial or personnel resources to acquire or discover additional product candidates; new product candidates may not succeed
in preclinical or clinical testing, or may be shown to have harmful side effects or may have other characteristics that may make
them unmarketable or unlikely to receive marketing approval; our competitors may develop alternatives that render our product candidates
obsolete or less attractive; the market for a product candidate may change during our development program so that such product
may become unprofitable to continue to develop; new product candidates may not be capable of being produced in commercial quantities
at an acceptable cost, or at all; and new product candidates may not be accepted as safe and effective by patients, the medical
community, or third-party payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may be forced to abandon our development
efforts for a program or programs that are unsuccessful, or we may not be able to identify, license, or discover additional product
candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Further,
research programs to identify new product candidates require substantial technical, financial and human resources. We may focus
our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>European data collection is governed by restrictive regulations
governing the collection, use, processing and cross-border transfer of personal information. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may collect, process, use or transfer personal
information from individuals located in the European Union in connection with our business, including in connection with conducting
clinical trials in the European Union. Additionally, we intend to commercialize D-PLEX<SUB>100</SUB>, and any of our product candidates
that receive marketing approval, in the European Union. The collection and use of personal health data in the European Union is
governed by the provisions of the General Data Protection Regulation ((EU) 2016/679), or the GDPR, along with other European Union
and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations.
These legislative acts (together with regulations and guidelines) impose requirements relating to having legal bases for processing
personal information relating to identifiable individuals and transferring such information outside of the EEA, including to the
United States, providing details to those individuals regarding the processing of their personal information, keeping personal
information secure, having data processing agreements with third parties who process personal information, responding to individuals&rsquo;
requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data
to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data
protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal
data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection
rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the
European Union may result in substantial fines, other administrative penalties and civil claims being brought against us, which
could have a material adverse effect on our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The United Kingdom&rsquo;s withdrawal from the European Union
may adversely impact our ability to obtain regulatory approvals of our product candidates in the United Kingdom, result in restrictions
or imposition of taxes and duties for importing our product candidates into the United Kingdom, and may require us to incur additional
expenses in order to develop, manufacture and commercialize our product candidates in the United Kingdom.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Following the result of a referendum in 2016, the United Kingdom
left the European Union on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed
to by the United Kingdom and the European Union, the United Kingdom was subject to a transition period until December 31, 2020,
or the Transition Period, during which European Union rules continued to apply. A trade and cooperation agreement that outlines
the future and trading relationship between the United Kingdom and the European Union was agreed to in December 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Since a significant proportion of the regulatory
framework in the United Kingdom applicable to our business and our product candidates is derived from European Union directives
and regulations, Brexit has had, and will continue to have, a material impact on the regulatory regime with respect to the development,
manufacture, importation, approval and commercialization of our product candidates in the United Kingdom. For example, Great Britain
is no longer covered by the centralized procedures for obtaining European Union-wide marketing authorizations from the EMA, and
a separate marketing authorization will be required to market our product candidates, including D-PLEX<SUB>100</SUB> in Great
Britain. It is currently unclear whether the Medicines&nbsp;&amp; Healthcare products Regulatory Agency in the United Kingdom
is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive.
Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would delay or
prevent us from commercializing our product candidates in the United Kingdom and limit our ability to generate revenue and achieve
and sustain profitability. We could face significant additional expenses to obtain regulatory approval for our products in the
United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we fail to comply with environmental, health and safety laws
and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the
success of our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research, development and manufacturing
activities and our third party manufacturers&rsquo; and suppliers&rsquo; activities involve the controlled storage, use and disposal of hazardous
materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers
are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&rsquo; facilities
pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities
under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste
products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of
these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is
the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable
for any resulting damages, such liability could exceed our resources, and state or federal or other applicable authorities may
curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations
are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot
be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our employees and independent contractors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are exposed to the risk of fraud or other
misconduct by our employees and independent contractors. Misconduct by these parties could include intentional failures to comply
with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with
federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose
unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject
to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Employee and independent contractor misconduct could also involve
the improper use of information obtained in the course of clinical trials, including individually identifiable information, creating
fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product candidates, which could result
in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees
and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government
could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Under applicable employment laws, we may not be able to enforce
covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our
former employees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We generally enter into non-competition agreements
with our employees and certain key consultants. These agreements prohibit our employees and certain key consultants, if they cease
working for us, from competing directly with us or working for our competitors or clients for a limited period of time. We may
be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for
us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working
for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For example, Israeli courts have required employers
seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company&rsquo;s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>International expansion of our business exposes us to business,
regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or
Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other than our headquarters and other operations
which are located in Israel (as further described below), we currently have limited international operations, but our business
strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product
candidates. We plan to retain sales representatives and third party distributors and conduct physician, infectious disease specialist,
hospital pharmacist and patient association outreach activities, as well as clinical trials, outside of the United States, European
Union and Israel. Doing business internationally involves a number of risks, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in">&#9679;</td>
    <TD>multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export
    and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits, and licenses;
    </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>failure by us to obtain regulatory approvals for the use of our product candidates in various countries; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>additional potentially relevant third-party patent rights; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>complexities and difficulties in obtaining protection and enforcing our intellectual property; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>difficulties in staffing and managing foreign operations;</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>complexities associated with managing multiple payor reimbursement regimes, government payors, prince controls or patient
    self-pay systems; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>limits in our ability to penetrate international markets; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional
    financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>an outbreak of a contagious disease, including COVID-19, which may cause us or our distributors, third party vendors and
    manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country;
    </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>natural disasters, political and economic instability, including wars, terrorism, and political unrest, boycotts, curtailment
    of trade, and other business restrictions; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>certain expenses including, among others, expenses for travel, translation and insurance; and </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities
    that may fall within the purview of the U.S. Foreign Corrupt Practices Act its books and records provisions, or its anti-bribery
    provisions. </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any of these factors could significantly harm
our future international expansion and operations and, consequently, our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Commercialization of Our Product Candidates
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have limited manufacturing experience and could experience
production problems that result in delays in our development or commercialization programs or otherwise adversely affect our business.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have limited experience manufacturing D-PLEX<SUB>100</SUB>.
Although we have established our own manufacturing facility to support current and future clinical trials, and have received regulatory
approvals for clinical manufacturing, and an initial commercial launch, we may be unable to produce commercial materials or meet
demand for D-PLEX<SUB>100</SUB> if we are unable to receive or maintain commercial regulatory approvals for our facility. Any such
failure could delay or prevent our development of D-PLEX<SUB>100</SUB> and would have a material adverse effect on our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The manufacturing process we use to produce
D-PLEX<SUB>100</SUB> has not been validated for commercial use. Although we have increased the scale of our manufacturing process
in order to produce sufficient quantities of D-PLEX<SUB>100</SUB> for our ongoing and planned clinical trials and at least the
first 30&nbsp;months following a commercial launch, if D-PLEX<SUB>100</SUB> is approved, in the future we will need to increase
the scale of our manufacturing process either at our facility or at third-party manufacturers, or both. We may not be successful
in producing sufficient quantities of D-PLEX<SUB>100</SUB>, due to several factors, including equipment malfunctions, facility
contamination, technical process challenges, raw material shortages or contamination, natural disasters, disruption in utility
services, human error or disruptions in the operations of our suppliers. Problems with the manufacturing process, even minor deviations
from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls,
product liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical-
and commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable
production yields and costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Slight deviations in the manufacturing process,
including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result
in lot failures or product recalls. There is no assurance we will not experience such failures at our own manufacturing facility
or that of a third party in the future. Lot failures or product recalls could cause us to delay product launches or clinical trials,
which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also may encounter problems hiring and retaining
the experienced specialist scientific, quality control and manufacturing personnel needed to operate our manufacturing process,
which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any problems in our manufacturing process or
facilities could make us a less attractive collaborator for potential partners, including biopharmaceutical companies, which could
limit our access to additional attractive development programs. Problems in our manufacturing process or facilities also could
restrict our ability to meet market demand for D-PLEX<SUB>100</SUB> or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We currently have no marketing and sales organization. If we
are unable to establish sales and marketing capabilities, or enter into agreements with third parties to market and sell our product
candidates, we may be unable to generate any product revenue. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have no experience selling and marketing
our product candidates, and we currently have no marketing or sales organization. To successfully commercialize any product candidates
that may result from our development programs, we will need to develop these capabilities, either on our own or with others. If
our product candidates receive regulatory approval, we intend to establish a sales and marketing organization independently or
by utilizing experienced third parties with technical expertise and supporting distribution capabilities to commercialize our product
candidates in major markets, all of which will be expensive, difficult and time consuming. Any failure or delay in the development
of our internal sales, marketing and distribution capabilities would adversely impact our ability to commercialize our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, given our lack of prior experience
in marketing and selling pharmaceutical products, our initial estimate of the size of the required sales force may be materially
more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we
may be required to hire sales representatives and third party distributors to adequately support the commercialization of our product
candidates, or we may incur excess costs if we hire more sales representatives than necessary. With respect to certain geographical
markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but
we may be unable to enter into such agreements on favorable terms, if at all. We also may enter into collaborations with large
pharmaceutical companies to develop and commercialize product candidates. If our future collaborators do not commit sufficient
resources to develop and commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities
on our own, we will be unable to generate sufficient product revenue to sustain our business. We may compete with companies that
currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party
to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our efforts to educate the medical community,
including physicians, hospital pharmacists and third-party payors on the benefits of our product candidates may require significant
resources and may never be successful. If any of our product candidates are approved but fail to achieve market acceptance among
physicians, patients or third-party payors, we will not be able to generate significant revenues from such product, which could
have a material adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are subject to significant regulatory oversight with respect
to manufacturing our product candidates. Delays in establishing and obtaining regulatory approval of our manufacturing process
and facility or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The preparation of drug products for clinical
trials or commercial sale is subject to extensive regulation. Before we can begin to commercially manufacture D-PLEX<SUB>100</SUB>
or any product candidate, whether in a third-party facility or in our own facility, we must obtain regulatory approvals from the
Israeli Ministry of Health, or MOH, the FDA and similar regulatory agencies, as applicable for our manufacturing process and facility.
A manufacturing authorization must also be obtained from the appropriate regulatory authorities in the European Union and worldwide.
In addition, we must pass a pre-approval inspection of our manufacturing facility by the FDA before D-PLEX<SUB>100</SUB> or any
product candidate can obtain marketing approval. In order to obtain approval, we will need to ensure that all of our processes,
methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If
any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or
disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable
replacement vendors. For example, in the past, a cGMP audit by the MOH of the manufacturing process in the facility of our contract
manufacturer for D-PLEX<SUB>100</SUB> resulted in certain critical observations, which have since been resolved. There can be no
guarantee, however, that future inspections by regulatory authorities of our manufacturing facilities or those of our contract
manufacturers will result in MOH&rsquo;s agreement that these critical observations have been resolved or that similar inspectional observations
will not be identified. If we do not demonstrate to the satisfaction of the applicable regulator that our manufacturing facilities,
or those of our contract manufacturers, are in compliance with applicable requirements, we may be materially delayed in the development
of our product candidates, which would materially harm our business. The cGMP requirements govern quality control of the manufacturing
process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort
in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements.
If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell
any product candidate that we may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our failure to comply with applicable regulations
could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension
or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and
criminal prosecutions, any of which could significantly and adversely affect supplies of any approved products and our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Operating our own manufacturing facility will
require additional investment, will be time-consuming and may be subject to delays, including because of shortage of labor or compliance
with regulatory requirements. In addition, operating a manufacturing facility may cost more than we currently anticipate. Delays
or problems in the build out of our manufacturing facility may adversely impact our ability to provide supply for the development
and commercialization of D-PLEX<SUB>100</SUB> as well as our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we receive marketing approval for our product candidates,
sales will be limited unless the product achieves broad market acceptance by physicians, patients, third-party payors, hospital
pharmacists, infectious disease specialists and others in the medical community. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The commercial success of our product candidates
will depend upon the acceptance of the product by the medical community, including physicians, patients, healthcare payors, hospital
pharmacists and infectious disease specialists. The degree of market acceptance of any approved product will depend on a number
of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in">&#9679;</td>
    <TD>the demonstration of clinical safety and efficacy of our product candidates in clinical trials; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the efficacy, potential and perceived advantages of our product candidates over alternative treatments; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the cost of treatment relative to alternative treatments; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the prevalence and severity of any adverse side effects; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>product labeling or product insert requirements of the FDA or other regulatory authorities, including any limitations
    or warnings contained in a product&rsquo;s approved labeling; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>distribution and use restrictions imposed by the FDA or agreed to by us as part of a mandatory or voluntary risk management
    plan; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>our ability to obtain third-party coverage and adequate reimbursement; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the willingness of patients to pay for drugs out of pocket in the absence of third-party coverage; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the demonstration of the effectiveness of our product candidates in reducing the cost of treatment; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the strength of marketing and distribution support; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the timing of market introduction of competitive products; </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>the availability of products and their ability to meet market demand; and </td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&#9679;</td>
    <TD>publicity concerning our product candidates or competing products and treatments. </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our product candidates are approved but do
not achieve an adequate level of acceptance by physicians, patients, healthcare payors, hospital pharmacists and infectious disease
specialists, we may not generate sufficient revenue from the product, and we may not become or remain profitable. In addition,
our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant
resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>It may be difficult for us to profitably sell our product candidates
if coverage and reimbursement for these products, or the procedures in which they are used, is limited by government authorities
and/or third-party payor policies. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to any healthcare reform measures
which may affect reimbursement, market acceptance and sales of our product candidates, if approved, will depend on, in part, the
extent to which the procedures utilizing our product candidates, performed by health care providers, will be covered by third party
payors, such as government health care programs, commercial insurance and managed care organizations. Our product candidates will
be purchased or provided by health care providers for utilization in certain surgical procedures. In the event health care providers
and patients accept our product candidates as medically useful, cost effective and safe, there is uncertainty regarding whether
our product candidates will be directly reimbursed, reimbursed through a bundled payment or if the product candidates will be included
in another type of value-based reimbursement program. Third party payors determine the extent to which new products or procedures
will be covered as a benefit under their plans and the level of reimbursement for any covered product or procedure which may utilize
a covered product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">When used in connection with surgical and certain
other procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the
payment received by the provider for the procedure only. Treating physicians are unlikely to use and order our products unless
coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which
utilize our products. A decision by a third-party payor not to cover or adequately reimburse for our product candidates or procedures
using our product candidates, could reduce physician utilization of our products once approved. Therefore, coverage and adequate
reimbursement for procedures which utilize new products is critical to the acceptance of such new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A primary trend in the U.S. healthcare industry
and elsewhere has been cost containment, including price controls, restrictions on coverage and reimbursement and requirements
for substitution of less expensive products and procedures. Third party payors decide which products and procedures they will pay
for and establish reimbursement and co-payment levels. Government and other third-party payors are increasingly challenging the
prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in
such procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement.
We cannot be sure that coverage will be available for our product candidates, if approved, or, if coverage is available, the level
of direct or indirect reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expect to experience pricing pressures in
connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence
of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general,
particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly
high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of
any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price
that we may receive for any approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Reimbursement by a third-party payor may depend
upon a number of factors including the third-party payor&rsquo;s determination that use of a product is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">a covered benefit or part of a covered benefit under its health plan; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">safe, effective and medically necessary; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">appropriate for the specific patient; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">cost-effective; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">neither experimental nor investigational. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the United States, third-party payors, including
private and governmental payors such as the Medicare and Medicaid programs, play an important role in determining the extent to
which procedures using new products will be covered and reimbursed. The Medicare and Medicaid programs are increasingly used as
models for how private payors and other governmental payors develop their coverage and reimbursement policies. It is difficult
to predict at this time what third-party payors will decide with respect to reimbursement for fundamentally novel products such
as ours, as there is no body of established practices and precedents for these new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Obtaining coverage and reimbursement approval
for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide
supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Additionally, we may not
be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage
or adequate reimbursement will be available for our product candidates, if approved. Also, we cannot be sure that reimbursement
amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available
only to limited levels, we may not be able to commercialize our product candidates, or achieve profitably at all, even if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our business entails a significant risk of clinical trial and/or
product liability and our ability to obtain sufficient insurance coverage could have a material effect on our business, financial
condition, results of operations or prospects. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business exposes us to significant clinical
trial and/or product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments.
Clinical trial and/or product liability claims could delay or prevent completion of our development programs. If we succeed in
marketing products, product liability claims could result in an FDA investigation of the safety and effectiveness of our products,
our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement
action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless
of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation,
costs to defend the related litigation, a diversion of management&rsquo;s time and our resources, substantial monetary awards to trial
participants or patients and a decline in our company valuation. While we currently have clinical trial liability insurance, we
do not have product liability insurance and do not anticipate obtaining product liability insurance until such time as we have
received FDA or other comparable foreign authority approval for a product and there is a product that is being provided to patients
outside of clinical trials. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities.
In some countries, the institution or the doctors involved do not have sufficient insurance to cover their activities. Furthermore,
clinical trial and product liability insurance are becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance at a reasonable cost to protect us against losses caused by clinical trial and product liability claims that could have
a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Ownership of Our Ordinary Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our executive officers, directors and principal shareholders
will maintain the ability to exert significant control over matters submitted to our shareholders for approval. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 3, 2021, our executive officers,
directors and principal shareholders who own more than 5% of our outstanding Ordinary Shares, in the aggregate, beneficially own
shares representing approximately 23.1% of our share capital. As a result, if these shareholders were to act together, they would
be able to exert significant influence over all matters submitted to our shareholders for approval (including a prospective acquisition
or other change of control of our company), as well as our management and affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be or may become classified as a passive foreign investment
company. If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences
as a result. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Generally, for any taxable year, if at least
75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive
income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment
company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest
gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce
passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares) and
rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct
of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including
having gains realized on the sale of our Ordinary Shares treated as ordinary income, rather than capital gain, the loss of the
preferential rate applicable to dividends received on our Ordinary Shares by individuals who are U.S. holders, and having interest
charges apply to distributions by us and gains from the sales of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our status as a PFIC will depend on the nature and composition
of our income and the nature, composition and value of our assets (which, assuming we are not a &ldquo;controlled foreign corporation,&rdquo;
or a CFC, under Section&nbsp;957(a) of the Internal Revenue Code of 1986, as amended, or the Code, for the year being tested, may
be determined based on the fair market value of each asset, with the value of goodwill and going concern value determined in large
part by reference to the market value of our Ordinary Shares, which may be volatile). Based upon the estimated value of our assets,
including any goodwill, and the nature and estimated composition of our income and assets, we may be classified as a PFIC for the
taxable year ended December&nbsp;31, 2020 and in future taxable years. In particular, so long as we do not generate revenue from
operations for any taxable year and do not receive any research and development grants, or even if we receive a research and development
grant, if such grant does not constitute gross income for United States federal income tax purposes, we likely will be classified
as a PFIC for such taxable year. Because the determination of whether we are a PFIC for any taxable year is a factual determination
made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The tax consequences that would apply if we
are classified as a PFIC would also be different from those described above if a U.S. shareholder were able to make a valid qualified
electing fund, or QEF, election. At this time, we do not expect to provide U.S. shareholders with the information necessary for
a U.S. shareholder to make a QEF election. Prospective investors should assume that a QEF election will not be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If a United States person is treated as owning at least 10% of
our shares, such holder may be subject to adverse U.S. federal income tax consequences. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If a United States person is treated as owning
(directly, indirectly or constructively) at least 10% of the value or voting power of our shares, such person may be treated as
a &ldquo;United States shareholder&rdquo; with respect to each &ldquo;controlled foreign corporation&rdquo; in our group (if any).
Because our group includes one or more U.S. subsidiaries, we expect that certain of our non-U.S. subsidiaries will be treated as
controlled foreign corporations (regardless of whether we are or are not treated as a controlled foreign corporation). A United
States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income
its pro rata share of &ldquo;Subpart&nbsp;F income,&rdquo; &ldquo;global intangible low-taxed income&rdquo; and investments in U.S.
property by controlled foreign corporations, whether or not we make any distributions. An individual that is a United States shareholder
with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that
would be allowed to a United States shareholder that is a U.S. corporation. A failure to comply with these reporting obligations
may subject you to significant monetary penalties and may prevent the statute of limitations with respect to your U.S. federal
income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist
investors in determining whether any of our non-U.S. subsidiaries are treated as a controlled foreign corporation or whether such
investor is treated as a United States shareholder with respect to any of such controlled foreign corporations or furnish to any
United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations.
A United States investor should consult their own advisors regarding the potential application of these rules to its investment
in the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>As a foreign private issuer, we are permitted, and intend, to
follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, and we will not
be subject to certain U.S. securities laws including, but not limited to, U.S. proxy rules and the filing of certain Exchange Act
reports. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a foreign private issuer, we will be permitted,
and intend, to follow certain home country corporate governance practices instead of those otherwise required by the Nasdaq Stock
Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise
apply to a U.S. company listed on The Nasdaq Global Market may provide less protection to you than what is accorded to investors
under the listing rules of Nasdaq applicable to domestic U.S. issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a foreign private issuer, we will be exempt
from the rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act, related to the furnishing and content
of proxy statements, including the applicable compensation disclosure requirements. Nevertheless, pursuant to regulations promulgated
under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation of
our five most highly compensated office holders on an individual basis. Such disclosure will not be as extensive as that required
of a U.S. domestic issuer. Our officers, directors and principal shareholders will also be exempt from the reporting and short-swing
profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange
Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will be exempt from filing quarterly reports with the SEC under the Exchange Act.
Moreover, we will not be required to comply with Regulation&nbsp;FD, which restricts the selective disclosure of material information,
although we intend to voluntarily adopt a corporate disclosure policy substantially similar to Regulation&nbsp;FD. These exemptions
and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible
in relation to a U.S. domestic issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We would lose our foreign private issuer status
if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S. citizens
or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory
and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign
private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the
SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify
certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and
modifications will involve additional costs. In addition, we would lose our ability to rely upon exemptions from certain corporate
governance requirements on U.S. stock exchanges that are available to foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are an emerging growth company and the reduced disclosure
requirements applicable to emerging growth companies may make our Ordinary Shares less attractive to investors. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an emerging growth company, as defined
in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public
companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For as long as we remain an emerging growth
company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public
companies that are not &ldquo;emerging growth companies.&rdquo; These exemptions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Section 107 of the JOBS Act, which provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. This means that an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards. As a result of this adoption, our financial statements may not be comparable to companies that comply with the public company effective date; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">reduced disclosure obligations regarding executive compensation; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will remain an emerging growth company until
the earliest of: (i)&nbsp;the last day of our fiscal year during which we have total annual gross revenues of at least $1.07&nbsp;billion;
(ii)&nbsp;December 31, 2025; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion
in non-convertible debt; or (iv)&nbsp;the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the Exchange
Act. We have opted out of the extended transition period made available to emerging growth companies to comply with newly adopted
public company accounting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">When we are no longer deemed to be an emerging
growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors
will find our Ordinary Shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find
our Ordinary Shares less attractive as a result, there may be a less active trading market for our Ordinary Shares and our share
price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Israeli Law and Our Operations in Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our headquarters and other significant operations are located
in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our executive offices, research and development
laboratories and manufacturing facility are located in Petach Tikva, Israel. In addition, the majority of our key employees, officers
and directors are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable
to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters,
employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted
for any other reason, such an event could delay our clinical trials or, if our product candidates are approved and we choose to
manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective
customers will likely expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are
unable to manufacture an approved product within a timeframe that meets our prospective customers&rsquo; expectations, our business,
prospects, financial results and reputation could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Political, economic and military conditions
in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts
have taken place between Israel and groups in its neighboring countries. In addition, several countries, principally in the Middle
East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli
companies whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities,
political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its
trading partners could adversely affect our operations and results of operations and the market price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our commercial insurance does not cover losses
that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government
is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war,
we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully
for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, our operations could be disrupted by
the obligations of our employees to perform military service. As of March 1, 2021, we had 65 full-time employees based in Israel.
Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36&nbsp;days
per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally,
they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in
the region, there were, at times, call-ups of military reservists, and it is possible that there will be additional call-ups in
the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could
occur and, therefore, harm our business and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our operations are subject to currency and interest rate fluctuations.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although our functional currency is the U.S.
dollar, and our financial records are maintained in U.S. dollars, we also incur expenses in Euros and New Israeli Shekels. In the
future, we expect that a substantial portion of our revenues will be generated in U.S. dollars, Euros and other foreign currencies,
although we currently incur a significant portion of our expenses in currencies other than U.S. dollars, mainly New Israeli Shekels.
As a result, we are affected by foreign currency exchange fluctuations through both translation risk and transaction risk, and
our financial results may be affected by fluctuations in the exchange rates of currencies in the countries in which our prospective
product candidates may be sold. We currently partially hedge our foreign currency exchange rate risk to decrease the risk of financial
exposure from fluctuations in the exchange rates of our principal operating currencies but these hedge agreements may not be sufficient
to fully protect us from the risks related to exchange rate fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We received Israeli government grants for certain of our research
and development activities, the terms of which may require us to pay royalties and to satisfy specified conditions in order to
manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required to
pay penalties and refund grants previously received. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research and development efforts have been
financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount of $5.4&nbsp;million that we received
from the IIA as of March 1, 2021. The last IIA-approved research and development grants ended on December&nbsp;31, 2018. With respect
to the royalty-bearing grants we are committed to pay royalties at a rate of 3.0% on sales proceeds from our products that were
developed under IIA programs up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an annual
rate of LIBOR applicable to U.S. dollar deposits. As of December 31, 2020, our contingent liabilities regarding IIA grants received
by us were in an aggregate amount of $5,139. We are further required to comply with the requirements of the Israeli Encouragement
of Industrial Research, Development and Technological Innovation Law, 5744-1984, as amended, and related regulations, or the Research
Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms of
these grants and the Research Law restrict the transfer or license of such know-how, and the transfer of manufacturing or manufacturing
rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary
approval of an IIA committee would be required for any transfer or license to third parties inside or outside of Israel of know
how or for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects of such technologies.
We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits
us to transfer technology or development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The transfer or license of IIA-supported technology
or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how outside of Israel
may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or know-how,
our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer
our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any
product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving
the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may
be reduced by any amounts that we are required to pay to the IIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Provisions of Israeli law and our amended and restated articles
of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of
control, even when the terms of such a transaction are favorable to us and our shareholders. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Israeli corporate law regulates mergers, requires
tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors,
officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example,
a merger may not be consummated unless at least 50&nbsp;days have passed from the date on which a merger proposal is filed by each
merging company with the Israel Registrar of Companies and at least 30&nbsp;days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must
approve a merger. Moreover, a tender offer for all of a company&rsquo;s issued and outstanding shares can only be completed if the acquirer
receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires
approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation
of the tender offer, the acquirer would hold at least 98% of the Company&rsquo;s outstanding shares. Furthermore, the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender
offer, claim that the consideration for the acquisition of the shares does not reflect their fair market value, and petition an
Israeli court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that
a shareholder that accepts the offer may not seek such appraisal rights, and the acquirer or the company published all required
information with respect to the tender offer prior to the tender offer&rsquo;s response date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Furthermore, Israeli tax considerations may
make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with
Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to
the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but
makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain
restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time
expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede
an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to
our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>It may be difficult to enforce a judgment of a U.S. court against
us and our executive officers and directors in Israel or the United States, to assert U.S. securities laws claims in Israel or
to serve process on our executive officers and directors and these experts. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We were incorporated in Israel. Substantially
all of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets of
these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including
a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States
and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in
the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult
for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts
may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate
forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli
law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also
be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result
of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded
by either a U.S. or foreign court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Your rights and responsibilities as a shareholder will be governed
in key respects by Israeli laws, which differs in some material respects from the rights and responsibilities of shareholders of
U.S. companies. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The rights and responsibilities of the holders
of our Ordinary Shares are governed by our amended and restated articles of association and by Israeli law. These rights and responsibilities
differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder
of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations
towards the company and other shareholders, and to refrain from abusing its power in such company, including, among other things,
in voting at a general meeting of shareholders on matters such as amendments to a company&rsquo;s amended and restated articles of association,
increases in a company&rsquo;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder
approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is
aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent
the appointment of a director or executive officer in the company has a duty of fairness toward the company. However, Israeli law
does not define the substance of this duty of fairness.<FONT STYLE="background-color: white">&nbsp;</FONT>See &ldquo;Item 6.C.
Board Practices&mdash;<FONT STYLE="background-color: white"> </FONT> Duties of Shareholders&rdquo; for additional information.
There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions.
These provisions may be interpreted to impose additional obligations and liabilities on holders of our Ordinary Shares that are
not typically imposed on shareholders of U.S. companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>The market price of our Ordinary Shares
may be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The trading price of our Ordinary Shares is
likely to be volatile. The stock market in general, and the market for pharmaceutical companies in particular, has experienced
extreme volatility that has often been unrelated to the operating performance of particular companies, including very recently
in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding
the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including
potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic,
may negatively affect the market price of our Ordinary Shares, regardless of our actual operating performance. As a result of this
volatility, you may not be able to sell your Ordinary Shares at or above the price you paid. The following factors, in addition
to other risk factors described in this section, may have a significant impact on the market price of our Ordinary Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">inability to obtain the approvals necessary to commence further clinical trials; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">unsatisfactory results of clinical trials; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">announcements of regulatory approvals or the failure to obtain them, or specific label indications or patient populations for their use, or changes or delays in the regulatory review process; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">announcements of therapeutic innovations or new products by us or our competitors; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">changes or developments in laws or regulations applicable to any candidate product in any of our platforms; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">changes in the structure of healthcare payment systems; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">any adverse changes to our relationship with manufacturers or suppliers, especially manufacturers of candidate products; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">any intellectual property infringement actions in which we may become involved; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">announcements concerning our competitors or the pharmaceutical industry in general; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">achievement of expected product sales and profitability or our failure to meet expectations; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">our commencement of, or involvement in, litigation; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">any major changes in our Board of Directors or management; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">legislation in the United States or any other territory relating to the sale or pricing of pharmaceuticals; and</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">coordinated buying or selling activity in our Ordinary Shares, including market manipulation.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our quarterly operating results fall below
the expectations of investors or securities analysts, the price of our Ordinary Shares could decline substantially. Furthermore,
any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe
that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication
of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the past, following periods of volatility
in the market price of a company&rsquo;s securities, securities class-action litigation often has been instituted against that company.
Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&rsquo;s
attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our business and operations would suffer in the event of computer
system failures, cyber attacks or a deficiency in our cybersecurity. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Despite the implementation of security measures
intended to secure our data against impermissible access and to preserve the integrity and confidentiality of our data, our internal
computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural
disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyber attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber
terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around
the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material
disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned
clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, including
under data privacy laws such as the GDPR, damage to our reputation, and the further development of our drug candidates could be
delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our future success depends in part on our ability to retain our
senior management team and to attract, retain and motivate other qualified personnel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are highly dependent on the members of our
senior management team. The loss of their services without a proper replacement may adversely impact the achievement of our objectives.
Our employees may leave our employment at any time. Recruiting and retaining other qualified employees, consultants and advisors
for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage
of skilled personnel in our industry, which is likely to continue for the foreseeable future. As a result, competition for skilled
personnel is intense, and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms
given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to
succeed in preclinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability
to recruit and retain qualified personnel, or the loss of the services of any members of our senior management team without proper
replacement, may impede the progress of our research, development and commercialization objectives. We do not maintain key man
insurance for our senior management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We will continue to incur significant increased costs as a result
of operating as a public company in the United States, and our management will be required to devote substantial time to new compliance
initiatives. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a public company whose Ordinary Shares are
listed in the United States, we are subject to an extensive regulatory regime, requiring us, among other things, to maintain various
internal controls and facilities and to prepare and file periodic and current reports and statements, including reports on the
effectiveness of our internal control over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002.
Complying with these requirements will be costly and time consuming. We will need to retain additional employees to supplement
our current finance staff, and we may not be able to do so in a timely manner, or at all. In the event that we are unable to demonstrate
compliance with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements,
we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or The Nasdaq Global Market, and investors
may lose confidence in our operating results and the price of our Ordinary Shares could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our independent registered public accounting
firm was not engaged to perform an audit of our internal control over financial reporting, and as long as we remain an emerging
growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we will be exempt
from the requirement to have an independent registered public accounting firm perform such audit. Accordingly, no such opinion
was expressed or will be expressed any during any such period. Once we cease to qualify as an emerging growth company our independent
registered public accounting firm will be required to attest to our management&rsquo;s annual assessment of the effectiveness of our
internal controls over financial reporting, which will entail additional costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Furthermore, we are only in the early stages
of determining formally whether our existing internal control over financial reporting systems are compliant with Section&nbsp;404
and whether there are any material weaknesses or significant deficiencies in our existing internal controls. These controls and
other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC
is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and
forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have never paid cash dividends on our share capital, and we
do not anticipate paying any cash dividends in the foreseeable future. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have never declared or paid cash dividends
on our Ordinary Shares. We currently anticipate that we will retain future earnings for the development, operation and expansion
of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital appreciation,
if any, of our Ordinary Shares will be investors&rsquo; sole source of gain for the foreseeable future. In addition, Israeli law limits
our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If securities or industry analysts do not publish or cease publishing
research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative
reports regarding our business or our shares, our share price and trading volume could decline. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The trading market for our Ordinary Shares will
be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or
our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us
or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our shares,
or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in
the financial markets, which in turn could cause our share price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><B><A NAME="aph010402a012"></A>ITEM 4.</B> </TD>
    <TD><FONT STYLE="text-transform: uppercase"><B>INFORMATION ON THE COMPANY</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b><A NAME="aph010402a013"></A>A.</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>History and Development of the Company.</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We were incorporated in the State of Israel
on February 28, 2008. Our Ordinary Shares are currently listed for trading on the Nasdaq Global Market under the symbol &ldquo;PYPD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our principal executive offices are located
at 18 Hasivim Street, Petach Tikva 4959376, Israel. Our telephone number in Israel is+972 (74)&nbsp;719-5700. Our website address
is<I>www.polypid.com</I>. The information contained on our website or available through our website is not incorporated by reference
into and should not be considered a part of this annual report on Form 20-F, and the reference to our website in this annual report
on Form 20-F is an inactive textual reference only. PolyPid Inc. is our agent in the United States, and its address is the Atrium
at 47 Maple Street, Suite 302A, Summit, New Jersey 07901.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an emerging growth company, as defined
in Section 2(a) of the Securities Act, as implemented under the JOBS Act. As such, we are eligible to, and intend to, take advantage
of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies
including but not limited to not being required to comply with the auditor attestation requirements of the SEC rules under Section
404 of the Sarbanes-Oxley Act. We could remain an emerging growth company until the earlier of (1) the last day of the fiscal year
(a) following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration
statement under the Securities Act, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which
we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that is held by non-affiliates
exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible
debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a foreign private issuer as defined by
the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC and certain regulations of the Nasdaq Stock Market, including the proxy rules, the
short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation. In addition, we are not required to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In 2020, 2019 and 2018 our capital expenditures
amounted to $0.8 million, $0.9 million and $3.1 million, respectively. Our current capital expenditures are primarily for manufacturing
facility and equipment, computers, software, research and development equipment and office improvements substantially all in Israel,
and we expect to finance these expenditures primarily from cash on hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b><A NAME="aph010402a014"></A>B.</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Business Overview. </b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a Phase&nbsp;3 clinical-stage biopharmaceutical
company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid
Encapsulation matriX, or PLEX, technology. Our product candidates are designed to address diseases with high unmet medical needs
by pairing our PLEX technology with drugs already approved by the U.S. Food and Drug Administration, or FDA. Our PLEX technology
is designed to deliver drugs directly to precise sites in the body at predetermined release rates and over durations ranging from
several days to several months. We believe that our PLEX technology and product candidates have the potential to cause a major
shift in the management of a wide variety of localized medical conditions, including SSIs, cancer, inflammation and pain. Our lead
product candidate, D-PLEX<SUB>100</SUB>, is in a potentially pivotal Phase&nbsp;3 clinical trial for abdominal (soft) tissue. We
initiated the first of two potentially pivotal Phase&nbsp;3 trials of D-PLEX<SUB>100</SUB>, which we refer to as SHIELD I and SHIELD
II, respectively, for the prevention of abdominal (soft tissue) SSIs, that we initiated in the third and fourth quarters of 2020,
respectively. We expect to report topline results from the first abdominal surgery trial at the end of 2021, and we initiated the
second Phase&nbsp;3 trial in December 2020. The World Health Organization, or WHO, estimates that SSIs result in up to $10&nbsp;billion
of additional hospital costs per year in the United States alone, and a further &euro;11&nbsp;billion per year in the European
Union. We believe that D-PLEX<SUB>100</SUB>, if approved, would be a significant improvement over the current standard of care,
which includes systemic administration of drugs. <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that our PLEX technology has the
potential to address many of the limitations of the current standard of care of systemic administration of drugs, resulting in
significantly improved patient outcomes and lower overall cost of treatment by enabling targeted and local delivery of medications
at predetermined and customizable release rates and duration. The systemic administration of drugs can have significant potential
disadvantages for the treatment of localized medical conditions in the body, including limited efficacy due to poor local drug
concentration, which often requires the use of a considerably higher quantity of drugs over a prolonged period of time and can
result in substantial side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX pairs our novel, proprietary PLEX technology
with doxycycline, a first-line, broad spectrum and FDA-approved antibiotic. In our clinical trials to date, patients treated with
D-PLEX demonstrated a reduction in SSIs compared to patients treated with the standard of care alone. Our lead product candidate,
D-PLEX<SUB>100</SUB>, is in two potentially pivotal Phase&nbsp;3 trials. The SHIELD I clinical trial for the prevention of abdominal
(soft tissue) SSIs was initiated in the third quarter of 2020. The SHIELD II clinical trial, which has broader eligibility criteria,
including minimally invasive surgical procedures, was initiated in the fourth quarter of 2020. We expect to report topline results
from the first trial at the end of 2021. Infections resulting from surgery can be fatal and create a significant public health
burden despite the extensive use of systemically administered antibiotics both pre- and post-operatively and other measures taken
to reduce infection risk in the intra-operative setting. SSIs occur in approximately 2% to 5% of all patients undergoing inpatient
surgery worldwide. The WHO and the Centers for Disease Control and Prevention, or CDC, have recently labeled SSIs as a high priority
unmet medical need due to the associated morbidity, mortality and economic cost burden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In October 2019, we reported topline data from
our Phase&nbsp;2 clinical trial of D-PLEX<SUB>100</SUB> for the prevention of SSIs in patients undergoing abdominal surgery. Patients
treated with D-PLEX<SUB>100</SUB> and the standard of care had a statistically significant reduction of 59% (p=0.0086) in deep
or superficial incisional SSIs or mortality for any reason within 30&nbsp;days of surgery, which was the primary endpoint for the
trial, as compared to patients who received the standard of care alone. In addition, there was a statistically significant difference
(p=0.0290) in patient deaths within 60&nbsp;days of surgery, with no deaths observed in the D-PLEX<SUB>100</SUB> treatment arm,
as compared to five deaths observed in the standard-of-care arm. In this trial, D-PLEX<SUB>100</SUB> was observed to be generally
well tolerated, with no confirmed drug-related serious adverse events, or SAEs, and did not increase wound healing impairment at
the incision site as compared to the control arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In January 2018, we reported data from our Phase&nbsp;1b/2
clinical trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs after cardiac surgery. None of the 58 patients treated
with D-PLEX<SUB>100</SUB> and the standard of care had a sternal infection within 90&nbsp;days post-surgery, which was the primary
endpoint of the trial, as compared to one patient in the group treated with the standard of care alone, representing a 4.3% infection
rate. In this trial, D-PLEX<SUB>100</SUB> was observed to be generally well tolerated, with no drug-related SAEs and no drug-related
wound healing issues at the incision site. The results of this trial were published in the <I>Journal of Cardiac Surgery</I> in
October 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2019, we initiated a potentially
pivotal Phase&nbsp;3 clinical trial of D-PLEX<SUB>100</SUB> for the prevention of sternal (bone) SSIs, and we enrolled the first
patient in February 2020. We expect to enroll an aggregate of between 1,284 and 1,600 cardiac surgery patients in the trial upon
resumption of enrollment. We paused enrollment in this trial in April 2020 in part due to the prioritization of SHIELD I and SHIELD
II trials and in part due to the COVID-19 pandemic, but we have informed investigators that they should continue monitoring currently
enrolled patients per the trial protocol. We anticipate conducting an interim analysis after a total of 850 patients have been
assessed for the presence of at least one sternal wound infection or mortality for any reason within 90&nbsp;days post-surgery.
We are currently prioritizing our SHIELD I and SHIELD II clinical trials, which we believe have the potential to serve as the basis
for an NDA. In February 2020, we held an end of Phase&nbsp;2 meeting with the FDA to discuss our proposed potentially pivotal Phase&nbsp;3
clinical trials of D-PLEX<SUB>100</SUB> for the prevention of abdominal (soft tissue) SSIs. We initiated the first Phase&nbsp;3
trial, SHIELD I, in this indication in July 2020 and the second Phase&nbsp;3 trial, SHIELD II, in December 2020. We expect to report
topline results from SHIELD I at the end of 2021. In addition, following the enrollment of 500 patients, the SHIELD I study design
provides for a blinded sample size re-estimation based on the overall infection rate observed in the study in order to determine
final target enrollment for the study. We intend to pursue a broad label for D-PLEX<SUB>100</SUB> for the prevention of SSIs, the
scope of which will depend on the clinical data generated from our Phase&nbsp;3 clinical trials and discussions with the FDA and
the EMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We intend to seek approval of D-PLEX<SUB>100</SUB>
under Section&nbsp;505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FFDCA, which provides an abbreviated pathway for marketing
approval by the FDA in the United States, and will seek approval under the comparable hybrid application pathway in the European
Union. Such abbreviated approval pathways may not lead to a faster development or review process compared to traditional approval
pathways and do not increase the likelihood that D-PLEX<SUB>100</SUB> will receive regulatory approval in the United States or
the European Union. We received two Qualified Infectious Disease Product, or QIDP, designations from the FDA for D-PLEX<SUB>100</SUB>
for the prevention of post-abdominal surgery incisional infection and for the prevention of sternal wound infection post-cardiac
surgery. The QIDP designation from the FDA confers, among other benefits, a five-year extension to any period of non-patent exclusivity
awarded upon approval, such as a three-year period of exclusivity for new clinical investigations of previously approved products,
which we expect for D-PLEX<SUB>100</SUB>, if approved. Additionally, in November 2018 we received Fast Track Designation from the
FDA for D-PLEX<SUB>100</SUB> for topical use for the prevention of sternal infections post-cardiac surgery, and in August 2020,
we received Fast Track Designation for D-PLEX<SUB>100</SUB> for the prevention of post abdominal surgery incisional infections.
Fast Track Designation could potentially expedite the FDA&rsquo;s review of D-PLEX<SUB>100</SUB> and enables early and frequent communication
with the FDA as we continue to generate data from our ongoing and planned clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In November 2020, we received breakthrough therapy
designation from the FDA for the prevention of SSIs in patients undergoing elective colorectal surgery based on the clinical results
of our Phase 2 trial. The breakthrough therapy designation is granted based on preliminary clinical evidence indicating that the
drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The breakthrough
therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening
condition so patients may have access to therapies through the FDA approval as soon as possible. The breakthrough therapy designation
allows for frequent discussions with the FDA and ensures that a dedicated senior team from the FDA reviews our product filling.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our PLEX technology consists of a proprietary
matrix of several thousand layers of chemically inactive and biocompatible polymers and lipids that physically embed the drug within
the layers. A drug stored within the PLEX layers is released over time in a controlled manner and in customizable, predetermined
amounts at the local site where it is administered. PLEX technology is designed to protect the embedded medication from the natural
enzymes and other biochemicals in the body that would otherwise degrade or alter the drug. Over time, natural hydration in the
body disintegrates the layers of PLEX, from the outer layer to the inner layers, which triggers a release of the medicine in an
unmodified, active form. We believe that these characteristics may enable our PLEX product candidates to be efficacious using only
a small fraction of the medicines required in systemic administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe our PLEX platform technology may
have broad therapeutic application for other localized medical conditions. Because our PLEX technology is designed to be agnostic
to the nature and size of the underlying drug, we believe it has the potential to be paired with a wide variety of currently marketed
drugs or product candidates in development, including small molecules, peptides, antibodies and other proteins, as well as nucleic
acid-based APIs, to create novel therapies in a broad range of locally delivered applications. We are pursuing research and development
programs for our PLEX platform in a variety of other potential indications where we have identified a targeted active pharmaceutical
ingredient, or API, for use with our PLEX technology, including for the treatment of cancer, inflammation and pain. We will consider
licensing rights to our PLEX technology for use with various biologics and small molecules. In addition, we are currently conducting
preclinical studies for OncoPLEX as an intratumoral therapy for the treatment of cancer. OncoPLEX utilizes the Company&rsquo;s
novel PLEX technology to provide prolonged and controlled local exposure to docetaxel, one of the most widely used chemotherapy
agents, in the intra-operative tumor resection setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 1, 2021, we have 96 issued patents,
including utility and composition of matter patents, and four allowed patent applications. Additionally, we have 29 pending patent
applications in the United States, the European Patent Office, Canada, Australia, China, Japan, Israel, Brazil, the Eurasian Patent
Organization, India, Mexico, New Zealand, the Philippines, Singapore, South Korea and Thailand. Our issued patents expire between
2029 and 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Our Pipeline </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>COVID-19 Pandemic </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business has been and will likely further
continue to be adversely affected by the effects of the recent and evolving COVID-19 pandemic, which has resulted in travel and
other restrictions in order to reduce the spread of the disease, including in Israel, the United States and the European Union
where we are conducting clinical trials. We have paused enrollment of our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention
of sternal SSIs in April 2020 in part due to the prioritization of SHIELD I and SHIELD II trials and in part due to the COVID-19
pandemic. We expect to resume enrollment when we believe it is safe to do so and anticipate conducting an interim analysis after
a total of 850&nbsp;patients have been assessed for the presence of at least one sternal wound infection or mortality for any reason
within 90&nbsp;days post-surgery. We see a limited impact of the COVID-19 on our SHIELD I and SHIELD II trials. We expect that
approximately 70% of patients enrolling in these trials are colorectal cancer patients in an urgent need of tumor removal and,
therefore, in high priority to go into surgery. We remain in close contact with our principal investigators and clinical sites
in order to assess the impact of the COVID-19 pandemic on our clinical trials, expected timelines and costs and to consider any
appropriate mitigating measures. Future patient enrollment, when we deem it appropriate, and clinical site initiation may be further
delayed due to prioritization of hospital resources toward the COVID-19 pandemic or challenges in patient enrollment or maintenance
due to quarantines or other interruptions to healthcare services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>State-of-the-Art Manufacturing Facility
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In October 2018, we completed the construction
of an approximately 10,500 square foot, state-of-the-art, sterile manufacturing facility in Israel to enhance supply chain control,
increase our supply capacity and meet clinical demand for our ongoing and planned clinical trials of D-PLEX<SUB>100</SUB>, as
well as for initial commercial demand if D-PLEX<SUB>100</SUB> is approved. The facility is designed to comply with the FDA&rsquo;s
current good manufacturing practice, or cGMP, regulations, and EMA regulations. In 2019, the facility was cGMP certified by Israel&rsquo;s
Ministry of Health, or IMOH, and inspected by a European Union-qualified person, enabling cGMP manufacturing of D-PLEX<SUB>100
</SUB>for our ongoing and planned potentially pivotal Phase&nbsp;3 clinical trials to be conducted in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Our Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our goal is to leverage our PLEX technology
to develop and commercialize a pipeline of potentially transformative therapies for the local and prolonged delivery of drugs to
address diseases with high unmet medical needs. The key elements of our strategy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Successfully complete clinical development of D-PLEX<sub>100</sub> for the prevention of SSIs.</i></b>&nbsp;We have completed a Phase&nbsp;2 clinical trial of D-PLEX<sub>100</sub> for the prevention of abdominal (soft tissue) SSIs after abdominal surgery and a Phase&nbsp;1b/2 clinical trial of D-PLEX<sub>100</sub> for the prevention of sternal (bone) SSIs after cardiac surgery. In February 2020, we enrolled our first patient in our potentially pivotal Phase&nbsp;3 clinical trial for the prevention of SSIs in cardiac surgeries. We have paused enrollment in this trial in part due to the prioritization of SHIELD I and SHIELD II trials and in part due to the COVID-19 pandemic, but we have informed investigators that they should continue monitoring current patients per the trial protocol. In February 2020, we held an end of Phase&nbsp;2 meeting with the FDA to discuss our proposed potentially pivotal Phase&nbsp;3 clinical trials of D-PLEX<sub>100</sub> for the prevention of abdominal (soft tissue) SSIs. Based on the feedback we received from the FDA, we initiated the first Phase&nbsp;3 trial in this indication in the third quarter of 2020 and the second Phase&nbsp;3 trial in the fourth quarter of 2020. We intend to pursue a broad label for D-PLEX<sub>100</sub> for the prevention of SSIs, the scope of which will depend on the clinical data generated from our potentially pivotal Phase&nbsp;3 clinical trials and discussions with the FDA and the EMA. We may also seek regulatory approval of D-PLEX<sub>100</sub> outside of the United States and Europe. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Pursue expedited regulatory pathways for our product candidates.</i></b>&nbsp;We are pursuing expedited pathways to approval for our portfolio
of product candidates. PLEX is paired with unmodified FDA- and/or EMA-approved drugs with established clinical safety, efficacy
and tolerability. Additionally, the polymers and lipids that we use in PLEX have been used in other medical products that have
been approved by the FDA and/or the EMA. Accordingly, we will pursue expedited clinical development and make regulatory submissions
for our product candidates, including D-PLEX<SUB>100</SUB>, that allow us to rely in part on previous findings of safety and efficacy
for the API, including the Section&nbsp;505(b)(2) approval pathway in the United States and the comparable hybrid application pathway
in the European Union. Further, D-PLEX<SUB>100</SUB> has received two QIDP designations from the FDA for the prevention of post-abdominal
surgery incisional infection and sternal wound infection post-cardiac surgery, which will provide an increased level of communication
with the FDA during the development process. We also received the FDA&rsquo;s Fast Track Designation for D-PLEX<SUB>100</SUB> for
topical use for the prevention of post-cardiac surgery sternal infections in November 2018, and in July 2020 for the prevention
of post abdominal surgery incisional infection, which could potentially expedite the FDA&rsquo;s review of our New Drug Application,
or NDA. We obtained breakthrough therapy designation in November 2020 for D-PLEX<SUB>100</SUB> for the prevention of surgical site
infections in patients undergoing elective colorectal surgery.</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Execute on our go-to-market commercial strategy.</i></b>&nbsp;If approved, we intend to launch D-PLEX<sub>100</sub>, and other future product candidates, in the United States using a direct salesforce targeting our primary market of hospitals where major surgeries are undertaken. We are also exploring potential partnering opportunities with leading pharmaceutical companies to maximize our commercial success and launch of any approved products in the United States. We may elect to also partner in parallel in the United States in order to maximize our commercial success and launch of any approved products. We believe that the cost-effectiveness and potential clinical benefits of D-PLEX<sub>100</sub> will support its commercial launch under existing Medicare rates given the associated mortality, morbidity and cost burden of SSIs and the associated penalties imposed on hospital reimbursement from the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. In addition, we believe that there may be opportunities for reimbursement for D-PLEX<sub>100</sub> under CMS programs. Outside of the United States, we intend to find a suitable partner or partners to launch our products in markets where respective commercial coverage is better served through such a partnership. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Expand our product pipeline for additional indications using our PLEX technology.</i></b>&nbsp;In addition to the development of D-PLEX<sub>100</sub> for the prevention of SSIs and OncoPLEX,&nbsp;&nbsp;PLEX has the potential for the prevention or treatment of other important, localized medical conditions. We are currently evaluating PLEX for the treatment of cancer in preclinical studies, and we are pursuing research and development programs for PLEX for the treatment of inflammation and pain. We intend to maximize the commercial potential of PLEX by exploring these additional indications, either independently or through collaborations with other biopharmaceutical companies. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Pursue research collaborations with biopharmaceutical companies.</i></b>&nbsp;We believe that our PLEX technology can be paired with a wide variety of marketed drugs or product candidates, including small molecules, peptides, antibodies and nucleic acid-based drugs. Many leading biopharmaceutical companies have marketed drugs or product candidates in development that have limited efficacy or safety due to systemic delivery and owing to potentially poor drug penetration from the blood stream into the needed organ or other target tissues, or viability for systemic administration due to instability, toxicity and cost. Pairing these drugs or product candidates with PLEX has the potential to address these limitations and potentially extend the drug&rsquo;s clinical benefit and lifecycle before and after patent expiration. We are beginning to engage in discussions with leading biopharmaceutical companies regarding licensing our PLEX technology for potential application in various therapeutic areas, including oncology. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Build a fully integrated biopharmaceutical company utilizing our manufacturing facility.</i></b> Our state-of-the-art, sterile manufacturing facility is cGMP
certified by the IMOH and inspected by a European Union-qualified person, enabling cGMP manufacturing of D-PLEX<SUB>100</SUB> for
our ongoing and planned potentially pivotal Phase&nbsp;3 clinical trials&nbsp;in the United States and Europe. Our manufacturing
facility will serve to enhance supply chain control, increase our supply capacity and meet clinical demand for our ongoing and
planned clinical trials of D-PLEX<SUB>100</SUB>. We estimate that our facility will meet commercial demand for at least the first
30&nbsp;months following a commercial launch of D-PLEX<SUB>100</SUB>, if approved. We intend to use this capacity as the basis
to build a fully integrated biopharmaceutical company, supported by our in-house research and development team and our anticipated
commercial infrastructure. If necessary to meet further commercial demand in the future, we may expand our manufacturing capabilities
or employ third-party contract manufacturing organizations.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>The Problem: Limitations to Current
Drug Delivery Systems </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The systemic administration of drugs may have
significant disadvantages for the treatment of localized medical conditions in the body, including limited efficacy due to poor
penetration from the blood stream into the needed organ or other target tissues and challenges related to sensitivity to blood
factors. This limited efficacy often results in the need to use a significantly higher quantity of drugs over a prolonged period
of time, which can result in substantial side effects. Additionally, systemic administration can be associated with complexities
of drug-drug interactions in the context of polypharmacy for patients with comorbid conditions. In the case of antibiotics, systemic
administration results in challenges related to the emergence of antibiotic resistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Localized delivery of medications for site-specific
conditions may have significant advantages over systemic administration because it has the potential to increase the efficacy and
clinical benefit of the treatment. Localized delivery may also reduce the risk of overall toxicity and adverse side effects, improve
patient compliance and enable a much lower amount of medicine to be used in treatment. In order to address the limitations of systemic
administration to treat localized medical conditions, an effective localized drug delivery system must be able to selectively deliver
the needed medication to the specific target site, ensure the appropriate concentration needed and release the active medication
in a controlled, consistent method over the entire desired treatment period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Existing localized treatments, including extended
release formulations based on polymer-only or lipid-only technologies, such as liposomal-based technologies, frequently suffer
from one or more of the following limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Short release periods.</i></b>&nbsp;An effective regimen to treat serious localized medical conditions, including infections, often needs to span weeks. For example, in the case of post-operative wound management, bacteria have the potential to proliferate in the wound, where blood supply is restricted. Most local delivery systems are able to generate sustained, local concentrations that are effective for only up to several days; however, the post-operative recovery phase may span for a longer period of time. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Lack of controlled drug release rates.</i></b>&nbsp;For a localized delivery system to be effective, it must deliver a non-toxic but adequate and constant dosage of the API to the target site throughout the release period. Current systems, often based only on polymers or only on lipids, have limited ability to control drug release rates. As a result, these systems often release the drug with an initial high burst manner, followed by a rapid decline in the release rate, ultimately generating low local drug concentration. This drug release profile is both less effective than a steadier more controlled delivery approach and may cause safety issues. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Active drug degradation.</i></b>&nbsp;Drugs often need to be isolated from body fluids to prevent rapid degradation and chemical changes to the underlying drug. In order to effectively administer such drugs locally over prolonged periods, the implanted drug reservoir needs to be protected until released, ideally in a non-hydrating form. We are not aware of any biodegradable, localized drug delivery systems in the market that can protect drugs from hydration inside the body over prolonged periods and subsequently release them unaltered in their active forms. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Susceptibility to drug migration.</i></b>&nbsp;Locally administered drugs reservoirs are more effective when they are anchored at the treatment site and unable to move or migrate in the body after application. Many localized delivery systems are susceptible to migration away from the treatment site after application. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Potential chemical modifications to underlying drug.</i></b>&nbsp;Currently developed localized delivery systems can modify or form chemical bonds with the underlying drug, which may alter its mechanism of action, potentially impeding the regulatory process for approval and making development longer and more expensive. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Limited application to different drug types.</i></b>&nbsp;Many localized delivery systems are suited only to a particular drug, or class of drugs, and are therefore limited in their broader clinical scope. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Difficult to use.</i></b>&nbsp;Localized delivery systems may require extensive training in their application and are difficult to use. Improper use can adversely affect the therapeutic benefit and physician acceptance of the product. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These disadvantages are significantly challenging
for the management of SSIs, where the controlled and prolonged local delivery of a drug is likely to be more effective in preventing
and managing an infection than a release profile of an initial high burst of drug over a shorter duration. While we believe that
localized drug delivery systems are well suited for the management of SSIs, it is important for these systems to overcome these
limitations in order to change the treatment paradigm for infection management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These limitations are particularly problematic
in treating infection caused by bacteria that are resistant to currently available treatments, such as methicillin-resistant <I>Staphylococcus
aureus</I>, or MRSA. The inability to generate a sufficiently high local concentration of a drug for an extended period of time
limits the drug&rsquo;s effectiveness in treating antibiotic-resistant bacterial infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Our Solution: PLEX Technology </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our PLEX technology is designed to overcome
the limitations of both systemic administration and current localized delivery systems. PLEX consists of a proprietary matrix of
several thousand alternating layers of chemically-inactive and biocompatible polymers and lipids that physically embed an active
medication in a protected reservoir between the layers. The technology is designed to enable localized drug delivery at customizable,
predetermined release rates and durations directly at the target site over periods ranging from several days to several months.
For example, D-PLEX<SUB>100</SUB> consists of approximately ten thousand layers of biodegradable polymers and lipids. Medications
stored between the PLEX matrix layers are released over time in a controlled manner and in customizable, predetermined amounts
by the gradual disintegration of the layers, from the outer layer to the inner layers. PLEX is designed to protect the embedded
drug from the body&rsquo;s natural hydration and enzymes that would otherwise degrade or alter the underlying drug. Over time, natural
hydration in the body disintegrates the outer layers of PLEX, which triggers release of the drug in an unmodified active form,
similar to continuous direct administration, as illustrated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe PLEX has a number of key design benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Constant, predetermined drug release rates over prolonged periods.</i></b>&nbsp;PLEX enables the pre-designed constant local release of active medication over a customizable, predetermined period to optimize the drug&rsquo;s clinical impact. This localized, targeted delivery is designed to generate effective and non-toxic concentration of the medications to reach clinical benefits not attainable by the systemic route. The release rate and period can be customized to range from a few days to several months based on the number of layers and the disintegration rate of the layers, as illustrated below: </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Direct access to, and penetration of, difficult-to-reach tissue.</i></b>&nbsp;Application of our PLEX product candidates may provide long lasting treatment even in challenging medical conditions or in tissues that are not easily or safely accessible using systemic or topical modalities. This includes surgical sites or other tissues with limited or interrupted blood supply. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Anchored to the treatment site.</i></b>&nbsp;PLEX physically embeds an API in a manner that anchors it to a specific location in the body and allows for administration where the medication is needed. Due to their particle mass, our product candidates have not been observed to move or migrate once applied to the intended treatment site. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Potential for improved drug safety profile.</i></b>&nbsp;Our PLEX product candidates can use a fraction of the medication required in systemic administration of currently marketed therapies, and these medications are physically embedded to minimize exposure to body fluids. Through controlled release, PLEX is designed to generate local concentrations of the needed medication that are therapeutically effective but not toxic. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>No chemical modification required to the embedded drug.</i></b>&nbsp;PLEX embedding does not require any chemical changes to the drug, which we believe will streamline our development process by allowing us to rely in part on prior studies of safety and efficacy and maintain the already proven mechanism of action. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Biocompatible.</i></b>&nbsp;The PLEX matrix gradually disintegrates in the body at predetermined rates, eliminating the need for additional medical procedures to remove the medication reservoir once depleted. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Easy to use.</i></b>&nbsp;D-PLEX<sub>100</sub> is supplied as a sterile powder that can be administered locally as a powder or paste during surgery directly to a variety of tissues and solid organs, as illustrated below. No additional training is required for the surgeon or medical provider. </font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Broad potential applicability.</i></b>&nbsp;Because PLEX is designed to be agnostic to the nature and size of the underlying drug, and no chemical bonds develop between the embedded medication and the PLEX components, we believe PLEX can be used for the improvement of a wide variety of medicines, including small molecules, peptides, proteins and other nucleic acids-based drugs. In our research and development programs, we have paired PLEX with small molecules, proteins, antibodies, peptides, nucleic acids-based drugs and growth factors. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Efficient and scalable manufacturing process.</i></b>&nbsp;Our PLEX product candidates are manufactured using a scalable process with well-defined operations. We believe that this highly specialized and precisely controlled manufacturing process enables us to manufacture product candidates reproducibly and efficiently for clinical and commercial applications. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Benefits of D-PLEX for the Prevention
of SSIs </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Doxycycline received FDA approval in 1967 and
is on the WHO&rsquo;s Essential Medicines List for drugs deemed to be among the safest and most effective for addressing important public
health needs today. Doxycycline has been safely used for decades in millions of patients globally and has the following additional
advantages over many other antibiotics:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">broad spectrum of anti-infective activity against both gram-positive and gram-negative bacteria; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">highly effective against <i>Staphylococcus aureus</i>, one of the most common bacteria associated with SSIs; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">potent against many MRSA strains; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">good tissue and cell penetration. </font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX<SUB>100</SUB> is designed to prevent
SSIs by releasing doxycycline locally to the surgical site at predetermined release rates and durations for up to four weeks. The
plasma concentration of doxycycline following treatment with D-PLEX<SUB>100</SUB> is lower than the plasma concentration following
the commonly used daily dose of orally administered doxycycline. We believe that this prolonged delivery following a single administration
and subsequent high local concentrations of the antibiotic supersedes any existing antibiotic delivery system, and as such may
offer advantages over systemic treatments in the prevention of SSIs, including against many antibiotic-resistant bacterial strains.
We believe that, by combining doxycycline with PLEX, D-PLEX<SUB>100</SUB> has the potential to overcome these limitations and deliver
significant advantages in the prevention of SSIs, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">localized, targeted delivery of an antibiotic at therapeutically effective concentrations for four weeks; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">significantly lower amounts of drug required, which may improve safety and reduce overall toxicity and adverse side effects due to lower systemic exposure; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">applicability to a wide range of bacteria strains that are considered resistant to commonly used antibiotics, including vancomycin-resistant bacteria, MRSA and doxycycline-resistant bacteria; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">increased penetration and access to the site of infection; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">simplicity of administration during surgery that requires no additional training; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">biodegradability of the technology components, such that no further procedures are required to remove the delivery system; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">minimized undesirable changes to the patient&rsquo;s microbiome; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">improved patient compliance. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX<SUB>100</SUB> has the potential to positively
impact the treatment paradigm for SSIs. For example, we have observed in our clinical trials that surgeons applying D-PLEX<SUB>100</SUB>
directly to an open wound during an initial surgery avoided repeated surgical interventions to treat an active infection. Moreover,
because it uses a smaller dose of doxycycline, we believe that D-PLEX<SUB>100</SUB> will not contribute to the growing problem
of antibiotic-resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, we believe D-PLEX<SUB>100</SUB> has
the potential to treat antibiotic-resistant bacterial infections, where the required concentrations of drugs to overcome the infection
cannot be delivered safely via systemic administration. In three investigator-initiated compassionate use cases, patients with
severe bone bacterial infections, including MRSA, were treated with D-PLEX<SUB>100</SUB> or D-PLEX<SUB>1000</SUB>, a predecessor
product candidate to D-PLEX<SUB>100</SUB>. After a single application of D-PLEX, the infection was eradicated in all patients.
In preclinical studies, we also observed that a single application of D-PLEX<SUB>100</SUB> substantially reduced MRSA and vancomycin-resistant
bacterial infections in surgical sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>The Burdens of SSIs </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Hospital acquired infections, or HAIs, are infections
that patients acquire when receiving medical treatment in a healthcare facility. According to the WHO, HAIs are the most frequent
adverse event affecting patient safety worldwide. SSIs are the second most common HAI in both the United States and the European
Union and occur in approximately 2% to 5% of all patients undergoing inpatient surgery worldwide despite accepted antibiotic strategies
intended to prevent infection. However, these figures are likely underestimated for a number of reasons, including surgeon underreporting
and negative reimbursement implications, and because approximately 50% of SSIs become evident only after a patient has been discharged.
Further, the incidence and morbidity of SSIs may differ based on the surgical procedure performed and underlying patient risk factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">SSIs prolong patient recovery and cause a substantial
increase in the clinical and economic burdens of surgery, due to longer hospital stays, as well as increased costs related to diagnostic
tests and management of the infection. Certain patients may require readmission, subsequent surgeries and other interventions,
as well as further outpatient care, due to SSIs. According to the WHO, SSIs account for an estimated $10&nbsp;billion of incremental
hospital costs per year in the United States and &euro;11&nbsp;billion per year in the European Union. Directly attributable costs
of SSIs range from approximately $11,000 to $26,000 per infection. In more complex infections involving a prosthetic joint or an
antimicrobial-resistant organism, the costs per case can exceed $90,000. SSIs are associated with approximately seven to eleven
additional post-operative hospital days, and patients with an SSI have a two to eleven times increased risk of death compared to
infection-free patients. Following discharge from the hospital, SSI patients may also require healthcare from other community care
services, further contributing to the overall economic burden of the infection. The CDC estimates that the financial costs of treating
SSIs will continue to increase, both because more surgeries are being performed and because surgical patients present with increasingly
complex comorbidities. Moreover, in the United States, CMS tracks SSI rates, particularly those following hysterectomies and colorectal
resection surgeries, and are increasingly using these statistics to deny reimbursement claims for certain SSIs or reduce total
annual CMS payments for hospitals that CMS deems to not meet certain quality metrics for the prevention of infection. CMS also
publishes the SSI incidence rate for hospitals, and, consequently, hospitals have economic and reputational, in addition to human,
incentives to prevent SSIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Despite the high incidence of SSIs, a large
proportion of SSIs are estimated to be preventable with the use of evidence-based measures. The prevention of SSIs is complex and
requires the implementation of a range of prevention and treatment approaches before, during and after surgery. Most significantly,
the WHO, CDC and other health organizations recommend the use of systemic and antiseptic measures prior to surgery to help prevent
SSIs; however, systemic administration of antibiotics comes with the risk of further development of antibiotic-resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Health Economic Benefits of D-PLEX<SUB>100</SUB>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that D-PLEX<SUB>100</SUB>, if approved,
may provide significant health economic benefits that play an important role in formulary decision making. Members of our management
team have experience in applying health economic outcomes research to support the launch of successful commercial products. Our
goal is to work directly with hospital customers, group purchasing organizations, integrated health networks, payors, quality improvement
organizations and key opinion leaders in the field of SSI prevention to deliver data showing the potential for demonstrable pharmacoeconomic
benefits from the use of D-PLEX<SUB>100</SUB>, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Reimbursement for surgical procedures is typically
capitated or fixed by third-party payors based on the specific surgical procedure performed. However, for many patients undergoing
high-risk surgeries or those with co-morbidities, the incidence of SSIs remains high, potentially leading to significant healthcare
cost burdens relative to the capitated reimbursement related to prolonged lengths of stay in the hospital, readmissions and additional
surgical and other interventions due to the infection. In addition to the direct cost of SSIs, the prolonged length of stay impacts
the hospital&rsquo;s capacity and its ability to admit new patients. Furthermore, hospitals continue to focus on quality improvements
to reduce SSIs to support optimal reimbursement and reduced penalties under CMS initiatives, such as the Hospital Acquired Condition
Reduction Program, Hospital Readmission Reduction Program and the Hospital Value-Based Purchasing Program. Following discharge
from the hospital, patients with an SSI may also rely on healthcare from other community care services, which further contributes
to the overall economic burden of the infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX<SUB>100</SUB> is designed to be applied
directly to the surgical site during the initial surgery and is intended to prevent SSIs and improve associated mortality and morbidity,
with potential broader healthcare economic benefits by reducing lengths of stay in the hospital, readmissions and additional surgical
and other interventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For example, in our Phase&nbsp;1b/2 clinical
trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs after cardiac surgery, we observed that patients treated with
D-PLEX<SUB>100</SUB> plus the standard of care had a 67% reduction in sternal wound discharge within 90&nbsp;days post-surgery,
as compared to the control arm. We also conducted a post-hoc analysis, which showed an 85% reduction in patients who were treated
with intravenous antibiotics due to sternum wound discharge within 90&nbsp;days post-surgery, as compared to the control arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We intend to complete potentially pivotal Phase&nbsp;3
trials in the abdominal (soft tissue) and sternal (bone) surgery settings. In such trials, we plan to evaluate health economic
outcomes in order to generate further evidence to potentially support approval by the FDA and EMA and, if D-PLEX<SUB>100</SUB>
is approved, broad adoption among healthcare providers and payors. We intend to further support any such data with publications
and post-marketing studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Our D-PLEX<SUB>100</SUB> Market
Opportunity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are initially focused on developing D-PLEX<SUB>100</SUB>
for the prevention of SSIs, where we believe there is a high unmet medical need, especially in surgeries that are at high-risk
for infection or infection-related complications. Further, patients with co-morbidities, including those who are diabetic, obese,
smokers, immunocompromised, aged 60 or over and those who are undergoing surgeries with a longer duration or a longer incision
size, are particularly at risk for SSI-related complications, even if they are not undergoing high-risk surgeries. We believe that
D-PLEX<SUB>100</SUB>, if approved, also has the potential to address the needs of these patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>SSIs in Soft Tissue Surgeries
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">SSIs are one of the most frequent complications
in abdominal surgeries, and they represent a significant cause of mortality and morbidity. SSIs occur in approximately 5% to 30%
of soft tissue surgeries, including approximately 10% to 15% of open abdominal surgeries, which represent the majority of the &ldquo;Selected
Gastrointestinal Surgeries&rdquo; below, approximately 15% to 30% of colorectal surgeries and up to 4% of hysterectomies. Patients
undergoing colorectal surgeries are at particularly high risk of developing SSIs because of the high risk of additional bacterial
contamination originating from the operated gastrointestinal organs. Abdominal SSIs are associated with an average of 18&nbsp;additional
post-operative hospital days. Patients undergoing abdominal surgery and that are subjected to an SSI are at greater risk of additional
complications such as hernias, which can significantly affect health outcomes and require additional corrective surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The table below provides the estimated sizes
of our soft tissue surgery addressable market opportunity in selected gastrointestinal surgeries and selected gynecological and
urologic surgeries in the United States, the EU-5, which, for purposes of the following data, includes France, Germany, Italy,
Spain and the United Kingdom, and the rest of the world, or ROW, which, for purposes of the following data, includes India, China,
Brazil and Japan, based on the number of procedures performed in 2017, according to a study we commissioned from Life Science Intelligence,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Surgeries&nbsp;<BR>
(2017)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; text-align: left">Selected Gastrointestinal Surgeries</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,984,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">EU-5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,816,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">ROW</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,789,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Selected Gynecological and Urologic Surgeries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">United States</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,096,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">EU-5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">720,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">827,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,233,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>SSIs in Bone Surgeries </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the context of cardiac surgeries, SSIs can
occur in 5% to 8% of procedures but carry a mortality rate of up to 40% for deep sternal wound infections, which are more difficult
to treat than superficial infections. Deep sternal wound SSIs are associated with an average of 35 post-operative hospital days,
compared with a mean of 11&nbsp;days for infection-free patients. The cost of care for a patient that develops a deep sternal wound
SSI can be as much as three times greater than the cost of care for an infection-free patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the context of orthopedic surgeries, SSIs
can occur in 0.5% to 4.0% of primary hip, knee and spine surgery and in 10% to 15% of general trauma and open fracture surgery.
Orthopedic SSIs are difficult to treat and associated with lifelong infection recurrence risk of 10% to 20%, including MRSA infections.
Further, bone healing may also be impaired, which can result in disabling complications, including amputation. Orthopedic SSIs
have been estimated to prolong total hospital stay by a median of two weeks per patient, approximately double readmission rates
and increase healthcare costs by more than 300% compared to infection-free patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The table below provides the estimated sizes
of our bone surgery addressable market opportunity in open heart surgeries and selected orthopedic surgeries, including both primary
and revision knee and hip replacements, open fractures and spine fusions, in the United States, the EU-5 and ROW, based on the
number of procedures performed in 2017, according to a study we commissioned from Life Science Intelligence,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Surgeries&nbsp;<BR>
(2017)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; text-align: left">Open Heart Surgeries</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">347,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">EU-5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">ROW</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Selected Orthopedic Surgeries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">United States</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,516,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">EU-5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,922,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,371,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Clinical Development of D-PLEX<SUB>100</SUB>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are currently conducting a potentially pivotal
Phase&nbsp;3 clinical trial of D-PLEX<SUB>100</SUB> for the prevention of SSIs in sternum (bone) surgeries and we also initiated
the first of two potentially pivotal Phase&nbsp;3 trials of D-PLEX<SUB>100</SUB> for the prevention of abdominal (soft tissue)
SSIs in the third quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Completed Clinical Trials of
D-PLEX<SUB>100</SUB> for the Prevention of SSIs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><I>Phase&nbsp;2 Clinical Trial for
D-PLEX</I><SUB>100</SUB><I> in the Prevention of SSIs after Abdominal Surgery </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In October 2019, we reported topline data from
our Phase&nbsp;2 clinical trial of D-PLEX<SUB>100</SUB> for the prevention of superficial and deep incisional SSIs after elective
abdominal colon surgery involving resection. This prospective, multicenter, randomized, controlled, single-blind, two-arm clinical
trial of 201 patients assessed the safety and efficacy of D-PLEX<SUB>100</SUB> with the standard of care, a prophylactic antibiotic
administered intravenously prior to surgery, compared to a standard of care control arm. The primary endpoint was the combination
of incisional SSIs and mortality rate as measured by the number and proportion of subjects with either an SSI event, as determined
by a blinded and independent adjudication committee, or mortality for any reason within 30&nbsp;days post-surgery. All subjects
were followed 60&nbsp;days post-surgery for the assessment of safety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We enrolled 201 patients between the ages of
19 and 92, with a median age of 64, who underwent surgery at eight sites in Israel between October 2018 and August 2019, and 101
patients were randomly assigned to receive D-PLEX<SUB>100</SUB>. Of these patients, 74% underwent surgery for cancer and 13% for
treatment of Crohn&rsquo;s disease, and 65% of the surgeries were minimally invasive (laparoscopies) and 35% were open surgeries (laparotomies).
The treatment and control arms were balanced across patient baseline characteristics such as age, sex and BMI, reason for the surgery
and type of surgery performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Patients treated with D-PLEX<SUB>100</SUB> had
a statistically significant reduction of 59% (p=0.0086) in deep or superficial incisional SSIs or mortality for any reason within
30&nbsp;days of surgery, which was the primary endpoint for the trial, as compared to patients who received the standard of care
as illustrated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">*</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">A result is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. The conventional method for determining the statistical significance of a result is known as the &ldquo;p-value,&rdquo; which represents the probability that random chance caused the result (e.g.,&nbsp;a p-value&nbsp;=&nbsp;0.01 means that there is a 1% probability that the difference between the control group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, in the 179 patients who completed
the trial without any major protocol deviations, patients treated with D-PLEX<SUB>100</SUB> achieved a statistically significant
reduction of 69% (p=0.0024) in the primary endpoint events of deep or superficial incisional SSIs or mortality for any reason within
30&nbsp;days of surgery as compared to patients who received the standard of care, as illustrated below. Two patients in the control
arm developed deep SSIs, as compared to no patients in the treatment arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, there was a statistically significant
difference (p=0.0290) in patient deaths within 60&nbsp;days of surgery, with no deaths observed in the D-PLEX<SUB>100</SUB> treatment
arm as compared to five deaths observed in the standard-of-care arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX<SUB>100</SUB> was observed to be generally
well tolerated, with no confirmed drug-related SAEs, and did not increase wound healing impairment at the incision site as compared
to the control arm. There were eight treatment emergent adverse events, or TEAEs, in eight patients treated with D-PLEX<SUB>100</SUB>
that were determined by the blinded investigator to be possibly drug-related, as illustrated below, versus 18&nbsp;TEAEs observed
in 13 patients in the control arm. Patients in the treatment arm also had 15 post-operative wound infection AEs, as compared to
23 in the control arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>D-PLEX<SUB>100</SUB></B><br> <B>Arm&nbsp;(N=99)</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Control&nbsp;Arm<BR> (N=100)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Total Number of Possibly-Related TEAEs</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">8</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">18</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Number of Patients with at Least One Possibly-Related TEAE</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><B>8 (8.0</B></TD><TD STYLE="font-weight: bold; text-align: left"><B>)%</B></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><B>13&nbsp;(13.1</B></TD><TD STYLE="font-weight: bold; text-align: left"><B>)%</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">General disorders and administration site conditions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4 (4.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3 (3.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Infections and infestations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2 (2.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10 (10.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Injury, poisoning and procedural complications</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1 (1.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0 (0.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Nervous system disorders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0 (0.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1 (1.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Skin and subcutaneous tissue disorders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0 (0.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2 (2.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Surgical and medical procedures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1 (1.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0 (0.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Vascular disorders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0 (0.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1 (1.0</TD><TD STYLE="text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, patients in both the treatment arm
and the control arm had a 4% rate of wound healing impairment, suggesting that D-PLEX<SUB>100</SUB> did not increase wound healing
impairment. We also evaluated patients using the ASEPSIS scale, a common method of assessing wound healing based on the need for
additional treatment, the presence of serious discharge, skin redness and/or drainage, the separation of deep tissue, the isolation
of bacteria and the duration of inpatient stay. Patients treated with D-PLEX<SUB>100</SUB> had lower average and cumulative ASEPSIS
assessment scores than patients in the control arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">More than 70% of the bacteria strains isolated
from patients&rsquo; SSIs were resistant to more than one type of commonly used antibiotics, with more than 60% considered multidrug
resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Patient pharmacokinetic data collected from
treated patients showed evidence of D-PLEX<SUB>100</SUB>-released doxycycline for approximately 30&nbsp;days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><I>Phase&nbsp;1b/2 Clinical Trial for
D-PLEX</I><SUB>100</SUB><I> in the Prevention of Sternal SSIs after Cardiac Surgery </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In January 2018, we reported data from our Phase&nbsp;1b/2
clinical trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs in patients undergoing cardiac surgery through median
sternotomy. This two-part trial was conducted in 81 patients at four sites in Israel, with a six-month safety follow-up period.
An independent, blinded adjudication committee reviewed all patients with an SSI as identified by the principal investigator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The first part was an open label, single arm
trial of 20 patients who received D-PLEX<SUB>100</SUB> together with the standard of care, which generally consists of a systemic
antibiotic given within one hour prior to surgery. Based on feedback from the FDA, the second part of the clinical trial was designed
as a randomized and single-blinded trial of 61 patients, divided in a two-to-one ratio between treatment and control arms. This
trial was not powered for statistical significance. One arm received D-PLEX<SUB>100</SUB> and the standard of care, and the second
arm received the standard of care alone. One patient randomized to the standard-of-care arm received D-PLEX<SUB>100</SUB>, and
two patients randomized to the D-PLEX<SUB>100</SUB> treatment group did not receive the study drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None of the 58 patients treated with D-PLEX<SUB>100</SUB>
and the standard of care had a sternal infection within 90&nbsp;days post-surgery, which was the primary endpoint of the trial,
as compared to one patient in the group treated with the standard of care alone, representing 4.3% infection rate. According to
recent literature, the expected infection rate for patients receiving the standard of care alone is 5% to 8%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In patients treated with D-PLEX<SUB>100</SUB>
plus the standard of care, we observed a 67% reduction in the number of patients with sternal wound discharge within 90&nbsp;days
post-surgery, as compared to the control arm. We also conducted a post-hoc analysis, which showed an 85% reduction in patients
who were treated with intravenous antibiotics due to sternum wound discharge within 90&nbsp;days post-surgery, as compared to the
control arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">D-PLEX<SUB>100</SUB> was observed to be generally
well tolerated, with no drug-related SAEs and no drug-related wound healing issues at the incision site. Patient pharmacokinetic
data collected from treated patients showed evidence of D-PLEX<SUB>100</SUB>-released doxycycline for approximately 30&nbsp;days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Phase&nbsp;3 Clinical Trials
of D-PLEX<SUB>100</SUB> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><I>Phase&nbsp;3 Clinical Trial for
the Prevention of SSIs after Abdominal Surgery </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Following our end of Phase&nbsp;2 meeting with
the FDA in February 2020, we initiated two potentially pivotal Phase&nbsp;3 clinical trials of D-PLEX<SUB>100</SUB> for the prevention
of SSIs after abdominal surgery. We initiated the first Phase&nbsp;3 trial (SHIELD I) in this indication in the third quarter of
2020, and we expect to report topline results from this trial at the end of 2021. We also initiated the second Phase&nbsp;3 trial
(SHIELD II) in December 2020. Both trials are designed to be prospective, multinational, multicenter, randomized, controlled, two-arm,
double-blinded trials to evaluate the efficacy and safety of D-PLEX<SUB>100</SUB> in combination with the standard of care, which
includes a prophylactic antibiotic administered prior to surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We initiated the first trial in Israel, with
additional sites in the United States and Europe, and anticipate enrolling between 616 and 900 patients, aged 18&nbsp;years and
older at screening, undergoing an elective colorectal surgery involving colon or rectal resection and with at least one incision
measuring greater than 10&nbsp;centimeters. Following the enrollment of 500 patients, the SHIELD I study design provides for a
blinded sample size re-estimation based on the overall infection rate observed in the study in order to determine final target
enrollment for the study. The second Phase&nbsp;3 trial (SHIELD II) is expected to enroll between 900 and 1,400 patients, aged
18&nbsp;years and older at screening, undergoing an elective colorectal surgery involving colon or rectal resection, with or without
a stoma, and with at least one incision measuring greater than seven centimeters, at sites in the United States, Europe and Israel.
The population for both trials is similar to the population evaluated in the Phase&nbsp;2 trial. Eligible patients in each trial
will be randomly allocated into two blinded arms to receive either D-PLEX<SUB>100</SUB> in combination with the standard of care
or the standard of care alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The primary endpoint of the trial is the combination
of incisional SSIs and mortality rate as measured by the proportion of subjects with either an SSIs event, as determined by a blinded
and independent adjudication committee, or mortality for any reason within 30 days post-surgery. Among the secondary endpoints,
we will evaluate health economic endpoints, including but not limited to the overall number of hospitalization days post-surgery,
number of re-admissions due to SSIs and number of antibiotic treatment days post-surgery. We will assess safety as evaluated by
adverse events, within 60&nbsp;days post-surgery, as well as incisional wound healing as assessed by a blinded investigator using
a visual examination and the modified Vancouver Scar Scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><I>Phase&nbsp;3 Clinical Trial for
the Prevention of Sternal SSIs after Cardiac Surgery </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2019, we initiated a potentially
pivotal Phase&nbsp;3 clinical trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs after cardiac surgery, and we enrolled
the first patient in February&nbsp;2020. We have paused enrollment in this trial in part due to the prioritization of SHIELD I
and SHIELD II trials and in part due to the COVID-19 pandemic, but we have informed investigators that they should continue monitoring
current patients per the trial protocol. We expect to resume enrollment when we believe it is safe to do so and anticipate conducting
an interim analysis after a total of 850 patients have been assessed for the presence of at least one sternal wound infection or
mortality for any reason within 90 days post-surgery. This trial is a prospective, multinational, multicenter, randomized, two-arm,
single-blinded trial to evaluate the efficacy and safety of D-PLEX<SUB>100</SUB> in combination with the standard of care, which
is a prophylactic antibiotic administered prior to surgery. We plan to run an adaptive design clinical trial and expect to enroll
between 1,284 and 1,600 patients, aged&nbsp;18 years and older, undergoing median sternotomy in cardiac surgery, with additional
SSI-related comorbidities, such as diabetes and abnormal body mass index, at sites in the United States, Europe and Israel. Eligible
patients will be randomly allocated into two arms to receive either D-PLEX<SUB>100</SUB> in combination with the standard of care
or the standard of care alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The primary efficacy endpoint for this clinical
trial is the infection rate as measured by the proportion of patients with at least one sternal wound infection event, including
deep and superficial sternal wound infections, as determined by a blinded and independent adjudication committee, or mortality
for any reason within 90&nbsp;days post-surgery. Among the secondary endpoints we will evaluate are health economic endpoints,
including but not limited to the overall number of hospitalization days post-surgery due to sternal infection, number of antibiotic
treatment days post-surgery and number of surgical interventions due to SSI within 90&nbsp;days post-surgery. We will also evaluate
safety for six months post-surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expect to conduct an interim analysis of
data from the clinical trial after a total of 850 patients have been assessed for the presence of at least one sternal wound infection
or mortality for any reason within 90&nbsp;days post-surgery. We have agreed on an initial Pediatric Study Plan with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are currently prioritizing our SHIELD I and
SHIELD II clinical trials, which we believe have the potential to serve as the basis for an NDA. We are currently evaluating next
clinical steps for an open-heart surgery Phase 3 trial, while we ensure that the SHIELD I and SHIELD II trials continue to progress
as planned, and intend to submit the bone surgery data as a supplement after the approval of the NDA for abdominal soft tissue
surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Additional Clinical Data in Support
of D-PLEX<SUB>100</SUB> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We completed a clinical trial of the safety
and efficacy of D-PLEX<SUB>1000</SUB>, a predecessor product candidate to D-PLEX<SUB>100</SUB>, for the prevention of infection
in contaminated bone following open tibia fractures in 51 patients. Given that D-PLEX<SUB>1000</SUB> is another product candidate
from the D-PLEX family, we believe these clinical trial results may also be relevant to the clinical development profile of D-PLEX<SUB>100</SUB>.
At the six-month follow-up period, patients treated with D-PLEX<SUB>1000</SUB> with the standard of care had no infections or infection-related
bone morbidities, including non-union of the bone, following surgery, as compared to 11.1% of the patients treated only with the
standard of care. D-PLEX<SUB>1000</SUB> was observed to be generally well tolerated, with no drug-related AEs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also conducted two pilot clinical trials
of D-PLEX<SUB>1000</SUB> in a total of 19&nbsp;patients with infected open long bone fractures. In these trials, patients treated
with D-PLEX<SUB>1000</SUB> with the standard of care had no bone infections at the treatment site in the six months following treatment.
In contrast, according to recent literature the expected infection rate for patients receiving the standard of care alone is 7%
to 19%. Additionally, at the six-month follow up date, no deaths, amputations or drug-related SAEs were observed in the treatment
arms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We do not plan to pursue further independent
development of D-PLEX<SUB>1000</SUB>, as we believe the prevention of SSIs in the orthopedic market can be adequately addressed
by D-PLEX<SUB>100</SUB>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>OncoPLEX - Preclinical Development
Program for Cancer </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2020, we announced positive preclinical
data from our new OncoPLEX intra-tumoral cancer therapy program. OncoPLEX utilizes our PLEX technology in the intra-operative tumor
resection setting to provide prolonged and controlled exposure to docetaxel, one of the most widely used chemotherapy agents, within
the tumor resected site, which is important to prevent the local tumor reoccurrence and the potential spreading of cancer cells.
In a syngeneic mouse model for solid tumors of colon carcinoma using cancer cells highly resistant to docetaxel, a single local
application of OncoPLEX at the intra-operative setting post tumor resection showed improved overall survival and significantly
less tumor recurrence, and reduced systemic toxicity compared to the group treated with six subsequent cycles of systemic docetaxel
treatment with 2-4 days gap between cycles. We intend to complete an IND package with additional preclinical studies in various
solid tumor types, followed by the initiation of a Phase 1 clinical trial in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Future Development of PLEX in other
Medical Applications </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our PLEX platform technology may have broad
applications for other localized medical conditions other than the prevention of SSIs. We have conducted research and development
for our PLEX platform in a variety of potential indications, including for the treatment of infection, cancer, inflammation and
pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>PLEX for Other Applications </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In our research and development programs, we
have paired PLEX with small molecules, proteins, antibodies, peptides, nucleic acids-based drugs and growth factors. We continue
to evaluate these research and development programs for potential development by us or in collaboration with leading biopharmaceutical
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Competition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The biopharmaceutical industry is intensely
competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced
companies that have significant competitive advantages over us, such as greater financial, research and development, manufacturing,
personnel and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals
from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target
or seek to have existing drugs approved for use in the indications that we target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These potential competitors may therefore introduce
competing products without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial
launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability
of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis,
products that are more effective, easier to administer or less costly than our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The current standard of care for preventing
SSIs involves the implementation of a range of treatment and prevention measures before, during and after surgery, including prophylactic
antibiotic administration, antiseptic measures and wound care. We anticipate that D-PLEX<SUB>100</SUB>, if approved, could be used
as a complementary part of many surgical protocols, rather than competitive, in addition to the current standard of care for the
prevention of SSIs. In addition, we are aware of other approved treatments that can be applied locally during surgery for the prevention
of SSIs, including triclosan-coated antiseptic sutures, negative wound pressure therapy, the CleanCision wound retraction and protection
system and a resorbable gentamicin-collagen sponge, which is approved in the European Union and Canada. In orthopedic surgeries,
we are aware of approved treatments for localized SSI prevention that pair bone cement or bone graft substitutes premixed with
an antibiotic. Further, we are aware of prior clinical development of a vaccine against <I>Staphylococcus aureus</I> that was halted
due to lack of efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may also face competition from companies
that are developing localized extended release delivery systems, including, among others, Pacira Pharmaceuticals,&nbsp;Inc., Heron
Therapeutics,&nbsp;Inc., Urogen Pharma&nbsp;Ltd., Flexion Therapeutics,&nbsp;Inc. and LIDDS AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Manufacturing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our PLEX product candidates are manufactured
using a scalable self-assembly process with well-defined operations. This highly specialized and precisely controlled process
enables us to manufacture product candidates consistently and efficiently for clinical and commercial applications. We have constructed
a state-of-the-art, sterile manufacturing facility that is designed to be cGMP compliant for the production of our product candidates
adjacent to our administrative headquarters in Petach Tikva, Israel. The manufacturing facility is cGMP certified by the IMOH
and inspected by a European Union-qualified person, enabling cGMP manufacturing of D-PLEX<SUB>100</SUB> for our ongoing and planned
potentially pivotal Phase&nbsp;3 clinical trials to be conducted in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We estimate that our facility will meet commercial
demand for at least the first 30&nbsp;months following a commercial launch of D-PLEX<SUB>100</SUB>, if approved. We intend to use
this capacity as the basis to build a fully integrated biopharmaceutical company, supported by our in-house research and development
team and our anticipated commercial infrastructure. We have already started planning expansion of our manufacturing capabilities
or employment of third-party contract manufacturing organizations to meet further commercial demand in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, we rely on third parties as needed
for the supply of certain raw materials necessary to manufacture our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Marketing, Sales and Distribution
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Given our current stage of development, we have
limited internal marketing, sales and distribution capabilities. We have established a wholly-owned United States subsidiary, PolyPid&nbsp;Inc.,
a Delaware corporation with operations in New Jersey, to support our potential commercialization efforts in the United States and
our clinical development program. We would intend to launch D-PLEX<SUB>100</SUB> and any future product candidates in the United
States following the FDA approval using a direct salesforce targeting our primary market of hospitals where major surgeries are
undertaken. We may elect to also partner in parallel in the United States in order to maximize our commercial success and launch
of any approved products. We believe that the potential clinical and economic benefits of D-PLEX<SUB>100</SUB> will support its
commercial launch under existing Medicare rates given the associated mortality, morbidity and cost burden of SSIs and the associated
penalties imposed on hospital reimbursement from CMS. In addition, we believe that there may be opportunities for reimbursement
of D-PLEX<SUB>100</SUB> under CMS programs. Outside the United States, we intend, where appropriate, to pursue commercialization
relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners that are
equipped to market or sell our products through their well-developed sales, marketing and distribution organizations in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we may out-license some or all
of our patent rights to more than one party to achieve the fullest development, marketing and distribution of any products we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Intellectual Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our patent estate includes patents and patent
applications with claims directed to our PLEX technology platform, D-PLEX<SUB>100</SUB> product candidate and claims for potential
future product candidates. As of March 1, 2021, our patent estate includes 96 issued patents, including utility and composition
of matter patents, two allowed patent applications and 29 pending patent applications for our product candidates, manufacturing
processes and methods of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our patents and patent applications primarily
relate to a polymer-lipid-based platform for sustained release of an active pharmaceutical agent at a target site. We have 35 issued
patents, and two pending patent applications in various countries worldwide related to compositions for sustained release of an
API, including a lipid-saturated matrix formed from a biodegradable polymer, as well as methods for producing such compositions
and methods of treatment through the use of such compositions. We also have 17 issued patents and one pending patent application
in various countries worldwide related to compositions for sustained release of an API including a lipid-saturated matrix formed
from a non-biodegradable polymer, as well as methods for producing such compositions and methods of treatment through the use of
such compositions. We also have 12 issued patents in various countries worldwide related to compositions for sustained release
of a nucleic agent including a lipid-saturated matrix formed from a biodegradable polymer, as well as methods for producing such
compositions and methods of treatment through the use of such compositions. We also have an issued Australian patent related to
compositions for sustained release of peptidic molecules, as well as methods for producing such compositions and methods of treatment
through the use of such compositions. We also have 23 issued patents, ed and four pending patent applications in various countries
worldwide related to methods for treating bone fractures through the use of biocompatible fillers coated with sustained release
antibiotic compositions, along with seven issued patents, one patent application that has been allowed and eight pending patent
applications in various countries worldwide related to methods for treating peri-implantitis and one issued patent, one allowed
patent application and several pending patent applications in various countries worldwide related to methods for preventing and
treating SSIs through similar processes. Our patent estate includes 10 issued United States patents as well as issued patents and/or
pending patent applications in Australia, Brazil, Canada, China, the Eurasian Patent Organization, the European Patent Office,
India, Israel, Japan, Mexico, New Zealand, the Philippines, Singapore, South Africa, South Korea, Thailand and the United States.
Our issued patents are expected to remain in effect between 2029 and 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to patents, we have two registered
trademarks. &ldquo;BonyPid&rdquo; which is registered with the United States Patent and Trademark Office, or the USPTO, with the
European Union Intellectual Property Office and with the Israeli Patent Office, and &ldquo;PolyPid&rdquo; which is registered with
the USPTO, with the Israeli Patent Office and with the following European Union countries: Benelux, France, Germany, Spain, Austria,
Italy, the United Kingdom, Ireland and Portugal. Furthermore, we rely upon trade secrets, know-how and continuing technological
innovation to develop and maintain our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Preparing and filing patent applications is
a joint endeavor of our research and development team and our in-house and external patent attorneys. Our patent attorneys conduct
patent prior-art searches and then analyze the data in order to provide our research and development team with recommendations
on a routine basis. This results in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">protecting our product candidates that are under development; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">encouraging pharmaceutical companies to negotiate development agreements with us; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">preventing competitors from attempting to design-around our inventions. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We initially submit applications to the USPTO
as provisional patent applications. Then typically we continue by filing non-provisional patent applications under the Patent Cooperation
Treaty, or the PCT, which is an international patent law treaty that provides a unified procedure for filing a single initial patent
application to later seek patent protection for an invention in any number of the member states of the PCT. Although a PCT application
does not itself issue as a patent, it acts as a placeholder allowing the applicant to seek protection in any of the member states
through national-phase applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Government Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA and comparable regulatory agencies in
state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacturing
and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development
activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking,
approval, import, export, distribution, advertising and promotion of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>U.S. Government Regulation of
Drug Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the United States, the FDA regulates drugs
under the FFDCA and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with
applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&rsquo;s refusal
to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The process required by the FDA before product
candidates may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">submission of an investigational new drug application, or IND, which must become effective before clinical trials may begin; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">submission to the FDA of an NDA and payment of user fees; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">satisfactory completion of an FDA advisory committee review, if applicable; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and good clinical practices, or GCPs; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">FDA approval of an NDA to permit commercial marketing for particular indications for use; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The testing and approval process requires substantial
time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology,
toxicity and drug product formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the
first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature,
together with manufacturing information, analytical data and any available clinical data or literature, among other things, to
the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes
effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions
about the conduct of the clinical trial by imposing a clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence
a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Clinical trials involve the administration of
the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements.
A separate submission to the existing IND must be made for each successive clinical trial conducted during product development,
as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct
the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications
to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it
is being conducted, including any changes to the study plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Regulatory authorities, an IRB or the sponsor
may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed
to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&rsquo;s or the IRB&rsquo;s requirements,
if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or competitive
climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical
trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In general, for purposes of NDA approval, human
clinical trials are typically conducted in three sequential phases that may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Phase&nbsp;1&mdash;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase&nbsp;1 clinical trials may also be used to gain an initial indication of product effectiveness. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Phase&nbsp;2&mdash;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase&nbsp;2 clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase&nbsp;3 clinical trials. </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Phase&nbsp;3&mdash;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done globally to support global registrations so long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called Phase&nbsp;4 studies may be made a condition to be satisfied
after approval. The results of Phase&nbsp;4 studies can confirm the effectiveness of a product candidate and can provide important
safety information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Clinical trials must be conducted under the
supervision of qualified investigators in accordance with GCP requirements, which includes the requirements that all research subjects
provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study
by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial
disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial,
the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical
analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted
within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The manufacture of investigational drugs for
the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients
imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further,
the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving
country as well as U.S. export requirements under the FFDCA. Progress reports detailing the results of the clinical trials must
be submitted at least annually to the FDA and the IRB and more frequently if serious adverse effects occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Concurrent with clinical trials, companies usually
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally,
appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate
does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Orange Book Listing </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In seeking approval for a drug through an NDA,
including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&rsquo;s product. Upon
approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products with
Therapeutic Equivalence Evaluations, also known as the Orange Book.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any applicant who files&nbsp;a 505(b)(2) NDA
referencing a drug listed in the Orange Book must certify to the FDA (1)&nbsp;that no patent information on the drug product that
is the subject of the application has been submitted to the FDA; (2)&nbsp;that such patent has expired; (3)&nbsp;the date on which
such patent expires; or (4)&nbsp;that such patent is invalid or will not be infringed upon by the manufacture, use or sale of the
drug product for which the application is submitted. This last certification is known as a Paragraph&nbsp;IV certification. Generally,
the 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the 505(b)(2) NDA applicant challenges
a listed patent through a Paragraph&nbsp;IV certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the applicant has provided a Paragraph&nbsp;IV
certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the holder of the NDA for
the reference listed drug and the patent owner once the application has been accepted for filing by the FDA. The applicant may
also elect to submit a &ldquo;section&nbsp;viii&rdquo; statement certifying that its proposed label does not contain (or carves out)
any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. The NDA holder or patent
owner may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing
of a patent infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;IV certification prevents the FDA from
approving the application until the earlier of 30&nbsp;months from the date of the lawsuit, expiration of the patent, settlement
of the lawsuit, a decision in the infringement case that is favorable to the applicant or such shorter or longer period as may
be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where a 505(b)(2) NDA applicant
files&nbsp;a Paragraph&nbsp;IV certification, the NDA holder or patent owner regularly take action to trigger the 30-month stay,
recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of a 505(b)(2) NDA could
be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&rsquo;s
decision to initiate patent litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Exclusivity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA provides periods of non-patent regulatory
exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation
represented by its approved drug for a period of three or five years following the FDA&rsquo;s approval of the NDA. Five years of exclusivity
are available to new chemical entities, or NCEs. An NCE is a drug that contains no active moiety that has been approved by the
FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the
drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing
of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction of two compounds),
chelate (<I>i.e.</I>, a chemical compound), or clathrate (<I>i.e.</I>, a polymer framework that traps molecules), of the molecule,
responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review
or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously
approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if
a Paragraph&nbsp;IV certification is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If a product is not eligible for the NCE exclusivity,
it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA, including a 505(b)(2)
NDA, if one or more new clinical trials, other than bioavailability or bioequivalence trials, was essential to the approval of
the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval
of ANDAs and 505(b)(2) NDAs for the particular condition of the new drug&rsquo;s approval or the change to a marketed product, such as
a new formulation for a previously approved drug. Five-year and three-year exclusivity will not delay the submission or approval
of a 505(b)(1) NDA; however, an applicant submitting a 505(b)(1) NDA would be required to conduct or obtain a right of reference
to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, under the GAIN Act, which was enacted
as part of the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law in July 2012, the FDA
may designate a product as a QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal drug
for human use intended to treat serious or life-threatening infections, including those caused by either (1)&nbsp;an antibiotic
or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2)&nbsp;a so-called &ldquo;qualifying pathogen&rdquo;
found on a list of potentially dangerous, drug-resistant organisms to established and maintained by the FDA. A sponsor must request
such designation before submitting a marketing application. We obtained QIDP designations for D-PLEX<SUB>100</SUB> for the prevention
of post-abdominal surgery incisional infection and the prevention of post-cardiac surgery sternal infection. Upon approving a marketing
application for a QIDP-designated product, the FDA will extend by an additional five years any non-patent marketing exclusivity
period awarded, such as a three-year exclusivity period awarded for new clinical investigations of previously approved products.
This extension is in addition to any pediatric exclusivity extension awarded, and the extension will be awarded only to a drug
first approved on or after the date of enactment of the GAIN Act. The GAIN Act prohibits the grant of an exclusivity extension
where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application
for a specified change to an approved product, or is an application for a product that does not meet the definition of QIDP based
on the uses for which it is ultimately approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Hatch Waxman Amendments and the
505(b)(2) Regulatory Approval Process </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Section&nbsp;505 of the FFDCA describes three
types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section&nbsp;505(b)(1)
NDA is an application that contains full reports of investigations of safety and efficacy. A Section&nbsp;505(b)(2) NDA is an application
that contains full reports of investigations of safety and efficacy, but where at least some of the information required for approval
comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right
of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&rsquo;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application. Specifically, the applicant may rely upon the FDA&rsquo;s prior findings of safety and efficacy for an approved product
that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform
additional studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new product
candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new
indication sought by the 505(b)(2) applicant. Lastly, the FDA permits marketing applications through Section&nbsp;505(j), which
establishes an abbreviated approval process for a generic version of approved drug products through the submission of an ANDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">An ANDA provides for marketing of a generic
drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics
and intended use, among other things, to a previously approved product. ANDAs are termed &ldquo;abbreviated&rdquo; because they are
generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic
applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator
drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a
subject&rsquo;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions
written for the reference listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Special FDA Expedited Review
and Approval Programs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA has various programs, including fast
track designation, breakthrough therapy designation, accelerated approval, and priority review, which are intended to expedite
or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening
diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide
important new drugs to patients earlier than under standard FDA review procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the fast track program, the sponsor of
a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent
with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine,
based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates
the potential to address an unmet medical need, or that the drug qualifies as a QIDP under the GAIN Act. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be
potentially superior to existing therapy based on efficacy or safety factors. We obtained a Fast Track designation in November
2018 for D-PLEX<SUB>100</SUB> for the prevention of post-cardiac surgery sternal infection and in July 2020 for the prevention
of post abdominal surgery incisional infection. Fast track designation provides additional opportunities for interaction with the
FDA&rsquo;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor
provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. However,
the FDA&rsquo;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA
may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, a sponsor can request breakthrough
therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening
disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
We obtained breakthrough therapy designation in November 2020 for D-PLEX<SUB>100</SUB> for the for the prevention of SSIs in patients
undergoing elective colorectal surgery. Drugs designated as breakthrough therapies are eligible for intensive guidance from the
FDA on an efficient drug development program, organizational commitment to the development and review of the product including
involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track
and breakthrough therapy products are also eligible for accelerated approval and/or priority review, if relevant criteria are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the FDA&rsquo;s accelerated approval regulations,
the FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit to patients over
existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing
compliance requirements, including the completion of Phase&nbsp;4 or post approval clinical trials to confirm the effect on the
clinical endpoint. Failure to conduct required post approval studies, or confirm a clinical benefit during post marketing studies,
will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved
under accelerated approval regulations are subject to prior review by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Once an NDA is submitted for a product intended
to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product, if approved,
would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review
an application is six months, rather than the standard review of ten months under current The Prescription Drug User Fee Act, or
PDUFA, guidelines. Under the current PDUFA agreement, these six and ten months review periods are measured from the 60-day filing
date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline
for review from the date of submission. Most products that are eligible for fast track breakthrough therapy designation are also
likely to be considered appropriate to receive a priority review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if a product qualifies for one or more
of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the
time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious
or life threatening disease is required to make available, such as by posting on its website, its policy on responding to requests
for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review
do not change the standards for approval and may not ultimately expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>NDA Submission and Review by
the FDA </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Assuming successful completion of the required
clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture and controls,
nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission
of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the time of the first submission
of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some
circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including
employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or
delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, under the Pediatric Research Equity
Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration
must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA may, on its own initiative or at the
request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for
use in adults or full or partial waivers from the pediatric data requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA must refer applications for drugs that
contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the
FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee.
The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory
committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to
whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA reviews applications to determine, among
other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate
to assure and preserve the product&rsquo;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the
facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the
manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA,
the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Once the FDA receives an application, it has
60&nbsp;days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the
application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA&rsquo;s NDA
review times may differ based on whether the application is a standard review or priority review application. The FDA may give
a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the
safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to
by the FDA under PDUFA, the FDA has set the review goal of 10&nbsp;months from the 60-day filing date to complete its initial review
of a standard NDA for a new molecular entity, or NME, and make a decision on the application. For non-NME standard applications,
the FDA has set the review goal of 10&nbsp;months from the date that the FDA receives the application to complete its initial review
and to make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs
within six months of the 60-day filing date and non-NME applications within six months of the date that the FDA receives the application.
Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates.
The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional
information or clarification regarding the submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Once the FDA&rsquo;s review of the application is
complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle
of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific
conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing,
or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application
resubmissions in either two or six months of the date that the FDA receives the application, depending on the kind of resubmission.
Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA may issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA may delay or refuse approval of an NDA
if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing
and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or
other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or following approval to mitigate
any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a
product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs.
After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional
labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new
safety information arise, additional testing, product labeling or FDA notification may be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If regulatory approval of a product is granted,
such approval may entail limitations on the indicated uses for which such product may be marketed or may include contraindications,
warnings or precautions in the product labeling, which has resulted in a Black Box warning. A Black Box warning is the strictest
warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence of an association
of a serious hazard with the drug. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing.
Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not
maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase&nbsp;4 post-marketing
studies to monitor the effect of approved products, and may limit further marketing of the product based on the results of these
post-marketing studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Post-approval Requirements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any products manufactured or distributed by
us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product
sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed
as a conditional of approval such as Phase&nbsp;4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements,
including adverse experiences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After approval, most changes to the approved
product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing,
annual user fee requirements for any approved products and the establishments at which such products are manufactured, as well
as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required
to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic
announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which
impose procedural and documentation requirements upon us and our third-party manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Changes to the manufacturing process are strictly
regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also require investigation
and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor
and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time,
money and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Later discovery of previously unknown problems
with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new
safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition
of distribution or other restrictions under a REMS program, among other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FDA closely regulates the marketing and
promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved
by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses
that are not described in the product&rsquo;s labeling and that differ from those tested by us and approved by the FDA. We, however,
are prohibited from marketing or promoting drugs for uses outside of the approved labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the distribution of prescription
pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution
of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors
by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements
to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of pharmaceutical
products related to product and tracking and tracing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Failure to comply with any of the FDA&rsquo;s requirements
could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such
as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical
hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials
or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension
of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government
contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution,
disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with
the FDA&rsquo;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal
and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result
in adverse publicity, among other adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Other Healthcare Regulations
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business activities, including but not limited to, research,
sales, promotion, distribution, medical education and other activities are subject to regulation by numerous regulatory and law
enforcement authorities in the United States in addition to the FDA, including the Department of Justice, the HHS and its various
divisions, including CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department
of Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations,
including those described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The federal Anti-Kickback Statute prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration,
directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual
for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements
between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. The
term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory
safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require
strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure
to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct
per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case
basis based on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care
Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent
requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer
needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the
statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for
purposes of the federal civil False Claims Act, or FCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The federal civil and criminal false claims
laws, including the FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented,
a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid programs, or knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease
or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and
Recovery Act of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S. government.
In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if
they are deemed to &ldquo;cause&rdquo; the submission of false or fraudulent claims. The FCA also permits a private individual acting
as a &ldquo;whistleblower&rdquo; to bring actions on behalf of the federal government alleging violations of the FCA and to share
in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for
treble damages and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated pharmaceutical
companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing
free products to customers with the expectation that the customers would bill federal programs for the products; providing consulting
fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &ldquo;off-label&rdquo; uses;
and submitting inflated best price information to the Medicaid Rebate Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a condition of receiving Medicaid coverage
for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their Average Manufacturer
Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple
source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part&nbsp;B, to also calculate and report
their average sales price, which is used to determine the Medicare Part&nbsp;B payment rate for the drug. In January 2016, CMS
issued a final rule regarding the Medicaid Drug Rebate Program, or MDRP, effective April&nbsp;1, 2016, that, among other things,
revised the manner in which the AMP is calculated by manufacturers participating in the program and implemented certain amendments
to the Medicaid rebate statute created under the ACA. In addition, the MDRP requires pharmaceutical manufacturers to enter into
and have in effect a National Drug Rebate Agreement, or NDRA, with the Secretary of HHS as a condition for states to receive federal
matching funds for the manufacturer&rsquo;s outpatient drugs furnished to Medicaid patients. On March&nbsp;23, 2018, CMS finalized updates
to the NDRA, or the Updated NDRA, to incorporate a number legislative and regulatory changes, including changes to align with certain
provisions of the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Drugs that are approved under a biologics license
application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the
manufacturer&rsquo;s best price for the drug and inflation penalties which can substantially increase rebate payments. For BLA and NDA
drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a different
price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than
a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers
to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting
false pricing information to the government creates potential federal False Claims Act liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">HIPAA created additional federal criminal statutes
that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private,
knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation
of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device a material
fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare
benefits, items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of some of these
criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific
intent to violate it, to have committed a violation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, the federal Open Payments program
pursuant to the Physician Payments Sunshine Act, created under Section&nbsp;6002 of the ACA and its implementing regulations, requires
some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&rsquo;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)and
teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals
and to report annually specified ownership and investment interests held by physicians and their immediate family members. Beginning
in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided
during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants,
certified nurse anesthetists and certified nurse midwives. Failure to submit timely, accurately and completely the required information
for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we may be subject to data privacy
and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements
relating to the privacy, security and transmission of individually identifiable health information held by covered entities and
their business associates. Among other things, HITECH makes HIPAA&rsquo;s security standards directly applicable to business associates,
defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information
in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties,
amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo;
fees and costs associated with pursuing federal civil actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many states have also adopted laws similar to
each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical
sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of
which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Ensuring that our internal operations and business
arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that
governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or
case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations were found to be in violation
of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal
and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations
and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance
with these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians
or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they
may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Coverage and Reimbursement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our ability to commercialize any products successfully
will also depend in part on the extent to which coverage and adequate reimbursement for the procedures utilizing our product candidates,
performed by health care providers, once approved, will be available from government health administration authorities, private
health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and
health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and
establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product, by a third-party payor,
the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.
Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party
payors to reimburse all or part of the costs associated with the procedures which utilize our products. When used in connection
with surgical and certain other procedures, our product candidates may not be reimbursed separately but their cost may instead
be bundled as part of the payment received by the provider for the procedure only. Treating physicians are unlikely to use and
order our products unless coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost
of the procedures which utilize our products. A decision by a third-party payor not to cover or adequately reimburse for our product
candidates or procedures using our product candidates, could reduce physician utilization of our products once approved. Therefore,
coverage and adequate reimbursement for procedures which utilize new products is critical to the acceptance of such new products.
Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost
therapeutic alternatives are already available or subsequently become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Government authorities and other third-party
payors are developing increasingly sophisticated methods of cost containment, such as including price controls, restrictions on
coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government and other third-party
payors are increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness
of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting to
limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists
among third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement
of newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement
can differ significantly from payor to payor and health care provider to health care provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We cannot be sure that coverage and reimbursement
will be available for any product that we commercialize, or the procedures which utilize such product, and, if reimbursement is
available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any
product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available
only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Healthcare Reform Measures </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The United States and some non-U.S. jurisdictions
are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system. Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For example, the pharmaceutical industry in
the United States has been affected by the passage of ACA, which, among other things: imposed new fees on entities that manufacture
or import certain branded prescription drugs; expanded pharmaceutical manufacturer obligations to provide discounts and rebates
to certain government programs; implemented a licensure framework for follow-on biologic products; expanded health care fraud and
abuse laws; revised the methodology by which rebates owed by manufacturers to the state and federal government under the Medicaid
Drug Rebate Program are calculated for certain drugs and biologics, including products that are inhaled, infused, instilled, implanted
or injected; imposed an additional rebate similar to an inflation penalty on new formulations of drugs; extended the Medicaid Drug
Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; expanded the 340B
program which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics
and community health centers; and provided incentives to programs that increase the federal government&rsquo;s comparative effectiveness
research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There have been executive, judicial and Congressional challenges
to certain aspects of the ACA. For example, President Trump has signed several Executive Orders and other directives designed to
delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance
mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While
Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the
ACA have been signed into law. The Tax Act includes a provision repealing, effective January&nbsp;1, 2019, the tax-based shared
responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &ldquo;individual mandate&rdquo;. Additionally, the 2020 federal spending package
permanently eliminated, effective January&nbsp;1, 2020, the ACA-mandated &ldquo;Cadillac&rdquo; tax on high-cost employer-sponsored
health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminated the health insurer tax. Further, the
Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&nbsp;1, 2019, to increase from
50&nbsp;percent to 70&nbsp;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare
Part&nbsp;D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &ldquo;donut hole&rdquo;. On
December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress as part of the Tax Act. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th&nbsp;Circuit
upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court
to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing
this case, but it is unknown when a decision will be reached. Although the Supreme Court has not yet ruled on the constitutionality
of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February
15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order
also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies
that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how
the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the
ACA and our business. It is unclear the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden
administration will impact the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other legislative changes have been proposed
and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things,
included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year, which went into effect in April 2013,
and due to subsequent legislative amendments, including the BBA, will remain in effect through 2030, unless additional U.S. Congressional
action is taken. COVID-19 relief legislation suspended the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2021.
In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things,
reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. Additionally, the Medicare Access and CHIP Reauthorization
Act of 2015, or MACRA, ended the use of the statutory formula for clinician payment and established a quality payment incentive
program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including
through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019,
CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact to overall physician
reimbursement as a result of the introduction of the Quality Payment Program remains unclear. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, there has been particular and increasing
legislative and enforcement interest in the United States with respect to drug pricing practices in recent years, particularly
with respect to drugs that have been subject to relatively large price increases over relatively short time periods. Specifically,
there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, reduce the cost of prescription drugs under Medicare and reform government program reimbursement methodologies for pharmaceutical
products. The Trump administration used several means to propose or implement drug pricing reform, including through federal budget
proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration
announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&rsquo;s
proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive
order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020,
HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors
under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation
of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation.
The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed
pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing
President Trump&rsquo;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered
drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United
States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final
rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.
In addition, individual states in the United States have become increasingly active in passing legislation and implementing regulations
designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In the future, there will likely continue to be proposals relating to the reform of the
U.S. healthcare system, some of which could further limit coverage and reimbursement of products. It is possible that additional
governmental action is taken in response to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>The Foreign Corrupt Practices
Act </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Foreign Corrupt Practices Act, or FCPA,
prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly
or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the
foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies
whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books
and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to
devise and maintain an adequate system of internal accounting controls for international operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Non-U.S. Government Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To the extent that any of our product candidates,
once approved, are sold in a country outside of the United States, we will be subject to similar foreign laws and regulations,
which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws
and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In order to market our future products in the
EEA (which is comprised of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein) and many other foreign
jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized
after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union; and </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the above described procedures, before
granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance
of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Data and Marketing Exclusivity
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the EEA, new products authorized for marketing,
or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing
authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical
trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization
in the European Union during a period of eight years from the date on which the reference product was first authorized in the European
Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in
the European Union until 10&nbsp;years have elapsed from the initial authorization of the reference product in the European Union.
The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&nbsp;years,
the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific
evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B><I>Pediatric Investigation Plan
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the EEA, marketing authorization applications
for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance
with a pediatric investigation plan, or PIP, agreed with the EMA&rsquo;s Pediatric Committee, or PDCO. The PIP sets out the timing and
measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought.
The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient
data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial
data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or
unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product
does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization
is obtained in all Member States of the European Union and study results are included in the product information, even when negative,
the product is eligible for six months&rsquo; supplementary protection certificate extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><B>Environmental, Health and Safety
Matters </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to extensive environmental, health
and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among other things: the use, storage,
registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals, air, water and ground contamination;
air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure to
properly dispose of chemicals, waste materials and sewage. Our operations use chemicals and produce waste materials and sewage
and require permits from various governmental authorities including, local municipal authorities, the Ministry of Environmental
Protection and the Ministry of Health. The Ministry of Environmental Protection and the MOH, local authorities and the municipal
water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations.
These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation.
If we fail to comply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal
sanctions, including the revocation of permits and licenses necessary to continue our business activities. In addition, we may
be required to pay damages or civil judgments in respect of third-party claims, including those relating to personal injury (including
exposure to hazardous substances we use, store, handle, transport, manufacture or dispose of), property damage or contribution
claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless
of comparative fault. We may be identified as a responsible party under such laws. Such developments could have a material adverse
effect on our business, financial condition and results of operations. In addition, laws and regulations relating to environmental,
health and safety matters are often subject to change. In the event of any changes or new laws or regulations, we could be subject
to new compliance measures or to penalties for activities that were previously permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b><A NAME="aph010402a015"></A>C.</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Organizational Structure. </b>&nbsp;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently have two wholly owned subsidiaries:
PolyPid&nbsp;Inc., a Delaware corporation with operations in New Jersey, and PolyPid Pharma SRL, a company organized under the
laws of Romania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b><A NAME="aph010402a016"></A>D.</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Property, Plant and Equipment. </b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our principal executive offices are located
at 18 Hasivim Street, Petach Tikva 4959376, Israel, where we lease an approximately 33,500 square foot facility. This Israeli facility
houses our administrative headquarters, research and development laboratories and state-of-the-art manufacturing facility. Our
monthly rent payment is NIS 206,768 (approximately $64,300).&nbsp;We also maintain an office at 47 Maple Street, Suite&nbsp;302A,
Summit, New Jersey, which serves as the headquarters for our wholly-owned subsidiary PolyPid Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><B><A NAME="aph010402a017"></A>ITEM 4A.</B> </TD>
    <TD><B>UNRESOLVED STAFF COMMENTS</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a018"></A>ITEM 5.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a019"></A>A.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating Results.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and
the related notes included elsewhere in this annual report on Form 20-F. The discussion below contains forward-looking statements
that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ
materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those
identified in &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; and under &ldquo;Risk Factors&rdquo; elsewhere
in this annual report on Form 20-F. Our discussion and analysis for the year ended December 31, 2018 can be found in our prospectus
dated <A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003886/a2241965z424b4.htm">June 25, 2020</A>, filed with the SEC on June 29, 2020. (Registration No. 333-238978).</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception in 2008, we have incurred
significant operating losses. Our operating loss for the years ended December&nbsp;31, 2019 and 2020 were $18.6&nbsp;million and
$26.3&nbsp;million, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of $132.3&nbsp;million. We expect
to continue to incur significant expenses and operating losses for the foreseeable future, and our losses may fluctuate significantly
from year to year. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue clinical development of D-PLEX<SUB>100</SUB>, including our ongoing Phase&nbsp;3 clinical trials for the prevention of SSIs in abdominal surgeries and post-cardiac sternal surgeries; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">file NDAs seeking regulatory approval for D-PLEX<SUB>100</SUB> pursuant to the FDA&rsquo;s Section&nbsp;505(b)(2) regulatory pathway in the United States and the hybrid application pathway in the European Union; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to invest in the preclinical research and development of any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to invest in our manufacturing facility and complete commercial process validation for the facility; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a commercial infrastructure to support the marketing, sale and distribution of D-PLEX<SUB>100</SUB> if it receives regulatory approval; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional research and development and general and administrative personnel to support our operations; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect our intellectual property portfolio; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional costs associated with operating as a public company following the completion of this offering. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not have any product candidates approved
for sale and have not generated any revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 30, 2020, we closed our initial
public offering, or IPO, whereby we sold 4,312,500 Ordinary Shares to the public (inclusive of 562,500 Ordinary Shares pursuant
to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by us from the
IPO were $62.8 million, net of underwriting discounts and other offering costs. Prior to our IPO, we financed our operations primarily
through private placements of equity securities and convertible debt, as well as grants from the Israel Innovation Authority, or
IIA, and the European Commission&rsquo;s Seventh Framework Programme for Research, or FP7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operating Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our current operating
expenses consist of three components&nbsp;&mdash;&nbsp;research and development expenses, marketing and business and development
expenses and general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Revenue</I></B></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have not generated any revenue
from product sales and do not expect to generate any revenue from product sales for at least the next several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Research and Development,
Net </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development, net consists
primarily of costs incurred in connection with our research and development activities. This includes conducting clinical trials
and preclinical studies, manufacturing development efforts and activities related to regulatory filings for product candidates,
as well as overhead costs. Our research and development expenses primarily consist of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries and personnel-related costs, including benefits and share-based compensation expense, for our scientific personnel for executing clinical trials, preclinical studies, regulatory activities and for performing research and development activities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to executing clinical trials and preclinical studies; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to acquiring, developing and manufacturing materials for such clinical trials and preclinical studies, including costs related to chemical, manufacturing and control, or CMC, activities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to our manufacturing facility, including the production of development batches; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of third-party suppliers; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees paid to consultants and other third parties who support the development of our product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to regulatory activities, including consulting fees, filing fees paid to regulatory agencies and other costs incurred in seeking regulatory approval of our product candidates; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocated facility-related costs and other related overhead costs. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are expensed
as incurred. We record accrued expenses for research and development activities conducted, on our behalf, by third-party service
providers, which include the performance of clinical trials and the conduct of preclinical studies and contract manufacturing activities.
We record these accrued expenses based upon research and development activities performed by such third-party service providers
and reported to us, and we include these costs in accrued liabilities in the consolidated balance sheets and within research and
development expense in the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We typically use our employee, consultant
and infrastructure resources across our development programs. We track outsourced development costs by product candidate but we
do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or preclinical
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From inception though December&nbsp;31,
2020, we incurred $76.9&nbsp;million in research and development expenses, net to advance the development of our clinical-stage
product candidates, as well as other preclinical research and development programs. As of December 31, 2020, we received royalty-bearing
grants of $5.1&nbsp;million in the aggregate from the IIA. Pursuant to the terms of the grants, we are required to pay royalties
of 3.0% to the IIA on revenues from sales of products for which the research and development was funded, in whole or in part, by
the IIA, up to a limit of 100% of the amount of the grant received, plus annual interest calculated at a rate based on 12-month
LIBOR. In addition, we must abide by other restrictions associated with the receipt of such grants under the R&amp;D Law that continues
to apply following repayment to IIA. These restrictions may impair our ability to outsource manufacturing, engage in change of
control transactions or otherwise transfer our knowledge outside of Israel and may require us to obtain IIA approval for certain
actions and transactions and pay additional amounts to the IIA. In addition, any change of control and any change of ownership
of our Ordinary Shares that would make a non-Israel citizen or resident an &ldquo;interested party&rdquo; as defined in the R&amp;D
Law requires prior written notice from the IIA. As of December&nbsp;31, 2020, we also received non-royalty bearing grants of $0.3&nbsp;million
in the aggregate from the IIA and $0.7&nbsp;million in the aggregate from the FP7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantially all of our research and development
expenses for the years ended December&nbsp;31, 2019 and 2020 were related to the development of D-PLEX<SUB>100</SUB>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our research and development
expenses will increase for the foreseeable future as we seek to advance D-PLEX<SUB>100</SUB> through Phase&nbsp;3 clinical trials,
including the cost of manufacturing drug supply for these clinical trials, further our preclinical studies and other research and
development programs. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts
that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material
net cash inflows will commence from sales of our product candidates. This is due to the numerous risks and uncertainties associated
with developing such product candidates, including the uncertainty of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrolment in and completion of clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing an appropriate safety profile; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt of marketing approvals from applicable regulatory authorities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued acceptable safety profiles of products following approval; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key research and development personnel. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our expenses may also increase if we encounter
further delays or setbacks in the enrolment or conduct of our clinical trials for D-PLEX<SUB>100</SUB> due to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A change in the outcome of any of these
variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability
associated with the development of that product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>General and Administrative
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses consist
primarily of salaries and personnel-related expenses, including benefits and share-based compensation expense, for employees performing
functions other than research and development. This includes personnel in executive, finance and administrative support functions.
Other general and administrative expenses include directors and officer&rsquo;s insurance, professional fees for auditing, tax and legal
services and other consulting fees, as well as facility-related costs not otherwise allocated to research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our general and administrative
expenses will increase in the future to support continued research and development activities. We expect increased expenses if
any of our product candidates receives regulatory approval and we determine to build a commercial infrastructure to support commercial
sales and marketing of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Marketing and Business and
Development </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing and business and development
expenses consist primarily of salaries and personnel-related expenses, including benefits and share-based compensation expense.
Other marketing and business and development expenses include professional fees and pre-commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our marketing and business development
expenses will increase if any of our product candidates receives regulatory approval and we determine to build a commercial infrastructure
to support commercial sales and marketing of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Financial Expense (Income),
Net </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial expense (income), net consists
of revaluation of our preferred share warrant liability, as well as interest income on our short-term and long-term deposits and
our foreign exchange gains and losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Comparison of the Year Ended
December&nbsp;31, 2019 and 2020 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our results
of operations for the year ended December&nbsp;31, 2019 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31, </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019 </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020 </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, net</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,083</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,954</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and business development expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">887</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,614</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,590</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,704</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,560</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,272</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial (income) expense, net</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; border-bottom: rgb(51,51,51) 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: #333333 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,655</FONT></TD>
    <TD>)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; border-bottom: rgb(51,51,51) 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: #333333 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,597</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,905</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,869</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed dividend </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(51,51,51) 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(51,51,51) 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: rgb(51,51,51) 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,114</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to ordinary shares</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #333333 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: #333333 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,905</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #333333 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: #333333 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,983</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Research and Development, Net
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development, net increased
by $2.9 million for the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2019. This increase was
primarily related to an increase of $1.4&nbsp;million in costs related to the initiation of SHIELD I and SHIELD II Phase 3 clinical
trials in abdominal surgery, an increase of $1.6 million in non-cash share-based compensation and an increase of $0.9 million in
personnel costs. These increases were offset by a decrease of $1.0&nbsp;million in pre-clinical costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Marketing and business development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing and business development expenses
increased by $0.7&nbsp;million for the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2019. This
increase was primarily related to increases of $0.3&nbsp;million in personnel costs and $0.4&nbsp;million in pre-commercialization
activities for the product candidate DPLEX100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>General and Administrative </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative increased by
$4.1&nbsp;million for the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2019. This increase was
primarily related to increases of $1.9 million in non-cash share-based compensation, $1.3 million in directors and officer&rsquo;s insurance
premiums, $0.5&nbsp;million in personnel costs and $0.4&nbsp;million in legal, professional and other costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Financial Expense (Income),
Net </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial expense (income), net increased
by $22.3&nbsp;million for the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2019. This increase
was driven by non-cash revaluation of our convertible preferred share warrant liability following the increase in fair value of
warrants issued in a series of private placements prior to the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Deemed dividend </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of Series E-1 Convertible Preferred
shares price protection conversion rights upon the completion of an initial public offering, the Company issued 158,967 Series
E-1 Convertible Preferred shares and recorded a beneficial feature of $2.1 million, which was accounted for as a deemed dividend
and was recorded as mezzanine equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Net Loss Attributable to Ordinary
Shares </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net loss attributable to ordinary shares
increased by $32.1&nbsp;million for the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2019. This
increase was primarily related to the increase in non-cash financial expense, net of $22.3&nbsp;million, the increase in general
and administrative of $4.1&nbsp;million, the increase in research and development, net of $2.9 million and the increase of marketing
and business development costs of $0.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Off-Balance Sheet Arrangements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not have any relationships with unconsolidated
entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities
that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange
traded contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Critical Accounting Policies
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements are
prepared in accordance with accepted accounting principles generally accepted in the United States. The preparation of our consolidated
financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities,
costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable
under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these
estimates. Our most critical accounting policies are summarized below. See note&nbsp;2 to our consolidated financial statements
beginning on page&nbsp;F-1 of this annual report on Form 20-F for a description of our other significant accounting policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Share-Based Compensation
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for share-based compensation
in accordance with ASC No.&nbsp;718, &ldquo;Compensation&mdash;Stock Compensation,&rdquo; which requires companies to estimate the
fair value of equity-based payment awards on the date of grant using the option-pricing model, or OPM. We recognize compensation
expenses for the value of our awards granted based on the straight-line attribution method over the requisite service period of
each of the awards. We recognize forfeitures of awards as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize compensation costs only for
those shares expected to vest using the straight-line method over the requisite service period of the award, which is generally
the option vesting term of three years. We recognize forfeitures of awards as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Option Valuations </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We selected the Black-Scholes-Merton model
as the most appropriate fair value method for our option awards. The Black-Scholes-Merton model requires a number of assumptions,
of which the most significant are the share price, volatility and the expected option term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Key Assumptions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Black-Scholes-Merton option-pricing
model requires the input of highly subjective assumptions, including the fair value of the underlying ordinary shares, the expected
volatility of the price of our ordinary shares, the expected term of the option, risk-free interest rates and the expected dividend
yield of our ordinary shares. These estimates involve inherent uncertainties and the application of the management&rsquo;s judgment.
If such inputs change and different assumptions are used, our share-based compensation expenses could be materially different in
the future. These assumptions are estimated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Fair Value of Ordinary Shares- Prior to the IPO, the fair
value was determined by the Company&rsquo;s board of directors, with input from management and valuation reports prepared by third-party
valuation specialists. After the IPO, the fair value of each ordinary share was based on the closing price of the Company&rsquo;s
publicly traded ordinary shares as reported on the date of the grant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; ">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Risk-Free Interest Rate- The risk-free rate for the expected
term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities
appropriate for the expected term of employee share option awards.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; ">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Expected Term- The expected term represents the period
that options are expected to be outstanding. For option grants that are considered to be &ldquo;plain vanilla,&rdquo; the Company
determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting
and the contractual life of the options.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; ">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Expected Volatility- As the Company has a short trading
history for its ordinary shares, the expected volatility is derived from the average historical share volatilities of several
unrelated public companies within the Company&rsquo;s industry that the Company considers to be comparable to its own business
over a period equivalent to the option&rsquo;s expected term.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; ">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Expected Dividend Yield- The Company has never declared
or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected
dividend yield of zero percent was used.&nbsp;If any of the assumptions used in the Black-Scholes-Merton model change significantly,
the share-based compensation expenses in future awards may differ materially as compared with the current awards granted.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We incurred non-cash share-based compensation
expense of $4.6 million, $1.0&nbsp;million and $1.0 million during the years ended December&nbsp;31, 2020, 2019 and 2018, respectively.
We expect to continue to grant share option awards in the future, and to the extent that we do, our actual share-based compensation
expenses recognized are likely to increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Valuation of Our Ordinary
Shares </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the IPO, the fair value of the
ordinary shares underlying our option awards was determined by our board of directors, with input from management. We believe that
our board of directors has the relevant experience and expertise to determine the fair value of our ordinary share as of each respective
grant date. The valuations of our ordinary shares were determined in accordance with the guidelines outlined in the American Institute
of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>,
or the AICPA Practice Aid. The assumptions used in the valuation model are based on future expectations combined with management
judgment. Our board of directors, with input from management, exercised significant judgment and considered numerous objective
and subjective factors to determine the fair value of our ordinary shares as of the date of each option grant, including the following
factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">independent valuations performed at periodic intervals by independent third-party valuation specialist; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our current business projections; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stage of development; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences and privileges of our convertible preferred shares; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current business conditions; </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of a liquidity event for the ordinary shares underlying these options, such as an initial public offering or sale of our company, given prevailing market conditions; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adjustments necessary due to the lack of marketability of our ordinary shares; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase of our preferred shares by third party investors in arms-length transactions; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance of comparable publicly traded companies. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">First, we determined value in an exit scenario
due to a liquidity event, such as an initial public offering using the market approach and based on discussions with investment
banks. In this scenario, all preferred shares, warrants to purchase preferred shares and options to purchase our ordinary shares
convert into, or are deemed to be exercised for, ordinary shares. The firm value is divided by the resulting number of shares to
determine a per share value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Second, the equity value was determined
based on, among other things, financing transactions with third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We then allocated the value between all
elements of our securities (preferred shares, ordinary shares, warrants for preferred shares and options for ordinary shares) using
the OPM, on the assumption that our preferred shares will benefit from their liquidation preference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the OPM, preferred and ordinary shares
are treated as a series of call options, with the preferred shares having an exercise price based on the liquidation preference
of the respective preferred share. The OPM operates through a series of Black-Scholes-Merton option pricing models, with the exercise
prices of the options representing the upper and lower bounds of the proceed ranges that a security holder would receive upon a
liquidity event. The strike prices occur at break points where the allocation of firm value changes among the various security
holders. The ordinary shares are presumed to have value only if funds available for distribution to shareholders exceed the value
of the respective liquidation preferences at the time of a liquidity event. The OPM requires an enterprise level input of firm
value or a transaction level input of specific security value (typically, a recently issued convertible preferred security) to
anchor the allocation of firm value among the various classes of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In making the final determination, we also
applied a discount for lack of marketability right, as applicable, to our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subsequent to the closing of our IPO, the
fair value of our ordinary shares is based on the closing price of our Ordinary Shares as reported on the date of the respective
grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Warrants to Purchase Convertible
Preferred Shares </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Warrants to purchase our convertible preferred
shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares are contingently
redeemable (upon a deemed liquidation event) and, therefore, may obligate us to transfer assets at some point in the future. The
warrants are subject to re-measurement to fair value at each balance sheet date and any change in fair value is recognized as a
component of financial income, net, in the statement of operations. On June 30, 2020, as a result of the IPO, the warrant liability
to convertible preferred shares has been classified to Warrants to Ordinary Shares in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B><I>Grants and Participation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Royalty-bearing grants from the IIA for
funding approved research and development projects are recognized at the time we are entitled to such grants, on the basis of the
costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not
probable when the grants are received, we do not record a liability for amounts received from the IIA until the related revenues
are recognized. Non-royalty-bearing grants from the IIA MAGNET program and from FP7 for funding approved research and development
projects are recognized at the time we are entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. In the event of failure of a project that was partly financed by the IIA, we
would not be obligated to pay any royalties or repay the amounts received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December&nbsp;31, 2020, we have received
royalty-bearing grants totaling $5.1&nbsp;million. Pursuant to the terms of the grants, we are required to pay royalties to the
IIA of 3.0% on revenues from sales of products developed financed in whole or in part by IIA, up to a limit of 100% of the grants
received, plus annual interest calculated on the 12-month LIBOR rate as published on the first business day of each calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we must abide by other restrictions
associated with the receipt of such grants under the R&amp;D Law that continue to apply following repayment to the IIA. These restrictions
may impair our ability to outsource manufacturing or otherwise transfer our knowledge outside of Israel, or engage in change of
control transactions, and may require us to obtain IIA approval for certain actions and transactions and pay additional amounts
to the IIA. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israel
citizen or resident an &ldquo;interested party&rdquo; as defined in the R&amp;D Law requires prior written notice from the IIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Qualitative and Quantitative
Disclosures about Market Risk </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Foreign Currency Exchange
Risk </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We operate primarily in Israel, and approximately
70% of our expenses are denominated in New Israeli Shekels, or NIS. We are therefore exposed to market risk, which represents the
risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. We are subject
to fluctuations in foreign currency rates in connection with these arrangements. Changes of 5% and 10% in the U.S. dollar/NIS exchange
rate would have increased/decreased operating expenses by approximately 3.5% and 7%, respectively, during the year ended December&nbsp;31,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently partially hedge our foreign
currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Interest Rate Risk </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not anticipate undertaking any significant
long-term borrowings. At present, our investments consist primarily of cash and cash equivalents and short-term deposits. We may
invest in investment-grade marketable securities with maturities of up to three years, including commercial paper, money market
funds, and government/non-government debt securities. The primary objective of our investment activities is to preserve principal
while maximizing the income that we receive from our investments without significantly increasing risk and loss. Our investments
may be exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value
of our investments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Inflation-Related Risks </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inflation generally affects us by increasing
our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local suppliers.
We do not believe that inflation had a material effect on our business, financial condition or results of operations during the
years ended December&nbsp;31, 2020, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>JOBS Act Transition Period </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;107 of the JOBS Act provides
that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B)
of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption
of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage
of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure
requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to
the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies
which may make comparison of our financials to those of other public companies more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an emerging growth company, as defined in Section 2(a)
of the Securities Act, as implemented under the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain
exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company,
we may rely on certain of these exemptions, including without limitation, (i)&nbsp;providing an auditor&rsquo;s attestation report
on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act and (ii)&nbsp;complying
with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation
or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements, known
as the auditor discussion and analysis. We will remain an emerging growth company until the earlier to occur of (1)&nbsp;the last
day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total
annual gross revenues of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a &ldquo;large accelerated filer&rdquo;
under the rules of the SEC, which means the market value of our Ordinary Shares that is held by non-affiliates exceeds $700.0&nbsp;million
as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt
during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a020"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity and Capital Resources.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Sources of Liquidity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have not generated
any revenue and have incurred operating losses and negative cash flows from our operations. Prior to our IPO, we funded our operations
primarily through the sale of equity securities and convertible debt. On June 30, 2020, we closed our IPO, whereby we sold 4,312,500
Ordinary Shares to the public (inclusive of 562,500 Ordinary Shares pursuant to the full exercise of an overallotment option granted
to the underwriters). The aggregate net proceeds received by us from the IPO were $62.8 million, net of underwriting discounts
and other offering costs. As of December&nbsp;31, 2020, we had $66.6&nbsp;million in cash, cash equivalents, short-term deposits
and long-term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently have no ongoing material financing
commitments, such as lines of credit or guarantees that are expected to affect our liquidity over the next five years, other than
our lease obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the foregoing, based on
our current assessment, we do not expect any material impact on our long-term liquidity due to the COVID-19 pandemic. However,
we will continue to assess the effect of the pandemic to our operations. The extent to which the COVID-19 pandemic will impact
our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence,
such as the ultimate geographic spread of the disease, the duration of the COVID-19 pandemic, any restrictions on the ability of
hospitals and trial sites to conduct trials that are not designed to address the COVID-19 pandemic, any further delays to enrolment
of our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs and the perceived effectiveness of actions
taken in Israel, the United States and Europe and other countries to contain and treat the disease. While the potential economic
impact brought by COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption
of global financial markets, reducing our ability to access capital in the future. In addition, a recession or long-term market
correction resulting from the spread of COVID-19 could materially affect our business and the value of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Cash Flows </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides information
regarding our cash flows for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(17,358</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(21,596</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,564</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,768</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,653</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net increase (decrease) in cash, cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,269</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">410</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Operating Activities </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities related
primarily to our net losses adjusted for non-cash charges and measurements and changes in components of working capital. Adjustments
to net loss for non-cash items mainly included depreciation, revaluation of convertible preferred share warrants and share-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities was
$21.6&nbsp;million for the year ended December&nbsp;31, 2020, as compared to $17.4&nbsp;million for the year ended December&nbsp;31,
2019. This increase was primarily related to increased research and development costs and associated general and administrative
expenses, as we initiated SHIELD I and SHIELD II Phase 3 clinical trials in abdominal surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Investing Activities </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities related
primarily to the purchase of short-term and long-term deposits and the acquisition of laboratory equipment, office equipment and
furniture and leasehold improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities was
$40.8&nbsp;million for the year ended December&nbsp;31, 2020, as compared to net cash provided by investing activities of $23.6&nbsp;million
for the year ended December&nbsp;31, 2019. This increase in net cash used in investing activities primarily related to the purchase
of short-term and log-term deposits.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Financing Activities </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash provided by financing activities
was $62.8&nbsp;million for the year ended December&nbsp;31, 2020, as compared to $37.7&nbsp;million for the year ended December&nbsp;31,
2019. The increase in net cash provided by financing activities is primarily related to the net proceeds from the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In October 2018 and February 2019, we issued
an aggregate of 1,187,887 Series E-1 preferred shares pursuant to a private placement, at a price per share of $13.30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June 2019 through August 2019, we issued an aggregate of
2,596,665 Series E-1 preferred shares pursuant to a private placement, at a price per share of $13.30. In addition, in connection
with the foregoing placement, we issued warrants to purchase 200,596 Series E-1 preferred shares to a placement agent. These warrants
are currently exercisable for Ordinary Shares rather than Series E-1 preferred shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Current Outlook </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have not generated any revenues
from the commercial sale of our product candidates, and we do not expect to generate revenue for at least the next several years.
We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to conduct clinical trials
and seek marketing approval for our product candidates, and as we continue the research and development of our other existing and
future product candidates. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant
commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing,
manufacturing and distribution are not the responsibility of potential collaborators. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that our existing cash and cash
equivalents, short-term deposits and long-term deposits will enable us to fund our operating expenses and capital expenditure requirements
for at least the next 12 months. We anticipate that these funds, will be sufficient to complete and report results from our SHIELD
I clinical trial. We anticipate that we will need to raise additional capital in order to complete the SHIELD II clinical trial,
as well as to resume enrolment in our Phase&nbsp;3 trial of D-PLEX<SUB>100</SUB> for the prevention of sternal SSIs. We anticipate
that we will need to raise additional capital in order to commercialize D-PLEX<SUB>100</SUB>, if approved, in any indication. Our
future capital requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of our ongoing clinical trials; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome of regulatory review of D-PLEX<SUB>100</SUB> and any future product candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of establishing and validating manufacturing processes and facilities for development and commercialization of D-PLEX<SUB>100</SUB> and any future product candidates, if approved, including our manufacturing facility; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and development requirements of any future product candidates that we may pursue; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval, which may be affected by market conditions, including obtaining coverage and adequate reimbursement of our product candidates from third-party payors, including government programs and managed care organizations, and competition; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain collaborations with biopharmaceutical companies on favorable terms, if at all; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we acquire or in-license other product candidates and technologies. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Identifying potential product candidates
and conducting clinical trials and preclinical studies is a time-consuming, expensive and uncertain process that takes many years
to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of product candidates that we do not expect to be commercially available for several years, if at all. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may
not be available to us on acceptable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until such time, if ever, as we can generate
substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants,
collaborations, strategic alliances and licensing arrangements. If we are unable to raise additional funds through equity or debt
financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization
efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a021"></A>E.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance Sheet Arrangements.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">We
do not have any off-balance sheet arrangements, as such term is defined under Item&nbsp;5.E of the instructions to Form 20-F, that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, expenses,
results of operations, liquidity, capital expenditures or capital resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a022"></A>F.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tabular Disclosure of Contractual Obligations.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our contractual
obligations at December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less&nbsp;than<BR> 1 Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1&nbsp;to&nbsp;3<BR> Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">4&nbsp;to&nbsp;5<BR> Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More&nbsp;than<BR> 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease obligations<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,236</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">566</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,403</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">Operating lease obligations consist of payments pursuant
to lease agreements for our facility in Israel and motor vehicle leases.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The commitment amounts in the table above
are associated with contracts that are enforceable and legally binding. The table does not include obligations under agreements
that we can cancel without a significant penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 9, 2020, we entered into an agreement
for an automatic filling machine for the Company&rsquo;s manufacturing plant in a total amount of EUR 1,326 thousand. We made a pre-payment
of EUR 372 thousand and intend to pay the remaining of the payments during 2021 according to the milestones of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into contracts in the normal course
of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These
contracts generally provide for termination upon notice, and therefore we believe that our non-cancellable obligations under these
agreements are not material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a023"></A>ITEM 6.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a024"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Senior Management.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information
regarding our executive officers, key employees and directors as of the date of this annual report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 26%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 64%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir Weisberg</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Emanuel, Ph.D.&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaul Mukhtar, Ph.D.&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Operating Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalit Hazan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Research and Development and Regulatory Affairs</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Non-Employee Directors</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob Harel</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yechezkel Barenholz, Ph.D.&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir Dror</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chaim Hurvitz</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itzhak Krinsky, Ph.D.&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat Tsour Segal</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert B. Stein, M.D., Ph.D.&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stanley Stern</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amir Weisberg, Chief Executive Officer, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Mr. Amir Weisberg</I> has served as our
Chief Executive Officer and a director since October 2010. From 2007 to 2010, Mr.&nbsp;Weisberg served as the chief executive officer
of Implant Protection&nbsp;Ltd. He has over 20&nbsp;years of entrepreneurial experience, including as chief executive officer of
several startup companies in the life science sphere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dikla Czaczkes Akselbrad, Executive Vice President, Chief
Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ms. Dikla Czaczkes Akselbrad </I>has
served as our Executive Vice President and Chief Financial Officer since December 2016. Prior to that time, Ms.&nbsp;Czaczkes
Akselbrad served as our Chief Strategy Officer from July 2014 to December 2016. Ms. Czaczkes Akselbrad has over 20 years of
experience in capital markets, finance and business development. Ms. Czaczkes Akselbrad served as a chief financial officer
of Compugen Ltd. (Nasdaq: CGEN) from February 2008 to May 2014. She holds a B.A. in accounting and economics and an M.B.A. in
finance, both from Tel Aviv University, and is a certified public accountant in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Noam Emanuel, Ph.D., Chief Scientific Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dr. Noam Emanuel, Ph.D.</I> has served
as our Chief Scientific Officer since April 2019. He previously served as a director from October 2008 to May 2020 and was our
Chief Technology Officer from October 2010 to April 2019. Dr.&nbsp;Emanuel has over 15&nbsp;years of experience in drug development,
drug delivery and immunology, including with respect to local, systemic and trans-dermal drug delivery systems, as well as in imaging
and diagnostics. He holds a Ph.D. in immunology and drug delivery from the Hebrew University of Jerusalem. <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shaul Mukhtar, Ph.D., Executive Vice President, Chief Operating
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dr. Shaul Mukhtar, Ph.D.</I> has served
as our Executive Vice President and Chief Operating Officer since February 2019. Dr.&nbsp;Mukhtar also serves as a consultant with
L.S.M. consulting services, a position he has held since February 2018, and as an affiliated partner with the GlobalClose Alliances
Group, a position he has held since July 2018. Dr.&nbsp;Mukhtar previously worked at Teva Pharmaceuticals Industries&nbsp;Ltd.,
most recently as the Senior Vice President, Chief Operating Officer and Regional Research and Development Manager for Teva Japan
and South Korea from 2013 to December 2017. Dr.&nbsp;Mukhtar holds a Ph.D. in pharmaceutical sciences from Hebrew University of
Jerusalem, and an M.B.A. in international business administration from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dalit Hazan, Vice President, Research and Development and
Regulatory Affairs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ms. Dalit Hazan</I> has served as our
Vice President, Research and Development and Regulatory Affairs since March 2018. Prior to that time, Ms.&nbsp;Hazan was the head
of Global Regulatory Affairs at Teva Pharmaceuticals Industries&nbsp;Ltd. From 2013 to April 2016. She holds a B.S. in biology
and a M.S. in physiology and pharmacology from the Sackler Faculty of Medicine at Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Jacob Harel, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Mr. Jacob Harel</I> has served as a director
since November 2017 and the chairman of our board of directors since December 2017. Mr.&nbsp;Harel currently serves as the Chief
Executive Officer of The Harel Group, a consulting firm that provides business development support to pharmaceutical companies,
which he founded in 2014. He holds a B.S. in economics from Haifa University and an M.B.A. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Yechezkel Barenholz, Ph.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dr. Yechezkel Barenholz, Ph.D.</I> has
served as a director since April 2008. Dr.&nbsp;Barenholz currently serves as head of the Laboratory of Membrane and Liposome Research
at the Department of Biochemistry of the Hadassah Medical School at the Hebrew University of Jerusalem, a position he has held
since 1978. He is the co-inventor of Doxil, the first nano-delivery system approved by the FDA. He holds a B.S., M.S. and Ph.D.
in biochemistry from the Hebrew University of Jerusalem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nir Dror, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Mr. Nir Dror</I> has served as a director
since May 2020. Mr.&nbsp;Dror currently serves as the Chief Financial Officer of Aurum Ventures M.K.I.&nbsp;Ltd., a position he
has held since 2013. He holds a B.A. and L.L.M. from Tel Aviv University and an M.B.A. from the University of Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Chaim Hurvitz, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. <I>Chaim Hurvitz</I> has served as a
director since February 2016. Mr.&nbsp;Hurvitz currently serves as Chief Executive Officer of CH Health, a private venture capital
firm, a position he has held since May 2011. He served as chairman of Galmed Pharmaceuticals&nbsp;Ltd. from 2011 to December 2018
and a director of UroGen Pharma&nbsp;Ltd. from May 2013 to December 2017. He holds a B.A. in political science and economics from
Tel Aviv University. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Itzhak Krinsky, Ph.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dr. Itzhak Krinsky, Ph.D.</I> has served
as a director since January 2019. Dr. Krinsky currently serves as a member of the audit committee of Globrands Ltd., a position
he has held since July 2018. Prior to that, Dr. Krinsky served as a member of the nominating and corporate governance committee
of Advanz Pharma Corp. (formerly known as Concordia Healthcare Corp), a position he held from May 2017 to September 2018. Dr.&nbsp;Krinsky
previously worked at Teva Pharmaceuticals Industries&nbsp;Ltd., most recently as a Senior Executive, Special Assignments from May
2016 to February 2017 and as the Chairman of Teva Japan and South Korea and Head of Business Development, Asia Pacific from October
2012 to April 2016. Dr.&nbsp;Krinsky served as a director of Kamada&nbsp;Ltd. from November 2017 to November 2019. He holds a B.A.
and M.A. in economics from Tel Aviv University and a Ph.D. in economics from McMaster University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anat Tsour Segal, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ms. Anat Tsour Segal</I> has served as
a director since April 2008. Ms.&nbsp;Segal founded Anat Segal Consulting&nbsp;&amp; Technology Investments, an independent consulting
and investment banking practice advising Israeli technology and healthcare companies, in January 2000. She has served as Chief
Executive Officer of Capital Nature since October 2018. From April 2003 to February 2016, she also served as the founder, chief
executive officer and a director of Xenia Venture Capital. She holds a B.A. in economics and management, an M.B.A. in finance and
an LL.B. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Robert B. Stein, M.D., Ph.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr.&nbsp;<I>Robert B. Stein, M.D., Ph.D.</I>,
has served as a director since June 2020. Dr.&nbsp;Stein currently serves as an Operating Partner at Samsara BioCapital, a position
he has held since January 2018, and he is the Principal Consultant at RBS Biotech Consulting,&nbsp;LLC, which he founded in August
2008. He previously served as the Chief Scientific Officer and Head of Research and Development of Agenus&nbsp;Inc. from January
2014 to January 2016 and as the President of Research and Development from January 2016 to April 2017. He has served on the boards
of directors of Protagenic Therapeutics,&nbsp;Inc. since February 2016 and Taro Pharmaceutical Industries&nbsp;Ltd. since February
2020. In August 2012, Dr.&nbsp;Stein filed a petition for personal bankruptcy under Chapter&nbsp;7 and Chapter&nbsp;11 of the federal
bankruptcy laws, which was subsequently discharged in May 2013. He holds a B.S. in biology and chemistry from Indiana University
and an M.D. and a Ph.D. in physiology and pharmacology from Duke University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stanley Stern, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. <I>Stanley Stern</I> has served as a
director since June 2020. Mr.&nbsp;Stern currently serves as the President of Alnitak Capital Partners, a position he has held
since he co-founded the firm in February 2013. He has served as the chairman of the board of directors of Audiocodes&nbsp;Ltd.
since December 2012 and has served as a member of the board of directors of Foamix,&nbsp;Ltd. since 2014, Ormat Technologies,&nbsp;Inc.
since November 2015 and Ekso Bionics Holdings,&nbsp;Inc. since December 2014. He holds a B.A. in economics and accounting from
the City University of New York, Queens College and an M.B.A. from Harvard University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Family Relationships</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no family relationships between
any members of our executive management and our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Arrangements for Election of Directors and Members of
Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors consists of nine
directors, each of whom will continue to serve pursuant to their appointment until the first annual general meeting of shareholders
held after IPO, which took place in June 2020. We are not a party to, and are not aware of, any voting agreements among our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a025"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents in the aggregate
all compensation we paid to all of our directors and senior management from January 1, 2020 through December 31, 2020. The table
does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All amounts reported in the tables below
reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.437 =
U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of
Israel during such period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salary&nbsp;<BR> and&nbsp;Related</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Benefits
                                         <SUP>(1)</SUP></B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR> Payments,<BR> Benefits<BR> and<BR> Perquisites</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Share-Based</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT><B><SUP>(2)</SUP></B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">All directors and senior management as a group, consisting of 14 persons as of December 31, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,002,301</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,454,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,423,509</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD>Represents the directors and senior management&rsquo;s gross
salary plus payment of mandatory social benefits made by the company on behalf of such officer. Such benefits may include, to the
extent applicable to the executive, payments, contributions and/or allocations for savings funds, education funds (referred to
in Hebrew as &ldquo;Keren Hishtalmut&rdquo;), pension, severance, risk insurances (e.g., life or work disability insurance) and
payments for social security.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>Computed based on Black-Scholes-Merton model.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the Israeli Companies
Law, we are required to disclose the compensation granted to our five most highly compensated officers. The table below reflects
the compensation granted during or with respect to the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary and&nbsp;Related Benefits</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus Payments, Benefits and Perquisites</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-Based Compensation</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Amir Weisberg</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">436,625</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">966,162</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,902,787</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dikla Czaczkes Akselbrad</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">261,170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">304,000</TD><TD STYLE="text-align: left"><SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">596,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,161,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Noam Emanuel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">304,823</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">966,162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,770,985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Taunia Markvicka</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">323,763</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">74,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">547,922</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dalit Hazan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">232,948</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">116,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">349,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: left">Includes a one-time bonus payment in the amount of $500,000
paid to Mr. Weisberg with respect to our IPO in June 2020. No equity was granted to Mr. Weisberg in 2017, 2018 and 2019.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: left">Includes a one-time bonus payment in the amount of $250,000
paid to Ms. Czaczkes Akselbrad with respect to our IPO in June 2020. No equity was granted to Ms. Czaczkes Akselbrad in 2017, 2018
and 2019.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: left">Includes a one-time bonus payment in the amount of $500,000
paid to Mr. Emanuel with respect to our IPO in June 2020. No equity was granted to Mr. Emanuel in 2017, 2018 and 2019.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: left">Includes a one-time bonus payment in the amount of $50,000 paid
to Ms. Markvicka with respect to our IPO in June 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into written employment
or services agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and most of them contain also customary provisions regarding assignment of inventions. However,
the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements
with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and
to the extent that these liabilities are not covered by directors and officers insurance. Members of our senior management may
be eligible for bonuses in accordance with our compensation policy and as set forth by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For a description of the terms of our options
and option plans, see &ldquo;Item 6. E. Share Ownership&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Directors&rsquo; Service Contracts </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than with respect to our directors
that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his or her engagement with our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2019, we entered into a master service
agreement with CTG Weld, a contract research organization, to conduct of a portion of a Phase&nbsp;3 clinical trial of D-PLEX<SUB>100</SUB>
in Eastern Europe for a total cost of $6.3&nbsp;million. Chaim Hurvitz, a director of our company, serves as a director for, and
is a shareholder of, CTG Weld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a026"></A>C.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board Practices.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Board of Directors </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our amended and restated articles
of association, our board of directors must consist of at least five directors and not more than eleven directors. Our board of
directors presently consists of nine members. We believe that Messrs.&nbsp;Harel, Dror and Hurvitz, Ms.&nbsp;Segal and Drs. Barenholz,
Krinsky and Stein are &ldquo;independent&rdquo; for purposes of the Nasdaq Stock Market rules. Under the Israeli Companies Law,
our board of directors is responsible for setting our general policies and supervising the performance of management. Our board
of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management.
Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board
of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to
the terms of the employment agreement that we have entered into with him. All other executive officers are also appointed by our
board of directors, and are subject to the terms of any applicable employment agreements that we may enter into with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than vacancies to be filled through
selection by the remaining members of our board, the Israeli Companies Law and our amended and restated articles of association
provide that directors are elected at the annual general meeting of our shareholders by a vote of the majority of the total voting
power of our company voting in person, by proxy or by other voting instrument at that meeting. We have only one class of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, our board
of directors is required to employ independent judgment and discretion when voting, and is prohibited from entering into any voting
arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the event
a director learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must
promptly take action to summon a meeting of the board of directors to address any such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the exemptions available
to foreign private issuers under Nasdaq Rules, we follow the requirements of the Nasdaq Rules with regard to the process of nominating
directors by means of our compensation, nominating and corporate governance committee, which is comprised of directors who our
board has deemed to be independent under Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our amended and restated articles
of association allows our board of directors to appoint directors to fill vacancies on our board of directors, including filling
empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal
to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors
may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the
next annual general meeting of our shareholders in which the other directors then in office are proposed to be replaced or reappointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Directors may be removed from office by
a resolution at a general meeting of shareholders adopted by a vote of 65% of the total voting power of our company in accordance
with the Israeli Companies Law and our amended and restated articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, and except
as described below, we would be required to include on our board of directors at least two members, each of whom qualifies as an
external director, and as to whom special qualifications and other provisions would be applicable. We would also be required to
include one such external director on each of our board committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under regulations promulgated under the
Israeli Companies Law, Israeli companies whose shares are traded on stock exchanges such as The Nasdaq Global Market that do not
have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&rsquo;s
shares are traded with respect to the appointment of independent directors and the composition of an audit committee and compensation
committee, may elect not to follow the Israeli Companies Law requirements with respect to the composition of its audit committee
and compensation committee and the appointment of external directors. As we do not have a controlling shareholder, and we comply
with the requirements of the Nasdaq Stock Market with respect to the composition of our board and such committees, we therefore
are exempt from the Israeli Companies Law requirements with respect thereto, including the appointment of external directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors is required to elect one director to
serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also release that
director from his or her position as chairman. Pursuant to the Israeli Companies Law, neither the chief executive officer nor any
of his or her relatives is permitted to serve as the chairman of the board of directors, and a company may not (subject to a certain
time-limited exemption, as described below) vest the chairman or any of his or her relatives with the chief executive officer&rsquo;s
authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer may not serve as the chairman
of the board of directors; the chairman may not be vested with authorities of a person who reports, directly or indirectly, to
the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company, but he
or she may serve as a director or chairman of a controlled company. However, and notwithstanding the foregoing, the Israeli Companies
Law permits the shareholders of a company to determine, for periods not exceeding three years from each such determination, that
the Chairman or his or her relative may serve as chief executive officer or be vested with the chief executive officer&rsquo;s
authorities, and that the chief executive officer or his or her relative may serve as Chairman or be vested with the Chairman&rsquo;s
authorities. Such determination of a company&rsquo;s shareholders requires either: (1) the approval of at least the majority of
the shares of those shareholders present and voting on the matter (other than controlling shareholders and those having a personal
interest in the determination); or (2) that the total number of shares opposing such determination does not exceed 2% of the total
voting power in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Director Independence </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although not required of foreign private
issuers under Nasdaq Rules, we comply with the requirements thereunder applicable to domestic listed companies that a majority
of the board of directors be deemed to be independent under such rules, as well as the independence requirements that are applicable
to our audit committee and compensation, nominating and corporate governance committee if we were a domestic listed company, as
described below. In light of this obligation, our board of directors has undertaken a review of the independence of our directors
under current rules and regulations of the SEC and Nasdaq Rules and considered whether any of our directors has a material relationship
with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities.
Based upon information requested from and provided by each director concerning such director&rsquo;s background, employment and affiliations,
including family relationships, our board of directors determined that Messrs.&nbsp;Harel, Dror and Hurvitz, Ms.&nbsp;Segal and
Drs. Barenholz, Krinsky and Stein, representing seven of our nine directors, are &ldquo;independent directors&rdquo; as defined under
current rules and regulations of the SEC and Nasdaq Rules. In making these determinations, our board of directors considered the
current and prior relationships that each non-employee director has with our company and all other facts and circumstances that
our board of directors deemed relevant in determining their independence, including the beneficial ownership of our share capital
by each non-employee director and the transactions involving them described in &ldquo;Item 7. B. &mdash; Related Party Transactions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Alternate Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our articles of association provide, consistent with the Israeli
Companies Law, that any director, and with respect to external directors &ndash; only subject to certain preconditions, may appoint
another person to serve as his or her alternate director, provided such person has the qualifications prescribed under the Israeli
Companies Law to be appointed and to serve as a director and is not already serving as a director or an alternate director of the
company. The term of an alternate director may be terminated at any time by the appointing director and automatically terminates
upon the termination of the term of the appointing director. An alternate director has the same rights and responsibilities as
a director. To date, there are no alternate director appointments in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Leadership Structure of the
Board </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the Israeli Companies
Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to serve
as chairman of the board of directors. Our board of directors has appointed Jacob Harel to serve as chairman of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Board Committees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law and our
amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any such
committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn
a resolution adopted by a committee it has formed; provided, however, that the board&rsquo;s decision shall not affect the ability of
third parties, who were not aware of such decision, to rely on the committee&rsquo;s resolution prior to the time it is overturned. Only
members of the board of directors can be members of a board committee, unless the committee is solely advisory. Our board of directors
has established two standing committees &ndash; the audit committee and the compensation committee, both of which are mandatory
under the Israeli Companies Law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Audit Committee </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Israeli Companies Law Requirements
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, we are
required to appoint an audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Nasdaq Listing Requirements
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under
the Nasdaq Rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom
is financially literate and one of whom has accounting or related financial management expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The members of our audit committee include Dr. Itzhak Krinsky,
Ms. Anat Tsour Segal and Dr. Yechezkel Barenholz. Dr. Krinsky serves as the chairman of our audit committee. All members of our
audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The Nasdaq
Global Market. Our board of directors has determined that each of Dr.&nbsp;Krinsky and Ms.&nbsp;Segal is an audit committee financial
expert as such term is defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq Rules. Each
of the members of our audit committee is &ldquo;independent&rdquo; as such term is defined in Rule&nbsp;10A-3(b)(1) under the Exchange
Act and satisfies the independent director requirements under the Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Audit Committee Role </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our audit committee charter sets forth the
responsibilities of the audit committee consistent with the rules and regulations of the SEC and the Nasdaq Rules, as well as the
requirements for such committee under the Israeli Companies Law, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">reviewing and monitoring, if applicable, legal matters with
significant impact, receiving reports regarding irregularities and legal compliance, acting according to the Company&rsquo;s &ldquo;whistleblower
policy&rdquo; and recommending actions to our board of directors if so required.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our audit committee provides assistance
to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial
reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit
committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy
itself that the auditors are independent of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, our audit
committee is responsible, among other things, for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies Law); </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing the approval process for certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal audit controls and internal auditor&rsquo;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&rsquo;s work and compensation and submitting a recommendation with respect thereto to our board of directors, depending on which of them is considering the appointment of our auditor; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&rsquo; complaints as to the financial management of our business and the protection to be provided to such employees. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Compensation, Nominating
and Corporate Governance Committee and Compensation Policy </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The composition of our compensation, nominating
and corporate governance committee meets the requirements for and guidance under the Nasdaq Rules and current SEC rules and regulations
applicable to domestic issuers. The members of this committee are Mr.&nbsp;Dror, Dr.&nbsp;Krinsky and Mr.&nbsp;Stern, each of whom
is independent in accordance with the Nasdaq rules. Mr. Dror serves as the chair of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Israeli Companies Law Requirements
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, the board
of directors of a public company must appoint a compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The duties of the compensation committee under the Israeli Companies
Law, include the recommendation to the company&rsquo;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a compensation policy. That policy must be adopted by the company&rsquo;s board of directors, after
considering the recommendations of the compensation, nominating and corporate governance committee, and will need to be approved
by the company&rsquo;s shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation.
A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the shares present and voting
at a meeting of shareholders called for such purpose, provided that either: (i)&nbsp;such majority includes at least a majority
of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation
arrangement, excluding abstentions; or (ii)&nbsp;the total number of shares of non-controlling shareholders and shareholders who
do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the
company&rsquo;s aggregate voting rights. Our board of directors and our shareholders have approved a compensation policy, which
will be in effect until the fifth anniversary of our IPO, which took place in June 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must (subject to
certain exemptions) set the framework and limitation for decisions concerning the financial terms of employment or engagement of
office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of
employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&rsquo;s long-term
objectives, business plan and policies, and creation of appropriate incentives for office holders. It must also consider, among
other things, the company&rsquo;s risk management, size and the nature of its operations. The compensation policy must furthermore consider
the following additional factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, expertise and accomplishments of the relevant office holder; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&rsquo;s roles and responsibilities and prior compensation agreements with him or her; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the terms offered and the average compensation of the company&rsquo;s personnel; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of disparities in salary upon work relationships in the company; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to financial payment upon termination of service, the period of service of the office holder, the terms of his or her compensation during such service period, the company&rsquo;s performance during that period of service, the person&rsquo;s contribution towards the company&rsquo;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-left: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The compensation policy must also include the following principles:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation and long-term performance and measurable criteria; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the company&rsquo;s financial statements; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for financial payment upon termination of service. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>&nbsp;</I></P>



<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><I>Compensation, Nominating and
Corporate Governance Committee Roles </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation, nominating and corporate
governance committee is responsible for (i)&nbsp;recommending the compensation policy to our board of directors for its approval
(and subsequent approval by our shareholders) and (ii)&nbsp;duties related to the compensation policy and to the compensation of
our office holders, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from a company&rsquo;s initial public offering, or otherwise three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from a company&rsquo;s initial public offering, or otherwise every three years); </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&rsquo;s approval; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the limited conditions exist which would allow for the compensation terms of a candidate for the position of the chief executive officer not to be brought for approval by the shareholders. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation, nominating and corporate
governance charter sets forth the responsibilities of the compensation, nominating and corporate committee, which include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the responsibilities set forth in the compensation policy; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-left: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In addition, our compensation, nominating and corporate governance committee is responsible for:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our corporate governance functions on behalf of the board; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations to the board regarding corporate governance issues; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and evaluating the performance of the board; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serving as a focal point for communication between director candidates, non-committee directors and our management; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting or recommending to the board for selection candidates to the board; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making other recommendations to the board regarding affairs relating to our directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Additional Committees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also have two additional non-statutory
committees: The Manufacturing Facility Committee is responsible for overseeing the Company&rsquo;s efforts in selecting and establishing
the future manufacturing facility of our products. The members of the committee are Mr. Hurvitz, Mr. Harel and Mr. Weisberg. Mr.
Hurvitz serves as the chair of the committee. We also established a Research Committee, which assists, supervises and advises on
the Company&rsquo;s research activities. The members of the Committee are Mr. Barenholtz and Mr. Stein. Mr. Barenholtz serves as
the chair of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Disclosure of Compensation
of Executive Officers </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so long as we qualify as a foreign private
issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable
to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer and other three
most highly compensated executive officers on an individual, rather than on an aggregate, basis. Nevertheless, under regulations
promulgated under the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated
office holders (as defined under the Israeli Companies Law) on an individual basis. This disclosure is not as extensive as that
required of a U.S. domestic issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Internal Auditor </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, the board
of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor
may not, among other things, be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who holds 5% or more of the company&rsquo;s outstanding shares or voting rights; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an office holder (including a director) of the company (or a relative thereof); or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a member of the company&rsquo;s independent accounting firm, or anyone on its behalf. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The role of the internal auditor is to examine,
among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer,
the chairman of the board and the chairman of the audit committee. The internal auditor is entitled to receive notice of audit
committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee
convene a meeting within a reasonable time to discuss an issue raised by the internal auditor. The internal auditor is responsible
for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee
for their approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our internal auditor is not an interested party in the Company
and not our employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Exculpation, Insurance and Indemnification
of Directors and Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, a company
may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and
restated articles of association include such a provision. A company may not exculpate in advance a director from liability arising
out of a breach of the duty of care with respect to a distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, a company
may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as
an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of
association include a provision authorizing such indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&rsquo;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&rsquo;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, incurred by the office holder (1)&nbsp;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i)&nbsp;no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii)&nbsp;no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&nbsp;in connection with a monetary sanction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection with an administrative procedure instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to the Securities Law. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, a company
may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder, if
and to the extent provided in the company&rsquo;s articles of association:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on the office holder in favor of a third party. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, a company
may not indemnify or insure an office holder against any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of a duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed with intent to derive illegal personal benefit; or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, exculpation,
indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board
of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Israeli
Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We obtained directors and officers liability insurance for the
benefit of our office holders in an amount standard for a company of our size. We intend to maintain such increased coverage and
pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. We entered into agreements with each
of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach
of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated articles
of association and Israeli law, including with respect to liabilities resulting from our IPO to the extent that these liabilities
are not covered by insurance. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities
arising under the Securities Act is against public policy and therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Duties of Shareholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an
acceptable manner in exercising his rights and performing his obligations toward the company and other shareholders, including,
among other things, in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&rsquo;s authorized share capital;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a027"></A>D.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees. </B>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 31, 2018, we had 49 full-time employees and 3 part-time
employees. On December 31, 2019, we had 53 full-time employees and 3 part-time employees. On December 31, 2020, we had 65 full-time
employees and 4 part-time employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March, 1, 2021, we had five full-time
senior management employees, including our Chief Executive Officer, Executive Vice President and Chief Financial Officer, Chief
Scientific Officer, Executive Vice President and Chief Operating Officer, and Vice President, Research and Development and Regulatory
Affairs. In addition, we currently have 63 full-time employees, four part-time employees and one full-time service provider. 69
of our employees are located in Israel and three employees located in New Jersey, the United States. None of our employees are
represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations with all
of our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent
rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued
in accordance with relevant labor laws by the Israeli Ministry of Economy and which apply such agreement provisions to our employees
even though they are not part of a union that has signed a collective bargaining agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our employment and consulting agreements
include employees&rsquo; and consultants&rsquo; undertakings with respect to non-competition, assignment to us of intellectual
property rights developed in the course of employment, and confidentiality. The enforceability of such provisions is limited by
Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aph010402a028"></A>E.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share Ownership.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See &ldquo;Item 7.A. Major Shareholders&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Amended and Restated 2012 Share
Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Amended and Restated 2012 Share Option
Plan, or the 2012 Plan, was adopted by our board of directors on August&nbsp;29, 2012 and amended on January&nbsp;30, 2018. The
2012 Plan provides for the grant of options to our directors, employees, office holders, service providers and consultants. A total
of 963,457 shares are reserved but unissued under our 2012 Plan as of the date of March 1, 2021. As of March 1, 2021, options to
purchase 2,617,314 Ordinary Shares were issued and outstanding with an exercise price of $5.78 per share, out of which options
to purchase 1,571,606 Ordinary Shares were vested as of that date, with an average exercise price of $4.91 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2012 Plan is administered by our board
of directors, which, on its own or upon the recommendation of a remuneration committee or any other similar committee of the board
of directors, shall determine, subject to applicable law, the identity of grantees of awards and various terms of the grant. With
respect to those grantees subject to Israeli taxation, the 2012 Plan provides for granting options in compliance with Section&nbsp;102
of the Israeli Income Tax Ordinance, 1961, or the Ordinance, under the capital gains track, and for grants to non-employee Israeli
service providers, consultants and shareholders who hold 10% or more of our total share capital or are otherwise controlling shareholders
pursuant to section&nbsp;3(i) of the Ordinance, as further detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;102 of the Ordinance allows
employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable
tax treatment for compensation in the form of shares or options. Our non-employee service providers and controlling shareholders
may only be granted options under section&nbsp;3(i) of the Ordinance, which does not provide for similar tax benefits. Section&nbsp;102
includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees
and also includes an additional alternative for the issuance of options or shares directly to the grantee. Section&nbsp;102(b)(2)
of the Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &ldquo;capital gain
track.&rdquo; However, under this track we are not allowed to deduct an expense with respect to the issuance of the options or shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Generally, options granted to our employees will vest over three
or four years, as may be determined by the board of directors at the time of the grant, and not be exercisable before the first
anniversary of the date of grant of options. With respect to the remainder of the options, they will become exercisable in equal
amounts of options at the end of each three-month period till the end of the third or fourth year from the date of grant, as the
case may be. Generally, options that are not exercised within ten years from the grant date shall expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than by will or laws of descent, neither
the options nor any right in connection with such options are assignable or transferable. If we terminate a grantee&rsquo;s employment
or service for any reason whatsoever, other than for cause, any options granted to such grantee that are not vested shall immediately
expire. All of the grantee&rsquo;s vested options shall be deemed expired on the earlier of: (a)&nbsp;the expiration date of such vested
options as was in effect immediately prior to such termination; or (b)&nbsp;three months following the date of such termination,
or if such termination is the result of death or disability of the grantee, 12&nbsp;months from the date of such termination. However,
for certain executives and other senior management, our board of directors (and shareholders where applicable) has resolved that
the expiration date of their vested options shall be between two to four years following the date of such termination. If we terminate
a grantee&rsquo;s employment or service for cause, all of the grantee&rsquo;s vested and unvested options will expire on the date of termination.
Also, and subject to applicable law, if the grantee&rsquo;s employment or services is terminated for cause, then we will have a right
of repurchase against any shares issued pursuant to the exercise of options. In the event that we exercise such right of repurchase,
we will pay such grantee for each such share being repurchased an amount equal to the price originally paid by the grantee for
such share. Alternatively, we may assign such rights of repurchase to our shareholders pro rata to their respective holdings of
our issued and outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are party to a merger or consolidation,
outstanding options and shares acquired under the 2012 Plan will be subject to the agreement of merger or consolidation, which
will provide for one or more of the following: (i)&nbsp;the assumption of such options by the surviving corporation or its parent,
(ii)&nbsp;the substitution by the surviving corporation or its parent of new options, or (iii)&nbsp;in the event that the successor
entity neither assumes nor substitutes all outstanding options, then each respective grantee shall have a period of 15&nbsp;days
to exercise his or her vested options, after which all remaining options, whether vested or not shall expire. For certain individuals,
if their position is terminated within a certain period after the transaction, their options shall accelerate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of any variation in our share
capital, including a share dividend, share split, combination or exchange of shares, recapitalization, or any other like event,
the number, class and kind of shares subject to the 2012 Plan and outstanding options, and the exercise prices of the options,
will be appropriately and equitably adjusted so as to maintain the proportionate number of shares without changing the aggregate
exercise price of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;30, 2018, our board of directors
adopted an appendix to the 2012 Plan for U.S. residents, which was approved by our shareholders on February&nbsp;8, 2018. Under
this appendix, the 2012 Plan provides for the granting of options to U.S. residents in compliance with the U.S. Internal Revenue
Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a029"></A>ITEM 7.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a030"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Major Shareholders. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information
regarding beneficial ownership of our Ordinary Shares as of March 3, 2021 by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our voting securities.</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">each of our directors and executive officers; and</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">all of our directors and executive officers as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as indicated in footnotes to this
table, we believe that the shareholder named in this table has sole voting and investment power with respect to all shares shown
to be beneficially owned by it, based on information provided to us by such shareholder. The shareholders listed below do not have
any different voting rights from any of our other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>No. of Shares</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Beneficially Owned <SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Percentage</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Owned <SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Holders of more than 5% of our voting securities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aurum Ventures M.K.I.&nbsp;Ltd. <SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,741,152</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.3</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shavit Capital Funds <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,277,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.8</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and executive officers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amir Weisberg <SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dikla Czaczkes Akselbrad <SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Noam Emanuel <SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">638,777</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dalit Hazan <SUP>(8)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taunia Markvicka <SUP>(9)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shaul Mukhtar <SUP>(10)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yechezkel Barenholz <SUP>(11)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,568</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nir Dror <SUP>(12)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,741,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jacob Harel <SUP>(13)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chaim Hurvitz <SUP>(14)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,008,419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Itzhak Krinsky <SUP>(15)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Anat Tsour Segal <SUP>(16)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert B. Stein <SUP>(17)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stanley Stern <SUP>(18)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All directors and executive officers as a group (14&nbsp;persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,367,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.1</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>*</TD>
    <TD>Under 1%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person, even if not the record owner, has or shares the underlying benefits of ownership. These benefits include the power to direct the voting or the disposition of the securities or to receive the economic benefit of ownership of the securities. A person also is considered to be the &ldquo;beneficial owner&rdquo; of securities that the person has the right to acquire within 60 days by option or other agreement. Beneficial owners include persons who hold their securities through one or more trustees, brokers, agents, legal representatives or other intermediaries, or through companies in which they have a &ldquo;controlling interest,&rdquo; which means the direct or indirect power to direct the management and policies of the entity.</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 18,745,142 Ordinary Shares issued and outstanding as of March 3, 2021.</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cropwell Limited is the beneficial owner of the shares owned by Aurum Ventures M.K.I.&nbsp;Ltd. Cropwell Limited is owned in equal parts by Brock Nominees Limited and Tenby Nominees Limited, as nominees for Credit Suisse Trust as trustee of the MK Special Assets Trust, the sole beneficiary of which is The MK Trust, of which Morris Kahn is the sole beneficiary. The address of Aurum Ventures M.K.I.&nbsp;Ltd. is 16 Abba Hillel Silver Street, Aurec House, Ramat Gan, 52506 Israel. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The beneficial ownership is based on the latest available filing made with the SEC on Schedule 13G on February 12, 2021 and consists of 1,277,641 Ordinary Shares. Gabriel Capital Management Ltd. (&ldquo;GCM&rdquo;) is the management company to certain affiliated funds (collectively, the &ldquo;Shavit Funds&rdquo;). As of December 31, 2020, the Shavit Funds held in the aggregate 1,238,166 of the aforementioned Ordinary Shares. GCM may be deemed to beneficially own such securities held by the Shavit Funds.&nbsp;Gabriel Leibler&nbsp;&nbsp;is the sole shareholder of the sole shareholder of GCM. Decisions regarding the voting and disposition of securities held by the Shavit Funds are subject to approval by certain internal investment committees comprising three or more individuals, of which Mr. Leibler is a member. In addition, as of December 31, 2020, Mr. Leibler separately held (i) 39,475 Ordinary Shares and (ii)&nbsp;options to purchase 17,925 Ordinary Shares that are not exercisable within 60 days and have a weighted average exercise price of $6.62. The address of Mr. Leibler is 4a Gidon Street, Jerusalem 9350604 Israel.</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&nbsp;146,464 Ordinary Shares and (ii)&nbsp;389,072 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Mr. Weisberg holds options to purchase 64,530 Ordinary Shares that are not exercisable within 60 days. Mr. Weisberg&rsquo;s options have expiration dates ranging from March 19, 2023 to June 18, 2030, and a weighted average exercise price of $5.65. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 134,640 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Czaczkes Akselbrad holds options to purchase 39,830 Ordinary Shares that are not exercisable within 60 days. Ms. Czaczkes Akselbrad&rsquo;s options have expiration dates ranging from July 10, 2024 to June 11, 2030, and a weighted average exercise price of $5.48. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&nbsp;203,150 Ordinary Shares and (ii)&nbsp;435,627 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Mr. Emanuel holds options to purchase 64,530 Ordinary Shares that are not exercisable within 60 days. Mr. Emanuel&rsquo;s options have expiration dates ranging from March 19, 2023 to June 11, 2030, and a weighted average exercise price of $5.19. &nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 10,358 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Hazan holds options to purchase 56,562 Ordinary Shares that are not exercisable within 60 days. Ms. Hazan&rsquo;s options have expiration dates ranging from April 5, 2026 to June 11, 2030, and a weighted average exercise price of $6.54. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, Ms. Markvicka&rsquo;s employment with the Company was terminated. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 19,904 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Mr. Mukhtar holds options to purchase 27,896 Ordinary Shares that are not exercisable within 60 days. Mr. Mukhtar&rsquo;s options have expiration dates ranging from March 19, 2029 to February 2, 2030, and a weighted average exercise price of $7.11. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&nbsp;82,793 Ordinary Shares and (ii)&nbsp;53,775 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Mr. Barenholz&rsquo;s options have an expiration date of March 19, 2023, and a weighted average exercise price of $0.22.</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of beneficial ownership of the shares set forth in note&nbsp;(3) above by Aurum Ventures M.K.I.&nbsp;Ltd.&nbsp;&nbsp;In addition, Mr. Dror has 17,925 Ordinary Shares that are not exercisable within 60 days. Mr. Dror&rsquo;s options have an expiration date of June 18, 2030, and a weighted average exercise price of $6.62. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 53,775 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Mr. Jacob&rsquo;s options have an expiration date of August 7, 2029, and a weighted average exercise price of $8.02. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&nbsp;875,977 Ordinary Shares held by Shirat Hachaim Ltd. and (ii) 132,442 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Hurvitz holds options to purchase 50,940 Ordinary Shares that are not exercisable within 60 days. Ms. Hurvitz&rsquo;s options have an expiration date of June 1, 2027, and a weighted average exercise price of $4.10. Chaim Hurvitz is the beneficial owner of Shirat Hachaim&nbsp;Ltd. The address of Shirat Hachaim&nbsp;Ltd. is 31 Yavne Street, Tel Aviv, Israel 65792. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&nbsp;25,000 Ordinary Shares and (ii)&nbsp;13,422 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Mr. Krinsky holds options to purchase 4,503 Ordinary Shares that are not exercisable within 60 days. Mr. Krinsky&rsquo;s options have an expiration date of August 7, 2029, and a weighted average exercise price of $8.65. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 32,265 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Ms. Tsour Segal&rsquo;s options have expiration dates ranging from June 1, 2027 to November 2, 2027, and a weighted average exercise price of $6.10. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of options to purchase 23,900 Ordinary Shares that are not exercisable within 60 days. Mr. Stein&rsquo;s options have an expiration date of June 18, 2030, and a weighted average exercise price of $6.62. </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Stern holds warrants to purchase 17,925 Ordinary Shares
        and options to purchase 23,900 Ordinary Shares that are not exercisable within 60 days. Mr. Stein&rsquo;s options have an expiration
        date of June 18, 2030, and a weighted average exercise price of $6.62.</P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>Changes in Ownership
of Major Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Over the course of 2020, there were no increases
in the percentage ownership of our major shareholders. On the other hand, there were decreases in the percentage ownership of entities
affiliated with (i) Aurum Ventures M.K.I.&nbsp;Ltd (from 15.8% to 10.8%) and (ii) Shavit Capital Funds (from 12.5% to 6.9%), which
was due to the dilution of their ownership as a result of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Over the course of 2019, there were no increases
in the percentage ownership of our major shareholders. On the other hand, there were decreases in the percentage ownership of entities
affiliated with (i) Aurum Ventures M.K.I.&nbsp;Ltd (from 20.3% to 15.8%), (ii) Shavit Capital Funds (from 15.4% to 12.5%), (iii)
Chaim Hurvitz (from 8.7% to 6.8%) and (iv) Noam Emanuel (from 5.3% to 4.1%), which was due to the dilution of their ownership as
a result of a private placement of our preferred shares, which were converted to our Ordinary Shares after our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Over the course of 2018 there were no increases in the percentage
ownership of our major shareholders. On the other hand, there were decreases in the percentage ownership of entities affiliated
with (i) Aurum Ventures M.K.I.&nbsp;Ltd (from 21.7% to 20.3%) and (ii) Shavit Capital Funds (from 16.4% to 15.4%), which was due
to the dilution of their ownership as a result of a private placement of our preferred shares, which were converted to our Ordinary
Shares after our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Record Holders </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of February 25, 2021, there were a total
of 333 holders of record of our shares, of which 264 record holders had registered addresses in the United States. This number
is not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders
reside, since many of these shares were held of record by brokers or other nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not controlled by another corporation,
by any foreign government or by any natural or legal persons except as set forth herein, and here are no arrangements known to
us which would result in a change in control of us at a subsequent date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a031"></A>B.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Related Party Transactions. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See &ldquo;Item 6.B. Compensation&rdquo;
for compensation to our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Ownership of our Ordinary Shares
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain of our existing shareholders, including entities affiliated
with certain of our directors and beneficial owners of greater than 5% of our share capital, purchased an aggregate of 837,000
of the 4,312,500 Ordinary Shares in IPO in June 2020 at the price per share to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Private Placements of our Securities
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Sale of Series&nbsp;E-1 Shares
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2018, February 2019 and August
2019, we entered into share purchase agreements with certain investors, including holders of greater than 5% of our Ordinary Shares,
pursuant to which we issued a total of 3,784,552 Series&nbsp;E-1 preferred shares for an aggregate purchase price of $50.3&nbsp;million,
or the Series&nbsp;E-1 Private Placement. The following table sets forth the aggregate number of Series&nbsp;E-1 preferred shares
issued to our related parties in the Series&nbsp;E-1 Private Placement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Participant</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series&nbsp;E-1<BR> Preferred <BR>
Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Shirat Hachaim&nbsp;Ltd.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">112,772</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Entities associated with Shavit Capital<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,181</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 2pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: left">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Affiliates of Shavit Capital whose securities are aggregated for purposes of reporting share ownership are Shavit Capital Fund&nbsp;III (US),&nbsp;L.P. and Shavit Capital Fund&nbsp;3 (Israel).&nbsp;L.P. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the closing of our IPO, all of our preferred shares
outstanding automatically converted into 12,679,944 Ordinary Shares, after giving effect to an anti-dilution adjustment relating
to our Series&nbsp;E-1 preferred shares, and have no further preferences, privileges or priority rights of any kind. Based on the
initial public offering price of $16.00, the anti-dilution adjustment of our Series&nbsp;E-1 preferred shares is equal to an aggregate
of 158,967 Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Advisory Agreement with Stanley
Stern </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2018, we entered into an advisory agreement for strategic
consulting services with Stanley Stern, a director of our company. Under the agreement, Mr.&nbsp;Stern is entitled to a one-time
cash fee of $225,000, paid to him following the closing of the IPO in 2020, and received a warrant to purchase 17,925 Ordinary
Shares at a purchase price of $0.05 per share and an exercise price equal to the IPO Ordinary Share price. The expiration date
of Mr. Stern&rsquo;s warrant is September 10, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Agreement with CTG Weld </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2019, we entered into a master service
agreement with CTG Weld, a contract research organization, to conduct of a portion of a Phase&nbsp;3 clinical trial of D-PLEX<SUB>100</SUB>
in Eastern Europe for a total cost of $6.3&nbsp;million. In 2020, we paid $717,000 for the services rendered by CTG Weld. Chaim
Hurvitz, a director of our company, serves as a director for, and is a shareholder of, CTG Weld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Agreements and Arrangements
With, and Compensation of, Directors and Executive Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain of our executive officers have employment
agreements with us, which contain customary provisions and representations, including confidentiality, non-competition, non-solicitation
and inventions assignment undertakings by the executive officers. Under current applicable Israeli employment laws, we may not
be able to enforce (either in whole or in part) covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Indemnification Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted by the Israeli
Companies Law. We entered into indemnification agreements with each of our directors and executive officers, undertaking to indemnify
them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from a public offering of
our shares, to the extent that these liabilities are not covered by insurance. We have also obtained directors and officers insurance
for each of our executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a032"></A>C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Interests of Experts and Counsel.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a033"></A>ITEM 8.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>FINANCIAL INFORMATION.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a034"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated Statements and Other Financial Information.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See &ldquo;Item 18. Financial Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not currently subject to any material
legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never declared or paid any cash
dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends,
if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli Companies Law imposes further
restrictions on our ability to declare and pay dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment of dividends may be subject to Israeli
withholding taxes. See &ldquo;Item 10. E. Taxation&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a035"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Significant Changes.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No significant change, other than as otherwise
described in this annual report on Form 20-F, has occurred in our operations since the date of our consolidated financial statements
included in this annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a036"></A>ITEM 9.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>THE OFFER AND LISTING</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a037"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Offer and Listing Details.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Ordinary Shares have been trading under
the symbol &ldquo;PYPD&rdquo; on the Nasdaq Global Market since June 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a038"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Plan of Distribution.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a039"></A>C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Markets.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Ordinary Shares have been listed for
trading on the Nasdaq Global Market since June 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a040"></A>D.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Selling Shareholders.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a041"></A>E.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Dilution.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a042"></A>F.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Expenses of the Issue.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a043"></A>ITEM 10.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>ADDITIONAL INFORMATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a044"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Share Capital.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Not
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a045"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Memorandum and Articles of Association.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of our articles of association is
attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item is set forth in Exhibit 2(d)
to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a046"></A>C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Material Contracts. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not entered into any material contract
within the two years prior to the date of this annual report on Form 20-F, other than contracts entered into in the ordinary course
of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a047"></A>D.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exchange Controls.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are currently no Israeli currency
control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or other
payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of
war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a048"></A>E.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Taxation.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Israeli Tax Considerations and Government Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a summary of the material
Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli income tax considerations
concerning the ownership and disposition of our Ordinary Shares by holders that purchase Ordinary Shares pursuant to the offering
and hold such Ordinary Shares as capital assets. This summary does not discuss all the aspects of Israeli income tax law that may
be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject
to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities
who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation
that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities
or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect as of
the date of this annual report on Form 20-F and does not take into account possible future amendments which may be under consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>General Corporate Tax Structure
in Israel </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of January&nbsp;1, 2018, Israeli resident
companies like us are generally subject to corporate tax at the rate of 23.0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capital gains derived by an Israeli resident
company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation will
be considered as an &ldquo;Israeli resident&rdquo; if it meets one of the following: (a)&nbsp;it was incorporated in Israel; or (b)&nbsp;the
management and control of its business are exercised in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Taxation of our Israeli Individual
Shareholders on Receipt of Dividends </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Israeli residents who are individuals are
generally subject to Israeli income tax for dividends paid on our Ordinary Shares (other than bonus shares or share dividends)
at a rate of 25.0%, or 30.0% if the recipient of such dividend is a &ldquo;substantial shareholder&rdquo; (as defined below) at the
time of distribution or at any time during the preceding 12-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of January&nbsp;1, 2017, an additional
income tax at a rate of 3.0% is imposed on high earners whose annual taxable income or gain exceeds certain thresholds (NIS&nbsp;651,600
as of January&nbsp;1, 2020).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A &ldquo;substantial Shareholder&rdquo; is
generally a person who alone, or together with his or her relative, as defined under section 88 of the Israeli Income Tax Ordinance
[New Version], 1961, or the Israeli Tax Ordinance, or another person who collaborates with him based on an agreement on substantive
matters of the company on a regular basis, holds, directly or indirectly, at least 10.0% of any of the &ldquo;means of control&rdquo;
of the corporation. &ldquo;Means of control&rdquo; generally include the right to vote in a general meeting of shareholders or receive
profits, nominate a director or an officer, receive assets upon liquidation, or instruct someone who holds any of the aforesaid
rights regarding the manner in which he or she is to exercise such right(s), and whether by virtue of shares, rights to shares
or other rights, or in any other manner, including by means of voting or trusteeship agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term &ldquo;Israeli resident&rdquo; for
individuals is generally defined under the Israeli Tax Ordinance, as an individual whose center of life is in Israel. According
to the Israeli Tax Ordinance, in order to determine the center of life of an individual, account will be taken of the individual&rsquo;s
family, economic and social connections, including: (a)&nbsp;the place of the individual&rsquo;s permanent home; (b)&nbsp;the place of
residence of the individual and the individual&rsquo;s family; (c)&nbsp;the place of the individual&rsquo;s regular or permanent place of business
or the place of the individual&rsquo;s permanent employment; (d)&nbsp;place of the individual&rsquo;s active and substantial economic interests;
(e)&nbsp;place of the individual&rsquo;s activities in organizations, associations and other institutions. The center of life of an individual
will be presumed to be in Israel if: (a)&nbsp;the individual was present in Israel for 183&nbsp;days or more in the tax year; or
(b)&nbsp;the individual was present in Israel for 30&nbsp;days or more in the tax year, and the total period of the individual&rsquo;s
presence in Israel in that tax year and the two previous tax years is 425&nbsp;days or more. The presumption in this paragraph
may be rebutted either by the individual or by the assessing officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Taxation of Israeli Resident
Corporations on Receipt of Dividends </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Israeli resident
corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on our Ordinary Shares unless
the distribution is from a Preferred Enterprise, as defined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Capital Gains Taxes Applicable
to Israeli Resident Shareholders </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The income tax
rate applicable to Real Capital Gain, which is the excess of the total capital gain over inflationary surplus computed generally
on the basis of the increase in the Israeli consumer price index between the date of purchase and the date of disposal, derived
by an Israeli individual from the sale of shares which had been purchased after January&nbsp;1, 2012, whether listed on a stock
exchange or not, is 25.0%. However, if such shareholder is considered a &ldquo;Substantial Shareholder&rdquo; (as defined above)
at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30.0%. As of January&nbsp;1,
2017, an additional income tax at a rate of 3% will be imposed on high earners whose annual taxable income or gain exceeds certain
thresholds (NIS 651,600).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, capital
gains derived by a shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary
business income, are taxed in Israel at ordinary income rates (currently, up to 47.0% +3% for individuals and as of January&nbsp;1,
2018, the corporate tax rate is 23.0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Taxation of Non-Israeli Shareholders
on Receipt of Dividends </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Non-Israeli
residents (individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our Ordinary
Shares at the rate of 25.0% (or 30.0% if such person or entity is a &ldquo;substantial shareholder&rdquo; at the time receiving the
dividend or on any date in the 12&nbsp;months preceding such date), which tax will be withheld at source, unless a tax certificate
is obtained from the Israeli Tax Authority authorizing withholding-exempt remittances or a reduced rate of tax pursuant to an applicable
tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-Israeli
resident who receives dividends from which tax was withheld is generally exempt from the duty to file tax returns in Israel in
respect of such income, provided such income was not derived from a business conducted in Israel by such taxpayer, and such taxpayer
has no other taxable sources of income in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For example,
under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes
on Income, as amended, Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed
25.0%, or 15.0% in the case of dividends paid out of the profits of an Approved Enterprise, subject to certain conditions. Where
the recipient is a U.S. corporation owning 10.0% or more of the issued and outstanding voting shares of the paying corporation
during the part of the paying corporation&rsquo;s taxable year which precedes the date of payment of the dividend and during the whole
of its prior taxable year (if any) and not more than 25.0% of the gross income of the paying corporation for such prior taxable
year (if any) consists of certain interest or dividends and the dividend is not paid from the profits of an Approved Enterprise,
the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Capital Gains Income Taxes
Applicable to Non-Israeli Shareholders </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provided certain
conditions are met, non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived
from the sale, exchange or disposition of our Ordinary Shares, provided that such gains were not derived from a permanent establishment
or business activity of such shareholders in Israel. However, non-Israeli corporations&rsquo; shareholders will not be entitled to the
foregoing exemptions if Israeli residents (i)&nbsp;have a controlling interest of more than 25.0% in such non-Israeli corporation
or (ii)&nbsp;are the beneficiaries of or are entitled to 25.0% or more of the revenues or profits of such non-Israeli corporation,
whether directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regardless of
whether shareholders may be liable for Israeli income tax on the sale of our Ordinary Shares, the payment of the consideration
may be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they
are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Tax Benefits Under the 2011
Amendment </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;1,
2011, new legislation amending the Investment Law came into effect, or the 2011 Amendment. The 2011 Amendment introduced a new
status of Preferred Enterprise. Subject to certain conditions, a Preferred Enterprise entitles the company to reduced corporate
tax rates, without limitations on dividends and other distributions, instead of full exemption from corporate tax. These preferred
corporate tax rates vary from 7.5% for Preferred Enterprises residing in a &ldquo;development zone,&rdquo; or 16.0% for Preferred
Enterprises residing in other zones in Israel. Dividend distributions are subject to 20% tax rate, subject to the provision of
the relevant tax treaty. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to
gain the status of Preferred Enterprise, a company must meet the conditions of competitive industrial company that contributes
to the GDP or comparative industrial company in the field of renewable energy. <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material U.S. Federal Income Tax Considerations</B> <B>to
U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The following discussion describes the material
U.S. federal income tax considerations relating to the ownership and disposition of our Ordinary Shares by U.S. Holders (as defined
below). This discussion applies to U.S. Holders that hold such Ordinary Shares as capital assets within the meaning of Section
1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based on the Code, U.S. Treasury regulations
promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of
which are subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income
tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject
to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, broker-dealers
and traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes,
tax-exempt entities, retirement plans, regulated investment companies, real estate investment trusts, certain former citizens or
residents of the United States, persons who hold Ordinary Shares as part of a &quot;straddle,&quot; &quot;hedge,&quot; &quot;conversion
transaction,&quot; &quot;synthetic security&quot; or integrated investment, persons who received their Ordinary Shares as compensatory
payments, persons that have a &quot;functional currency&quot; other than the U.S. dollar, persons that own directly, indirectly
or through attribution 10% or more of our shares by vote or value, persons subject to special tax accounting rules as a result
of any item of gross income with respect to the shares being taken into account in an applicable financial statement, corporations
that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in such
pass-through entities). This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal
estate, gift or alternative minimum tax or Medicare tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">As used in this discussion, the term &quot;U.S.
Holder&quot; means a beneficial owner of Ordinary Shares that is, for U.S. federal income tax purposes, (1) an individual who is
a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes)
created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the
income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court
within the United States is able to exercise primary supervision over its administration and one or more United States persons
have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations
to be treated as a domestic trust for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">If an entity or arrangement treated as a
partnership for U.S. federal income tax purposes holds Ordinary Shares, the U.S. federal income tax consequences relating to an
investment in the ordinary shares will depend in part upon the status and activities of such entity or arrangement and the particular
partner. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable
to it and its partners of the ownership and disposition of Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">THE FOLLOWING SUMMARY IS INCLUDED HEREIN
FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND
SALE OF ORDINARY SHARES AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX
LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Passive Foreign Investment
Company Consequences </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In general, a corporation organized outside
the United States will be treated as PFIC for any taxable year in which either (1) at least 75% of its gross income is &quot;passive
income&quot;, the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that
produce passive income or are held for the production of passive income, the PFIC asset test. Passive income for this purpose generally
includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives
rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held
as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally,
in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in
which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Our status as a PFIC will depend on the nature
and composition of our income and the nature, composition and value of our assets (which, assuming we are not a CFC under Section
957(a) of the Code for the year being tested, may be determined based on the fair market value of each asset, with the value of
goodwill and going concern value being determined in large part by reference to the market value of our Ordinary Shares, which
may be volatile). Based upon the estimated value of our assets, including any goodwill, and the nature and estimated composition
of our income and assets, we may be classified as a PFIC for the taxable year ended December 31, 2020 and in future taxable years
In particular, so long as we do not generate revenue from operations for any taxable year and do not receive any research and development
grants, or even if we receive a research and development grant, if such grant does not constitute gross income for U.S. federal
income tax purposes, we likely will be classified as a PFIC for such taxable year. Even if we determine that we are not a PFIC
for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully
challenge our position. Our status as a PFIC is a fact-intensive determination made on an annual basis after the end of each taxable
year. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for our taxable year ended December 31,
2020 and also expresses no opinion with regard to our expectations regarding our PFIC status in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">If we are a PFIC in any taxable year during
which a U.S. Holder owns Ordinary Shares, the U.S. Holder could be liable for additional taxes and interest charges under the &quot;PFIC
excess distribution regime&quot; upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual
distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder's holding period for the Ordinary Shares,
and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of the Ordinary Shares, whether or not
we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by
allocating the distribution or gain ratably over the U.S. Holder's holding period for Ordinary Shares. The amount allocated to
the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the
first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated
to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to
ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added
to the tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">If we are a PFIC for any year during which
a U.S. Holder holds Ordinary Shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years
during which the U.S. Holder holds the Ordinary Shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder
makes a &quot;deemed sale&quot; election with respect to the Ordinary Shares. If the election is made, the U.S. Holder will be
deemed to sell the Ordinary Shares it holds at their fair market value on the last day of the last taxable year in which we qualified
as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed
sale election, the U.S. Holder's Ordinary Shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">If we are a PFIC for any taxable year during
which a U.S. Holder holds Ordinary Shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier PFIC),
such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be
taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares
of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each
U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">If we are a PFIC, a U.S. Holder will not
be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on Ordinary Shares if such U.S.
Holder makes a valid &quot;mark-to-market&quot; election for our Ordinary Shares. A mark-to-market election is available to a U.S.
Holder only for &quot;marketable stock.&quot; Our Ordinary Shares will be marketable stock as long as they remain listed on the
Nasdaq Global Market and are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.
If a mark-to-market election is in effect, a U.S. Holder generally would take into account, as ordinary income for each taxable
year of the U.S. holder, the excess of the fair market value of Ordinary Shares held at the end of such taxable year over the adjusted
tax basis of such Ordinary Shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the
adjusted tax basis of such Ordinary Shares over their fair market value at the end of the taxable year, but only to the extent
of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election.
The U.S. Holder's tax basis in Ordinary Shares would be adjusted to reflect any income or loss recognized as a result of the mark-to-market
election. Any gain from a sale, exchange or other disposition of Ordinary Shares in any taxable year in which we are a PFIC would
be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss
(to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">A mark-to-market election will not apply
to Ordinary Shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent
taxable year in which we become a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire
in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect
to any lower-tier PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder's mark-to-market election
for the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The tax consequences that would apply if
we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid QEF election. At this
time, we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election. Prospective
investors should assume that a QEF election will not be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Each U.S. person that is an investor of a
PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury
Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the
statute of limitations with respect to U.S. federal income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The U.S. federal income tax rules relating to PFICs are very
complex. U.S. Holders are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the ownership
and disposition of Ordinary Shares, the consequences to them of an investment in a PFIC, any elections available with respect to
the Ordinary Shares and the IRS information reporting obligations with respect to the ownership and disposition of Ordinary Shares
of a PFIC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: justify"><B><I>Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We do not anticipate declaring or paying
dividends to holders of our ordinary stock in the foreseeable future. However, if we make a distribution contrary to the expectation,
subject to the discussion above under &quot;&mdash;<I>Passive Foreign Investment Company Consequences</I>,&quot; a U.S. Holder
that receives a distribution with respect to Ordinary Shares generally will be required to include the gross amount of such distribution
in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder's pro rata share of our
current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution
received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder's pro rata share of our current and accumulated
earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax
basis of the U.S. Holder's Ordinary Shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder's
Ordinary Shares, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in accordance
with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Distributions on Ordinary Shares that are
treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and
generally will constitute passive category income. Subject to certain complex conditions and limitations, Israeli taxes withheld
on any distributions on Ordinary Shares may be eligible for credit against a U.S. Holder's federal income tax liability. The rules
relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult their tax advisors regarding
the availability of a foreign tax credit in their particular circumstances and the possibility of claiming an itemized deduction
(in lieu of the foreign tax credit) for any foreign taxes paid or withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Dividends paid by a &quot;qualified foreign
corporation&quot; are eligible for taxation to non-corporate U.S. holders at a reduced capital gains rate rather than the marginal
tax rates generally applicable to ordinary income provided that certain requirements are met. Each U.S. Holder is advised to consult
its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Each
U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard
to its particular circumstances. Distributions on Ordinary Shares that are treated as dividends generally will not be eligible
for the &quot;dividends received&quot; deduction generally allowed to corporate shareholders with respect to dividends received
from U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">A non-United States corporation (other than
a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally
will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with
the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision
and which includes an exchange of information provision, or (b) with respect to any dividend it pays on Ordinary Shares that are
readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Israel for
purposes of, and are eligible for the benefits of, the U.S.-Israel Treaty, although there can be no assurance in this regard. Further,
the IRS has determined that the U.S.-Israel Treaty is satisfactory for purposes of the qualified dividend rules and that it includes
an exchange of information provision. Our Ordinary Shares will also generally be considered to be readily tradable on an established
securities market in the United States if they are listed on The Nasdaq Global Market, as we intend the Ordinary Shares to be.
Therefore, subject to the discussion above under &quot;&mdash;Passive Foreign Investment Company Consequences,&quot; if the U.S.-Israel
Treaty is applicable, or if our Ordinary Shares are readily tradable on an established securities market in the United States,
such dividends will generally be &quot;qualified dividend income&quot; in the hands of individual U.S. Holders, provided that certain
conditions are met, including holding period and the absence of certain risk reduction transaction requirements. Each U.S. Holder
is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Sale, Exchange or Other Disposition
of Ordinary Shares </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Subject to the discussion above under &quot;&mdash;<I>Passive
Foreign Investment Company Consequences</I>,&quot; a U.S. Holder generally will recognize capital gain or loss for U.S. federal
income tax purposes upon the sale, exchange or other disposition of Ordinary Shares in an amount equal to the difference, if any,
between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange
or other disposition and such U.S. Holder's adjusted tax basis in the Ordinary Shares. Such capital gain or loss generally will
be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of
sale, exchange or other disposition, the Ordinary Shares were held by the U.S. Holder for more than one year. Any capital gain
of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital
losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of Ordinary Shares will generally
be gain or loss from sources within the United States for U.S. foreign tax credit purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Information Reporting and
Backup Withholding </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">U.S. Holders may be required to file certain
U.S. information reporting returns with the IRS with respect to an investment in Ordinary Shares, including, among others, IRS
Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &quot;<I>Passive Foreign Investment Company
Consequences</I>&quot;, each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information.
U.S. Holders paying more than US$100,000 for Ordinary Shares may be required to file IRS Form 926 (Return by a U.S. Transferor
of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails
to comply with the required information reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Dividends on and proceeds from the sale or
other disposition of Ordinary Shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup
withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification
number or otherwise establish a basis for exemption (usually on IRS Form W-9), or (2) is described in certain other categories
of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding
tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will
be allowed as a refund or a credit against a U.S. Holder's U.S. federal income tax liability if the required information is furnished
by the U.S. Holder on a timely basis to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">U.S. Holders should consult their own tax advisors regarding
the backup withholding tax and information reporting rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a049"></A>F.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Dividends and Paying Agents.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a050"></A>G.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Statement by Experts.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a051"></A>H.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Documents on Display.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the information reporting
requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with the
SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC are also available to the public through the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a foreign private issuer, we are exempt
from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and
principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the
Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange
Act. However, we file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the
SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm,
and may submit to the SEC, on a Form 6-K, unaudited quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain a corporate website www.polypid.com.
Information contained on, or that can be accessed through, our website and the other websites referenced above do not constitute
a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form 20-F solely as
inactive textual references.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a052"></A>I.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsidiary Information.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a053"></A>ITEM 11.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ordinary course of our operations,
we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Quantitative and Qualitative Disclosure
About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are exposed to market risks in the ordinary
course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in
financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that have
a credit rating of at least A-minus. Accordingly, a substantial majority of our cash and cash equivalents is held in deposits that
bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced.
Our market risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following
paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Foreign Currency Exchange Risk </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We operate primarily
in Israel, and approximately 70% of our expenses are denominated in New Israeli Shekels, or NIS. We are therefore exposed to market
risk, which represents the risk of loss that may impact our financial position due to adverse changes in financial market prices
and rates. We are subject to fluctuations in foreign currency rates in connection with these arrangements. Changes of 5% and 10%
in the U.S. dollar/NIS exchange rate would have increased/decreased operating expenses by approximately 3.5% and 7%, respectively,
in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently partially hedge our foreign
currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.
<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a054"></A>ITEM 12.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a055"></A>A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Debt Securities.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a056"></A>B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants and rights.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a057"></A>C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other Securities.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 128 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph010402a059"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a060"></A>ITEM 13.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a061"></A>ITEM 14.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In June 2020, we sold 4,312,500 Ordinary
Shares in the IPO at a public offering price of $16.00 per share, for aggregate gross proceeds to us of $69.0 million. The net
offering proceeds to us, after deducting underwriting discounts and commissions totaling approximately $4.8 million and offering
expenses totaling approximately $1.4 million were approximately $62.8 million. The offering commenced on June 5, 2020 and did not
terminate before all of the securities registered in the registration statement were sold. The effective dates of the registration
statements, File Nos. 333-238978 and 333-239442, for the IPO of our Ordinary Shares were June 25, 2020. Barclays Capital Inc. acted
as sole book-running manager and as representative of the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The net proceeds from IPO have been used,
and are expected to continue to be used, as described in the final prospectus for the IPO filed with the SEC on June 29, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a062"></A>ITEM 15.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>CONTROLS AND PROCEDURES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(a) Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our disclosure controls
and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Our management, including
our Chief Executive Officer and Chief Financial Officer, recognizes that any control system, no matter how well designed and operated,
is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly,
an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all
control issues and instances of fraud, if any, have been detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure
controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2020,
or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure
controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required
to be included in periodic filings under the Exchange Act and that such information is accumulated and communicated to management,
including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(b) Management&rsquo;s Annual Report
on Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This annual report does not include a report of management&rsquo;s
assessment regarding internal control over financial reporting or an attestation report of the company&rsquo;s registered public
accounting firm due to a transition period established by rules of the SEC for newly public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(c) Attestation Report of the Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This annual report does not include a report of management&rsquo;s
assessment regarding internal control over financial reporting or an attestation report of the company&rsquo;s registered public
accounting firm due to a transition period established by rules of the SEC for newly public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(d) Changes in Internal Control over
Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the year ended December 31, 2020,
there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a063"></A>ITEM 16A.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AUDIT COMMITTEE FINANCIAL EXPERT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors has determined that
each of Dr.&nbsp;Krinsky and Ms.&nbsp;Segal is an audit committee financial expert as such term is defined by the SEC rules and
has the requisite financial experience as defined by the Nasdaq Rules. Each of the members of our audit committee is &ldquo;independent&rdquo;
as such term is defined in Rule&nbsp;10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under
the Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a064"></A>ITEM 16B.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CODE OF ETHICS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted
a Corporate Code of Ethics and Conduct applicable to all of our directors and employees, including our Chief Executive Officer,
Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a
&ldquo;code of ethics&rdquo; as defined in Item&nbsp;16B of Form&nbsp;20-F promulgated by the SEC. The full text of the Corporate
Code of Ethics and Conduct is posted on our website at www.polypid.com. Information contained on, or that can be accessed through,
our website does not constitute a part of this annual report and is not incorporated by reference herein. If we make any amendment
to the Corporate Code of Ethics and Conduct or grant any waivers, including any implicit waiver, from a provision of such code,
we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a065"></A>ITEM 16C.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Kost, Forer, Gabbay&nbsp;&amp;
Kasierer, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of Ernst&nbsp;&amp;
Young Global, has served as our principal independent registered public accounting firm for each of the two years ended December
31, 2019 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table
provides information regarding fees paid by us to Kost, Forer, Gabbay&nbsp;&amp; Kasierer and/or other member firms of Ernst&nbsp;&amp;
Young Global for all services, including audit services, for the years ended December 31, 2019 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year Ended</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December 31,</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit fees <SUP>(1) </SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">90,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">228,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit-related fees <SUP>(2) </SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All other fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,135</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">93,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">497,135</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes professional services rendered in connection with the
audit of our annual financial statements, review of our interim financial statements and tax returns. All of the services provided
were approved by audit committee on August 5, 2020 and by our board of directors on August 18, 2020.</P></TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left">(2)</TD><TD STYLE="text-align: left">Includes professional services rendered in connection with the
fees relating to the IPO. All of the services provided were approved by our board of directors on February 6, 2020. Pursuant to
the regulations promulgated under the Israeli Companies Law, pre-approval of audit fees is only mandatory for a public company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Pre-Approval of Auditors&rsquo; Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under our audit committee
charter our audit committee is responsible for, among other things: (1) pre-approving audit and non-audit services provided to
us by the independent registered public accounting firm; and (2) subject to the board of directors&rsquo; and shareholders&rsquo;
approval, if and to the extent required by applicable law, the audit committee shall have the authority to approve all audit engagement
fees and terms and all non-audit engagements, as may be permissible, with the independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a066"></A>ITEM 16D.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a067"></A>ITEM 16E.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a068"></A>ITEM 16F.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CHANGE IN REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a069"></A>ITEM 16G.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CORPORATE GOVERNANCE</B> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Sarbanes-Oxley Act, as well as related
rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with various corporate governance
practices. In addition, we are required to comply with the Nasdaq Stock Market rules. Under those rules, we may elect to follow
certain corporate governance practices permitted under the Israeli Companies Law in lieu of compliance with corresponding corporate
governance requirements otherwise imposed by the Nasdaq Stock Market rules for U.S. domestic issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Israeli law and practice
and subject to the exemption set forth in Rule 5615 of the Nasdaq Stock Market rules, we have elected to follow the provisions
of the Israeli Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Proxy Statements.</I>&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to comply with certain Nasdaq Rules regarding the provision of proxy statements for general meetings of shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1.35pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Quorum</I>. As permitted under
the Israeli Companies Law and pursuant to our amended and restated articles of association, the quorum required for an ordinary
meeting of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in
accordance with the Israeli Companies Law, who hold at least 33&#8531;% of the voting power of our shares. A meeting adjourned
for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time
or date if so specified in the summons or notice of the meeting. At the reconvened meeting, in general any shareholder present
in person or by proxy shall constitute a lawful quorum, instead of 33&#8531;% of the issued share capital required under
the Nasdaq Rules. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.35pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 29px; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Nomination of our directors</I>. The nominations for directors, which are presented to our shareholders
by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our articles
of association and the Israeli Companies Law. Nominations need not be made by a nominating committee of our board of directors
consisting solely of independent directors or by a vote consisting solely of our independent directors in order to determine which
persons shall be nominated for election by our shareholders, as required under the Nasdaq Stock Market rules.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1.35pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Independent Directors</I>. Under the Israeli Companies Law, we would be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications and other provisions would be applicable. We would also be required to include one such external director on each of our board committees. However, as we do not have a controlling shareholder, and we comply with the requirements of the Nasdaq Stock Market with respect to the composition of our board and such committees, we therefore are exempt from the Israeli Companies Law requirements with respect thereto, including the appointment of external directors. We are required, however, to ensure that all members of our audit committee are &ldquo;independent&rdquo; under the Nasdaq Rules, and we must also ensure that a majority of the members of our audit committee are &ldquo;independent directors&rdquo; as defined in the Israeli Companies Law. Furthermore, Israeli law does not require, and our independent directors do not conduct regularly scheduled meetings at which only they are present, as otherwise required by the Nasdaq Stock Market rules.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1.35pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Shareholder Approval.</I>&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to comply with certain Nasdaq Rules regarding shareholder approval for certain issuances of securities under Nasdaq Rule&nbsp;5635. In particular, under the Nasdaq Rules, shareholder approval is generally required for: (i)&nbsp;an acquisition of shares or assets of another company that involves the issuance of 20% or more of the acquirer&rsquo;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest (or such persons collectively have a 10% or greater interest) in the target company or the assets to be acquired or the consideration to be received and the present or potential issuance of Ordinary Shares, or securities convertible into or exercisable for Ordinary Shares, could result in an increase in outstanding Ordinary Shares or voting power of 5% or more; (ii)&nbsp;the issuance of shares leading to a change of control; (iii)&nbsp;adoption or amendment of a stock option or purchase plan or other equity compensation arrangements, pursuant to which stock may be acquired by officers, directors, employees or consultants (with certain limited exception); and (iv)&nbsp;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors or officers or 5% shareholders) if such equity is issued (or sold) at below a specified minimum price. By contrast, under the Israeli Companies Law, the adoption of, and material changes to, equity-based compensation plans generally require the approval of the board of directors and the compensation committee of the board of directors. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.35pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1.35pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Approval of Related Party Transactions</I>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transactions as set forth in the Israeli Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.35pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1.35pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Annual Shareholders Meeting.</I>&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to comply with Nasdaq Stock Market Rule 5620(a), which requires a listed company to hold its annual shareholders meeting within one year of the company&rsquo;s fiscal year-end. Under the Israeli Companies Law, we are required to hold an annual shareholders meeting each calendar year and within 15 months of the last annual shareholders meeting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to take all actions necessary
for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley
Act of 2002, the rules adopted by the SEC and the Nasdaq Stock Market corporate governance rules and listing standards. Because
we are a foreign private issuer, our directors and senior management are not subject to short-swing profit and insider trading
reporting obligations under Section&nbsp;16 of the Exchange Act. They are, however, subject to the obligations to report changes
in share ownership under Section&nbsp;13 of the Exchange Act and related SEC rules.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a070"></A>ITEM 16H.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>MINE SAFETY DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph010402a071"></A><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a072"></A>ITEM 17.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>FINANCIAL STATEMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have elected to provide financial statements
and related information pursuant to Item&nbsp;18.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a073"></A>ITEM 18.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>FINANCIAL STATEMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements and
the related notes required by this Item are included in this annual report on Form 20-F beginning on page&nbsp;F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="aph010402a074"></A>ITEM 19.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBITS. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000110465920079705/tm2023812d2_ex3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association of PolyPid Ltd., filed as Exhibit 3.1 to Form 6-K (File No. 001-38428) filed on July 1, 2020, and incorporated
    herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.1</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0pt 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-4_2.htm">Form of Warrant to purchase Series&nbsp;E-1 Preferred Shares, filed as Exhibit 4.2 to form F-1 (File No. &nbsp;333-238978) filed on June 5, 2020, and incorporated herein by reference.</A></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex2-2_polypid.htm">Description of Securities (filed herewith).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003758/a2241928zex-10_1.htm">Form of Officer Indemnity and Exculpation Agreement, filed as Exhibit 10.1 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003758/a2241928zex-10_5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy, filed as Exhibit 3.2 to
    Form F-1 (File No. &nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-238978</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
    filed on June 22, 2020, and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated PolyPid &nbsp;Ltd. 2012
    Share Option Plan , filed as Exhibit 10.2 to form F-1 (File No. &nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-238978</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
    filed on June 5, 2020, and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_4.htm">Lease Agreement, dated March 27, 2014, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4 as Exhibit 10.4 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_41.htm">Addendum to Lease Agreement, dated July 1, 2014, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.1 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_42.htm">Second Addendum to Lease Agreement, dated July 23, 2017, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.2 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_43.htm">Third Addendum to Lease Agreement, dated November 28, 2017, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.3 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_44.htm">Fourth Addendum to Lease Agreement, dated January 22, 2018, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.4 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_45.htm">Fifth Addendum to Lease Agreement, dated November 4, 2018, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.5 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_46.htm">Sixth Addendum to Lease Agreement, dated December 15, 2019, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.6 to Form F-1 (File No. &nbsp;333-238978) filed on June 22, 2020, and incorporated herein by reference.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 91%"><A HREF="f20f2020ex8-1_polypid.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD>
    <TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-decoration: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex12-1_polypid.htm">Certification
    of the Principal Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD>
    <TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex12-2_polypid.htm">Certification
    of the Principal Financial and Accounting Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex13-1_polypid.htm">Certification
    of the Principal Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex13-2_polypid.htm">Certification
    of the Principal Financial and Accounting Officer pursuant to 18 U.S.C. 1350, furnished herewith.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f20f2020ex15-1_polypid.htm">Consent
    of Kost, Forer, Gabbay&nbsp;&amp; Kasierer, Certified Public Accountants (Israel), an independent registered public accounting
    firm and a member firm of Ernst&nbsp;&amp; Young Global.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following financial information from the
    Registrant&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2020, formatted in XBRL (eXtensible Business
    Reporting Language): (i) Report of Independent Registered Public Accounting Firm; (ii) Consolidated Balance Sheets; (iii)
    Consolidated Statements of Operations; (iv) Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&rsquo;
    Equity (Deficit); (v) Consolidated Statements of Cash Flows; and (vi) Notes to the Consolidated Financial Statements, tagged
    as blocks of text and in detail.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registrant hereby certifies that it
meets all of the requirements for filing on Form&nbsp;20-F and that it has duly caused and authorized the undersigned to sign this
annual report on Form 20-F filed on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>POLYPID LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 5, 2021</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>POLYPID LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF DECEMBER&nbsp;31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><B>Report of Independent Registered Public Accounting Firm</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-2</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.7pt; text-align: justify"><A HREF="#a_002"><B>Consolidated Balance Sheets </B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-3 - F-4</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.7pt; text-align: justify"><A HREF="#a_003"><B>Consolidated Statements of Operations</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-5</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in; text-align: justify"><A HREF="#a_004"><B>Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&rsquo; Equity (Deficit) &nbsp;</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-6</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.7pt; text-align: justify"><A HREF="#a_005"><B>Consolidated Statements of Cash Flows </B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-7</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.7pt; text-align: justify"><A HREF="#a_006"><B>Notes to Consolidated Financial Statements</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><B>F-8 - F-33</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 137; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><IMG SRC="fin_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 40%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Kost Forer Gabbay &amp; Kasierer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">144 Menachem Begin Road, Building
        A,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tel-Aviv 6492102, Israel</P></TD>
    <TD STYLE="vertical-align: middle; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 40%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tel: +972-3-6232525</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fax: +972-3-5622555</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ey.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><A NAME="a_001"></A><B>REPORT OF INDEPENDENT AUDITORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To the Shareholders&rsquo; and Board of Directors
of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POLYPID LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Consolidated Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Polypid Ltd. and subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019, the related consolidated
statements of operations, changes in convertible preferred shares and shareholders&rsquo; equity (deficit) and cash flows for each of
the three years in the period ended December 31, 2020 and the related notes (collectively referred to as the &ldquo;consolidated
financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects,
the financial position of the Company at December 31, 2020 and 2019, and the consolidated results of its operations and its cash
flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting
principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on
our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 62%">/s/ <FONT STYLE="font-size: 10pt">KOST FORER GABBAY &amp;
    KASIERER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 38%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">A Member of Ernst &amp; Young Global</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We have served as the Company&rsquo;s auditor
    since 2010.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">March 5, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_002"></A><B>CONSOLIDATED
BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;dollars in thousands (except
share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,319</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,924</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Short-term deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in">Prepaid expenses and other receivables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,334</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Long-term assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,121</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Long-term deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in">Other long-term assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">637</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Total long-term assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,647</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,351</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">75,847</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,752</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><B>POLYPID LTD AND ITS SUBSIDIARIES</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><B>CONSOLIDATED
BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;dollars in thousands (except
share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 1.1pt">Trade payables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,581</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 1.1pt">Other payables and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">998</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.1pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 1.1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,579</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.1pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.1pt">Long-term liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.1pt">Other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">251</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 1.1pt">Warrants to convertible preferred shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,241</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.1pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 1.1pt">Total long-term liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">193</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,492</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.1pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.1pt">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Convertible preferred shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 0.5in">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares with no par value - Authorized: 0 and 17,916,412 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 0 and 12,520,977 shares at December 31, 2020 and 2019, respectively.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">106,313</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -11.35pt; padding-left: 14.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Shareholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -11.35pt; padding-left: 22.7pt">Share capital -</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -11.35pt; padding-left: 0.5in">Ordinary shares with no par value - Authorized: 47,800,000 and 22,520,977 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 18,494,739 and 562,748 shares at December 31, 2020 and 2019, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,671</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(132,286</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(93,303</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -11.35pt; padding-left: 14.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Total shareholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,777</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(87,632</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -11.35pt; padding-left: 14.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total liabilities, convertible preferred shares and shareholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">75,847</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,752</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; padding-left: 2.85pt; text-align: center"><FONT STYLE="font-size: 10pt">March
    5, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-left: 2.85pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; padding-left: 2.85pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; border-bottom: white 1pt solid; padding-left: 2.85pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-left: 2.85pt; text-align: center"><FONT STYLE="font-size: 10pt">Date of approval
    of the consolidated</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 2.85pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Amir Weisberg</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Dikla Czaczkes-Akselbrad</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 2.85pt; text-align: center"><FONT STYLE="font-size: 10pt">financial statements</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 2.85pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Executive Vice President &amp; Chief Financial
    Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><B>POLYPID LTD AND ITS SUBSIDIARIES</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 1.5pt solid"><A NAME="a_003"></A><B>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;dollars in thousands (except
share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; width: 64%; text-align: left; padding-left: 0pt">Research and development, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">16,954</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">14,083</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">12,550</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; text-align: left; padding-left: 0pt">Marketing and business development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">887</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">549</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,590</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Financial (income) expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,655</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,281</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Net (profit) loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">36,869</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,905</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,917</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Deemed dividend</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Net loss attributable to Ordinary shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,983</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,905</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,917</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Basic net (profit) loss per Ordinary share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.48</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23.69</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Diluted net loss per Ordinary share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.48</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23.69</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.86</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of Ordinary shares used in computing basic net (profit) loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,582,405</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">562,451</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">561,113</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of Ordinary shares used in computing diluted net loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,582,405</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">562,451</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">613,358</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><B>POLYPID LTD AND ITS SUBSIDIARIES</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>





<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A NAME="a_004"></A><B>CONSOLIDATED
STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND CHANGES IN SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;dollars in thousands (except
share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Convertible Preferred shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shareholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional paid-in capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total shareholders&rsquo; </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>deficit </B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balances as of January 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">8,736,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">59,983</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">59,983</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">558,447</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3,669</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(92,315</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(88,646</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,778</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of series E-1 Preferred shares, net (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">718,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balances as of December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,454,433</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,688</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,398</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,710</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,523</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of series E-1 Preferred shares, net (**)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,066,544</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,905</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,905</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balances as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,520,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">562,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,303</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87,632</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note&nbsp;1e)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,312,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Conversion of Convertible Preferred shares to Ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,520,977</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,313</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,313</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,520,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Deemed dividend related to Series E-1 Preferred shares (see Note 9e)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Reclassification of Warrants into equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,614</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise of Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">939,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise of Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(36,869</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(36,869</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balances as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">18,494,739</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">205,063</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(132,286</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">72,777</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(*)</TD><TD STYLE="text-align: justify">Net of issuance costs of $187 in cash.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(**)</TD><TD STYLE="text-align: justify">Net of issuance costs of $3,822 in cash and warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><B>POLYPID LTD AND ITS SUBSIDIARIES</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><A NAME="a_005"></A><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;dollars in thousands (except
share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December&nbsp;31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Net profit (loss)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(36,869</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(6,905</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,917</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash used&nbsp;in <BR>operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">411</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Re-evaluation of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,365</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,473</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.35pt">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Decrease (increase) in receivables and prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,917</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Decrease in deferred equity offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Decrease in advance on account of collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(600</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Decrease (increase) in other long-term assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">Increase (decrease) in trade payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(607</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(887</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 28.35pt">Increase (decrease) in other payables and accrued expenses and other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">847</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,540</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">560</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,358</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,678</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Short-term deposits, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,472</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Long-term deposits, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,120</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Pre-payment for equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(395</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 19.85pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(781</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(879</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,074</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash provided by (used in) investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,768</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Proceeds from issuance of convertible Preferred shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Proceeds from Issuance of Ordinary shares in connection with IPO, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Issuance of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 19.85pt">Proceeds from exercise of options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,653</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Increase (decrease) in cash, cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,269</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents and restricted cash at the beginning of the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,498</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents and restricted cash at the end of the year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,908</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,498</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,767</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><U>Non-cash activity:</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Purchase of property and equipment included in trade payable</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">600</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Issuance of E-1 warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">680</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the consolidated financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><A NAME="a_006"></A><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
1:-&#9;GENERAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">PolyPid Ltd. (the &ldquo;Company&rdquo;)
                                         was incorporated under the laws of Israel and commenced operations on February&nbsp;28,
                                         2008. The Company is a clinical-stage pharmaceutical company focused on developing and
                                         commercializing novel, locally administered therapies using its PLEX (Polymer-Lipid Encapsulation
                                         matriX) technology. The Company&rsquo;s product candidates are designed to address unmet medical
                                         needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined
                                         release rates and durations over extended periods ranging from days to several months.
                                         The Company is initially focused on the development of its lead product candidate, D-PLEX,
                                         which incorporates an antibiotic, for the prevention of surgical site infection in bone
                                         and soft tissue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company wholly-owns subsidiaries
in the Unites States of America and Romania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Through
December 31, 2020, the Company has been primarily engaged in research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">The Company&rsquo;s activities since
                                         inception have consisted of performing research and development activities. Successful
                                         completion of the Company&rsquo;s development programs and, ultimately, the attainment of profitable
                                         operations is dependent on future events, including, among other things, its ability
                                         to secure financing; obtain marketing approval from regulatory authorities; access potential
                                         markets; build a sustainable customer base; attract, retain and motivate qualified
                                         personnel; and develop strategic alliances. The Company&rsquo;s operations are funded by its
                                         shareholders and research and development grants and the Company intends to seek further
                                         private or public financing as well as make applications for further research and development
                                         grants for continuing its operations. Although management believes that the Company will
                                         be able to successfully fund its operations, there can be no assurance that the Company
                                         will be able to do so or that the Company will ever operate profitably.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute
its business plan, the Company will need to complete phase III clinical studies and certain development activities as well as
manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&rsquo;s product
candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing
and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately
be unsuccessful. Any delays in completing these activities could adversely impact the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2020, the
Company had cash, cash equivalents, short-term deposits and long-term deposits of $66,596. During the year ended December&nbsp;31,
2020, the Company incurred a net loss of $36,869 and had negative cash flows from operating activities of $21,596. In addition,
the Company had an accumulated deficit of $132,286 at December 31, 2020.</P>





<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 1:-&#9;GENERAL (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company&rsquo;s
future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies;
(ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production
batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">There can
be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">c</FONT>.</TD><TD STYLE="text-align: justify">On
                                         March 11, 2020, the World Health Organization declared the outbreak of a respiratory
                                         disease caused by a new coronavirus as a &ldquo;pandemic&rdquo; which is now known as
                                         COVID-19. The outbreak has impacted thousands of individuals worldwide. In response,
                                         many countries have implemented measures to combat the outbreak which have impacted global
                                         business operations. The Company&rsquo;s business is likely to be adversely affected by the
                                         effects of the recent and evolving COVID-19 pandemic, which has resulted in travel and
                                         other restrictions in order to reduce the spread of the disease, including in Israel,
                                         the United States and the European Union where the Company is conducting or planning
                                         clinical trials. No impairments were recorded as of the balance sheet date as no triggering
                                         events or changes in circumstances had occurred; however, due to significant uncertainty
                                         surrounding the situation, management&rsquo;s judgment regarding this could change in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.2pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">On June 21, 2020, the Company&rsquo;s Board of Directors resolved to consolidate the
                                                              Company&rsquo;s share capital by applying a reverse share split at a ratio of 1.046:1 (the &ldquo;Reverse Split Ratio&rdquo;)
                                                              and to cancel the shares&rsquo; par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1
                                                              Ordinary share with no par value (the &ldquo;Split&rdquo;). The Split was  applied in the same proportion and manner to all
                                                              of the Company&rsquo;s authorized, issued and outstanding securities, including preferred shares, options and warrants. See
                                                              Note 10.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">On June 30, 2020, the Company
                                         closed its initial public offering (&ldquo;IPO&rdquo;) whereby 4,312,500 Ordinary shares
                                         were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant
                                         to the full exercise of an overallotment option granted to the underwriters). The aggregate
                                         net proceeds received by the Company from the offering were $62,757, net of underwriting
                                         discounts and other offering costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: -27.75pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The consolidated financial
statements are prepared according to United States generally accepted accounting principles (&ldquo;U.S. GAAP&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Use of estimates:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation
of the consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&rsquo;s
management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of
share-based awards, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and
the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Consolidated financial statements
                                         in U.S.&nbsp;dollars:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The accompanying
consolidated financial statements have been prepared in U.S.&nbsp;dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A substantial portion of the Company&rsquo;s expenses are incurred
in New Israeli Shekels (&ldquo;NIS&rdquo;). However, the Company finances its operations mainly in U.S. dollars, a substantial
portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated
in U.S. dollars. As such, the Company&rsquo;s management believes that the U.S. dollar is the currency of the primary economic environment
in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&nbsp;dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Transactions and balances denominated in U.S. dollars are presented
at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance
with Accounting Standards Codification (&ldquo;ASC&rdquo;) No. 830, &ldquo;Foreign Currency Matters&rdquo;. All transaction gains
and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income
or expenses, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Principles of consolidation:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The consolidated
financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Reclassifications:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Certain prior years amounts
have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated
net loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">Cash equivalents:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or
less, at the date acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">f.</TD><TD STYLE="text-align: justify">Restricted cash:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Restricted
cash is primarily invested in certificates of deposit and is used as security for the Company&rsquo;s lease commitments and hedging
activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets
and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, as reported on the balance sheets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,319</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,924</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Restricted cash, as reported on the balance sheets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Restricted cash in other long-term assets, as reported on the balance sheets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,908</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,498</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">g.</TD><TD STYLE="text-align: justify">Short-term deposits:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Short-term bank deposit is a
deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging
from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value
due to their short maturities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">h.</TD><TD STYLE="text-align: justify">Long-term deposits:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A Long-term bank deposit is
a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per
annum, as of December 31, 2020. Long-term deposits are presented at cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">Property and equipment, net:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets at the following rates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Computers, software and laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">15&nbsp;-&nbsp;33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Furniture and office equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 18%; text-align: center">15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">Over the shorter of the term of the lease or its useful life</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Down payments for property and
equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the
corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">j.</TD><TD STYLE="text-align: justify">Impairment of long-lived assets:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company&rsquo;s long-lived assets are reviewed for impairment
in accordance with ASC 360, &ldquo;Property, Plant and Equipment&rdquo;, whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset
exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">k.</TD><TD STYLE="text-align: justify">Research and development expenses:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Research
and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting
fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory
approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&rsquo;s intellectual property
rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities
related costs. The Company charges research and development expenses as expenses when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">l.</TD><TD STYLE="text-align: justify">Basic and diluted net loss (profit)
                                         per share:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company computes net loss (profit) per share using the two-class
method required for participating securities. The two-class method requires income available to ordinary shareholders for the period
to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as
if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating
securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders
of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require
the holders of such shares to participate in the Company&rsquo;s losses. As such,&nbsp;during the periods when the Company is in
a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under
the two-class method as these securities did not have a contractual obligation to share in the Company&rsquo;s losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&rsquo;s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary
shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of
potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially
dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature
of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the
effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">m.</TD><TD STYLE="text-align: justify">Accounting for share-based payments:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Share-based compensation expense related to share-based awards
is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite
service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value
of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company&rsquo;s
Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine
the fair value of the share awards represent management&rsquo;s best estimates. These estimates involve inherent uncertainties
and the application of management&rsquo;s judgment. Forfeitures are accounted for as they occur instead of estimating the number
of awards expected to be forfeited.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">n.</TD><TD STYLE="text-align: justify">Grants and participations:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Royalty-bearing
grants from the Israeli Innovation Authority (&ldquo;IIA&rdquo;) (previously known as Office of the Chief Scientist) of the Ministry
of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company
is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&rsquo;s Seventh Framework Programme for
Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such
grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Since the
payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received
from IIA until the related revenues are recognized.&nbsp;In the event of failure of a project that was partly financed by IIA,
the Company will not be obligated to pay any royalties or repay the amounts received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company recognizes participations in research and development,
as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research
and development expenses incurred during the period is recognized as other income within operating income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">o.</TD><TD STYLE="text-align: justify">Convertible preferred shares
                                         and convertible preferred shares warrant liability:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The terms
of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&nbsp;shares allowed the holders to redeem shares, under
certain circumstances, outside of the Company&rsquo;s control. Therefore, these shares were classified as mezzanine equity on the balance
sheet and not included as a component of shareholders&rsquo; deficit before the IPO. The carrying value of the convertible preferred
shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the
convertible preferred shares will be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Warrants
to purchase the Company&rsquo;s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair
value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the
Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance
sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">p.</TD><TD STYLE="text-align: justify">Fair value of financial instruments:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
applies ASC 820, &ldquo;Fair Value Measurements and Disclosures&rdquo; (&ldquo;ASC 820&rdquo;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &ldquo;exit price&rdquo;) in an
orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In determining
fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Unobservable
inputs are inputs that reflect the Company&rsquo;s assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Fair value
is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or a liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A three-tier
fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%">&#9679;</TD><TD STYLE="text-align: justify">Level
                                         1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical
                                         assets and liabilities.</TD></TR>                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%">&#9679;</TD><TD STYLE="text-align: justify">Level
                                         2 - Include other inputs that are directly or indirectly observable in the marketplace.</TD></TR>                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%">&#9679;</TD><TD STYLE="text-align: justify">Level
                                         3 - Unobservable inputs which are supported by little or no market activity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value hierarchy also
requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The financial
instruments carried at fair value on the Company&rsquo;s consolidated balance sheets as of December 31, 2019 are warrants to convertible
preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The following
methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The carrying
amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables,
trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such
instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">q.</TD><TD STYLE="text-align: justify">Income taxes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
accounts for income taxes in accordance with ASC 740, &ldquo;Income Taxes&rdquo; (&ldquo;ASC 740&rdquo;). ASC 740 prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax
assets to their estimated realizable value, if needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">ASC 740
contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that
it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including
resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized
tax benefits was recorded as a result of ASC 740.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&rsquo;s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">r.</TD><TD STYLE="text-align: justify">Concentration of credit risks:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash, cash
equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be
in excess of insured limits and are not insured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">in other jurisdictions.
Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge
a portion of the Company&rsquo;s non-dollar currency exposure. Counterparties to the Company&rsquo;s derivative instruments are all major
financial institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">s.</TD><TD STYLE="text-align: justify">Severance pay:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All the Company&rsquo;s employees
who are Israeli citizens have subscribed to Section&nbsp;14 of Israel&rsquo;s Severance Pay Law, 5723-1963
(&ldquo;Section&nbsp;14&rdquo;). Pursuant to Section&nbsp;14, employees covered by this section are entitled to monthly
deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with
Section&nbsp;14 release the Company from any future severance liabilities in respect of those employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Neither severance
pay liability nor severance pay fund under Section&nbsp;14 for such employees is recorded on the Company&rsquo;s consolidated balance
sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Severance
pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">t.</TD><TD STYLE="text-align: justify">Derivative financial instruments:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for derivatives and hedging based on ASC
815, &ldquo;Derivatives and hedging&rdquo;, as amended and related interpretations (&ldquo;ASC 815&rdquo;). ASC 815 requires the
Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is
so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against
the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions)
or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The ineffective portion of a derivative&rsquo;s change in fair value
is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included
in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts
in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative
instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from
such instruments is recognized immediately as &ldquo;financial income, net&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company measured the fair value of the contracts in accordance
with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices
and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was
$62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December
31, 2019 and 2018 amounted to $10 and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">u.</TD><TD STYLE="text-align: justify">Contingent liabilities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for its contingent liabilities in accordance
with ASC 450, &ldquo;Contingencies&rdquo;. A provision is recorded when it is both probable that a liability has been incurred and
the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect
the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining
to a particular matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company is occasionally
a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any
pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of
operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">Recently adopted Accounting Pronouncements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As an &ldquo;emerging
growth company&rdquo;, the Jumpstart Our Business Startups Act (&ldquo;JOBS Act&rdquo;) allows the Company to delay adoption of
new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private
companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below
reflect this election<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In June 2018, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
issued Accounting Standards Update (&ldquo;ASU&rdquo;) No.&nbsp;2018-07, &ldquo;Improvements to Nonemployee Share-Based Payment
Accounting,&rdquo; which simplifies the accounting for share-based payments granted to nonemployees for goods and services and
aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.
The Company adopted the guidance as of January&nbsp;1, 2020. The adoption of the standard didn&rsquo;t have a material impact on the
Company&rsquo;s consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">w.</TD><TD STYLE="text-align: justify">Recently Issued Accounting Pronouncements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In February 2016, the FASB issued
ASU No. 2016-02, &ldquo;Leases,&rdquo; which would require lessees to recognize assets and liabilities on the balance sheet for
most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner
similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance
states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for
the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1,
2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of
the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure
requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current
and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU
2016-02 will have on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-&#9;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2017, the FASB issued
ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies
the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their
hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements,
expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure
requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January
1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its
Consolidated Statements of Operations or Cash Flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2018, the FASB issued ASU No. 2018-15, &ldquo;Intangibles-Goodwill
and Other-Internal-Use Software (Subtopic 350-40): Customer&rsquo;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract,&rdquo; which aligns the requirements for capitalizing implementation costs incurred in
a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop
or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally
over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that
of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and
interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the
effect that ASU 2018-15 will have on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, &ldquo;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&rdquo; which simplifies the accounting for income taxes by removing
a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for
intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses
that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in
fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12
will have on its consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
3:-&#9;PREPAID EXPENSES AND OTHER RECEIVABLES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 0pt">Government authorities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">177</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Lease deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,334</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">417</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
4:-&#9;PROPERTY AND EQUIPMENT, NET</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify">Cost:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 0pt">Computers and software</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">449</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">389</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,356</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Furniture and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,478</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,353</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,026</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,136</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,124</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Depreciated cost</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,890</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,121</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Depreciation expenses amounted to $1,012, $947 and $411 for
the years ended December&nbsp;31, 2020, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
5:-&#9;OTHER PAYABLES AND ACCRUED EXPENSES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 0pt">Employees and payroll accruals</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">971</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">673</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">681</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">IIA deferred grant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,903</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">998</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
6:-&#9;COMMITMENTS AND CONTINGENT LIABILITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">The Company&rsquo;s facilities are
                                         leased under operating lease agreements for periods ending no later than 2027. The Company
                                         also leases motor vehicles under various operating leases, the latest of which expires
                                         in 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
6:-&#9;COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Future minimum
lease payments under operating leases as of December&nbsp;31, 2020 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">As of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">2021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,236</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,181</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">425</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,403</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December
31, 2020, the Company made advance payments on account of car leases in the amount of $75.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Rental and lease expenses for the years ended December&nbsp;31,
2020, 2019 and 2018 were $1,035, $&nbsp;1,027 and $1,073, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">In connection with its research
                                         and development programs, through December 31, 2020, the Company received participation
                                         payments from the IIA in the aggregate amount of $5,139. In return for IIA&rsquo;s participation,
                                         the Company is committed to pay royalties at a rate of 3% of sales of the developed products,
                                         up to 100% of the amount of grants received plus interest at LIBOR rate. Through December
                                         31, 2020, no royalties have been paid or accrued.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">On December 22, 2016, the Company received a written demand for a finder&rsquo;s fee in an
                                                              amount of $250, in connection with the second financing round that occurred in 2016. In September 2017, a suit was filed
                                                              against the Company in the Tel-Aviv Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court
                                                              ruling, which ruled in favor of the Company, discharging the entire claim, and accordingly reversed the related
                                                              provision.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">On January 9, 2020, the Company
                                         entered into an agreement for an automatic filling machine for the Company&rsquo;s manufacturing
                                         plant in a total amount of EUR 1,326. The Company paid a pre-payment of EUR 372 and will
                                         pay the remaining of the payments during 2021 according to the milestones of the agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.5pt; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
7:-&#9;FAIR VALUE MEASUREMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments measured at fair value on a recurring
basis include warrants to convertible preferred shares (see Note 9). The warrants are classified as a liability in accordance with
ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation
(the share price) were determined based on management&rsquo;s assumptions. To calculate the fair value of the warrants, the Company first
calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing
two scenarios of option pricing model and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes
model was utilized to calculate the warrants&rsquo; value in each one of the scenarios. 50% probability for each one of the scenarios
was applied to derive the weighted average fair value of the warrants.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
7:-&#9;FAIR VALUE MEASUREMENTS (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2019:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario the underlying share price
was between $13.25 - $13.40 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 69.11%, risk
free interest rates of 1.82%, dividend yield of 0%, and expected term of 2.25 years. Under the IPO scenario the underlying share
price was $12.18 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value of the series
E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series E-1 Preferred
share warrants as of December 31, 2019 was $563.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario, the underlying share
price was $10.29 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&nbsp;D-2
Preferred share warrants as of December&nbsp;31, 2019 (exercise price of $9.24): expected volatility of 69.11%, risk free interest
rates of 1.82%, dividend yield of 0% and expected term of 2.25&nbsp;years. Under the IPO scenario, the underlying share price was
$12.18 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&nbsp;D-2
Preferred share warrants as of December&nbsp;31, 2019 (exercise price of $9.24): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42&nbsp;years. Accordingly, the fair value of the series&nbsp;D-2
Preferred share warrants as of December&nbsp;31, 2019 was $11,275.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario, the underlying share
price was $4.35 for the Convertible Preferred A shares. The following assumptions were used to estimate the value of the series&nbsp;A
Preferred share warrants as of December&nbsp;31, 2019 (exercise price of NIS&nbsp;0.84 ($0.24)): expected volatility of 69.11%,
risk free interest rates of 1.82%, dividend yield of 0% and expected term of 2.25&nbsp;years. Under the IPO scenario, the underlying
share price was $12.18 for the Convertible Preferred&nbsp;A shares. The following assumptions were used to estimate the value of
the series&nbsp;A Preferred share warrants as of December&nbsp;31, 2019 (exercise price of NIS&nbsp;0.84 ($0.24)): expected volatility
of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42&nbsp;years. Accordingly, the fair
value of the series&nbsp;A Preferred share warrants as of December&nbsp;31, 2019 was $403.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario,
the underlying share price was $16 for the series E-1 Preferred shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of June 30, 2020: exercise price of $15.95, expected volatility of 78.07%, risk
free interest rates of 0.76%, dividend yield of 0%, and expected term of 4.17 years. Accordingly, the fair value of the series
E-1 Preferred share warrants as of June 30, 2020 was $1,868.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
7:-&#9;FAIR VALUE MEASUREMENTS (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario, the underlying share price was
$16 for the series D-2 Preferred shares. The following assumptions were used to estimate the value of the series D-2 Preferred
share warrants as of June 30, 2020: exercise price of $9.24, expected volatility of 82.48%, risk free interest rates of 0.46%,
dividend yield of 0%, and expected term of 0.6 years. Accordingly, the fair value of the series D-2 Preferred share warrants as
of June 30, 2020 was $20,930. As of June 30, 2020, as part of the IPO 1,123,570 Warrants have been exercised on cashless basis
into 475,049 Ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario, the underlying share price was
$16 for the series A Preferred shares. The following assumptions were used to estimate the value of the series A Preferred share
warrants as of June 30, 2020: exercise price of 0.84 NIS ($0.23) and dividend yield of 0%. Accordingly, the fair value of the series
A Preferred share warrants as of June 30, 2020 was $816. As of June 30, 2020, as part of the IPO, 53,775 Warrants have been exercised
into 53,775 Ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 30, 2020, as a
result of the IPO, the warrant liability to Convertible Preferred shares has been classified to Warrants to Ordinary shares
in equity.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The change in
the fair value of the Preferred share warrant liability is summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">12,241</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">22,926</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Issuance of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">680</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Change in fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,365</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Reclassification of Warrants into equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,614</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">End of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,241</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
8:-&#9;INCOME TAXES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Corporate tax rates:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The corporate tax rate in Israel
in 2020, 2019 and 2018 was 23%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Net operating losses carryforward:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has accumulated losses for tax purposes as of December 31, 2020 in the amount of approximately $96,385 which may be carried forward
and offset against taxable income in the future for an indefinite period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Deferred taxes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for
income tax purposes. The Company&rsquo;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
8:-&#9;INCOME TAXES (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Significant
components of the Company&rsquo;s deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Reserves and allowances</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">173</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Temporary differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,644</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss carryforward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,168</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred tax assets before valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,783</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less - valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,783</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable
income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable
future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In 2019 and 2018, the main reconciling item of the Company&rsquo;s
statutory tax rate of 23% and the effective tax rate of 0% is tax loss carryforwards, for which a full valuation allowance was
provided.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Tax assessment:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2020,
the Company&rsquo;s tax years until December 31, 2015 are subject to the statute of limitation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: right; text-indent: 0in"><B>POLYPID
LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
9:-&#9;CONVERTIBLE PREFERRED SHARES AND WARRANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">The Composition of the Company&rsquo;s
                                         Convertible Preferred shares is as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;A Convertible Preferred shares with no par value</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">537,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">483,975</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;A-1 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">896,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798,950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;B Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">566,386</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;B-1 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,751,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;C-1 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">645,923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;C-2 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">454,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;D-1 Convertible Preferred shares of NIS&nbsp;0 par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,509,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,376,512</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;D-2 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,868,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;D-3 Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">576,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&nbsp;E Convertible Preferred shares with no par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,135,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">851,795</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Series&nbsp;E-1 Convertible Preferred shares with no par value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,736,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,058,986</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,916,412</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,520,977</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company issued Series A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Preferred shares between February 2008 and September 2019. The Company classifies the convertible preferred shares outside
of shareholders&rsquo; deficit as required by&nbsp;ASC&nbsp;480-10-S99-3A and ASR 268, since these preferred shares are entitled
to liquidation preferences which may trigger a distribution of cash or assets that is not solely within the Company&rsquo;s control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Upon completion of the IPO, all convertible preferred shares
outstanding, totaling 12,520,977 shares, were automatically converted into Ordinary shares and their carrying value of $106,300
was reclassified into shareholders&rsquo; equity.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Preferred shares rights:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Up to completion of the IPO on June 30, 2020, series A, A-1,
B, B-1, C-1,C-2, D-1,D-3, E and E-1 convertible preferred shares conferred upon their holders all the rights conferred by Ordinary
shares, in addition to certain rights stipulated in the Company&rsquo;s previous Articles of Association (the &ldquo;Previous Articles&rdquo;),
inter alia, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><I>Dividend
rights - </I>the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E
and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration
or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend
or distribution was declared by the Company&rsquo;s board of directors, an amount equal to 6% per annum of the applicable original issue
price for such preferred shares (the &ldquo;Preference Dividend&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
9:-&#9;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preference order was such that Series E-1, E, D, C-2, C-1,
B-1, B, A-1 and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above order,
any distribution of any asset, capital, earnings or surplus funds of the Company. After the Preference Dividend has been paid in
full, the preferred shareholders&rsquo; were entitled to participate pro-rata and pari-passu, on an as converted basis with the Ordinary
shareholders&rsquo; in the receipt of any additional dividend distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><I>Liquidation
rights -</I> In the event of any event of liquidation or deemed liquidation
event, the Company was required to distribute to the holders of convertible preferred shares, prior to and in preference to any
payments to any of the holders of any other classes of shares, a per share amount equal to the original issuance price plus 6%
annual interest compounded annually from the date of issuance and up to the date of liquidation for each of their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Holders of Series E-1, E preferred shares and D preferred shares
were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original
issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount
equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The liquidation order was such that Series E-1, E, D, C-2 and
C-1, B-1, B A-1, and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above
order any distribution of any asset, capital, earnings or surplus funds of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All remaining assets shall be distributed among all the shareholders
pro rata in proportion to the number of Ordinary shares held by them on an as converted basis. The original issue price of the
Series&nbsp;A, A-1, B, B-1 and C-1 Convertible Preferred shares was $1.51, $1.76, $3.60, $5.06, and $6.95 per share, respectively,
Series C-2, D-1 and D-3 was $9.23 per share and Series E and E-1 was $13.30 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><I>Voting
rights</I> - each holder of Series&nbsp;A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Convertible Preferred share was entitled to one&nbsp;vote per each share held by it (on an as converted basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><I>Conversion
</I>- each preferred share was convertible into Ordinary shares, at
the holder&rsquo;s option, or automatically upon a qualified initial public offering (&ldquo;Qualified IPO&rdquo;) of the Company or upon
written demand of the Investor Majority (as defined in the Previous Articles).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Each share of Series A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 was convertible into Ordinary shares
on a 1-for-1 ratio. The conversion price per preferred share was to be adjusted in the event of recapitalizations, splits, Ordinary
share dividends and standard anti-dilution events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
9:-&#9;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Financing rounds:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During August 2018 through
February 2019, the Company entered into a Securities Purchase Agreement (the &ldquo;2018 SPA&rdquo;) with new and existing investors
for an aggregate amount of up to $35,000. The Company received $15,577 and issued to the investors 1,187,887 series E-1 Preferred
shares (net of $187 issuance costs in cash in 2018) at a price per share of $13.30. As part of the 2018 SPA, the Company converted
274,434 series E Preferred shares into series E-1 Preferred shares to holders of series E Preferred shares who participated in
the 2018 SPA pursuant to the conversion rights of the 2018 SPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During June 2019, the Company prepared a Private Placement Memorandum
(the &ldquo;2019 PPM&rdquo;) which includes the 2018 SPA and allowed the Company to raise up to $50,000 from new and existing shareholders.
From June to August 2019, the Company received $30,717 and issued to the investors 2,596,665 series E-1 Preferred shares, net of
$3,142 issuance costs in cash and warrants in amount $680 at a price of $13.30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Warrants to purchase Preferred
                                         shares:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In March 2008, in connection with a March 2008 Founders and
Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the &ldquo;A warrants&rdquo;),
with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of
an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at
least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and
(3) the sale of substantially all of the Company&rsquo;s assets or substantially all of the shares to another party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In connection with the first financing round that occurred in
2016, the Company granted to certain investors warrants to purchase up to 2,775,398 D-2 Preferred shares (&ldquo;D-2 warrants&rdquo;)
at a price per share of $9.23.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The survival of D-2 warrants is limited to a period ending upon
the earlier of: (i) the lapse of 5 years from closing; or (ii) a deemed liquidation event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The D-2 warrants will be exercised
automatically if they are still outstanding on the final day of the warrant period as defined in the warrants grant letter,
and if the fair market value of a warrant share is more than the exercise price for such share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All outstanding A warrants and D-2 warrants are classified
as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which
is not solely in the control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 28, 2019, in connection with 2019 PPM, the Company included
the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the &ldquo;E-1 warrants&rdquo;)
at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new
investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years
from closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
9:-&#9;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2020, 200,596 E-1 warrants, 648,519 D-2 warrants
and 17,925 Warrants are outstanding and may be converted into Ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">Deemed dividend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As part of Series E-1 Convertible Preferred shares price protection
conversion rights upon the completion of an initial public offering, the Company issued 158,967 Series E-1 Convertible Preferred
shares and recorded a beneficial feature of $2,114 which was accounted for as a deemed dividend and was recorded as mezzanine equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-&#9;SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">General:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 21, 2020, the Company&rsquo;s Board of Directors resolved
to consolidate the Company&rsquo;s share capital by applying an additional reverse share split and cancelling the shares&rsquo;
par value (See Note 1d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Following
the reverse share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible
loans, warrants, exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated
financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Ordinary share capital is composed
                                         as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 9%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 9%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 9%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; width: 9%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Ordinary shares with no par value</TD><TD STYLE="font-weight: normal; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: right">47,800,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: right">18,494,739</TD><TD STYLE="padding-bottom: 4pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: right">22,466,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: normal; text-align: right">562,748</TD><TD STYLE="padding-bottom: 4pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Ordinary shares rights:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Ordinary shares confer upon their holders the right to participate
in the general meetings of the Company, to vote at such meetings (each share represents one vote), and to participate in any distribution
of dividends or any other distribution of the Company&rsquo;s property, including the distribution of surplus assets upon liquidation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Share option plans:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other
key employees of up to 3,672,094 Ordinary shares. The options granted generally have a three-year vesting period and expire ten
years after the date of grant. Options granted under the Company&rsquo;s option plan that are cancelled or forfeited before expiration
become available for future grant. As of December 31, 2020, 1,019,457 of the Company&rsquo;s options were available for future grants.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-&#9;SHAREHOLDERS&rsquo; EQUITY (DEFICIT) (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A summary
of the status of options to employees under the Company&rsquo;s option plan as of December&nbsp;31, 2020 and 2019 and changes during
the relevant period ended on that date is presented below:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31, 2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of options</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>price</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&nbsp;<BR> average&nbsp;<BR> remaining&nbsp;<BR> contractual<BR> life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,217,985</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,411</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.04</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,064,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(395</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(89,157</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.99</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,193,392</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9,263</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6.58</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,306,421</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.78</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6,686</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.63</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,193,392</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9,263</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6.58</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31, 2019</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of options</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>price</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&nbsp;<BR> average&nbsp;<BR> remaining&nbsp;<BR> contractual<BR> life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,234,955</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.59</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.96</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,523</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(97,663</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">6.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,217,985</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.62</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">3,411</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.04</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,108,207</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">3,406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.66</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,217,985</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.62</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">3,406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.04</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-&#9;SHAREHOLDERS&rsquo; EQUITY (DEFICIT) (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Black-Scholes
assumptions used to value the employee options at the grant dates are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2020
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 74.35%-84.77%, risk free interest rates of 0.23%-1.38%, dividend yield of 0%, and an expected term of 5-6 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2019
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 69.8%-76.14%, risk free interest rates of 2.26%-3.13%, dividend yield of 0%, and an expected term of 6-7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2018
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 91.44%-96.87%, risk free interest rates of 3.43%-3.90%, dividend yield of 0%, and an expected term of 6-7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">These
assumptions and estimates were determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify">Fair
                                         Value of Ordinary Shares- Prior to the IPO, the fair value was determined by the Company&rsquo;s
                                         board of directors, with input from management and valuation reports prepared by third-party
                                         valuation specialists. After the IPO, the fair value of each Ordinary share was based
                                         on the closing price of the Company&rsquo;s publicly traded Ordinary shares as reported
                                         on the date of the grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Risk-Free&nbsp;Interest
                                         Rate- The risk-free rate for the expected term of the options is based on the Black-Scholes
                                         option pricing model on the yields of U.S. Treasury securities with maturities appropriate
                                         for the expected term of employee share option awards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify">Expected
                                         Term- The expected term represents the period that options are expected to be outstanding.
                                         For option grants that are considered to be &ldquo;plain vanilla,&rdquo; the Company
                                         determines the expected term using the simplified method. The simplified method deems
                                         the term to be the average of the time-to-vesting and the contractual life of the options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify">Expected
                                         Volatility- As the Company has a short trading history for its Ordinary shares, the expected
                                         volatility is derived from the average historical share volatilities of several unrelated
                                         public companies within the Company&rsquo;s industry that the Company considers to be
                                         comparable to its own business over a period equivalent to the option&rsquo;s expected
                                         term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Expected
                                         Dividend Yield- The Company has never declared or paid any cash dividends and does not
                                         presently plan to pay cash dividends in the foreseeable future. As a result, an expected
                                         dividend yield of zero percent was used.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-&#9;SHAREHOLDERS&rsquo; EQUITY (DEFICIT) (Cont.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The total
equity-based compensation expense related to all of the Company&rsquo;s equity-based awards recognized for the three years ended December&nbsp;31,
2020, 2019 and 2018, was comprised as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,806</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Marketing and business development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,631</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">706</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">739</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,577</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">976</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">995</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December
31, 2020, there were unrecognized compensation costs of $10,071, which are expected to be recognized over a weighted average period
of approximately 2.7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The options
outstanding as of December&nbsp;31, 2020 are comprised, as&nbsp;follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise <BR>
price ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options<BR>
 outstanding </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31, 2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted average remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>contractual term</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options exercisable as&nbsp;of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted average remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>contractual term</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">*)0.22</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">249,561</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">*)0.22</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">249,561</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">*)0.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,229</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,229</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.88</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.98</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,940</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.53</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,731</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,858</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">904,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">11.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">90,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.86</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,193,392</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6.58</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,306,421</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.78</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.63</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The exercise price of the options is denominated in NIS and
was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.</P></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-&#9;SHAREHOLDERS&rsquo; EQUITY (DEFICIT) (Cont.)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">Options issued to non-employees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Outstanding
options granted to consultants as of December&nbsp;31, 2020 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Grant date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options <BR>
outstanding </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as of </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31, 2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average <BR>
Exercise </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>per share</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercisable</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as of </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31, 2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable <BR>
through</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-indent: -12pt; padding-left: 12pt">March 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22,258</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22,258</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%; padding-left: 5.6pt">March 2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">October 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">October&nbsp;2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">June 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">June 2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">September 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">September&nbsp;2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">April 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">April 2026</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">December 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">March 2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">June 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">June 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">August 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">August 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">November 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">March 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">August 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">August 2029</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">June 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">88,430</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">6.62</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.6pt">June 2030</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">433,852</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,789</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; padding-left: 5.6pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
11:-&#9;FINANCIAL EXPENSES, NET</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; text-align: justify; padding-left: 0pt">Financial expenses:&#8239;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; text-align: left">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; text-align: left">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White; text-align: left">&nbsp;</TD><TD STYLE="background-color: White; text-align: right">&nbsp;</TD><TD STYLE="background-color: White; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; padding-left: 0pt">Revaluation of warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,373</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Foreign currency transaction loss, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial expenses, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,390</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">318</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Financial income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Interest from deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(474</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(60</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Revaluation of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,365</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,473</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Foreign currency transaction gains, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(243</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial income:</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(793</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,599</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Financial expense (income), net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,597</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(11,655</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(24,281</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
12:-&#9;BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The following
table sets forth the computation of the Company&rsquo;s basic and diluted net loss per Ordinary share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Year ended December 31,</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: justify; text-indent: 0pt">Basic net loss (profit) per share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>2020</B> &nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>2018</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">36,869</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,905</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,917</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Preferred share preference</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Net income allocated to preferred shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Deemed dividend</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable to Ordinary shareholders</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">42,916</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,327</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">(89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Weighted average Ordinary shares outstanding</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">9,582,405</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">562,451</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">561,113</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Basic net loss (profit) per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.48</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23.69</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Numerator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable for basic computation</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">42,916</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,327</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">(89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Revaluation of warrants to convertible preferred shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">616</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss attributable to Ordinary shareholders</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">42,916</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,327</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">527</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Number of shares used in basic calculation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,582,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">562,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average effect of dilutive securities Warrants to convertible preferred shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">52,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Number of shares used in diluted calculation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">9,582,405</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">562,451</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">613,358</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">4.48</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23.69</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.86</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 168 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>POLYPID LTD AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.&nbsp;dollars in thousands (except share and per share
data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
13:-&#9;RELATED PARTIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Through February 2016, several management members also provided
services to the Company as service providers. As of December 31, 2020 and 2019, the Company has recorded a provision for severance
pay liability for such service providers in the amounts of $193 and $251, respectively. These amounts are included in &ldquo;Other
Liabilities&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In July 2019, the Company entered into a master service agreement
with a third-party provider (the &ldquo;provider&rdquo;) to conduct a portion of a phase 3 clinical trial in eastern Europe for a
total cost of $6,288. One of the Company&rsquo;s directors serves as a director and shareholder in the provider. During the year ended
December 31, 2020, the Company recognized $717 as expense as part of the research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
14:-&#9;SUBSEQUENT EVENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-weight: normal">The
Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated
financial statements to identify matters that require additional disclosure. For its annual consolidated financial statements
as of December&nbsp;31, 2020 and for the year then ended, the Company evaluated subsequent events through March&nbsp;5, 2021,
the date that the consolidated financial statements were issued. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During January to March 2021, 580,028 warrants to purchase Ordinary
shares were exercised on a cashless basis into 115,982 Ordinary shares, out of which 419,068 warrants were exercised by related
parties. In addition, during February 2021 68,491 warrants to purchase Ordinary shares were exercised into 68,491 Ordinary shares
for a total consideration of $633.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-33</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>2
<FILENAME>f20f2020ex2-2_polypid.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of Rights of Each Class
of Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Type and Class of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">PolyPid Ltd.&rsquo;s
(the &ldquo;Company&rdquo;) authorized share capital consists of 47,800,000 ordinary shares, no par value per share (&ldquo;Ordinary
Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Number and Purposes and Objects of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company&rsquo;s
registration number with the Israeli Registrar of Companies is 51-410592-3. The Company&rsquo;s purpose is set forth in section
3 of the Company&rsquo;s amended and restated articles of association and includes every lawful purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Powers of the Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company&rsquo;s
board of directors (&ldquo;Board&rdquo;) may exercise all powers that are not required under the Israeli Companies Law of 1999
(the &ldquo;Companies Law&rdquo;) or under the Company&rsquo;s amended and restated articles of association, other than the powers
which are to be exercised or taken by the Company&rsquo;s shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preemptive Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
Ordinary Shares are not redeemable and are not subject to any preemptive right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Rights of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the Company&rsquo;s amended and restated articles of association, no director shall be disqualified by
virtue of his or her office from holding any office or place of profit in the Company or in any company in which the Company shall
be a shareholder or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any
such contract, or any contract or arrangement entered into by or on behalf of the Company in which any director shall be in any
way interested, be avoided, nor, other than as required under the Companies Law, shall any director be liable to account to the
Company for any profit arising from any such office or place of profit or realized by any such contract or arrangement by reason
only of such director&rsquo;s holding that office or of the fiduciary relations thereby established, but the nature of his or her
interest, as well as any material fact or document, must be disclosed by him at the meeting of the Board at which the contract
or arrangement is first considered, if his or her interest then exists, or, in any other case, at no later than the first meeting
of the Board after the acquisition of his or her interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations or Qualifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rights of the Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
Ordinary Shares shall confer upon the holders thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal right to attend and to vote at all of the Company&rsquo;s general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attends the meeting and participates in the voting, either in person or by a proxy or by a written ballot, to one vote;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal right to participate in distribution of dividends, if any, whether payable in cash or in bonus shares, in distribution of assets or in any other distribution, on a per share pro rata basis; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal right to participate, upon the Company&rsquo;s dissolution, in the distribution of the Company&rsquo;s assets legally available for distribution, on a per share pro rata basis.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Election of
Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Pursuant
to the Company&rsquo;s amended and restated articles of association, the Company&rsquo;s directors are elected solely at an annual
general meeting of the Company&rsquo;s shareholders and serve on the Board until the next annual general meeting of the Company&rsquo;s
shareholders following his or her appointment, or until they cease to act as Board members pursuant to the provisions of the Company&rsquo;s
amended and restated articles of association or any applicable law. The Board may at any time and from time to time appoint any
person as a director to fill a vacancy (whether such vacancy is due to a director no longer serving or due to the number of directors
serving being less than the maximum number of eleven, as stated in the Company&rsquo;s amended and restated articles of association).
In the event of one or more such vacancies in the Board, the continuing directors may continue to act in every matter, provided,
however, that if they number less than the minimum number of five, as provided in the Company&rsquo;s amended and restated articles
of association, they may only act in an emergency or to fill the office of director which has become vacant up to a number equal
to the minimum number of five. The office of a director that was appointed by the Board to fill any vacancy shall only be for the
remaining period of time during which the director whose service has ended was filled would have held office, or in case of a vacancy
due to the number of directors serving being less than the maximum number of eleven, the Board shall determine at the time of appointment
the class pursuant to Section 34 of the Company&rsquo;s amended and restated articles of association to which the additional director
shall be assigned. The Company is not currently required to have external directors serving on Board, based on an exemption that
the Company has elected to be governed by under the Companies Law regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annual and Special Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Under
Israeli law, the Company is required to hold an annual general meeting of&nbsp;the Company&rsquo;s shareholders once every calendar
year, at such time and place which shall be determined by&nbsp;the Board, which must be no later than 15 months after the date
of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special
general meetings.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote
at general meetings are the shareholders of record on a date to be decided by the Board, that will be in any event not more than
the maximum period and not less than the minimum period permitted by the Companies Law. Resolutions regarding the following matters
must be passed at a general meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to&nbsp;the Company&rsquo;s amended and restated articles of association;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of&nbsp;the Board&rsquo;s powers by a general meeting if&nbsp;the Board&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination of&nbsp;the Company&rsquo;s auditors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment of directors (other than in the cases specified in the Company&rsquo;s amended and restated articles of association);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions of&nbsp;the Company&rsquo;s authorized share capital; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger (as such term is defined in the Companies Law).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Notices</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">The Companies Law requires that a notice
of any annual or special general meeting be provide to shareholders at least 21 days prior to the meeting, and if the agenda of
the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereafter, among others,
the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or
an approval of a merger, notice must be provided at least 35 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Quorum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">As
permitted under the Companies Law, the quorum required for the Company&rsquo;s general meetings consists of at least two shareholders
present in person, by proxy, written ballot or voting by means of electronic voting system, who hold or represent between them
in the aggregate at least one third of the total outstanding voting rights. If within half an hour of the time set forth for the
general meeting a quorum is not present, the general meeting shall stand adjourned either (i) to the same day of the following
week, at the same hour and in the same place (ii) to such other date, time and place as prescribed in the notice to the shareholders
and in such adjourned meeting or (iii) to such day and at such time and place as the chairperson of the general meeting shall determine
(which may be earlier or later than the date pursuant to clause (i) above). If no quorum is present within half an hour of the
time arranged, any number of shareholders participating in the meeting, shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Access to Corporate Records</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the Companies
Law, shareholders are provided access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register
and principal shareholders register, articles of association and annual audited financial statements; and any document that the
Company is required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents
are publicly available and may be found and inspected at the Israeli Registrar of Companies. In addition, shareholders may request
to be provided with any document related to an action or transaction requiring shareholder approval under the related party transaction
provisions of the Companies Law. The Company may deny this request if the Company believes it has not been made in good faith or
if such denial is necessary to protect the Company&rsquo;s interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adoption of Resolutions</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Except as required by the Companies Law
or the Company&rsquo;s amended and restated articles of association, a resolution of the shareholders shall be adopted if approved
by the holders of a simple majority of the voting power represented at the general meeting in person or by proxy and voting thereon,
as one class, and disregarding abstentions from the count of the voting power present and voting. Without limiting the generality
of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes a higher majority or pursuant
to which a provision requiring a higher majority would have been deemed to have been incorporated into the Company&rsquo;s amended
and restated articles of association, but resolutions with respect to which the Companies Law allows the Company&rsquo;s amended
and restated articles of association to provide otherwise, shall be adopted by a simple majority of the voting power represented
at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the
voting power present and voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Changing Rights Attached to Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">If at any time
the share capital of the Company is divided into different classes of shares, the rights attached to any class, unless
otherwise provided by the Companies Law or the Company&rsquo;s amended and restated articles of association, may be modified
or cancelled by the Company by a resolution of the general meeting of the holders of all shares as one class, without any
required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights
attached to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Limitations on the Rights to Own Ordinary
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="background-color: white">There
are no limitations on the right to own&nbsp;</FONT>the Company&rsquo;s&nbsp;<FONT STYLE="background-color: white">securities</FONT><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Provisions Restricting Change in Control
of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">There
are no specific provisions of the Company&rsquo;s amended and restated articles of association that would have an effect of delaying,
deferring or preventing a change in control of the Company or that would operate only with respect to a merger, acquisition or
corporate restructuring involving the Company (or the Company&rsquo;s subsidiaries). However, as described below, certain provisions
of the Companies Law may have such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger
have the transaction approved by its board of directors and, unless certain requirements described under the Companies Law are
met, a vote of the majority of its shareholders, and, in the case of the target company, also a majority vote of each class of
its shares. For purposes of the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved
if shares representing a majority of the voting power present at the shareholders meeting and which are not held by the other party
to the merger (or by any person or group of persons acting in concert who holds 25% or more of the voting power or the right to
appoint 25% or more of the directors of the other party) vote against the merger. If, however, the merger involves a merger with
a company&rsquo;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the
merger is instead subject to the same Special Majority (as defined below) approval that governs all extraordinary transactions
with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent
the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be
unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of
creditors. In addition, a merger may not be completed unless at least (1) 50 days have passed from the time that the requisite
proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company and (2) 30 days
have passed since the merger was approved by the shareholders of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special
Majority&rdquo; is defined in the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger (excluding a personal interest that did not result from the shareholder&rsquo;s relationship with the controlling shareholder) have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares voted against the merger, does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
Companies Law also provides that an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the
company, unless there is already another holder of at least 25% or more of the voting rights in the company, or (2) the purchaser
would become a holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of
the voting rights in the company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement
that received shareholders&rsquo; approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights
in the company which resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was
from a holder of more than 45% of the voting rights in the company which resulted in the acquirer becoming a holder of more than
45% of the voting rights in the company. A &ldquo;special&rdquo; tender offer must be extended to all shareholders. In general,
a &ldquo;special&rdquo; tender offer may be consummated only if (1) at least 5% of the voting power attached to the company&rsquo;s
outstanding shares will be acquired by the offeror and (2) the offer is accepted by a majority of the offerees who notified the
company of their position in connection with such offer (excluding the offeror, controlling shareholders, holders of 25% or more
of the voting rights in the company or anyone on their behalf, or any person having a personal interest in the acceptance of the
tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares
of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer,
unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding
shares, the acquisition must be made by means of a tender offer for all of the outstanding shares. In general, if less than 5%
of the outstanding shares are not tendered in the tender offer and more than half of the offerees who have no personal interest
in the offer tendered their shares, all the shares that the acquirer offered to purchase will be transferred to it by operation
of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the
issued and outstanding share capital of the company or of the applicable class of shares. Shareholders may request appraisal rights
in connection with a full tender offer for a period of six months following the consummation of the tender offer, but the acquirer
is entitled to stipulate, under certain conditions, that tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Differences Between Law of Different
Jurisdictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Companies
Law and the Company&rsquo;s amended and restated articles of association, the Board may exercise all powers and take all actions
that are not required under law or under the Company&rsquo;s amended and restated articles to be exercised or taken by the shareholders,
including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in the Company&rsquo;s Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The general meeting
may, by a simple majority vote of the shareholders attending the general meeting and subject to the provisions of the Companies
Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase the Company&rsquo;s registered share capital by the creation of new shares from the existing class or a new class, as determined by the general meeting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel any registered share capital which has not been taken or agreed to be taken by any person;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide all or any of the Company&rsquo;s share capital into shares of larger nominal value than the Company&rsquo;s existing shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subdivide the Company&rsquo;s existing shares or any of them, the Company&rsquo;s share capital or any of it, into shares of smaller nominal value than is fixed; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce the Company&rsquo;s share capital and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and consent required, by the Companies Law.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company does not
have any debt securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants and Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company does not
have any warrants or rights that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company does not
have any other securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>f20f2020ex8-1_polypid.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
8.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PolyPid Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PolyPid Pharma SRL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Romania</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>f20f2020ex12-1_polypid.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Amir Weisberg, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this annual report on Form 20&ndash;F of
PolyPid Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
[language omitted in accordance with Exchange Act Rule 13a-14(a)] for the company and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">b) [paragraph omitted in accordance with Exchange Act
Rule 13a-14(a)];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">c) Evaluated the effectiveness of the company&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">d) Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit
committee of the company&rsquo;s board of directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 5, 2021</FONT></TD>
    <TD NOWRAP STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>f20f2020ex12-2_polypid.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dikla Czaczkes Akselbrad, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this annual report on Form 20&ndash;F of
PolyPid Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
[language omitted in accordance with Exchange Act Rule 13a-14(a)] for the company and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">b) [paragraph omitted in accordance with Exchange Act
Rule 13a-14(a)];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">c) Evaluated the effectiveness of the Company&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">d) Disclosed in this report any change in the Company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The Company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit
committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 5, 2021</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Dikla Czaczkes Akselbrad </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dikla Czaczkes Akselbrad </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer</FONT></TD></TR>
</TABLE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>f20f2020ex13-1_polypid.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C.&nbsp;Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the filing of the Annual
Report on Form 20-F for the period ended December 31, 2020 (the &ldquo;Report&rdquo;) by PolyPid Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) the Report
fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 5, 2021</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amir Weisberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer</FONT></TD></TR>
</TABLE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>f20f2020ex13-2_polypid.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C.&nbsp;Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the filing of the Annual
Report on Form 20-F for the period ended December 31, 2020 (the &ldquo;Report&rdquo;) by PolyPid Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) the Report
fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 5, 2021</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Dikla Czaczkes Akselbrad </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dikla Czaczkes Akselbrad </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer</FONT></TD></TR>
</TABLE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>f20f2020ex15-1_polypid.htm
<DESCRIPTION>CONSENT OF KOST, FORER, GABBAY & KASIERER, CERTIFIED PUBLIC ACCOUNTANTS (ISRAEL), AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND A MEMBER FIRM OF ERNST & YOUNG GLOBAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the incorporation by reference
in the Registration Statement on Form S-8 (No. 333-239517) pertaining to the Amended and Restated 2012 Share Option Plan of PolyPid
Ltd. of our report dated March&nbsp;5, 2021 with respect to the consolidated financial statements of PolyPid Ltd. (the &ldquo;Company&rdquo;),
included in this Annual Report (Form&nbsp;20-F)&nbsp;for the year ended December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 167.5pt; text-align: left; direction: ltr; unicode-bidi: embed; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 5, 2021</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Member of Ernst &amp; Young Global</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M\05E\6 .5)/&Z@*U<MQ;64;&^V6&(Z.9/18HG75Q*J+#(O[%B>O]RL7KG_\
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M0O;<C7.; M/**A7I\(K/2YZHUBJD]^JY>#WZ3NA[CV]UI51>YCACC;(7W'?
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MA^NCJ-'._/!'$MQB*@/] X6ZVBY!O76N^UAF6J6KAQLW/#4 %!5-O(59WKM
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98!8'B5P8H43H='1T  ##[ZDZD]3$)>/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #J DT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBL7Q)X
MCT/PAX?UKQ5XFU.UT7P[X=TR]UG6]7OG\JSTS2].MY+J^OKJ0!BD%M;Q22R,
M%)"J< GBOGY?VR/V:W573XG6;(ZAE8>'?&!#*P!5@?\ A'N0000>XH ];GL_
MBB9YS;:_X'2V,\IMHY_#&MRSQVYD8P)-+'XHB269(]JRR)%$CN&98T4A1%]B
M^*__ $,/@+_PE=>_^:RO*_\ AL7]FW_HIMI_X3OC#_YGJ/\ AL7]FW_HIMI_
MX3OC#_YGJ]%9E-)+ZEE3LDKO+,.V[)*[?MM6[7;ZMM]3QWDM.3<O[2SY<S<K
M1SO%QBN9MVC%8>T8J]HQ6D8J,5HD>J?8OBO_ -##X"_\)77O_FLH^Q?%?_H8
M? 7_ (2NO?\ S65Y7_PV+^S;_P!%-M/_  G?&'_S/4?\-B_LV_\ 13;3_P )
MWQA_\SU/^TY_] 64_P#AKP__ ,N%_8E+_H9\0?\ A\QG_P SGJGV+XK_ /0P
M^ O_  E=>_\ FLH^Q?%?_H8? 7_A*Z]_\UE>5_\ #8O[-O\ T4VT_P#"=\8?
M_,]1_P -B_LV_P#13;3_ ,)WQA_\SU']IS_Z LI_\->'_P#EP?V)2_Z&?$'_
M (?,9_\ ,YZI]B^*_P#T,/@+_P )77O_ )K*/L7Q7_Z&'P%_X2NO?_-97E?_
M  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\ T4VT_P#"=\8?_,]1_:<_^@+*
M?_#7A_\ Y<']B4O^AGQ!_P"'S&?_ #.>J?8OBO\ ]##X"_\ "5U[_P":RC[%
M\5_^AA\!?^$KKW_S65Y7_P -B_LV_P#13;3_ ,)WQA_\SU'_  V+^S;_ -%-
MM/\ PG?&'_S/4?VG/_H"RG_PUX?_ .7!_8E+_H9\0?\ A\QG_P SGJGV+XK_
M /0P^ O_  E=>_\ FLH^Q?%?_H8? 7_A*Z]_\UE>5_\ #8O[-O\ T4VT_P#"
M=\8?_,]1_P -B_LV_P#13;3_ ,)WQA_\SU']IS_Z LI_\->'_P#EP?V)2_Z&
M?$'_ (?,9_\ ,YZI]B^*_P#T,/@+_P )77O_ )K*/L7Q7_Z&'P%_X2NO?_-9
M7E?_  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\ T4VT_P#"=\8?_,]1_:<_
M^@+*?_#7A_\ Y<']B4O^AGQ!_P"'S&?_ #.>J?8OBO\ ]##X"_\ "5U[_P":
MRC[%\5_^AA\!?^$KKW_S65Y7_P -B_LV_P#13;3_ ,)WQA_\SU'_  V+^S;_
M -%-M/\ PG?&'_S/4?VG/_H"RG_PUX?_ .7!_8E+_H9\0?\ A\QG_P SGJGV
M+XK_ /0P^ O_  E=>_\ FLH^Q?%?_H8? 7_A*Z]_\UE>5_\ #8O[-O\ T4VT
M_P#"=\8?_,]1_P -B_LV_P#13;3_ ,)WQA_\SU']IS_Z LI_\->'_P#EP?V)
M2_Z&?$'_ (?,9_\ ,YZI]B^*_P#T,/@+_P )77O_ )K*/L7Q7_Z&'P%_X2NO
M?_-97E?_  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\ T4VT_P#"=\8?_,]1
M_:<_^@+*?_#7A_\ Y<']B4O^AGQ!_P"'S&?_ #.>J?8OBO\ ]##X"_\ "5U[
M_P":RC[%\5_^AA\!?^$KKW_S65Y7_P -B_LV_P#13;3_ ,)WQA_\SU'_  V+
M^S;_ -%-M/\ PG?&'_S/4?VG/_H"RG_PUX?_ .7!_8E+_H9\0?\ A\QG_P S
MGJGV+XK_ /0P^ O_  E=>_\ FLH^Q?%?_H8? 7_A*Z]_\UE>5_\ #8O[-O\
MT4VT_P#"=\8?_,]1_P -B_LV_P#13;3_ ,)WQA_\SU']IS_Z LI_\->'_P#E
MP?V)2_Z&?$'_ (?,9_\ ,YZI]B^*_P#T,/@+_P )77O_ )K*/L7Q7_Z&'P%_
MX2NO?_-97E?_  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\ T4VT_P#"=\8?
M_,]1_:<_^@+*?_#7A_\ Y<']B4O^AGQ!_P"'S&?_ #.>J?8OBO\ ]##X"_\
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MSU'_  V+^S;_ -%-M/\ PG?&'_S/4?VG/_H"RG_PUX?_ .7!_8E+_H9\0?\
MA\QG_P SGJGV+XK_ /0P^ O_  E=>_\ FLH^Q?%?_H8? 7_A*Z]_\UE>5_\
M#8O[-O\ T4VT_P#"=\8?_,]1_P -B_LV_P#13;3_ ,)WQA_\SU']IS_Z LI_
M\->'_P#EP?V)2_Z&?$'_ (?,9_\ ,YZI]B^*_P#T,/@+_P )77O_ )K*/L7Q
M7_Z&'P%_X2NO?_-97E?_  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\ T4VT
M_P#"=\8?_,]1_:<_^@+*?_#7A_\ Y<']B4O^AGQ!_P"'S&?_ #.>J?8OBO\
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M/L7Q7_Z&'P%_X2NO?_-97E?_  V+^S;_ -%-M/\ PG?&'_S/4?\ #8O[-O\
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M77O_ )K*/L7Q7_Z&'P%_X2NO?_-97E?_  V+^S;_ -%-M/\ PG?&'_S/4?\
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M_L<=&_\ 4=U:@#._X>(^$?\ HF7BS_P;Z'_\<H_X>(^$?^B9>+/_  ;Z'_\
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M*D1\QD1E0%B 6_MC_P#!8CX=?L=?';7?@5XC^"WCOQIJFAZ'X:UR7Q!H.O\
MARPTZXB\2Z:NI0P1VNH_Z6DEJC"*5G^5W!9!MP3^"O[-?_)Q/P(_[*_\._\
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M+/\ P;Z'_P#'*_%\?&GX/OXV\)?#>#XH> [OQUX]TCQ!KW@KPUI_B?2=1O\
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MO!0I4IT\NDZWUB%/ZS/-'/-)XAXFK7A6UM._;.\&V/B2\\6'PU\2)I=:\/\
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M,B-[C_PYM_X*)_\ 1"K/_P .1\.__FDH_P"'-O\ P43_ .B%6?\ X<CX=_\
MS249AQ9X;9K##4\?Q5PKB:>%Q5/&T:<\]R_V?UBE2KTJ<ZD/K'+5C".(J25.
MHI4_:*E4<92HP1GDGAYXX\.U,=6R?P_X\P5;,,OJY9B:U/A7-G6^IUJ^%Q%6
MG2J/"<]"52>#I0E5I.%7V,Z]&-2$:]23[^;_ (*1?#CQ#XZOO%?CCX=?%'78
MK3XM_&7XC>!I!XUB-]X*TKXAI\,V\,>&8K>#4M*CU72O#\O@74A=>'9=1MO#
M*7.LVFKVVGW=UI[6\\L/_!2OX>6_BC0/%EW\)?%?B>X\-?'_ ,<?%/PAH^LZ
MGX>TC3/A[X.^(.H^/;_Q%H&C?V"(;7QCKTE[XQM->T.^\8:09O"?B#2KB71M
M<6SU)8;/SO\ X<V_\%$_^B%6?_AR/AW_ /-)1_PYM_X*)_\ 1"K/_P .1\._
M_FDKY9T?!EKE_P!9LB4%06&C3CQ=1A"%%4ZM.4*<85X.E[6-:I[=TI4W7<I^
MU<E4K1K?H*Q?TFU[SX$XHE4>+GC95I^'N(J5:F)E6H5X5*\JN%JK$?5YX:C]
M5CB(5HX6,*:H*+HX>>&^<OBW\>O"GQA^/?@;XB^);?Q8/!/@W1_ 7AUAIVA>
M%-+\:7VC> V>XL0;1=2O](NKYY?)L1J&MZWJNHR:=$C7E_.\-O!'PO[3GQ,\
M)_&CX^?%/XN^"]-\3:-HGQ*\7:IXT_L;Q8VDRZOI.H:[</>:AIWGZ+))975C
M:W#F.QN2([B: !KB)),Y^Q_^'-O_  43_P"B%6?_ (<CX=__ #24?\.;?^"B
M?_1"K/\ \.1\._\ YI*^BP?$OAM@*N"JX7C#AZF\!EM3*<-3_P!8\ Z$<'5Q
M4<;44J/M%&=:6)@JCK.49+6,8*#:/BLTX)\<LXPN:87'^&W%]6.<9[2XBQM9
M<&YM'%2S*A@)992=/$>R<Z>&A@I.DL,H3B[1G*HYQ4C\P:_:3X@_\JX/CW_L
MXC3/_5N^&:\9_P"'-O\ P43_ .B%6?\ X<CX=_\ S25^G'C'_@GI^UQJG_!%
M+Q=^R/8?#"WG^/NI_&>P\5V/@K_A,?",<4V@0_$70M>EOO\ A()-770(V72[
M.YN!;2:@MPQC$0C\QU4_#>*O&'">8Y1PY3R_B;(<;4H<;\-XNM3PF:X+$3I8
M6A/,77Q%2-*M)PH45.#J59)0ASQYFN97_5_H]>&OB'DG$?&E?.>!^*\JHXOP
MPXRR["U<PR',L)3Q&/Q5/*5AL'1G7P\(U,3B'3J*C1BW4J<D^6+Y7;^(&OJ'
M]C?]H#2?V7_C]X?^,VM^&+CQC8:%X1^*?A__ (1ZW&F2+>WGCWX:>*O VFRW
MUMK,4VEZAI%E?^(+>]UG2[R*2+5-+M[NP*,;@ _;W_#AK_@J;_T;A9?^'6^%
MG_S5T?\ #AK_ (*F_P#1N%E_X=;X6?\ S5U\[BN).$<9AJ^$K\09-*AB:4Z-
M6,<TPT'*G424DIQJJ46TMXM-=&MU]AE_!'B-EF.PF8X3@_B.&*P5>GB</.>1
MXRI&-:DW*$I4YT7&:3=^62<7I=-:/-^#O_!4SQ=X5\*:3I?Q5MO&/C'6_P#A
M;GB+Q9XGC\(77AOP9X&U;X4S_LMZ[^SSX,^$-EX$TNST_P /67A;P?>:G9:W
MI_AXZ:?#D&EV3Q0VC:JZW!]F\/?\%4O@?X3T3X#>&?"/PF^+WA;0/AE/XI'C
M6TFUWPUXZO?%WAGQS\*O WP[\;_#V'7O%^M3>(4T?Q3=>$KW4SXITO5O!VO>
M&DU#2&\-V5G+H"PWWE?_  X:_P""IO\ T;A9?^'6^%G_ ,U='_#AK_@J;_T;
MA9?^'6^%G_S5UX=;_B'=:<IO.<II\\YSE"CG-"C2<ITYTK^RA+D]R%2:I74G
M3;O&5TC[##2\:,-"$%PSGM9PA3IQJXGAO$5ZRA3KT\2XJM*FII5:M.#K*/*J
ML5RRBHZ'-_&C_@HIX1^)'[+%W^SWX+^%^J?#B.Z\/2^!)M(G_L/QKX?O/"UG
M\;=8^,&@:_<^,-=O/^$K@\=VRZG!I.MZU:Z%_;.OW]K<:A>>*VL-2NM)/@WB
MC]H/X-K^Q9X4_9G^&.A_%+P3XHN?%=C\2_CCJ5Q%X*O/#'QN^)5C)/8Z#>ZW
MK,-XOBO2_!WPW\-W=]9?#[PA::?]E&M:EJ7B#7)KF_NEE@^G?^'#7_!4W_HW
M"R_\.M\+/_FKH_X<-?\ !4W_ *-PLO\ PZWPL_\ FKKJH8[@7#QIPHY_ED(4
MLP_M-1_MJA-5,6HRC&=?VDY^WC#FE*G&HVZ=27M(S4XTY4_/Q66^+.-J8BKB
M>$,ZJ5<1DW]A2FN&\33E2R]SC.<,-[*G26&G5Y(0K3I)*K2C[*=/V<ZL:OY
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M711_9^!_Z!*'_@M?_)!_:V:?]#+,/_"W%?\ RXY3_A!/!/\ T*NE?]]ZG_\
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M3O7=K?!S*\'*R;B?HT/ 7@M@Q'A32R%7<Q#:H0J@@%FQJ/"Y(&3@9('<4I\
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M]I_XX^&_AQ^T/\0OA]XK\!_L;_ _XF?LK? GPWI&B^(O#?[0/[1GBGXS>/\
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MB?\ W:>2+JETEYG[^/\ \%DO@^AY^"WQ/8=.-=\)CGGU8^E5W_X+-_!Q"?\
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MR=?@;\5OPU_P?]>[#UJL_P#P6_\ @JF?^+%?%@X[_P#"0>#<=?\ ?K\VH_\
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MH.M?R3S=6^A_F:S)^WX?UKBJ<"<.QVHXW;_H8XG_ .1/4I>*O&,[<V*P+O\
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MIBG](?%OQ]^"O@GP;J_CW7?BCX%?PUH_@+Q=\3WFT3Q3H7B/4M8\"> ],O\
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MP@[VS[!O2VD<7W_[ CYFAX3>(D7[W"V/6O6>"7_N^S\%Y>GX-_(5ER=&^O\
M6OWP?_@W^_:D8''QD^ ?MFX\>=_IX7]/7\ZJ/_P;[?M3-G'QE^ 0S_T\>//7
M/_0K_P!17!4XWX4=[9WA'K?X<5_\QGK4?"[CZ/Q<-8U>M3!]DNF-9^ \_?\
MX'63+W_WC_6OZ I/^#>[]JER<?&?X  <];CQ]WS_ -2L?:J+_P#!O)^U8V<?
M&G]GT=QFX\?GG_PE:X*W&7#$F[9QAGO]G$];?]0AZ^'\->.(I<W#V,7K4PG:
MW_06?S\3=6^A_F:S)^WX?UK^@^3_ (-W/VKWZ?&K]GOGKFY^( XY_P"I4/K[
M53D_X-U/VL7Z?&S]GD>F;GX@\=?3PI[UP5>+>''MFN'>G\F)_P#F4]>CX><9
M1MS9%B5;O4POEVQ3['\\T_5O\_Q&JM?MK^T-_P $,_VD_P!G;X(_$[X[^+?B
MS\#];\,_"SPO/XKUO2/#MQXV;7=0L;>[M;5[?2UU'PW:6+7;/=QLHN;B&+:K
M9<'%?GI^RG^Q9^T5^V=XO/A3X$^ [O6[*QN(HO$_CS5V?1_AWX+@D(W3^)/%
M,\36D<ZH2\6C:<M_KMYC%KIT@.X*EG658FAB,91QU"6&PTE"O6E*5.%*3@IJ
M,G5A2?-*+3BHQFY748J4FHMXCAG/L'BL+E^(RS$QQF+@YX?#PC&K4JPC-TY2
M2HSJ*,8RNI.;@HI.3:BG)?*A8*,DXR0H[DLQ"JJ@<LS,0JJ 69B%4$D"OVO_
M &%/^")?Q_\ VI$T?X@?&?\ M+]GSX&WPAO;>]US2MWQ.\=:9)M8?\(?X/U!
M8SI&G7L1(B\2^*H[>UV,)[#2]53!/] '["G_  1J_9R_9$.D>//'<5E\?OCS
M:"&Z3QEXITB+_A"?!FH*%8CX>>"KW[3;Q7%O*&$/B?Q$;_6VP);.+2,^4/V$
M=W=B[LSLW)9F+,>W))).!@#T  ' KX?..-*E3GP^3Q=*#O&6/K0_>26S>%H3
M35-/6U;$1<MI0PZT9^I\->&-.E[/&<1356HK3AEM";]G![KZUB(-.;6EZ5!J
M*>DZSU1XS\ ?@+\-_P!F7X4>%O@M\)K+6['P/X0@EBTR/Q'XCU;Q3K$\UR_F
MWEW>:KJ]Q-('NI]THL;".QTBQ#>1ING6=NHB'LE%%?!RE*<I3G*4YSE*<YS;
ME.<Y-RE.4GK*4FVVWN^VB7Z]3ITZ-.%&C"-*E2A&G3IPBHPA""Y8PA%72C%*
MR5W^84445)9%/!;W<$]I=V\%W:74$UM=VEW!%<VMU:W$;0W%M=6TZ207-M<0
MN\4]O-&\,T3O'*CHS*:^FZ9IFBZ=8Z1HNF:;HNCZ9:PV6F:1H]A::7I.F6-N
M@2WLM.TVPAM[*QLX$ 2&UM((H(E&V.-169XMT?4_$/A/Q3X>T7Q-JG@G6M>\
M-Z[HFC^--#M["[UOP?JNJZ9=6.G>*M&M-5AN-,NM5\/7D\.KZ=;ZC;S6,]W:
M0QW<3P,ZGF_A'X-\3?#OX7> ? GC3XF>)?C/XM\)>&--T+Q%\6O&5AI.E^*_
MB'JME&4N?%/B#3M"BAT>SU/4"09H;"/R@(U9Y)IFEFDR;?MTO8WC[*3^L7A[
MKYU^ZM\?O?'I[NFI=E[-OVBYO:)>QM.[7(W[6_\ #M%_N[-^TO*Z]RYYOXM^
M!7P-\8?%"7QKXKOK6^\;WVL?#_4KSPQ>>+]+%GJMQ\/_  C\1/!_AO3;SP9/
M(;F^TR_\,?%#QC!K&F-"R:VL]G<MMCL0)/&/"'_!.3]GKP-I_ACPWX?UGXSQ
M^ ?#GA_PMX7O_AM>_$RXO_!OCW1/ WQ#\4?%#P58_$9;C2'\1^)K7PWXL\7:
MI);V:^(=/L]4TF#3-'U^#5K*S9)[OQR_9P\0^)OCM+\=?A5X)^%UE\4=)_98
M^,_@GP1\3_$>A^&YM=T;XZZUKG@NX^%6K7%S=Z7>ZG(-*TK2-:L[7Q!(EW#H
M,4HLY(9;.[EM9OC?Q7X6_P""B-A?>!_A]HVI?M%:1=>+F^-?B+P#8ZM\=/AG
MJGB[X?MH.@_ ZU\&:U^T/\6;?PO>>%?'O@NW^(ES\2_$&G?#;07E\1:EX&U5
M] 5=3-G_ &;I/AUY4J=::K9=[1NI-TYTW./-%5(6NKRYN9RO+E5M8IQM)N/L
M8=5ITH1HYJJ,?9P=2E6G&*@U"KS*"C?W:4(V4WRS7/HXR4%4_0/XO_LC?"GX
MV^,[WQM\3?%7Q/U+4E\/ZWIWA/2HO'UOI.B_#&YUF'1(]=\9?#>VBTA=3T+7
M)6T#1KV=M0U36O"EGJ4#ZD/#T5U>W$DG(:?^P5\$8;[PQJ[>+?C3KBZ5?2ZQ
MKT&I_$\ZAI7Q:GNOC!J/[0,4WQ1BM]&AC\4P0_%G5)/%UC_9,N@QI'!::.&D
MT(2V$^1\7? /[1B?%OP+XVT;0-.^,L;?"#]H_P"%5QJ'A,^$?AE%X NOBJWP
MYF\$WNK>'O&OB_4#XRTK3KKPQJW]JZII&^_99+2-O#:I(T<GA47P*_X*0:!X
M9\1W'A;XGZW:^+KSP!XN\(:?X9U?Q=X4N_AWX-M-+^&OP4M_A]?^"?#UMHNG
MP>'?%M[XRTGXSVMOX@DOOLVGR:KI5UJ0MM"&G"Q=1T54FI9=)KFO)<[BW=QJ
M7LY*,K3C3BU%67-&*>\&J3K^RIJ.;4J2Y%&,)5+**]^DX)1IN=.*C)OFG&/,
MFY6<G&J?5DG['WP TK2?#^@WU]XBL;'3X_AQHVAQZKX\ALIKZ3X9VGQ.L/!E
ME%)>1P?VE?B'XN^,Q=V]NCSZC--I<B0QG3E$V7)^P;\#'M$T@ZC\4D\/)?:;
M>2>&$\=$:'.D'P0'[.GBC3+BW?2'NGTKXD?":*ST'X@6@O%DU&_TVRUK19_#
M^H)/)/\ )'[07[$W[2G[0/P3^!'A+Q)K^K>(?&?@'3OVEM<UF_\ BK:?#?5O
M%4T?B_08+?X9^ M0U1;KQC9Z?J&HV]L_A"+XQ^%-<O?'W@"-K/Q9%XA75;:=
MY-W6OAE_P4,NF^/6IP^//B+97&K7UM)\(O WA7QE\.+;P>GARW\5:/JO@[PS
M:>*=3\8V?B_PE/I/@VTN_ GQ4\0:9;Z!K.LR76I>*M'OO%FHG3XIH3I.4T\L
MO3Y8N+A)W?[N4I<SC>,KR3BK)-Z[M-*XQJ.$90SJ"J<]13C.<HJ+]M&G"<'9
MM\\&ZLI/E5.*^+6Y[CK7_!/O]G>+P7I?A[4/%GQ2\+Z'H>A:EX1UG7-'\?>'
M? EUXL\ ZWJOA"_'@'X@:CHOA31]-UOPU%K/@SPI+93R6UCXDN;JUEMKWQ!?
MQ:O?6MS]B1_#+X:VOC1OB)'\,OAU;_$/[:VHOXX3P+X8A\9M?R0"WENY/$Z:
M6NO&YFM#]EFF:_\ .EM&-N[M"Q0_F]\3/AE^W%\3Y_&/P[U[0+>3X<7DOB[6
MDU&3XJ>$]2\/>(AK'BG]GWQ/\.O!]AI4VGV/BJ%OA8?"OQ:MUUS7+/3H+NXN
M[2YMQ?\ ]M1"QW/V;?@[^U1\)?B)\)]$UV;XB:K\*/#GB#X]6OQ%A\9?&C1_
M%'A?4--\5?$3QQXM\$_$/PVMIJESXUUW6-1TO5?#&AVO@#Q=HR:3X5LDU'4[
M/4]!U6SFM];UISIPJ-1RRIR3<8-RC*4DX>[S6G%JUI-*SBVUJ^JSJTZE2BY5
M<VI3J0C4G&DJS:E&HG4E!2@Z?OSE%J5.:G&[6D;V?JNK_L-?LJ>'K^_^(OB!
M-8T&6UT#^Q-3\2Z[\0CI&C6=C/\ '9/CY'J%[-J/V71;;6F^($ZZ#;:[.$U
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M<6$U[9Q>%I$MFG_5K^SOC5_T-OPL_P#"'\6?_-K1_9WQJ_Z&WX6?^$/XL_\
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M/_MRTS_VWKS[]K#_ )-G^/'_ &2OQI_Z8[RO0?%G_(A_]N6F?^V]=^5_\C+
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MT;P7)\1++3=<\12N&CL/#VC^+[V^U2X,-M8>?+<19_#']KO]L7X6?&#XE_\
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MH7C?3OA)XR\8:E\1M$\->)[&6/4O"]SXVTCPO=:UITUM>1VD"7"JGVY^SO\
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M58SZ5IVKZOIUCK.D3WU^\.EV5_;^"[J[^,4/C"^MH_#>FZ=8M\,]1M7\6/\
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MUK5JU5^QPN%I.-2O54VYTJ-*M6C^6^+?BWPSX.<,+B/B-8G%U,7B?[/R7)<
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M/P^_Z*#X _'QQX4'\]8K_.DGBC&2$7J>P]16+<0Q<?NUZD=.PS7)/P@C"_\
MQD-1[?\ ,JI=?^Y\]*E](VO4M?A*A&_;.:[_ />>C_1U_P"%A?#W_HH7P_\
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MI>)I5U/-9ZE;V]TNGSQI=3VMQ;I+&?\ /CG@BP/W:\DYX]JR)HHT;*HJG)Y
MYYSGG\*YX^'\*56E.KFCKTH5:<ZM%X*--5J<))SI.<<6Y0517BY1]Z*=XZI'
M54\7L1B<-7I4<FCA:]2C5A1Q$<?.I+#U91M3K*$L(HS=.5I<DO=EK%Z-G^A'
M^Q1_P4S_ &8_VXM-M=.\!^(6\#_%V.T$^M?!+QU=6=EXP@>- ;FX\*WBM'IO
MCO1XVW%+S0F.H118;4=(L&RM?H1T)!!!!(((P01P00>00>"#R#7^6WIVHZCH
MVHV&L:/J%_I&L:5=0W^EZOI5[<Z;JFF7UNXDM[W3M0LI8+RRNX)%5X;FVFBF
MC< JX-?T5?L*_P#!?+X@_#C^Q?AM^V=9:I\6/ L0M]/L?C+H=O"_Q4\-6J[(
MHG\6Z8OD6?Q$TZV3F:_C:P\6+&K.\VM2XB;R\XX,Q&&Y\1E3GBZ"O*6$FT\7
M26K:HS?+'%12VA/V>(LK*59VO[_#?B;A,9[/"9]&&"Q+M"..IQ?U.M)V2=:"
MYI863ZSCST+N[5)7M_7U17FWPE^,7PL^//@;2_B5\&O'OAOXC^!M71?LOB#P
MS?I>007!4,^G:M:-LO\ 0]7MR=EUI&L6MEJ%NX*O!C#'TFOB6G&4HRC*,X2<
M9PG&4)PE%VE&<)*,H23WC*,6NUFF_P!5A.%2$:E.<*E.<5.%2G*,X3C)7C*$
MX2E&46MI1DT^^C2****104444 %%%% %/4=1T_1]/O\ 5]7O[+2M)TFRN]3U
M75=3N[>PTW2]-L()+J_U'4;^[DAM;&PL;6*6YO+RYEBM[:WBDFFD2-&84/#?
MB7PWXS\/Z-XL\'>(M"\6^%/$6GV^K>'O%'AC5K#7O#NOZ5=KOM=3T76M+GNM
M.U/3[E/F@N[.XF@D .UR58"?7-$T;Q-HFL^&O$FDZ=K_ (<\1Z3J6@>(-!UB
MTAU#2-<T/6+.;3]6T?5;"Y22WOM-U.PN+BSOK.='AN;::6&161R*R? O@7P5
M\,/!GACX<_#;PGX>\!^ /!6CVGA[P?X*\)Z7:Z)X9\+Z#8*4LM'T/2+*.*TT
M_3[92WE6\**H9G=MSNS'/][[565/V/([OWO:>TYE:R^'EY;WZW*]SD?Q^UYU
M96A[/V?*[MN_M/:<]K)+DY+MOFLCR'Q;^TQX'\'_ !)\6_"^\\-_$35-6\!>
M!M!^(/C7Q#HV@:,_@KPUH7BA-9D\.V^HZ_J_B;1Y&U;5AH.HB"TM-.NK:W9(
M5OKZT^T1D]:/C]\"GN;RR@^,OPPN[_3]7UOP]>Z=8^-_#]_J-MXB\-:?)JGB
M+P])8V=]/=#7=!L(GGU?2O*^UZ=\L5W'%/)%&_Q_^T/X-_8[D^+_ ,6'^-7B
MS_A#_B?\;_@AI?@N'QOKG@2Z73O W@?X8^&_&OBS7++P1\5;[PQ<>&;'Q'K/
MA1O$7B3Q!X,N?$,FIZEI&@-=VFD2+$RR>6:)'^QS)#^SOJ'A_P"-7C?PMI_A
MSX]?$TV6KM\'O$W@WQ/?^-_C-X^B\4ZS\+_BSXSO?!&EZA\)O"OCG6?&WA_0
M5TGQS'I>G_$K1]2\+31S3WXTW6(?'EC\53J58N>'DE4FDG**E%*I3A&-DUJE
M/F;D[6=[Z,]6.#PU2E2FH8V,G3@Y2C0E.G.3HU9SE&5I7BZE/V<(P5])2>D;
M2^L/%'[<GP!\._#;X6?&#2;[QI\2/AM\7_#?BSQOX7\3_"_P==>*[?3_  #X
M"T2T\1^./'/BJT>[TN^T/P[X3T>\ANM:(M[S5X&6>W@TFXN()(QZ+XB_:B_9
MV\*PZ5<:Q\9/ 20ZS\1?!_PFM&L-=M=5>W^(7CZ&\N/!_AO5X=/:XGT2XUN+
M3[UK>XU6*UM(VMI8IYHYHI8X_P ^-"@_8K\8>$_V>O"&J^(_%'[4&D_L>Z!\
M5M2\)^%M9^&$&DIXC\$:=X):\TKQ7J7AK6-+\(:5X^\+Z3X9\*IHW@3QEX?%
M[X7\?:O:WEU?7=Y*ES+#WWPO_8R\#>*/%WQ3^+NA?&[XSW/CG5/C!\+/$MOJ
M_C33_"NMW/A2]^$?B37_ (K^#--LM,OX[S2M4\.:MX=^,-[X=$)M])6Q\/'2
M_L5E:ZYI4]]>13QV/J2M3="JYQBXQCRWCRPBZCLFF[RYDDY/6VJ5KZ3P> IQ
M;K/&T%"51.4Z3_>J=:HL/&THITVJ*ISJ2]G9MRC&+DGR_<FF?'SX.:A86%Y=
M_$CP7X;N;[P?<>/WT/Q1XL\,Z1KNF^#;-KA;SQ)JUD=8N(;+1[-;6>>[U'[7
M+9P6L;W<DXMTEDCI:#^TA\!/%?CCP!\.?"GQ;\#^*?%OQ4\,^+?&'P\L_#6N
M6FO6'BSP]X$UG3_#WBZ\TK6M*>[TF6;0]8U.VL[RP-VM\&CO76!DL;DQ_'-G
M_P $M?@=8V_B?3T\3>(KS3_%OPYD\!ZB^L^'?"FM:YIM[)X/E^'\GBKPSK]]
M:O+X?GN?"$G]E:AH%M8R:5>L;J8RPPZC?V<_T?X*_98\-?#SXPZ;\8_"7BW7
M-,U&W\4?&K7]8\,#1/#$GAW6].^-\W@'4M:\,H%L(KW0+/P]K_PX\/:SHFJ:
M++#J5SYNJ:;JAN+.\S'U*KFGNIT*:]ZTF[7M=).W.HM6U;5MW[ONZ\LZ>6)3
MY,1B9RY)NFG2C"//RR<(R=IS24^5.][J]W'FO";PG^UU\&/$OA[Q;XVUK4]1
M^%?P[\)^+M9\#K\2?C*?#?P\\#^*?$?A[7_$/AK5[+PAJVH^)KBXU'[+JOA?
M651-2L-'N[NTMA?65I<6S-(GH6L_'WX$>'#X@7Q!\:_A/HC>$]%T+Q'XH&J?
M$#PO9GPYX?\ %/V7_A%M;UOSM37^SM+\3B]LV\.WESLBUR.Z@ETPW44BN?F+
MP3^P#X!\'I>6$_B^37="D^/6M_M!V.GM\,?AKHFIMXNU^+XGPW5EXN\2Z9I9
MU/X@VUFGQ3U:/1]5\2(VLZ5!I.DP6]QY;7?F3Z;^P-X&\-^"[/P[X-^(?BKP
MYXGT/Q;\&/'/A;Q_<>%? 7B;4=&\0_!#X.VWP.\-_P!H^'->T:X\/>*M(U'P
M6E_->Z1K430Z;KNI'4]"ET^6PLPLQJYK&&M"$Y)2=Y<L974JNBBI<KT]GRZK
MF79MVJ5/*G/W<3B(1<DM*7,E"U+WG*:Y^:_MG)<K2]SD32:EZT?VL?@^OQ1N
M/A9+JLT,]KI\NLR^.I;C11\-O[#B^&6D_%K^WD\6+JS6SZ++X2UJQ:#4EB-K
M+?%XDD-OY=R^IXL_:D^!/A.Z^$NGO\1_"/B+5OC?XP\)^#_AKHOA;Q/X<U?6
M?$S>+]=E\.6OB73=,358[R^\*:/JL%Q!K^JV,-RVGM;747V>6YM;B"+Y8O\
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MF?#WQ-H(U;X77.C77A/PAJ%^W@FZUJ_\97^LZM=:A>LWQ1\)+/Q)\%_#-_\
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M$^//B?I%MX>M5@\'?$/X6>%OAMXJ\,:+X2U?2_&OBOP?\1O E_IGCR35-/\
M%MAKD4OB'31I46N:;X4UA=5TJ/Y9\0_\%A_A;:^(+OQ?X@_932W\$_"/X?\
M[4FO^,;[6O%_@#5?CA\--9^ /B[X;>#H/!?A[P9!HU[&TOCG3?B?X5UV]MM
M\1W$6B^%-7M_$<=UK&B6%\[]-X9_X*J_#N7PW9'P+^P_XOL[6VT'X>QZWX>.
MM?"GX?V^CZ_\??VCM0_9I\(>$-*LM8TO29-;T?QOXYT9O$%_XF?2M'T>X\)1
MPWFKV U.VCTTQ];]Z5L?42Y+*+IU927[NG'FV_FC)VYKI*5FVVU:R[$*FN?*
M%*3D_P!Y&MAH0NZM2HHV=;3]U)0LM&O923Y;*IZQ^Q9_P4GO/VF?'/P]^%7B
M#X37^BW?BCP+X@FM/BU%XK\-OIWC'X@?#3X3? ;XH_$: _#33;9[_P %:-<:
M;\=]#.@SMKVLPM?:=J6GA!;):7LWZM5^(L/_  6(_9H\-Z)'K]O^SSJOAW6]
M.TM]0;PYI^I?"K3/$MK(?@G\9/B?XOBT4V*P-J&FZ/%^SOJ?PYU'Q!IA&DZM
M>S^%9YI8-)L!:VU?XB_\%9_%EY\./CJOA/X$^(/@O\4?A!X%^)/Q(TVZ\=^+
M?AU\2O"_BC_AG+QW\#Q\:/A^UIX4O3=V4NM^ ?C-X<A\,^)W$2?VUJM[':0K
M<:#%+J';ALSI4:<HU\1+$SNW#EI2]V*C%\CD[:JZMS:VTO)LY\3E.*K5E*AE
MSP5*7)!PJ8BG.//*I*'M$W-RY9.4$_9PE"-DXI1T7[A44I>*4)-"KI#/'%<0
MQR_ZV.*XC2:..7//F(DBI)_M@TE>Y&2E&,EM)*2OO9I/7SUU\SP2*X$[6UTM
MJ2+IK2[6U(ZB[:UF%J1[BX,6,<YK^6?]G*[\(Z1^U9\*+OXOBU7PO8?%K3F\
M7OK"YL(+F+6)T2XUA9@5^P6VN_9)]2^T Q+;1SF=3&'!_J>!*D%200001P01
MR"#Z@\BOQ+_;C_80\87?B[7/C%\$M!F\2Z3XEN)]7\8^!M)B1];T;6YMTNI:
MQH6GJ5;5='U64O>7%C9+)J%A?2W)2WGM)D,'[_X$<29%@*_%_"F>YBLDI\:Y
M*LMP6=>VAA?JF+CA\UP;HK&5)4Z>%K5:&;2Q&!JUJM*@\;A8T:E:C*M2F_Y"
M^ECP5Q7FV&\.?$'A3)GQ37\,.)GGF9<,?5ZF._M#+WC,BS)5WEU&%6MC\/1Q
M.00PF9T,/0Q&)CEN.GB*6'Q$,/7IQ_HY^(NK>!=/^'/C#5_B#=:0/AY%X5U>
MX\4W&J26[:/-X:ETZ;[>L[RDP3P7=F[11(I<W+2QQ0AY)$5OX*=7:Q;4-0;3
M$DCTQKZ^;38YLF6/3FN)&L4EW$MYB6AA63<2=X;)S7KOB/6OC5/HD7@3Q)JG
MQ6F\/:4T:P>#M;NO%[Z/I[6^1#&F@7SFSM_LS B&/[*H@(/EJN*\LN-"U[)_
MXD6M]"/^0/J/H/\ IV_7I7[;X)^#\/"'#<11K<5X?B">?XG!5*:PU-8+ X?"
MY?#$QP]54:N88KVN.Q,<4_K%>G-48T:=.A1E5A^\7\N_2B^DA5^D;CN#)87P
M\QO"%/A#!9G2KRQU2699KC,?FT\#+%T/K%#*<#[#*L'/ IX3"UJ<L3/$U:N*
MQ,:%7]T^2N.I^A_D*RI^WX?UKJI] UXDXT'7#P?^81J/H/\ IVK+G\/^(./^
M)!KO_@GU+MG/_+K7['7KT+O]_0V_Y_4?/_I\?S-AL%C-/]CQ?3_F%Q/9?]0Y
MR-Q]\?C_ #K(N.OX_P!6KKKCP_X@+9'A_72!G.-&U/US_P ^M9%QX>\0D\>'
M]>Z_] ;4O4_].M>36K4;O]]1Z_\ +ZCY_P#3T^APF#QB2OA,5_X38C_Y0<C/
MU;_/\1K&N.OX_P!6KL)_#WB++?\ %/:_TS_R!-4Z9)_Y]/2L>X\.^(L_\B[X
M@Z_] 35/4_\ 3I7E5ZU&R_?4?_!U+S_Z>GT.&P>+T_V3%=/^8;$?_*#D[CJ?
MH?Y"LBX[?[IKKY_#GB,DX\.>(3P?^8'JOH/^G2LFX\.>)#C'ASQ"?E(XT/53
MSZ?\>E>36K4=?WM+9?\ +VEY_P#3P]_"X3%_] N*^S_S#8CL_P#IR<;<=3]#
M_(5E3]OP_K773^&_$F3CPWXB/!Z:%JI[#TM*RYO#7B4_\RUXCXZ_\2'5\<9[
M_8Z\FM5I:_O:6S_Y>T^__7P^BP^$Q6G^RXG_ ,)Z_=_].3C9^WX?UK(N.OX_
MU:NRF\,^)C_S+/B3CD_\2#5^V?\ ISK'N/#7B;)_XIGQ)P2?^1?U@]V_Z<J\
MJM5I.]JM+=_\O:?;_KX>_A<+BKK_ &;$?^"*WE_TZ./N.A^I_F*QKCM_O&NT
MG\,^)SG'ACQ*>2?^1?UCU'_3E6-<>&/%!Z>%_$Q^8G_D7M9]_P#IR_3K7E5J
MM+7][3Z?\O*?G_T\/HL-A<5=?[-B-U_RXK=W_P!.CC;CH?J?YBLNXZ?A_1J[
M"?POXI(./"WB<\G_ )EW6?4?].59D_A;Q20<>%O$_I_R+NL]>?\ IQKRJ]6E
M9_O:?7_EY3[K^^>]A\-B;K_9Z_\ X)J]W_T[.*FZGZC^59$_;\/ZUVDWA;Q5
MD_\ %*^*.",_\4YK7IC_ )\?6LB?PKXKX_XI3Q3V_P"9;UOW_P"G&O*K5:6O
M[RGO_P _(=O\9]%A<-B+1_V>O_X)J]E_<.+GZ+]3_*L>XZ_C_5J[:?PKXLP/
M^*3\5=<_\BUKG_R!7/ZEH'B"QA:ZOO#^OV%JC*'NK[1-4LK9"[%4#W%S:10H
MSL0J*S@NQ"J">*\FK4INR52#;T24X-MWV24G=GO8?#UXQ;E0K))-MNE4222U
M;;@DDNK;,"BI(()[JXMK2U@GN[R\N(K2SL[6&6YN[RZN'$<%K:6T"23W-S/(
MRQPV\$<DTKD)&C,0*_?[]A3_ ((0?%_XUC1/B1^U==:Q\"OA9<BUU&R\ 6\4
M*_&3QG8R;9HA<VEU'-:?#K2KN(J#=:U#<^(WB<FWT2U)2X'E9CFF!RNC[;&U
MXTD[^SIKWZU:27P4:,;U*DM5=I*$;WG4@M7[N3Y%FF>XA8?+<+.LTU[2J_<P
M]"+=N>M7DE3@M[)MSE9J$)/1?G)_P3Z\0_MQ:-\==-MOV$3XVO/B+>26I\0Z
M%HD(O? &HZ,LR[W^*UEJC+X1B\-*H82ZCX@DM;BV3>VE7D5V(\_Z!GPNE^*$
M_P ._"$WQJLO VG?%>31;5_'5C\-+S5]0\"VVO%?])B\.WFNQ0ZI-9@;=YN$
M:-+@RI;2S6RPROSGP-^ 'P9_9I\!V7PT^!GP]T#X=>#[01O/9Z-;9U'7+Q$"
M-JOBC7;DRZQXEU>;&Z74-7O+J4,2L @BVQ+[!7Y'GN<0SG%*M3P5'"PIIQC4
MY4\97CM'ZS5@U3Y8[PI1C5=-MWKO6+_HWA+AJMPW@I4*V98C&U*MI3HN<E@<
M/+1R6%I34IJ3VG5<J:FEI12M)%%%%>&?6!1110 4444 %%%% 'Q-^T)^REXP
M_:(^(-Q>^*?BIH$/P=7X4>,/A]X<^'$G@'4+SQ'X%\6^/="U70O%/Q=\-^*D
M\7VFAWWC2YL;K3]'TI?$GA34K70/"T7B#1=*^S7'BW5-27AIOV-OC%K'B/0=
M>\9_'WP+XQT_5OBZOQJ^-?@VY^#>LZ-X4^(OC/1?"WA#P'\.I] MM,^)1O\
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MFWC6Q->NVZM1R4N6\5:,/=O:U.-H)WE)W44VY2;;YF@HHHKH, HHHH ****
M"BBB@ KT7X8_\C!<?]@Z7_T;%7G5>B_#'_D8+C_L'2_^C8J\O._^11F'_8-+
M_P!*IGM\-?\ )09-_P!C##_^Y#M/C'_R2+XJ?]DX\<?^HQJE5?@?_P D5^$'
M_9+OA_\ ^HGI-6OC'_R2+XJ?]DX\<?\ J,:I57X'_P#)%?A!_P!DN^'_ /ZB
M>DU^1G]&G'?M8?\ )L_QX_[)7XT_],=Y7H/BS_D0_P#MRTS_ -MZ\^_:P_Y-
MG^/'_9*_&G_ICO*]!\6D#P&22 /L6F<G@?\ +O7?E?\ R,L!_P!AF'_].Q/&
MXB_Y$.<_]BW%_P#II'@%?SJ?MZV=I\+?^"K?@OX\?$W]L_XA_P#!/3PGXO\
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M223LDDDDM.B21ES+NOO7^8ZE!((()!!R"."#Z@]C3-Z?WE_[Z'^-&]/[R_\
M?0_QHL^S^Y_Y!S+^9?>O\R5I'8EF;>QZLX#,?JS D_B:3<?1?^^$_P#B:CWI
M_>7_ +Z'^-&]/[R_]]#_ !I<B_E7_@/_  !\_P#?7_@2?YMO\23<?1?^^$_^
M)HW'T7_OA/\ XFH]Z?WE_P"^A_C1O3^\O_?0_P :.1?RK[@Y_P"\OOB2;O9/
M^^$_^)HW'T7_ +X3_P")J/>G]Y?^^A_C1O3^\O\ WT/\:.1?RK[@Y_[R^^))
MN/HO_?"?_$TF?]E/^_:?_$TS>G]Y?^^A_C1O3^\O_?0_QHY%_*ON_P" '/\
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M077=?>O\QU>B_#'_ )&"X_[!TO\ Z-BKSC>G]Y?^^A_C7HWPQ93X@N &!/\
M9TO (/\ RUBKRL[3_LC,-'_NTNC_ )J?D>YPTU_K!DVJ_P"1AA^J_P"GGF=K
M\8_^21?%3_LG'CC_ -1C5*J_ _\ Y(K\(/\ LEWP_P#_ %$])JU\8_\ DD7Q
M4_[)QXX_]1C5*J_ _P#Y(K\(/^R7?#__ -1/2:_(S^C3COVL/^39_CQ_V2OQ
MI_Z8[RO2M;\2Z/X8\.:1=:U8:QJ-I=1V-HL&C>&]6\3S"4VGG*\]CH]C?SQ0
M*(CFXEA6%9"B%P[H#YK^UA_R;/\ 'C_LE?C3_P!,=Y6Y\4_%6M^#OAS8ZSH%
MQ%:Z@)]#M1+-;172>3<0D2KY4P*98*N&QE<<=:J+Y9*6NCO[LG%Z=I+6+\UJ
MB914HN+46I*S4HJ<6GNI1DG&2:W333ZIE;_A:WP^_P"A3\;_ /AHO&W_ ,S5
M'_"UOA]_T*?C?_PT7C;_ .9JOF3_ (7_ /%'_H,Z?_X);'_XFC_A?_Q1_P"@
MSI__ ();'_XFM_K$OYL1_P"%=;_,Y_JE'_GSA/\ PCPW_P J/IO_ (6M\/O^
MA3\;_P#AHO&W_P S5'_"UOA]_P!"GXW_ /#1>-O_ )FJ^9/^%_\ Q1_Z#.G_
M /@EL?\ XFC_ (7_ /%'_H,Z?_X);'_XFCZQ+^;$?^%=;_,/JE'_ )\X3_PC
MPW_RH^F_^%K?#[_H4_&__AHO&W_S-4?\+6^'W_0I^-__  T7C;_YFJ^9/^%_
M_%'_ *#.G_\ @EL?_B:/^%__ !1_Z#.G_P#@EL?_ (FCZQ+^;$?^%=;_ ##Z
MI1_Y\X3_ ,(\-_\ *CZ;_P"%K?#[_H4_&_\ X:+QM_\ ,U1_PM;X??\ 0I^-
M_P#PT7C;_P"9JOF3_A?_ ,4?^@SI_P#X);'_ .)H_P"%_P#Q1_Z#.G_^"6Q_
M^)H^L2_FQ'_A76_S#ZI1_P"?.$_\(\-_\J/IO_A:WP^_Z%/QO_X:+QM_\S5'
M_"UOA]_T*?C?_P -%XV_^9JOF3_A?_Q1_P"@SI__ ();'_XFC_A?_P 4?^@S
MI_\ X);'_P")H^L2_FQ'_A76_P P^J4?^?.$_P#"/#?_ "H^F_\ A:WP^_Z%
M/QO_ .&B\;?_ #-4?\+6^'W_ $*?C?\ \-%XV_\ F:KYD_X7_P#%'_H,Z?\
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M^?.$_P#"/#?_ "H^F_\ A:WP^_Z%/QO_ .&B\;?_ #-4?\+6^'W_ $*?C?\
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MA]_T*?C?_P -%XV_^9JOF3_A?_Q1_P"@SI__ ();'_XFC_A?_P 4?^@SI_\
MX);'_P")H^L2_FQ'_A76_P P^J4?^?.$_P#"/#?_ "H^F_\ A:WP^_Z%/QO_
M .&B\;?_ #-4?\+6^'W_ $*?C?\ \-%XV_\ F:KYD_X7_P#%'_H,Z?\ ^"6Q
M_P#B:/\ A?\ \4?^@SI__@EL?_B:/K$OYL1_X5UO\P^J4?\ GSA/_"/#?_*C
MZ;_X6M\/O^A3\;_^&B\;?_,U1_PM;X??]"GXW_\ #1>-O_F:KYD_X7_\4?\
MH,Z?_P""6Q_^)H_X7_\ %'_H,Z?_ ."6Q_\ B:/K$OYL1_X5UO\ ,/JE'_GS
MA/\ PCPW_P J/IO_ (6M\/O^A3\;_P#AHO&W_P S5'_"UOA]_P!"GXW_ /#1
M>-O_ )FJ^9/^%_\ Q1_Z#.G_ /@EL?\ XFC_ (7_ /%'_H,Z?_X);'_XFCZQ
M+^;$?^%=;_,/JE'_ )\X3_PCPW_RH^F_^%K?#[_H4_&__AHO&W_S-4?\+6^'
MW_0I^-__  T7C;_YFJ^9/^%__%'_ *#.G_\ @EL?_B:/^%__ !1_Z#.G_P#@
MEL?_ (FCZQ+^;$?^%=;_ ##ZI1_Y\X3_ ,(\-_\ *CZ;_P"%K?#[_H4_&_\
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MHO&W_P S5'_"UOA]_P!"GXW_ /#1>-O_ )FJ^9/^%_\ Q1_Z#.G_ /@EL?\
MXFC_ (7_ /%'_H,Z?_X);'_XFCZQ+^;$?^%=;_,/JE'_ )\X3_PCPW_RH^F_
M^%K?#[_H4_&__AHO&W_S-4?\+6^'W_0I^-__  T7C;_YFJ^9/^%__%'_ *#.
MG_\ @EL?_B:/^%__ !1_Z#.G_P#@EL?_ (FCZQ+^;$?^%=;_ ##ZI1_Y\X3_
M ,(\-_\ *CZ;_P"%K?#[_H4_&_\ X:+QM_\ ,U1_PM;X??\ 0I^-_P#PT7C;
M_P"9JOF3_A?_ ,4?^@SI_P#X);'_ .)H_P"%_P#Q1_Z#.G_^"6Q_^)H^L2_F
MQ'_A76_S#ZI1_P"?.$_\(\-_\J/IO_A:WP^_Z%/QO_X:+QM_\S5'_"UOA]_T
M*?C?_P -%XV_^9JOF3_A?_Q1_P"@SI__ ();'_XFC_A?_P 4?^@SI_\ X);'
M_P")H^L2_FQ'_A76_P P^J4?^?.$_P#"/#?_ "H^F_\ A:WP^_Z%/QO_ .&B
M\;?_ #-4?\+6^'W_ $*?C?\ \-%XV_\ F:KYD_X7_P#%'_H,Z?\ ^"6Q_P#B
M:/\ A?\ \4?^@SI__@EL?_B:/K$OYL1_X5UO\P^J4?\ GSA/_"/#?_*CZ;_X
M6M\/O^A3\;_^&B\;?_,U1_PM;X??]"GXW_\ #1>-O_F:KYD_X7_\4?\ H,Z?
M_P""6Q_^)H_X7_\ %'_H,Z?_ ."6Q_\ B:/K$OYL1_X5UO\ ,/JE'_GSA/\
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M@[4KWPM8ZCK<"ZII%E<RYK]M)(WBD>*1=LD3M'(IZJZ,593]&!'X4 ,HHHH
M\I\1?'CX'^#_ (B:'\(O%OQ>^'7ACXJ^)K"#5/#GPZU[Q1IVE^+M<TZZ&H&S
MO--TFZECEN(K[^R=573U#"74'TV^2RCN'MI%7'UC]IG]G3P_9?#74M;^.7PR
MT[3_ (SV1U+X07DWB>TEA^)^FK-96[ZEX'-J+A_$&GQSZGIL,U]9HUK#+?V:
M2RHT\8/RI\5_V$&^.7[8GB;XZ^.?&%XOPN@^$_[/]EX<^&7AR^TZVG\4_&'X
M%^,?BAXO\):_\2WG\/W>O6W@WPMJ?C/3M5T&S\+^(M'_ +?U&WO[;Q#%=Z;;
M16TGSE\)OV*OVLO!<O\ P3NO=>\/?#UY_P!B'X.?$7X&^)H_AE^U!XR\!7GC
MJR\5ZA\.=0L?&D.LZ3\,!))H<3>%=2B\2?"+78'LM72;3!=:P8W98P#]8?"G
MQ@^$WCR^TG3/ _Q,\#^,-3U[PUJ_C/1=.\-^(M/U:^U/PCH'B>;P3KGB6UM;
M262;^QM(\96USX4U"\E2)+;Q#:W.E.!=V\T<?HM?C'\)/V=?VA_V(?B7\>/V
M@SH_P?\ %'_#8/C70]<^*EIX8\/^,=;L?V7]?U3XL>/=4$_@[PSX6TRV\4^-
M/@)#X,\0:=JWB^VTY]#U%_C5?:MXF-LVDZG/):=]HG[:O[9%SXDTK0O&/['-
MWX T/Q!-HUP?B#-H/Q*\5Z!\/_#DTOPMTGQ3K_CC1M&M8=9N[WPGJ_C#Q+JZ
M^&M(:.^U[PG9:==6D\%UH'C VP!^KU%?)WP-^-?Q>^)'Q,\7^%/&7PL_X1;P
MKHNE^+;FVUN/0/&FC7&CZOX>^(DOA+PMI&JZCXEB31?%+_%3P1''\6?#\GA3
M \,Z'/'HVN?:;PK=-]63SP6K6J7=Q;VCWUP+2P2ZGBMGOKLQRRBTL4F=&O+L
MQ03S"VMA+.8H)Y1'Y<,C* 2T5";FU6YALC=V@OKF*[GMK'[5;_;;B'3S$-0F
M@M/,^T31:>;BW&H211,EB;BW%TT)GA#V?+DP#L?!7>#M;!3GYQQRO!^;IP>:
M &45(8I06!CD!4 L"C J" 06&. 0003P013"".2"!DC)!'*G##Z@\$=CUH 2
MBBB@ HK*U[7=%\+:%K7B?Q)J5MHWA[PYI5_KFNZM>-LM=-TG2[:2\O[R<]2L
M-O$[!%!>5]L4:M(ZJ?YO?V@O^"N?QM\7^(]1M?@++I_PG^'=E<R1:1JUYH^G
M:SXZ\0VL<A2+5M5NM7BNM/T)+U0)8-'T^S:6UBD2.[OI[@.  ?TK9'J/S%&1
MZC\Q7\B4G_!1/]M^%UBG_:"\:6\KQ^;'%<Z'X6MI)(B<"6..?PU&\D6>/,16
M3/&[-)_P\4_;<_Z.'\6_^"KPA_\ ,[0!_69XP\5Z-X%\(^*?&_B&2XB\/^#O
M#^K>)]<ELK=KV\BTC1;.6_U"6ULXV62[GCMH9'CMXV#S, B?,0*Y[X6_%OX9
M_&SPM;^-/A1XUT+QQX=N(XWDNM&NA)=Z;)(H?[)K>E2B+4]%O8\[9+74[2VD
M#9V[UPQ_D\\1?MZ_MA^+?#^N^%/$?QX\4:MX=\3:1J&@Z]I4^F>%HX-2T?5;
M:2TU"PF>#08ITBNK:62%VAEBE56)CD1L$?/7P[^(_C_X1^)+3QA\,/&.O^!?
M$MEY8BU7P]J$MG)/%&1BUU&VR]GJUDP4++9:G;W=K(A(:(YS0!_<917X7_LW
M_P#!8:QNOL'A?]J+PT-.G/E6R_%;P)I[R:?(>$%SXK\%QL]Q:%OOW&H>&Y)X
M!AI#H\0)K]J?!?C?P;\1_#ECXP^'_BK0?&GA;445[/7O#FHP:G82;E#>5*\#
M&2SND!Q+97L=O=PL"LL","* .GHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFR21Q1O+-+%!#$C22S
MSRQP00QH,O+--*R10Q(H+/)(ZHB@LS  FH[>XMKN""[L[JUO;2YC$UM>65S!
M>6=S"Q($UM=6TDMO<1$@@20R.A((#9!  )J*@NKNTL;:>\O[NUL+*UC::ZO;
MZY@L[.UA3&^:ZN[F2*WMX4R-\LTB1KD;F&13HYX)8S+#/!-"/,S-#-%+"/*+
M+*#+&[1@PLK),"V8G1TDVLC  $M%,CDCFC26&2.:&5%DBFAD26&6-QE)(I8V
M:.2-U(9)$9D=2&5B"#59M2TQ%U!WU32XTT@HNL22ZC91QZ.TD,=S&NKR23JF
MEM);30W,:W[6[26\T,Z!HI8W8 N44=51P0R2*'C=2&21&^ZZ.I*NC#E64E6&
M""00:* "BBB@ HHHH *^D/V9?^1QUO\ [ (_]+8Z^;Z^D/V9?^1QUO\ [ (_
M]+8Z /IGXQ_\DB^*G_9./''_ *C&J55^!_\ R17X0?\ 9+OA_P#^HGI-6OC'
M_P DB^*G_9./''_J,:I57X'_ /)%?A!_V2[X?_\ J)Z30!QW[6'_ ";/\>/^
MR5^-/_3'>5%\>O\ DDME_P!?_AW_ -%/4O[6'_)L_P >/^R5^-/_ $QWE1?'
MK_DDME_U_P#AW_T4] 'PM1110!^$VE?L5?LV?M:_\%./^"FFH?'WP1K_ (ON
M_ NF?L567A=]&^)OQ,^'T=A;Z[\$+^?5%N(/A]XL\-0ZJ]Q+86ACFU5+R6U6
M(I:O"DLJO]/_ /#F[_@G3_T17QQ_XDC^TA_\]*O,?A)\=_@5\&?^"F7_  5*
MMOC)\;/A'\([GQ#8_L/W'A^W^)WQ%\)^!)]>@T_X':K%J$^C1>)M5TU]3AL)
M+BWCO)+-9DMGN(4F*-*@/W1_PW%^Q%_T>;^RC_XD'\*__FHH _*/]M__ ()M
M?L:_L[_"?X9_%SX0?#/Q5X:\?^'/VP/V+;32-7U/XU?&GQC8V]OKO[2'@+2M
M42;P]XQ\>:YX>O3/8SRQ1O>Z9.]K(5N+5H;A$D7^@K5/^0EJ/_7]=_\ I1)7
MXR_\%%/VI?V7OB;\!/ '@OX:?M+? #XC>,]5_;%_8BFTOPAX$^+_ ("\6^*-
M2AT_]ICX?WFH2V&@Z%KM]J=W%8V<<EW>/!;2+;6T;SS%(D9A^S6J?\A+4?\
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M(TGJ-(^"O[1VH_M!6GC;Q7=>%K'X2^&/BYX2\:>%/"]OX]\1^*9;>R\+Z?\
M&CPU-XFLK?Q)<ZK<V&M:YX3\8?#ZVU/3+=M"M'O]-U:/^S9$TVWU75/OBB@#
M\T-6_9&^+$/Q!\8>-?!VHCP]JD7CK]IKQYX'\1V_Q3\2P7%SJWQGUOX,ZWX.
M%UIQ>X;3-,TF'P3XKTKQ3X<NA)H%](VG3M8:E:WB?9>L\%_ 3]IVRUS2=8\<
M?%7Q'XHDL/'7CKQ1XDTN7XEWFA>"?&$R>%OB%#\-KK3-.\,6P\1Z+X;NO$>N
M>!D\5>$+^XALM.A\+V]]8:-<-8R/J_Z!T4 ?DSH_PF_;>F\<Z-X4\1ZWKFFV
M^L:=XW\5Z1K/ASXP^*(_ 7PE^V_$OX*SV4&L7EY/KMUX_P!7LM M/BW9^'_!
MNJ:SJ#?V+XA%U&+>V:2#1?KO]DS1_B_9>%?'^I?&?7?$6LZQ+\2O$?@KP*/$
M$FH133?"7X57MUX)\!^,[G2M02*6Q\2?$ZTM+OQIXIO"C/K,]WIU]Y\]N;9S
M]69.,9.,YQGC/3..F<$C-!))R22>.2<G@8')]!P/:@!**** /A?_ (*5OKB?
ML2_&TZ$9P[6GA9-9-ONWCPR_BS1UUSS-O/V?[.4%SGY3 7#D)FOR@_X(D>%/
MV>?&'[;=AIW[0%MX:U*>U\"ZMJ'P;T3QDEC+X;U?XH6^JZ5Y<<MIJ0.G:AKM
MEX>;5+SPW872RF6^26:SADO[:UV_T7>(_#NA^+_#VN^$_$^F6^L^&_$^D:AH
M.O:3=C-OJ.DZI;26E[:R8^9#)#*WERIB2&41S1D21J1_-?\ 'W_@DW\?_ /B
MB\O/@79K\7/ $E\;SP]]DUC3]&^('AR)9?-L['5[#4;G3XKZ[TTA$M]>T6]8
MW'EQW,MO9W)9: /Z1_\ @MAX%_9KD_8;^)/B#XGZ/X+TKX@:'96G_"BM8%GI
MMCXR'Q".H64>FZ-X8F@2+4KRQOK=YX?$6F1&;3AHANKV\@0VD$\/\,/UK[J\
M0_L/?\%"/%\UG<>,/A)\8/%\^G0M;Z=-XL\:V7B:73X'QO@L)-;\77[6<3X&
M^.V,2O@;@<#&!_P[Q_;:_P"C=?&?_@?X5_\ E_0!\:45]:>(?V$/VP?"F@:Y
MXJ\1_ 7Q;I/A[PUI-_KVO:K<7OAIK?3-'TNWDN]0OYU@UR69HK6VBDFD6&*2
M4JI"1LV ?F/PUX=\0^--;T[PSX.T#6?%?B/5Y$BTO0?#VFW>K:M?O(0$\BRL
MXI9MGS O-(J01+EI944$@ QZ^@OV9O%O[27ACXDV,'[+5UXZD\>W\L7G^'_!
MMM-JNFZO;B1<_P#"6:'.LGAZ;21_RWO-=2"&"/<RWD+ ,/TI_9N_X(_^+O$7
MV#Q1^TUX@D\#:._E7*?#/PC>6M[XRO8SM<6_B+Q&@N-*\-*X^2:UTM=4U2,%
ME,]G*,C]S?A7\'OA=\$/#4?A'X3>!]"\#Z&JK]ICTBV_XF&JRJH4W6NZS<&7
M5=;NWQN:?4;N?#$F-(P=M &;\$+[XW:C\.M%NOVA=!\"^'/B;(@_M73?A]J=
MYJ>C+#Y:>5->&Y0V]EJ\C%S?:?I5YJ6EVS@+:WKJ2B>M444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4ZIX \
M9W_QI\(?$VS^,WC+1_ 'ASP+XD\*:Y\ K/2?#TO@+QQXBUJ]2YTKXAZWK5Q;
M-XFL]?\ #$"FRTZRT^Y6PGB6,RF(->1W?JU% 'B7[2_@;Q%\3_V=?CA\-O"$
M%G=>*_'GPR\3^%?#EOJ,\%MIT^KZO:?9[2._FNGBMELF<G[4MQ)'#-#O@DD1
M92P^/5_9:_:-^%>A_$31_@9\6]1L6G^%WB#Q'X'TC0XO"OPR^%,?Q^\>?$,W
M?C6WT7X3::E[IOA71=(^&EK%I_PWCDU\^'M%\7WTOB&]G?49KFZA_2^B@#\K
M?$WP8_; \5>#=>\!^+-4^*/C_0_%'P4U[PYX:_M;XG?#3PKIV@>+]4\3^*KS
M4],^/OARSO?$%U\2IG\-3^"M)\!>(]"\2ZR^D'2KV?7[N#4I+F[N^NT#X/?M
MAZ=XCM]3/C35M+\/Z7XLL4L_ >E>+O!]I\/M;\'>)_B1\<+SXCW?B?PQ;Z(!
MJVL'P%K?PI;2));N&>#4[2XE@6?5+?59KC])** /RGC^'W[>6B?#3Q1X=M;'
MQEJ?Q#;PY\-O#_A#6?#_ ,=?!?A'X5>&_"MAX1\,V.JVOAKP-HD>@:[;_%#0
M/&-IXAO/$FKOK&A^&_%FAWL<>GZP]G%:Z(.GNOV>OC%XF^!7QCTOXO>$+[QI
M\2_B/XG_ &<?'MY9^!/%'PQBN]6\??#CX-_#W0/$_B"^L/']O+\+_%&@V7Q&
M\.ZH=8\ ^,+<^'O&WAXRB)8UDLG3],:* /Q]U7X,_M^>%/"'Q(M_AGI<>G?%
M+XBZQ\*?%"ZWX3^-UMH7PF\$ZAH'P,T'PEJ'AKP#\/M4U.S.D^'-(^(OAYX-
M9T:YNHO"D_AR_P!-O=.L/%5K9SZ;'Q]MXB_;?^*OQ3^/7A[PEXL^+?A^ZT3Q
MQ+:'1]/O5TO2;?X8:!\1=>TN^_X1-O$\G@GPW\/_ (DZEI\GA63PMI>FZU]G
M\=_#K2O$'B-_$=OJ.HI:77[95(\TTB)&\LCQQC$:.[,B#&,(I)"C  ^4#@4
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M'_"B/BE_T+L/_@XTK_Y*H \AHKU[_A1'Q2_Z%V'_ ,'&E?\ R51_PHCXI?\
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M'&E?_)5 'D-%>O?\*(^*7_0NP_\ @XTK_P"2J/\ A1'Q2_Z%V'_P<:5_\E4
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M_P#DJC_A1'Q2_P"A=A_\'&E?_)5 'D-%>O?\*(^*7_0NP_\ @XTK_P"2J/\
MA1'Q2_Z%V'_P<:5_\E4 >0T5Z]_PHCXI?]"[#_X.-*_^2J/^%$?%+_H78?\
MP<:5_P#)5 'D-?2'[,O_ "..M_\ 8!'_ *6QUQO_  HCXI?]"[#_ .#C2O\
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MZ?\ )'\?_DC\_O\ A9W[)'_1<OBK_P"%U\?:/^%G?LD?]%R^*O\ X77Q]K]
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M .%U\?:/^%G?LD?]%R^*O_A=?'VOT!HH]I/^9_A_\B'LZ?\ )'\?_DC\_O\
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M^_X6=^R1_P!%R^*O_A=?'VC_ (6=^R1_T7+XJ_\ A=?'VOT!HH]I/^9_A_\
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,U9'56! ],HJ"C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !\ A8# 2(  A$! Q$!_\0
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M?]?<8W]I:A_T -1_\"=(_P#EC1_:6H?] #4?_ G2/_EC6S11RO\ F?\ 5O\
M+^M;E_)?C_G_ %]QC?VEJ'_0 U'_ ,"=(_\ EC1_:6H?] #4?_ G2/\ Y8UL
MT4<K_F?]6_R_K6Y?R7X_Y_U]QC?VEJ'_ $ -1_\  G2/_EC1_:6H?] #4?\
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M!/6+)PR$#:#O4G! \PE^ /Q"5=W]J^' 1D ";4,Y(Z@-;89A_"N0"3GI7/\
MPK^'FM>--9N'U1'M/#^D7,\%W<;]DM_=VSE5AL596#0,V7ENB"%7]V@WD['+
M!Y"\/B*E/$4W&G%.2@WSJ33Y5'F5W)M:6WW9G#..-EF& PV(R_$4ZN(J-4>>
M*]DXQ<75E4E&\5&$=6Y-:;79]WVUW%>0PW%NRR0SHLD4JL&1XV&Y74CJ",$=
M.OUJT0#P:HV-E#I]M;VEM%'#;VR+%%&G"I&JX 48Z<#@G/<G.2;W.3S]!Z5\
M>[7?+?EN^6^]KNU_.Q^QT^?V</:\JJ<D>=1;<>?E7,HMZM7O8****184444
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MJ.@1Z5^T]\,;'2IKV\F@T^.VL]+^/'AW1].#7NIZCI>F16^E?$FQT>)M8O\
M1-%T'7E^T+I%^L?'C:E6EA<54H8:GB:U.TZ=.JW&/-!1DI7CKI:[BOBVZGV'
M!F88+"9G+#9A#"?5<RPM7+YUL7@Z.,C06(YH^UIQK)J%1<_N5$URRLUJKGR3
M^U'_ ,%B)_C/X4U_P59:+J'Q%BU;PGX3\*^(K?Q*TNB?"SPWXVB\0R^*=2\6
M_#_0=/M?#GBK1(TL[+PUH&B6WCJP\6V-JJ7[75W-;V=Y/K_X<_$;X\^)?BCJ
M-[:7E[I.D)XHUF[@O?"WPU\/Z'X$\%Z=XIUR]BUB%[S2_"MII7A+4;9[/3##
M9MK$$L\7AG2M/L$N%$]QG ^'GP,^*/QX75;KPGIVO^.M)TVXTK0O&6IZ DW_
M  A?A#1_'^HQ^'/AAX[\1>/E$?AWP9H-REQ+NU;QI>6]C:WNHW)NKB.*PU7[
M%^P/P?\ ^"0VI:=X6U/XI?M.^,=-^&7PQL#\6O#'QFO/#?BWPI\--#\":U\/
MM*M=+^%_Q1L/V@_'-OJ7PI\::!KFO2);7=OX8T>ZU6.&RM(UGEU.RU:PE_,Z
MKSO-92G5J3HTIRO4IT^;!X6+NHVKU9.$ZT(?"E9V5DMS]J6)X*X.RV6&AB%*
M+D\0Z>(Q#S"I7JR4)NKA\OC-X3#5:O)2Y)58)I0IZ^ZK_BWX4\*^-OBOXCT'
MX>^&M,U.W\4_$:_;1_!_@WPG8OJGB:^^(.IWT\,&A6>GLQ>*35-,M)D_XDT\
M2//<:G=/M5K@C]0OV=_^"2'Q]^*4&I7LUG9^ ]>F\*_$'QSX0T"YL[OQQX]T
M3XE^"O$$/@/7?A=\1+#1;@3? 1_$$]O>0VNM?$F\CTBVF&HR+]H.F3FX^IO$
M'_!3'_@F!^Q]8:_X._9H\%0?M.^-;JV^&OBGQSX7^$=M#\"_V;]9\7?!#0[@
M:?\ $:?XH_$^QU[XE>+O$;ZM=OJ+S?#!=+M/$=[IFF>5;7UV9[N^^4/&/_!4
M+]MG]LSX\?L]?!70Y?@#^RY\+-<U+43:^%VL/BAX7^!'BG1O'&FR12^'_P!J
M*#6UDU_XD:38BU6RBU:\TC2M)_MK7]1UR8_9+][FW]S#\+1C"I%4JF88[V7M
M8X"C4]A2G:*DY>TDY5*D)1U?-/EDKMP2;/D,P\1L]S*%=<.9;44*-%>TQ=2'
MUC%0H>TE3I3C!16&PJ<VHP4:%U.R4VVC[UTSQ%_P2._X)W_$BVLK_P 67OQW
M^.?P]^*%]\2/!7@/X5Z%HW[2GQYT"*+X:CP]XT^$GQ!\;:4FF_L\:'X5.NMX
MCU^UT6.&\\1Z'''9W[:E9ZI8Z?<V/TK_ ,$P_P!J^R_X*&?MD^ _&'P?_9NT
M#X0_ 7]@;X)_&3Q)\,-*TOXAVOB[Q9KVO?M$&R\'>&O"7BZ[EL;+PUX O;K3
M]"\9:[;>$]'N)]'T=;R*[DNOL:0H*NJ_\$Y_^"07_!.WX<?\)KXU^#5C^UY^
MT/XTL;9O!'PWU[Q#-JOAS5/']GX9D\3>+=,^$?AVY-A9>"OA381'4O&/BCQ/
MXAM?%FF^!OA]:P7GB#Q!%9VD,-Q^@G_!&O\ 9"F\"_L)>,?&6L6=U\'/B)^W
M)K_B[XWZW_PJN2W\/ZG\+/!OC2.[TKX/^'?AOK$NG71L[#P;\/AIVL^#[F[T
MV<64NM/=G3XI9IXA]5@<(L.J5.G3IX&FZ4(U(TZ<7.E4G95>>48OVBI;6B[M
MJZ/R[&8W$9A#$8C,L;CJN8.I3A&-?FJT^67-[:<I2G:G*G9<L%3UNVK-'N'[
M+?[77[;OQ6^+_P"T9X0^.7["^M_!;0?AU<^"XOAK8IXU\-7VI^)-,UQ_$Z:A
MK5SX[U+5]/\ !7B^"4:5926Z^"(VM=$:66SU*:YGFMY1]$_$?7KS1O!_Q#\:
MZQ^S[XO\)W.G> _%UU=>*/!6O^ -5\6S2/HUW##;:=HWAGQ''=Z_K5S<S)%H
MT5Y%-%#J)BE$MLP$H^7OV4?^"8.L?LU:S\<;R\_;(_:3^(*?%SQMHGBNVUB[
M\6QZ/XVB33= &ERQ>.-=N+;7X/%NLR29>#6;"P\.QBP6*TDTA)(?-?[0F^ W
MC'0O#_C2+P7\>?C%<>+==\(:QX>T#4_B1XG_ .$KT#PQJFJVXM[;Q3;Z19:+
MH<TNKZ*2;W3G34(D2ZC02IY;R8]'&9#E^'JO"X;B2IF5'W73QM7+UAUS8BG3
ME57+4INI3C0G.<;I\S5)\J]Z)Y.&C6H-<F/J^TYWRU))2C;VCE!3BDU*"7*N
M7E?NKE:O>_YM:C\9]#/B#Q#I?BOX]?M0>$?LL-CIVK^'8/AC=6T_P\\8ZOI^
MF:+'X7O;>QN];DN=:UC5/%26FG2Z#J&RUO1:1-J$T=_INI/]C_#7]N+X$:;9
M?#OX6VTWQGU+Q.^DV'AS2HM<^$'C>#6-8?0V\,^'%U+5KE[!],M)M6OM9LY/
M,N[^(R,NHW#F."V>1\[X3_#WQ]\(O&4'BG]H7]M#0_B-IKV2V=QX,\4W'ASP
M[X6M;O2-*T'3/"_B?2;?7-7N;^T\2/>:1J6NZ]=K>FVFUC5GETV"$Q2R-],'
M]I?]F2&X>VF_:$^!<5S#@R6\GQ9\ K/$))-B;HSKP:,._P"[7<N"VY1RQS\_
M#()Y+C)_4<\PN80J6=6LX8V:<7-RE3BL5B;TY4VVH^SI1IM6LK))>GFV8YWF
M/L*&(Q.#Q.'PZC*'U;*:.#:DXJ$W4GAJ%&56HU&+E4J.=V[[MM_0$;$ELG)!
MZ<<#+8Z<8X."!DC&<D9,F#R"<Y]L?RKR/2?CU\#-8"?V-\9OA3JXFXA.F?$3
MP??^<0[1GR_LFL2AR) 8_D'+@KC=D5Z=9:IINI1B;3K^SOX2,K+8W4%Y&0&*
MG#VTDJD;@5//4$=0<?0*479*:;]5K;1_CIW/)<)QWA./?FC);;[Q5OGL7Z*;
MO7!). .Y!7^>,_A2;TX^8<D 8.<D] ,=<^WXU9(^BDR/4?F*6E=/9I@%%%%,
M HHHH X[QW_R+Z_]A_PA_P"I;HE,TK_D>O&/_8%\&_\ HSQ/3_'?_(OK_P!A
M_P (?^I;HE,TK_D>O&/_ &!?!O\ Z,\3UE+XU_BC^3*7POY_G$[!US@X)QG
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M".OJ.*=74<9QWCO_ )%\?]A_PA_ZENB4S2O^1Z\8_P#8%\&_^C/$]/\ '?\
MR+Z_]A_PC_ZENB5XQ\7_ !UXX^'4?C_Q1\//AIJ'Q:\2VEM\,+>'P9I6J0:5
MJ%W8:AKFNV.IZA!<SPW&[^R;.>2_:".%GN!$$S&@>1,*DE!N;O:+3:2NWH]D
MKO\  Z,/0GB:M/#TW!5*TU3@ZDX4J:E)JSG4J.,(1TUE.48KJT?2Q9",%EQS
MW';KW[8Y]*0NO9E)]-P'OUZ=.<>G/2OC[XO:#^TE\3?$.J?#_P #>++#X*_#
M[4/!NB:Q8_&#0!8:_P#$33_&$&O,FO>$/^$;U*XCT^+3+O16ADAU^W626TN8
M9(=TWVE8T^6?B]\5K;]DSXN77BW7C^VC\?/%D?P=L8=+\.Z!HDVM?!?5IK""
MVT[6-5N(/#FF+IN@^)4GTA]?\1ZE?VYL]$CU:YDM!<2WMI8B*F*C24I3A*-.
M,E%S:T6EV[)2DULE9:WTU/9P/#U7,)T\-A<31KX^M3J5*6!H?O*GN<O*JM:4
MZ6&HJ3;YW.LW2C%RG&SC?]8)[NWBQ&\\,<CAV1'EC5G$0#R%58Y(1>7(4A!\
MS8'-?,?Q3_:0MO"VG>/=/^&7@7Q7\=OB1\/[SPQ:^(?AIX'BCL=:LH?%4[I:
M7G]K^(8;3P_+#9VL<NH7L=C>:A=P6JQO):I',DM?(>A>&O!/[;'Q!^$7QA\>
M?#S]H[P1:>,/V9_%]K;:-/K$NG_""'2/'5Y)HNIV5_J.DWUKJ>G?$B6QN%U7
MP_<RZ?I=QJ7A^73[UXHY[26S3SBU^(?Q3^/'A'PM\'OAAX$\1?!WX4_#/Q3X
MA\!?$+XB>+/'>M'QYI\GP<U&SLOA=_PAWC#0-;T*3Q+KWC"X\.:EIGBS3+N_
MU>[T66X6T\1VJ6]W;SW>,\7/EO%12J65&23=2;LG*T)QCR<J?-=WBTKM6/5P
MO#-*%=+$.-:>!]F\WI8BI2P^"P53ZQ7I.A*O1Q4JN,Y_82@E@^2HYS7)-<MS
M[5^&?[2'Q,\27^O>%_B-^SCXT^%WCQ]"\1^)?AUX5U#Q%H?BBT\:Z5X>LHG:
M#6?&GABTN?!GP_UB_P!6N+;2K+3O$VK@:@LEQJ.F2WMMIVI):_#%GX(T3P-^
MU&O[1WPPLX_'_C&TDUZV^+?[.:>(M;\7_'G2/BE\0;K1X/'<WA/4_$7Q%\,?
M#2'P?\,M!U6RML:7H.J6-[I2:W/I&LSP0Z5;VWS=\=?V^O@+\!];U/XAW_AW
M6M'^*'Q&UOQ)X%UKQK^TUXA\1_#GQ+X"\'>&]?.HZKX U/P9X32[\4?$;1=!
M;Q3JY^$VC^&O#.I^'KJX>]T_4/'MM]HO-23\=?VE/^"QWA?15T#P[^P_8_&J
M"+PA'X%L4\>?%GQ_X@TCPG>VGP\2#^QM=\/?"BRN[[78;G4!IMFVK'Q3XPET
M[Q'927EKK'A^ZEOYYEX:F+C.GS.7M9TJNE[*IS0ENHQA&/->^FL;)+NCZ7+\
MHQ%#'8B.&I+**>;X26%J8&G*I7P;PSI7K_693KXK%4<+*<8^R;K+$2JJ52$X
MQBT_UG^(G[#7A7XJ?$36/B=\8_&WCC5_"'Q].O:M/K_BKQ%HLG@K]E'0M8@T
MOQGJ?PA_:!\.KXNUO0;G3_$/B*[T[PCIVH?#WQ_X(FT]Y[-_M%FR6.JWGT9'
M^RU\)_V4/ OCK]J>T^#7P!TSXHR_#S4?$OB30O&7@.62_O/'/@C6-,TC0'^'
M^@>*/'&O7^A:4? &D7<NA:%I6O6M[J>OOI5]JNMI#J%REE_([\0O^"G?[:WQ
M(\-2^"HOB?I7PP\%:E);3ZGX*^"7@;PM\*/"^NW8^Q1G4=<TWP_8R76IW5Q/
M90RB+4+Z8K+$J.BP6206_P ;^)/B!X\\8W$NI^./&_B[QO-G[2UUXL\6Z[XE
MEU74)B^R>Z.KWEVMS+)Y3M"L.5-K#),S!9(V3BC]5BY2IX:+JR?.JE6+DX3>
MG,N=R3=Y-Z).SY6[)'T4GQ3CE1PN+SJH\ H0P\\+0JSI4<3E].4.;#.-)48T
MJ52-.$)**;;@JU_:2FG_ 'T_#7]N_P#9R\8^#]+UKX@?M*?"?X$?"KX@?!G4
MM$U/X":[XD\,_#3XO?"S6QK^M6-IJ^BS> ?$5[-X5DOO#.I6T%TJ7S7MEJFF
MZ1J_AQM(DN+VW;X"^,GQ"_X([Z;K'P=\!>!_VC_!$=OXO^)&D7_B#5?!OBG1
MKB?0_#OA^UO/&VN:]XUG\0[-9U[0O&$^EVN@>++W1Y[KQ/--K<-[(LEO]J9?
MXY'DF^S1- LLMU=3->B+;YCW,:S21PM+<JKMMN;AIIBI#'8()%!55+LNM,M9
M_$"7L]C#/>Z3;ZXNG73F7[1:+%I4]I</;SX3"RQV@8D@&,2 ('9"3I5JPJ0@
MJU"G5E%)<SOH]%*T7\*?\NR5[=#"CPS4PN,Q6(PN8XS!8:JZDU@\,XNDO=FJ
M4:KE?ZPZ2E[LZD93E*,92;=V_P"CW]KV/]@7X<^,?#?Q6_9W^._P%^,7PV^(
MGB:PTOXQ> ]7UG3[*]^&7B:UO=/L-/\ V@_!UOJ&FK?ZA'H<%JH\:>"]+6*3
MQ!J=MHNM12!GOKV'R#Q=^P5JWCGX@Z1I_P"S[^VU\ O'^BG4Y?&?BCQI>_%O
MX=>&O VI0>)'UW^S/"V@^#+K6;SQ-:7]EIVDZ3<:OX5O+/4=%T&R\0V)TW5M
M8O=.O=WX4;[A]/C0VS7#6^HSJ!(LKN(XP\L:DR(Z7 (TUBQ(S*I*[MRJ'P=&
MT.XTZ\ULW^IOJUEXGU)M6L)+]?+^QM>EIH[;< RB-KKS;5AA(HU*NPV/(H\B
MMEV!Q,JJE1E2C5G!\M"K*GR^SC&.CU;YFE*3MULEU/O<ISC/<JPF#^J8W!U\
M9@:%?"N69Y?'$U,50K6E1=>-XTY5L-33C"I3<74CRNKS.$3]^OBG^P5^U'\'
M?#]_XP\17?@>;1?#VFZSXBF\>>';)=?\/>&?#^AZ?-97FM:GXG_M:UU4ZC?Z
M=J$Y&MZ7I5OI6EBQNDDM3#JEO:ISW[/G_!1KXL_L^>+CKLL/B3XM:-XI\%VW
M@;5M8U'5/'%EXT\3>"M5CT_Q%92^#O'FKZGX9MO VNZ;$%O] 'A[1]2COKJ1
M7;3I[BW*U^*VE?$;XD_"ZRU77OAYXX^(6FZTEEJ.GW5MI_C?7[:YNM,UVZCO
M+FW2'[=-97.D74UHIOM+FLY+4G3POV>9+A _=WW[87[3/Q"\%V_A3QW?>&O$
MOAZXTB"30[_Q?X7\/:YXBTJRT];>WAB2X73;&ZF6]@2=3+&&>WTYY(U6V)(&
M-3 U,.^? 8BK0FES*/,Y.;C%:2<K74K*+?;4WP^:/'TI4.(L%@\PP>)KQI5<
M10IPPM3"0J7E*I3H\M6HU"HHR48233IKDY7=G]O'[-/[8OP2^/\ \&/!/AC7
M_P!H/QG\/]<\#:IJ,VG?"_Q?+:^,/&_Q \"Z)J/A?Q/X<M?CAJ_QF\)>(+;Q
M+X]O&TB]TFZUKPQK&DVL5QK4MSIZZ=>0VD>B_;WP=\/?M0ZKXJT+X@7/[1=B
MWPY^(?Q#UWXIZI\&_B!X"\)ZKX]\#_#S6-#MI[+X*:!XO\(>*M3T:0>%=6U"
M*XO_ !'#=:S%;6HT^&QN)K6\S-_FW>&/$.F76MZ%KFO:_KO@/6[/4)]5-QX:
MGU2YT)+PB!=$O="47;:AX:N;*TC:-9;<7J6\C1K&PC5X6_HT_9/_ ."C.BQ?
M OP'\"_B;:^-M)\$?#C7)(_!'[4/P-^+$O@CQU\-M"\6W03Q)=?&?S-)NK_4
M-.T&UU#4-;U1K#2[NPO5\-^'M-N["]UB>PF';@,ZQ#K3AFN'>&C2C'DQ,*DW
M&I.*2Y:EHVC=7M;2[UZ27S/$/A_DRPLY\%9S1SK%8NM5CB\LQN78;ZS@\+B/
MWDZN"J8N,*N)K4ZJC=TI2QL8J3I-Q3IR_I2^,'@/PEX^O/'TW[-OAWX?>*?C
MY\-/VA/A'\1_B=H7C+5_'FAZ<WBK3=+L LEQJ5KJ=EIT6OK\.K][O0$BBU;P
MI]IC@.IZ3/>2*Z?4/P0UGXWZW:^/+CXU>$/#'@N6T^)OC'3/AM9^&]8.L3ZK
M\+-.NXK7PAX@\23)+<6EOX@URW2XU&>RMG06EO-;13VT$ZR1GYK_ &0O'UE\
M7/A[\/O%4'Q8O=5\??#KP/K?A[QMHZ^+- UZS\?/K%KI2> /BY\2[2Q\.^'_
M !!K3^(_".A:5XQ\%:F+/P_$VD^*]81[>ZF\N:#S_P"*_P"TKXB_9\\8Z3\3
M_C)\"/C=XG\.>%OA[INA7OQ1_9T-]XW^$OBC4/&][8WM^[?""+6+CQ1;IX<O
M+&,:9XEU**XO+9;N_@\Q[.\A:3Z9XJ@H4\9[1JG*'-I&4H6?6?)&37+&]V[*
M][VT/R&ME^88FK7X<A@J5;&82<HTYXAJ&9.</9PG1PLL36PD*M*I*GS4*4*=
M3$1I25.FJG+/E_1KQSX\\+?#7PIKOC;QMK"Z/X8\,V$FIZUJ9M=2U%[&QCDC
MC>Y.GZ3:WNHW 1I57;:V<\O)8)L5F'BMK^V5^S+>>+O&/@-?C1X*MO%_P_\
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M<Z5<1'P/HNB%M2TW2;&PU'1(Y=8UC5E:;2[O5K1;.WWM8?VB+>9(_P"(D_\
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M@\3-XALK[7=3U&*W>W/@>R&JZQ;-<Z?I>DZ?M22OY*OVQO\ @O?XDU"S\1_
M_P#X)S?#VR_9Y^%4VM:Q=7/Q@?2;.R^*GBK5-4U:YO=7\0^$] N+>?3/ )\1
M7=S<WDVL>(H=;\:W(F\Y3I,KB*/\EOVN/VS_ -J/]O7XB?\ "??M >.KY]'@
MG$WA'X=:,=3TCX;?#;1]0E/V-_#?AF)F62\M4EDM;_Q1KD>I^*=8V"&YU*"
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M<R_9]3L#&DLI7=LF7-!;'0+J.)4U7[&EK^[2?4(I@CQM*WF0")HIX'B%LRH
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M\%6\L.J>/[*VL]:E\,Z,UUH\MT?$&A:'IEL\=T+66\N;F>(0GTWQO\5=5LO
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M;VNH$0WR6&H6LCQ-&^PQ.I=S$XD"B,M(3X7XCL?%MM#XC^'MWX;T[XAZ%O\
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M2V>M>'K>9EL8'(\F>_\ "[6W]G3RE'8_:--CM5AC)5W5XE7_ $J6_P""7/\
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M! \OX:^"HC@C! ,>B*>G7^F*_/\ B;QC\/\ BBG.EC_"?+G&:LY+%X:-5/\
MFC5HX.C*]W=:VN?7\+\"<<\+S57"^(^<2FI7Y.>O]7<=$HRH3K5(-:*]TW;J
MC_,HU+PYX\TJ.)O$?A'5;011%7N<+K=E-$KAE,US"T=_:0LPC)C6S>T4(L+(
M(C(]<D!H=XS17TEI;AI9598YK62U9IQ-(Z7!C<W49N[M8DGCE03@1BUMI/)1
MI'_U"V_9Z_9^91')\%OA&Z@!=DGP\\'N"O92KZ000>PQWXK.D_9B_9KF+L?@
M'\$RTA7?(/A;X#9V:-M\19VT)F=X6),3,2T.3Y6S)S_-G$N2\'9GBI8O(,GQ
MV0592NXK'0Q-)*][*#IK1/NWN?TIPMXA<5Y13IX?/,7A\\I06DUAUAJUTEJV
MG*G.79SB[-:;L_SA/V4?VJOC?^PE\7=*^,OP(\6P/;7%SIUOXY\ 3ZGYO@GX
MI>&K&225_#?C&ULVE@1Q;&_O],\06L<FK>&9KB.ZT.YD'VK39_\ 0"_8+_X*
M ? K]OKX4VWCKX5:];6?C'1K+3HOBA\)]0U&"X\9_##Q'>QLSZ;K-NL5LVHZ
M-<RQ3-X>\56%O_8VO6*+) T%Y'=6-M[RG[,'[-:1B)/@'\$U0*J!4^%?@)%V
MQNTB(%70 NU)'=U4#"2.[  LV=C0O@)\"_"]Q/=>%_A#\+O#5U=01VMS<^'/
M GA70KFZMXI3+%;W5SH^EV<]U DK^9';SR21)*WFI&LA)/F9=@L7@O:0J8I8
MFBW^[BX*#@TUJ[75][I;O4RXHXAR_B&K#%TLJ> QNBK5H58RC7BD[.I3C"*<
MUHE+HKK9V/5V@AE8M+$&<A06(;) )*\#@;220<=>>M8^G^&])TB>.71K.+2(
M,W+W&GZ=!!9Z==W%T\!>]N[6WAC6>]3R L5RWSHLDN\MD8YZS\$?#/4(GGL/
M#GA.\@CGN+5Y;2STZYC2ZM)GM[NW>2 R(L]M/&\-Q"Q$L$J/'*J.K*ML?#OP
M".GA/PV#GC&EVF<^QVY_*O3:<DKJ-].OST=O^'/E%)I-*4DG:Z5[.VUUS6=N
MEUITL,^&^/\ A$K$\<WWB \?]C)K'\LT5U>F:?IVE6<&G:5;6UE86B"*WL[.
M..&VMX\LPCBAB"QQJ69G("@LS,Q)))HJHJT4NR2);NV^[+]?F]_P5%^,_P"T
M7\+OV:KWP?\ L=?#OQC\1OVKOCSKME\'/@E;>%-.M6MO!&I^(H9[GQ?\5O$W
MB;79;#P7X/TGX<>![/7O$.F:GXSUO2-'U+Q>GAK1!/)-?;!^D-0RR!"%*LY(
M+!4!)P.N57)(SP"1MR0"1D$M@G9I]C^-[]CSXC?M\_ GP/\ "[]B2.+]K?\
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M^R?\!O@[X>^&WP\D^'_CCP,G_"$Z+^U7^T+XE\=?$2[\?_%'3+"72O VC?\
M")>'M:\,7U]8VUK_ &#^<-K$Q2JN95)82+CR696?.-RHQ1FC<<R)B0#YUW>!
M?%_]EW]F[]H/Q#\//%GQQ^!'PI^+OB+X4:I/K/PXUKXC^ ]!\9ZEX)U*>ZT^
M\EOO#EUK5C=G36FOM'TK4&\O,3WNEZ=>[!<V5O+&]K:N^][;[:6Z[^?5!S)N
M[6][[;-)=ONVW/R._:&\??M0S_"G_@DGHWQ"T)O'7CB^T/5OVG_VJ_B+=? '
M7?B!X5\%>/OV?/V2]:^).@ZU?>"_AWX?OM9\-7LG[1WB?P6/#FB^"[2W\8ZM
M;:-JNC^%;*]OQ<0)G_!?]HK]O6'_ ()&?&CXW_$[XF>+E_:TN-7\=:/\,/B'
M\0OV9=7B\.6=];:UI7A7PUXN\"?"/X4_!J+XD7WP8\6W]OJVO_#+7OBG\%XO
M&7AW3M=TIOB9I.M:'HEQJ^J_OZL^54^3,"=^<*PP5QN+%1@$YXS\Q(8 9!%.
M,R@<*[#@,4)8JNTL&9@=P&,#=G)SD9 .!>4MK6T?:U_QO]UQ*22M9;W7IV/Y
M&]6^,G_!3VP\9>'?VC;/Q/\ MG7OC[X7?\$C;;XJZ#^S[\2OV=/"0T+XF_&S
MXJ?%G5='\;V'Q%T;X6?#?3O"6K_$#X,>%--^'OQ%U3PEX0D\&?$K6X=,3P_X
M6T70=)\0^._#=SZ]\+?C!_P5X^,/B;P+\&_ O[0_Q%MOAO\ $#]J?QU-X'_;
M<^)O[$GA#P1X[\4_LL_"#]G'2-?^)5QJ?P/UCP=X6\*>$H/&G[17BZQ\%_L^
MZYXOTGPOXBUO1/#^JZA>Q^([#39;G5/W<TC]LWX+:]^TO\7_ -E;29O%E_\
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M<IP!'/@,1N <#Y5W$LX/*XX!8G<>!SQ2/<+&"SQR@'D</DD#.U1C.['15Y8
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M\3^%[*Z\1V<<=I;NJMI:*]F]M'WOWWO_ ,-L"=[OD32U].G8_G7_ &:O&_\
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M'QIXHE\1WMQK&JW6KZ/KTFC:]'8V/],QF"DD0S$J<857)(&-QV@8.-QVD_?
M.PD\4X3#=CRY2<L,[7905&>21\I(/&!D\\8Y(H[:WZW:_P"#ILM_\T2Y:644
MKK=6_P MK=/F?R9V'[:__!6_7O#?[27Q@T23XQ/_ ,()\#OB7\3_ ![\#-;_
M &-(O"]A^SE\2/!7[5/@C3_ '[/7P0\2ZMX$MO%O[1'CCQG^S7I/Q+U/QYJ$
MU[X[T-I;[P_XC\+ZIHFH:EHFF1]?\5_VIO\ @L/XR\:_LW>%_AYXAU']F#3O
MVH=<^(_QM\-^(?B9^S%XD^(,G@#P3XL^->B>"/V=OV6_&>G^!?@G\3;71O%'
MACX/P'XO?&I?&VI_#?Q'+J/C>XT>U^*?A_3O!>H35_2]XE^*_P .O!_BGPAX
M&\3>+M#T7QO\0K'QEJ/@3P;?:G!#XK\9V7@#3+;6O&L_A703)_:6M1>&=,O;
M"\UEK"&06$5]8^?L:ZMUDR/@C\9/#?Q\^%'@3XP^$=&\:Z)X9^(&AIX@T;3?
M'_A75?!'BVRL9+FZM8X_$/A?65CU+1+QS:O,EI?H)3;RV\S86=30M6FI?F^W
M2[\KW\WVL^9:7BM/E?UMY_Y'Y=_ GQ5^W[XJ^$'[>O[1GQ2^*GBEM)FNOVLO
M#/['O[//AO\ 9Y\*^&O'/P]TOX,^(/B!X7^'WQ%L=1UG3KOQ%\3/$WQ)U#PM
M;ZOX!\-^)M*O- G\.WWAJ9[GQ+-J=Q>R?D/\&-8_;\\*?L[_ +*<WA#7/C#\
M6_VC/#W["'PRB\(_'7XZ_LY:GJOCGX:?M2?\%!_VR_ACX(\?Z'=_\)3X)T;5
M+KPS^SM\,_!7Q)O/&UAXJ-S>7_A-=%U[Q'K4&G#PW>V_]B(F53RLBAR<%E88
MVAR22P& V %P2<NHP,BN+^(WQ'\(_"?X>^.?BCX]U6#P]X'^''A#Q)XY\6Z[
M?RB&TTKPSX2TF[US6]3FEE9$$-KIUE<3[FD EVJH/S @2OHFMT]5>ZLM-UY-
MOOT0E*SVW>B7_ 6O8_F6TO\ :)_X+(?"J;XA>-[CQGXX_:;T+PUX+_X*K7W@
M'X7:G^R/X:^']YXLM?V7?%?A7X>_LO>,/$>I^"/"=IK]SXH^*7CO7-7\2>#_
M  ;X7BTVV\7_  @\-3C3-&\1:S,_B(>[_"3XK_\ !0.[_P""3'[='QD^/_Q0
MG_:8^+'B+X4_%*Q_9ZT3X:?L[?$#X;>/M)US4/AG)X2_X1^U\+ZA\'?@YXH\
M:";XFZY]N\)W.E_#1Y-/T:V&F2>)O%=[976J+^P?PB_;'^"7Q<^%7P!^+(U/
M7/A=IO[3FHOH?P;\'_&_1+KX5_$OQ;KYM_$6J6_A^T\">(Y$UIM<OO#WA;6?
M%NGV$*3RW7A*!?$,1_LZ5):]!^!WQX\!?M"^"M0\?_#B36;KPOI_Q#^*GPS6
M^U;3)M,.I>(/@_\ $7Q)\+_%]SI/F2S#4=#/BKPGK,>BZO;RF'5K&W6[A2-'
M**U;=/KLE9?\/K^'D.]E;EZIZ^7RZ['\DGPT_:P_X*-?L#_LW_ K3_#6J^/?
MV@/V?? _[47[//[$W[.7A#7OV9]"^ OQ.^/^CZ]^Q=XX\-W_ (6\,>"/%_AO
M1/B#;?#[X=_M8^'_  3;:1X\US3X/'6N^'=*\;:AK6I:_I5OOG_43]MKP;^V
MC;>%O^"/?PB\3?M.?&?1O'<G[3O@*\_;#_: ^ /PBAO]!\7>(?A_\*_$/C!8
MO$V@>%O OB'3?"G@;QC\4;2T\)Z/I^OZ+9_#:^L-1:;QY;S'3M.$'ZJ?M4>)
M_P!G[X,^!A^U;\??"&F:W9_LR1:KXR\+^*F\(6WB[QGX%OO%45GX'U*\^'MO
M=!;RR\2>(;/6H/#?G:5+::E>V-[/IL<C1W$T,_U(LH$8/ER #"J%5@21D= /
M7((.1GU&2%:_DVGKK=[;ZV5G=>0KI6LK)=/3SW?_  VG?^-OX#_&O_@JE^SS
M\%_CE\8_!OA_XB^*-3_:*^!7[0?[:D7PB\9?LV7<5C\!/C3^T#^W/H?P_P#A
MEK=]JFA^#]5^*GQ"U[P3\!I?%/Q2\?\ PRO+35)M/\+^&?#D.A>"8-*MIY-6
M_HG_ ."9^K_M+>)/V5_#GBG]J?XP:;\;?B!XC\7^.=3T+QO9_##6?A->2?#M
M->DT_P 'Z9KOAK7OAE\%[Z^UFRM[&]DD\3)\*O ]EKUA>:?=V&CRV@@U&^^_
M%G4IN\J;[JG: [O@DC("Y)X!PP)+ $ G! ?YZX!6.5U[,JLX.!G(89W CHV<
M$_*2#G!;L[:VV:5]%W\NMTWH#::V5[WOUVL3/G:VWEMIP/?!Q^M?R$_M'>%/
M&'[0O[5O[8S_  Z^&7[5%Q^V]JG_  4$_9K^%_[+WC[PWH?[0?@'P/\ LY_L
MT_ _P[\$(OB+\==2^)"1:%\%)_A)XDOH_C$=3T"/5==U+XCZEJ=MI$NBWRSQ
MS6']><<HE4,%8 Y^\,$>Q'KZCM3@%))!).<\LQ /L"<#\ *;7-;73T_'I_3%
M%\OG_77^D?R36'_!2/\ X*B>-_ASXLMO!WPT^.VB?%30O@U\?KV^G\8_LIZY
MH'A[2OCY\=_V[O#_ .S]^R/X$TR/5_AY;'Q58_LS_!=]6^(WQ+U#1H[[P_K^
MC:@NI>(]9U1;"XO[#U#6?C)_P5D\/?MG_#7]EP?M&?&7Q4GA3]I?X!?"KQAX
MNL/V#_!6C?#'XN? '6?AWJ'Q[^.7[1_BOXIGP5KO@?X?3?:HKK]FKX4^#?!7
MC,SV>H^%I=1\8V=WX@UXZW8?U#R$("V&/(R-[#(SG@DX&.I QD#!XJ(3 O@1
MS!N3AE=00I*[L<C'!Z#D%>I9 5RI.R>MK[/RUW[ZKMN/F7\J_"_ET_I:'\9W
M[*.L?MNR_#OX$^+O'_@/X\?M=?%'X:>!_P#@IC_P4>F\+_M$? S5=,\0>!/V
MFO#/C'_A5?[._P"SUX&U?5?!OAK6-)\07%_XL\0>,M.L]&OKT7.A2:UX:^&4
M*> +?0K"R^COA#^T7_P5N^)4>C>"/"_QR^(NM^$?BS\?/V:O"GA[]J_XA?L-
MZ1\,M3\ :+9? KXH_&;]MFPT/X-Z[X#\.R7_ ,*/!]_X<\&_"GX7>+_B-H4&
MK7GQ0UB]\/6WBKQ;#8?;KS^J(3C/$4V-@?+!P,.<X&2<D=^FW@9&[ =YHSCR
MI<GH&#[FR"<<YR%Z'DA"><<9%K=I[M=-$UVUM\EH/GVNKOOM^G?;];'X W?[
M3G_!0+PU_P $G?V0?BC\0-4\:^$_VC_C-\1/AYX9_:!^-^D?LS7OC[QY^S]\
M%O&/B_QOJD_QEU;]F[PMX4U*WN?&UG\/M&\#>%=6TT>";CP_X>\9>,9?$.I>
M''TS37TV;XY_9,T3]L']MG]O_P#8GB_;0\?^,;ZQ_8Y^ /QI_:IU_P"&WC/X
M2_#+P>^N>(O'_P"TGXR^%/[&?CKXO_#C3-#>V^''QR\4_ CP]??$JZL[>+1M
M9\ W.@6I\+67AFZ\1>,8K[^J/Q?XMT;P3X4\2^,O$;S6GA_PEX=UKQ1K=XL;
MNUMH_A_2[G6-3GZH"T-E:3NJ-*GF,NTL 21X%^SY;?LZW?@>]_:Q^#OPY\.^
M!+;]J?PEX,^/_CCQA'X+T[P?XW\?6&L^![+6?#&O?$VXCC&I7NN:3X3NHH$@
MUF]N3I$<L]I"R_O'D++UVTMZ)WWTM9_\'5+F5F[6=W9_I]Q_,G^T)^TC^W[\
M5_VIO$7BGQ3X2_:%?X>_LF?';]N[XP>"OV=-)_9)U:W^&>C1_LD?!'QOX+_8
MX\7Q?'"?P<OB3XN_$_X^?%+XB^'_ (AZ;X5T+6/$W@%_#;VT::3I^I^'3_:G
MLOQ2_:'_ ."OO[/EY#\!=7^*GQ0^.?QU^(W[,_[.@\ ^/_"/[%>D6?P[T3]H
M3]HG]IS0/#/Q"\17>J>%_!NN>"=#\%_LH?![0]=L]6@\>^(+6^\5WOCG2=6U
M+P^TT,=YI7])OP)^-G@S]HGX,_#'X\?#N/7CX#^+G@GP_P#$'P>_B#2;G1-8
MF\-^)[&'4M&N;_2IWD>PFNK&:"Z6W:60^3-'(C,KY/JIE\S(6*8') .UU4,K
M9W'D+PPSR,GIT)P:;75U9I)=MNNK?KL/FVTV\UTMY>76][O4_F0_82_;S_;8
M_:1_X*::3\'_ !A\4/$UE\-QX;_;3^)7QA_9WU3]GCPWX.\*_!KP7\*_C/:_
M ;]F'0_#GQGO- @\8?$?6/'D4M_\4?%OB.RUW4?#&I3BQT[P[=1V5IJ^FP\-
M^T!^U1_P5^\-:#\8/BWX0\8^*_"7PP^+'[<OQ=_9Y^#>F7W[+;:LW[+/[.?P
MAUK78-*^.WB"^\+_  >^+WQ$\7:U\>-6\*'P5\/[CQ!\)_&7@WP]IOB*TUZ5
M=5N]6TR]TS]^?A[\'_V,_P!D;Q@UG\,_AQ\!OV?O'O[3?C2^M5MO"7AKPGX#
M\5_&OQOI6D^(/&^I644=C;VFI>+M4T[1[?Q3XIEL8S<1Z;:MK6KO#&9KJ=_K
M/SE93E) N1R=PW!@&&QN W7L<#'!P,T67EI;HWVMU\O/0.97O;1[+2UNO377
M9^1_)/\ &KXD?\%&?A=K7C3XY:<=6U_]H32_@K_P3M_8O\2_M1Z?^S[\0K;P
M3X.TKXA:?\9OVG/VG?CEX1^%$'PA^(^I6YGU2_\ @]\*]5:Z^#_B.P\'^-]1
MLW\3>"M*DTI_#^E==XR_:8_X*TZ?XV_9R^#<WQ=^*]OX[_L']A/3=;\7?#+]
MA*75/AM^T*/VB?BAXAOOVCOBS\0O%?COX8QVOP+TO]G[X3:3I'@ZR\*V]MX%
M\4WWQ+U2?7M=\(V6FZK;:+H7]5/F[LAH91C!^7=DY_N$;21D8;&%&1N.&&03
M#/*2 \G'SYVH0N\KQQDD$$;B "PZ"E;7?_R5[^?;N_O[!S+^5;WO?7O;TWV[
M_,_D3\;?MX_\%9;;X=?&>^\(ZG\3KNS\;?MOM\+?!?[1FJ_LF>*-%^%?P/\
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M37+*[2PGN7TW3C=>2OE3/86#31F2UAVFW7L]GKMYO7;]4PNK[6WOM_PVEO\
MA^O\V?P _;._X*[_ !"^//P'T;XJ>/X/A/\ #?X?_L__  #^*?Q6AU/]DKXD
M^.XOVH+?Q=^S>?CA\:O$^F77PV^ ^NZ)HT?A[Q7K<'PM\*>'_"/Q7^&VL:+K
M/A*^TJ?PIXU\2>(+"R;WWPO^U-^VC9_\$</V^?C[^T'\6OB9I?QYT>P^-'AG
MX%?$:]^#OA'X.VNJ:W/HNF>%_ACK?[/7A/6OA]X \:WGPV\:^.M?L]+\#2?&
M3P):?%?2;^34+"6]\0R:=H_B&[_I*BEB0>3%!(D<"1Q@)&8XU  54CC 55"
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M/&VNZMX9\">!8O WB_P1>VGPN\/2^ M8N=*\.7<MM/\ T\% SDDME=N,,P!
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M^WKJWPV@\(6&C_#W4?A]\1=>_;.\7:5^S3>?M<?&C1O!'[(GQ1^/S?#SP_\
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M&'Q&\":1#K(\3Z=J=G8Z<W]7]%#C?JUMM;I\OQW!3:[/?>_7YZ?(_FF\7_\
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MQB\=?#&SLOVE?B7XN^&OAOPM\0/$]AX*-J=4TGX+_"[P;J'BCP:^JW.IV_\
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%%,1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, EH# 2(  A$! Q$!_\0
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MPF QSQ,)\T(9Q/"K#J$HSIJ-:E7J*4IM33]YMI*4HQBE+Z3H_P _Y_.O!_\
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M Q7_ ,H#^T,=_P!"7&?^%66__-![E17AO_" _&/_ *+L>2.OPV\.<X[?\?\
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M)?:8);R/<O\ _@J+^SU;_:?$S:MJ&C> O!/@;]H/Q?\ &*V\6^#OB+H7Q5\
MS_L^R?#Y?$VD#X<GPG/<:C>)!\1?#^HFV-_#?:AIVK:/=>'+764NY_LNK<?\
M$O\ ]G&X\"VOP_DU7XGC0[/]G7PG^S%%*OBO3AJ+?#KP9\3W^+6D7$ET= */
MXE;Q0_E7FJ&(6\^DXLUL(ILW54/B5_P3?_98UK4?BOXI\<^*_'.A'XX1_%SP
MWXGN;KQSH6C6!G_:#T_X/Z!XELM!DU#1=EMJ,T?P5\'0^&('EO)H+RXU@&&^
M-]!':@%W7_\ @JO^QYX5\)7OB?Q-XI\;^'M3TKQ;XK\(:U\.=;^&?C+2_BOH
M=SX%\,V?C?QAK6J_#J]TR'Q':^&/#_@C4+/Q;>:_]E>RDTB<+:-<:C'-81XU
M[_P4N^&7B[]H;]G3X*_ F*Z^)7A_XL_%CQ/\./&'Q17PGXPA^&^F2^'O@OXD
M^*<^E>#/B$;.U\)Z]XRT^?3]%L-=T-;J[DTU+W4;*:*/5M-O(;2W\7?^"6O[
M/GQ<^*FI?&^Y\0?$/PQ\5]0\?:GX\B\5Z6_P^\1PV$FO>!=)^'WB/PO;^&/B
M+X \:>%IO#&M:+HFFW=Q!?:-<ZQ9:S;+?:7K-E$\]K+E:Q_P3 \!:7XFO/'?
MPA^,GQ@^&GB#1_&?Q/\ C%\,_"%KJGA*^^$/@#X]_%GX9^(OAQXJ^*=EX._X
M0Z+6)I+Y_$=_XR?PG%XGM?"MMXNEN;K2=*TW3[N73P ?7?Q;_:=^&GP=\<^
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MG5?#>M6HTUI_A]8>"X=5\..=%U2&ZCCAEC /;/B_^W[^S5\"/B3XN^%GQ/\
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M7TWXR>&/&5KX?\'_  VT/P&_B_P_XQTN!H+J^\(WVDZKILUW8^(-'U99A)&
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M:LK+Q+'X@U>\OM:L[KP]<0P+I&CQ:8MO=Z?,BH)I;C4A*S7BS,LA6,Q((PX
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MVL?$+Q_%XN\'7/Q$\.^*_".EV>IR:==^$[OP#:3>*M0U*^U73[CP[9_9]/\
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M(O-D#2>6N5CW;%RJBIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY_%OQ/\ #NG:"GQ-OM5L7C_M&+Q'X>T:'P_=>+A?6EK-I&DK8ZAJ"06;+<$
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M+XL:(_PV\1?V5#XCNO!ZZE?^,-7\/)*D=ZWZ->+/^"F?["7PT^%_Q0\;:/\
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M?B76_#6N:;JFAWUKKFGZDR-:"_@L[NW^]:^3OVNU5O!WP[# ,!\<O@^P# ,
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MJG@G4O%S'PG9:O\ &[X<6?PR^*#Z-;6FG6NK:=#XJT:QM]6FC76)7TWQ,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=>G#_D38G_L:8+_U!QI\]6_Y*O+_ /LG<U_]6V5'TC1117F'T(4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q?$G_(NZ_\ ]@75?_2&>O"/V0O^3;?A+_V+3_\ IWU.O=_$G_(NZ_\
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M,TH\2<U#V]3)W!8K&/$^RI8Q2>#:E]0C1<JK4<1"7)]:E-.G-<WLHQ=BJO\
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MEC/K'LJ&+CS2:E_9_L>:L^50?+];Y^;VFOLN32U5GPX_;^PAG2O+!?5O:UL
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M?&SX3^/#X@7P;X_\+^)&\*6[W?B-=(U:UO3HUM&;A7GU#R9&^S1*UI<JSR8
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M/"YSXQU$9(Z^%]:[9XSY'!_S@T?ZG<4_]"',_P#PFE_F'_$3?#[;_7'(+_\
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M8G0Q1!5^5&C50HX4XJ?^S=.-R;W[!9_;&"*;O[-";DK%GR@9]GFD1@GRQO\
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M[H1>_FCQQ?V7?@>1SX0GZ_\ 0<U?V_Z>NGMTI_\ PRY\#_\ H4)O7_D.:O\
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M52CB88S+<HE"4*51M*.+PF+PT*^%Q,&K5Z47B:5.5K8B<91E*K_PS%\"?^A
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MUI,Y'_AFOX$?]$R\/GZR:J?YZC4B_LT_ <J,_#'P_P#]_=6]?^PE6W\)KO\
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MASX_3_$/PYK.F>,C9_8/[/6W\#V;#7=).J_:;O8;PXM?L#^:/WT8H_M7-/\
MH99A_P"%V,_^:@_U>R#_ *$>3?\ AIRS_P"8#H/^%.?"+_HEOP^_\)'0_P#Y
M"J?_ (4W\(?^B6?#W_PD-#_^0JXWX->,?VC?'_C[Q]X8^)7[+6I_!7PEX9M]
M0E\(?$#4?B7X8\7VGQ GMM5FL;.VMM$T;_3]"_M#3XXM6$M_\MO'.+9P9D-2
M_!/QG^T7\1-&^)=_\4/V6M5^!NI^#X!)X'T;4OB7X9\92?$^?[+JL_V>SN]$
M(@\.CS[*PM#+J?&_58I,;+>7!_:N:?\ 0SS'_P +L9_\U!_J[D'_ $(\F_\
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MP?U^)WUW\"_@I>^6;KX2_#N8Q!@A/A72H]H;&1B""'.<#[^[&/EQSF$?L]?
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M_ /@CX8^(?AO^R/J_P 9?%'C*Q>Z\=^!K#XI^%/"5S\+;M=.L+I=/O=9U?\
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M7\5V]I:^$)_%+VLWAGQ):6U]<):0VJ0MJ.F1PV[G4?#Z3E].@CA=E&H/@O\
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M\3:FJDA0"542' )&0,\"N7\ST#O\ = !1@#H,5P7_"OM._Z#7BW_ ,*?4_\
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>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %< E,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^\.6;6]0U
MO5;.SU2WTZWTZ+3\*UBET\DEU'+)([2/,F/N*JJ% 4 DYSQ8_LWQ+G'_  DL
M'N?[(AYX)'_+QVQ_/\':7_R,WB?_ '-%_P#1,]=,<;QQU!)P#DX!]!D]OKTS
MVK2K5E3E&$8TTO9TWK2A)WE!-MMQ;=VWU_0X*%"%:-2I.==R=;$1]W$5H)*-
M:<8I1C-1244DDDM#EAIGB4@G_A);?CUT>'TS_P _/.1TYI?[,\2]_$UOR<'_
M (D\0S@$][C_ !_PZM1@>YQ]>@X]>W3MT[4I[?7^AJ77J)7:I+R]C3O_ .D[
M_P##&OU2E_-B/_"K$?\ RPY3^S/$W_0RV^#G/_$HAYP<?\_/Y<>OT#3IOB7;
MD^)8.0,YTB$]?4?:?YG'H375\8'ID]N/O<=N/3DC@G@]D/ R<<JH'UY)_3_/
M%+ZQ/M2_\$T]]-/A\_ZN'U2E_-B/_"K$?_+#ECIOB4$ ^)8.<?\ ,'A_4_:<
M<?ID=:!IGB8_\S-;\]<Z/$.G3K<_C_A71RW$$;9DFBC"XSYDB1XQDG[[+T )
M/H.M5UU33"P U"P+%BJ*+RV+%OF^4#S2=V Q"KSA6R.#2^L5.U+I?]S3TOW]
MW9] ^ITOYL1_X4XC_P"6&(--\3$9_P"$E@Y_Z@\/.#C_ )^><<],_GP3^S/$
MO/\ Q4T'!P?^)1"<]"/^7CG@CGGOQ71BXMMI_P!(@.& 8^;%C(8<$[NO(X/.
M2!CD5-E2A((*GH1C!X'([$>X[#(YYI_6)]52Z?\ +FGKW^ST_$/JE+^;$?\
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MP3_PDL'_ ()HOKS_ *3[=2<?TZCCCC'3C [CU)/^>ISS305V'C@9). !W[Y
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M_P""J?\ \B:?5*7\V(_\*<1_\L.4_LKQ1_T,MOSU_P")/%S_ .3-']E>*/\
MH9;?GK_Q)XN?_)FNKHH]M/M3_P#!5/\ ^1#ZI2_FQ'_A3B/_ )8<I_97BC_H
M9;?GK_Q)XN?_ "9H_LKQ1_T,MOSU_P")/%S_ .3-=711[:?:G_X*I_\ R(?5
M*7\V(_\ "G$?_+#E/[*\4?\ 0RV_/7_B3Q<_^3-']E>*/^AEM^>O_$GBY_\
M)FNKHH]M/M3_ /!5/_Y$/JE+^;$?^%.(_P#EARG]E>*/^AEM^>O_ !)XN?\
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M=IMG%'>:U>6UG%'9Z=8PKI_ACPKI@MX ^C:3"&%)VLEZ):W=[-N[VUVTL/\
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M@?\ 8%U__P!*]"J7QE_R*OB#_L$:A_Z2RUT0^/#_ /;O_IR1YLOX6:?XY_\
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M/+<^#7O+T> /CA'I=A'&H\1Z5X5&CGXA#3M.:_\ $6BWC:C<K/=^'+5).O\
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M(&VTN&QM;V**(P/%#86$MO<WF]NQ^)'P'_9E\1:?'IGQATGPWKMAO^V6MO\
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M[2Z5H+BVN8)5>.:">)WCEBD5DD1F5@02#\;VGPRUEOBGKWPF\/\ Q7\>:/\
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MBUFN[34?#.L6AM-?T^YM"$NXM1\+Z];6FN630EES+-IT<3HRRPS21LKU_/\
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MZ_J%I9W<MO!9Z,MSJ9=WV?S].ZO>_6^WF%HV^)?*_P"MM;NRMV/UXS]?R/\
MA0649RRC'7) Q]:^'?V>?A;IOC3P,?%MY>_$C2O#FL:K?R_#NXF^(/C'2?%^
MK>#;6[N;;2O%/B>71_$$>E-<>*-C:[H2:=:V9M_#-YHJZ@)]4%W*>5_:Q\$:
ME\+?A#XX^(&A?'C]HO3-;6V30? WAGP_XVFU2YUSXA>,KFU\)_#_ $"PAU"T
MO-1N'N/%>J:4!''=$^5]IN+TS6Z7 +3?5)?._P"B)/OW4=5TS1[62^U?4+'2
M[&(9DO=1O+>QM8P 6)DN+J2&%  "26<<#/05X9X1_:B^!WCSXEW?PI\)>/-'
M\0^*H+:XN;%M$G76="UD:?9VM]K,.D^)-*^V:#<7NB0WUH-2T]]1CU".1Y5C
MM9!9W;0\-\&_AY\,/$]WXJGU/2-:^(GB+X?ZI9_#;5/B'\2=;NO&T_B+6="T
M+2KWQ+_83ZK>7T6F6>F>(-3U#1M4L[:VLHX]=T_4X5MQ'"A;ZET_0=#TB.*+
M2='TK3(8#(T,6GZ=9V<<32@B1XDMH8Q&T@)WE "X)#9R:-?)?>_\AZ>NGI9F
MO3)/]7)_N-_Z":?3)/\ 5R?[C?\ H)JENO5?FB7L_1_DSE_"/_(N:5_UP?\
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M6^&U[:WVVT5];6\_O+_<#)[?4<-[8Y]?_K4$'#\GOZ?W1[4I^\/P_D]!Z/\
MC_Z"*2LWUWWZWNOROOU)%7H/H/Y4M(O0?0?RI:U6R]%^0!7)^,O^05:?]C!X
M;_\ 3Y85UE<GXR_Y!5I_V,'AO_T^6%:TOXL/\7Z2.7&_[K7_ ,#_ $.J_@_X
M#_2N:\+'&DJ?^HEK7''_ $%KS_/7'\ZZ7^#_ (#_ $KFO"Q_XE(]M2UOC./^
M8M>\Y!X'6I?\&?\ U\IV^Z02_P![H?\ 8/7_ /2J!TN06_ ]Q[>AZ]?RR*=3
M1R<]@,=<\G'\L?CG-.K.-[:Z:W^_Y_A^IU&9K6F1:SH^JZ1<#,.J:=>Z?+D
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MN[U;5M/U^[ETW]+?$_CR"P^'&K?$3P:NA>-[.U\/2^(]'>'Q;I&C>'-=TZ.
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M)-'TK7;?Q)IFE8M)]5AT_66MDN)M1N)O)/'4;>*_C5<^(-#TD:_]K^,7P/\
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MU_D;'P>^&MA\(_AQX8\!65TVISZ1:2W&O:])!#;77BCQ9K%W/K/B_P 6ZA#
MJ0IJ/BCQ+?ZIKU^L:K&MS?R)&JQJBCTRBBF(*9)_JY/]QO\ T$T^F2?ZN3_<
M;_T$TUNO5?FA/9^C_)G+^$?^1<TK_K@__H^6BCPC_P BYI7_ %P?_P!'RT5T
MS^.7^)_F>5A_X%'_ *]4_P#TE#M*_P"1E\3?[FD?^D\]=01^?_Z_<>IKEM+.
M/$OB<?[&C_K!.*Z@D[@O8C/<'OWS[=L5A7:4_-TJ7X4XV\CMPG\*?_81B?\
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M444 <K??\CAH'_8%U_\ ]*]"J7QE_P BKX@_[!&H?^DLM17W_(X:!_V!=?\
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MCJN,IQC5E66;1KUJ>"PM"G' U:2P[H_5J\JU3$R=;FQ--JA*G2YO6=(_:/\
M@OK5ZUG8^-[/<--U_5DNKNRU33].GT_PK<-:^))[;4;ZS@LIUT.92NHK%,3
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M^^U_Q_SD>HR>?#_SUC_[[7_'_.1ZC)9]G]S_ ,@YH_S1_P# E_F2T5%Y\/\
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M_'_.1ZC)Y\/_ #UC_P"^U_Q_SD>HS?(OY%_X#VV^STZ=B>>/\T?_  )?YD@
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MJ_\ 87O/YK6_6!H/35?^PO>?S6K7PS_[=_,PJ?Q:/_;_ .43?HHHJ#<****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT]M,T;X*D8K6E*+3L_M.U_O_ *V]#GJ)IZK:*OIV5GHUW\CN****U,PHHHH
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MH-PHHHH **** /F#XE_"KX;>#?$'CG]I^YTEKSXBZ1X9T@IK=_Y.I2:7X?\
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MI-_\2[J']J3XSBV6WT?X/^!;R70_@GX0NM.ALXI;/Q!J>D[KKQ8=-DFBCM?
MOP[M+VP= EM=ZK;1AV;GE5O>,->C;O;LUJM>UE>^CN=4<.TU*J^5--I)KFE>
MTHO?W;=Y->CU/(?$7[3G[2W[;NJ2^'/V<M%\3^#/A)X/NKKP[KG[3'QEU.[^
M$WP?T9H];&HO-X8\(V:P:SXAULM/-#::5/>:[/>13,\OAS3DWLG[P_"'0?#O
MC'0OA#X7UCQ+XKU_0[KP;XJ@\&QV6J7.DZ%?0?"A_#?A75+?4=#OH[NZNHM;
MO[S4[NW&H7,\ITR*$RN9G9E_,[4?V3]>UOQ/X?\ BG^V5\6/$>GZBMBT7A#]
MEOX-:7+<Z](JVX&G>#_"O@KPRU]I7PM\)W@%K'X@MM+MI?$WB47$T/B/Q'I,
M;/$_Z:>#9?%&G0^#=(L?!.C_  ,\,>!M6TFT\*Z';);:YXO\.^&_BBM]8-:2
MZ=:'^P]!TR/Q!;SZ9#;K=7TMM<VL$%ZD<T!0M-?:3MT6MVU:ZMT5MKOK=]A5
M>6R5-Q5KIM)V;>S4GK)WV<4H[I.[=_SR_P""EWAK1M'B_9A\:^%],E\)6/C"
M+7)?$$3W6HS"ZUJ$:1J,^E:K:7EW)8W%RLJW,:K,H6!K>X:&+:7(\A^%T5Q?
M_%SX8Q'^R=.AO?&7A.>YN-0NXHX=.EBO;69XI81M+M<01BTLW\Q(Y+IHT5&\
MP _0?[>/AG39O@)X-UR36-;U.30OVBO%7@K6'U>ZGU.PO+**X\42VUQ#IJ1F
M/1[C5VM]/GCGT[R5AEN3'#*;0E:^,?@O?>%-<^,?PKL;Y5N+)/B7X4MM8GOF
MFBO=2>RN4BM$+.P6:"RO9;>2YGD+11B%F50YP/Q?BY1H<0XQ.2<L72P52-*H
MWR1;I*G[J3=XSY&YJ"C:]G=V9_IWX&8JMFOT9ZTE0C3618#CG 3Q6&I0J8FL
ME'&8SFK04*;J5*4,3"G0C6J5/:*,;2I4M%_1]J_BK4?#6HZ]8Z=X9U7Q#<,=
M+OK&VL00LD-Y9);S/+.PV1(MQ:3%FPQ9F4<9S6!IVI^,]0\?>&K^\\.Z3X7M
M=<TN^T6]GEEEUC5IK?2YCKBZ.QA,5MIYG#7+VUR?-9I%GB9581[NC\7G4-/U
MW3KG3=.%XUSI%W'<P_:E@>4:=/;R6J6(<%);F2.YN<6Z$&5$\S!,>:\2U7Q=
MXQ\0?$'PGX$N_#NI>%-)U"[OKZ_U'3+J/4_$B:3'I<EA%J,0L4E/AV"YOKT6
MD&HWRH5BCN+C:0J!ON<HJQQ/#=.-16I1PM?#SCR\J2H^TI25FW))J-]6DU9J
MRU/\Z:D*-2A*:<75A&<Y2YI<UXWY$XM*%V^5^XW)[-=#X6_X*RRVJ^(O@<LV
MFPMYEIXP1[[9-]J$+2:5$+222-@K6TLLBL\3KF*3$H;&0?R2LYM5MI[(QPP"
M&PO$N(B\HEMYK:SO[>XBCG$I7$,<$9AF@E;YX?O$J.?V>_X*FZ+J]Y;?!*2W
M6(:1;WWB6WN]3\R$W,>H26VG/9P!G7SI'N;:UNI<1(8VN8@TN%((_,3P+<>'
MO^$F\-:'8:-#K/B7Q+X@T'0=*O\ QD%O?!OANXO]5L[5+ZX\-6,D$NK732S9
MN7U6\AT\*8K9;>[ E6OR-8?ZQCE[2M&@IU8*,FK\UIPC&G&,;JI)\L%%*22<
MFG-)-G^J_P!'WB+^R_HZ9%7P^6ULVK83#\3PK8?#5J=J%..89O.>)Q6(JR_V
M*C2HRG4JM0K2A"$>2A-SBC]]O#WC?P]>^+?!?COP]X:UJZT.Z=+FQ&EZ*MG)
MK=S<>"HM)M9/#VDRF&]O-,ENK.X\B^CB73UMQ)<K(J.7;RWQ?\9_#&E6VB^!
M/%M_X=^$6L>,[CQAJNA6'Q6\%SR>'/$=S<:M=3:AI^H^-X$N-.TK7);W5YKZ
M'2KURK0-8:A;S.L3(>ST7P_)H/Q?^)NN:E?20:1\-OA1XJ^R7CSHD:P7&CZ1
M"%\J(10Z=;6JV^I75M;6T4=LB7B0Q)_HN:_,/]KKX>_M=>%M:^&NK?LGVFI?
M&#PYK?A#39OB1^SOKLVE^+-'U35=3M]<\7S:S+X%\6VL>FA]%\,-H&G0R6&K
M:?K1U6\TZ-)[%9UN!_0\(S]G%:<T8:I144Y>XG9))^\TW9*^_J?Y%XRI3KX_
M%5%.HX5<15E3G6J3JU%3E5JRIJ52<I.7+"48IR;T2NELOT"TKPI\&+-_"WAV
MQ\4_9/'NB:SX7U;QCJT/C2.+3K+0-7\->(9[>Z\.:VMW?:%?WNI?\(Y+;:=;
M?:;J^M9C%+=6=IY\4<GU!IGP;\06N@^#K?PI\8OB!H"3V)NK2*YET3Q5;V5[
M<6ESJ$]_=2W=M =3FW7,UJ75U28SF9E# ,O\NDOQ+_9X^.-O%\/?'UAXQ_9D
M^(_A.XN9+_P)*-<U?X>>&?$%W:Q7>M3ZI\/-<V>-/"&IWBP00W5_8V^N^'H8
MK>%K;Q!]F))]*\'?%3]LK]ENVM_$GPR^(NJ^)?ASH]I:,+E=2'Q2^%PTNY27
M439W-A<W3ZAX?F6* QW,T5_IB6"(V5;<BL^=)^]!K16DKNST5VKWLMEO8S^K
MN<?<JI/=1J))._:5FO3_ "/W?^"'A/X_:IIOCV/PC\8?#WAJVL/B!JFEWK:S
M\,+?5]7OKJWLM.F?4[B3^V[.&.2]M[J">.-$>- PVD(0H^DO!7PU^,^F>*--
MU_Q[^T#>>,=+L(KM9/"6C?#W0/!VD:A<3QF*VEU"[CO]9U&>.T#-*L,$MH)I
MQ&[N$0QO^9G[.W_!4'X8^$M'TRT_:'\(:G\);WX@S2^*(?'>F%_$?@#6;EK+
M2[$R7"VIDUSPU<SVEO;7S6FHZ>(4LIK:Z2X:"99#^PO@CX@^!_B5H5KXG^'_
M (LT#QCH%[&LEMJWA[5+35+-@XRJN]K*[02[<%H9EBE7^)!6])Q<8VE=KI=I
MKK:VGETL<M6-2$GS0LGL[*SVVDKK7I9_F=A10#G_ ".OI]116QB%%%% !111
M0 4444 %8&@]-5_["]Y_-:WZP-!Z:K_V%[S^:U:^&?\ V[^9A4_BT?\ M_\
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M35?^PO>?S6M^L#0>FJ_]A>\_FM6OAG_V[^9A4_BT?^W_ ,HF_1114&X4444
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M=HK;F::;/2I14*,9MJ*EHHI7<I/RWG-Z<J^&-UU.)^,'[1,7A_X*^)OA_P#
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M^W_RB;]%%%0;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,_BA+/MO/B%XGTW4%^UK8>'V@\CPK8WP02:CNU9K4?8+"XN/Z00@QD* 3VY
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M7_"CRX_^>:?]\K_A1[G:7WQ_R"U?^:E_X#/_ #,K_A(-#_Z"MC_X$1_XT?\
M"0:'_P!!6Q_\"(_\:U?+C_YYI_WRO^%'EQ_\\T_[Y7_"CW.TOOC_ )!:O_-2
M_P# 9_YF5_PD&A_]!6Q_\"(_\:/^$@T/_H*V/_@1'_C6KY<?_/-/^^5_PH\N
M/_GFG_?*_P"%'N=I??'_ ""U?^:E_P" S_S,K_A(-#_Z"MC_ .!$?^-'_"0:
M'_T%;'_P(C_QK5\N/_GFG_?*_P"%'EQ_\\T_[Y7_  H]SM+[X_Y!:O\ S4O_
M  &?^9E?\)!H?_05L?\ P(C_ ,:/^$@T/_H*V/\ X$1_XUJ^7'_SS3_OE?\
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M &7PQH=_<:?HFGW-NHO-6N;F:62VB2&8?H@1D8I&1'!#HK XR&4$<<@\CJ"
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ 4X# 2(  A$! Q$!_\0
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MBB@#I_\ A-O&?_0W>*?_  H]:_\ DZC_ (3;QG_T-WBG_P */6O_ ).KF**
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M].NM(O+R2T65K:VEO+FZU2'[$;EXI[NV>RECNT@6"0!&)IOB'XM3W>LWNO\
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M@ KW?]FS_DKV@?\ 8.\1?^FB:O"*]W_9L_Y*]H'_ &#O$7_IHFH _3FBBB@
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M[C?^@FO\H[_@O?\ \I>_VW_^RA>"?_5+?#"O]7&3_5R?[C?^@FO\H[_@O?\
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M)/AEXQD'B;4=)\#VS:G;Z=I]M8W*PO/J.@IK>L3:5X/TO6K7Q+XET..?\?\
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M*/A.#5?AEK]M!/;>%O$6NRVMW+!\+>#/^#A?X&7_ (7U3XK?%']FS]H?X,_
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M/]X1_P#G<5_"Q11_Q#7A'_H!K_\ A;BO_E@?\1 XE_Z"J/\ X34?_D3^Z?\
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MFO\ 0HK_ #U_^#0W_D^+]I;_ +-3C_\ 5P^":_T**_F/Q)_Y*W'_ /7G!?\
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M_P E>T#_ +!WB+_TT35X17N_[-G_ "5[0/\ L'>(O_31-0!^G-%%% !1110
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M5/R_N>OW^1_D6?\ #H;_ (*>?]&,?M%_^$3'_P#+.C_AT-_P4\_Z,8_:+_\
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M#OCS5?'EWXPT&#3M#\5:R/[,T?5[33I=1>VU:6(ZAIUG/;@'Q%9?!?XX:/\
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M@OBO\%;+P-_P3>O[3X;^*9O#]M=_%O\ X*Z?#/X%?$JZBCTZPOU?Q=\(M8^
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3>QK:H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $= 6(# 2(  A$! Q$!_\0
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M7Q1^V;XM\:?LP?#O]J*ZGTSX_P#PM^ 3Z#X9^+'BC7_#?@'PR+'XL:>L&O\
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MHQ'5@#DC<>>O X]: "BBB@ HHHH ]W_9L_Y*]H'_ &#O$7_IHFK].,]<$?\
MU_?G^E?SU_'?]N7P#_P3J\!C]J#XF>#_ !IX[\)Z!XAT;P5<>'? '_"/_P#"
M1SW_ (^6^TK3KR#_ (2;5]$TK['92VLDE]YFHI.(V0V\4S!EKXW_ .(OC]C#
M_HV']JO\O@O_ //+KV\OX;SW-J#Q66Y;B<90525)U:48.*J1LW%WJ1=TFFU;
MKN>3CL]RG+JJH8['4<-6E!34)N2DX/12249:7O;KIJC^MVBOY(O^(OC]C#_H
MV']JO\O@O_\ /+H_XB^/V,/^C8?VJ_R^"_\ \\NN_P#U(XL_Z$6._P# :?\
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MC!!D*@@G^(/_ (5Q\0_^B?\ CW_PA_%O_P IJ_U@_P!FT _%W0 ?^@=XB_\
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ML31Q="CB</-5*-:$:D)Q=TXR5]?-7LUNFFGJA:***P.@**** "BBB@ HHHH
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MU*<4N:<()RJ49M:R32;C=OEDM+)L_B$_X(H_\%"]5_X)X?MN^ _&NLZW+8_
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M1?\ IHFK].:_,;]FS_DKV@?]@[Q%_P"FB:OTYH **** "BBB@ HHHH ****
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MDT?Y8?\ !.75]>U'XEZ"OBRZ_P""H4OBK_A4-V_B./\ :X^/O[+WQ-^#?]O
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MY4Z<TG9WLVG;IU./$8W"T&Z=?%4*,W%M*I4A!ZII-*4DVKV6E_T/\MC]H_\
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M1BE=N4DHI-MI)M./$W$,Y1A#,L9*3=HJ,VW)](I)-MO2R2;;N?N/_P 1+?\
MP5^SG_AH'P'_ .(_?"/_ .4'T_(4#_@Y<_X*_'('[07@/_PP'PC_ %_XD/M[
M<U^0'Q)_9K_:(^#7A7PQXY^+WP'^,GPK\%>-;BXM?!WB[XB_#/QGX+\->*;F
MUBEGN+?0==\1:-I^F:E<1V\,USY%O=--+:PRW<"2VT4LR<G\(_!WA[XF_$KP
M9X!U_P"*'@#X1:-XKUN+2-1^)?Q'OK^+P-X+MI;>YG;6_$\FA6FIZLFEQO;I
M;NUC8W,RSW-N"@C,CISOAS@OV,JZRO)ZE*"FY3I*%5?NTW-15*M4E.<;-.$(
MSFVK*+E:,NA9WQ5*K"BL9CXU)N*49NI"W/I%R<XQ45UYI-*UW>Q^U?\ Q$N?
M\%?^I_:!\!^P_P"% ?",XQD?] #/3CG_ /6?\1+G_!7[_HX'P'_XC_\ "3_Y
M0U\R?M!_\$Q[#X'_ +*-W^U[X<_;=_9-^/?PY'Q-TWX0Z!IWPCF^*QUOQGX[
MN8;74==T3PG-XP\$>'](UFX\%^'[D^)/%WV2[EAT;3(3%>3PZC<6=E<?EA66
M7Y#P5FE*=? Y1EU>E3K3H3E]5JTW&K3LITW&M&C-2BVE+W-'I>Z:5XW.>*<N
MJ1HXO,,53J3IQJQ7MHRO"3?*TX2DM;.UWJM=C]ZO^(ES_@K]_P!' ^ __$?_
M (2?_*&C_B)<_P""OW_1P/@/_P 1_P#A)_\ *&OP5HKT/]3^%O\ H0Y=_P""
M7_\ )G'_ *T9_P#]#3%?^#&?O5_Q$N?\%?O^C@? ?_B/_P )/_E#1_Q$N?\
M!7[_ *.!\!_^(_\ PD_^4-?@K11_J?PM_P!"'+O_  2__DP_UHS_ /Z&F*_\
M&,_K1_X)F?\ !>[_ (*<_M(?M]_LI? KXM_&OP?K_P -/BC\6M/\*>-=%L/@
MM\-/#]WJ6B7&@>(;^6UMM9TG1K?4].D>ZL;5Q=6,\4Z^7L#A7=6_T&XB3'&2
M<DHI)/4DJ">?J?2O\E3_ ((K_P#*5K]@_P#[+YI/?_J5O%G/X>_^-?ZU</\
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MK3_DHVC?]B=8_P#IXUNOT/K\\/VM/^2C:-_V)UC_ .GC6Z /EZBBB@ HHHH
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MOAIX<M?'OA;1V:'[5=:MX8NK?5H&M8S _)C?^:'<V"-S88Y(R<$CN1G!/O\
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MXG_Q5 #J*;O3_GI'_P!_$_\ BJ-Z?\](_P#OXG_Q5 #J*;O3_GI'_P!_$_\
MBJ-Z?\](_P#OXG_Q5 #J*;O3_GI'_P!_$_\ BJ-Z?\](_P#OXG_Q5 #J*;O3
M_GI'_P!_$_\ BJ-Z?\](_P#OXG_Q5 'O/[-G_)7M _[!WB+_ --$U?IS7Y@?
MLX7%O#\6]!DFN+>)!I_B$%Y)HD0;M)F"@LS@#)X&3R:_2W^V-)_Z">G_ /@=
M:?\ QZ@#2HK-_MC2?^@GI_\ X'6G_P >H_MC2?\ H)Z?_P"!UI_\>H TJ*S?
M[8TG_H)Z?_X'6G_QZC^V-)_Z">G_ /@=:?\ QZ@#2K^2+_@[X_Y,Q_9A]/\
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MXL_\)?Q!_P#*VCZWA/\ H*PO_A10_P#EH?4\7_T"XC_P15_^5GZ._P#!%?\
MY2M?L(?]E]TG_P!1?Q97^M7%_JHO^N:?^@BO\G#_ ((P>&?$MC_P53_84NK[
MPWXBL;2'X]Z.TUU>Z!K-I;0*?#'BM=TUS<V,4$:[B%W/(HRP&>03_J^Q:QI/
ME1?\3+3^(TZWMKD?*/6;_P#77\_^*]6G5SS!2I5*=1++8J].I"I&ZQ%71RA*
M:3\KWM8_;/#>E4I91B8U:<Z<GC)-1G"4)6=.-M)1B_PW-:BLW^V-)_Z">G_^
M!UI_\>H_MC2?^@GI_P#X'6G_ ,>K\N/T0TJ*SQJVF$ B_LB",@B[MR#GN"),
M$>A'6B@#$_X0/P/_ -"9X4_\)W2/_D.C_A _ W_0F>%/7_D7=(_^0_\ (XKJ
MZ* .4_X0/P/_ -"9X4_\)W2/_D.E'@7P4OW?"'A=0>R^'M( [?\ 3G[#\AZ5
MU5% '+?\(/X+_P"A1\,?^$_I'_R'1_P@_@O_ *%'PQ_X3^D?_(==310!RW_"
M#^"_^A1\,?\ A/Z1_P#(='_"#^"_^A1\,?\ A/Z1_P#(==310!RW_"#^"_\
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M_P#P@_@O_H4?#'_A/Z1_\AT?\(/X+_Z%'PQ_X3^D?_(==310!RW_  @_@O\
MZ%'PQ_X3^D?_ "'1_P (/X+_ .A1\,?^$_I'_P AUU-% '*GP-X*/#>$/"[#
MT;P_I!'KG_CS_P ]J3_A _ __0F>%/\ PG=(_P#D.NKHH Y3_A _ _\ T)GA
M3_PG=(_^0Z/^$#\#_P#0F>%/_"=TC_Y#KJZ* .4_X0/P/_T)GA3_ ,)W2/\
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M&T[KZ_\ 'K^O?M2_\(AX4_Z%K0.N?^0/IO7U_P"/;K7XK_%O_@J]^T5^RU\
M_P!FK]I7]KS]A[PY\'_A/\2/VBO^%)_M*>(O!G[5GA/XW:9^RUX*\3Z]IWAG
MX7_'34-?\#?#T:!\0?!'B+7)[_3O&-C#?^%+_P !74.D6;SZ]J6O6VGP=K^S
MS_P5ZT?XV_ ;]I?]L74?V>OB;IW['_PN^-6K?"3]G;XB?"W2/&7Q]^)O[5^C
M^&?$,_A#7_BMX0^#/P_\!'6?#O@"?Q8B:+X:U,:SXEMKZ&WUK6/$5[X4T[1+
MMB>UJ_\ /VI_X,G_ /)A[&E_SZI?^"X?_('ZY?\ "(>%?^A:T'U_Y ^F]?\
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MNKHI%',CP5X-4!5\)>&550 JC0=*   P  +3  '  X HKIJ* "BBB@ HHHH
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MO%>G^&I_'5QIUM;Z+=V$EQ-?:CIEM+_93@8QV],#'?C&.X./I1M7&T* #U
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M1110 4444 %%%% !1110 4444 ?A[_P<=^!/''Q"_P"",_[:6E>!+;4-2NM
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BE=:E>075_(+A0#U"BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L & # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BHY9HH1F1U4>YJA-K$:Y$*%SZG@5Q8K,L+A%^^FD^V[^Y:FD*4Y
M_"C3J":\@@^_(,_W1R:PYK^YGX:0JOHO JM7S&+XM7PX:'SE_DOU9TPP?\S-
M6;62>(8\>[?X5%97,T^HQ>9(S#GCMT/:L^K>F?\ (0B_'^1KQJ&:8O%XVE[6
M;:YHZ;+==%^MS>5*$(.RZ'0T456EO[>([0V]O[J#-?H];$4J$>:K)17G_7Y'
MFQBY;(LTC,J+N9@H]2<5FO=WTW$%LR#U8<_K4!TV]G;=-(,_[39KR:V<3>F$
MH2F^]G%?>[,U5%?;DD7)M5MX^$S(?;@?G6=-JEQ+D*1&O^SU_.K2:*/XYB?9
M5JPFE6J]59O]YO\ "O+K4,^QNDFJ<>R=ORN_Q-5+#PVU,%F+$EB23W-*D<DG
MW$9OH,UTB6L$?W84'OBIJQI<(S;O6J_<OU;*>,7V4<ZFG73](B!_M'%6$T:8
M_?D1?IS6U17I4N%L##X^:7SM^2,GBZCV,U-&B'WY7;Z<59AL;>!PZ)\PZ$DU
M9HKU*&4X*@U*G22:Z[O\;F4JTY;L:\:2??4,/0\C\J555!A5 'L*YK4?'.F:
M9J$UG-!=M)$VUBB*0?IEJJ_\+'T?_GVOO^^$_P#BJ[E"*?-;4B[V.PHKG]'\
M8Z;K5[]D@2XCE*EE$JJ V.PP3SW_  JE-\0=+@F>&6TOTDC8JRF-,@CJ/O50
MCK:*R]$U^SU^"66T$B^4VUDE ##/0\$\=?RI^M:W::%9K<W>]E9MBI& 6)_$
MB@#1HKD4^(FE22*B6E^SL0% C3)/_?5=:I)4$@J2.AZB@!:*** "BBB@#QKQ
M;_R-6H?]=/Z"I/#WA>?Q!%/)%<QQ")@I#J3G-1^+?^1JU#_KI_056TS7M2T=
M)$L+GR5D(+#8K9(^H- '66OP^U&SNHKF#4H%EB8,IV'J*C\?Z&T4D>KQ(,28
M2X"] W9OQZ?@/6LJW\:>()+F)&U#*LX!'DQ],_[M>J7MG#?V4UI.NZ*52K#^
MOUH \C\*:S_8VMQR.V+>7]W-[ ]#^!Y_.K'C36O[6UIHXFS;6V8TP>&/\3?G
MQ^%8VIZ?-I6HSV4X^>)L9_O#L?Q%-L+*;4;^&S@&9)6"CV]2?8#F@#J_ &A_
M:KUM4G7]U;G$0/\ $_K^'\S7I=5=.L(=,T^&S@&(XEQGU/<GZGFK5 !1110
M4444 >->+?\ D:M0_P"NG]!6MX,GT*&VNQJXLRY=?+^T1ACC!SC(H\1^&=9O
M?$-Y<6]B\D,CY5@R\C ]ZR_^$/U__H&R?]]K_C0!W@OO!BL&5=+!!R"(%X_2
MMJQU:PU-G%E=1SE "VSMFO*?^$/U_P#Z!LG_ 'VO^-==X$T74=*GO6OK9H1(
MJ!<D'."<]#0!C?$< :];$ 9-L,_]]-4?P[ /B20D XMF(]OF6M;QQH6IZIJ\
M$UE:--&L 4L& P=S'')]ZC\$Z!JFEZW)/>VC0Q&!E#%@><KQP?8T >@4444
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0^>FP;NF.O6IJ "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>pypd-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:pypd="http://Polypid.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="pypd-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c2_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c3_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c5_AsOf31Dec2017_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2017_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2017_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2017_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c11_From1Jan2018To31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2018To31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c14_AsOf31Dec2018_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c16_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c23_AsOf31Dec2019_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c31_AsOf31Dec2020_ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c35_From2Jun2020To21Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2020-06-02</startDate>
      <endDate>2020-06-21</endDate>
    </period>
  </context>
  <context id="c36_From25Jun2020To30Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-25</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c37_From25Jun2020To30Jun2020_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-25</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c38_From25Jun2020To30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2020-06-25</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c39_AsOf31Dec2020_MinimumMember_ShortTermDepositsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c40_AsOf31Dec2020_MaximumMember_ShortTermDepositsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c41_AsOf31Dec2020_MinimumMember_LongTermDepositsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:LongTermDepositsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Dec2020_MaximumMember_LongTermDepositsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:LongTermDepositsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c43_From1Jan2020To31Dec2020_MinimumMember_SoftwareAndSoftwareDevelopmentCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jan2020To31Dec2020_MaximumMember_SoftwareAndSoftwareDevelopmentCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c45_From1Jan2020To31Dec2020_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c46_From1Jan2020To31Dec2020_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c47_AsOf31Dec2020_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c48_AsOf31Dec2019_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c49_AsOf31Dec2020_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c50_AsOf31Dec2019_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c51_AsOf31Dec2020_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Dec2019_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c53_AsOf31Dec2020_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c54_AsOf31Dec2019_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c55_From17Dec2016To22Dec2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2016-12-17</startDate>
      <endDate>2016-12-22</endDate>
    </period>
  </context>
  <context id="c56_From25Sep2017To30Sep2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2017-09-25</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="c57_From5Jan2020To9Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <startDate>2020-01-05</startDate>
      <endDate>2020-01-09</endDate>
    </period>
  </context>
  <context id="c58_AsOf31Dec2019_MinimumMember_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c59_AsOf31Dec2019_MaximumMember_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c60_AsOf31Dec2019_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1PreferredShareWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c62_AsOf31Dec2019_ConvertiblePreferredE1SharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredE1SharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c63_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1PreferredShareWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c64_AsOf31Dec2019_ConvertiblePreferredD2SharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c66_AsOf31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c67_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c68_AsOf31Dec2019_ConvertiblePreferredASharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredASharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c70_AsOf31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c71_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c72_AsOf30Jun2020_ConvertiblePreferredD2SharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c74_From1Jun2020To30Jun2020_SeriesE1PreferredShareWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1PreferredShareWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c75_AsOf30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c76_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredD2SharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c77_AsOf30Jun2020_ConvertiblePreferredASharesMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:ConvertiblePreferredASharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c78_AsOf30Jun2020_SeriesAPreferredShareWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c79_From1Jun2020To30Jun2020_SeriesAPreferredShareWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c80_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c81_From1Jun2020To30Jun2020_SeriesAPreferredShareWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c82_AsOf30Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c83_AsOf31Dec2019_SeriesAPreferredShareWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAPreferredShareWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c84_AsOf31Dec2020_ReservesAndAllowancesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:ReservesAndAllowancesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c85_AsOf31Dec2019_ReservesAndAllowancesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:ReservesAndAllowancesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c86_AsOf31Dec2020_TemporaryDifferencesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:TemporaryDifferencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c87_AsOf31Dec2019_TemporaryDifferencesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:TemporaryDifferencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf31Dec2020_IssaunceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:IssaunceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c89_AsOf31Dec2019_IssaunceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:IssaunceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c90_AsOf31Dec2020_LossCarryforwardMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:LossCarryforwardMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c91_AsOf31Dec2019_LossCarryforwardMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pypd:LossCarryforwardMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c92_AsOf31Dec2020_SeriesAConvertiblePreferredMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAConvertiblePreferredMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c93_AsOf31Dec2020_SeriesA1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c94_AsOf31Dec2020_SeriesBConvertiblePreferredMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesBConvertiblePreferredMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c95_AsOf31Dec2020_SeriesB1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesB1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c96_AsOf31Dec2020_SeriesC1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesC1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c97_AsOf31Dec2020_SeriesC2ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesC2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c98_AsOf31Dec2020_SeriesEConvertiblePreferredMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesEConvertiblePreferredMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c99_AsOf28Feb2019_SecuritiesPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-02-28</instant>
    </period>
  </context>
  <context id="c100_From1Aug2018To28Feb2019_SecuritiesPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2019-02-28</endDate>
    </period>
  </context>
  <context id="c101_AsOf28Feb2019_SeriesE1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-02-28</instant>
    </period>
  </context>
  <context id="c102_From1Aug2018To28Feb2019_SeriesE1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2019-02-28</endDate>
    </period>
  </context>
  <context id="c103_From1Jan2018To31Dec2018_SecuritiesPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c104_From1Jun2019To30Jun2019_PrivatePlacementMemorandumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pypd:PrivatePlacementMemorandumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c105_From1Jun2019To31Aug2019_PrivatePlacementMemorandumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pypd:PrivatePlacementMemorandumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c106_AsOf31Aug2019_SeriesE1ConvertiblePreferredSharesMember_PrivatePlacementMemorandumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pypd:PrivatePlacementMemorandumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-31</instant>
    </period>
  </context>
  <context id="c107_AsOf30Jun2019_PrivatePlacementMemorandumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pypd:PrivatePlacementMemorandumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c108_From1Mar2008To31Mar2008_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-03-01</startDate>
      <endDate>2008-03-31</endDate>
    </period>
  </context>
  <context id="c109_AsOf31Dec2016_SeriesD2ConvertiblePreferredSharesMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="c110_From1Jun2019To28Jun2019_SeriesD2ConvertiblePreferredSharesMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-06-28</endDate>
    </period>
  </context>
  <context id="c111_AsOf31Dec2020_SeriesE1ConvertiblePreferredSharesMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c112_AsOf31Dec2020_SeriesD2ConvertiblePreferredSharesMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c113_AsOf31Dec2020_SeriesAConvertiblePreferredMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAConvertiblePreferredMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c114_AsOf31Dec2020_SeriesE1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c115_From1Jan2020To31Dec2020_SeriesE1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c116_AsOf31Dec2020_SeriesAConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c117_AsOf31Dec2019_SeriesAConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c118_AsOf31Dec2019_SeriesA1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c119_AsOf31Dec2020_SeriesBConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c120_AsOf31Dec2019_SeriesBConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c121_AsOf31Dec2019_SeriesB1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesB1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c122_AsOf31Dec2019_SeriesC1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesC1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c123_AsOf31Dec2019_SeriesC2ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesC2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c124_AsOf31Dec2020_SeriesD1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c125_AsOf31Dec2019_SeriesD1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c126_AsOf31Dec2020_SeriesD2ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c127_AsOf31Dec2019_SeriesD2ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD2ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c128_AsOf31Dec2020_SeriesD3ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD3ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c129_AsOf31Dec2019_SeriesD3ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesD3ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c130_AsOf31Dec2020_SeriesEConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesEConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c131_AsOf31Dec2019_SeriesEConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesEConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c132_AsOf31Dec2019_SeriesE1ConvertiblePreferredSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pypd:SeriesE1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c133_From1Jan2020To31Dec2020_OfficerMember_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c134_From1Jan2020To31Dec2020_DirectorMember_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c135_From1Jan2020To31Dec2020_AdvisorsMember_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pypd:AdvisorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c136_From1Jan2020To31Dec2020_ManagementMember_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c137_From1Jan2020To31Dec2020_OtherKeyEmployeesMember_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pypd:OtherKeyEmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c138_From1Jan2020To31Dec2020_TwoThousandTwelveShareOptionPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c139_From1Jan2020To31Dec2020_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c140_From1Jan2020To31Dec2020_MinimumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c141_From1Jan2020To31Dec2020_MaximumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c142_From1Jan2019To31Dec2019_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c143_From1Jan2019To31Dec2019_MinimumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c144_From1Jan2019To31Dec2019_MaximumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c145_From1Jan2018To31Dec2018_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c146_From1Jan2018To31Dec2018_MinimumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c147_From1Jan2018To31Dec2018_MaximumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c148_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c149_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c150_From1Jan2018To31Dec2018_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c151_From1Jan2020To31Dec2020_MarketingAndBusinessDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c152_From1Jan2019To31Dec2019_MarketingAndBusinessDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c153_From1Jan2018To31Dec2018_MarketingAndBusinessDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c154_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c155_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c156_From1Jan2018To31Dec2018_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c157_From1Jan2020To31Dec2020_ExercisePrice022Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice022Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c158_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice022Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice022Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c159_From1Jan2020To31Dec2020_ExercisePrice175Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice175Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c160_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice175Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice175Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c161_From1Jan2020To31Dec2020_ExercisePrice359Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice359Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c162_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice359Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice359Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c163_From1Jan2020To31Dec2020_ExercisePrice507Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice507Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c164_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice507Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice507Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c165_From1Jan2020To31Dec2020_ExercisePrice923Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice923Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c166_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice923Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePrice923Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c167_From1Jan2020To31Dec2020_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c168_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c169_From1Jan2020To31Dec2020_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c170_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c171_From1Jan2020To31Dec2020_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c172_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c173_From1Jan2020To31Dec2020_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c174_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c175_From1Jan2020To31Dec2020_ExercisePriceNineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c176_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceNineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c177_From1Jan2020To31Dec2020_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c178_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c179_From1Jan2020To31Dec2020_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c180_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c181_From1Jan2020To31Dec2020_ExercisePriceTwelveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceTwelveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c182_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTwelveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceTwelveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c183_From1Jan2020To31Dec2020_ExercisePriceThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c184_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c185_From1Jan2020To31Dec2020_ExercisePriceFourtheenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFourtheenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c186_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFourtheenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFourtheenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c187_From1Jan2020To31Dec2020_ExercisePriceFifteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFifteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c188_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFifteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pypd:ExercisePriceFifteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c189_From1Jan2020To31Dec2020_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c190_AsOf31Dec2020_MarchTwoThousandThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:MarchTwoThousandThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c191_From1Jan2020To31Dec2020_MarchTwoThousandThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:MarchTwoThousandThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c192_AsOf31Dec2020_OctoberTwoThousandThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c193_From1Jan2020To31Dec2020_OctoberTwoThousandThirteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c194_AsOf31Dec2020_JuneTwoThousandFourteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandFourteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c195_From1Jan2020To31Dec2020_JuneTwoThousandFourteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandFourteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c196_AsOf31Dec2020_SeptemberTwoThousandFourteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c197_From1Jan2020To31Dec2020_SeptemberTwoThousandFourteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c198_AsOf31Dec2020_AprilTwoThousandSixteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c199_From1Jan2020To31Dec2020_AprilTwoThousandSixteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c200_AsOf31Dec2020_DecemberTwoThousandSixteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c201_From1Jan2020To31Dec2020_DecemberTwoThousandSixteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c202_AsOf31Dec2020_JuneTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c203_From1Jan2020To31Dec2020_JuneTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c204_AsOf31Dec2020_AugustTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AugustTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c205_From1Jan2020To31Dec2020_AugustTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AugustTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c206_AsOf31Dec2020_NovemberTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c207_From1Jan2020To31Dec2020_NovemberTwoThousandSeventeenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c208_AsOf31Dec2020_AugustTwoThousandNineteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AugustTwoThousandNineteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c209_From1Jan2020To31Dec2020_AugustTwoThousandNineteenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AugustTwoThousandNineteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c210_AsOf31Dec2020_JuneTwoThousandTwentyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c211_From1Jan2020To31Dec2020_JuneTwoThousandTwentyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c212_From5Jul2019To31Jul2019_EasternEuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pypd:EasternEuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-05</startDate>
      <endDate>2019-07-31</endDate>
    </period>
  </context>
  <context id="c213_From1Jan2020To31Dec2020_DirectorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c214_AsOf31Mar2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c215_From1Mar2021To31Mar2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-03-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c216_From31Jan2021To31Mar2021_RelatedPartiesMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pypd:RelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-31</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c217_AsOf28Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-02-28</instant>
    </period>
  </context>
  <context id="c218_From1Feb2021To28Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-01</startDate>
      <endDate>2021-02-28</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="eur">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="ilsPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:ILS</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_shares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">Net of issuance costs of $187 in cash.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_shares" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesIssuedForServices-c11_From1Jan2018To31Dec2018_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesIssuedForServices-c11_From1Jan2018To31Dec2018_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesIssuedForServices-c11_From1Jan2018To31Dec2018_CommonStockMember_shares" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c13_From1Jan2018To31Dec2018_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c13_From1Jan2018To31Dec2018_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c13_From1Jan2018To31Dec2018_RetainedEarningsMember_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c4_From1Jan2018To31Dec2018_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c4_From1Jan2018To31Dec2018_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c4_From1Jan2018To31Dec2018_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_shares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_1" xml:lang="en-US">Net of issuance costs of $3,822 in cash and warrants.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_shares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_usd" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesIssuedForServices-c20_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:href="#_StockIssuedDuringPeriodSharesIssuedForServices-c20_From1Jan2019To31Dec2019_CommonStockMember_shares"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesIssuedForServices-c20_From1Jan2019To31Dec2019_CommonStockMember_shares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c22_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c22_From1Jan2019To31Dec2019_RetainedEarningsMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c22_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodValueIssuedForServices-c3_From1Jan2019To31Dec2019_usd" xlink:href="#_StockIssuedDuringPeriodValueIssuedForServices-c3_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodValueIssuedForServices-c3_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1-c157_From1Jan2020To31Dec2020_ExercisePrice022Member_shares" xlink:href="#_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1-c157_From1Jan2020To31Dec2020_ExercisePrice022Member_shares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_2" xml:lang="en-US">The exercise price of the options is denominated in NIS and was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1-c157_From1Jan2020To31Dec2020_ExercisePrice022Member_shares" xlink:to="ftnt_2" order="1"/>
  </link:footnoteLink>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentAnnualReport contextRef="c0_From1Jan2020To31Dec2020">true</dei:DocumentAnnualReport>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentShellCompanyReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentTransitionReport>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">20-F</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001611842</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-38428</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">L2</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">PolyPid Ltd.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">18494739</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">4319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">3924000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">390000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">375000</us-gaap:RestrictedCashCurrent>
  <pypd:ShorttermDeposits unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">40157000</pypd:ShorttermDeposits>
  <pypd:ShorttermDeposits unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">22685000</pypd:ShorttermDeposits>
  <us-gaap:OtherReceivables unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">2334000</us-gaap:OtherReceivables>
  <us-gaap:OtherReceivables unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">417000</us-gaap:OtherReceivables>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">47200000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">27401000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">5890000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">6121000</us-gaap:PropertyPlantAndEquipmentNet>
  <pypd:LongtermDeposits unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">22120000</pypd:LongtermDeposits>
  <pypd:LongtermDeposits unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">637000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">230000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LongTermInvestments unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">28647000</us-gaap:LongTermInvestments>
  <us-gaap:LongTermInvestments unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">6351000</us-gaap:LongTermInvestments>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">75847000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">33752000</us-gaap:Assets>
  <us-gaap:AccountsPayableTradeCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">974000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">1581000</us-gaap:AccountsPayableTradeCurrent>
  <pypd:OtherPayablesAndAccruedExpenses unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1903000</pypd:OtherPayablesAndAccruedExpenses>
  <pypd:OtherPayablesAndAccruedExpenses unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">998000</pypd:OtherPayablesAndAccruedExpenses>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">2877000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">2579000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherLiabilities unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">193000</us-gaap:OtherLiabilities>
  <us-gaap:OtherLiabilities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">251000</us-gaap:OtherLiabilities>
  <pypd:WarrantToConvertiblePreferredShares unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <pypd:WarrantToConvertiblePreferredShares unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">12241000</pypd:WarrantToConvertiblePreferredShares>
  <pypd:TotalLongtermLiabilities unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">193000</pypd:TotalLongtermLiabilities>
  <pypd:TotalLongtermLiabilities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">12492000</pypd:TotalLongtermLiabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">106313000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">205063000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">5671000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">-132286000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">-93303000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">72777000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">-87632000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">75847000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">33752000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">17916412</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">12520977</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">12520977</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockNoParValue unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommonStockNoParValue unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">47800000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">22520977</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">18494739</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">562748</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">18494739</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">562748</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">16954000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">14083000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">12550000</us-gaap:ResearchAndDevelopmentExpense>
  <pypd:MarketingAndBusinessDevelopmentExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1614000</pypd:MarketingAndBusinessDevelopmentExpenses>
  <pypd:MarketingAndBusinessDevelopmentExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">887000</pypd:MarketingAndBusinessDevelopmentExpenses>
  <pypd:MarketingAndBusinessDevelopmentExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">549000</pypd:MarketingAndBusinessDevelopmentExpenses>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">7704000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">3590000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">5265000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-26272000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-18560000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-18364000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-10597000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">11655000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">24281000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-36869000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-6905000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">5917000</us-gaap:NetIncomeLoss>
  <pypd:DeemedDividend unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">2114000</pypd:DeemedDividend>
  <pypd:DeemedDividend unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:DeemedDividend unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <pypd:NetLossAttributableToOrdinarySharesAsReported unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-38983000</pypd:NetLossAttributableToOrdinarySharesAsReported>
  <pypd:NetLossAttributableToOrdinarySharesAsReported unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-6905000</pypd:NetLossAttributableToOrdinarySharesAsReported>
  <pypd:NetLossAttributableToOrdinarySharesAsReported unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">5917000</pypd:NetLossAttributableToOrdinarySharesAsReported>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">4.48</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">23.69</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">-0.16</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">4.48</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">23.69</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">0.86</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">9582405</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">562451</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="INF">561113</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">9582405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">562451</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="INF">613358</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c5_AsOf31Dec2017_ConvertiblePreferredSharesMember" decimals="INF">8736425</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c5_AsOf31Dec2017_ConvertiblePreferredSharesMember" decimals="-3">59983000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c6_AsOf31Dec2017_CommonStockMember" decimals="INF">558447</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2017_AdditionalPaidInCapitalMember" decimals="-3">3669000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2017_RetainedEarningsMember" decimals="-3">-92315000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2017" decimals="-3">-88646000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c11_From1Jan2018To31Dec2018_CommonStockMember" decimals="INF">2778</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">995000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">995000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="_StockIssuedDuringPeriodSharesIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_shares" unitRef="shares" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" decimals="INF">718008</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember_usd" unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" decimals="-3">9364000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="_StockIssuedDuringPeriodSharesIssuedForServices-c11_From1Jan2018To31Dec2018_CommonStockMember_shares" unitRef="shares" contextRef="c11_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c13_From1Jan2018To31Dec2018_RetainedEarningsMember_usd" unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c4_From1Jan2018To31Dec2018_usd" unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_RetainedEarningsMember" decimals="-3">5917000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c14_AsOf31Dec2018_ConvertiblePreferredSharesMember" decimals="INF">9454433</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31Dec2018_ConvertiblePreferredSharesMember" decimals="-3">69347000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c15_AsOf31Dec2018_CommonStockMember" decimals="INF">561225</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c16_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">4688000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2018_RetainedEarningsMember" decimals="-3">-86398000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="-3">-81710000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c20_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">1523</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">976000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">976000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="_StockIssuedDuringPeriodSharesIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_shares" unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" decimals="INF">3066544</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember_usd" unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" decimals="-3">36966000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="_StockIssuedDuringPeriodSharesIssuedForServices-c20_From1Jan2019To31Dec2019_CommonStockMember_shares" unitRef="shares" contextRef="c20_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember_usd" unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c22_From1Jan2019To31Dec2019_RetainedEarningsMember_usd" unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="_StockIssuedDuringPeriodValueIssuedForServices-c3_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="-3">-6905000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c23_AsOf31Dec2019_ConvertiblePreferredSharesMember" decimals="INF">12520977</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31Dec2019_ConvertiblePreferredSharesMember" decimals="-3">106313000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c24_AsOf31Dec2019_CommonStockMember" decimals="INF">562748</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">5671000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2019_RetainedEarningsMember" decimals="-3">-93303000</us-gaap:StockholdersEquity>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">4577000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">4577000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">62757000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">62757000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" decimals="INF">-12520977</pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" decimals="-3">-106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">12520977</pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">158967</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">2114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="-3">-2114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <pypd:ReclassificationOfWarrantsIntoEquity unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <pypd:ReclassificationOfWarrantsIntoEquity unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">23614000</pypd:ReclassificationOfWarrantsIntoEquity>
  <pypd:ReclassificationOfWarrantsIntoEquity unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <pypd:ReclassificationOfWarrantsIntoEquity unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">23614000</pypd:ReclassificationOfWarrantsIntoEquity>
  <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <pypd:ExerciseOfWarrants unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">939152</pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares>
  <pypd:ExerciseOfWarrants unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">13000</pypd:ExerciseOfWarrants>
  <pypd:ExerciseOfWarrants unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <pypd:ExerciseOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">13000</pypd:ExerciseOfWarrants>
  <pypd:StockIssuedDuringPeriodIssuanceOfWarrants unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <pypd:StockIssuedDuringPeriodIssuanceOfWarrants unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">1000</pypd:StockIssuedDuringPeriodIssuanceOfWarrants>
  <pypd:StockIssuedDuringPeriodIssuanceOfWarrants unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <pypd:StockIssuedDuringPeriodIssuanceOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1000</pypd:StockIssuedDuringPeriodIssuanceOfWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">395</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="-3">-36869000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c31_AsOf31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf31Dec2020_ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c32_AsOf31Dec2020_CommonStockMember" decimals="INF">18494739</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">205063000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31Dec2020_RetainedEarningsMember" decimals="-3">-132286000</us-gaap:StockholdersEquity>
  <pypd:NetOfIssuanceCosts unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">187000</pypd:NetOfIssuanceCosts>
  <pypd:NetOfIssuanceCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">3822000</pypd:NetOfIssuanceCosts>
  <us-gaap:Depreciation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1012000</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">947000</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">411000</us-gaap:Depreciation>
  <pypd:ReevaluationOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">11373000</pypd:ReevaluationOfWarrants>
  <pypd:ReevaluationOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-11365000</pypd:ReevaluationOfWarrants>
  <pypd:ReevaluationOfWarrants unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-24473000</pypd:ReevaluationOfWarrants>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">4577000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">976000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">995000</us-gaap:ShareBasedCompensation>
  <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1917000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
  <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-69000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
  <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-306000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
  <us-gaap:IncreaseDecreaseInDeferredCharges unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-1088000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <pypd:IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-600000</pypd:IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">12000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-11000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-5000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-607000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">449000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-887000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">847000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-1540000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">560000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-21596000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-17358000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-16678000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsForProceedsFromShortTermInvestments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17472000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
  <us-gaap:PaymentsForProceedsFromShortTermInvestments unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">22685000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
  <us-gaap:PaymentsForProceedsFromShortTermInvestments unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-14031000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
  <pypd:PaymentsAcquireToLongtermDepositsNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">22120000</pypd:PaymentsAcquireToLongtermDepositsNet>
  <pypd:PrepaymentForEquipments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">395000</pypd:PrepaymentForEquipments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">781000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">879000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3074000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-40768000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-23564000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">10957000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <pypd:ProceedsFromIssuanceOfConvertiblePreferredSharesNet unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">37646000</pypd:ProceedsFromIssuanceOfConvertiblePreferredSharesNet>
  <pypd:ProceedsFromIssuanceOfConvertiblePreferredSharesNet unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">9364000</pypd:ProceedsFromIssuanceOfConvertiblePreferredSharesNet>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">62757000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">13000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">7000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">24000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">62774000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">37653000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">9388000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-3269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3667000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">4498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="-3">7767000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c9_AsOf31Dec2017" decimals="-3">4100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">4908000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">600000</pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable>
  <pypd:IssuanceOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">680000</pypd:IssuanceOfWarrants>
  <us-gaap:BasisOfAccounting contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
1:-	GENERAL&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;PolyPid Ltd. (the &amp;#x201c;Company&amp;#x201d;)
                                         was incorporated under the laws of Israel and commenced operations on February&amp;#xa0;28,
                                         2008. The Company is a clinical-stage pharmaceutical company focused on developing and
                                         commercializing novel, locally administered therapies using its PLEX (Polymer-Lipid Encapsulation
                                         matriX) technology. The Company&amp;#x2019;s product candidates are designed to address unmet medical
                                         needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined
                                         release rates and durations over extended periods ranging from days to several months.
                                         The Company is initially focused on the development of its lead product candidate, D-PLEX,
                                         which incorporates an antibiotic, for the prevention of surgical site infection in bone
                                         and soft tissue.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company wholly-owns subsidiaries
in the Unites States of America and Romania.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Through
December 31, 2020, the Company has been primarily engaged in research and development.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;The Company&amp;#x2019;s activities since
                                         inception have consisted of performing research and development activities. Successful
                                         completion of the Company&amp;#x2019;s development programs and, ultimately, the attainment of profitable
                                         operations is dependent on future events, including, among other things, its ability
                                         to secure financing; obtain marketing approval from regulatory authorities; access potential
                                         markets; build a sustainable customer base; attract, retain and motivate qualified
                                         personnel; and develop strategic alliances. The Company&amp;#x2019;s operations are funded by its
                                         shareholders and research and development grants and the Company intends to seek further
                                         private or public financing as well as make applications for further research and development
                                         grants for continuing its operations. Although management believes that the Company will
                                         be able to successfully fund its operations, there can be no assurance that the Company
                                         will be able to do so or that the Company will ever operate profitably.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute
its business plan, the Company will need to complete phase III clinical studies and certain development activities as well as
manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&amp;#x2019;s product
candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing
and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately
be unsuccessful. Any delays in completing these activities could adversely impact the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of December 31, 2020, the
Company had cash, cash equivalents, short-term deposits and long-term deposits of $66,596. During the year ended December&amp;#xa0;31,
2020, the Company incurred a net loss of $36,869 and had negative cash flows from operating activities of $21,596. In addition,
the Company had an accumulated deficit of $132,286 at December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company&amp;#x2019;s
future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies;
(ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production
batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company&amp;#x2019;s product candidates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;There can
be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;c&lt;/font&gt;.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;On
                                         March 11, 2020, the World Health Organization declared the outbreak of a respiratory
                                         disease caused by a new coronavirus as a &amp;#x201c;pandemic&amp;#x201d; which is now known as
                                         COVID-19. The outbreak has impacted thousands of individuals worldwide. In response,
                                         many countries have implemented measures to combat the outbreak which have impacted global
                                         business operations. The Company&amp;#x2019;s business is likely to be adversely affected by the
                                         effects of the recent and evolving COVID-19 pandemic, which has resulted in travel and
                                         other restrictions in order to reduce the spread of the disease, including in Israel,
                                         the United States and the European Union where the Company is conducting or planning
                                         clinical trials. No impairments were recorded as of the balance sheet date as no triggering
                                         events or changes in circumstances had occurred; however, due to significant uncertainty
                                         surrounding the situation, management&amp;#x2019;s judgment regarding this could change in the future.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;On June 21, 2020, the Company&amp;#x2019;s Board of Directors resolved to consolidate the
                                                              Company&amp;#x2019;s share capital by applying a reverse share split at a ratio of 1.046:1 (the &amp;#x201c;Reverse Split Ratio&amp;#x201d;)
                                                              and to cancel the shares&amp;#x2019; par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1
                                                              Ordinary share with no par value (the &amp;#x201c;Split&amp;#x201d;). The Split was  applied in the same proportion and manner to all
                                                              of the Company&amp;#x2019;s authorized, issued and outstanding securities, including preferred shares, options and warrants. See
                                                              Note 10.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;e.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;On June 30, 2020, the Company
                                         closed its initial public offering (&amp;#x201c;IPO&amp;#x201d;) whereby 4,312,500 Ordinary shares
                                         were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant
                                         to the full exercise of an overallotment option granted to the underwriters). The aggregate
                                         net proceeds received by the Company from the offering were $62,757, net of underwriting
                                         discounts and other offering costs.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">66596000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <pypd:DescriptionOfReverseShareSplit contextRef="c35_From2Jun2020To21Jun2020">the Company&amp;#x2019;s Board of Directors resolved to consolidate the Company&amp;#x2019;s share capital by applying a reverse share split at a ratio of 1.046:1 (the &amp;#x201c;Reverse Split Ratio&amp;#x201d;) and to cancel the shares&amp;#x2019; par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &amp;#x201c;Split&amp;#x201d;). The Split was applied in the same proportion and manner to all of the Company&amp;#x2019;s authorized, issued and outstanding securities, including preferred shares, options and warrants.</pypd:DescriptionOfReverseShareSplit>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c36_From25Jun2020To30Jun2020_IPOMember" decimals="INF">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c37_From25Jun2020To30Jun2020_OverAllotmentOptionMember" decimals="INF">562500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <pypd:AggregateNetProceeds unitRef="usd" contextRef="c38_From25Jun2020To30Jun2020" decimals="-3">62757000</pypd:AggregateNetProceeds>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
2:-	SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The consolidated financial
statements are prepared according to United States generally accepted accounting principles (&amp;#x201c;U.S. GAAP&amp;#x201d;)&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The preparation
of the consolidated financial statements in conformity with U.S.&amp;#xa0;GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&amp;#x2019;s
management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of
share-based awards, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and
the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Consolidated financial statements
                                         in U.S.&amp;#xa0;dollars:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The accompanying
consolidated financial statements have been prepared in U.S.&amp;#xa0;dollars.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A substantial portion of the Company&amp;#x2019;s expenses are incurred
in New Israeli Shekels (&amp;#x201c;NIS&amp;#x201d;). However, the Company finances its operations mainly in U.S. dollars, a substantial
portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated
in U.S. dollars. As such, the Company&amp;#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment
in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&amp;#xa0;dollar.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Transactions and balances denominated in U.S. dollars are presented
at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance
with Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) No. 830, &amp;#x201c;Foreign Currency Matters&amp;#x201d;. All transaction gains
and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income
or expenses, as appropriate.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Principles of consolidation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The consolidated
financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Reclassifications:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Certain prior years amounts
have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated
net loss.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;e.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Cash equivalents:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or
less, at the date acquired.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;f.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Restricted cash:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Restricted
cash is primarily invested in certificates of deposit and is used as security for the Company&amp;#x2019;s lease commitments and hedging
activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets
and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,924&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash, as reported on the balance sheets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;390&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;375&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash in other long-term assets, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,908&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,498&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;g.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Short-term deposits:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify&quot;&gt;A Short-term bank deposit is a
deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging
from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value
due to their short maturities.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in; text-align: left&quot;&gt;h.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Long-term deposits:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A Long-term bank deposit is
a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per
annum, as of December 31, 2020. Long-term deposits are presented at cost.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;i.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Property and equipment, net:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets at the following rates:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Computers, software and laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;15&amp;#xa0;-&amp;#xa0;33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Furniture and office equipment&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Down payments for property and
equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the
corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;j.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Impairment of long-lived assets:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company&amp;#x2019;s long-lived assets are reviewed for impairment
in accordance with ASC 360, &amp;#x201c;Property, Plant and Equipment&amp;#x201d;, whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset
exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;k.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Research and development expenses:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Research
and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting
fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory
approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&amp;#x2019;s intellectual property
rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities
related costs. The Company charges research and development expenses as expenses when incurred.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;l.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Basic and diluted net loss (profit)
                                         per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company computes net loss (profit) per share using the two-class
method required for participating securities. The two-class method requires income available to ordinary shareholders for the period
to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as
if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating
securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders
of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require
the holders of such shares to participate in the Company&amp;#x2019;s losses. As such,&amp;#xa0;during the periods when the Company is in
a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under
the two-class method as these securities did not have a contractual obligation to share in the Company&amp;#x2019;s losses.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The
Company&amp;#x2019;s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary
shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of
potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially
dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature
of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the
effects of potentially dilutive shares of Ordinary shares are anti-dilutive.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;m.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Accounting for share-based payments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Share-based compensation expense related to share-based awards
is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite
service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value
of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company&amp;#x2019;s
Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine
the fair value of the share awards represent management&amp;#x2019;s best estimates. These estimates involve inherent uncertainties
and the application of management&amp;#x2019;s judgment. Forfeitures are accounted for as they occur instead of estimating the number
of awards expected to be forfeited.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;n.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Grants and participations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Royalty-bearing
grants from the Israeli Innovation Authority (&amp;#x201c;IIA&amp;#x201d;) (previously known as Office of the Chief Scientist) of the Ministry
of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company
is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&amp;#x2019;s Seventh Framework Programme for
Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such
grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Since the
payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received
from IIA until the related revenues are recognized.&amp;#xa0;In the event of failure of a project that was partly financed by IIA,
the Company will not be obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company recognizes participations in research and development,
as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research
and development expenses incurred during the period is recognized as other income within operating income.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;o.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Convertible preferred shares
                                         and convertible preferred shares warrant liability:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The terms
of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&amp;#xa0;shares allowed the holders to redeem shares, under
certain circumstances, outside of the Company&amp;#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance
sheet and not included as a component of shareholders&amp;#x2019; deficit before the IPO. The carrying value of the convertible preferred
shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the
convertible preferred shares will be redeemed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Warrants
to purchase the Company&amp;#x2019;s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair
value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the
Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance
sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;p.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Fair value of financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
applies ASC 820, &amp;#x201c;Fair Value Measurements and Disclosures&amp;#x201d; (&amp;#x201c;ASC 820&amp;#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &amp;#x201c;exit price&amp;#x201d;) in an
orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In determining
fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Unobservable
inputs are inputs that reflect the Company&amp;#x2019;s assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available in the circumstances.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Fair value
is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A three-tier
fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical
                                         assets and liabilities.&lt;/td&gt;&lt;/tr&gt;                                                                          &lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         2 - Include other inputs that are directly or indirectly observable in the marketplace.&lt;/td&gt;&lt;/tr&gt;                                                                                                                                          &lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         3 - Unobservable inputs which are supported by little or no market activity.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The fair value hierarchy also
requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value&lt;font style=&quot;font-size: 10pt&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The financial
instruments carried at fair value on the Company&amp;#x2019;s consolidated balance sheets as of December 31, 2019 are warrants to convertible
preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The following
methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The carrying
amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables,
trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such
instruments.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;q.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Income taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
accounts for income taxes in accordance with ASC 740, &amp;#x201c;Income Taxes&amp;#x201d; (&amp;#x201c;ASC 740&amp;#x201d;). ASC 740 prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax
assets to their estimated realizable value, if needed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;ASC 740
contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that
it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including
resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized
tax benefits was recorded as a result of ASC 740.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The
Company&amp;#x2019;s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;r.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Concentration of credit risks:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Cash, cash
equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be
in excess of insured limits and are not insured.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;in other jurisdictions.
Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge
a portion of the Company&amp;#x2019;s non-dollar currency exposure. Counterparties to the Company&amp;#x2019;s derivative instruments are all major
financial institutions.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;s.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Severance pay:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;All the Company&amp;#x2019;s employees
who are Israeli citizens have subscribed to Section&amp;#xa0;14 of Israel&amp;#x2019;s Severance Pay Law, 5723-1963
(&amp;#x201c;Section&amp;#xa0;14&amp;#x201d;). Pursuant to Section&amp;#xa0;14, employees covered by this section are entitled to monthly
deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with
Section&amp;#xa0;14 release the Company from any future severance liabilities in respect of those employees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Neither severance
pay liability nor severance pay fund under Section&amp;#xa0;14 for such employees is recorded on the Company&amp;#x2019;s consolidated balance
sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Severance
pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;t.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Derivative financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company accounts for derivatives and hedging based on ASC
815, &amp;#x201c;Derivatives and hedging&amp;#x201d;, as amended and related interpretations (&amp;#x201c;ASC 815&amp;#x201d;). ASC 815 requires the
Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is
so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against
the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions)
or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The ineffective portion of a derivative&amp;#x2019;s change in fair value
is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included
in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts
in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative
instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from
such instruments is recognized immediately as &amp;#x201c;financial income, net&amp;#x201d;.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company measured the fair value of the contracts in accordance
with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices
and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was
$62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December
31, 2019 and 2018 amounted to $10 and $0, respectively.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;u.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Contingent liabilities&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company accounts for its contingent liabilities in accordance
with ASC 450, &amp;#x201c;Contingencies&amp;#x201d;. A provision is recorded when it is both probable that a liability has been incurred and
the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect
the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining
to a particular matter.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company is occasionally
a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any
pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of
operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;v.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Recently adopted Accounting Pronouncements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As an &amp;#x201c;emerging
growth company&amp;#x201d;, the Jumpstart Our Business Startups Act (&amp;#x201c;JOBS Act&amp;#x201d;) allows the Company to delay adoption of
new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private
companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below
reflect this election&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In June 2018, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;)
issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No.&amp;#xa0;2018-07, &amp;#x201c;Improvements to Nonemployee Share-Based Payment
Accounting,&amp;#x201d; which simplifies the accounting for share-based payments granted to nonemployees for goods and services and
aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.
The Company adopted the guidance as of January&amp;#xa0;1, 2020. The adoption of the standard didn&amp;#x2019;t have a material impact on the
Company&amp;#x2019;s consolidated statements of operations.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;w.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Recently Issued Accounting Pronouncements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In February 2016, the FASB issued
ASU No. 2016-02, &amp;#x201c;Leases,&amp;#x201d; which would require lessees to recognize assets and liabilities on the balance sheet for
most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner
similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance
states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for
the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1,
2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of
the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure
requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current
and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU
2016-02 will have on its consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In August 2017, the FASB issued
ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies
the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their
hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements,
expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure
requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January
1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its
Consolidated Statements of Operations or Cash Flows.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In August 2018, the FASB issued ASU No. 2018-15, &amp;#x201c;Intangibles-Goodwill
and Other-Internal-Use Software (Subtopic 350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract,&amp;#x201d; which aligns the requirements for capitalizing implementation costs incurred in
a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop
or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally
over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that
of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and
interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the
effect that ASU 2018-15 will have on its consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU No. 2019-12, &amp;#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201d; which simplifies the accounting for income taxes by removing
a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for
intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses
that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in
fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12
will have on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The preparation
of the consolidated financial statements in conformity with U.S.&amp;#xa0;GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&amp;#x2019;s
management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of
share-based awards, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and
the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <pypd:ConsolidatedFinancialStatementsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Consolidated financial statements
                                         in U.S.&amp;#xa0;dollars:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The accompanying
consolidated financial statements have been prepared in U.S.&amp;#xa0;dollars.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A substantial portion of the Company&amp;#x2019;s expenses are incurred
in New Israeli Shekels (&amp;#x201c;NIS&amp;#x201d;). However, the Company finances its operations mainly in U.S. dollars, a substantial
portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated
in U.S. dollars. As such, the Company&amp;#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment
in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&amp;#xa0;dollar.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Transactions and balances denominated in U.S. dollars are presented
at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance
with Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) No. 830, &amp;#x201c;Foreign Currency Matters&amp;#x201d;. All transaction gains
and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income
or expenses, as appropriate.&lt;/p&gt;</pypd:ConsolidatedFinancialStatementsPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Principles of consolidation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The consolidated
financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllIN9+ieYY6uE53J4wheBnfE++t8RQhzBXg=] CSR-->
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Reclassifications:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Certain prior years amounts
have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated
net loss.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;e.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Cash equivalents:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or
less, at the date acquired.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <pypd:RestrictedCashPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;f.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Restricted cash:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Restricted
cash is primarily invested in certificates of deposit and is used as security for the Company&amp;#x2019;s lease commitments and hedging
activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets
and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,924&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash, as reported on the balance sheets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;390&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;375&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash in other long-term assets, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,908&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,498&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</pypd:RestrictedCashPolicyTextBlock>
  <pypd:ShorttermDepositsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;g.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Short-term deposits:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify&quot;&gt;A Short-term bank deposit is a
deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging
from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value
due to their short maturities.&lt;/p&gt;</pypd:ShorttermDepositsPolicyTextBlock>
  <pypd:LongtermDepositsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;&lt;td style=&quot;width: 0.5in; text-align: left&quot;&gt;h.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Long-term deposits:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A Long-term bank deposit is
a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per
annum, as of December 31, 2020. Long-term deposits are presented at cost.&lt;/p&gt;</pypd:LongtermDepositsPolicyTextBlock>
  <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate unitRef="pure" contextRef="c39_AsOf31Dec2020_MinimumMember_ShortTermDepositsMember" decimals="3">0.004</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate unitRef="pure" contextRef="c40_AsOf31Dec2020_MaximumMember_ShortTermDepositsMember" decimals="4">0.0121</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;i.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Property and equipment, net:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets at the following rates:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Computers, software and laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;15&amp;#xa0;-&amp;#xa0;33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Furniture and office equipment&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Down payments for property and
equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the
corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate unitRef="pure" contextRef="c41_AsOf31Dec2020_MinimumMember_LongTermDepositsMember" decimals="3">0.011</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate unitRef="pure" contextRef="c42_AsOf31Dec2020_MaximumMember_LongTermDepositsMember" decimals="4">0.0125</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;j.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Impairment of long-lived assets:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company&amp;#x2019;s long-lived assets are reviewed for impairment
in accordance with ASC 360, &amp;#x201c;Property, Plant and Equipment&amp;#x201d;, whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset
exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;k.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Research and development expenses:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Research
and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting
fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory
approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&amp;#x2019;s intellectual property
rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities
related costs. The Company charges research and development expenses as expenses when incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;l.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Basic and diluted net loss (profit)
                                         per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company computes net loss (profit) per share using the two-class
method required for participating securities. The two-class method requires income available to ordinary shareholders for the period
to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as
if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating
securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders
of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require
the holders of such shares to participate in the Company&amp;#x2019;s losses. As such,&amp;#xa0;during the periods when the Company is in
a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under
the two-class method as these securities did not have a contractual obligation to share in the Company&amp;#x2019;s losses.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The
Company&amp;#x2019;s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary
shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of
potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially
dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature
of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the
effects of potentially dilutive shares of Ordinary shares are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;m.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Accounting for share-based payments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Share-based compensation expense related to share-based awards
is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite
service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value
of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company&amp;#x2019;s
Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine
the fair value of the share awards represent management&amp;#x2019;s best estimates. These estimates involve inherent uncertainties
and the application of management&amp;#x2019;s judgment. Forfeitures are accounted for as they occur instead of estimating the number
of awards expected to be forfeited.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <pypd:GrantsAndParticipationsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;n.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Grants and participations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Royalty-bearing
grants from the Israeli Innovation Authority (&amp;#x201c;IIA&amp;#x201d;) (previously known as Office of the Chief Scientist) of the Ministry
of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company
is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&amp;#x2019;s Seventh Framework Programme for
Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such
grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Since the
payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received
from IIA until the related revenues are recognized.&amp;#xa0;In the event of failure of a project that was partly financed by IIA,
the Company will not be obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company recognizes participations in research and development,
as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research
and development expenses incurred during the period is recognized as other income within operating income.&lt;/p&gt;</pypd:GrantsAndParticipationsPolicyTextBlock>
  <pypd:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;o.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Convertible preferred shares
                                         and convertible preferred shares warrant liability:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The terms
of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&amp;#xa0;shares allowed the holders to redeem shares, under
certain circumstances, outside of the Company&amp;#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance
sheet and not included as a component of shareholders&amp;#x2019; deficit before the IPO. The carrying value of the convertible preferred
shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the
convertible preferred shares will be redeemed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Warrants
to purchase the Company&amp;#x2019;s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair
value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the
Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance
sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.&lt;/p&gt;</pypd:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;p.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Fair value of financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
applies ASC 820, &amp;#x201c;Fair Value Measurements and Disclosures&amp;#x201d; (&amp;#x201c;ASC 820&amp;#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &amp;#x201c;exit price&amp;#x201d;) in an
orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In determining
fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Unobservable
inputs are inputs that reflect the Company&amp;#x2019;s assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available in the circumstances.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Fair value
is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A three-tier
fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical
                                         assets and liabilities.&lt;/td&gt;&lt;/tr&gt;                                                                          &lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         2 - Include other inputs that are directly or indirectly observable in the marketplace.&lt;/td&gt;&lt;/tr&gt;                                                                                                                                          &lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                         3 - Unobservable inputs which are supported by little or no market activity.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The fair value hierarchy also
requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value&lt;font style=&quot;font-size: 10pt&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The financial
instruments carried at fair value on the Company&amp;#x2019;s consolidated balance sheets as of December 31, 2019 are warrants to convertible
preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The following
methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The carrying
amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables,
trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such
instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;q.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Income taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
accounts for income taxes in accordance with ASC 740, &amp;#x201c;Income Taxes&amp;#x201d; (&amp;#x201c;ASC 740&amp;#x201d;). ASC 740 prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax
assets to their estimated realizable value, if needed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;ASC 740
contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that
it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including
resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized
tax benefits was recorded as a result of ASC 740.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The
Company&amp;#x2019;s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;r.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Concentration of credit risks:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Cash, cash
equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be
in excess of insured limits and are not insured.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;in other jurisdictions.
Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge
a portion of the Company&amp;#x2019;s non-dollar currency exposure. Counterparties to the Company&amp;#x2019;s derivative instruments are all major
financial institutions.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <pypd:SeverancePayPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;s.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Severance pay:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;All the Company&amp;#x2019;s employees
who are Israeli citizens have subscribed to Section&amp;#xa0;14 of Israel&amp;#x2019;s Severance Pay Law, 5723-1963
(&amp;#x201c;Section&amp;#xa0;14&amp;#x201d;). Pursuant to Section&amp;#xa0;14, employees covered by this section are entitled to monthly
deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with
Section&amp;#xa0;14 release the Company from any future severance liabilities in respect of those employees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Neither severance
pay liability nor severance pay fund under Section&amp;#xa0;14 for such employees is recorded on the Company&amp;#x2019;s consolidated balance
sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Severance
pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.&lt;/p&gt;</pypd:SeverancePayPolicyTextBlock>
  <pypd:DerivativeFinancialInstrumentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;t.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Derivative financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company accounts for derivatives and hedging based on ASC
815, &amp;#x201c;Derivatives and hedging&amp;#x201d;, as amended and related interpretations (&amp;#x201c;ASC 815&amp;#x201d;). ASC 815 requires the
Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is
so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against
the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions)
or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The ineffective portion of a derivative&amp;#x2019;s change in fair value
is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included
in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts
in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative
instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from
such instruments is recognized immediately as &amp;#x201c;financial income, net&amp;#x201d;.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company measured the fair value of the contracts in accordance
with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices
and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was
$62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December
31, 2019 and 2018 amounted to $10 and $0, respectively.&lt;/p&gt;</pypd:DerivativeFinancialInstrumentsPolicyTextBlock>
  <pypd:monthlyDepositsAtARate unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0833</pypd:monthlyDepositsAtARate>
  <us-gaap:SeveranceCosts1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">394000</us-gaap:SeveranceCosts1>
  <us-gaap:SeveranceCosts1 unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">346000</us-gaap:SeveranceCosts1>
  <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;u.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Contingent liabilities&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company accounts for its contingent liabilities in accordance
with ASC 450, &amp;#x201c;Contingencies&amp;#x201d;. A provision is recorded when it is both probable that a liability has been incurred and
the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect
the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining
to a particular matter.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company is occasionally
a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any
pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of
operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.&lt;/p&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
  <us-gaap:DerivativeFairValueOfDerivativeNet unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">62000</us-gaap:DerivativeFairValueOfDerivativeNet>
  <us-gaap:DerivativeFairValueOfDerivativeNet unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">8000</us-gaap:DerivativeFairValueOfDerivativeNet>
  <us-gaap:UnrealizedGainLossOnDerivatives unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">81000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">10000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">0</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;v.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Recently adopted Accounting Pronouncements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As an &amp;#x201c;emerging
growth company&amp;#x201d;, the Jumpstart Our Business Startups Act (&amp;#x201c;JOBS Act&amp;#x201d;) allows the Company to delay adoption of
new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private
companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below
reflect this election&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In June 2018, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;)
issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No.&amp;#xa0;2018-07, &amp;#x201c;Improvements to Nonemployee Share-Based Payment
Accounting,&amp;#x201d; which simplifies the accounting for share-based payments granted to nonemployees for goods and services and
aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.
The Company adopted the guidance as of January&amp;#xa0;1, 2020. The adoption of the standard didn&amp;#x2019;t have a material impact on the
Company&amp;#x2019;s consolidated statements of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <pypd:RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;w.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Recently Issued Accounting Pronouncements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In February 2016, the FASB issued
ASU No. 2016-02, &amp;#x201c;Leases,&amp;#x201d; which would require lessees to recognize assets and liabilities on the balance sheet for
most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner
similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance
states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for
the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1,
2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of
the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure
requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current
and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU
2016-02 will have on its consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In August 2017, the FASB issued
ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies
the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their
hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements,
expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure
requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January
1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its
Consolidated Statements of Operations or Cash Flows.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In August 2018, the FASB issued ASU No. 2018-15, &amp;#x201c;Intangibles-Goodwill
and Other-Internal-Use Software (Subtopic 350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract,&amp;#x201d; which aligns the requirements for capitalizing implementation costs incurred in
a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop
or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally
over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that
of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and
interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the
effect that ASU 2018-15 will have on its consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU No. 2019-12, &amp;#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201d; which simplifies the accounting for income taxes by removing
a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for
intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses
that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in
fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12
will have on its consolidated financial statements and related disclosures.&lt;/p&gt;</pypd:RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock>
  <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,319&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,924&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash, as reported on the balance sheets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;390&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;375&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Restricted cash in other long-term assets, as reported on the balance sheets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,908&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,498&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">390000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">375000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <pypd:RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">199000</pypd:RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent>
  <pypd:RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">199000</pypd:RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent>
  <pypd:CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">4908000</pypd:CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows>
  <pypd:CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">4498000</pypd:CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows>
  <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Computers, software and laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;15&amp;#xa0;-&amp;#xa0;33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Furniture and office equipment&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
  <pypd:PropertyPlantAndEquipmentPercent unitRef="pure" contextRef="c43_From1Jan2020To31Dec2020_MinimumMember_SoftwareAndSoftwareDevelopmentCostsMember" decimals="2">0.15</pypd:PropertyPlantAndEquipmentPercent>
  <pypd:PropertyPlantAndEquipmentPercent unitRef="pure" contextRef="c44_From1Jan2020To31Dec2020_MaximumMember_SoftwareAndSoftwareDevelopmentCostsMember" decimals="2">0.33</pypd:PropertyPlantAndEquipmentPercent>
  <pypd:PropertyPlantAndEquipmentPercent unitRef="pure" contextRef="c45_From1Jan2020To31Dec2020_FurnitureAndFixturesMember" decimals="2">0.15</pypd:PropertyPlantAndEquipmentPercent>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c46_From1Jan2020To31Dec2020_LeaseholdImprovementsMember">Over the shorter of the term of the lease or its useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <pypd:PrepaidExpensesAndOtherReceivablesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
3:-	PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Government authorities&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;177&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,888&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Lease deposits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Others&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;139&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,334&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;417&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</pypd:PrepaidExpensesAndOtherReceivablesTextBlock>
  <pypd:PrepaidExpensesAndOtherReceivablesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Government authorities&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;177&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,888&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Lease deposits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Others&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;139&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,334&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;417&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</pypd:PrepaidExpensesAndOtherReceivablesDisclosureTextBlock>
  <pypd:GovernmentAuthorities unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">283000</pypd:GovernmentAuthorities>
  <pypd:GovernmentAuthorities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">177000</pypd:GovernmentAuthorities>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1888000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">180000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <pypd:LeaseDeposits unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">24000</pypd:LeaseDeposits>
  <pypd:LeaseDeposits unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">18000</pypd:LeaseDeposits>
  <us-gaap:OtherAssets unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">139000</us-gaap:OtherAssets>
  <us-gaap:OtherAssets unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">42000</us-gaap:OtherAssets>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">2334000</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">417000</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
4:-	PROPERTY AND EQUIPMENT, NET&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;Cost:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Computers and software&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;449&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;389&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,356&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;152&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;147&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Leasehold improvements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,478&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,353&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9,026&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;8,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,136&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,124&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Depreciated cost&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,890&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6,121&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Depreciation expenses amounted to $1,012, $947 and $411 for
the years ended December&amp;#xa0;31, 2020, 2019 and 2018, respectively.&lt;/p&gt;&lt;br/&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;Cost:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Computers and software&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;449&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;389&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,356&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;152&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;147&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Leasehold improvements&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,478&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,353&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9,026&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;8,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,136&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,124&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Depreciated cost&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,890&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6,121&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c47_AsOf31Dec2020_ComputerEquipmentMember" decimals="-3">449000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c48_AsOf31Dec2019_ComputerEquipmentMember" decimals="-3">389000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c49_AsOf31Dec2020_LaboratoryEquipmentMember" decimals="-3">3947000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c50_AsOf31Dec2019_LaboratoryEquipmentMember" decimals="-3">3356000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c51_AsOf31Dec2020_FurnitureAndFixturesMember" decimals="-3">152000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c52_AsOf31Dec2019_FurnitureAndFixturesMember" decimals="-3">147000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c53_AsOf31Dec2020_LeaseholdImprovementsMember" decimals="-3">4478000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c54_AsOf31Dec2019_LeaseholdImprovementsMember" decimals="-3">4353000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">9026000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">8245000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">3136000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">2124000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
5:-	OTHER PAYABLES AND ACCRUED EXPENSES&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;971&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;673&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;681&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;319&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;IIA deferred grant &lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;241&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other expenses&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;6&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,903&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;998&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 0pt&quot;&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;971&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;673&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;681&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;319&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;IIA deferred grant &lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;241&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other expenses&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;6&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,903&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;998&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">971000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">673000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">681000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">319000</us-gaap:AccruedLiabilitiesCurrent>
  <pypd:IsraelInnovationAuthorityGrantReceived unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">241000</pypd:IsraelInnovationAuthorityGrantReceived>
  <pypd:IsraelInnovationAuthorityGrantReceived unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">10000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">6000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1903000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">998000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
6:-	COMMITMENTS AND CONTINGENT LIABILITIES&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;The Company&amp;#x2019;s facilities are
                                         leased under operating lease agreements for periods ending no later than 2027. The Company
                                         also leases motor vehicles under various operating leases, the latest of which expires
                                         in 2023.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Future minimum
lease payments under operating leases as of December&amp;#xa0;31, 2020 are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify&quot;&gt;As of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 87%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,236&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,181&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;995&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2024&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2025&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;Thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;425&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,403&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of December
31, 2020, the Company made advance payments on account of car leases in the amount of $75.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Rental and lease expenses for the years ended December&amp;#xa0;31,
2020, 2019 and 2018 were $1,035, $&amp;#xa0;1,027 and $1,073, respectively.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;In connection with its research
                                         and development programs, through December 31, 2020, the Company received participation
                                         payments from the IIA in the aggregate amount of $5,139. In return for IIA&amp;#x2019;s participation,
                                         the Company is committed to pay royalties at a rate of 3% of sales of the developed products,
                                         up to 100% of the amount of grants received plus interest at LIBOR rate. Through December
                                         31, 2020, no royalties have been paid or accrued.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;On December 22, 2016, the Company received a written demand for a finder&amp;#x2019;s fee in an
                                                              amount of $250, in connection with the second financing round that occurred in 2016. In September 2017, a suit was filed
                                                              against the Company in the Tel-Aviv Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court
                                                              ruling, which ruled in favor of the Company, discharging the entire claim, and accordingly reversed the related
                                                              provision.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;On January 9, 2020, the Company
                                         entered into an agreement for an automatic filling machine for the Company&amp;#x2019;s manufacturing
                                         plant in a total amount of EUR 1,326. The Company paid a pre-payment of EUR 372 and will
                                         pay the remaining of the payments during 2021 according to the milestones of the agreement.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">75000</us-gaap:OperatingLeasePayments>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1035000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">1027000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1073000</us-gaap:LeaseAndRentalExpense>
  <pypd:ProceedsFromParticipationPayments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">5139000</pypd:ProceedsFromParticipationPayments>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c0_From1Jan2020To31Dec2020">the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2020, no royalties have been paid or accrued.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
  <pypd:FindersFee unitRef="usd" contextRef="c55_From17Dec2016To22Dec2016" decimals="-3">250000</pypd:FindersFee>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c56_From25Sep2017To30Sep2017">In September 2017, a suit was filed against the Company in the Tel-Aviv Magistrates Court in an amount of $250.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
  <pypd:PaymentsToAutomaticFilingMachine unitRef="eur" contextRef="c57_From5Jan2020To9Jan2020" decimals="-3">250000</pypd:PaymentsToAutomaticFilingMachine>
  <pypd:PrepaymentForAutomaticFilingMachine unitRef="eur" contextRef="c57_From5Jan2020To9Jan2020" decimals="-3">372000</pypd:PrepaymentForAutomaticFilingMachine>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify&quot;&gt;As of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 87%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,236&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,181&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;995&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2024&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2025&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;Thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;425&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,403&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1236000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1181000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">995000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">283000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">283000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">425000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">4403000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
7:-	FAIR VALUE MEASUREMENTS&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Financial instruments measured at fair value on a recurring
basis include warrants to convertible preferred shares (see Note 9). The warrants are classified as a liability in accordance with
ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation
(the share price) were determined based on management&amp;#x2019;s assumptions. To calculate the fair value of the warrants, the Company first
calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing
two scenarios of option pricing model and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes
model was utilized to calculate the warrants&amp;#x2019; value in each one of the scenarios. 50% probability for each one of the scenarios
was applied to derive the weighted average fair value of the warrants.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of December 31, 2019:&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the liquidation scenario the underlying share price
was between $13.25 - $13.40 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 69.11%, risk
free interest rates of 1.82%, dividend yield of 0%, and expected term of 2.25 years. Under the IPO scenario the underlying share
price was $12.18 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value of the series
E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series E-1 Preferred
share warrants as of December 31, 2019 was $563.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the liquidation scenario, the underlying share
price was $10.29 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&amp;#xa0;D-2
Preferred share warrants as of December&amp;#xa0;31, 2019 (exercise price of $9.24): expected volatility of 69.11%, risk free interest
rates of 1.82%, dividend yield of 0% and expected term of 2.25&amp;#xa0;years. Under the IPO scenario, the underlying share price was
$12.18 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&amp;#xa0;D-2
Preferred share warrants as of December&amp;#xa0;31, 2019 (exercise price of $9.24): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42&amp;#xa0;years. Accordingly, the fair value of the series&amp;#xa0;D-2
Preferred share warrants as of December&amp;#xa0;31, 2019 was $11,275.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the liquidation scenario, the underlying share
price was $4.35 for the Convertible Preferred A shares. The following assumptions were used to estimate the value of the series&amp;#xa0;A
Preferred share warrants as of December&amp;#xa0;31, 2019 (exercise price of NIS&amp;#xa0;0.84 ($0.24)): expected volatility of 69.11%,
risk free interest rates of 1.82%, dividend yield of 0% and expected term of 2.25&amp;#xa0;years. Under the IPO scenario, the underlying
share price was $12.18 for the Convertible Preferred&amp;#xa0;A shares. The following assumptions were used to estimate the value of
the series&amp;#xa0;A Preferred share warrants as of December&amp;#xa0;31, 2019 (exercise price of NIS&amp;#xa0;0.84 ($0.24)): expected volatility
of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42&amp;#xa0;years. Accordingly, the fair
value of the series&amp;#xa0;A Preferred share warrants as of December&amp;#xa0;31, 2019 was $403.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of June 30, 2020:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the IPO scenario,
the underlying share price was $16 for the series E-1 Preferred shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of June 30, 2020: exercise price of $15.95, expected volatility of 78.07%, risk
free interest rates of 0.76%, dividend yield of 0%, and expected term of 4.17 years. Accordingly, the fair value of the series
E-1 Preferred share warrants as of June 30, 2020 was $1,868.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the IPO scenario, the underlying share price was
$16 for the series D-2 Preferred shares. The following assumptions were used to estimate the value of the series D-2 Preferred
share warrants as of June 30, 2020: exercise price of $9.24, expected volatility of 82.48%, risk free interest rates of 0.46%,
dividend yield of 0%, and expected term of 0.6 years. Accordingly, the fair value of the series D-2 Preferred share warrants as
of June 30, 2020 was $20,930. As of June 30, 2020, as part of the IPO 1,123,570 Warrants have been exercised on cashless basis
into 475,049 Ordinary shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;According to the IPO scenario, the underlying share price was
$16 for the series A Preferred shares. The following assumptions were used to estimate the value of the series A Preferred share
warrants as of June 30, 2020: exercise price of 0.84 NIS ($0.23) and dividend yield of 0%. Accordingly, the fair value of the series
A Preferred share warrants as of June 30, 2020 was $816. As of June 30, 2020, as part of the IPO, 53,775 Warrants have been exercised
into 53,775 Ordinary shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;On June 30, 2020, as a
result of the IPO, the warrant liability to Convertible Preferred shares has been classified to Warrants to Ordinary shares
in equity.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The change in
the fair value of the Preferred share warrant liability is summarized below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,241&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,926&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;680&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;11,373&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,365&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Reclassification of Warrants into equity&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(23,614&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;End of period&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;12,241&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <pypd:WeightedAverageFairValueOfWarrantsPercenatge unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.50</pypd:WeightedAverageFairValueOfWarrantsPercenatge>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c58_AsOf31Dec2019_MinimumMember_ConvertiblePreferredStockMember" decimals="2">13.25</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c59_AsOf31Dec2019_MaximumMember_ConvertiblePreferredStockMember" decimals="2">13.40</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c60_AsOf31Dec2019_ConvertiblePreferredStockMember" decimals="2">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember" decimals="4">0.6911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember" decimals="4">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c62_AsOf31Dec2019_ConvertiblePreferredE1SharesMember_IPOMember" decimals="2">12.18</us-gaap:SharePrice>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c62_AsOf31Dec2019_ConvertiblePreferredE1SharesMember_IPOMember" decimals="2">15.95</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c63_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember_IPOMember" decimals="4">0.6403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c63_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember_IPOMember" decimals="4">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c63_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember_IPOMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c63_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember_IPOMember">P153D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c61_From1Jan2019To31Dec2019_SeriesE1PreferredShareWarrantsMember" decimals="-3">563000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c64_AsOf31Dec2019_ConvertiblePreferredD2SharesMember" decimals="2">10.29</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c64_AsOf31Dec2019_ConvertiblePreferredD2SharesMember" decimals="2">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember" decimals="4">0.6911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember" decimals="4">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c66_AsOf31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember" decimals="2">12.18</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c66_AsOf31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember" decimals="2">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c67_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember" decimals="4">0.6403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c67_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember" decimals="4">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c67_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c67_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember_IPOMember">P153D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c65_From1Jan2019To31Dec2019_ConvertiblePreferredD2SharesMember" decimals="-3">11275000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c68_AsOf31Dec2019_ConvertiblePreferredASharesMember" decimals="2">4.35</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember" decimals="4">0.6911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember" decimals="4">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c70_AsOf31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">12.18</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c71_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="4">0.6403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c71_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="4">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c71_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c71_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember">P153D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c69_From1Jan2019To31Dec2019_SeriesAPreferredShareWarrantsMember" decimals="-3">403000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c72_AsOf30Jun2020_ConvertiblePreferredD2SharesMember" decimals="0">16</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c72_AsOf30Jun2020_ConvertiblePreferredD2SharesMember" decimals="2">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember" decimals="4">0.7807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember" decimals="4">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember">P4Y62D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c74_From1Jun2020To30Jun2020_SeriesE1PreferredShareWarrantsMember" decimals="-3">1868000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c75_AsOf30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember" decimals="0">16</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c75_AsOf30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember" decimals="2">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c76_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember" decimals="4">0.8248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c76_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember" decimals="4">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c76_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c76_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember_IPOMember">P219D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember" decimals="-3">20930000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <pypd:CashlessOrdinaryShares unitRef="shares" contextRef="c73_From1Jun2020To30Jun2020_ConvertiblePreferredD2SharesMember" decimals="INF">475049</pypd:CashlessOrdinaryShares>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c77_AsOf30Jun2020_ConvertiblePreferredASharesMember_IPOMember" decimals="0">16</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="ilsPershares" contextRef="c78_AsOf30Jun2020_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c79_From1Jun2020To30Jun2020_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <pypd:FairValueOfSeriesAPreferredShareWarrants unitRef="usd" contextRef="c80_AsOf30Jun2020" decimals="-3">816000</pypd:FairValueOfSeriesAPreferredShareWarrants>
  <pypd:WarrantsExercisedShares unitRef="shares" contextRef="c81_From1Jun2020To30Jun2020_SeriesAPreferredShareWarrantsMember" decimals="INF">53775</pypd:WarrantsExercisedShares>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c82_AsOf30Jun2020_IPOMember" decimals="INF">53775</us-gaap:SharesIssued>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c83_AsOf31Dec2019_SeriesAPreferredShareWarrantsMember" decimals="2">0.24</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c70_AsOf31Dec2019_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">0.24</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c78_AsOf30Jun2020_SeriesAPreferredShareWarrantsMember_IPOMember" decimals="2">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,241&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,926&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;680&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;11,373&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,365&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Reclassification of Warrants into equity&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(23,614&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;End of period&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;12,241&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <pypd:FairValueofPreferredShareWarrantLiability unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">12241000</pypd:FairValueofPreferredShareWarrantLiability>
  <pypd:FairValueofPreferredShareWarrantLiability unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="-3">22926000</pypd:FairValueofPreferredShareWarrantLiability>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:FairValueAdjustmentOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">680000</us-gaap:FairValueAdjustmentOfWarrants>
  <pypd:ChangeInFairValues unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">11373000</pypd:ChangeInFairValues>
  <pypd:ChangeInFairValues unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-11365000</pypd:ChangeInFairValues>
  <pypd:ReclassificationsOfWarrantsIntoEquity unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">23614000</pypd:ReclassificationsOfWarrantsIntoEquity>
  <pypd:ReclassificationsOfWarrantsIntoEquity unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:FairValueofPreferredShareWarrantLiability unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
8:-	INCOME TAXES&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Corporate tax rates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify&quot;&gt;The corporate tax rate in Israel
in 2020, 2019 and 2018 was 23%.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Net operating losses carryforward:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
has accumulated losses for tax purposes as of December 31, 2020 in the amount of approximately $96,385 which may be carried forward
and offset against taxable income in the future for an indefinite period.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Deferred taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for
income tax purposes. The Company&amp;#x2019;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Significant
components of the Company&amp;#x2019;s deferred tax assets are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Reserves and allowances&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;190&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;173&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,644&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,204&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Issuance costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;957&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Loss carryforward&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,168&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15,406&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;26,959&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,783&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Less - valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(26,959&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(17,783&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable
income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable
future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In 2019 and 2018, the main reconciling item of the Company&amp;#x2019;s
statutory tax rate of 23% and the effective tax rate of 0% is tax loss carryforwards, for which a full valuation allowance was
provided.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Tax assessment:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
has net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2020,
the Company&amp;#x2019;s tax years until December 31, 2015 are subject to the statute of limitation in Israel.&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">96385000</us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">0.23</us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Reserves and allowances&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;190&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;173&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,644&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,204&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Issuance costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;957&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Loss carryforward&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,168&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15,406&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;26,959&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,783&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Less - valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(26,959&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(17,783&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c84_AsOf31Dec2020_ReservesAndAllowancesMember" decimals="-3">190000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c85_AsOf31Dec2019_ReservesAndAllowancesMember" decimals="-3">173000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c86_AsOf31Dec2020_TemporaryDifferencesMember" decimals="-3">3644000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c87_AsOf31Dec2019_TemporaryDifferencesMember" decimals="-3">2204000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c88_AsOf31Dec2020_IssaunceCostsMember" decimals="-3">957000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c89_AsOf31Dec2019_IssaunceCostsMember" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c90_AsOf31Dec2020_LossCarryforwardMember" decimals="-3">22168000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c91_AsOf31Dec2019_LossCarryforwardMember" decimals="-3">15406000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">26959000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">17783000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">26959000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">17783000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <pypd:ConvertiblePreferredSharesAndWarrantsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
9:-	CONVERTIBLE PREFERRED SHARES AND WARRANTS&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;The Composition of the Company&amp;#x2019;s
                                         Convertible Preferred shares is as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;A Convertible Preferred shares with no par value&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;537,750&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;483,975&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;A-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;896,250&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;798,950&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;B Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;597,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;566,386&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;B-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,867,562&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,751,309&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;C-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;717,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;645,923&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;C-2 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;454,100&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;410,197&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-1 Convertible Preferred shares of NIS&amp;#xa0;0 par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,509,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,376,512&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-2 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,868,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-3 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;597,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;576,944&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;E Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,135,250&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;851,795&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;E-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,736,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,058,986&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;17,916,412&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;12,520,977&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company issued Series A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Preferred shares between February 2008 and September 2019. The Company classifies the convertible preferred shares outside
of shareholders&amp;#x2019; deficit as required by&amp;#xa0;ASC&amp;#xa0;480-10-S99-3A and ASR 268, since these preferred shares are entitled
to liquidation preferences which may trigger a distribution of cash or assets that is not solely within the Company&amp;#x2019;s control.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Upon completion of the IPO, all convertible preferred shares
outstanding, totaling 12,520,977 shares, were automatically converted into Ordinary shares and their carrying value of $106,300
was reclassified into shareholders&amp;#x2019; equity.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Preferred shares rights:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Up to completion of the IPO on June 30, 2020, series A, A-1,
B, B-1, C-1,C-2, D-1,D-3, E and E-1 convertible preferred shares conferred upon their holders all the rights conferred by Ordinary
shares, in addition to certain rights stipulated in the Company&amp;#x2019;s previous Articles of Association (the &amp;#x201c;Previous Articles&amp;#x201d;),
inter alia, the following:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;&lt;i&gt;Dividend
rights - &lt;/i&gt;the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E
and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration
or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend
or distribution was declared by the Company&amp;#x2019;s board of directors, an amount equal to 6% per annum of the applicable original issue
price for such preferred shares (the &amp;#x201c;Preference Dividend&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The preference order was such that Series E-1, E, D, C-2, C-1,
B-1, B, A-1 and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above order,
any distribution of any asset, capital, earnings or surplus funds of the Company. After the Preference Dividend has been paid in
full, the preferred shareholders&amp;#x2019; were entitled to participate pro-rata and pari-passu, on an as converted basis with the Ordinary
shareholders&amp;#x2019; in the receipt of any additional dividend distributed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;&lt;i&gt;Liquidation
rights -&lt;/i&gt; In the event of any event of liquidation or deemed liquidation
event, the Company was required to distribute to the holders of convertible preferred shares, prior to and in preference to any
payments to any of the holders of any other classes of shares, a per share amount equal to the original issuance price plus 6%
annual interest compounded annually from the date of issuance and up to the date of liquidation for each of their shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Holders of Series E-1, E preferred shares and D preferred shares
were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original
issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount
equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The liquidation order was such that Series E-1, E, D, C-2 and
C-1, B-1, B A-1, and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above
order any distribution of any asset, capital, earnings or surplus funds of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;All remaining assets shall be distributed among all the shareholders
pro rata in proportion to the number of Ordinary shares held by them on an as converted basis. The original issue price of the
Series&amp;#xa0;A, A-1, B, B-1 and C-1 Convertible Preferred shares was $1.51, $1.76, $3.60, $5.06, and $6.95 per share, respectively,
Series C-2, D-1 and D-3 was $9.23 per share and Series E and E-1 was $13.30 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;&lt;i&gt;Voting
rights&lt;/i&gt; - each holder of Series&amp;#xa0;A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Convertible Preferred share was entitled to one&amp;#xa0;vote per each share held by it (on an as converted basis).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;&lt;i&gt;Conversion
&lt;/i&gt;- each preferred share was convertible into Ordinary shares, at
the holder&amp;#x2019;s option, or automatically upon a qualified initial public offering (&amp;#x201c;Qualified IPO&amp;#x201d;) of the Company or upon
written demand of the Investor Majority (as defined in the Previous Articles).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Each share of Series A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 was convertible into Ordinary shares
on a 1-for-1 ratio. The conversion price per preferred share was to be adjusted in the event of recapitalizations, splits, Ordinary
share dividends and standard anti-dilution events.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Financing rounds:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;During August 2018 through
February 2019, the Company entered into a Securities Purchase Agreement (the &amp;#x201c;2018 SPA&amp;#x201d;) with new and existing investors
for an aggregate amount of up to $35,000. The Company received $15,577 and issued to the investors 1,187,887 series E-1 Preferred
shares (net of $187 issuance costs in cash in 2018) at a price per share of $13.30. As part of the 2018 SPA, the Company converted
274,434 series E Preferred shares into series E-1 Preferred shares to holders of series E Preferred shares who participated in
the 2018 SPA pursuant to the conversion rights of the 2018 SPA.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;During June 2019, the Company prepared a Private Placement Memorandum
(the &amp;#x201c;2019 PPM&amp;#x201d;) which includes the 2018 SPA and allowed the Company to raise up to $50,000 from new and existing shareholders.
From June to August 2019, the Company received $30,717 and issued to the investors 2,596,665 series E-1 Preferred shares, net of
$3,142 issuance costs in cash and warrants in amount $680 at a price of $13.30.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Warrants to purchase Preferred
                                         shares:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In March 2008, in connection with a March 2008 Founders and
Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the &amp;#x201c;A warrants&amp;#x201d;),
with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of
an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at
least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and
(3) the sale of substantially all of the Company&amp;#x2019;s assets or substantially all of the shares to another party.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In connection with the first financing round that occurred in
2016, the Company granted to certain investors warrants to purchase up to 2,775,398 D-2 Preferred shares (&amp;#x201c;D-2 warrants&amp;#x201d;)
at a price per share of $9.23.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The survival of D-2 warrants is limited to a period ending upon
the earlier of: (i) the lapse of 5 years from closing; or (ii) a deemed liquidation event.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The D-2 warrants will be exercised
automatically if they are still outstanding on the final day of the warrant period as defined in the warrants grant letter,
and if the fair market value of a warrant share is more than the exercise price for such share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;All outstanding A warrants and D-2 warrants are classified
as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which
is not solely in the control of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;On June 28, 2019, in connection with 2019 PPM, the Company included
the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the &amp;#x201c;E-1 warrants&amp;#x201d;)
at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new
investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years
from closing.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of December 31, 2020, 200,596 E-1 warrants, 648,519 D-2 warrants
and 17,925 Warrants are outstanding and may be converted into Ordinary shares.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;e.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Deemed dividend:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As part of Series E-1 Convertible Preferred shares price protection
conversion rights upon the completion of an initial public offering, the Company issued 158,967 Series E-1 Convertible Preferred
shares and recorded a beneficial feature of $2,114 which was accounted for as a deemed dividend and was recorded as mezzanine equity.&lt;/p&gt;&lt;br/&gt;</pypd:ConvertiblePreferredSharesAndWarrantsTextBlock>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">12520977</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">106300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <pypd:AnnualInterestPercentage unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="2">0.06</pypd:AnnualInterestPercentage>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c92_AsOf31Dec2020_SeriesAConvertiblePreferredMember" decimals="2">1.51</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c93_AsOf31Dec2020_SeriesA1ConvertiblePreferredSharesMember" decimals="2">1.76</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c94_AsOf31Dec2020_SeriesBConvertiblePreferredMember" decimals="2">3.60</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c95_AsOf31Dec2020_SeriesB1ConvertiblePreferredSharesMember" decimals="2">5.06</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c96_AsOf31Dec2020_SeriesC1ConvertiblePreferredSharesMember" decimals="2">6.95</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c97_AsOf31Dec2020_SeriesC2ConvertiblePreferredSharesMember" decimals="2">9.23</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c98_AsOf31Dec2020_SeriesEConvertiblePreferredMember" decimals="2">13.30</us-gaap:SharePrice>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c99_AsOf28Feb2019_SecuritiesPurchaseAgreementMember" decimals="-3">35000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:ProceedsFromIssuanceOfDebt unitRef="usd" contextRef="c100_From1Aug2018To28Feb2019_SecuritiesPurchaseAgreementMember" decimals="-3">15577000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c101_AsOf28Feb2019_SeriesE1ConvertiblePreferredSharesMember" decimals="INF">1187887</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromIssuanceOfDebt unitRef="usd" contextRef="c102_From1Aug2018To28Feb2019_SeriesE1ConvertiblePreferredSharesMember" decimals="-3">187000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c101_AsOf28Feb2019_SeriesE1ConvertiblePreferredSharesMember" decimals="2">13.30</us-gaap:SharePrice>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c103_From1Jan2018To31Dec2018_SecuritiesPurchaseAgreementMember" decimals="INF">274434</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ProceedsFromIssuanceOfDebt unitRef="usd" contextRef="c104_From1Jun2019To30Jun2019_PrivatePlacementMemorandumMember" decimals="-3">50000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt unitRef="usd" contextRef="c105_From1Jun2019To31Aug2019_PrivatePlacementMemorandumMember" decimals="-3">30717000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c106_AsOf31Aug2019_SeriesE1ConvertiblePreferredSharesMember_PrivatePlacementMemorandumMember" decimals="INF">2596665</us-gaap:SharesIssued>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c104_From1Jun2019To30Jun2019_PrivatePlacementMemorandumMember" decimals="-3">3142000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c104_From1Jun2019To30Jun2019_PrivatePlacementMemorandumMember" decimals="-3">680000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c107_AsOf30Jun2019_PrivatePlacementMemorandumMember" decimals="2">13.30</us-gaap:SharePrice>
  <pypd:WarrantsPurchaseDescription contextRef="c108_From1Mar2008To31Mar2008_WarrantMember">in connection with a March 2008 Founders and Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the &amp;#x201c;A warrants&amp;#x201d;), with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and (3) the sale of substantially all of the Company&amp;#x2019;s assets or substantially all of the shares to another party.</pypd:WarrantsPurchaseDescription>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c109_AsOf31Dec2016_SeriesD2ConvertiblePreferredSharesMember_WarrantMember" decimals="INF">2775398</us-gaap:SharesIssued>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c109_AsOf31Dec2016_SeriesD2ConvertiblePreferredSharesMember_WarrantMember" decimals="2">9.23</us-gaap:SharePrice>
  <pypd:WarrantsPurchaseDescription contextRef="c110_From1Jun2019To28Jun2019_SeriesD2ConvertiblePreferredSharesMember_WarrantMember">in connection with 2019 PPM, the Company included the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the &amp;#x201c;E-1 warrants&amp;#x201d;) at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years from closing.</pypd:WarrantsPurchaseDescription>
  <pypd:WarrantsIssued unitRef="shares" contextRef="c111_AsOf31Dec2020_SeriesE1ConvertiblePreferredSharesMember_WarrantMember" decimals="INF">200596</pypd:WarrantsIssued>
  <pypd:WarrantsIssued unitRef="shares" contextRef="c112_AsOf31Dec2020_SeriesD2ConvertiblePreferredSharesMember_WarrantMember" decimals="INF">648519</pypd:WarrantsIssued>
  <pypd:WarrantsIssued unitRef="shares" contextRef="c113_AsOf31Dec2020_SeriesAConvertiblePreferredMember_WarrantMember" decimals="INF">17925</pypd:WarrantsIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c114_AsOf31Dec2020_SeriesE1ConvertiblePreferredSharesMember" decimals="INF">158967</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c115_From1Jan2020To31Dec2020_SeriesE1ConvertiblePreferredSharesMember" decimals="-3">2114000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <pypd:DividendRightsDescription contextRef="c0_From1Jan2020To31Dec2020">the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend or distribution was declared by the Company&amp;#x2019;s board of directors, an amount equal to 6% per annum of the applicable original issue price for such preferred shares (the &amp;#x201c;Preference Dividend&amp;#x201d;).</pypd:DividendRightsDescription>
  <pypd:LiquudationRightsDescription contextRef="c0_From1Jan2020To31Dec2020">Holders of Series E-1, E preferred shares and D preferred shares were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.</pypd:LiquudationRightsDescription>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;A Convertible Preferred shares with no par value&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;537,750&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;483,975&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;A-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;896,250&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;798,950&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;B Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;597,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;566,386&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;B-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,867,562&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,751,309&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;C-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;717,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;645,923&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;C-2 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;454,100&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;410,197&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-1 Convertible Preferred shares of NIS&amp;#xa0;0 par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,509,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,376,512&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-2 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,868,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;D-3 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;597,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;576,944&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;E Convertible Preferred shares with no par value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,135,250&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;851,795&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Series&amp;#xa0;E-1 Convertible Preferred shares with no par value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,736,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,058,986&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;17,916,412&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;12,520,977&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c116_AsOf31Dec2020_SeriesAConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c116_AsOf31Dec2020_SeriesAConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c117_AsOf31Dec2019_SeriesAConvertiblePreferredSharesMember" decimals="INF">537750</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c117_AsOf31Dec2019_SeriesAConvertiblePreferredSharesMember" decimals="INF">483975</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c93_AsOf31Dec2020_SeriesA1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c93_AsOf31Dec2020_SeriesA1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c118_AsOf31Dec2019_SeriesA1ConvertiblePreferredSharesMember" decimals="INF">896250</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c118_AsOf31Dec2019_SeriesA1ConvertiblePreferredSharesMember" decimals="INF">798950</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c119_AsOf31Dec2020_SeriesBConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c119_AsOf31Dec2020_SeriesBConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c120_AsOf31Dec2019_SeriesBConvertiblePreferredSharesMember" decimals="INF">597500</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c120_AsOf31Dec2019_SeriesBConvertiblePreferredSharesMember" decimals="INF">566386</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c95_AsOf31Dec2020_SeriesB1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c95_AsOf31Dec2020_SeriesB1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c121_AsOf31Dec2019_SeriesB1ConvertiblePreferredSharesMember" decimals="INF">1867562</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c121_AsOf31Dec2019_SeriesB1ConvertiblePreferredSharesMember" decimals="INF">1751309</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c96_AsOf31Dec2020_SeriesC1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c96_AsOf31Dec2020_SeriesC1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c122_AsOf31Dec2019_SeriesC1ConvertiblePreferredSharesMember" decimals="INF">717000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c122_AsOf31Dec2019_SeriesC1ConvertiblePreferredSharesMember" decimals="INF">645923</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c97_AsOf31Dec2020_SeriesC2ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c97_AsOf31Dec2020_SeriesC2ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c123_AsOf31Dec2019_SeriesC2ConvertiblePreferredSharesMember" decimals="INF">454100</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c123_AsOf31Dec2019_SeriesC2ConvertiblePreferredSharesMember" decimals="INF">410197</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c124_AsOf31Dec2020_SeriesD1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c124_AsOf31Dec2020_SeriesD1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c125_AsOf31Dec2019_SeriesD1ConvertiblePreferredSharesMember" decimals="INF">2509500</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c125_AsOf31Dec2019_SeriesD1ConvertiblePreferredSharesMember" decimals="INF">2376512</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c126_AsOf31Dec2020_SeriesD2ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c126_AsOf31Dec2020_SeriesD2ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c127_AsOf31Dec2019_SeriesD2ConvertiblePreferredSharesMember" decimals="INF">2868000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c127_AsOf31Dec2019_SeriesD2ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c128_AsOf31Dec2020_SeriesD3ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c128_AsOf31Dec2020_SeriesD3ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c129_AsOf31Dec2019_SeriesD3ConvertiblePreferredSharesMember" decimals="INF">597500</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c129_AsOf31Dec2019_SeriesD3ConvertiblePreferredSharesMember" decimals="INF">576944</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c130_AsOf31Dec2020_SeriesEConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c130_AsOf31Dec2020_SeriesEConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c131_AsOf31Dec2019_SeriesEConvertiblePreferredSharesMember" decimals="INF">1135250</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c131_AsOf31Dec2019_SeriesEConvertiblePreferredSharesMember" decimals="INF">851795</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c114_AsOf31Dec2020_SeriesE1ConvertiblePreferredSharesMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c132_AsOf31Dec2019_SeriesE1ConvertiblePreferredSharesMember" decimals="INF">5736000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c132_AsOf31Dec2019_SeriesE1ConvertiblePreferredSharesMember" decimals="INF">4058986</us-gaap:PreferredStockSharesIssued>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
10:-	SHAREHOLDERS&amp;#x2019; EQUITY (DEFICIT)&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;a.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;General:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;On June 21, 2020, the Company&amp;#x2019;s Board of Directors resolved
to consolidate the Company&amp;#x2019;s share capital by applying an additional reverse share split and cancelling the shares&amp;#x2019;
par value (See Note 1d).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Following
the reverse share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible
loans, warrants, exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated
financial statements.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;b.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Ordinary share capital is composed
                                         as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;background-color: White; width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Ordinary shares with no par value&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;47,800,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;18,494,739&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;22,466,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;562,748&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;c.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Ordinary shares rights:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Ordinary shares confer upon their holders the right to participate
in the general meetings of the Company, to vote at such meetings (each share represents one vote), and to participate in any distribution
of dividends or any other distribution of the Company&amp;#x2019;s property, including the distribution of surplus assets upon liquidation.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;d.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Share option plans:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Company
has authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other
key employees of up to 3,672,094 Ordinary shares. The options granted generally have a three-year vesting period and expire ten
years after the date of grant. Options granted under the Company&amp;#x2019;s option plan that are cancelled or forfeited before expiration
become available for future grant. As of December 31, 2020, 1,019,457 of the Company&amp;#x2019;s options were available for future grants.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;A summary
of the status of options to employees under the Company&amp;#x2019;s option plan as of December&amp;#xa0;31, 2020 and 2019 and changes during
the relevant period ended on that date is presented below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&amp;#xa0;&lt;br/&gt; average&amp;#xa0;&lt;br/&gt; remaining&amp;#xa0;&lt;br/&gt; contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,411&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,064,959&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.08&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(395&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(89,157&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;5.99&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercisable options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,306,421&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.78&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6,686&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&amp;#xa0;&lt;br/&gt; average&amp;#xa0;&lt;br/&gt; remaining&amp;#xa0;&lt;br/&gt; contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,234,955&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.59&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,608&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.96&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;82,216&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.04&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1,523&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.54&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(97,663&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;6.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,411&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercisable options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,108,207&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.29&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.66&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The Black-Scholes
assumptions used to value the employee options at the grant dates are as follows:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The fair value for options granted to employees during 2020
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 74.35%-84.77%, risk free interest rates of 0.23%-1.38%, dividend yield of 0%, and an expected term of 5-6 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The fair value for options granted to employees during 2019
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 69.8%-76.14%, risk free interest rates of 2.26%-3.13%, dividend yield of 0%, and an expected term of 6-7 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The fair value for options granted to employees during 2018
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 91.44%-96.87%, risk free interest rates of 3.43%-3.90%, dividend yield of 0%, and an expected term of 6-7 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;These
assumptions and estimates were determined as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;o&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Fair
                                         Value of Ordinary Shares- Prior to the IPO, the fair value was determined by the Company&amp;#x2019;s
                                         board of directors, with input from management and valuation reports prepared by third-party
                                         valuation specialists. After the IPO, the fair value of each Ordinary share was based
                                         on the closing price of the Company&amp;#x2019;s publicly traded Ordinary shares as reported
                                         on the date of the grant.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;o&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Risk-Free&amp;#xa0;Interest
                                         Rate- The risk-free rate for the expected term of the options is based on the Black-Scholes
                                         option pricing model on the yields of U.S. Treasury securities with maturities appropriate
                                         for the expected term of employee share option awards.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;o&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Expected
                                         Term- The expected term represents the period that options are expected to be outstanding.
                                         For option grants that are considered to be &amp;#x201c;plain vanilla,&amp;#x201d; the Company
                                         determines the expected term using the simplified method. The simplified method deems
                                         the term to be the average of the time-to-vesting and the contractual life of the options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;o&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Expected
                                         Volatility- As the Company has a short trading history for its Ordinary shares, the expected
                                         volatility is derived from the average historical share volatilities of several unrelated
                                         public companies within the Company&amp;#x2019;s industry that the Company considers to be
                                         comparable to its own business over a period equivalent to the option&amp;#x2019;s expected
                                         term.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 5%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;o&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Expected
                                         Dividend Yield- The Company has never declared or paid any cash dividends and does not
                                         presently plan to pay cash dividends in the foreseeable future. As a result, an expected
                                         dividend yield of zero percent was used.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The total
equity-based compensation expense related to all of the Company&amp;#x2019;s equity-based awards recognized for the three years ended December&amp;#xa0;31,
2020, 2019 and 2018, was comprised as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,806&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;180&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;239&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Marketing and business development&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;140&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,631&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;706&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;739&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,577&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;976&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;995&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;As of December
31, 2020, there were unrecognized compensation costs of $10,071, which are expected to be recognized over a weighted average period
of approximately 2.7 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The options
outstanding as of December&amp;#xa0;31, 2020 are comprised, as&amp;#xa0;follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Exercise &lt;br/&gt;
price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options&lt;br/&gt;
 outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted average exercise price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;contractual term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options exercisable as&amp;#xa0;of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted average exercise price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;contractual term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;249,561&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;249,561&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;107,904&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;107,904&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;83,503&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;83,503&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;200,229&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;200,229&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;29,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;29,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;51,385&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.98&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;51,385&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.98&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.19&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.19&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;66,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.84&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;66,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.84&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,589&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.78&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,461&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.77&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15,035&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;10,940&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.53&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;46,069&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.30&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,004&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;58,731&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.11&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,858&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.11&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;904,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;168,898&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.44&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;90,100&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,306,421&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.78&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;*)&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;The exercise price of the options is denominated in NIS and
was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.5in&quot;&gt;e.&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Options issued to non-employees:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Outstanding
options granted to consultants as of December&amp;#xa0;31, 2020 were as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid&quot;&gt;Grant date&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options &lt;br/&gt;
outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Average &lt;br/&gt;
Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Exercisable &lt;br/&gt;
through&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 54%; text-indent: -12pt; padding-left: 12pt&quot;&gt;March 2013&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,258&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.76&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,258&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; width: 9%; padding-left: 5.6pt&quot;&gt;March 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;October 2013&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;October&amp;#xa0;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2014&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;June 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;September 2014&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;September&amp;#xa0;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;April 2016&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,975&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,975&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;April 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;December 2016&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,170&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,170&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;March 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;197,722&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;136,594&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;June 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;August 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.29&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;August 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;November 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;March 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;August 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;71,700&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;August 2029&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;88,430&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; padding-left: 5.6pt&quot;&gt;June 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;433,852&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;276,789&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 4pt; padding-left: 5.6pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c133_From1Jan2020To31Dec2020_OfficerMember_TwoThousandTwelveShareOptionPlanMember" decimals="INF">3672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c134_From1Jan2020To31Dec2020_DirectorMember_TwoThousandTwelveShareOptionPlanMember" decimals="INF">3672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c135_From1Jan2020To31Dec2020_AdvisorsMember_TwoThousandTwelveShareOptionPlanMember" decimals="INF">3672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c136_From1Jan2020To31Dec2020_ManagementMember_TwoThousandTwelveShareOptionPlanMember" decimals="INF">3672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c137_From1Jan2020To31Dec2020_OtherKeyEmployeesMember_TwoThousandTwelveShareOptionPlanMember" decimals="INF">3672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c138_From1Jan2020To31Dec2020_TwoThousandTwelveShareOptionPlanMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod contextRef="c0_From1Jan2020To31Dec2020">P10Y</pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod>
  <pypd:StockOptionsAvailableForFutureGrants unitRef="shares" contextRef="c138_From1Jan2020To31Dec2020_TwoThousandTwelveShareOptionPlanMember" decimals="INF">1019457</pypd:StockOptionsAvailableForFutureGrants>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum unitRef="pure" contextRef="c139_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="4">0.7435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum unitRef="pure" contextRef="c139_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="4">0.8477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum unitRef="pure" contextRef="c139_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="4">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum unitRef="pure" contextRef="c139_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="4">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c139_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c140_From1Jan2020To31Dec2020_MinimumMember_EmployeeStockMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c141_From1Jan2020To31Dec2020_MaximumMember_EmployeeStockMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum unitRef="pure" contextRef="c142_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="3">0.698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum unitRef="pure" contextRef="c142_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="4">0.7614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum unitRef="pure" contextRef="c142_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="4">0.0226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum unitRef="pure" contextRef="c142_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="4">0.0313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c142_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c143_From1Jan2019To31Dec2019_MinimumMember_EmployeeStockMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c144_From1Jan2019To31Dec2019_MaximumMember_EmployeeStockMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum unitRef="pure" contextRef="c145_From1Jan2018To31Dec2018_EmployeeStockMember" decimals="4">0.9144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum unitRef="pure" contextRef="c145_From1Jan2018To31Dec2018_EmployeeStockMember" decimals="4">0.9687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum unitRef="pure" contextRef="c145_From1Jan2018To31Dec2018_EmployeeStockMember" decimals="4">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum unitRef="pure" contextRef="c145_From1Jan2018To31Dec2018_EmployeeStockMember" decimals="4">0.0390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c145_From1Jan2018To31Dec2018_EmployeeStockMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c146_From1Jan2018To31Dec2018_MinimumMember_EmployeeStockMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c147_From1Jan2018To31Dec2018_MaximumMember_EmployeeStockMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <pypd:UnrecognizedCompensationCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">10071000</pypd:UnrecognizedCompensationCosts>
  <pypd:RecognizedOverWeightedAveragePeriod contextRef="c0_From1Jan2020To31Dec2020">P2Y255D</pypd:RecognizedOverWeightedAveragePeriod>
  <us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Authorized&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Issued and outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: left; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;background-color: White; width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 9%; font-weight: bold; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; width: 1%; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Ordinary shares with no par value&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;47,800,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;18,494,739&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;22,466,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: normal; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: normal; text-align: right&quot;&gt;562,748&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: normal; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&amp;#xa0;&lt;br/&gt; average&amp;#xa0;&lt;br/&gt; remaining&amp;#xa0;&lt;br/&gt; contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,411&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,064,959&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.08&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(395&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(89,157&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;5.99&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercisable options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,306,421&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.78&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6,686&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&amp;#xa0;&lt;br/&gt; average&amp;#xa0;&lt;br/&gt; remaining&amp;#xa0;&lt;br/&gt; contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,234,955&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.59&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4,608&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.96&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;82,216&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.04&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1,523&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.54&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(97,663&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;6.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,411&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Exercisable options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,108,207&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.29&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.66&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,217,985&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;3,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">1217985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="2">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">3411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2020To31Dec2020">P5Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1064959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">7.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">-395</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised>
  <pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">6.80</pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">-89157</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">5.99</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">2193392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">9263000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding contextRef="c0_From1Jan2020To31Dec2020">P6Y211D</pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">1306421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">6686000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2020To31Dec2020">P4Y229D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">2193392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">5.72</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">9263000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest contextRef="c0_From1Jan2020To31Dec2020">P6Y211D</pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c18_AsOf31Dec2018" decimals="INF">1234955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c18_AsOf31Dec2018" decimals="2">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="-3">4608000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c3_From1Jan2019To31Dec2019">P5Y350D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">82216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">8.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">-1523</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised>
  <pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">4.54</pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1 unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">-97663</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">6.50</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled>
  <pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding contextRef="c3_From1Jan2019To31Dec2019">P5Y14D</pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">1108207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="2">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">3406000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c3_From1Jan2019To31Dec2019">P4Y240D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">1217985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="2">4.62</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">3406000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest contextRef="c3_From1Jan2019To31Dec2019">P5Y14D</pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest>
  <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,806&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;180&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;239&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;Marketing and business development&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;140&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,631&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;706&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;739&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4,577&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;976&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;995&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c148_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-3">1806000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c149_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-3">180000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c150_From1Jan2018To31Dec2018_ResearchAndDevelopmentExpenseMember" decimals="-3">239000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c151_From1Jan2020To31Dec2020_MarketingAndBusinessDevelopmentMember" decimals="-3">140000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c152_From1Jan2019To31Dec2019_MarketingAndBusinessDevelopmentMember" decimals="-3">90000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c153_From1Jan2018To31Dec2018_MarketingAndBusinessDevelopmentMember" decimals="-3">17000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c154_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember" decimals="-3">2631000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c155_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember" decimals="-3">706000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c156_From1Jan2018To31Dec2018_GeneralAndAdministrativeExpenseMember" decimals="-3">739000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">4577000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">976000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">995000</us-gaap:AllocatedShareBasedCompensationExpense>
  <pypd:ScheduleOfOptionOutstandingTablesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Exercise &lt;br/&gt;
price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options&lt;br/&gt;
 outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted average exercise price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;contractual term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options exercisable as&amp;#xa0;of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted average exercise price ($)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;contractual term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;249,561&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;249,561&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;*)0.22&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;107,904&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;107,904&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.75&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;83,503&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;83,503&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.33&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.07&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.36&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;200,229&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;200,229&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.23&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;29,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;29,947&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;51,385&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.98&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;51,385&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.98&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.19&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.19&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;66,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.84&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;66,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.84&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,589&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.78&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,461&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.77&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15,035&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;10,940&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.65&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.53&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;46,069&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.30&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,004&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.02&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;58,731&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.11&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,858&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.80&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.11&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;904,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;168,898&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.44&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;90,100&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,193,392&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;5.72&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;6.58&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,306,421&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.78&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</pypd:ScheduleOfOptionOutstandingTablesTextBlock>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c157_From1Jan2020To31Dec2020_ExercisePrice022Member">P2Y76D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 id="_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1-c157_From1Jan2020To31Dec2020_ExercisePrice022Member_shares" unitRef="shares" contextRef="c157_From1Jan2020To31Dec2020_ExercisePrice022Member" xs:nil="true"/>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c158_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice022Member">P2Y76D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c159_From1Jan2020To31Dec2020_ExercisePrice175Member" decimals="INF">107904</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c159_From1Jan2020To31Dec2020_ExercisePrice175Member" decimals="2">1.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c159_From1Jan2020To31Dec2020_ExercisePrice175Member">P2Y76D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c159_From1Jan2020To31Dec2020_ExercisePrice175Member" decimals="INF">107904</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c160_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice175Member" decimals="2">1.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c160_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice175Member">P2Y76D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c161_From1Jan2020To31Dec2020_ExercisePrice359Member" decimals="INF">83503</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c161_From1Jan2020To31Dec2020_ExercisePrice359Member" decimals="2">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c161_From1Jan2020To31Dec2020_ExercisePrice359Member">P2Y120D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c161_From1Jan2020To31Dec2020_ExercisePrice359Member" decimals="INF">83503</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c162_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice359Member" decimals="2">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c162_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice359Member">P2Y120D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c163_From1Jan2020To31Dec2020_ExercisePrice507Member" decimals="INF">260296</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c163_From1Jan2020To31Dec2020_ExercisePrice507Member" decimals="2">5.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c163_From1Jan2020To31Dec2020_ExercisePrice507Member">P3Y131D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c163_From1Jan2020To31Dec2020_ExercisePrice507Member" decimals="INF">260296</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c164_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice507Member" decimals="2">5.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c164_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice507Member">P3Y131D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c165_From1Jan2020To31Dec2020_ExercisePrice923Member" decimals="INF">200229</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c165_From1Jan2020To31Dec2020_ExercisePrice923Member" decimals="2">9.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c165_From1Jan2020To31Dec2020_ExercisePrice923Member">P4Y321D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c165_From1Jan2020To31Dec2020_ExercisePrice923Member" decimals="INF">200229</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c166_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice923Member" decimals="2">9.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c166_From1Jan2020To31Dec2020_StockOptionMember_ExercisePrice923Member">P4Y321D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c167_From1Jan2020To31Dec2020_ExercisePriceFiveMember" decimals="INF">29947</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c167_From1Jan2020To31Dec2020_ExercisePriceFiveMember" decimals="2">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c167_From1Jan2020To31Dec2020_ExercisePriceFiveMember">P5Y153D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c167_From1Jan2020To31Dec2020_ExercisePriceFiveMember" decimals="INF">29947</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c168_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFiveMember" decimals="2">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c168_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFiveMember">P5Y153D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c169_From1Jan2020To31Dec2020_ExercisePriceSixMember" decimals="INF">51385</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c169_From1Jan2020To31Dec2020_ExercisePriceSixMember" decimals="2">3.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c169_From1Jan2020To31Dec2020_ExercisePriceSixMember">P5Y357D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c169_From1Jan2020To31Dec2020_ExercisePriceSixMember" decimals="INF">51385</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c170_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSixMember" decimals="2">3.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c170_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSixMember">P5Y357D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c171_From1Jan2020To31Dec2020_ExercisePriceSevenMember" decimals="INF">20914</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c171_From1Jan2020To31Dec2020_ExercisePriceSevenMember" decimals="2">4.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c171_From1Jan2020To31Dec2020_ExercisePriceSevenMember">P6Y69D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c171_From1Jan2020To31Dec2020_ExercisePriceSevenMember" decimals="INF">20914</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c172_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSevenMember" decimals="2">4.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c172_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceSevenMember">P6Y69D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c173_From1Jan2020To31Dec2020_ExercisePriceEightMember" decimals="INF">1195</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c173_From1Jan2020To31Dec2020_ExercisePriceEightMember" decimals="2">4.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c173_From1Jan2020To31Dec2020_ExercisePriceEightMember">P6Y146D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c173_From1Jan2020To31Dec2020_ExercisePriceEightMember" decimals="INF">1195</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c174_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceEightMember" decimals="2">4.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c174_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceEightMember">P6Y146D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c175_From1Jan2020To31Dec2020_ExercisePriceNineMember" decimals="INF">66326</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c175_From1Jan2020To31Dec2020_ExercisePriceNineMember" decimals="2">7.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c175_From1Jan2020To31Dec2020_ExercisePriceNineMember">P6Y306D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c175_From1Jan2020To31Dec2020_ExercisePriceNineMember" decimals="INF">66326</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c176_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceNineMember" decimals="2">7.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c176_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceNineMember">P6Y306D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c177_From1Jan2020To31Dec2020_ExercisePriceTenMember" decimals="INF">7589</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c177_From1Jan2020To31Dec2020_ExercisePriceTenMember" decimals="2">8.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c177_From1Jan2020To31Dec2020_ExercisePriceTenMember">P7Y284D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c177_From1Jan2020To31Dec2020_ExercisePriceTenMember" decimals="INF">5461</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c178_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTenMember" decimals="2">8.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c178_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTenMember">P7Y281D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c179_From1Jan2020To31Dec2020_ExercisePriceElevenMember" decimals="INF">15035</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c179_From1Jan2020To31Dec2020_ExercisePriceElevenMember" decimals="2">8.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c179_From1Jan2020To31Dec2020_ExercisePriceElevenMember">P7Y226D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c179_From1Jan2020To31Dec2020_ExercisePriceElevenMember" decimals="INF">10940</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c180_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceElevenMember" decimals="2">8.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c180_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceElevenMember">P7Y193D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c181_From1Jan2020To31Dec2020_ExercisePriceTwelveMember" decimals="INF">46069</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c181_From1Jan2020To31Dec2020_ExercisePriceTwelveMember" decimals="2">8.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c181_From1Jan2020To31Dec2020_ExercisePriceTwelveMember">P8Y109D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c181_From1Jan2020To31Dec2020_ExercisePriceTwelveMember" decimals="INF">35004</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c182_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTwelveMember" decimals="2">8.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c182_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceTwelveMember">P8Y116D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c183_From1Jan2020To31Dec2020_ExercisePriceThirteenMember" decimals="INF">58731</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c183_From1Jan2020To31Dec2020_ExercisePriceThirteenMember" decimals="2">6.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c183_From1Jan2020To31Dec2020_ExercisePriceThirteenMember">P9Y40D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c183_From1Jan2020To31Dec2020_ExercisePriceThirteenMember" decimals="INF">14858</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c184_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceThirteenMember" decimals="2">6.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c184_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceThirteenMember">P9Y40D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c185_From1Jan2020To31Dec2020_ExercisePriceFourtheenMember" decimals="INF">904608</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c185_From1Jan2020To31Dec2020_ExercisePriceFourtheenMember" decimals="2">6.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c185_From1Jan2020To31Dec2020_ExercisePriceFourtheenMember">P9Y164D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c185_From1Jan2020To31Dec2020_ExercisePriceFourtheenMember" decimals="INF">168898</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c186_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFourtheenMember" decimals="2">6.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c186_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFourtheenMember">P9Y160D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c187_From1Jan2020To31Dec2020_ExercisePriceFifteenMember" decimals="INF">90100</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c187_From1Jan2020To31Dec2020_ExercisePriceFifteenMember" decimals="2">11.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c187_From1Jan2020To31Dec2020_ExercisePriceFifteenMember">P9Y313D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c187_From1Jan2020To31Dec2020_ExercisePriceFifteenMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c188_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFifteenMember" decimals="2">11.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c188_From1Jan2020To31Dec2020_StockOptionMember_ExercisePriceFifteenMember" xs:nil="true"/>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2193392</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">5.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c0_From1Jan2020To31Dec2020">P6Y211D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1306421</pypd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c189_From1Jan2020To31Dec2020_StockOptionMember" decimals="2">4.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <pypd:WeightedAverageRemainingContractualTermYear contextRef="c189_From1Jan2020To31Dec2020_StockOptionMember">P4Y229D</pypd:WeightedAverageRemainingContractualTermYear>
  <pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid&quot;&gt;Grant date&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options &lt;br/&gt;
outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Average &lt;br/&gt;
Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center&quot;&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Exercisable &lt;br/&gt;
through&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 54%; text-indent: -12pt; padding-left: 12pt&quot;&gt;March 2013&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,258&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.76&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,258&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; width: 9%; padding-left: 5.6pt&quot;&gt;March 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;October 2013&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;October&amp;#xa0;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2014&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;June 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;September 2014&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.06&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,719&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;September&amp;#xa0;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;April 2016&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,975&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,975&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;April 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;December 2016&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,170&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,170&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;March 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;197,722&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.10&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;136,594&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;June 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;August 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.29&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5,617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;August 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;November 2017&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;17,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;March 2027&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;August 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;71,700&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,195&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;August 2029&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;June 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;88,430&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;6.62&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; padding-left: 5.6pt&quot;&gt;June 2030&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: -12pt; padding-left: 12pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-left: 5.6pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;433,852&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;276,789&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 4pt; padding-left: 5.6pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c190_AsOf31Dec2020_MarchTwoThousandThirteenMember" decimals="INF">22258</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c190_AsOf31Dec2020_MarchTwoThousandThirteenMember" decimals="2">1.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c190_AsOf31Dec2020_MarchTwoThousandThirteenMember" decimals="INF">22258</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c191_From1Jan2020To31Dec2020_MarchTwoThousandThirteenMember">March 2023</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c192_AsOf31Dec2020_OctoberTwoThousandThirteenMember" decimals="INF">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c192_AsOf31Dec2020_OctoberTwoThousandThirteenMember" decimals="2">5.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c192_AsOf31Dec2020_OctoberTwoThousandThirteenMember" decimals="INF">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c193_From1Jan2020To31Dec2020_OctoberTwoThousandThirteenMember">October 2023</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c194_AsOf31Dec2020_JuneTwoThousandFourteenMember" decimals="INF">5617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c194_AsOf31Dec2020_JuneTwoThousandFourteenMember" decimals="2">5.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c194_AsOf31Dec2020_JuneTwoThousandFourteenMember" decimals="INF">5617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c195_From1Jan2020To31Dec2020_JuneTwoThousandFourteenMember">June 2024</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c196_AsOf31Dec2020_SeptemberTwoThousandFourteenMember" decimals="INF">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c196_AsOf31Dec2020_SeptemberTwoThousandFourteenMember" decimals="2">5.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c196_AsOf31Dec2020_SeptemberTwoThousandFourteenMember" decimals="INF">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c197_From1Jan2020To31Dec2020_SeptemberTwoThousandFourteenMember">September 2024</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c198_AsOf31Dec2020_AprilTwoThousandSixteenMember" decimals="INF">5975</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c198_AsOf31Dec2020_AprilTwoThousandSixteenMember" decimals="2">3.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c198_AsOf31Dec2020_AprilTwoThousandSixteenMember" decimals="INF">5975</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c199_From1Jan2020To31Dec2020_AprilTwoThousandSixteenMember">April 2026</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c200_AsOf31Dec2020_DecemberTwoThousandSixteenMember" decimals="INF">7170</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c200_AsOf31Dec2020_DecemberTwoThousandSixteenMember" decimals="2">3.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c200_AsOf31Dec2020_DecemberTwoThousandSixteenMember" decimals="INF">7170</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c201_From1Jan2020To31Dec2020_DecemberTwoThousandSixteenMember">March 2023</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c202_AsOf31Dec2020_JuneTwoThousandSeventeenMember" decimals="INF">197722</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c202_AsOf31Dec2020_JuneTwoThousandSeventeenMember" decimals="2">4.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c202_AsOf31Dec2020_JuneTwoThousandSeventeenMember" decimals="INF">136594</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c203_From1Jan2020To31Dec2020_JuneTwoThousandSeventeenMember">June 2027</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c204_AsOf31Dec2020_AugustTwoThousandSeventeenMember" decimals="INF">5617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c204_AsOf31Dec2020_AugustTwoThousandSeventeenMember" decimals="2">9.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c204_AsOf31Dec2020_AugustTwoThousandSeventeenMember" decimals="INF">5617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c205_From1Jan2020To31Dec2020_AugustTwoThousandSeventeenMember">August 2027</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c206_AsOf31Dec2020_NovemberTwoThousandSeventeenMember" decimals="INF">17925</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c206_AsOf31Dec2020_NovemberTwoThousandSeventeenMember" decimals="2">7.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c206_AsOf31Dec2020_NovemberTwoThousandSeventeenMember" decimals="INF">17925</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c207_From1Jan2020To31Dec2020_NovemberTwoThousandSeventeenMember">March 2027</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c208_AsOf31Dec2020_AugustTwoThousandNineteenMember" decimals="INF">71700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c208_AsOf31Dec2020_AugustTwoThousandNineteenMember" decimals="2">8.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c208_AsOf31Dec2020_AugustTwoThousandNineteenMember" decimals="INF">64195</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c209_From1Jan2020To31Dec2020_AugustTwoThousandNineteenMember">August 2029</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c210_AsOf31Dec2020_JuneTwoThousandTwentyMember" decimals="INF">88430</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c210_AsOf31Dec2020_JuneTwoThousandTwentyMember" decimals="2">6.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c211_From1Jan2020To31Dec2020_JuneTwoThousandTwentyMember">June 2030</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">433852</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">276789</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
11:-	FINANCIAL EXPENSES, NET&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;background-color: White; text-align: justify; padding-left: 0pt&quot;&gt;Financial expenses:&amp;#x202f;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: justify; padding-left: 0pt&quot;&gt;Revaluation of warrants&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;11,373&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Foreign currency transaction loss, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;276&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Others&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total financial expenses, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11,390&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;318&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Financial income:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Interest from deposits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(474&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(60&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(126&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Revaluation of warrants&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,365&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(24,473&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Foreign currency transaction gains, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(243&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(245&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total financial income:&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(793&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(11,670&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(25,599&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Financial expense (income), net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;10,597&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(11,655&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(24,281&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;background-color: White; text-align: justify; padding-left: 0pt&quot;&gt;Financial expenses:&amp;#x202f;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;background-color: White; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: justify; padding-left: 0pt&quot;&gt;Revaluation of warrants&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;11,373&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Foreign currency transaction loss, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;276&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Others&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;17&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total financial expenses, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;11,390&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;318&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Financial income:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Interest from deposits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(474&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(60&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(126&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Revaluation of warrants&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(11,365&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(24,473&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;Foreign currency transaction gains, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(243&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(245&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total financial income:&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(793&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(11,670&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(25,599&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Financial expense (income), net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;10,597&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(11,655&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(24,281&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
  <pypd:FinancialExpenseRevaluationOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">11373000</pypd:FinancialExpenseRevaluationOfWarrants>
  <pypd:FinancialExpenseRevaluationOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:FinancialExpenseRevaluationOfWarrants unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:ForeignCurrencyTransactionLossBeforeTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ForeignCurrencyTransactionLossBeforeTax unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ForeignCurrencyTransactionLossBeforeTax unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">276000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17000</us-gaap:OtherExpenses>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">15000</us-gaap:OtherExpenses>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">42000</us-gaap:OtherExpenses>
  <us-gaap:InvestmentIncomeInvestmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">11390000</us-gaap:InvestmentIncomeInvestmentExpense>
  <us-gaap:InvestmentIncomeInvestmentExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">15000</us-gaap:InvestmentIncomeInvestmentExpense>
  <us-gaap:InvestmentIncomeInvestmentExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">318000</us-gaap:InvestmentIncomeInvestmentExpense>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">474000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">60000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">126000</us-gaap:InvestmentIncomeInterest>
  <pypd:RevaluationOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <pypd:RevaluationOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">11365000</pypd:RevaluationOfWarrants>
  <pypd:RevaluationOfWarrants unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">24473000</pypd:RevaluationOfWarrants>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">243000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">245000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <pypd:FinancialOtherIncome unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">76000</pypd:FinancialOtherIncome>
  <pypd:FinancialOtherIncome unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:FinancialOtherIncome unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:InvestmentIncomeNonoperating unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">793000</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">11670000</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNonoperating unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">25599000</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InvestmentIncomeNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">10597000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-11655000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-24281000</us-gaap:InvestmentIncomeNet>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
12:-	BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;The following
table sets forth the computation of the Company&amp;#x2019;s basic and diluted net loss per Ordinary share:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;Basic net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;2020&lt;/b&gt; &amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;36,869&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6,905&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(5,917&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Preferred share preference&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,933&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,422&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,439&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Net income allocated to preferred shareholders&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,389&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Deemed dividend&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;2,114&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit) attributable to Ordinary shareholders&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Weighted average Ordinary shares outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;561,113&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Basic net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.48&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;23.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(0.16&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Diluted net loss (profit) per share:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit) attributable for basic computation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Revaluation of warrants to convertible preferred shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;616&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss attributable to Ordinary shareholders&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;527&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Number of shares used in basic calculation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;561,113&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Weighted average effect of dilutive securities Warrants to convertible preferred shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;52,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Number of shares used in diluted calculation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;613,358&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Diluted net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.48&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;23.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;0.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;Basic net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;2020&lt;/b&gt; &amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;36,869&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6,905&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(5,917&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Preferred share preference&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,933&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,422&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,439&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Net income allocated to preferred shareholders&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,389&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Deemed dividend&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;2,114&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit) attributable to Ordinary shareholders&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Weighted average Ordinary shares outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;561,113&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt; text-indent: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Basic net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.48&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;23.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(0.16&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Diluted net loss (profit) per share:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss (profit) attributable for basic computation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;(89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Revaluation of warrants to convertible preferred shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;616&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Allocation of net loss attributable to Ordinary shareholders&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;42,916&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;13,327&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;527&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Number of shares used in basic calculation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;561,113&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in&quot;&gt;Weighted average effect of dilutive securities Warrants to convertible preferred shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;52,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Number of shares used in diluted calculation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;9,582,405&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;562,451&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;613,358&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Diluted net loss (profit) per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;4.48&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;23.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;0.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">36869000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">6905000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-5917000</us-gaap:ProfitLoss>
  <pypd:PreferredSharePreference unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3933000</pypd:PreferredSharePreference>
  <pypd:PreferredSharePreference unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">6422000</pypd:PreferredSharePreference>
  <pypd:PreferredSharePreference unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">4439000</pypd:PreferredSharePreference>
  <pypd:NetIncomeAllocatedToPreferredShareholders unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <pypd:NetIncomeAllocatedToPreferredShareholders unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:NetIncomeAllocatedToPreferredShareholders unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1389000</pypd:NetIncomeAllocatedToPreferredShareholders>
  <pypd:DeemedDividends unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">2114000</pypd:DeemedDividends>
  <pypd:DeemedDividends unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:DeemedDividends unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">42916000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">13327000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-89000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <pypd:NetIncomeLossAvailableToBasicComputation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">42916000</pypd:NetIncomeLossAvailableToBasicComputation>
  <pypd:NetIncomeLossAvailableToBasicComputation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">13327000</pypd:NetIncomeLossAvailableToBasicComputation>
  <pypd:NetIncomeLossAvailableToBasicComputation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-89000</pypd:NetIncomeLossAvailableToBasicComputation>
  <pypd:RevaluationOfWarrantsToConvertiblePreferredShares unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <pypd:RevaluationOfWarrantsToConvertiblePreferredShares unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:RevaluationOfWarrantsToConvertiblePreferredShares unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">616000</pypd:RevaluationOfWarrantsToConvertiblePreferredShares>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">42916000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">13327000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">527000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">9582405</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">562451</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="INF">561113</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="INF">52245</pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
13:-	RELATED PARTIES&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;Through February 2016, several management members also provided
services to the Company as service providers. As of December 31, 2020 and 2019, the Company has recorded a provision for severance
pay liability for such service providers in the amounts of $193 and $251, respectively. These amounts are included in &amp;#x201c;Other
Liabilities&amp;#x201d;.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;In July 2019, the Company entered into a master service agreement
with a third-party provider (the &amp;#x201c;provider&amp;#x201d;) to conduct a portion of a phase 3 clinical trial in eastern Europe for a
total cost of $6,288. One of the Company&amp;#x2019;s directors serves as a director and shareholder in the provider. During the year ended
December 31, 2020, the Company recognized $717 as expense as part of the research and development expenses.&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <pypd:ServiceProvidersInAmount unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">193000</pypd:ServiceProvidersInAmount>
  <pypd:ServiceProvidersInAmount unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">251000</pypd:ServiceProvidersInAmount>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c212_From5Jul2019To31Jul2019_EasternEuropeMember" decimals="-3">6288000</us-gaap:CostOfRevenue>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c213_From1Jan2020To31Dec2020_DirectorMember" decimals="-3">717000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt&quot;&gt;NOTE
14:-	SUBSEQUENT EVENTS&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;&lt;font style=&quot;font-weight: normal&quot;&gt;The
Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated
financial statements to identify matters that require additional disclosure. For its annual consolidated financial statements
as of December&amp;#xa0;31, 2020 and for the year then ended, the Company evaluated subsequent events through March&amp;#xa0;5, 2021,
the date that the consolidated financial statements were issued. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify&quot;&gt;During January to March 2021, 580,028 warrants to purchase Ordinary
shares were exercised on a cashless basis into 115,982 Ordinary shares, out of which 419,068 warrants were exercised by related
parties. In addition, during February 2021 68,491 warrants to purchase Ordinary shares were exercised into 68,491 Ordinary shares
for a total consideration of $633.&lt;/p&gt;&lt;br/&gt;</us-gaap:ScheduleOfSubsequentEventsTextBlock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c214_AsOf31Mar2021_SubsequentEventMember" decimals="INF">580028</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits unitRef="shares" contextRef="c215_From1Mar2021To31Mar2021_SubsequentEventMember" decimals="INF">115982</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <pypd:WarrantsExercised unitRef="shares" contextRef="c216_From31Jan2021To31Mar2021_RelatedPartiesMember_SubsequentEventMember" decimals="INF">419068</pypd:WarrantsExercised>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c217_AsOf28Feb2021_SubsequentEventMember" decimals="INF">68491</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits unitRef="shares" contextRef="c218_From1Feb2021To28Feb2021_SubsequentEventMember" decimals="INF">68491</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c218_From1Feb2021To28Feb2021_SubsequentEventMember" decimals="0">633</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>pypd-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://Polypid.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:pypd="http://Polypid.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet" id="pypd_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals" id="pypd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedComprehensiveIncome" id="pypd_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityType2or3" id="pypd_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals" id="pypd_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders&#8217; Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedCashFlow" id="pypd_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/General" id="pypd_r_General">
        <link:definition>007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPolicies" id="pypd_r_SignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivables" id="pypd_r_PrepaidExpensesandOtherReceivables">
        <link:definition>009 - Disclosure - Prepaid Expenses and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNet" id="pypd_r_PropertyandEquipmentNet">
        <link:definition>010 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpenses" id="pypd_r_OtherPayablesandAccruedExpenses">
        <link:definition>011 - Disclosure - Other Payables and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities" id="pypd_r_CommitmentsandContingentLiabilities">
        <link:definition>012 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FairValueMeasurements" id="pypd_r_FairValueMeasurements">
        <link:definition>013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxes" id="pypd_r_IncomeTaxes">
        <link:definition>014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrants" id="pypd_r_ConvertiblePreferredSharesandWarrants">
        <link:definition>015 - Disclosure - Convertible Preferred Shares and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityDeficit" id="pypd_r_ShareholdersEquityDeficit">
        <link:definition>016 - Disclosure - Shareholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FinancialExpensesNet" id="pypd_r_FinancialExpensesNet">
        <link:definition>017 - Disclosure - Financial Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare" id="pypd_r_BasicandDilutedNetLossProfitPerShare">
        <link:definition>018 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/RelatedParties" id="pypd_r_RelatedParties">
        <link:definition>019 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SubsequentEvents" id="pypd_r_SubsequentEvents">
        <link:definition>020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy" id="pypd_r_AccountingPoliciesByPolicy">
        <link:definition>021 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables" id="pypd_r_SignificantAccountingPoliciesTables">
        <link:definition>022 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables" id="pypd_r_PrepaidExpensesandOtherReceivablesTables">
        <link:definition>023 - Disclosure - Prepaid Expenses and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables" id="pypd_r_PropertyandEquipmentNetTables">
        <link:definition>024 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpensesTables" id="pypd_r_OtherPayablesandAccruedExpensesTables">
        <link:definition>025 - Disclosure - Other Payables and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables" id="pypd_r_CommitmentsandContingentLiabilitiesTables">
        <link:definition>026 - Disclosure - Commitments and Contingent Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FairValueMeasurementsTables" id="pypd_r_FairValueMeasurementsTables">
        <link:definition>027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxesTables" id="pypd_r_IncomeTaxesTables">
        <link:definition>028 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables" id="pypd_r_ConvertiblePreferredSharesandWarrantsTables">
        <link:definition>029 - Disclosure - Convertible Preferred Shares and Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityDeficitTables" id="pypd_r_ShareholdersEquityDeficitTables">
        <link:definition>030 - Disclosure - Shareholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FinancialExpensesNetTables" id="pypd_r_FinancialExpensesNetTables">
        <link:definition>031 - Disclosure - Financial Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables" id="pypd_r_BasicandDilutedNetLossProfitPerShareTables">
        <link:definition>032 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/GeneralDetails" id="pypd_r_GeneralDetails">
        <link:definition>033 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails" id="pypd_r_SignificantAccountingPoliciesDetails">
        <link:definition>034 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable" id="pypd_r_ScheduleofRestrictionsonCashandCashEquivalentsTable">
        <link:definition>035 - Disclosure - Significant Accounting Policies (Details) - Schedule of Restrictions on Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable" id="pypd_r_ScheduleofPropertyandequipmentusefullifeTable">
        <link:definition>036 - Disclosure - Significant Accounting Policies (Details) - Schedule of Property and equipment useful life</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable" id="pypd_r_ScheduleofprepaidexpensesandotherreceivablesTable">
        <link:definition>037 - Disclosure - Prepaid Expenses and Other Receivables (Details) - Schedule of prepaid expenses and other receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails" id="pypd_r_PropertyandEquipmentNetDetails">
        <link:definition>038 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable" id="pypd_r_ScheduleofpropertyandequipmentTable">
        <link:definition>039 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable" id="pypd_r_ScheduleofotherpayablesandaccruedexpensesTable">
        <link:definition>040 - Disclosure - Other Payables and Accrued Expenses (Details) - Schedule of other payables and accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails" id="pypd_r_CommitmentsandContingentLiabilitiesDetails">
        <link:definition>041 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable" id="pypd_r_ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable">
        <link:definition>042 - Disclosure - Commitments and Contingent Liabilities (Details) - Schedule of future minimum lease payments under operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FairValueMeasurementsDetails" id="pypd_r_FairValueMeasurementsDetails">
        <link:definition>043 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable" id="pypd_r_ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable">
        <link:definition>044 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of the preferred share warrants liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxesDetails" id="pypd_r_IncomeTaxesDetails">
        <link:definition>045 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable" id="pypd_r_ScheduleofdeferredtaxassetsTable">
        <link:definition>046 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllL5o4l+dZENvsCDxOgmuOaZxUDF5mzD93c=] CSR-->
      <link:roleType roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails" id="pypd_r_ConvertiblePreferredSharesandWarrantsDetails">
        <link:definition>047 - Disclosure - Convertible Preferred Shares and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable" id="pypd_r_ScheduleofconvertiblepreferredsharesTable">
        <link:definition>048 - Disclosure - Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityDeficitDetails" id="pypd_r_ShareholdersEquityDeficitDetails">
        <link:definition>049 - Disclosure - Shareholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable" id="pypd_r_ScheduleofordinarysharecapitalTable">
        <link:definition>050 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of ordinary share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable" id="pypd_r_ScheduleofstatusofoptionstoemployeesTable">
        <link:definition>051 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of status of options to employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable" id="pypd_r_ScheduleofequitybasedawardsrecognizedTable">
        <link:definition>052 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofoptionsoutstandingTable" id="pypd_r_ScheduleofoptionsoutstandingTable">
        <link:definition>053 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable" id="pypd_r_ScheduleofoutstandingoptionsgrantedTable">
        <link:definition>054 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleoffinancialexpensesnetTable" id="pypd_r_ScheduleoffinancialexpensesnetTable">
        <link:definition>055 - Disclosure - Financial Expenses, Net (Details) - Schedule of financial expenses net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable" id="pypd_r_ScheduleofbasicanddilutednetlossperordinaryshareTable">
        <link:definition>056 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share (Details) - Schedule of basic and diluted net loss per ordinary share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/RelatedPartiesDetails" id="pypd_r_RelatedPartiesDetails">
        <link:definition>057 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SubsequentEventsDetails" id="pypd_r_SubsequentEventsDetails">
        <link:definition>058 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
  <xs:element name="PrepaidExpensesAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ConvertiblePreferredSharesAndWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
  <xs:element name="ScheduleOfConvertiblePreferredSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfConvertiblePreferredSharesAbstract"/>
  <xs:element name="ScheduleOfOrdinaryShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
  <xs:element name="ScheduleOfStatusOfOptionsToEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
  <xs:element name="ScheduleOfEquityBasedAwardsRecognizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract"/>
  <xs:element name="ScheduleOfOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOptionsOutstandingAbstract"/>
  <xs:element name="ScheduleOfOutstandingOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfFinancialExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfFinancialExpensesNetAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract"/>
  <xs:element name="ShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareCapitalAbstract"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_CostAbstract"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumberOfSharesAbstract"/>
  <xs:element name="NumberOfSharesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumberOfSharesAbstract0"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DenominatorAbstract"/>
  <xs:element name="DilutedNetLossProfitPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DilutedNetLossProfitPerShareAbstract"/>
  <xs:element name="NumeratorAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumeratorAbstract0"/>
  <xs:element name="DenominatorAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DenominatorAbstract0"/>
  <xs:element name="ShorttermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShorttermDeposits"/>
  <xs:element name="LongtermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LongtermDeposits"/>
  <xs:element name="OtherPayablesAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_OtherPayablesAndAccruedExpenses"/>
  <xs:element name="WarrantToConvertiblePreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantToConvertiblePreferredShares"/>
  <xs:element name="TotalLongtermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_TotalLongtermLiabilities"/>
  <xs:element name="MarketingAndBusinessDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_MarketingAndBusinessDevelopmentExpenses"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DeemedDividend"/>
  <xs:element name="NetLossAttributableToOrdinarySharesAsReported" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NetLossAttributableToOrdinarySharesAsReported"/>
  <xs:element name="ConversionOfConvertiblePreferredSharesToOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
  <xs:element name="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
  <xs:element name="ReclassificationOfWarrantsIntoEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReclassificationOfWarrantsIntoEquity"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
  <xs:element name="StockIssuedDuringPeriodIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockIssuedDuringPeriodIssuanceOfWarrants"/>
  <xs:element name="NetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NetOfIssuanceCosts"/>
  <xs:element name="ReevaluationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReevaluationOfWarrants"/>
  <xs:element name="DecreaseincreaseInReceivablesAndPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
  <xs:element name="IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement"/>
  <xs:element name="PaymentsAcquireToLongtermDepositsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PaymentsAcquireToLongtermDepositsNet"/>
  <xs:element name="PrepaymentForEquipments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaymentForEquipments"/>
  <xs:element name="ProceedsFromIssuanceOfConvertiblePreferredSharesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet"/>
  <xs:element name="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
  <xs:element name="IssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IssuanceOfWarrants"/>
  <xs:element name="PrepaidExpensesAndOtherReceivablesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
  <xs:element name="ConvertiblePreferredSharesAndWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock"/>
  <xs:element name="ConsolidatedFinancialStatementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
  <xs:element name="RestrictedCashPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RestrictedCashPolicyTextBlock"/>
  <xs:element name="ShorttermDepositsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShorttermDepositsPolicyTextBlock"/>
  <xs:element name="LongtermDepositsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LongtermDepositsPolicyTextBlock"/>
  <xs:element name="GrantsAndParticipationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_GrantsAndParticipationsPolicyTextBlock"/>
  <xs:element name="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeverancePayPolicyTextBlock"/>
  <xs:element name="DerivativeFinancialInstrumentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DerivativeFinancialInstrumentsPolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock"/>
  <xs:element name="ScheduleOfOptionOutstandingTablesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOptionOutstandingTablesTextBlock"/>
  <xs:element name="ScheduleOfOutstandingOptionGrantedTablesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
  <xs:element name="RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent"/>
  <xs:element name="CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows"/>
  <xs:element name="PropertyPlantAndEquipmentPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PropertyPlantAndEquipmentPercent"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_GovernmentAuthorities"/>
  <xs:element name="LeaseDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LeaseDeposits"/>
  <xs:element name="IsraelInnovationAuthorityGrantReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IsraelInnovationAuthorityGrantReceived"/>
  <xs:element name="FairValueofPreferredShareWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FairValueofPreferredShareWarrantLiability"/>
  <xs:element name="ChangeInFairValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ChangeInFairValues"/>
  <xs:element name="ReclassificationsOfWarrantsIntoEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReclassificationsOfWarrantsIntoEquity"/>
  <xs:element name="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
  <xs:element name="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable"/>
  <xs:element name="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
  <xs:element name="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1"/>
  <xs:element name="WeightedAverageRemainingContractualTermYear" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageRemainingContractualTermYear"/>
  <xs:element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable"/>
  <xs:element name="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
  <xs:element name="FinancialExpenseRevaluationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialExpenseRevaluationOfWarrants"/>
  <xs:element name="RevaluationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RevaluationOfWarrants"/>
  <xs:element name="FinancialOtherIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialOtherIncome"/>
  <xs:element name="PreferredSharePreference" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PreferredSharePreference"/>
  <xs:element name="NetIncomeAllocatedToPreferredShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NetIncomeAllocatedToPreferredShareholders"/>
  <xs:element name="DeemedDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DeemedDividends"/>
  <xs:element name="NetIncomeLossAvailableToBasicComputation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NetIncomeLossAvailableToBasicComputation"/>
  <xs:element name="RevaluationOfWarrantsToConvertiblePreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RevaluationOfWarrantsToConvertiblePreferredShares"/>
  <xs:element name="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_GeneralDetailsLineItems"/>
  <xs:element name="DescriptionOfReverseShareSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DescriptionOfReverseShareSplit"/>
  <xs:element name="AggregateNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_AggregateNetProceeds"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="monthlyDepositsAtARate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_monthlyDepositsAtARate"/>
  <xs:element name="ProceedsFromParticipationPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ProceedsFromParticipationPayments"/>
  <xs:element name="FindersFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FindersFee"/>
  <xs:element name="PaymentsToAutomaticFilingMachine" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PaymentsToAutomaticFilingMachine"/>
  <xs:element name="PrepaymentForAutomaticFilingMachine" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaymentForAutomaticFilingMachine"/>
  <xs:element name="FairValueMeasurementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_FairValueMeasurementsDetailsTable"/>
  <xs:element name="FairValueMeasurementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FairValueMeasurementsDetailsLineItems"/>
  <xs:element name="WeightedAverageFairValueOfWarrantsPercenatge" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageFairValueOfWarrantsPercenatge"/>
  <xs:element name="CashlessOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_CashlessOrdinaryShares"/>
  <xs:element name="FairValueOfSeriesAPreferredShareWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FairValueOfSeriesAPreferredShareWarrants"/>
  <xs:element name="WarrantsExercisedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsExercisedShares"/>
  <xs:element name="ConvertiblePreferredSharesandWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable"/>
  <xs:element name="ConvertiblePreferredSharesandWarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems"/>
  <xs:element name="AnnualInterestPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_AnnualInterestPercentage"/>
  <xs:element name="WarrantsPurchaseDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsPurchaseDescription"/>
  <xs:element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsIssued"/>
  <xs:element name="DividendRightsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DividendRightsDescription"/>
  <xs:element name="LiquudationRightsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LiquudationRightsDescription"/>
  <xs:element name="ShareholdersEquityDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDeficitDetailsTable"/>
  <xs:element name="ShareholdersEquityDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDeficitDetailsLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod"/>
  <xs:element name="StockOptionsAvailableForFutureGrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockOptionsAvailableForFutureGrants"/>
  <xs:element name="UnrecognizedCompensationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnrecognizedCompensationCosts"/>
  <xs:element name="RecognizedOverWeightedAveragePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RecognizedOverWeightedAveragePeriod"/>
  <xs:element name="RelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_RelatedPartiesDetailsTable"/>
  <xs:element name="RelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RelatedPartiesDetailsLineItems"/>
  <xs:element name="ServiceProvidersInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ServiceProvidersInAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SubsequentEventsDetailsLineItems"/>
  <xs:element name="WarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsExercised"/>
  <xs:element name="AdvisorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AdvisorsMember"/>
  <xs:element name="AprilTwoThousandSixteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AprilTwoThousandSixteenMember"/>
  <xs:element name="AugustTwoThousandNineteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AugustTwoThousandNineteenMember"/>
  <xs:element name="AugustTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AugustTwoThousandSeventeenMember"/>
  <xs:element name="ConvertiblePreferredASharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredASharesMember"/>
  <xs:element name="ConvertiblePreferredD2SharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredD2SharesMember"/>
  <xs:element name="ConvertiblePreferredE1SharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredE1SharesMember"/>
  <xs:element name="ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesMember"/>
  <xs:element name="DecemberTwoThousandSixteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DecemberTwoThousandSixteenMember"/>
  <xs:element name="EasternEuropeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_EasternEuropeMember"/>
  <xs:element name="ExercisePrice022Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePrice022Member"/>
  <xs:element name="ExercisePrice175Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePrice175Member"/>
  <xs:element name="ExercisePrice359Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePrice359Member"/>
  <xs:element name="ExercisePrice507Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePrice507Member"/>
  <xs:element name="ExercisePrice923Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePrice923Member"/>
  <xs:element name="ExercisePriceEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceEightMember"/>
  <xs:element name="ExercisePriceElevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceElevenMember"/>
  <xs:element name="ExercisePriceFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceFifteenMember"/>
  <xs:element name="ExercisePriceFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceFiveMember"/>
  <xs:element name="ExercisePriceFourtheenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceFourtheenMember"/>
  <xs:element name="ExercisePriceNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceNineMember"/>
  <xs:element name="ExercisePriceSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceSevenMember"/>
  <xs:element name="ExercisePriceSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceSixMember"/>
  <xs:element name="ExercisePriceTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceTenMember"/>
  <xs:element name="ExercisePriceThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceThirteenMember"/>
  <xs:element name="ExercisePriceTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceTwelveMember"/>
  <xs:element name="IssaunceCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_IssaunceCostsMember"/>
  <xs:element name="JuneTwoThousandFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_JuneTwoThousandFourteenMember"/>
  <xs:element name="JuneTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_JuneTwoThousandSeventeenMember"/>
  <xs:element name="JuneTwoThousandTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_JuneTwoThousandTwentyMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LaboratoryEquipmentMember"/>
  <xs:element name="LongTermDepositsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LongTermDepositsMember"/>
  <xs:element name="LossCarryforwardMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LossCarryforwardMember"/>
  <xs:element name="MarchTwoThousandThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_MarchTwoThousandThirteenMember"/>
  <xs:element name="MarketingAndBusinessDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_MarketingAndBusinessDevelopmentMember"/>
  <xs:element name="NovemberTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NovemberTwoThousandSeventeenMember"/>
  <xs:element name="OctoberTwoThousandThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_OctoberTwoThousandThirteenMember"/>
  <xs:element name="OtherKeyEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_OtherKeyEmployeesMember"/>
  <xs:element name="PrivatePlacementMemorandumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrivatePlacementMemorandumMember"/>
  <xs:element name="RelatedPartiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RelatedPartiesMember"/>
  <xs:element name="ReservesAndAllowancesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReservesAndAllowancesMember"/>
  <xs:element name="SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SecuritiesPurchaseAgreementMember"/>
  <xs:element name="SeptemberTwoThousandFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeptemberTwoThousandFourteenMember"/>
  <xs:element name="SeriesA1ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesA1ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesAConvertiblePreferredMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesAConvertiblePreferredMember"/>
  <xs:element name="SeriesAConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesAConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesAPreferredShareWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesAPreferredShareWarrantsMember"/>
  <xs:element name="SeriesB1ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesB1ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesBConvertiblePreferredMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesBConvertiblePreferredMember"/>
  <xs:element name="SeriesBConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesBConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesC1ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesC1ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesC2ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesC2ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesD1ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesD1ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesD2ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesD2ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesD3ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesD3ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesE1ConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesE1ConvertiblePreferredSharesMember"/>
  <xs:element name="SeriesE1PreferredShareWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesE1PreferredShareWarrantsMember"/>
  <xs:element name="SeriesEConvertiblePreferredMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesEConvertiblePreferredMember"/>
  <xs:element name="SeriesEConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeriesEConvertiblePreferredSharesMember"/>
  <xs:element name="ShortTermDepositsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShortTermDepositsMember"/>
  <xs:element name="TemporaryDifferencesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_TemporaryDifferencesMember"/>
  <xs:element name="TwoThousandTwelveShareOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_TwoThousandTwelveShareOptionPlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>pypd-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedComprehensiveIncome" roleURI="http://Polypid.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofRestrictionsonCashandCashEquivalentsTable" roleURI="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofprepaidexpensesandotherreceivablesTable" roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofotherpayablesandaccruedexpensesTable" roleURI="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDeposits" xlink:href="pypd-20201231.xsd#pypd_ShorttermDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="pypd_ShorttermDeposits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20201231.xsd#pypd_LongtermDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="pypd_LongtermDeposits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_OtherPayablesAndAccruedExpenses" xlink:href="pypd-20201231.xsd#pypd_OtherPayablesAndAccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pypd_OtherPayablesAndAccruedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20201231.xsd#pypd_TotalLongtermLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="us-gaap_OtherLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_WarrantToConvertiblePreferredShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="pypd_WarrantToConvertiblePreferredShares" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="pypd_TotalLongtermLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:href="pypd-20201231.xsd#pypd_NetLossAttributableToOrdinarySharesAsReported"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividend" xlink:href="pypd-20201231.xsd#pypd_DeemedDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:to="pypd_DeemedDividend" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ReevaluationOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pypd_ReevaluationOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllIN9+ieYY6uE2R09fCYFW8kWQvkj9P+AMc=] CSR-->
    <loc xlink:type="locator" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:href="pypd-20201231.xsd#pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20201231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:href="pypd-20201231.xsd#pypd_PaymentsAcquireToLongtermDepositsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pypd_PaymentsAcquireToLongtermDepositsNet" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForEquipments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pypd_PrepaymentForEquipments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:href="pypd-20201231.xsd#pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:href="pypd-20201231.xsd#pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:label="pypd_GovernmentAuthorities" xlink:href="pypd-20201231.xsd#pypd_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="pypd_GovernmentAuthorities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseDeposits" xlink:href="pypd-20201231.xsd#pypd_LeaseDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="pypd_LeaseDeposits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_OtherAssets" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20201231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>pypd-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedComprehensiveIncome" roleURI="http://Polypid.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityType2or3" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_General" roleURI="http://Polypid.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPolicies" roleURI="http://Polypid.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PrepaidExpensesandOtherReceivables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNet" roleURI="http://Polypid.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_OtherPayablesandAccruedExpenses" roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilities" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurements" roleURI="http://Polypid.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxes" roleURI="http://Polypid.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrants" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficit" roleURI="http://Polypid.com/role/ShareholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FinancialExpensesNet" roleURI="http://Polypid.com/role/FinancialExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_BasicandDilutedNetLossProfitPerShare" roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_RelatedParties" roleURI="http://Polypid.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SubsequentEvents" roleURI="http://Polypid.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_AccountingPoliciesByPolicy" roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPoliciesTables" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PrepaidExpensesandOtherReceivablesTables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNetTables" roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_OtherPayablesandAccruedExpensesTables" roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilitiesTables" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurementsTables" roleURI="http://Polypid.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxesTables" roleURI="http://Polypid.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrantsTables" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficitTables" roleURI="http://Polypid.com/role/ShareholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FinancialExpensesNetTables" roleURI="http://Polypid.com/role/FinancialExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_BasicandDilutedNetLossProfitPerShareTables" roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofRestrictionsonCashandCashEquivalentsTable" roleURI="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofPropertyandequipmentusefullifeTable" roleURI="http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofprepaidexpensesandotherreceivablesTable" roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofpropertyandequipmentTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofotherpayablesandaccruedexpensesTable" roleURI="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable" roleURI="http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofdeferredtaxassetsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofconvertiblepreferredsharesTable" roleURI="http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofordinarysharecapitalTable" roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofstatusofoptionstoemployeesTable" roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofequitybasedawardsrecognizedTable" roleURI="http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofoptionsoutstandingTable" roleURI="http://Polypid.com/role/ScheduleofoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofoutstandingoptionsgrantedTable" roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleoffinancialexpensesnetTable" roleURI="http://Polypid.com/role/ScheduleoffinancialexpensesnetTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofbasicanddilutednetlossperordinaryshareTable" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_GeneralDetails" roleURI="http://Polypid.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPoliciesDetails" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNetDetails" roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurementsDetails" roleURI="http://Polypid.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxesDetails" roleURI="http://Polypid.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrantsDetails" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficitDetails" roleURI="http://Polypid.com/role/ShareholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_RelatedPartiesDetails" roleURI="http://Polypid.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SubsequentEventsDetails" roleURI="http://Polypid.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#DocumentAndEntityInformation" roleURI="http://Polypid.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDeposits" xlink:href="pypd-20201231.xsd#pypd_ShorttermDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="pypd_ShorttermDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20201231.xsd#pypd_LongtermDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="pypd_LongtermDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OtherPayablesAndAccruedExpenses" xlink:href="pypd-20201231.xsd#pypd_OtherPayablesAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pypd_OtherPayablesAndAccruedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OtherLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_WarrantToConvertiblePreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="pypd_WarrantToConvertiblePreferredShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20201231.xsd#pypd_TotalLongtermLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="pypd_TotalLongtermLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_StockholdersEquityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_StockholdersEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividend" xlink:href="pypd-20201231.xsd#pypd_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="pypd_DeemedDividend" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:href="pypd-20201231.xsd#pypd_NetLossAttributableToOrdinarySharesAsReported"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="pypd_NetLossAttributableToOrdinarySharesAsReported" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_ConvertiblePreferredSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExerciseOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ExerciseOfWarrants" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_NetOfIssuanceCosts" xlink:href="pypd-20201231.xsd#pypd_NetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="pypd_NetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ReevaluationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pypd_ReevaluationOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20201231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:href="pypd-20201231.xsd#pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:href="pypd-20201231.xsd#pypd_PaymentsAcquireToLongtermDepositsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pypd_PaymentsAcquireToLongtermDepositsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pypd_PrepaymentForEquipments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20201231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_IssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pypd_IssuanceOfWarrants" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherReceivables">
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/OtherPayablesandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrants">
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialExpensesNet">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_RestrictedCashPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ShorttermDepositsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_LongtermDepositsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_LongtermDepositsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_GrantsAndParticipationsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_GrantsAndParticipationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_GrantsAndParticipationsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_SeverancePayPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_DerivativeFinancialInstrumentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/OtherPayablesandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables">
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOptionOutstandingTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOptionOutstandingTablesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="pypd_ScheduleOfOptionOutstandingTablesTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialExpensesNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:href="pypd-20201231.xsd#pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:href="pypd-20201231.xsd#pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyPlantAndEquipmentPercent" xlink:href="pypd-20201231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="pypd_PropertyPlantAndEquipmentPercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_GovernmentAuthorities" xlink:href="pypd-20201231.xsd#pypd_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_GovernmentAuthorities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseDeposits" xlink:href="pypd-20201231.xsd#pypd_LeaseDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_LeaseDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_OtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryEquipmentMember" xlink:href="pypd-20201231.xsd#pypd_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pypd_LaboratoryEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20201231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueofPreferredShareWarrantLiability" xlink:href="pypd-20201231.xsd#pypd_FairValueofPreferredShareWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="pypd_FairValueofPreferredShareWarrantLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ChangeInFairValues" xlink:href="pypd-20201231.xsd#pypd_ChangeInFairValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="pypd_ChangeInFairValues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationsOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationsOfWarrantsIntoEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="pypd_ReclassificationsOfWarrantsIntoEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReservesAndAllowancesMember" xlink:href="pypd-20201231.xsd#pypd_ReservesAndAllowancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="pypd_ReservesAndAllowancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TemporaryDifferencesMember" xlink:href="pypd-20201231.xsd#pypd_TemporaryDifferencesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="pypd_TemporaryDifferencesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IssaunceCostsMember" xlink:href="pypd-20201231.xsd#pypd_IssaunceCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="pypd_IssaunceCostsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LossCarryforwardMember" xlink:href="pypd-20201231.xsd#pypd_LossCarryforwardMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="pypd_LossCarryforwardMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable">
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesAConvertiblePreferredSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesA1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesA1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesA1ConvertiblePreferredSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesBConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesBConvertiblePreferredSharesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesB1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesB1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesB1ConvertiblePreferredSharesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesC1ConvertiblePreferredSharesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC2ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesC2ConvertiblePreferredSharesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesD1ConvertiblePreferredSharesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD2ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesD2ConvertiblePreferredSharesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD3ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD3ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesD3ConvertiblePreferredSharesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesEConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredSharesMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllL5o4l+dZENvoN1N9Nsb4ReFina4yNe0Ak=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesEConvertiblePreferredSharesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesE1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesE1ConvertiblePreferredSharesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfSharesAbstract" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:to="pypd_NumberOfSharesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofordinarysharecapitalTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfSharesAbstract0" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:to="pypd_NumberOfSharesAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pypd_MarketingAndBusinessDevelopmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice022Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePrice022Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice175Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice175Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePrice175Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice359Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice359Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePrice359Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice507Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice507Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePrice507Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice923Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice923Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePrice923Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFiveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceSixMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceSixMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceSevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceSevenMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceEightMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceEightMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceNineMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceNineMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceTenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceTenMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceElevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceElevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceElevenMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceTwelveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTwelveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceTwelveMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceThirteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceThirteenMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFourtheenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFourtheenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceFourtheenMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFifteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFifteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pypd_ExercisePriceFifteenMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualTermYear" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualTermYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="pypd_WeightedAverageRemainingContractualTermYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_AwardDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MarchTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_MarchTwoThousandThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_MarchTwoThousandThirteenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OctoberTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_OctoberTwoThousandThirteenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandFourteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_JuneTwoThousandFourteenMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeptemberTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_SeptemberTwoThousandFourteenMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AprilTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_AprilTwoThousandSixteenMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DecemberTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_DecemberTwoThousandSixteenMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_JuneTwoThousandSeventeenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AugustTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_AugustTwoThousandSeventeenMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NovemberTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_NovemberTwoThousandSeventeenMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AugustTwoThousandNineteenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandNineteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_AugustTwoThousandNineteenMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandTwentyMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_JuneTwoThousandTwentyMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffinancialexpensesnetTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFinancialExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpenseRevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_FinancialExpenseRevaluationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="pypd_FinancialExpenseRevaluationOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_OtherExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="pypd_RevaluationOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialOtherIncome" xlink:href="pypd-20201231.xsd#pypd_FinancialOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="pypd_FinancialOtherIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PreferredSharePreference" xlink:href="pypd-20201231.xsd#pypd_PreferredSharePreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_PreferredSharePreference" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NetIncomeAllocatedToPreferredShareholders" xlink:href="pypd-20201231.xsd#pypd_NetIncomeAllocatedToPreferredShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_NetIncomeAllocatedToPreferredShareholders" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividends" xlink:href="pypd-20201231.xsd#pypd_DeemedDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_DeemedDividends" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NetIncomeLossAvailableToBasicComputation" xlink:href="pypd-20201231.xsd#pypd_NetIncomeLossAvailableToBasicComputation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_NetIncomeLossAvailableToBasicComputation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RevaluationOfWarrantsToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrantsToConvertiblePreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_RevaluationOfWarrantsToConvertiblePreferredShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsTable" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionOfReverseShareSplit" xlink:href="pypd-20201231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_DescriptionOfReverseShareSplit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateNetProceeds" xlink:href="pypd-20201231.xsd#pypd_AggregateNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_AggregateNetProceeds" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShortTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_ShortTermDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pypd_ShortTermDepositsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LongTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_LongTermDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pypd_LongTermDepositsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_monthlyDepositsAtARate" xlink:href="pypd-20201231.xsd#pypd_monthlyDepositsAtARate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_monthlyDepositsAtARate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromParticipationPayments" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_ProceedsFromParticipationPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FindersFee" xlink:href="pypd-20201231.xsd#pypd_FindersFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_FindersFee" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsToAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PaymentsToAutomaticFilingMachine"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_PaymentsToAutomaticFilingMachine" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForAutomaticFilingMachine"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_PrepaymentForAutomaticFilingMachine" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="pypd_FairValueMeasurementsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueMeasurementsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_FairValueMeasurementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_FairValueMeasurementsDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesE1PreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1PreferredShareWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesE1PreferredShareWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredE1SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredE1SharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_ConvertiblePreferredE1SharesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredD2SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredD2SharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_ConvertiblePreferredD2SharesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredASharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredASharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_ConvertiblePreferredASharesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAPreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAPreferredShareWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesAPreferredShareWarrantsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageFairValueOfWarrantsPercenatge" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageFairValueOfWarrantsPercenatge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_WeightedAverageFairValueOfWarrantsPercenatge" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_CashlessOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_CashlessOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_CashlessOrdinaryShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueOfSeriesAPreferredShareWarrants" xlink:href="pypd-20201231.xsd#pypd_FairValueOfSeriesAPreferredShareWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_FairValueOfSeriesAPreferredShareWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsExercisedShares" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercisedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_WarrantsExercisedShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails">
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesAConvertiblePreferredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesA1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesA1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesA1ConvertiblePreferredSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesBConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesBConvertiblePreferredMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesB1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesB1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesB1ConvertiblePreferredSharesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesC1ConvertiblePreferredSharesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC2ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesC2ConvertiblePreferredSharesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesEConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesEConvertiblePreferredMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesE1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesE1ConvertiblePreferredSharesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD2ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pypd_SeriesD2ConvertiblePreferredSharesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SecuritiesPurchaseAgreementMember" xlink:href="pypd-20201231.xsd#pypd_SecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pypd_SecuritiesPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PrivatePlacementMemorandumMember" xlink:href="pypd-20201231.xsd#pypd_PrivatePlacementMemorandumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pypd_PrivatePlacementMemorandumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AnnualInterestPercentage" xlink:href="pypd-20201231.xsd#pypd_AnnualInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_AnnualInterestPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsPurchaseDescription" xlink:href="pypd-20201231.xsd#pypd_WarrantsPurchaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_WarrantsPurchaseDescription" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsIssued" xlink:href="pypd-20201231.xsd#pypd_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_WarrantsIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DividendRightsDescription" xlink:href="pypd-20201231.xsd#pypd_DividendRightsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_DividendRightsDescription" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LiquudationRightsDescription" xlink:href="pypd-20201231.xsd#pypd_LiquudationRightsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_LiquudationRightsDescription" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20201231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AdvisorsMember" xlink:href="pypd-20201231.xsd#pypd_AdvisorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pypd_AdvisorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OtherKeyEmployeesMember" xlink:href="pypd-20201231.xsd#pypd_OtherKeyEmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pypd_OtherKeyEmployeesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionsAvailableForFutureGrants" xlink:href="pypd-20201231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_StockOptionsAvailableForFutureGrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_UnrecognizedCompensationCosts" xlink:href="pypd-20201231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_UnrecognizedCompensationCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20201231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_RecognizedOverWeightedAveragePeriod" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_RelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_RelatedPartiesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_EasternEuropeMember" xlink:href="pypd-20201231.xsd#pypd_EasternEuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pypd_EasternEuropeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ServiceProvidersInAmount" xlink:href="pypd-20201231.xsd#pypd_ServiceProvidersInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_ServiceProvidersInAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_CostOfRevenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesMember" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pypd_RelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsExercised" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_WarrantsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>pypd-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Total long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20201231.xsd#pypd_TotalLongtermLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pypd_TotalLongtermLiabilities_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="pypd_TotalLongtermLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible preferred shares and shareholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (profit) loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net profit(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:href="pypd-20201231.xsd#pypd_NetLossAttributableToOrdinarySharesAsReported"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl" xml:lang="en-US">Net loss attributable to Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:to="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:href="pypd-20201231.xsd#pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule of Property and equipment useful life [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:to="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="pypd_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule of other payables and accrued expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of future minimum lease payments under operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract_lbl" xml:lang="en-US">Schedule of change in the fair value of the preferred share warrants liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueofPreferredShareWarrantLiability" xlink:href="pypd-20201231.xsd#pypd_FairValueofPreferredShareWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="pypd_FairValueofPreferredShareWarrantLiability_lbl" xml:lang="en-US">Beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueofPreferredShareWarrantLiability" xlink:to="pypd_FairValueofPreferredShareWarrantLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="pypd_FairValueofPreferredShareWarrantLiability_lbl0" xml:lang="en-US">End of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueofPreferredShareWarrantLiability" xlink:to="pypd_FairValueofPreferredShareWarrantLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="pypd_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsAbstract_lbl" xml:lang="en-US">Convertible Preferred Shares And Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="pypd_ConvertiblePreferredSharesAndWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfConvertiblePreferredSharesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfConvertiblePreferredSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfConvertiblePreferredSharesAbstract_lbl" xml:lang="en-US">Schedule of convertible preferred shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfConvertiblePreferredSharesAbstract" xlink:to="pypd_ScheduleOfConvertiblePreferredSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOrdinaryShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of ordinary share capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:to="pypd_ScheduleOfOrdinaryShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract_lbl" xml:lang="en-US">Schedule of status of options to employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding, Beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Outstanding, Ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate intrinsic value, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract_lbl" xml:lang="en-US">Schedule of equity-based awards recognized [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract" xlink:to="pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOptionsOutstandingAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of options outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOptionsOutstandingAbstract" xlink:to="pypd_ScheduleOfOptionsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionsGrantedAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOutstandingOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of outstanding options granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionsGrantedAbstract" xlink:to="pypd_ScheduleOfOutstandingOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFinancialExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfFinancialExpensesNetAbstract_lbl" xml:lang="en-US">Schedule of financial expenses net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfFinancialExpensesNetAbstract" xlink:to="pypd_ScheduleOfFinancialExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per ordinary share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents, as reported on the balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDeposits" xlink:href="pypd-20201231.xsd#pypd_ShorttermDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShorttermDeposits_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDeposits" xlink:to="pypd_ShorttermDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Prepaid expenses and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl" xml:lang="en-US">Long-term assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20201231.xsd#pypd_LongtermDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LongtermDeposits_lbl" xml:lang="en-US">Long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OtherPayablesAndAccruedExpenses" xlink:href="pypd-20201231.xsd#pypd_OtherPayablesAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OtherPayablesAndAccruedExpenses_lbl" xml:lang="en-US">Other payables and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OtherPayablesAndAccruedExpenses" xlink:to="pypd_OtherPayablesAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl" xml:lang="en-US">Long-term liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_WarrantToConvertiblePreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantToConvertiblePreferredShares_lbl" xml:lang="en-US">Warrants to convertible preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantToConvertiblePreferredShares" xlink:to="pypd_WarrantToConvertiblePreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Convertible preferred shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred shares: Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares with no par value - Authorized: 0 and 17,916,412 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 0 and 12,520,977 shares at December 31, 2020 and 2019, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Convertible preferred shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Convertible Preferred shares, Issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity (deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareCapitalAbstract" xlink:href="pypd-20201231.xsd#pypd_ShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareCapitalAbstract_lbl" xml:lang="en-US">Share capital -</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareCapitalAbstract" xlink:to="pypd_ShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Share capital - Ordinary shares with no par value - Authorized: 47,800,000 and 22,520,977 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 18,494,739 and 562,748 shares at December 31, 2020 and 2019, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl" xml:lang="en-US">Marketing and business development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividend" xlink:href="pypd-20201231.xsd#pypd_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (profit) loss per Ordinary share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic net loss (profit) per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per Ordinary share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of Ordinary shares used in computing basic net (profit) loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average Ordinary shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of Ordinary shares used in computing diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Number of shares used in diluted calculation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of Options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of series E-1 Preferred shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of series E-1 Preferred shares, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NetOfIssuanceCosts" xlink:href="pypd-20201231.xsd#pypd_NetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NetOfIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetOfIssuanceCosts" xlink:to="pypd_NetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Sale of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl" xml:lang="en-US">Conversion of Convertible Preferred shares to Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl" xml:lang="en-US">Conversion of Convertible Preferred shares to Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xml:lang="en-US">Deemed dividend related to Series E-1 Preferred shares (see Note 9e)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Deemed dividend related to Series E-1 Preferred shares (see Note 9e) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl" xml:lang="en-US">Reclassification of Warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExerciseOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl" xml:lang="en-US">Exercise of Warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" xlink:to="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ReevaluationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReevaluationOfWarrants_lbl" xml:lang="en-US">Re-evaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:href="pypd-20201231.xsd#pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl" xml:lang="en-US">Decrease in advance on account of collaboration agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:to="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in other payables and accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl" xml:lang="en-US">Proceeds from issuance of convertible Preferred shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:to="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance of Ordinary shares in connection with IPO, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Issuance of warrants cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20201231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl" xml:lang="en-US">Purchase of property and equipment included in trade payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_IssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of E-1 warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial (income) expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20201231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl" xml:lang="en-US">Decrease (increase) in receivables and prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Decrease in deferred equity offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Decrease (increase) in other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Short-term deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:href="pypd-20201231.xsd#pypd_PaymentsAcquireToLongtermDepositsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet_lbl" xml:lang="en-US">Long-term deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:to="pypd_PaymentsAcquireToLongtermDepositsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_PrepaymentForEquipments_lbl" xml:lang="en-US">Pre-payment for equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Convertible Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesMember" xlink:to="pypd_ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash, as reported on the balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:href="pypd-20201231.xsd#pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent_lbl" xml:lang="en-US">Restricted cash in other long-term assets, as reported on the balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:to="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and equipment useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyPlantAndEquipmentPercent" xlink:href="pypd-20201231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, plant and equipment,description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER RECEIVABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GovernmentAuthorities" xlink:href="pypd-20201231.xsd#pypd_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GovernmentAuthorities" xlink:to="pypd_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseDeposits" xlink:href="pypd-20201231.xsd#pypd_LeaseDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LeaseDeposits_lbl" xml:lang="en-US">Lease deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseDeposits" xlink:to="pypd_LeaseDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CostAbstract" xlink:href="pypd-20201231.xsd#pypd_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CostAbstract" xlink:to="pypd_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER PAYABLES AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other payables and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20201231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl" xml:lang="en-US">IIA deferred grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum lease payments under operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of change in the fair value of the preferred share warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ChangeInFairValues" xlink:href="pypd-20201231.xsd#pypd_ChangeInFairValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ChangeInFairValues_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ChangeInFairValues" xlink:to="pypd_ChangeInFairValues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock_lbl" xml:lang="en-US">CONVERTIBLE PREFERRED SHARES AND WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of convertible preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfSharesAbstract" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="pypd_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of ordinary share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfSharesAbstract0" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumberOfSharesAbstract0_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract0" xlink:to="pypd_NumberOfSharesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of status of options to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual life (years), Beginning Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl" xml:lang="en-US">Weighted Average Remaining Contractual life (years), Ending Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual life (years), Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested and expected to vest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl" xml:lang="en-US">Weighted Average Remaining Contractual life (years), Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US">Schedule of equity-based awards recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOptionOutstandingTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOptionOutstandingTablesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ScheduleOfOptionOutstandingTablesTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOptionOutstandingTablesTextBlock" xlink:to="pypd_ScheduleOfOptionOutstandingTablesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualTermYear" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualTermYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageRemainingContractualTermYear_lbl" xml:lang="en-US">Weighted average remaining contractual term (year)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualTermYear" xlink:to="pypd_WeightedAverageRemainingContractualTermYear_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl" xml:lang="en-US">Number options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl" xml:lang="en-US">Number of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl" xml:lang="en-US">Schedule of outstanding options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Average Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl" xml:lang="en-US">Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl" xml:lang="en-US">Schedule of financial expenses net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract_lbl" xml:lang="en-US">Financial expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpenseRevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_FinancialExpenseRevaluationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FinancialExpenseRevaluationOfWarrants_lbl" xml:lang="en-US">Revaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseRevaluationOfWarrants" xlink:to="pypd_FinancialExpenseRevaluationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction loss, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Total financial expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNetAbstract_lbl" xml:lang="en-US">Financial income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Financial expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumeratorAbstract" xlink:href="pypd-20201231.xsd#pypd_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Allocation of net loss (profit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PreferredSharePreference" xlink:href="pypd-20201231.xsd#pypd_PreferredSharePreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PreferredSharePreference_lbl" xml:lang="en-US">Preferred share preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PreferredSharePreference" xlink:to="pypd_PreferredSharePreference_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NetIncomeAllocatedToPreferredShareholders" xlink:href="pypd-20201231.xsd#pypd_NetIncomeAllocatedToPreferredShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NetIncomeAllocatedToPreferredShareholders_lbl" xml:lang="en-US">Net income allocated to preferred shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetIncomeAllocatedToPreferredShareholders" xlink:to="pypd_NetIncomeAllocatedToPreferredShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividends" xlink:href="pypd-20201231.xsd#pypd_DeemedDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DeemedDividends_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Allocation of net loss (profit) attributable to Ordinary shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DenominatorAbstract" xlink:href="pypd-20201231.xsd#pypd_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract" xlink:to="pypd_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DilutedNetLossProfitPerShareAbstract" xlink:href="pypd-20201231.xsd#pypd_DilutedNetLossProfitPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DilutedNetLossProfitPerShareAbstract_lbl" xml:lang="en-US">Diluted net loss (profit) per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DilutedNetLossProfitPerShareAbstract" xlink:to="pypd_DilutedNetLossProfitPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumeratorAbstract0" xlink:href="pypd-20201231.xsd#pypd_NumeratorAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumeratorAbstract0_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract0" xlink:to="pypd_NumeratorAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NetIncomeLossAvailableToBasicComputation" xlink:href="pypd-20201231.xsd#pypd_NetIncomeLossAvailableToBasicComputation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NetIncomeLossAvailableToBasicComputation_lbl" xml:lang="en-US">Allocation of net loss (profit) attributable for basic computation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetIncomeLossAvailableToBasicComputation" xlink:to="pypd_NetIncomeLossAvailableToBasicComputation_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RevaluationOfWarrantsToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrantsToConvertiblePreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RevaluationOfWarrantsToConvertiblePreferredShares_lbl" xml:lang="en-US">Revaluation of warrants to convertible preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RevaluationOfWarrantsToConvertiblePreferredShares" xlink:to="pypd_RevaluationOfWarrantsToConvertiblePreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Allocation of net loss attributable to Ordinary shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DenominatorAbstract0" xlink:href="pypd-20201231.xsd#pypd_DenominatorAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DenominatorAbstract0_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract0" xlink:to="pypd_DenominatorAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Number of shares used in basic calculation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl" xml:lang="en-US">Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationsOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationsOfWarrantsIntoEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_ReclassificationsOfWarrantsIntoEquity_lbl" xml:lang="en-US">Reclassification of Warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationsOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationsOfWarrantsIntoEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less-valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_RevaluationOfWarrants_lbl" xml:lang="en-US">Revaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RevaluationOfWarrants" xlink:to="pypd_RevaluationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction gains, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialOtherIncome" xlink:href="pypd-20201231.xsd#pypd_FinancialOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_FinancialOtherIncome_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialOtherIncome" xlink:to="pypd_FinancialOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Total financial income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computers, software and laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryEquipmentMember" xlink:href="pypd-20201231.xsd#pypd_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryEquipmentMember" xlink:to="pypd_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ReservesAndAllowancesMember" xlink:href="pypd-20201231.xsd#pypd_ReservesAndAllowancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReservesAndAllowancesMember_lbl" xml:lang="en-US">Reserves and allowances [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReservesAndAllowancesMember" xlink:to="pypd_ReservesAndAllowancesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TemporaryDifferencesMember" xlink:href="pypd-20201231.xsd#pypd_TemporaryDifferencesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_TemporaryDifferencesMember_lbl" xml:lang="en-US">Temporary differences [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TemporaryDifferencesMember" xlink:to="pypd_TemporaryDifferencesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IssaunceCostsMember" xlink:href="pypd-20201231.xsd#pypd_IssaunceCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IssaunceCostsMember_lbl" xml:lang="en-US">Issuance costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssaunceCostsMember" xlink:to="pypd_IssaunceCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LossCarryforwardMember" xlink:href="pypd-20201231.xsd#pypd_LossCarryforwardMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LossCarryforwardMember_lbl" xml:lang="en-US">Loss carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LossCarryforwardMember" xlink:to="pypd_LossCarryforwardMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesAConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series A Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAConvertiblePreferredSharesMember" xlink:to="pypd_SeriesAConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesA1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesA1ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesA1ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series A-1 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesA1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesA1ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesBConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesBConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series B Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesBConvertiblePreferredSharesMember" xlink:to="pypd_SeriesBConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesB1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesB1ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesB1ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series B-1 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesB1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesB1ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC1ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesC1ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series C-1 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesC1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesC1ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesC2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC2ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesC2ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series C-2 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesC2ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesC2ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD1ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesD1ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series D-1 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD1ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD2ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesD2ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series D-2 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD2ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD2ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesD3ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD3ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesD3ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series D-3 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD3ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD3ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesEConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesEConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series E Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesEConvertiblePreferredSharesMember" xlink:to="pypd_SeriesEConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesE1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesE1ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Series E-1 Convertible Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesE1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesE1ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MarketingAndBusinessDevelopmentMember_lbl" xml:lang="en-US">Marketing and business development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentMember" xlink:to="pypd_MarketingAndBusinessDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice022Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePrice022Member_lbl" xml:lang="en-US">Exercise Price 0.22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice022Member" xlink:to="pypd_ExercisePrice022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice175Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice175Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePrice175Member_lbl" xml:lang="en-US">Exercise Price 1.75 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice175Member" xlink:to="pypd_ExercisePrice175Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice359Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice359Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePrice359Member_lbl" xml:lang="en-US">Exercise Price 3.59 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice359Member" xlink:to="pypd_ExercisePrice359Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice507Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice507Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePrice507Member_lbl" xml:lang="en-US">Exercise Price 5.07 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice507Member" xlink:to="pypd_ExercisePrice507Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePrice923Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice923Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePrice923Member_lbl" xml:lang="en-US">Exercise Price 9.23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice923Member" xlink:to="pypd_ExercisePrice923Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFiveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price 3.10 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFiveMember" xlink:to="pypd_ExercisePriceFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceSixMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price 3.93 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceSixMember" xlink:to="pypd_ExercisePriceSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceSevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price 4.10 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceSevenMember" xlink:to="pypd_ExercisePriceSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceEightMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price 4.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceEightMember" xlink:to="pypd_ExercisePriceEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceNineMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price 7.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceNineMember" xlink:to="pypd_ExercisePriceNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceTenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price 8.42 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceTenMember" xlink:to="pypd_ExercisePriceTenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceElevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceElevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price 8.65 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceElevenMember" xlink:to="pypd_ExercisePriceElevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceTwelveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTwelveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price 8.02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceTwelveMember" xlink:to="pypd_ExercisePriceTwelveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceThirteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise Price 6.80 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceThirteenMember" xlink:to="pypd_ExercisePriceThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFourtheenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFourtheenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceFourtheenMember_lbl" xml:lang="en-US">Exercise Price 6.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFourtheenMember" xlink:to="pypd_ExercisePriceFourtheenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceFifteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFifteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price 11.04 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFifteenMember" xlink:to="pypd_ExercisePriceFifteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MarchTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_MarchTwoThousandThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MarchTwoThousandThirteenMember_lbl" xml:lang="en-US">March 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarchTwoThousandThirteenMember" xlink:to="pypd_MarchTwoThousandThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OctoberTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OctoberTwoThousandThirteenMember_lbl" xml:lang="en-US">October 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OctoberTwoThousandThirteenMember" xlink:to="pypd_OctoberTwoThousandThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandFourteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_JuneTwoThousandFourteenMember_lbl" xml:lang="en-US">June 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandFourteenMember" xlink:to="pypd_JuneTwoThousandFourteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeptemberTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeptemberTwoThousandFourteenMember_lbl" xml:lang="en-US">September 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeptemberTwoThousandFourteenMember" xlink:to="pypd_SeptemberTwoThousandFourteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AprilTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AprilTwoThousandSixteenMember_lbl" xml:lang="en-US">April 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AprilTwoThousandSixteenMember" xlink:to="pypd_AprilTwoThousandSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DecemberTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DecemberTwoThousandSixteenMember_lbl" xml:lang="en-US">December 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecemberTwoThousandSixteenMember" xlink:to="pypd_DecemberTwoThousandSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_JuneTwoThousandSeventeenMember_lbl" xml:lang="en-US">June 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandSeventeenMember" xlink:to="pypd_JuneTwoThousandSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AugustTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AugustTwoThousandSeventeenMember_lbl" xml:lang="en-US">August 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AugustTwoThousandSeventeenMember" xlink:to="pypd_AugustTwoThousandSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NovemberTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NovemberTwoThousandSeventeenMember_lbl" xml:lang="en-US">November 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NovemberTwoThousandSeventeenMember" xlink:to="pypd_NovemberTwoThousandSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AugustTwoThousandNineteenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandNineteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AugustTwoThousandNineteenMember_lbl" xml:lang="en-US">August 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AugustTwoThousandNineteenMember" xlink:to="pypd_AugustTwoThousandNineteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandTwentyMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_JuneTwoThousandTwentyMember_lbl" xml:lang="en-US">June 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandTwentyMember" xlink:to="pypd_JuneTwoThousandTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash equivalents, short-term deposits and long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionOfReverseShareSplit" xlink:href="pypd-20201231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DescriptionOfReverseShareSplit_lbl" xml:lang="en-US">Description of reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionOfReverseShareSplit" xlink:to="pypd_DescriptionOfReverseShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateNetProceeds" xlink:href="pypd-20201231.xsd#pypd_AggregateNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AggregateNetProceeds_lbl" xml:lang="en-US">Aggregate net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Short-term deposit bearing interest percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Long-term deposit bearing interest percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_monthlyDepositsAtARate" xlink:href="pypd-20201231.xsd#pypd_monthlyDepositsAtARate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_monthlyDepositsAtARate_lbl" xml:lang="en-US">Monthly deposits percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value of the options contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Profits (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Advance payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental and lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromParticipationPayments" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ProceedsFromParticipationPayments_lbl" xml:lang="en-US">Participation payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Commitments and Contingent liabilities, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FindersFee" xlink:href="pypd-20201231.xsd#pypd_FindersFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FindersFee_lbl" xml:lang="en-US">Finder&apos;s fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsToAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PaymentsToAutomaticFilingMachine"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PaymentsToAutomaticFilingMachine_lbl" xml:lang="en-US">Automatic filing machine (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsToAutomaticFilingMachine" xlink:to="pypd_PaymentsToAutomaticFilingMachine_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForAutomaticFilingMachine"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PrepaymentForAutomaticFilingMachine_lbl" xml:lang="en-US">Pre-payment for automatic filing machine (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForAutomaticFilingMachine" xlink:to="pypd_PrepaymentForAutomaticFilingMachine_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageFairValueOfWarrantsPercenatge" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageFairValueOfWarrantsPercenatge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl" xml:lang="en-US">Weighted average fair value of the warrants, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageFairValueOfWarrantsPercenatge" xlink:to="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CashlessOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_CashlessOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CashlessOrdinaryShares_lbl" xml:lang="en-US">Cashless ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashlessOrdinaryShares" xlink:to="pypd_CashlessOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueOfSeriesAPreferredShareWarrants" xlink:href="pypd-20201231.xsd#pypd_FairValueOfSeriesAPreferredShareWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl" xml:lang="en-US">Fair value of series A Preferred share warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueOfSeriesAPreferredShareWarrants" xlink:to="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsExercisedShares" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercisedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsExercisedShares_lbl" xml:lang="en-US">Warrants exercised shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsExercisedShares" xlink:to="pypd_WarrantsExercisedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Corporate tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl" xml:lang="en-US">Amount of approximately (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_lbl" xml:lang="en-US">Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Convertible preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Carrying value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AnnualInterestPercentage" xlink:href="pypd-20201231.xsd#pypd_AnnualInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AnnualInterestPercentage_lbl" xml:lang="en-US">Annual interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AnnualInterestPercentage" xlink:to="pypd_AnnualInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt issued (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs in cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsPurchaseDescription" xlink:href="pypd-20201231.xsd#pypd_WarrantsPurchaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsPurchaseDescription_lbl" xml:lang="en-US">Warrants to purchase, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsPurchaseDescription" xlink:to="pypd_WarrantsPurchaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsIssued" xlink:href="pypd-20201231.xsd#pypd_WarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsIssued_lbl" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsIssued" xlink:to="pypd_WarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial feature value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DividendRightsDescription" xlink:href="pypd-20201231.xsd#pypd_DividendRightsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DividendRightsDescription_lbl" xml:lang="en-US">Dividend rights, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DividendRightsDescription" xlink:to="pypd_DividendRightsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LiquudationRightsDescription" xlink:href="pypd-20201231.xsd#pypd_LiquudationRightsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LiquudationRightsDescription_lbl" xml:lang="en-US">Liquudation rights, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LiquudationRightsDescription" xlink:to="pypd_LiquudationRightsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock option vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl" xml:lang="en-US">Granted stock option expire period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionsAvailableForFutureGrants" xlink:href="pypd-20201231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl" xml:lang="en-US">Stock options available for future grants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllIN9+ieYY6uE2JYwCdM2Lw57DW8XRO394E=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rates, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rates, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnrecognizedCompensationCosts" xlink:href="pypd-20201231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnrecognizedCompensationCosts_lbl" xml:lang="en-US">Unrecognized compensation costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20201231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl" xml:lang="en-US">Recognized over weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ServiceProvidersInAmount" xlink:href="pypd-20201231.xsd#pypd_ServiceProvidersInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ServiceProvidersInAmount_lbl" xml:lang="en-US">Service providers in amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ServiceProvidersInAmount" xlink:to="pypd_ServiceProvidersInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Ordinary shares exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsExercised" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsExercised" xlink:to="pypd_WarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Consolidated financial statements in U.S. dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_LongtermDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LongtermDepositsPolicyTextBlock_lbl" xml:lang="en-US">Long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDepositsPolicyTextBlock" xlink:to="pypd_LongtermDepositsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss (profit) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Accounting for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GrantsAndParticipationsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_GrantsAndParticipationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_GrantsAndParticipationsPolicyTextBlock_lbl" xml:lang="en-US">Grants and participations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GrantsAndParticipationsPolicyTextBlock" xlink:to="pypd_GrantsAndParticipationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Convertible preferred shares and convertible preferred shares warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_DerivativeFinancialInstrumentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl" xml:lang="en-US">Derivative financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" xlink:to="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xml:lang="en-US">Contingent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShortTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_ShortTermDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShortTermDepositsMember_lbl" xml:lang="en-US">Short-Term Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShortTermDepositsMember" xlink:to="pypd_ShortTermDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LongTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_LongTermDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LongTermDepositsMember_lbl" xml:lang="en-US">Long-Term Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongTermDepositsMember" xlink:to="pypd_LongTermDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred E-1 Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesE1PreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1PreferredShareWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesE1PreferredShareWarrantsMember_lbl" xml:lang="en-US">Series E-1 Preferred Share Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesE1PreferredShareWarrantsMember" xlink:to="pypd_SeriesE1PreferredShareWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pypd_SeriesE1PreferredShareWarrantsMember_lbl0" xml:lang="en-US">series E-1 Preferred share warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesE1PreferredShareWarrantsMember" xlink:to="pypd_SeriesE1PreferredShareWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredE1SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredE1SharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredE1SharesMember_lbl" xml:lang="en-US">Convertible Preferred E-1 Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredE1SharesMember" xlink:to="pypd_ConvertiblePreferredE1SharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredD2SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredD2SharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredD2SharesMember_lbl" xml:lang="en-US">Convertible Preferred D-2 Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredD2SharesMember" xlink:to="pypd_ConvertiblePreferredD2SharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredASharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredASharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredASharesMember_lbl" xml:lang="en-US">Convertible Preferred A Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredASharesMember" xlink:to="pypd_ConvertiblePreferredASharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pypd_ConvertiblePreferredASharesMember_lbl0" xml:lang="en-US">Convertible Preferred A shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredASharesMember" xlink:to="pypd_ConvertiblePreferredASharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAPreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAPreferredShareWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesAPreferredShareWarrantsMember_lbl" xml:lang="en-US">Series A Preferred Share Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAPreferredShareWarrantsMember" xlink:to="pypd_SeriesAPreferredShareWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesAConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesAConvertiblePreferredMember_lbl" xml:lang="en-US">Series A Convertible Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAConvertiblePreferredMember" xlink:to="pypd_SeriesAConvertiblePreferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesBConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesBConvertiblePreferredMember_lbl" xml:lang="en-US">Series B Convertible Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesBConvertiblePreferredMember" xlink:to="pypd_SeriesBConvertiblePreferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeriesEConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeriesEConvertiblePreferredMember_lbl" xml:lang="en-US">Series E Convertible Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesEConvertiblePreferredMember" xlink:to="pypd_SeriesEConvertiblePreferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SecuritiesPurchaseAgreementMember" xlink:href="pypd-20201231.xsd#pypd_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SecuritiesPurchaseAgreementMember" xlink:to="pypd_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrivatePlacementMemorandumMember" xlink:href="pypd-20201231.xsd#pypd_PrivatePlacementMemorandumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PrivatePlacementMemorandumMember_lbl" xml:lang="en-US">Private Placement Memorandum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrivatePlacementMemorandumMember" xlink:to="pypd_PrivatePlacementMemorandumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20201231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember_lbl" xml:lang="en-US">2012 Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_AdvisorsMember" xlink:href="pypd-20201231.xsd#pypd_AdvisorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AdvisorsMember_lbl" xml:lang="en-US">Advisors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdvisorsMember" xlink:to="pypd_AdvisorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OtherKeyEmployeesMember" xlink:href="pypd-20201231.xsd#pypd_OtherKeyEmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OtherKeyEmployeesMember_lbl" xml:lang="en-US">Other Key Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OtherKeyEmployeesMember" xlink:to="pypd_OtherKeyEmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_EasternEuropeMember" xlink:href="pypd-20201231.xsd#pypd_EasternEuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_EasternEuropeMember_lbl" xml:lang="en-US">Eastern Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_EasternEuropeMember" xlink:to="pypd_EasternEuropeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesMember" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RelatedPartiesMember_lbl" xml:lang="en-US">Related Parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesMember" xlink:to="pypd_RelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of deferred tax assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable_lbl" xml:lang="en-US">Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems_lbl" xml:lang="en-US">Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of options outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of outstanding options granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsTable" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GeneralDetailsTable" xlink:to="pypd_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GeneralDetailsLineItems_lbl" xml:lang="en-US">General (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="pypd_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueMeasurementsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FairValueMeasurementsDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueMeasurementsDetailsTable" xlink:to="pypd_FairValueMeasurementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FairValueMeasurementsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FairValueMeasurementsDetailsLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueMeasurementsDetailsLineItems" xlink:to="pypd_FairValueMeasurementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Shares and Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems_lbl" xml:lang="en-US">Convertible Preferred Shares and Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsTable" xlink:to="pypd_ShareholdersEquityDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDeficitDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDeficitDetailsLineItems" xlink:to="pypd_ShareholdersEquityDeficitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesDetailsTable" xlink:to="pypd_RelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_RelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="pypd_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AggregateNetProceeds_lbl0" xml:lang="en-US">Amount related to net proceeds from initial public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AnnualInterestPercentage_lbl0" xml:lang="en-US">Annual interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AnnualInterestPercentage" xlink:to="pypd_AnnualInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ChangeInFairValues_lbl0" xml:lang="en-US">Change in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ChangeInFairValues" xlink:to="pypd_ChangeInFairValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl0" xml:lang="en-US">Consolidated financial statements in U.S. dollars policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl0" xml:lang="en-US">Amount related to conversion of Convertible Preferred shares to ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl0" xml:lang="en-US">Conversion of Convertible Preferred shares to ordinary shares, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl0" xml:lang="en-US">Convertible preferred shares and convertible preferred shares warrant liability policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl0" xml:lang="en-US">Decrease (increase) in receivables and prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DeemedDividend_lbl0" xml:lang="en-US">Amount declared as dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DeemedDividends_lbl0" xml:lang="en-US">Deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl0" xml:lang="en-US">Derivative financial instruments policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" xlink:to="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DividendRightsDescription_lbl0" xml:lang="en-US">Dividend rights, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DividendRightsDescription" xlink:to="pypd_DividendRightsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl0" xml:lang="en-US">Fair value of series A Preferred share warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueOfSeriesAPreferredShareWarrants" xlink:to="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FairValueofPreferredShareWarrantLiability_lbl1" xml:lang="en-US">Amount related to fair value of preferred share warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueofPreferredShareWarrantLiability" xlink:to="pypd_FairValueofPreferredShareWarrantLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FinancialExpenseRevaluationOfWarrants_lbl0" xml:lang="en-US">Financial expense revaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseRevaluationOfWarrants" xlink:to="pypd_FinancialExpenseRevaluationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FinancialOtherIncome_lbl0" xml:lang="en-US">Financial other income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialOtherIncome" xlink:to="pypd_FinancialOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FindersFee_lbl0" xml:lang="en-US">Finder&apos;s fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_GrantsAndParticipationsPolicyTextBlock_lbl0" xml:lang="en-US">Grants and participations policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GrantsAndParticipationsPolicyTextBlock" xlink:to="pypd_GrantsAndParticipationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl0" xml:lang="en-US">Increase Decrease in advances on account of collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:to="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl0" xml:lang="en-US">Israel Innovation Authority grant received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IssuanceOfWarrants_lbl0" xml:lang="en-US">Issuance of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LiquudationRightsDescription_lbl0" xml:lang="en-US">Liquudation rights, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LiquudationRightsDescription" xlink:to="pypd_LiquudationRightsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LongtermDeposits_lbl0" xml:lang="en-US">Amount available in long term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LongtermDepositsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of Long-term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDepositsPolicyTextBlock" xlink:to="pypd_LongtermDepositsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl0" xml:lang="en-US">Amount related to Marketing and business development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl0" xml:lang="en-US">Net loss attributable to ordinary shares as reported.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:to="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NetOfIssuanceCosts_lbl0" xml:lang="en-US">Amount of issuance costs net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetOfIssuanceCosts" xlink:to="pypd_NetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_OtherPayablesAndAccruedExpenses_lbl0" xml:lang="en-US">Amount related to other payables and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OtherPayablesAndAccruedExpenses" xlink:to="pypd_OtherPayablesAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet_lbl0" xml:lang="en-US">Long-term deposits, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:to="pypd_PaymentsAcquireToLongtermDepositsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PaymentsToAutomaticFilingMachine_lbl0" xml:lang="en-US">Amount for purchase of manufacturing plant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsToAutomaticFilingMachine" xlink:to="pypd_PaymentsToAutomaticFilingMachine_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PrepaymentForAutomaticFilingMachine_lbl0" xml:lang="en-US">Amount related to pre-payment for automatic filing machine.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForAutomaticFilingMachine" xlink:to="pypd_PrepaymentForAutomaticFilingMachine_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PrepaymentForEquipments_lbl0" xml:lang="en-US">Pre-payment for equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl0" xml:lang="en-US">Proceeds from issuance of convertible Preferred shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:to="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ProceedsFromParticipationPayments_lbl0" xml:lang="en-US">Participation payments received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl0" xml:lang="en-US">Property, plant and equipment percent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl0" xml:lang="en-US">Purchase of property and equipment included in trade payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl0" xml:lang="en-US">Recently Issued Accounting Pronouncements and not yet adopted policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl0" xml:lang="en-US">Reclassification of Warrants into equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReclassificationsOfWarrantsIntoEquity_lbl0" xml:lang="en-US">Reclassification of Warrants into equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationsOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationsOfWarrantsIntoEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl0" xml:lang="en-US">Recognized over a weighted average period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReevaluationOfWarrants_lbl0" xml:lang="en-US">Re-evaluation of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl0" xml:lang="en-US">Restricted cash policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RevaluationOfWarrants_lbl0" xml:lang="en-US">Revaluation of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RevaluationOfWarrants" xlink:to="pypd_RevaluationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">Severance pay policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl0" xml:lang="en-US">The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl0" xml:lang="en-US">The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl0" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, pptions, expire period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl0" xml:lang="en-US">Short-term deposits policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl0" xml:lang="en-US">Exercise of Warrants, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl0" xml:lang="en-US">Issuance of Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" xlink:to="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl0" xml:lang="en-US">Stock options available for future grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_UnrecognizedCompensationCosts_lbl0" xml:lang="en-US">Amount of unrecognized compensation costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WarrantsExercised_lbl0" xml:lang="en-US">Number of warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsExercised" xlink:to="pypd_WarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl0" xml:lang="en-US">Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl0" xml:lang="en-US">Weighted average fair value of the warrants, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageFairValueOfWarrantsPercenatge" xlink:to="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_monthlyDepositsAtARate_lbl0" xml:lang="en-US">Monthly deposits percentage rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AnnualInterestPercentage_lbl1" xml:lang="en-US">AnnualInterestPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AnnualInterestPercentage" xlink:to="pypd_AnnualInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">SecuritiesPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SecuritiesPurchaseAgreementMember" xlink:to="pypd_SecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PreferredSharePreference_lbl0" xml:lang="en-US">PreferredSharePreference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PreferredSharePreference" xlink:to="pypd_PreferredSharePreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl1" xml:lang="en-US">NetLossAttributableToOrdinarySharesAsReported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesAsReported" xlink:to="pypd_NetLossAttributableToOrdinarySharesAsReported_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NovemberTwoThousandSeventeenMember_lbl0" xml:lang="en-US">NovemberTwoThousandSeventeenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NovemberTwoThousandSeventeenMember" xlink:to="pypd_NovemberTwoThousandSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NetIncomeLossAvailableToBasicComputation_lbl0" xml:lang="en-US">NetIncomeLossAvailableToBasicComputation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetIncomeLossAvailableToBasicComputation" xlink:to="pypd_NetIncomeLossAvailableToBasicComputation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ChangeInFairValues_lbl1" xml:lang="en-US">ChangeInFairValues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ChangeInFairValues" xlink:to="pypd_ChangeInFairValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OctoberTwoThousandThirteenMember_lbl0" xml:lang="en-US">OctoberTwoThousandThirteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OctoberTwoThousandThirteenMember" xlink:to="pypd_OctoberTwoThousandThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePrice022Member_lbl0" xml:lang="en-US">ExercisePrice022Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice022Member" xlink:to="pypd_ExercisePrice022Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReevaluationOfWarrants_lbl1" xml:lang="en-US">ReevaluationOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FairValueofPreferredShareWarrantLiability_lbl2" xml:lang="en-US">FairValueofPreferredShareWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueofPreferredShareWarrantLiability" xlink:to="pypd_FairValueofPreferredShareWarrantLiability_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesAPreferredShareWarrantsMember_lbl0" xml:lang="en-US">SeriesAPreferredShareWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAPreferredShareWarrantsMember" xlink:to="pypd_SeriesAPreferredShareWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PaymentsToAutomaticFilingMachine_lbl1" xml:lang="en-US">PaymentsToAutomaticFilingMachine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsToAutomaticFilingMachine" xlink:to="pypd_PaymentsToAutomaticFilingMachine_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl1" xml:lang="en-US">IsraelInnovationAuthorityGrantReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareCapitalAbstract_lbl0" xml:lang="en-US">ShareCapitalAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareCapitalAbstract" xlink:to="pypd_ShareCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_JuneTwoThousandTwentyMember_lbl0" xml:lang="en-US">JuneTwoThousandTwentyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandTwentyMember" xlink:to="pypd_JuneTwoThousandTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DenominatorAbstract_lbl0" xml:lang="en-US">DenominatorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract" xlink:to="pypd_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialOtherIncome_lbl1" xml:lang="en-US">FinancialOtherIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialOtherIncome" xlink:to="pypd_FinancialOtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OtherKeyEmployeesMember_lbl0" xml:lang="en-US">OtherKeyEmployeesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OtherKeyEmployeesMember" xlink:to="pypd_OtherKeyEmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GrantsAndParticipationsPolicyTextBlock_lbl1" xml:lang="en-US">GrantsAndParticipationsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GrantsAndParticipationsPolicyTextBlock" xlink:to="pypd_GrantsAndParticipationsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsIssued_lbl0" xml:lang="en-US">WarrantsIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsIssued" xlink:to="pypd_WarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_EasternEuropeMember_lbl0" xml:lang="en-US">EasternEuropeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_EasternEuropeMember" xlink:to="pypd_EasternEuropeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LongtermDeposits_lbl1" xml:lang="en-US">LongtermDeposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceFourtheenMember_lbl0" xml:lang="en-US">ExercisePriceFourtheenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFourtheenMember" xlink:to="pypd_ExercisePriceFourtheenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredE1SharesMember_lbl0" xml:lang="en-US">ConvertiblePreferredE1SharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredE1SharesMember" xlink:to="pypd_ConvertiblePreferredE1SharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TotalLongtermLiabilities_lbl0" xml:lang="en-US">TotalLongtermLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="pypd_TotalLongtermLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LiquudationRightsDescription_lbl1" xml:lang="en-US">LiquudationRightsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LiquudationRightsDescription" xlink:to="pypd_LiquudationRightsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IssaunceCostsMember_lbl0" xml:lang="en-US">IssaunceCostsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssaunceCostsMember" xlink:to="pypd_IssaunceCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RevaluationOfWarrantsToConvertiblePreferredShares_lbl0" xml:lang="en-US">RevaluationOfWarrantsToConvertiblePreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RevaluationOfWarrantsToConvertiblePreferredShares" xlink:to="pypd_RevaluationOfWarrantsToConvertiblePreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePrice923Member_lbl0" xml:lang="en-US">ExercisePrice923Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice923Member" xlink:to="pypd_ExercisePrice923Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumeratorAbstract_lbl0" xml:lang="en-US">NumeratorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl1" xml:lang="en-US">FairValueOfSeriesAPreferredShareWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FairValueOfSeriesAPreferredShareWarrants" xlink:to="pypd_FairValueOfSeriesAPreferredShareWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RevaluationOfWarrants_lbl1" xml:lang="en-US">RevaluationOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RevaluationOfWarrants" xlink:to="pypd_RevaluationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">LaboratoryEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryEquipmentMember" xlink:to="pypd_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceEightMember_lbl0" xml:lang="en-US">ExercisePriceEightMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceEightMember" xlink:to="pypd_ExercisePriceEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl1" xml:lang="en-US">StockOptionsAvailableForFutureGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AggregateNetProceeds_lbl1" xml:lang="en-US">AggregateNetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NetOfIssuanceCosts_lbl1" xml:lang="en-US">NetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetOfIssuanceCosts" xlink:to="pypd_NetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceElevenMember_lbl0" xml:lang="en-US">ExercisePriceElevenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceElevenMember" xlink:to="pypd_ExercisePriceElevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl1" xml:lang="en-US">ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl1" xml:lang="en-US">RestrictedCashPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesD3ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesD3ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD3ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD3ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl1" xml:lang="en-US">ConversionOfConvertiblePreferredSharesToOrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePrice359Member_lbl0" xml:lang="en-US">ExercisePrice359Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice359Member" xlink:to="pypd_ExercisePrice359Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceNineMember_lbl0" xml:lang="en-US">ExercisePriceNineMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceNineMember" xlink:to="pypd_ExercisePriceNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PaymentsAcquireToLongtermDepositsNet_lbl1" xml:lang="en-US">PaymentsAcquireToLongtermDepositsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsAcquireToLongtermDepositsNet" xlink:to="pypd_PaymentsAcquireToLongtermDepositsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl1" xml:lang="en-US">WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl1" xml:lang="en-US">DerivativeFinancialInstrumentsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DerivativeFinancialInstrumentsPolicyTextBlock" xlink:to="pypd_DerivativeFinancialInstrumentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl1" xml:lang="en-US">RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OtherPayablesAndAccruedExpenses_lbl1" xml:lang="en-US">OtherPayablesAndAccruedExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OtherPayablesAndAccruedExpenses" xlink:to="pypd_OtherPayablesAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrivatePlacementMemorandumMember_lbl0" xml:lang="en-US">PrivatePlacementMemorandumMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrivatePlacementMemorandumMember" xlink:to="pypd_PrivatePlacementMemorandumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePrice175Member_lbl0" xml:lang="en-US">ExercisePrice175Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice175Member" xlink:to="pypd_ExercisePrice175Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceSixMember_lbl0" xml:lang="en-US">ExercisePriceSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceSixMember" xlink:to="pypd_ExercisePriceSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent_lbl0" xml:lang="en-US">RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:to="pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_JuneTwoThousandSeventeenMember_lbl0" xml:lang="en-US">JuneTwoThousandSeventeenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandSeventeenMember" xlink:to="pypd_JuneTwoThousandSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock_lbl0" xml:lang="en-US">ConvertiblePreferredSharesAndWarrantsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndWarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesAConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesAConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAConvertiblePreferredSharesMember" xlink:to="pypd_SeriesAConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsExercisedShares_lbl0" xml:lang="en-US">WarrantsExercisedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsExercisedShares" xlink:to="pypd_WarrantsExercisedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceThirteenMember_lbl0" xml:lang="en-US">ExercisePriceThirteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceThirteenMember" xlink:to="pypd_ExercisePriceThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl1" xml:lang="en-US">MarketingAndBusinessDevelopmentExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl1" xml:lang="en-US">ReclassificationOfWarrantsIntoEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesC2ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesC2ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesC2ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesC2ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOptionOutstandingTablesTextBlock_lbl0" xml:lang="en-US">ScheduleOfOptionOutstandingTablesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOptionOutstandingTablesTextBlock" xlink:to="pypd_ScheduleOfOptionOutstandingTablesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LossCarryforwardMember_lbl0" xml:lang="en-US">LossCarryforwardMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LossCarryforwardMember" xlink:to="pypd_LossCarryforwardMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl1" xml:lang="en-US">IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:to="pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ServiceProvidersInAmount_lbl0" xml:lang="en-US">ServiceProvidersInAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ServiceProvidersInAmount" xlink:to="pypd_ServiceProvidersInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CostAbstract_lbl0" xml:lang="en-US">CostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CostAbstract" xlink:to="pypd_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl1" xml:lang="en-US">ShorttermDepositsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AdvisorsMember_lbl0" xml:lang="en-US">AdvisorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdvisorsMember" xlink:to="pypd_AdvisorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShortTermDepositsMember_lbl0" xml:lang="en-US">ShortTermDepositsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShortTermDepositsMember" xlink:to="pypd_ShortTermDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesB1ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesB1ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesB1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesB1ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl0" xml:lang="en-US">WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeptemberTwoThousandFourteenMember_lbl0" xml:lang="en-US">SeptemberTwoThousandFourteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeptemberTwoThousandFourteenMember" xlink:to="pypd_SeptemberTwoThousandFourteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FindersFee_lbl1" xml:lang="en-US">FindersFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DenominatorAbstract0_lbl0" xml:lang="en-US">DenominatorAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract0" xlink:to="pypd_DenominatorAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TemporaryDifferencesMember_lbl0" xml:lang="en-US">TemporaryDifferencesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TemporaryDifferencesMember" xlink:to="pypd_TemporaryDifferencesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl1" xml:lang="en-US">ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl1" xml:lang="en-US">StockIssuedDuringPeriodExerciseOfWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl0" xml:lang="en-US">ScheduleOfOutstandingOptionGrantedTablesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumeratorAbstract0_lbl0" xml:lang="en-US">NumeratorAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract0" xlink:to="pypd_NumeratorAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesBConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesBConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesBConvertiblePreferredSharesMember" xlink:to="pypd_SeriesBConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MarketingAndBusinessDevelopmentMember_lbl0" xml:lang="en-US">MarketingAndBusinessDevelopmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentMember" xlink:to="pypd_MarketingAndBusinessDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceFiveMember_lbl0" xml:lang="en-US">ExercisePriceFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFiveMember" xlink:to="pypd_ExercisePriceFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsExercised_lbl1" xml:lang="en-US">WarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsExercised" xlink:to="pypd_WarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl1" xml:lang="en-US">ProceedsFromIssuanceOfConvertiblePreferredSharesNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:to="pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentPercent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl1" xml:lang="en-US">DecreaseincreaseInReceivablesAndPrepaidExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantToConvertiblePreferredShares_lbl0" xml:lang="en-US">WarrantToConvertiblePreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantToConvertiblePreferredShares" xlink:to="pypd_WarrantToConvertiblePreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceTenMember_lbl0" xml:lang="en-US">ExercisePriceTenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceTenMember" xlink:to="pypd_ExercisePriceTenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceFifteenMember_lbl0" xml:lang="en-US">ExercisePriceFifteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceFifteenMember" xlink:to="pypd_ExercisePriceFifteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_JuneTwoThousandFourteenMember_lbl0" xml:lang="en-US">JuneTwoThousandFourteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandFourteenMember" xlink:to="pypd_JuneTwoThousandFourteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnrecognizedCompensationCosts_lbl1" xml:lang="en-US">UnrecognizedCompensationCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DilutedNetLossProfitPerShareAbstract_lbl0" xml:lang="en-US">DilutedNetLossProfitPerShareAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DilutedNetLossProfitPerShareAbstract" xlink:to="pypd_DilutedNetLossProfitPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesC1ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesC1ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesC1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesC1ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesE1ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesE1ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesE1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesE1ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl1" xml:lang="en-US">WeightedAverageFairValueOfWarrantsPercenatge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageFairValueOfWarrantsPercenatge" xlink:to="pypd_WeightedAverageFairValueOfWarrantsPercenatge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LongtermDepositsPolicyTextBlock_lbl1" xml:lang="en-US">LongtermDepositsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDepositsPolicyTextBlock" xlink:to="pypd_LongtermDepositsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageRemainingContractualTermYear_lbl0" xml:lang="en-US">WeightedAverageRemainingContractualTermYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualTermYear" xlink:to="pypd_WeightedAverageRemainingContractualTermYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CashlessOrdinaryShares_lbl0" xml:lang="en-US">CashlessOrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashlessOrdinaryShares" xlink:to="pypd_CashlessOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl1" xml:lang="en-US">CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:to="pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DeemedDividend_lbl1" xml:lang="en-US">DeemedDividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShorttermDeposits_lbl0" xml:lang="en-US">ShorttermDeposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDeposits" xlink:to="pypd_ShorttermDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceSevenMember_lbl0" xml:lang="en-US">ExercisePriceSevenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceSevenMember" xlink:to="pypd_ExercisePriceSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesEConvertiblePreferredMember_lbl0" xml:lang="en-US">SeriesEConvertiblePreferredMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesEConvertiblePreferredMember" xlink:to="pypd_SeriesEConvertiblePreferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ProceedsFromParticipationPayments_lbl1" xml:lang="en-US">ProceedsFromParticipationPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MarchTwoThousandThirteenMember_lbl0" xml:lang="en-US">MarchTwoThousandThirteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarchTwoThousandThirteenMember" xlink:to="pypd_MarchTwoThousandThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodIssuanceOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodIssuanceOfWarrants" xlink:to="pypd_StockIssuedDuringPeriodIssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NetIncomeAllocatedToPreferredShareholders_lbl0" xml:lang="en-US">NetIncomeAllocatedToPreferredShareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetIncomeAllocatedToPreferredShareholders" xlink:to="pypd_NetIncomeAllocatedToPreferredShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredD2SharesMember_lbl0" xml:lang="en-US">ConvertiblePreferredD2SharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredD2SharesMember" xlink:to="pypd_ConvertiblePreferredD2SharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl1" xml:lang="en-US">PurchaseOfPropertyAndEquipmentIncludedInTradePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesA1ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesA1ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesA1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesA1ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialExpenseRevaluationOfWarrants_lbl1" xml:lang="en-US">FinancialExpenseRevaluationOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseRevaluationOfWarrants" xlink:to="pypd_FinancialExpenseRevaluationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesD2ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesD2ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD2ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD2ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DividendRightsDescription_lbl1" xml:lang="en-US">DividendRightsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DividendRightsDescription" xlink:to="pypd_DividendRightsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePrice507Member_lbl0" xml:lang="en-US">ExercisePrice507Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePrice507Member" xlink:to="pypd_ExercisePrice507Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DecemberTwoThousandSixteenMember_lbl0" xml:lang="en-US">DecemberTwoThousandSixteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecemberTwoThousandSixteenMember" xlink:to="pypd_DecemberTwoThousandSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesE1PreferredShareWarrantsMember_lbl1" xml:lang="en-US">SeriesE1PreferredShareWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesE1PreferredShareWarrantsMember" xlink:to="pypd_SeriesE1PreferredShareWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl1" xml:lang="en-US">ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DescriptionOfReverseShareSplit_lbl0" xml:lang="en-US">DescriptionOfReverseShareSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionOfReverseShareSplit" xlink:to="pypd_DescriptionOfReverseShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AugustTwoThousandSeventeenMember_lbl0" xml:lang="en-US">AugustTwoThousandSeventeenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AugustTwoThousandSeventeenMember" xlink:to="pypd_AugustTwoThousandSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl1" xml:lang="en-US">ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AprilTwoThousandSixteenMember_lbl0" xml:lang="en-US">AprilTwoThousandSixteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AprilTwoThousandSixteenMember" xlink:to="pypd_AprilTwoThousandSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesBConvertiblePreferredMember_lbl0" xml:lang="en-US">SeriesBConvertiblePreferredMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesBConvertiblePreferredMember" xlink:to="pypd_SeriesBConvertiblePreferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReservesAndAllowancesMember_lbl0" xml:lang="en-US">ReservesAndAllowancesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReservesAndAllowancesMember" xlink:to="pypd_ReservesAndAllowancesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl1" xml:lang="en-US">RecognizedOverWeightedAveragePeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LongTermDepositsMember_lbl0" xml:lang="en-US">LongTermDepositsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongTermDepositsMember" xlink:to="pypd_LongTermDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredASharesMember_lbl1" xml:lang="en-US">ConvertiblePreferredASharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredASharesMember" xlink:to="pypd_ConvertiblePreferredASharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl0" xml:lang="en-US">PrepaidExpensesAndOtherReceivablesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumberOfSharesAbstract0_lbl0" xml:lang="en-US">NumberOfSharesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract0" xlink:to="pypd_NumberOfSharesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaymentForEquipments_lbl1" xml:lang="en-US">PrepaymentForEquipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">PrepaidExpensesAndOtherReceivablesDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AugustTwoThousandNineteenMember_lbl0" xml:lang="en-US">AugustTwoThousandNineteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AugustTwoThousandNineteenMember" xlink:to="pypd_AugustTwoThousandNineteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LeaseDeposits_lbl0" xml:lang="en-US">LeaseDeposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseDeposits" xlink:to="pypd_LeaseDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReclassificationsOfWarrantsIntoEquity_lbl1" xml:lang="en-US">ReclassificationsOfWarrantsIntoEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationsOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationsOfWarrantsIntoEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsPurchaseDescription_lbl0" xml:lang="en-US">WarrantsPurchaseDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsPurchaseDescription" xlink:to="pypd_WarrantsPurchaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DeemedDividends_lbl1" xml:lang="en-US">DeemedDividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceTwelveMember_lbl0" xml:lang="en-US">ExercisePriceTwelveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceTwelveMember" xlink:to="pypd_ExercisePriceTwelveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesMember_lbl0" xml:lang="en-US">RelatedPartiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesMember" xlink:to="pypd_RelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExerciseOfWarrants_lbl1" xml:lang="en-US">ExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember_lbl0" xml:lang="en-US">TwoThousandTwelveShareOptionPlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IssuanceOfWarrants_lbl1" xml:lang="en-US">IssuanceOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesMember" xlink:to="pypd_ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesD1ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesD1ConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesD1ConvertiblePreferredSharesMember" xlink:to="pypd_SeriesD1ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_monthlyDepositsAtARate_lbl1" xml:lang="en-US">monthlyDepositsAtARate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumberOfSharesAbstract_lbl0" xml:lang="en-US">NumberOfSharesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="pypd_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaymentForAutomaticFilingMachine_lbl1" xml:lang="en-US">PrepaymentForAutomaticFilingMachine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForAutomaticFilingMachine" xlink:to="pypd_PrepaymentForAutomaticFilingMachine_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GovernmentAuthorities_lbl0" xml:lang="en-US">GovernmentAuthorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GovernmentAuthorities" xlink:to="pypd_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesEConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">SeriesEConvertiblePreferredSharesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesEConvertiblePreferredSharesMember" xlink:to="pypd_SeriesEConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl1" xml:lang="en-US">SeverancePayPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeriesAConvertiblePreferredMember_lbl0" xml:lang="en-US">SeriesAConvertiblePreferredMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeriesAConvertiblePreferredMember" xlink:to="pypd_SeriesAConvertiblePreferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US">ConsolidatedFinancialStatementsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl0" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl0" xml:lang="en-US">Investment Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract_lbl0" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremiumAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl0" xml:lang="en-US">Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl0" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl0" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_lbl0" xml:lang="en-US">Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl0" xml:lang="en-US">Investment Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0" xml:lang="en-US">Derivative, Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl0" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl0" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl0" xml:lang="en-US">Preferred Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl0" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAbstract_lbl0" xml:lang="en-US">Investment Income, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl0" xml:lang="en-US">Long-term Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0" xml:lang="en-US">Schedule of Subsequent Events [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl1" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl2" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl0" xml:lang="en-US">Investment Income, Investment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl0" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl0" xml:lang="en-US">Features of Convertible Preferred Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Public Utility Property, Plant, and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl0" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Capital Leased Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>pypd-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 03 23:09:29 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedComprehensiveIncome" roleURI="http://Polypid.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityType2or3" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_General" roleURI="http://Polypid.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPolicies" roleURI="http://Polypid.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PrepaidExpensesandOtherReceivables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNet" roleURI="http://Polypid.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_OtherPayablesandAccruedExpenses" roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilities" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurements" roleURI="http://Polypid.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxes" roleURI="http://Polypid.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrants" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficit" roleURI="http://Polypid.com/role/ShareholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FinancialExpensesNet" roleURI="http://Polypid.com/role/FinancialExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_BasicandDilutedNetLossProfitPerShare" roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_RelatedParties" roleURI="http://Polypid.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SubsequentEvents" roleURI="http://Polypid.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_AccountingPoliciesByPolicy" roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPoliciesTables" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PrepaidExpensesandOtherReceivablesTables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNetTables" roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_OtherPayablesandAccruedExpensesTables" roleURI="http://Polypid.com/role/OtherPayablesandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilitiesTables" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurementsTables" roleURI="http://Polypid.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxesTables" roleURI="http://Polypid.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrantsTables" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficitTables" roleURI="http://Polypid.com/role/ShareholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FinancialExpensesNetTables" roleURI="http://Polypid.com/role/FinancialExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_BasicandDilutedNetLossProfitPerShareTables" roleURI="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofRestrictionsonCashandCashEquivalentsTable" roleURI="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofPropertyandequipmentusefullifeTable" roleURI="http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofprepaidexpensesandotherreceivablesTable" roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofpropertyandequipmentTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofotherpayablesandaccruedexpensesTable" roleURI="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable" roleURI="http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofdeferredtaxassetsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofconvertiblepreferredsharesTable" roleURI="http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofordinarysharecapitalTable" roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofstatusofoptionstoemployeesTable" roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofequitybasedawardsrecognizedTable" roleURI="http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofoptionsoutstandingTable" roleURI="http://Polypid.com/role/ScheduleofoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofoutstandingoptionsgrantedTable" roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleoffinancialexpensesnetTable" roleURI="http://Polypid.com/role/ScheduleoffinancialexpensesnetTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ScheduleofbasicanddilutednetlossperordinaryshareTable" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_GeneralDetails" roleURI="http://Polypid.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SignificantAccountingPoliciesDetails" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_PropertyandEquipmentNetDetails" roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_FairValueMeasurementsDetails" roleURI="http://Polypid.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_IncomeTaxesDetails" roleURI="http://Polypid.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ConvertiblePreferredSharesandWarrantsDetails" roleURI="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_ShareholdersEquityDeficitDetails" roleURI="http://Polypid.com/role/ShareholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_RelatedPartiesDetails" roleURI="http://Polypid.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#pypd_r_SubsequentEventsDetails" roleURI="http://Polypid.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20201231.xsd#DocumentAndEntityInformation" roleURI="http://Polypid.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermDeposits" xlink:href="pypd-20201231.xsd#pypd_ShorttermDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ShorttermDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermDeposits" xlink:href="pypd-20201231.xsd#pypd_LongtermDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="LongtermDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherPayablesAndAccruedExpenses" xlink:href="pypd-20201231.xsd#pypd_OtherPayablesAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="OtherPayablesAndAccruedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OtherLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_WarrantToConvertiblePreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="WarrantToConvertiblePreferredShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalLongtermLiabilities" xlink:href="pypd-20201231.xsd#pypd_TotalLongtermLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="TotalLongtermLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_StockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="MarketingAndBusinessDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="pypd-20201231.xsd#pypd_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="DeemedDividend" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossAttributableToOrdinarySharesAsReported" xlink:href="pypd-20201231.xsd#pypd_NetLossAttributableToOrdinarySharesAsReported"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="NetLossAttributableToOrdinarySharesAsReported" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ConvertiblePreferredSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfConvertiblePreferredSharesToOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20201231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ReclassificationOfWarrantsIntoEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrants" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodExerciseOfWarrantsShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodIssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_StockIssuedDuringPeriodIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodIssuanceOfWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="NetOfIssuanceCosts" xlink:href="pypd-20201231.xsd#pypd_NetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="NetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_ReevaluationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ReevaluationOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20201231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="DecreaseincreaseInReceivablesAndPrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" xlink:href="pypd-20201231.xsd#pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsAcquireToLongtermDepositsNet" xlink:href="pypd-20201231.xsd#pypd_PaymentsAcquireToLongtermDepositsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsAcquireToLongtermDepositsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForEquipments" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PrepaymentForEquipments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredSharesNet" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfConvertiblePreferredSharesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20201231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfWarrants" xlink:href="pypd-20201231.xsd#pypd_IssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherReceivables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="PrepaidExpensesAndOtherReceivablesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/OtherPayablesandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrants">
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndWarrantsTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="ConvertiblePreferredSharesAndWarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialExpensesNet">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConsolidatedFinancialStatementsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCashPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RestrictedCashPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ShorttermDepositsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermDepositsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_LongtermDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LongtermDepositsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantsAndParticipationsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_GrantsAndParticipationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantsAndParticipationsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeFinancialInstrumentsPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_DerivativeFinancialInstrumentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DerivativeFinancialInstrumentsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" xlink:href="pypd-20201231.xsd#pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" xlink:href="pypd-20201231.xsd#pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="PrepaidExpensesAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/OtherPayablesandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables">
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionOutstandingTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOptionOutstandingTablesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfOptionOutstandingTablesTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfOutstandingOptionGrantedTablesTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialExpensesNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" xlink:href="pypd-20201231.xsd#pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" xlink:href="pypd-20201231.xsd#pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract" xlink:to="CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentPercent" xlink:href="pypd-20201231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="pypd-20201231.xsd#pypd_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="GovernmentAuthorities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseDeposits" xlink:href="pypd-20201231.xsd#pypd_LeaseDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="LeaseDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_OtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="pypd-20201231.xsd#pypd_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20201231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="IsraelInnovationAuthorityGrantReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherPayablesAndAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofPreferredShareWarrantLiability" xlink:href="pypd-20201231.xsd#pypd_FairValueofPreferredShareWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="FairValueofPreferredShareWarrantLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValues" xlink:href="pypd-20201231.xsd#pypd_ChangeInFairValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="ChangeInFairValues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationsOfWarrantsIntoEquity" xlink:href="pypd-20201231.xsd#pypd_ReclassificationsOfWarrantsIntoEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="ReclassificationsOfWarrantsIntoEquity" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueofPreferredShareWarrantLiability_0" xlink:href="pypd-20201231.xsd#pypd_FairValueofPreferredShareWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract" xlink:to="FairValueofPreferredShareWarrantLiability_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20201231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReservesAndAllowancesMember" xlink:href="pypd-20201231.xsd#pypd_ReservesAndAllowancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="ReservesAndAllowancesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryDifferencesMember" xlink:href="pypd-20201231.xsd#pypd_TemporaryDifferencesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="TemporaryDifferencesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssaunceCostsMember" xlink:href="pypd-20201231.xsd#pypd_IssaunceCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="IssaunceCostsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossCarryforwardMember" xlink:href="pypd-20201231.xsd#pypd_LossCarryforwardMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="LossCarryforwardMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredSharesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfConvertiblePreferredSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePreferredSharesAbstract" xlink:to="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesA1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesA1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesA1ConvertiblePreferredSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredSharesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesB1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesB1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesB1ConvertiblePreferredSharesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesC1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesC1ConvertiblePreferredSharesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesC2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC2ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesC2ConvertiblePreferredSharesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtBSSFTjV4Jbes6flvgFx4SqvPtYkq1cuIs++EqUbBlDoGuEMXoiJ6x55K/PmOFEwAk06zGoEn3jCgC6C3rFbWPimMqfEu1UllL5o4l+dZENvkG3ATag/aG2UJ1LkROP9Qs=] CSR-->
    <loc xlink:type="locator" xlink:label="SeriesD1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesD1ConvertiblePreferredSharesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesD2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD2ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesD2ConvertiblePreferredSharesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesD3ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD3ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesD3ConvertiblePreferredSharesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesEConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesEConvertiblePreferredSharesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesE1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesE1ConvertiblePreferredSharesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesTable" xlink:to="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsScheduleofconvertiblepreferredsharesLineItems" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofordinarysharecapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOrdinaryShareCapitalAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract0" xlink:href="pypd-20201231.xsd#pypd_NumberOfSharesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinaryShareCapitalAbstract" xlink:to="NumberOfSharesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityBasedAwardsRecognizedAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfEquityBasedAwardsRecognizedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityBasedAwardsRecognizedAbstract" xlink:to="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20201231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="MarketingAndBusinessDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedTable" xlink:to="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingAbstract" xlink:to="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice022Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice022Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice175Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice175Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice175Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice359Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice359Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice359Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice507Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice507Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice507Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice923Member" xlink:href="pypd-20201231.xsd#pypd_ExercisePrice923Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice923Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceFiveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSixMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceSixMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceSevenMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceEightMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceEightMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceNineMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceNineMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceTenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceTenMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceElevenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceElevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceElevenMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceTwelveMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceTwelveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceTwelveMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceThirteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceThirteenMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceFourtheenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFourtheenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceFourtheenMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceFifteenMember" xlink:href="pypd-20201231.xsd#pypd_ExercisePriceFifteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceFifteenMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingTable" xlink:to="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualTermYear" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageRemainingContractualTermYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="WeightedAverageRemainingContractualTermYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionsGrantedAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsGrantedAbstract" xlink:to="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarchTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_MarchTwoThousandThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="MarchTwoThousandThirteenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OctoberTwoThousandThirteenMember" xlink:href="pypd-20201231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OctoberTwoThousandThirteenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandFourteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneTwoThousandFourteenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeptemberTwoThousandFourteenMember" xlink:href="pypd-20201231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="SeptemberTwoThousandFourteenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AprilTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AprilTwoThousandSixteenMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberTwoThousandSixteenMember" xlink:href="pypd-20201231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="DecemberTwoThousandSixteenMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneTwoThousandSeventeenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AugustTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AugustTwoThousandSeventeenMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NovemberTwoThousandSeventeenMember" xlink:href="pypd-20201231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="NovemberTwoThousandSeventeenMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AugustTwoThousandNineteenMember" xlink:href="pypd-20201231.xsd#pypd_AugustTwoThousandNineteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AugustTwoThousandNineteenMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwoThousandTwentyMember" xlink:href="pypd-20201231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneTwoThousandTwentyMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20201231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffinancialexpensesnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialExpensesNetAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfFinancialExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialExpenseRevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_FinancialExpenseRevaluationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="FinancialExpenseRevaluationOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_OtherExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfWarrants" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="RevaluationOfWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialOtherIncome" xlink:href="pypd-20201231.xsd#pypd_FinancialOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="FinancialOtherIncome" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:href="pypd-20201231.xsd#pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredSharePreference" xlink:href="pypd-20201231.xsd#pypd_PreferredSharePreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="PreferredSharePreference" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncomeAllocatedToPreferredShareholders" xlink:href="pypd-20201231.xsd#pypd_NetIncomeAllocatedToPreferredShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="NetIncomeAllocatedToPreferredShareholders" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividends" xlink:href="pypd-20201231.xsd#pypd_DeemedDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="DeemedDividends" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossAvailableToBasicComputation" xlink:href="pypd-20201231.xsd#pypd_NetIncomeLossAvailableToBasicComputation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="NetIncomeLossAvailableToBasicComputation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfWarrantsToConvertiblePreferredShares" xlink:href="pypd-20201231.xsd#pypd_RevaluationOfWarrantsToConvertiblePreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="RevaluationOfWarrantsToConvertiblePreferredShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GeneralDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfReverseShareSplit" xlink:href="pypd-20201231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="DescriptionOfReverseShareSplit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNetProceeds" xlink:href="pypd-20201231.xsd#pypd_AggregateNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="AggregateNetProceeds" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_ShortTermDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="ShortTermDepositsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsMember" xlink:href="pypd-20201231.xsd#pypd_LongTermDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="LongTermDepositsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="SignificantAccountingPoliciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="monthlyDepositsAtARate" xlink:href="pypd-20201231.xsd#pypd_monthlyDepositsAtARate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="monthlyDepositsAtARate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromParticipationPayments" xlink:href="pypd-20201231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ProceedsFromParticipationPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FindersFee" xlink:href="pypd-20201231.xsd#pypd_FindersFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="FindersFee" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsToAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PaymentsToAutomaticFilingMachine"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="PaymentsToAutomaticFilingMachine" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAutomaticFilingMachine" xlink:href="pypd-20201231.xsd#pypd_PrepaymentForAutomaticFilingMachine"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="PrepaymentForAutomaticFilingMachine" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_FairValueMeasurementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueMeasurementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesE1PreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1PreferredShareWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesE1PreferredShareWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredE1SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredE1SharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ConvertiblePreferredE1SharesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredD2SharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredD2SharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ConvertiblePreferredD2SharesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredASharesMember" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredASharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ConvertiblePreferredASharesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAPreferredShareWarrantsMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAPreferredShareWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAPreferredShareWarrantsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="FairValueMeasurementsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageFairValueOfWarrantsPercenatge" xlink:href="pypd-20201231.xsd#pypd_WeightedAverageFairValueOfWarrantsPercenatge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="WeightedAverageFairValueOfWarrantsPercenatge" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessOrdinaryShares" xlink:href="pypd-20201231.xsd#pypd_CashlessOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="CashlessOrdinaryShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfSeriesAPreferredShareWarrants" xlink:href="pypd-20201231.xsd#pypd_FairValueOfSeriesAPreferredShareWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="FairValueOfSeriesAPreferredShareWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedShares" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercisedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="WarrantsExercisedShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails">
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesAndWarrantsAbstract" xlink:to="ConvertiblePreferredSharesandWarrantsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesAConvertiblePreferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesA1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesA1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesA1ConvertiblePreferredSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesBConvertiblePreferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesB1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesB1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesB1ConvertiblePreferredSharesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesC1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesC1ConvertiblePreferredSharesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesC2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesC2ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesC2ConvertiblePreferredSharesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesEConvertiblePreferredMember" xlink:href="pypd-20201231.xsd#pypd_SeriesEConvertiblePreferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesEConvertiblePreferredMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesE1ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesE1ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesE1ConvertiblePreferredSharesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesD2ConvertiblePreferredSharesMember" xlink:href="pypd-20201231.xsd#pypd_SeriesD2ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesD2ConvertiblePreferredSharesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementMemorandumMember" xlink:href="pypd-20201231.xsd#pypd_PrivatePlacementMemorandumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivatePlacementMemorandumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementMember" xlink:href="pypd-20201231.xsd#pypd_SecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="SecuritiesPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsTable" xlink:to="ConvertiblePreferredSharesandWarrantsDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInterestPercentage" xlink:href="pypd-20201231.xsd#pypd_AnnualInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="AnnualInterestPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsPurchaseDescription" xlink:href="pypd-20201231.xsd#pypd_WarrantsPurchaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="WarrantsPurchaseDescription" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssued" xlink:href="pypd-20201231.xsd#pypd_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="WarrantsIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DividendRightsDescription" xlink:href="pypd-20201231.xsd#pypd_DividendRightsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="DividendRightsDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquudationRightsDescription" xlink:href="pypd-20201231.xsd#pypd_LiquudationRightsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredSharesandWarrantsDetailsLineItems" xlink:to="LiquudationRightsDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsTable" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_ShareholdersEquityDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDeficitDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisorsMember" xlink:href="pypd-20201231.xsd#pypd_AdvisorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="AdvisorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherKeyEmployeesMember" xlink:href="pypd-20201231.xsd#pypd_OtherKeyEmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="OtherKeyEmployeesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20201231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwelveShareOptionPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_EmployeeStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="ShareholdersEquityDeficitDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" xlink:href="pypd-20201231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsAvailableForFutureGrants" xlink:href="pypd-20201231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="StockOptionsAvailableForFutureGrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationCosts" xlink:href="pypd-20201231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="UnrecognizedCompensationCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20201231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="RecognizedOverWeightedAveragePeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsTable" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EasternEuropeMember" xlink:href="pypd-20201231.xsd#pypd_EasternEuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="EasternEuropeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="RelatedPartiesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ServiceProvidersInAmount" xlink:href="pypd-20201231.xsd#pypd_ServiceProvidersInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="ServiceProvidersInAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="pypd-20201231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesMember" xlink:href="pypd-20201231.xsd#pypd_RelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercised" xlink:href="pypd-20201231.xsd#pypd_WarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="WarrantsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="pypd-20201231.xsd#pypd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721542392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PolyPid Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">18,494,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715497544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,319<span></span>
</td>
<td class="nump">$ 3,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShorttermDeposits', window );">Short-term deposits</a></td>
<td class="nump">40,157<span></span>
</td>
<td class="nump">22,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,200<span></span>
</td>
<td class="nump">27,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,890<span></span>
</td>
<td class="nump">6,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_LongtermDeposits', window );">Long-term deposits</a></td>
<td class="nump">22,120<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term assets</a></td>
<td class="nump">28,647<span></span>
</td>
<td class="nump">6,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">75,847<span></span>
</td>
<td class="nump">33,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_OtherPayablesAndAccruedExpenses', window );">Other payables and accrued expenses</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantToConvertiblePreferredShares', window );">Warrants to convertible preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_TotalLongtermLiabilities', window );">Total long-term liabilities</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">12,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred shares: Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares with no par value - Authorized: 0 and 17,916,412 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 0 and 12,520,977 shares at December 31, 2020 and 2019, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">106,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital - Ordinary shares with no par value - Authorized: 47,800,000 and 22,520,977 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 18,494,739 and 562,748 shares at December 31, 2020 and 2019, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">205,063<span></span>
</td>
<td class="nump">5,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(132,286)<span></span>
</td>
<td class="num">(93,303)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity (deficit)</a></td>
<td class="nump">72,777<span></span>
</td>
<td class="num">(87,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred shares and shareholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 75,847<span></span>
</td>
<td class="nump">$ 33,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount available in long term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_OtherPayablesAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to other payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_OtherPayablesAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShorttermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShorttermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_TotalLongtermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_TotalLongtermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantToConvertiblePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantToConvertiblePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715684776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,916,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">47,800,000<span></span>
</td>
<td class="nump">22,520,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">18,494,739<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">18,494,739<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370714796824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net</a></td>
<td class="nump">$ 16,954<span></span>
</td>
<td class="nump">$ 14,083<span></span>
</td>
<td class="nump">$ 12,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_MarketingAndBusinessDevelopmentExpenses', window );">Marketing and business development expenses</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,704<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">26,272<span></span>
</td>
<td class="nump">18,560<span></span>
</td>
<td class="nump">18,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial (income) expense, net</a></td>
<td class="nump">10,597<span></span>
</td>
<td class="num">(11,655)<span></span>
</td>
<td class="num">(24,281)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (profit) loss</a></td>
<td class="nump">36,869<span></span>
</td>
<td class="nump">6,905<span></span>
</td>
<td class="num">(5,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NetLossAttributableToOrdinarySharesAsReported', window );">Net loss attributable to Ordinary shares</a></td>
<td class="nump">$ 38,983<span></span>
</td>
<td class="nump">$ 6,905<span></span>
</td>
<td class="num">$ (5,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (profit) loss per Ordinary share (in Dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per Ordinary share (in Dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary shares used in computing basic net (profit) loss per share (in Shares)</a></td>
<td class="nump">9,582,405<span></span>
</td>
<td class="nump">562,451<span></span>
</td>
<td class="nump">561,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary shares used in computing diluted net loss per share (in Shares)</a></td>
<td class="nump">9,582,405<span></span>
</td>
<td class="nump">562,451<span></span>
</td>
<td class="nump">613,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount declared as dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_MarketingAndBusinessDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to Marketing and business development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_MarketingAndBusinessDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NetLossAttributableToOrdinarySharesAsReported">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss attributable to ordinary shares as reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NetLossAttributableToOrdinarySharesAsReported</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370716889688">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Convertible Preferred Shares</div></th>
<th class="th"><div>Number of ordinary shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,669<span></span>
</td>
<td class="num">$ (92,315)<span></span>
</td>
<td class="num">$ (88,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,736,425<span></span>
</td>
<td class="nump">558,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of series E-1 Preferred shares, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 9,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of series E-1 Preferred shares, net (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">718,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net profit(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 69,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
<td class="num">(86,398)<span></span>
</td>
<td class="num">(81,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,454,433<span></span>
</td>
<td class="nump">561,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of series E-1 Preferred shares, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 36,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of series E-1 Preferred shares, net (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,066,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net profit(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,905)<span></span>
</td>
<td class="num">(6,905)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 106,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,671<span></span>
</td>
<td class="num">(93,303)<span></span>
</td>
<td class="num">(87,632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,520,977<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,577<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,757<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">62,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e) (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares', window );">Conversion of Convertible Preferred shares to Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (106,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,313<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares', window );">Conversion of Convertible Preferred shares to Ordinary shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,520,977)<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Deemed dividend related to Series E-1 Preferred shares (see Note 9e)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="num">(2,114)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Deemed dividend related to Series E-1 Preferred shares (see Note 9e) (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">158,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ReclassificationOfWarrantsIntoEquity', window );">Reclassification of Warrants into equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ExerciseOfWarrants', window );">Exercise of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares', window );">Exercise of Warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">939,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodIssuanceOfWarrants', window );">Issuance of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net profit(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,869)<span></span>
</td>
<td class="num">(36,869)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,063<span></span>
</td>
<td class="num">$ (132,286)<span></span>
</td>
<td class="nump">$ 72,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,494,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of issuance costs of $187 in cash.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net of issuance costs of $3,822 in cash and warrants.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to conversion of Convertible Preferred shares to ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Preferred shares to ordinary shares, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReclassificationOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Warrants into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReclassificationOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of Warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockIssuedDuringPeriodIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockIssuedDuringPeriodIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721441496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders&#8217; Equity (Deficit) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NetOfIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 3,822<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance costs net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715593576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net profit (loss)</a></td>
<td class="num">$ (36,869)<span></span>
</td>
<td class="num">$ (6,905)<span></span>
</td>
<td class="nump">$ 5,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ReevaluationOfWarrants', window );">Re-evaluation of warrants</a></td>
<td class="nump">11,373<span></span>
</td>
<td class="num">(11,365)<span></span>
</td>
<td class="num">(24,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses', window );">Decrease (increase) in receivables and prepaid expenses</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Decrease in deferred equity offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement', window );">Decrease in advance on account of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease (increase) in other long-term assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(607)<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="num">(887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in other payables and accrued expenses and other liabilities</a></td>
<td class="nump">847<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,596)<span></span>
</td>
<td class="num">(17,358)<span></span>
</td>
<td class="num">(16,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Short-term deposits, net</a></td>
<td class="num">(17,472)<span></span>
</td>
<td class="num">(22,685)<span></span>
</td>
<td class="nump">14,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PaymentsAcquireToLongtermDepositsNet', window );">Long-term deposits, net</a></td>
<td class="num">(22,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaymentForEquipments', window );">Pre-payment for equipment</a></td>
<td class="num">(395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(781)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
<td class="num">(3,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(40,768)<span></span>
</td>
<td class="num">(23,564)<span></span>
</td>
<td class="nump">10,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet', window );">Proceeds from issuance of convertible Preferred shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,646<span></span>
</td>
<td class="nump">9,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance of Ordinary shares in connection with IPO, net</a></td>
<td class="nump">62,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of warrants</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">62,774<span></span>
</td>
<td class="nump">37,653<span></span>
</td>
<td class="nump">9,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">410<span></span>
</td>
<td class="num">(3,269)<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">4,498<span></span>
</td>
<td class="nump">7,767<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">$ 4,908<span></span>
</td>
<td class="nump">4,498<span></span>
</td>
<td class="nump">7,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable', window );">Purchase of property and equipment included in trade payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IssuanceOfWarrants', window );">Issuance of E-1 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease (increase) in receivables and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in advances on account of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IncreaseDecreaseInDecreaseInAdvancesOnAccountOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PaymentsAcquireToLongtermDepositsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term deposits, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PaymentsAcquireToLongtermDepositsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaymentForEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-payment for equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaymentForEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible Preferred shares, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ProceedsFromIssuanceOfConvertiblePreferredSharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of property and equipment included in trade payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReevaluationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Re-evaluation of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReevaluationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719650920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">GENERAL</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
1:-	GENERAL</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">PolyPid Ltd. (the &#x201c;Company&#x201d;)
                                         was incorporated under the laws of Israel and commenced operations on February&#xa0;28,
                                         2008. The Company is a clinical-stage pharmaceutical company focused on developing and
                                         commercializing novel, locally administered therapies using its PLEX (Polymer-Lipid Encapsulation
                                         matriX) technology. The Company&#x2019;s product candidates are designed to address unmet medical
                                         needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined
                                         release rates and durations over extended periods ranging from days to several months.
                                         The Company is initially focused on the development of its lead product candidate, D-PLEX,
                                         which incorporates an antibiotic, for the prevention of surgical site infection in bone
                                         and soft tissue.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company wholly-owns subsidiaries
in the Unites States of America and Romania.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Through
December 31, 2020, the Company has been primarily engaged in research and development.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">The Company&#x2019;s activities since
                                         inception have consisted of performing research and development activities. Successful
                                         completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable
                                         operations is dependent on future events, including, among other things, its ability
                                         to secure financing; obtain marketing approval from regulatory authorities; access potential
                                         markets; build a sustainable customer base; attract, retain and motivate qualified
                                         personnel; and develop strategic alliances. The Company&#x2019;s operations are funded by its
                                         shareholders and research and development grants and the Company intends to seek further
                                         private or public financing as well as make applications for further research and development
                                         grants for continuing its operations. Although management believes that the Company will
                                         be able to successfully fund its operations, there can be no assurance that the Company
                                         will be able to do so or that the Company will ever operate profitably.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute
its business plan, the Company will need to complete phase III clinical studies and certain development activities as well as
manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&#x2019;s product
candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing
and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately
be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2020, the
Company had cash, cash equivalents, short-term deposits and long-term deposits of $66,596. During the year ended December&#xa0;31,
2020, the Company incurred a net loss of $36,869 and had negative cash flows from operating activities of $21,596. In addition,
the Company had an accumulated deficit of $132,286 at December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company&#x2019;s
future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies;
(ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production
batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company&#x2019;s product candidates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">There can
be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><font style="font-size: 10pt">c</font>.</td><td style="text-align: justify">On
                                         March 11, 2020, the World Health Organization declared the outbreak of a respiratory
                                         disease caused by a new coronavirus as a &#x201c;pandemic&#x201d; which is now known as
                                         COVID-19. The outbreak has impacted thousands of individuals worldwide. In response,
                                         many countries have implemented measures to combat the outbreak which have impacted global
                                         business operations. The Company&#x2019;s business is likely to be adversely affected by the
                                         effects of the recent and evolving COVID-19 pandemic, which has resulted in travel and
                                         other restrictions in order to reduce the spread of the disease, including in Israel,
                                         the United States and the European Union where the Company is conducting or planning
                                         clinical trials. No impairments were recorded as of the balance sheet date as no triggering
                                         events or changes in circumstances had occurred; however, due to significant uncertainty
                                         surrounding the situation, management&#x2019;s judgment regarding this could change in the future.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">On June 21, 2020, the Company&#x2019;s Board of Directors resolved to consolidate the
                                                              Company&#x2019;s share capital by applying a reverse share split at a ratio of 1.046:1 (the &#x201c;Reverse Split Ratio&#x201d;)
                                                              and to cancel the shares&#x2019; par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1
                                                              Ordinary share with no par value (the &#x201c;Split&#x201d;). The Split was  applied in the same proportion and manner to all
                                                              of the Company&#x2019;s authorized, issued and outstanding securities, including preferred shares, options and warrants. See
                                                              Note 10.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">On June 30, 2020, the Company
                                         closed its initial public offering (&#x201c;IPO&#x201d;) whereby 4,312,500 Ordinary shares
                                         were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant
                                         to the full exercise of an overallotment option granted to the underwriters). The aggregate
                                         net proceeds received by the Company from the offering were $62,757, net of underwriting
                                         discounts and other offering costs.</td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719655864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
2:-	SIGNIFICANT ACCOUNTING POLICIES</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The consolidated financial
statements are prepared according to United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;)</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation
of the consolidated financial statements in conformity with U.S.&#xa0;GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s
management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of
share-based awards, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and
the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Consolidated financial statements
                                         in U.S.&#xa0;dollars:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The accompanying
consolidated financial statements have been prepared in U.S.&#xa0;dollars.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A substantial portion of the Company&#x2019;s expenses are incurred
in New Israeli Shekels (&#x201c;NIS&#x201d;). However, the Company finances its operations mainly in U.S. dollars, a substantial
portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated
in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment
in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#xa0;dollar.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Transactions and balances denominated in U.S. dollars are presented
at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance
with Accounting Standards Codification (&#x201c;ASC&#x201d;) No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains
and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income
or expenses, as appropriate.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The consolidated
financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Reclassifications:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Certain prior years amounts
have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated
net loss.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Cash equivalents:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or
less, at the date acquired.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">f.</td><td style="text-align: justify">Restricted cash:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Restricted
cash is primarily invested in certificates of deposit and is used as security for the Company&#x2019;s lease commitments and hedging
activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets
and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, as reported on the balance sheets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,319</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,924</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Restricted cash, as reported on the balance sheets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">390</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">375</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Restricted cash in other long-term assets, as reported on the balance sheets</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,908</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,498</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">g.</td><td style="text-align: justify">Short-term deposits:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Short-term bank deposit is a
deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging
from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value
due to their short maturities.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.5in; text-align: left">h.</td><td style="text-align: justify">Long-term deposits:</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A Long-term bank deposit is
a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per
annum, as of December 31, 2020. Long-term deposits are presented at cost.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">i.</td><td style="text-align: justify">Property and equipment, net:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets at the following rates:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Computers, software and laboratory equipment</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">15&#xa0;-&#xa0;33</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Furniture and office equipment</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 18%; text-align: center">15</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt">Leasehold improvements</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">Over the shorter of the term of the lease or its useful life</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Down payments for property and
equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the
corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">j.</td><td style="text-align: justify">Impairment of long-lived assets:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company&#x2019;s long-lived assets are reviewed for impairment
in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset
exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">k.</td><td style="text-align: justify">Research and development expenses:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Research
and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting
fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory
approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property
rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities
related costs. The Company charges research and development expenses as expenses when incurred.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">l.</td><td style="text-align: justify">Basic and diluted net loss (profit)
                                         per share:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company computes net loss (profit) per share using the two-class
method required for participating securities. The two-class method requires income available to ordinary shareholders for the period
to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as
if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating
securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders
of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require
the holders of such shares to participate in the Company&#x2019;s losses. As such,&#xa0;during the periods when the Company is in
a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under
the two-class method as these securities did not have a contractual obligation to share in the Company&#x2019;s losses.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&#x2019;s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary
shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of
potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially
dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature
of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the
effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">m.</td><td style="text-align: justify">Accounting for share-based payments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Share-based compensation expense related to share-based awards
is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite
service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value
of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company&#x2019;s
Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine
the fair value of the share awards represent management&#x2019;s best estimates. These estimates involve inherent uncertainties
and the application of management&#x2019;s judgment. Forfeitures are accounted for as they occur instead of estimating the number
of awards expected to be forfeited.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">n.</td><td style="text-align: justify">Grants and participations:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Royalty-bearing
grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) (previously known as Office of the Chief Scientist) of the Ministry
of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company
is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#x2019;s Seventh Framework Programme for
Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such
grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Since the
payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received
from IIA until the related revenues are recognized.&#xa0;In the event of failure of a project that was partly financed by IIA,
the Company will not be obligated to pay any royalties or repay the amounts received.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company recognizes participations in research and development,
as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research
and development expenses incurred during the period is recognized as other income within operating income.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">o.</td><td style="text-align: justify">Convertible preferred shares
                                         and convertible preferred shares warrant liability:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The terms
of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#xa0;shares allowed the holders to redeem shares, under
certain circumstances, outside of the Company&#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance
sheet and not included as a component of shareholders&#x2019; deficit before the IPO. The carrying value of the convertible preferred
shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the
convertible preferred shares will be redeemed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Warrants
to purchase the Company&#x2019;s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair
value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the
Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance
sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an
orderly transaction between market participants at the measurement date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In determining
fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Unobservable
inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available in the circumstances.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Fair value
is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or a liability.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A three-tier
fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical
                                         assets and liabilities.</td></tr>                                                                          <tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: justify">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         2 - Include other inputs that are directly or indirectly observable in the marketplace.</td></tr>                                                                                                                                          <tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: justify">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         3 - Unobservable inputs which are supported by little or no market activity.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value hierarchy also
requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<font style="font-size: 10pt">.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The financial
instruments carried at fair value on the Company&#x2019;s consolidated balance sheets as of December 31, 2019 are warrants to convertible
preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The following
methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The carrying
amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables,
trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such
instruments.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">q.</td><td style="text-align: justify">Income taxes:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax
assets to their estimated realizable value, if needed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">ASC 740
contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that
it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including
resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized
tax benefits was recorded as a result of ASC 740.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&#x2019;s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">r.</td><td style="text-align: justify">Concentration of credit risks:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash, cash
equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be
in excess of insured limits and are not insured.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">in other jurisdictions.
Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge
a portion of the Company&#x2019;s non-dollar currency exposure. Counterparties to the Company&#x2019;s derivative instruments are all major
financial institutions.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">s.</td><td style="text-align: justify">Severance pay:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All the Company&#x2019;s employees
who are Israeli citizens have subscribed to Section&#xa0;14 of Israel&#x2019;s Severance Pay Law, 5723-1963
(&#x201c;Section&#xa0;14&#x201d;). Pursuant to Section&#xa0;14, employees covered by this section are entitled to monthly
deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with
Section&#xa0;14 release the Company from any future severance liabilities in respect of those employees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Neither severance
pay liability nor severance pay fund under Section&#xa0;14 for such employees is recorded on the Company&#x2019;s consolidated balance
sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Severance
pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">t.</td><td style="text-align: justify">Derivative financial instruments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for derivatives and hedging based on ASC
815, &#x201c;Derivatives and hedging&#x201d;, as amended and related interpretations (&#x201c;ASC 815&#x201d;). ASC 815 requires the
Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is
so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against
the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions)
or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The ineffective portion of a derivative&#x2019;s change in fair value
is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included
in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts
in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative
instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from
such instruments is recognized immediately as &#x201c;financial income, net&#x201d;.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company measured the fair value of the contracts in accordance
with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices
and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was
$62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December
31, 2019 and 2018 amounted to $10 and $0, respectively.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">u.</td><td style="text-align: justify">Contingent liabilities</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for its contingent liabilities in accordance
with ASC 450, &#x201c;Contingencies&#x201d;. A provision is recorded when it is both probable that a liability has been incurred and
the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect
the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining
to a particular matter.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company is occasionally
a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any
pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of
operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">v.</td><td style="text-align: justify">Recently adopted Accounting Pronouncements</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As an &#x201c;emerging
growth company&#x201d;, the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of
new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private
companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below
reflect this election<font style="font-family: Times New Roman, Times, Serif">.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In June 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#xa0;2018-07, &#x201c;Improvements to Nonemployee Share-Based Payment
Accounting,&#x201d; which simplifies the accounting for share-based payments granted to nonemployees for goods and services and
aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.
The Company adopted the guidance as of January&#xa0;1, 2020. The adoption of the standard didn&#x2019;t have a material impact on the
Company&#x2019;s consolidated statements of operations.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently Issued Accounting Pronouncements</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In February 2016, the FASB issued
ASU No. 2016-02, &#x201c;Leases,&#x201d; which would require lessees to recognize assets and liabilities on the balance sheet for
most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner
similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance
states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for
the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1,
2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of
the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure
requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current
and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU
2016-02 will have on its consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2017, the FASB issued
ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies
the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their
hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements,
expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure
requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January
1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its
Consolidated Statements of Operations or Cash Flows.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2018, the FASB issued ASU No. 2018-15, &#x201c;Intangibles-Goodwill
and Other-Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract,&#x201d; which aligns the requirements for capitalizing implementation costs incurred in
a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop
or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally
over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that
of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and
interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the
effect that ASU 2018-15 will have on its consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201d; which simplifies the accounting for income taxes by removing
a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for
intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses
that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in
fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12
will have on its consolidated financial statements and related disclosures.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719669112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesTextBlock', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
3:-	PREPAID EXPENSES AND OTHER RECEIVABLES</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Government authorities</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">283</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Prepaid expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,888</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Lease deposits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,334</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">417</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719655864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
4:-	PROPERTY AND EQUIPMENT, NET</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">Cost:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Computers and software</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">449</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">389</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Laboratory equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,356</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Furniture and office equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">152</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">147</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,478</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,136</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Depreciated cost</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,890</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,121</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Depreciation expenses amounted to $1,012, $947 and $411 for
the years ended December&#xa0;31, 2020, 2019 and 2018, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719360952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER PAYABLES AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
5:-	OTHER PAYABLES AND ACCRUED EXPENSES</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Employees and payroll accruals</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">971</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">673</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Accrued expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">681</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">319</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">IIA deferred grant </td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">241</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,903</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">998</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719649512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
6:-	COMMITMENTS AND CONTINGENT LIABILITIES</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">The Company&#x2019;s facilities are
                                         leased under operating lease agreements for periods ending no later than 2027. The Company
                                         also leases motor vehicles under various operating leases, the latest of which expires
                                         in 2023.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Future minimum
lease payments under operating leases as of December&#xa0;31, 2020 are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">As of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,236</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,181</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">995</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">425</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,403</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December
31, 2020, the Company made advance payments on account of car leases in the amount of $75.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Rental and lease expenses for the years ended December&#xa0;31,
2020, 2019 and 2018 were $1,035, $&#xa0;1,027 and $1,073, respectively.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">In connection with its research
                                         and development programs, through December 31, 2020, the Company received participation
                                         payments from the IIA in the aggregate amount of $5,139. In return for IIA&#x2019;s participation,
                                         the Company is committed to pay royalties at a rate of 3% of sales of the developed products,
                                         up to 100% of the amount of grants received plus interest at LIBOR rate. Through December
                                         31, 2020, no royalties have been paid or accrued.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">On December 22, 2016, the Company received a written demand for a finder&#x2019;s fee in an
                                                              amount of $250, in connection with the second financing round that occurred in 2016. In September 2017, a suit was filed
                                                              against the Company in the Tel-Aviv Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court
                                                              ruling, which ruled in favor of the Company, discharging the entire claim, and accordingly reversed the related
                                                              provision.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">On January 9, 2020, the Company
                                         entered into an agreement for an automatic filling machine for the Company&#x2019;s manufacturing
                                         plant in a total amount of EUR 1,326. The Company paid a pre-payment of EUR 372 and will
                                         pay the remaining of the payments during 2021 according to the milestones of the agreement.</td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719624936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
7:-	FAIR VALUE MEASUREMENTS</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments measured at fair value on a recurring
basis include warrants to convertible preferred shares (see Note 9). The warrants are classified as a liability in accordance with
ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation
(the share price) were determined based on management&#x2019;s assumptions. To calculate the fair value of the warrants, the Company first
calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing
two scenarios of option pricing model and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes
model was utilized to calculate the warrants&#x2019; value in each one of the scenarios. 50% probability for each one of the scenarios
was applied to derive the weighted average fair value of the warrants.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2019:&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario the underlying share price
was between $13.25 - $13.40 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 69.11%, risk
free interest rates of 1.82%, dividend yield of 0%, and expected term of 2.25 years. Under the IPO scenario the underlying share
price was $12.18 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value of the series
E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series E-1 Preferred
share warrants as of December 31, 2019 was $563.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario, the underlying share
price was $10.29 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&#xa0;D-2
Preferred share warrants as of December&#xa0;31, 2019 (exercise price of $9.24): expected volatility of 69.11%, risk free interest
rates of 1.82%, dividend yield of 0% and expected term of 2.25&#xa0;years. Under the IPO scenario, the underlying share price was
$12.18 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series&#xa0;D-2
Preferred share warrants as of December&#xa0;31, 2019 (exercise price of $9.24): expected volatility of 64.03%, risk free interest
rates of 1.87%, dividend yield of 0%, and expected term of 0.42&#xa0;years. Accordingly, the fair value of the series&#xa0;D-2
Preferred share warrants as of December&#xa0;31, 2019 was $11,275.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the liquidation scenario, the underlying share
price was $4.35 for the Convertible Preferred A shares. The following assumptions were used to estimate the value of the series&#xa0;A
Preferred share warrants as of December&#xa0;31, 2019 (exercise price of NIS&#xa0;0.84 ($0.24)): expected volatility of 69.11%,
risk free interest rates of 1.82%, dividend yield of 0% and expected term of 2.25&#xa0;years. Under the IPO scenario, the underlying
share price was $12.18 for the Convertible Preferred&#xa0;A shares. The following assumptions were used to estimate the value of
the series&#xa0;A Preferred share warrants as of December&#xa0;31, 2019 (exercise price of NIS&#xa0;0.84 ($0.24)): expected volatility
of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42&#xa0;years. Accordingly, the fair
value of the series&#xa0;A Preferred share warrants as of December&#xa0;31, 2019 was $403.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of June 30, 2020:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario,
the underlying share price was $16 for the series E-1 Preferred shares. The following assumptions were used to estimate the value
of the series E-1 Preferred share warrants as of June 30, 2020: exercise price of $15.95, expected volatility of 78.07%, risk
free interest rates of 0.76%, dividend yield of 0%, and expected term of 4.17 years. Accordingly, the fair value of the series
E-1 Preferred share warrants as of June 30, 2020 was $1,868.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario, the underlying share price was
$16 for the series D-2 Preferred shares. The following assumptions were used to estimate the value of the series D-2 Preferred
share warrants as of June 30, 2020: exercise price of $9.24, expected volatility of 82.48%, risk free interest rates of 0.46%,
dividend yield of 0%, and expected term of 0.6 years. Accordingly, the fair value of the series D-2 Preferred share warrants as
of June 30, 2020 was $20,930. As of June 30, 2020, as part of the IPO 1,123,570 Warrants have been exercised on cashless basis
into 475,049 Ordinary shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">According to the IPO scenario, the underlying share price was
$16 for the series A Preferred shares. The following assumptions were used to estimate the value of the series A Preferred share
warrants as of June 30, 2020: exercise price of 0.84 NIS ($0.23) and dividend yield of 0%. Accordingly, the fair value of the series
A Preferred share warrants as of June 30, 2020 was $816. As of June 30, 2020, as part of the IPO, 53,775 Warrants have been exercised
into 53,775 Ordinary shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 30, 2020, as a
result of the IPO, the warrant liability to Convertible Preferred shares has been classified to Warrants to Ordinary shares
in equity.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The change in
the fair value of the Preferred share warrant liability is summarized below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,241</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,926</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Issuance of warrants</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">680</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">11,373</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,365</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Reclassification of Warrants into equity</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,614</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">End of period</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,241</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370723485048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
8:-	INCOME TAXES</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Corporate tax rates:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The corporate tax rate in Israel
in 2020, 2019 and 2018 was 23%.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Net operating losses carryforward:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has accumulated losses for tax purposes as of December 31, 2020 in the amount of approximately $96,385 which may be carried forward
and offset against taxable income in the future for an indefinite period.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Deferred taxes:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for
income tax purposes. The Company&#x2019;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Significant
components of the Company&#x2019;s deferred tax assets are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Reserves and allowances</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Temporary differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,644</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,204</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">957</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss carryforward</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,168</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15,406</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">26,959</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,783</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,959</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,783</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable
income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable
future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In 2019 and 2018, the main reconciling item of the Company&#x2019;s
statutory tax rate of 23% and the effective tax rate of 0% is tax loss carryforwards, for which a full valuation allowance was
provided.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Tax assessment:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2020,
the Company&#x2019;s tax years until December 31, 2015 are subject to the statute of limitation in Israel.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719629080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesAndWarrantsAbstract', window );"><strong>Convertible Preferred Shares And Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesAndWarrantsTextBlock', window );">CONVERTIBLE PREFERRED SHARES AND WARRANTS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
9:-	CONVERTIBLE PREFERRED SHARES AND WARRANTS</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">The Composition of the Company&#x2019;s
                                         Convertible Preferred shares is as follows:</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;A Convertible Preferred shares with no par value</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">537,750</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">483,975</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;A-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">896,250</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">798,950</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;B Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">597,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">566,386</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;B-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,867,562</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,751,309</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;C-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">717,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">645,923</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;C-2 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">454,100</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">410,197</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-1 Convertible Preferred shares of NIS&#xa0;0 par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,509,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,376,512</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-2 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,868,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-3 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">597,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">576,944</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;E Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,135,250</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">851,795</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Series&#xa0;E-1 Convertible Preferred shares with no par value</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,736,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,058,986</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">17,916,412</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">12,520,977</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company issued Series A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Preferred shares between February 2008 and September 2019. The Company classifies the convertible preferred shares outside
of shareholders&#x2019; deficit as required by&#xa0;ASC&#xa0;480-10-S99-3A and ASR 268, since these preferred shares are entitled
to liquidation preferences which may trigger a distribution of cash or assets that is not solely within the Company&#x2019;s control.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Upon completion of the IPO, all convertible preferred shares
outstanding, totaling 12,520,977 shares, were automatically converted into Ordinary shares and their carrying value of $106,300
was reclassified into shareholders&#x2019; equity.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Preferred shares rights:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Up to completion of the IPO on June 30, 2020, series A, A-1,
B, B-1, C-1,C-2, D-1,D-3, E and E-1 convertible preferred shares conferred upon their holders all the rights conferred by Ordinary
shares, in addition to certain rights stipulated in the Company&#x2019;s previous Articles of Association (the &#x201c;Previous Articles&#x201d;),
inter alia, the following:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><i>Dividend
rights - </i>the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E
and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration
or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend
or distribution was declared by the Company&#x2019;s board of directors, an amount equal to 6% per annum of the applicable original issue
price for such preferred shares (the &#x201c;Preference Dividend&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preference order was such that Series E-1, E, D, C-2, C-1,
B-1, B, A-1 and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above order,
any distribution of any asset, capital, earnings or surplus funds of the Company. After the Preference Dividend has been paid in
full, the preferred shareholders&#x2019; were entitled to participate pro-rata and pari-passu, on an as converted basis with the Ordinary
shareholders&#x2019; in the receipt of any additional dividend distributed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><i>Liquidation
rights -</i> In the event of any event of liquidation or deemed liquidation
event, the Company was required to distribute to the holders of convertible preferred shares, prior to and in preference to any
payments to any of the holders of any other classes of shares, a per share amount equal to the original issuance price plus 6%
annual interest compounded annually from the date of issuance and up to the date of liquidation for each of their shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Holders of Series E-1, E preferred shares and D preferred shares
were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original
issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount
equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The liquidation order was such that Series E-1, E, D, C-2 and
C-1, B-1, B A-1, and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above
order any distribution of any asset, capital, earnings or surplus funds of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All remaining assets shall be distributed among all the shareholders
pro rata in proportion to the number of Ordinary shares held by them on an as converted basis. The original issue price of the
Series&#xa0;A, A-1, B, B-1 and C-1 Convertible Preferred shares was $1.51, $1.76, $3.60, $5.06, and $6.95 per share, respectively,
Series C-2, D-1 and D-3 was $9.23 per share and Series E and E-1 was $13.30 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><i>Voting
rights</i> - each holder of Series&#xa0;A, A-1, B, B-1, C-1, C-2, D-1, D-3,
E and E-1 Convertible Preferred share was entitled to one&#xa0;vote per each share held by it (on an as converted basis).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><i>Conversion
</i>- each preferred share was convertible into Ordinary shares, at
the holder&#x2019;s option, or automatically upon a qualified initial public offering (&#x201c;Qualified IPO&#x201d;) of the Company or upon
written demand of the Investor Majority (as defined in the Previous Articles).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Each share of Series A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 was convertible into Ordinary shares
on a 1-for-1 ratio. The conversion price per preferred share was to be adjusted in the event of recapitalizations, splits, Ordinary
share dividends and standard anti-dilution events.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Financing rounds:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During August 2018 through
February 2019, the Company entered into a Securities Purchase Agreement (the &#x201c;2018 SPA&#x201d;) with new and existing investors
for an aggregate amount of up to $35,000. The Company received $15,577 and issued to the investors 1,187,887 series E-1 Preferred
shares (net of $187 issuance costs in cash in 2018) at a price per share of $13.30. As part of the 2018 SPA, the Company converted
274,434 series E Preferred shares into series E-1 Preferred shares to holders of series E Preferred shares who participated in
the 2018 SPA pursuant to the conversion rights of the 2018 SPA.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During June 2019, the Company prepared a Private Placement Memorandum
(the &#x201c;2019 PPM&#x201d;) which includes the 2018 SPA and allowed the Company to raise up to $50,000 from new and existing shareholders.
From June to August 2019, the Company received $30,717 and issued to the investors 2,596,665 series E-1 Preferred shares, net of
$3,142 issuance costs in cash and warrants in amount $680 at a price of $13.30.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Warrants to purchase Preferred
                                         shares:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In March 2008, in connection with a March 2008 Founders and
Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the &#x201c;A warrants&#x201d;),
with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of
an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at
least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and
(3) the sale of substantially all of the Company&#x2019;s assets or substantially all of the shares to another party.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In connection with the first financing round that occurred in
2016, the Company granted to certain investors warrants to purchase up to 2,775,398 D-2 Preferred shares (&#x201c;D-2 warrants&#x201d;)
at a price per share of $9.23.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The survival of D-2 warrants is limited to a period ending upon
the earlier of: (i) the lapse of 5 years from closing; or (ii) a deemed liquidation event.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The D-2 warrants will be exercised
automatically if they are still outstanding on the final day of the warrant period as defined in the warrants grant letter,
and if the fair market value of a warrant share is more than the exercise price for such share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All outstanding A warrants and D-2 warrants are classified
as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which
is not solely in the control of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 28, 2019, in connection with 2019 PPM, the Company included
the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the &#x201c;E-1 warrants&#x201d;)
at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new
investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years
from closing.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December 31, 2020, 200,596 E-1 warrants, 648,519 D-2 warrants
and 17,925 Warrants are outstanding and may be converted into Ordinary shares.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Deemed dividend:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As part of Series E-1 Convertible Preferred shares price protection
conversion rights upon the completion of an initial public offering, the Company issued 158,967 Series E-1 Convertible Preferred
shares and recorded a beneficial feature of $2,114 which was accounted for as a deemed dividend and was recorded as mezzanine equity.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719570136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
10:-	SHAREHOLDERS&#x2019; EQUITY (DEFICIT)</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">General:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">On June 21, 2020, the Company&#x2019;s Board of Directors resolved
to consolidate the Company&#x2019;s share capital by applying an additional reverse share split and cancelling the shares&#x2019;
par value (See Note 1d).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Following
the reverse share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible
loans, warrants, exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated
financial statements.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Ordinary share capital is composed
                                         as follows:</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Ordinary shares with no par value</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">18,494,739</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">22,466,000</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">562,748</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Ordinary shares rights:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Ordinary shares confer upon their holders the right to participate
in the general meetings of the Company, to vote at such meetings (each share represents one vote), and to participate in any distribution
of dividends or any other distribution of the Company&#x2019;s property, including the distribution of surplus assets upon liquidation.</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Share option plans:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
has authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other
key employees of up to 3,672,094 Ordinary shares. The options granted generally have a three-year vesting period and expire ten
years after the date of grant. Options granted under the Company&#x2019;s option plan that are cancelled or forfeited before expiration
become available for future grant. As of December 31, 2020, 1,019,457 of the Company&#x2019;s options were available for future grants.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A summary
of the status of options to employees under the Company&#x2019;s option plan as of December&#xa0;31, 2020 and 2019 and changes during
the relevant period ended on that date is presented below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&#xa0;<br/> average&#xa0;<br/> remaining&#xa0;<br/> contractual<br/> life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,217,985</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.62</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,411</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.04</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,064,959</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.08</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(395</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(89,157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">5.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">9,263</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,306,421</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.78</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6,686</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.63</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">9,263</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2019</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&#xa0;<br/> average&#xa0;<br/> remaining&#xa0;<br/> contractual<br/> life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,234,955</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.59</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,608</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">82,216</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.04</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1,523</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.54</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,663</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">6.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217,985</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.62</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,411</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.04</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,108,207</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.29</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.66</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217,985</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.62</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.04</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Black-Scholes
assumptions used to value the employee options at the grant dates are as follows:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2020
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 74.35%-84.77%, risk free interest rates of 0.23%-1.38%, dividend yield of 0%, and an expected term of 5-6 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2019
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 69.8%-76.14%, risk free interest rates of 2.26%-3.13%, dividend yield of 0%, and an expected term of 6-7 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value for options granted to employees during 2018
is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected
volatility of 91.44%-96.87%, risk free interest rates of 3.43%-3.90%, dividend yield of 0%, and an expected term of 6-7 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">These
assumptions and estimates were determined as follows:</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</font></td><td style="text-align: justify">Fair
                                         Value of Ordinary Shares- Prior to the IPO, the fair value was determined by the Company&#x2019;s
                                         board of directors, with input from management and valuation reports prepared by third-party
                                         valuation specialists. After the IPO, the fair value of each Ordinary share was based
                                         on the closing price of the Company&#x2019;s publicly traded Ordinary shares as reported
                                         on the date of the grant.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif">o</font></td><td style="text-align: justify">Risk-Free&#xa0;Interest
                                         Rate- The risk-free rate for the expected term of the options is based on the Black-Scholes
                                         option pricing model on the yields of U.S. Treasury securities with maturities appropriate
                                         for the expected term of employee share option awards.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</font></td><td style="text-align: justify">Expected
                                         Term- The expected term represents the period that options are expected to be outstanding.
                                         For option grants that are considered to be &#x201c;plain vanilla,&#x201d; the Company
                                         determines the expected term using the simplified method. The simplified method deems
                                         the term to be the average of the time-to-vesting and the contractual life of the options.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</font></td><td style="text-align: justify">Expected
                                         Volatility- As the Company has a short trading history for its Ordinary shares, the expected
                                         volatility is derived from the average historical share volatilities of several unrelated
                                         public companies within the Company&#x2019;s industry that the Company considers to be
                                         comparable to its own business over a period equivalent to the option&#x2019;s expected
                                         term.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif">o</font></td><td style="text-align: justify">Expected
                                         Dividend Yield- The Company has never declared or paid any cash dividends and does not
                                         presently plan to pay cash dividends in the foreseeable future. As a result, an expected
                                         dividend yield of zero percent was used.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The total
equity-based compensation expense related to all of the Company&#x2019;s equity-based awards recognized for the three years ended December&#xa0;31,
2020, 2019 and 2018, was comprised as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">180</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Marketing and business development</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">140</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">90</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">706</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">739</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation expense</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4,577</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">995</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As of December
31, 2020, there were unrecognized compensation costs of $10,071, which are expected to be recognized over a weighted average period
of approximately 2.7 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The options
outstanding as of December&#xa0;31, 2020 are comprised, as&#xa0;follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise <br/>
price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options<br/>
 outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual term</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options exercisable as&#xa0;of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual term</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">249,561</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">249,561</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">107,904</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">107,904</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">83,503</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.33</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">83,503</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.33</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,296</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.36</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,296</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.36</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">200,229</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">200,229</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">29,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">29,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.42</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">51,385</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.98</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">51,385</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.98</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.19</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.19</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.40</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">66,326</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">66,326</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,589</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.78</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,461</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15,035</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">10,940</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.53</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">46,069</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,004</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.32</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">58,731</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.11</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,858</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.11</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">904,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.45</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">168,898</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.44</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,306,421</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.78</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.63</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*)</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The exercise price of the options is denominated in NIS and
was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.</p></td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Options issued to non-employees:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Outstanding
options granted to consultants as of December&#xa0;31, 2020 were as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options <br/>
outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average <br/>
Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable <br/>
through</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-indent: -12pt; padding-left: 12pt">March 2013</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,258</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.76</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,258</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="text-align: center; width: 9%; padding-left: 5.6pt">March 2023</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">October 2013</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">October&#xa0;2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">June 2014</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">June 2024</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">September 2014</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">September&#xa0;2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">April 2016</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">April 2026</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">December 2016</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">March 2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">June 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">136,594</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">June 2027</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">August 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.29</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">August 2027</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">November 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">March 2027</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">August 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">August 2029</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">June 2020</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,430</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">6.62</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.6pt">June 2030</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">433,852</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">276,789</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.6pt">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719498680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
11:-	FINANCIAL EXPENSES, NET</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; text-align: justify; padding-left: 0pt">Financial expenses:&#x202f;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 0pt">Revaluation of warrants</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,373</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Foreign currency transaction loss, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">276</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial expenses, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">318</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Financial income:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Interest from deposits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(474</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(126</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Revaluation of warrants</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,365</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(24,473</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Foreign currency transaction gains, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(243</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(245</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial income:</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,599</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Financial expense (income), net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,597</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,655</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(24,281</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370723400008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss (Profit) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
12:-	BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The following
table sets forth the computation of the Company&#x2019;s basic and diluted net loss per Ordinary share:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>Year ended December 31,</b></font></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Basic net loss (profit) per share</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>2020</b> &#xa0;</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>2018</b></font></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,869</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,905</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,917</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Preferred share preference</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,933</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,422</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,439</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Net income allocated to preferred shareholders</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,389</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(89</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Weighted average Ordinary shares outstanding</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">562,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">561,113</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Basic net loss (profit) per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23.69</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(0.16</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Numerator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable for basic computation</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(89</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Revaluation of warrants to convertible preferred shares</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">616</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">527</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Number of shares used in basic calculation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,582,405</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">562,451</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">561,113</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average effect of dilutive securities Warrants to convertible preferred shares</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">52,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Number of shares used in diluted calculation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">562,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">613,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23.69</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.86</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719400472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
13:-	RELATED PARTIES</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Through February 2016, several management members also provided
services to the Company as service providers. As of December 31, 2020 and 2019, the Company has recorded a provision for severance
pay liability for such service providers in the amounts of $193 and $251, respectively. These amounts are included in &#x201c;Other
Liabilities&#x201d;.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In July 2019, the Company entered into a master service agreement
with a third-party provider (the &#x201c;provider&#x201d;) to conduct a portion of a phase 3 clinical trial in eastern Europe for a
total cost of $6,288. One of the Company&#x2019;s directors serves as a director and shareholder in the provider. During the year ended
December 31, 2020, the Company recognized $717 as expense as part of the research and development expenses.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370728212600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">NOTE
14:-	SUBSEQUENT EVENTS</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><font style="font-weight: normal">The
Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated
financial statements to identify matters that require additional disclosure. For its annual consolidated financial statements
as of December&#xa0;31, 2020 and for the year then ended, the Company evaluated subsequent events through March&#xa0;5, 2021,
the date that the consolidated financial statements were issued. </font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">During January to March 2021, 580,028 warrants to purchase Ordinary
shares were exercised on a cashless basis into 115,982 Ordinary shares, out of which 419,068 warrants were exercised by related
parties. In addition, during February 2021 68,491 warrants to purchase Ordinary shares were exercised into 68,491 Ordinary shares
for a total consideration of $633.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370714848280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation
of the consolidated financial statements in conformity with U.S.&#xa0;GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s
management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of
share-based awards, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and
the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConsolidatedFinancialStatementsPolicyTextBlock', window );">Consolidated financial statements in U.S. dollars</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">b.</td><td style="text-align: justify">Consolidated financial statements
                                         in U.S.&#xa0;dollars:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The accompanying
consolidated financial statements have been prepared in U.S.&#xa0;dollars.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A substantial portion of the Company&#x2019;s expenses are incurred
in New Israeli Shekels (&#x201c;NIS&#x201d;). However, the Company finances its operations mainly in U.S. dollars, a substantial
portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated
in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment
in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#xa0;dollar.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Transactions and balances denominated in U.S. dollars are presented
at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance
with Accounting Standards Codification (&#x201c;ASC&#x201d;) No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains
and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income
or expenses, as appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The consolidated
financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">d.</td><td style="text-align: justify">Reclassifications:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Certain prior years amounts
have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated
net loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">e.</td><td style="text-align: justify">Cash equivalents:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or
less, at the date acquired.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RestrictedCashPolicyTextBlock', window );">Restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">f.</td><td style="text-align: justify">Restricted cash:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Restricted
cash is primarily invested in certificates of deposit and is used as security for the Company&#x2019;s lease commitments and hedging
activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets
and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, as reported on the balance sheets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,319</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,924</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Restricted cash, as reported on the balance sheets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">390</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">375</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Restricted cash in other long-term assets, as reported on the balance sheets</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,908</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,498</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShorttermDepositsPolicyTextBlock', window );">Short-term deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">g.</td><td style="text-align: justify">Short-term deposits:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Short-term bank deposit is a
deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging
from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value
due to their short maturities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_LongtermDepositsPolicyTextBlock', window );">Long-term deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left">h.</td><td style="text-align: justify">Long-term deposits:</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A Long-term bank deposit is
a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per
annum, as of December 31, 2020. Long-term deposits are presented at cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">i.</td><td style="text-align: justify">Property and equipment, net:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets at the following rates:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Computers, software and laboratory equipment</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">15&#xa0;-&#xa0;33</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Furniture and office equipment</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 18%; text-align: center">15</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt">Leasehold improvements</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">Over the shorter of the term of the lease or its useful life</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Down payments for property and
equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the
corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">j.</td><td style="text-align: justify">Impairment of long-lived assets:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company&#x2019;s long-lived assets are reviewed for impairment
in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset
exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">k.</td><td style="text-align: justify">Research and development expenses:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Research
and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting
fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory
approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property
rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities
related costs. The Company charges research and development expenses as expenses when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss (profit) per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">l.</td><td style="text-align: justify">Basic and diluted net loss (profit)
                                         per share:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company computes net loss (profit) per share using the two-class
method required for participating securities. The two-class method requires income available to ordinary shareholders for the period
to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as
if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating
securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders
of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require
the holders of such shares to participate in the Company&#x2019;s losses. As such,&#xa0;during the periods when the Company is in
a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under
the two-class method as these securities did not have a contractual obligation to share in the Company&#x2019;s losses.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&#x2019;s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary
shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of
potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially
dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature
of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the
effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for share-based payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">m.</td><td style="text-align: justify">Accounting for share-based payments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Share-based compensation expense related to share-based awards
is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite
service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value
of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company&#x2019;s
Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine
the fair value of the share awards represent management&#x2019;s best estimates. These estimates involve inherent uncertainties
and the application of management&#x2019;s judgment. Forfeitures are accounted for as they occur instead of estimating the number
of awards expected to be forfeited.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_GrantsAndParticipationsPolicyTextBlock', window );">Grants and participations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">n.</td><td style="text-align: justify">Grants and participations:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Royalty-bearing
grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) (previously known as Office of the Chief Scientist) of the Ministry
of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company
is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#x2019;s Seventh Framework Programme for
Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such
grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Since the
payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received
from IIA until the related revenues are recognized.&#xa0;In the event of failure of a project that was partly financed by IIA,
the Company will not be obligated to pay any royalties or repay the amounts received.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company recognizes participations in research and development,
as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research
and development expenses incurred during the period is recognized as other income within operating income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock', window );">Convertible preferred shares and convertible preferred shares warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">o.</td><td style="text-align: justify">Convertible preferred shares
                                         and convertible preferred shares warrant liability:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The terms
of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#xa0;shares allowed the holders to redeem shares, under
certain circumstances, outside of the Company&#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance
sheet and not included as a component of shareholders&#x2019; deficit before the IPO. The carrying value of the convertible preferred
shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the
convertible preferred shares will be redeemed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Warrants
to purchase the Company&#x2019;s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair
value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the
Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance
sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an
orderly transaction between market participants at the measurement date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In determining
fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Unobservable
inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available in the circumstances.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Fair value
is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or a liability.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">A three-tier
fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</p><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical
                                         assets and liabilities.</td></tr>                                                                          <tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: justify">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         2 - Include other inputs that are directly or indirectly observable in the marketplace.</td></tr>                                                                                                                                          <tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: justify">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 5%">&#x25cf;</td><td style="text-align: justify">Level
                                         3 - Unobservable inputs which are supported by little or no market activity.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The fair value hierarchy also
requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<font style="font-size: 10pt">.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The financial
instruments carried at fair value on the Company&#x2019;s consolidated balance sheets as of December 31, 2019 are warrants to convertible
preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The following
methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The carrying
amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables,
trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such
instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">q.</td><td style="text-align: justify">Income taxes:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax
assets to their estimated realizable value, if needed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">ASC 740
contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that
it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including
resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized
tax benefits was recorded as a result of ASC 740.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The
Company&#x2019;s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">r.</td><td style="text-align: justify">Concentration of credit risks:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Cash, cash
equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be
in excess of insured limits and are not insured.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">in other jurisdictions.
Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company
utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge
a portion of the Company&#x2019;s non-dollar currency exposure. Counterparties to the Company&#x2019;s derivative instruments are all major
financial institutions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">s.</td><td style="text-align: justify">Severance pay:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">All the Company&#x2019;s employees
who are Israeli citizens have subscribed to Section&#xa0;14 of Israel&#x2019;s Severance Pay Law, 5723-1963
(&#x201c;Section&#xa0;14&#x201d;). Pursuant to Section&#xa0;14, employees covered by this section are entitled to monthly
deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with
Section&#xa0;14 release the Company from any future severance liabilities in respect of those employees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Neither severance
pay liability nor severance pay fund under Section&#xa0;14 for such employees is recorded on the Company&#x2019;s consolidated balance
sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Severance
pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DerivativeFinancialInstrumentsPolicyTextBlock', window );">Derivative financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">t.</td><td style="text-align: justify">Derivative financial instruments:</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for derivatives and hedging based on ASC
815, &#x201c;Derivatives and hedging&#x201d;, as amended and related interpretations (&#x201c;ASC 815&#x201d;). ASC 815 requires the
Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is
so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against
the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions)
or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The ineffective portion of a derivative&#x2019;s change in fair value
is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included
in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts
in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative
instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from
such instruments is recognized immediately as &#x201c;financial income, net&#x201d;.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company measured the fair value of the contracts in accordance
with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices
and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was
$62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December
31, 2019 and 2018 amounted to $10 and $0, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">u.</td><td style="text-align: justify">Contingent liabilities</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for its contingent liabilities in accordance
with ASC 450, &#x201c;Contingencies&#x201d;. A provision is recorded when it is both probable that a liability has been incurred and
the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect
the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining
to a particular matter.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company is occasionally
a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any
pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of
operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted Accounting Pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">v.</td><td style="text-align: justify">Recently adopted Accounting Pronouncements</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">As an &#x201c;emerging
growth company&#x201d;, the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of
new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private
companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below
reflect this election<font style="font-family: Times New Roman, Times, Serif">.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In June 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#xa0;2018-07, &#x201c;Improvements to Nonemployee Share-Based Payment
Accounting,&#x201d; which simplifies the accounting for share-based payments granted to nonemployees for goods and services and
aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.
The Company adopted the guidance as of January&#xa0;1, 2020. The adoption of the standard didn&#x2019;t have a material impact on the
Company&#x2019;s consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently Issued Accounting Pronouncements</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In February 2016, the FASB issued
ASU No. 2016-02, &#x201c;Leases,&#x201d; which would require lessees to recognize assets and liabilities on the balance sheet for
most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner
similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance
states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for
the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1,
2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of
the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure
requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current
and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU
2016-02 will have on its consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2017, the FASB issued
ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies
the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their
hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements,
expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure
requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January
1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its
Consolidated Statements of Operations or Cash Flows.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In August 2018, the FASB issued ASU No. 2018-15, &#x201c;Intangibles-Goodwill
and Other-Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract,&#x201d; which aligns the requirements for capitalizing implementation costs incurred in
a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop
or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally
over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that
of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and
interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the
effect that ASU 2018-15 will have on its consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201d; which simplifies the accounting for income taxes by removing
a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for
intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses
that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in
fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12
will have on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statements in U.S. dollars policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred shares and convertible preferred shares warrant liability policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DerivativeFinancialInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DerivativeFinancialInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_GrantsAndParticipationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and participations policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_GrantsAndParticipationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LongtermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Long-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LongtermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncements and not yet adopted policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RecentlyIssuedAccountingPronouncementsAndNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Severance pay policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShorttermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term deposits policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShorttermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370730017208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, as reported on the balance sheets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,319</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,924</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Restricted cash, as reported on the balance sheets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">390</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">375</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Restricted cash in other long-term assets, as reported on the balance sheets</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,908</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,498</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment useful life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Computers, software and laboratory equipment</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">15&#xa0;-&#xa0;33</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 79%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Furniture and office equipment</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 18%; text-align: center">15</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: 0pt; padding-left: 0pt">Leasehold improvements</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">Over the shorter of the term of the lease or its useful life</td><td style="text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370723565352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Government authorities</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">283</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Prepaid expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,888</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Lease deposits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,334</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">417</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370728212600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">Cost:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Computers and software</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">449</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">389</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Laboratory equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,356</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Furniture and office equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">152</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">147</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,478</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,136</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Depreciated cost</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,890</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,121</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715481672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other payables and accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 0pt">Employees and payroll accruals</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">971</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">673</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Accrued expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">681</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">319</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">IIA deferred grant </td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">241</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,903</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">998</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370728082408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments under operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">As of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,236</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,181</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">995</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">425</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,403</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719400472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of change in the fair value of the preferred share warrants liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,241</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,926</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Issuance of warrants</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">680</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Change in fair value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">11,373</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,365</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Reclassification of Warrants into equity</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,614</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">End of period</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,241</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719383144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Reserves and allowances</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Temporary differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,644</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,204</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">957</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss carryforward</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,168</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15,406</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">26,959</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,783</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,959</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,783</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370728154856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesAndWarrantsAbstract', window );"><strong>Convertible Preferred Shares And Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible preferred shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;A Convertible Preferred shares with no par value</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">537,750</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">483,975</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;A-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">896,250</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">798,950</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;B Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">597,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">566,386</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;B-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,867,562</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,751,309</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;C-1 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">717,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">645,923</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;C-2 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">454,100</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">410,197</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-1 Convertible Preferred shares of NIS&#xa0;0 par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,509,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,376,512</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-2 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,868,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;D-3 Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">597,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">576,944</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Series&#xa0;E Convertible Preferred shares with no par value</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,135,250</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">851,795</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Series&#xa0;E-1 Convertible Preferred shares with no par value</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,736,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,058,986</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">17,916,412</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">12,520,977</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721351320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock', window );">Schedule of ordinary share capital</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold">&#xa0;</td>
    <td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td><td style="background-color: White; width: 9%; font-weight: bold; text-align: right">&#xa0;</td><td style="background-color: White; width: 1%; font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Ordinary shares with no par value</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">18,494,739</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">22,466,000</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td><td style="font-weight: normal; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: normal; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: normal; text-align: right">562,748</td><td style="padding-bottom: 4pt; font-weight: normal; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of status of options to employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&#xa0;<br/> average&#xa0;<br/> remaining&#xa0;<br/> contractual<br/> life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,217,985</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.62</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,411</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.04</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,064,959</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.08</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(395</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(89,157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">5.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">9,263</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,306,421</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.78</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6,686</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.63</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">9,263</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2019</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted&#xa0;<br/> average&#xa0;<br/> remaining&#xa0;<br/> contractual<br/> life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,234,955</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.59</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,608</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">82,216</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.04</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1,523</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.54</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -28.35pt; padding-left: 28.35pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,663</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">6.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217,985</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.62</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,411</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.04</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Exercisable options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,108,207</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.29</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.66</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -28.35pt; padding-left: 28.35pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -28.35pt; padding-left: 28.35pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,217,985</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.62</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.04</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of equity-based awards recognized</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">180</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Marketing and business development</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">140</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">90</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">706</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">739</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation expense</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4,577</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">995</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfOptionOutstandingTablesTextBlock', window );">Schedule of options outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise <br/>
price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options<br/>
 outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual term</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options exercisable as&#xa0;of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual term</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">249,561</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">249,561</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">*)0.22</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">107,904</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">107,904</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.75</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">83,503</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.33</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">83,503</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.59</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.33</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,296</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.36</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,296</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.07</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.36</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">200,229</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">200,229</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.23</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">29,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">29,947</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.42</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">51,385</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.98</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">51,385</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.98</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.19</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.19</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.40</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">66,326</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">66,326</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,589</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.78</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,461</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15,035</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">10,940</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.65</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.53</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">46,069</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,004</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.02</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.32</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">58,731</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.11</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,858</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.11</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">904,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.45</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">168,898</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.44</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,193,392</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">6.58</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,306,421</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.78</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">4.63</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock', window );">Schedule of outstanding options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options <br/>
outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average <br/>
Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, 2020</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable <br/>
through</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: justify">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-indent: -12pt; padding-left: 12pt">March 2013</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,258</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.76</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,258</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="text-align: center; width: 9%; padding-left: 5.6pt">March 2023</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">October 2013</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">October&#xa0;2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">June 2014</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">June 2024</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">September 2014</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.06</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">September&#xa0;2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">April 2016</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">April 2026</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">December 2016</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">March 2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">June 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.10</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">136,594</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">June 2027</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">August 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.29</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5,617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">August 2027</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -12pt; padding-left: 12pt">November 2017</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">March 2027</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">August 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,195</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">August 2029</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">June 2020</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,430</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">6.62</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.6pt">June 2030</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: center; padding-left: 5.6pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">433,852</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">276,789</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.6pt">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfOptionOutstandingTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfOptionOutstandingTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370813216824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of financial expenses net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; text-align: justify; padding-left: 0pt">Financial expenses:&#x202f;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White">&#xa0;</td>
    <td style="background-color: White; text-align: left">&#xa0;</td><td style="background-color: White; text-align: right">&#xa0;</td><td style="background-color: White; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 0pt">Revaluation of warrants</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,373</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Foreign currency transaction loss, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">276</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial expenses, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">318</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Financial income:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Interest from deposits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(474</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(126</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0pt">Revaluation of warrants</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(11,365</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(24,473</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">Foreign currency transaction gains, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(243</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(245</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">Total financial income:</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,599</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt">Financial expense (income), net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,597</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,655</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(24,281</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719909288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss (Profit) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per ordinary share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-align: justify; text-indent: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>Year ended December 31,</b></font></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Basic net loss (profit) per share</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>2020</b> &#xa0;</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;<b>2018</b></font></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,869</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,905</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,917</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Preferred share preference</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,933</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,422</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,439</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Net income allocated to preferred shareholders</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,389</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(89</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Weighted average Ordinary shares outstanding</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">562,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">561,113</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt; text-indent: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Basic net loss (profit) per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23.69</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(0.16</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Numerator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss (profit) attributable for basic computation</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(89</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Revaluation of warrants to convertible preferred shares</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">616</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Allocation of net loss attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,327</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">527</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Number of shares used in basic calculation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,582,405</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">562,451</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">561,113</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average effect of dilutive securities Warrants to convertible preferred shares</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">52,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Number of shares used in diluted calculation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">562,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">613,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Diluted net loss (profit) per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23.69</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.86</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370717046664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents, short-term deposits and long-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,869)<span></span>
</td>
<td class="num">$ (6,905)<span></span>
</td>
<td class="nump">$ 5,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,596)<span></span>
</td>
<td class="num">(17,358)<span></span>
</td>
<td class="num">$ (16,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (132,286)<span></span>
</td>
<td class="num">$ (93,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DescriptionOfReverseShareSplit', window );">Description of reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#x2019;s Board of Directors resolved to consolidate the Company&#x2019;s share capital by applying a reverse share split at a ratio of 1.046:1 (the &#x201c;Reverse Split Ratio&#x201d;) and to cancel the shares&#x2019; par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#x201c;Split&#x201d;). The Split was applied in the same proportion and manner to all of the Company&#x2019;s authorized, issued and outstanding securities, including preferred shares, options and warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_AggregateNetProceeds', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 62,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of ordinary shares (in Shares)</a></td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of ordinary shares (in Shares)</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AggregateNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to net proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AggregateNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DescriptionOfReverseShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DescriptionOfReverseShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715615272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_monthlyDepositsAtARate', window );">Monthly deposits percentage rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expense</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of the options contracts</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Profits (losses)</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Short-Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Short-term deposit bearing interest percentage rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Long-Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term deposit bearing interest percentage rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Short-Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Short-term deposit bearing interest percentage rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Long-Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term deposit bearing interest percentage rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_monthlyDepositsAtARate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits percentage rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_monthlyDepositsAtARate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pypd_LongTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pypd_LongTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719865448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Restrictions on Cash and Cash Equivalents - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract', window );"><strong>Schedule of Restrictions on Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, as reported on the balance sheets</a></td>
<td class="nump">$ 4,319<span></span>
</td>
<td class="nump">$ 3,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, as reported on the balance sheets</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent', window );">Restricted cash in other long-term assets, as reported on the balance sheets</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows', window );">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</a></td>
<td class="nump">$ 4,908<span></span>
</td>
<td class="nump">$ 4,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_CashCashEquivalentsAndRestrictedCashAsReportedInStatementsOfCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RestricteRestrictedCashAndInvestmentsCurrentdCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfRestrictionsOnCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370717497256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Property and equipment useful life<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computers, software and laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PropertyPlantAndEquipmentPercent', window );">Property, plant and equipment</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computers, software and laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PropertyPlantAndEquipmentPercent', window );">Property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PropertyPlantAndEquipmentPercent', window );">Property, plant and equipment</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, plant and equipment,description</a></td>
<td class="text">Over the shorter of the term of the lease or its useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PropertyPlantAndEquipmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, plant and equipment percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PropertyPlantAndEquipmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370644756072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Receivables (Details) - Schedule of prepaid expenses and other receivables - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Schedule of prepaid expenses and other receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_LeaseDeposits', window );">Lease deposits</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Others</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total</a></td>
<td class="nump">$ 2,334<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LeaseDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LeaseDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfPrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721490712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370717031320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,026<span></span>
</td>
<td class="nump">$ 8,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(3,136)<span></span>
</td>
<td class="num">(2,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">5,890<span></span>
</td>
<td class="nump">6,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,947<span></span>
</td>
<td class="nump">3,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,478<span></span>
</td>
<td class="nump">$ 4,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721506472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Payables and Accrued Expenses (Details) - Schedule of other payables and accrued expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract', window );"><strong>Schedule of other payables and accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IsraelInnovationAuthorityGrantReceived', window );">IIA deferred grant</a></td>
<td class="nump">241<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,903<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IsraelInnovationAuthorityGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Israel Innovation Authority grant received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IsraelInnovationAuthorityGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfOtherPayablesAndAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370714858376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th">
<div>Dec. 22, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental and lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ProceedsFromParticipationPayments', window );">Participation payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Commitments and Contingent liabilities, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In September 2017, a suit was filed against the Company in the Tel-Aviv Magistrates Court in an amount of $250.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2020, no royalties have been paid or accrued.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FindersFee', window );">Finder's fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PaymentsToAutomaticFilingMachine', window );">Automatic filing machine (in Euro) | &#8364;</a></td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PrepaymentForAutomaticFilingMachine', window );">Pre-payment for automatic filing machine (in Euro) | &#8364;</a></td>
<td class="nump">&#8364; 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FindersFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finder's fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FindersFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PaymentsToAutomaticFilingMachine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for purchase of manufacturing plant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PaymentsToAutomaticFilingMachine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaymentForAutomaticFilingMachine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to pre-payment for automatic filing machine.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaymentForAutomaticFilingMachine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ProceedsFromParticipationPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Participation payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ProceedsFromParticipationPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370715592008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details) - Schedule of future minimum lease payments under operating leases<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract', window );"><strong>Schedule of future minimum lease payments under operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="nump">$ 1,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2024</a></td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 4,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370643500648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageFairValueOfWarrantsPercenatge', window );">Weighted average fair value of the warrants, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="nump">$ 3,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueOfSeriesAPreferredShareWarrants', window );">Fair value of series A Preferred share warrants (in Dollars) | $</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares (in Shares) | shares</a></td>
<td class="nump">53,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1PreferredShareWarrantsMember', window );">series E-1 Preferred share warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value (in Dollars) | $</a></td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1PreferredShareWarrantsMember', window );">series E-1 Preferred share warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">153 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredE1SharesMember', window );">Convertible Preferred E-1 Shares [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredD2SharesMember', window );">Convertible Preferred D-2 Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="nump">0.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 62 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value (in Dollars) | $</a></td>
<td class="nump">$ 20,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_CashlessOrdinaryShares', window );">Cashless ordinary shares (in Shares) | shares</a></td>
<td class="nump">475,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredD2SharesMember', window );">Convertible Preferred D-2 Shares [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="nump">0.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">219 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">153 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredASharesMember', window );">Convertible Preferred A shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredASharesMember', window );">Convertible Preferred A shares [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAPreferredShareWarrantsMember', window );">Series A Preferred Share Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsExercisedShares', window );">Warrants exercised shares (in Shares) | shares</a></td>
<td class="nump">53,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAPreferredShareWarrantsMember', window );">Series A Preferred Share Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">153 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_CashlessOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_CashlessOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FairValueMeasurementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FairValueMeasurementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FairValueOfSeriesAPreferredShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of series A Preferred share warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FairValueOfSeriesAPreferredShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageFairValueOfWarrantsPercenatge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value of the warrants, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageFairValueOfWarrantsPercenatge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1PreferredShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesE1PreferredShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredE1SharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredE1SharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredD2SharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredD2SharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_ConvertiblePreferredASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAPreferredShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesAPreferredShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370723459784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of change in the fair value of the preferred share warrants liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract', window );"><strong>Schedule of change in the fair value of the preferred share warrants liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueofPreferredShareWarrantLiability', window );">Beginning of year</a></td>
<td class="nump">$ 12,241<span></span>
</td>
<td class="nump">$ 22,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ChangeInFairValues', window );">Change in fair value</a></td>
<td class="nump">11,373<span></span>
</td>
<td class="num">(11,365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ReclassificationsOfWarrantsIntoEquity', window );">Reclassification of Warrants into equity</a></td>
<td class="num">(23,614)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FairValueofPreferredShareWarrantLiability', window );">End of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ChangeInFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ChangeInFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FairValueofPreferredShareWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to fair value of preferred share warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FairValueofPreferredShareWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReclassificationsOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Warrants into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReclassificationsOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfChangeInTheFairValueOfThePreferredShareWarrantsLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370717455416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Corporate tax rates</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes', window );">Amount of approximately (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,385,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit', window );">Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of investments for Federal income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(2)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401367&amp;loc=d3e600178-122990<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax benefit for remeasurement of deferred tax liability from change in tax rate pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370716874200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">$ 26,959<span></span>
</td>
<td class="nump">$ 17,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less-valuation allowance</a></td>
<td class="num">(26,959)<span></span>
</td>
<td class="num">(17,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_ReservesAndAllowancesMember', window );">Reserves and allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_TemporaryDifferencesMember', window );">Temporary differences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">3,644<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_IssaunceCostsMember', window );">Issuance costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">957<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_LossCarryforwardMember', window );">Loss carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">$ 22,168<span></span>
</td>
<td class="nump">$ 15,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_ReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_ReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_TemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_TemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_IssaunceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_IssaunceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_LossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pypd_LossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370642168184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2008</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Carrying value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_AnnualInterestPercentage', window );">Annual interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of warrants cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DividendRightsDescription', window );">Dividend rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend or distribution was declared by the Company&#x2019;s board of directors, an amount equal to 6% per annum of the applicable original issue price for such preferred shares (the &#x201c;Preference Dividend&#x201d;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_LiquudationRightsDescription', window );">Liquudation rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of Series E-1, E preferred shares and D preferred shares were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pypd_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pypd_PrivatePlacementMemorandumMember', window );">Private Placement Memorandum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issued (in Dollars)</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs in cash (in Dollars)</a></td>
<td class="nump">3,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of warrants cost (in Dollars)</a></td>
<td class="nump">$ 680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsPurchaseDescription', window );">Warrants to purchase, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">in connection with a March 2008 Founders and Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the &#x201c;A warrants&#x201d;), with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and (3) the sale of substantially all of the Company&#x2019;s assets or substantially all of the shares to another party.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredMember', window );">Series A Convertible Preferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredMember', window );">Series A Convertible Preferred [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember', window );">Series A-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredMember', window );">Series B Convertible Preferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember', window );">Series B-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,751,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember', window );">Series C-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember', window );">Series C-2 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredMember', window );">Series E Convertible Preferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember', window );">Series E-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial feature value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember', window );">Series E-1 Convertible Preferred Shares [Member] | Private Placement Memorandum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,596,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember', window );">Series E-1 Convertible Preferred Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember', window );">Series D-2 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember', window );">Series D-2 Convertible Preferred Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems', window );"><strong>Convertible Preferred Shares and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsPurchaseDescription', window );">Warrants to purchase, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">in connection with 2019 PPM, the Company included the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the &#x201c;E-1 warrants&#x201d;) at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years from closing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AnnualInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual interest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AnnualInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesandWarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DividendRightsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend rights, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DividendRightsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LiquudationRightsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquudation rights, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LiquudationRightsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsPurchaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsPurchaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pypd_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pypd_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pypd_PrivatePlacementMemorandumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pypd_PrivatePlacementMemorandumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370642033048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,916,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">537,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">483,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember', window );">Series A-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">896,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">798,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">597,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">566,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember', window );">Series B-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,867,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,751,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember', window );">Series C-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">645,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember', window );">Series C-2 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">454,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">410,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD1ConvertiblePreferredSharesMember', window );">Series D-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,509,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,376,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember', window );">Series D-2 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,868,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD3ConvertiblePreferredSharesMember', window );">Series D-3 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">597,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">576,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredSharesMember', window );">Series E Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,135,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">851,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember', window );">Series E-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred shares, Authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,736,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred shares, Issued and outstanding</a></td>
<td class="nump">158,967<span></span>
</td>
<td class="nump">4,058,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesB1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesC1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesC2ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesD1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesD2ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesD3ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesD3ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesEConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pypd_SeriesE1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370716982872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">1,064,959<span></span>
</td>
<td class="nump">82,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod', window );">Granted stock option expire period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_UnrecognizedCompensationCosts', window );">Unrecognized compensation costs (in Dollars)</a></td>
<td class="nump">$ 10,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RecognizedOverWeightedAveragePeriod', window );">Recognized over weighted average period</a></td>
<td class="text">2 years 255 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.35%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
<td class="nump">91.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.77%<span></span>
</td>
<td class="nump">76.14%<span></span>
</td>
<td class="nump">96.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rates, minimum</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">2.26%<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rates, maximum</a></td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">3.13%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember', window );">2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_StockOptionsAvailableForFutureGrants', window );">Stock options available for future grants (in Shares)</a></td>
<td class="nump">1,019,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officers [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pypd_AdvisorsMember', window );">Advisors [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pypd_OtherKeyEmployeesMember', window );">Other Key Employees [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in Shares)</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RecognizedOverWeightedAveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized over a weighted average period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RecognizedOverWeightedAveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, pptions, expire period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockOptionsAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options available for future grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockOptionsAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_UnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_UnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pypd_AdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pypd_AdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pypd_OtherKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pypd_OtherKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370719436456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of ordinary share capital - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NumberOfSharesAbstract0', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares Authorized</a></td>
<td class="nump">47,800,000<span></span>
</td>
<td class="nump">22,520,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares Issued</a></td>
<td class="nump">18,494,739<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="nump">18,494,739<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NumberOfSharesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NumberOfSharesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370716922744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of status of options to employees - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract', window );"><strong>Schedule of status of options to employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance (in Shares)</a></td>
<td class="nump">1,217,985<span></span>
</td>
<td class="nump">1,234,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning balance</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance (in Dollars)</a></td>
<td class="nump">$ 3,411<span></span>
</td>
<td class="nump">$ 4,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual life (years), Beginning Outstanding</a></td>
<td class="text">5 years 14 days<span></span>
</td>
<td class="text">5 years 350 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted (in Shares)</a></td>
<td class="nump">1,064,959<span></span>
</td>
<td class="nump">82,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 7.08<span></span>
</td>
<td class="nump">$ 8.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised', window );">Number of Options, Exercised (in Shares)</a></td>
<td class="num">(395)<span></span>
</td>
<td class="num">(1,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value, Exercised</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1', window );">Number of Options, Forfeited and cancelled (in Shares)</a></td>
<td class="num">(89,157)<span></span>
</td>
<td class="num">(97,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance (in Shares)</a></td>
<td class="nump">2,193,392<span></span>
</td>
<td class="nump">1,217,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding, Ending balance</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance (in Dollars)</a></td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="nump">$ 3,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding', window );">Weighted Average Remaining Contractual life (years), Ending Outstanding</a></td>
<td class="text">6 years 211 days<span></span>
</td>
<td class="text">5 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable options (in Shares)</a></td>
<td class="nump">1,306,421<span></span>
</td>
<td class="nump">1,108,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable options</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable options (in Dollars)</a></td>
<td class="nump">$ 6,686<span></span>
</td>
<td class="nump">$ 3,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual life (years), Exercisable options</a></td>
<td class="text">4 years 229 days<span></span>
</td>
<td class="text">4 years 240 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in Shares)</a></td>
<td class="nump">2,193,392<span></span>
</td>
<td class="nump">1,217,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate intrinsic value, Vested and expected to vest (in Dollars)</a></td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="nump">$ 3,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest', window );">Weighted Average Remaining Contractual life (years), Vested and expected to vest</a></td>
<td class="text">6 years 211 days<span></span>
</td>
<td class="text">5 years 14 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721570904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,577<span></span>
</td>
<td class="nump">$ 976<span></span>
</td>
<td class="nump">$ 995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember', window );">Marketing and business development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 2,631<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDeficitDetailsScheduleofequitybasedawardsrecognizedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370643911352">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,193,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 211 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,306,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 229 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice022Member', window );">Exercise Price 0.22 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice022Member', window );">Exercise Price 0.22 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice175Member', window );">Exercise Price 1.75 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice175Member', window );">Exercise Price 1.75 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice359Member', window );">Exercise Price 3.59 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice359Member', window );">Exercise Price 3.59 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice507Member', window );">Exercise Price 5.07 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">260,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years 131 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">260,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice507Member', window );">Exercise Price 5.07 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years 131 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice923Member', window );">Exercise Price 9.23 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 321 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice923Member', window );">Exercise Price 9.23 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 321 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFiveMember', window );">Exercise Price 3.10 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 153 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFiveMember', window );">Exercise Price 3.10 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 153 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSixMember', window );">Exercise Price 3.93 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 357 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSixMember', window );">Exercise Price 3.93 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 357 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSevenMember', window );">Exercise Price 4.10 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 69 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSevenMember', window );">Exercise Price 4.10 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 69 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceEightMember', window );">Exercise Price 4.18 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceEightMember', window );">Exercise Price 4.18 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceNineMember', window );">Exercise Price 7.70 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 306 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceNineMember', window );">Exercise Price 7.70 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 306 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTenMember', window );">Exercise Price 8.42 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 284 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTenMember', window );">Exercise Price 8.42 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 281 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceElevenMember', window );">Exercise Price 8.65 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 226 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceElevenMember', window );">Exercise Price 8.65 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 193 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTwelveMember', window );">Exercise Price 8.02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 109 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTwelveMember', window );">Exercise Price 8.02 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 116 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceThirteenMember', window );">Exercise Price 6.80 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 40 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceThirteenMember', window );">Exercise Price 6.80 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 40 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFourtheenMember', window );">Exercise Price 6.62 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">904,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 164 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFourtheenMember', window );">Exercise Price 6.62 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 160 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFifteenMember', window );">Exercise Price 11.04 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1', window );">Number of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 313 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Number options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFifteenMember', window );">Exercise Price 11.04 [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualTermYear', window );">Weighted average remaining contractual term (year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The exercise price of the options is denominated in NIS and was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDeficitDetailsScheduleofoptionsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageRemainingContractualTermYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageRemainingContractualTermYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice175Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice175Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice359Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice359Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice507Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice507Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice923Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePrice923Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFourtheenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFourtheenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pypd_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370717370440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">433,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">276,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_MarchTwoThousandThirteenMember', window );">March 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">22,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">22,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">March 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_OctoberTwoThousandThirteenMember', window );">October 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">October 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandFourteenMember', window );">June 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">June 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_SeptemberTwoThousandFourteenMember', window );">September 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">September 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_AprilTwoThousandSixteenMember', window );">April 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">April 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_DecemberTwoThousandSixteenMember', window );">December 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">March 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandSeventeenMember', window );">June 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">197,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">136,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">June 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_AugustTwoThousandSeventeenMember', window );">August 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">August 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_NovemberTwoThousandSeventeenMember', window );">November 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_AugustTwoThousandNineteenMember', window );">August 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">71,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable</a></td>
<td class="nump">64,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">August 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandTwentyMember', window );">June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">88,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">June 2030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDeficitDetailsScheduleofoutstandingoptionsgrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_MarchTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_MarchTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_OctoberTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_OctoberTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_JuneTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_SeptemberTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_SeptemberTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_AprilTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_AprilTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_DecemberTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_DecemberTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_JuneTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_AugustTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_AugustTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_NovemberTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_NovemberTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_AugustTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_AugustTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_JuneTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370642035064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses, Net (Details) - Schedule of financial expenses net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfFinancialExpensesNetAbstract', window );"><strong>Schedule of financial expenses net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FinancialExpenseRevaluationOfWarrants', window );">Revaluation of warrants</a></td>
<td class="nump">$ 11,373<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency transaction loss, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Others</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Total financial expenses, net</a></td>
<td class="nump">11,390<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest from deposits</a></td>
<td class="num">(474)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RevaluationOfWarrants', window );">Revaluation of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,365)<span></span>
</td>
<td class="num">(24,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign currency transaction gains, net</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_FinancialOtherIncome', window );">Other</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Total financial income:</a></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(11,670)<span></span>
</td>
<td class="num">(25,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Financial expense (income), net</a></td>
<td class="nump">$ 10,597<span></span>
</td>
<td class="num">$ (11,655)<span></span>
</td>
<td class="num">$ (24,281)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialExpenseRevaluationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial expense revaluation of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialExpenseRevaluationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RevaluationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RevaluationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfFinancialExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfFinancialExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370721587512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss (Profit) Per Share (Details) - Schedule of basic and diluted net loss per ordinary share - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract', window );"><strong>Schedule of basic and diluted net loss per ordinary share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Allocation of net loss (profit)</a></td>
<td class="nump">$ 36,869<span></span>
</td>
<td class="nump">$ 6,905<span></span>
</td>
<td class="num">$ (5,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_PreferredSharePreference', window );">Preferred share preference</a></td>
<td class="nump">3,933<span></span>
</td>
<td class="nump">6,422<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NetIncomeAllocatedToPreferredShareholders', window );">Net income allocated to preferred shareholders</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_DeemedDividends', window );">Deemed dividend</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net loss (profit) attributable to Ordinary shareholders</a></td>
<td class="nump">$ 42,916<span></span>
</td>
<td class="nump">$ 13,327<span></span>
</td>
<td class="num">$ (89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average Ordinary shares outstanding (in Shares)</a></td>
<td class="nump">9,582,405<span></span>
</td>
<td class="nump">562,451<span></span>
</td>
<td class="nump">561,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss (profit) per share (in Dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_NetIncomeLossAvailableToBasicComputation', window );">Allocation of net loss (profit) attributable for basic computation</a></td>
<td class="nump">$ 42,916<span></span>
</td>
<td class="nump">$ 13,327<span></span>
</td>
<td class="num">$ (89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RevaluationOfWarrantsToConvertiblePreferredShares', window );">Revaluation of warrants to convertible preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Allocation of net loss attributable to Ordinary shareholders</a></td>
<td class="nump">$ 42,916<span></span>
</td>
<td class="nump">$ 13,327<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Number of shares used in basic calculation (in Shares)</a></td>
<td class="nump">9,582,405<span></span>
</td>
<td class="nump">562,451<span></span>
</td>
<td class="nump">561,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares', window );">Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Number of shares used in diluted calculation (in Shares)</a></td>
<td class="nump">9,582,405<span></span>
</td>
<td class="nump">562,451<span></span>
</td>
<td class="nump">613,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NetIncomeAllocatedToPreferredShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NetIncomeAllocatedToPreferredShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NetIncomeLossAvailableToBasicComputation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NetIncomeLossAvailableToBasicComputation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PreferredSharePreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PreferredSharePreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RevaluationOfWarrantsToConvertiblePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RevaluationOfWarrantsToConvertiblePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfBasicAndDilutedNetLossPerOrdinaryShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370642051848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_ServiceProvidersInAmount', window );">Service providers in amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,954<span></span>
</td>
<td class="nump">$ 14,083<span></span>
</td>
<td class="nump">$ 12,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pypd_EasternEuropeMember', window );">Eastern Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost</a></td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ServiceProvidersInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ServiceProvidersInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pypd_EasternEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pypd_EasternEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140370716892904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase ordinary shares</a></td>
<td class="nump">580,028<span></span>
</td>
<td class="nump">68,491<span></span>
</td>
<td class="nump">580,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Ordinary shares exercised</a></td>
<td class="nump">115,982<span></span>
</td>
<td class="nump">68,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock Issued During Period, Value, Conversion of Units (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pypd_RelatedPartiesMember', window );">Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pypd_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pypd_RelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pypd_RelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%9_;CU3^R;G26J4[/6L2V2R41\SZ:7U"ORG/I4WS\GC_E5FGU23C&P@-SJ\
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MOB!6T%,33A"$!YA-H1#&=L1QASAV(KYC$A>JAG"N$A%@(8A]4V-SZ5BQP %
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M(>=Z7D!N7C@LN:^$ 9EUWPR#30B%Z4!=0WL#@9L>%JPLJ=2-0G.ZU5@D:?5
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MP)\O,XZC]9?2P?YN\^5_4$L#!!0    ( #> 95*[^ISP>@(  '<%   8
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M"7C/5&G:(Y*X54D<_0ZU>N->J%4)#O&F=KQ-\.IAL\%MS?%Z(7),3[O"-?.
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MU8Q D-= +ZFDJQ?IQ_.L^A2DF"0X,_X74;B!FFW(GWC7EBC<G, X-$Z^(L?
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M=; (DRPBDQ2=YU-,A!\I9G#&F@:%M>M*,=YQ>9PE",\D:_#.1.>"^QGQ>X*
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ME"TTDJ/@3N:R^.1*MJD5)RWPO>^V<'%/0G?K8BUM5QL"))V6O09K\6F,EJ"
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M)Q!% UK#_L"Z84LNF.)B"]C6)'0&T3FM8;=G7=6BS%1-,,W!5ZLLQ@-7OQN
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M<2B,@SY?<ZX.ADG0/IK1;U!+ P04    "  W@&52LQ6IT8 %   &#   &0
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MN11U[A[UYC?9XIFPOD3GUO_2IGD[B7J4U-;IHA6&!X4JFW_QK>5A1^!X](9
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MB(X&1Y,>F6;J;#9.5W[26V@'\OTRPZ N#3_ _5)KM]VP@6[TO_@74$L#!!0
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MYWK-X D5Z?4QRYV/^LVCS-B1H4BR.NWW35_)C;0D(\AQ:"]LDMS<Z/V&.@R
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MU#/:1<NCX.7UX6)^'KY\X7L(!@$WU=+G<RQ50"0OQ*6^0^)EB>>4ZG$.MQD
M7,-N0?$M*V0"@[NM;7 J'.R*R3MVORLTU+DY'?=08/%7)Y[O#(=_X:^MXC'!
MGD@H)D0I//&ACZ;\RMA3'>6PANR1B[S9YU'M.<Q0>L;9Z0/$6XWT\(621087
ME)2Y955L4[AN665)><#!^F*^)/?1H^OVZ-IQ8BVI0J(\;J4F_;QEE:;6SP?0
M.LB$/5>0*6@!B)S> A+8FO<*3!5L-%[HWA8&5#[A7V94"=NTQ6BD72.A4_=A
M>'"H0QI[=FL:WSB4HK\DM5V-#U72%[^UY;%%RJ\NIA"RAX@CU1;R+A]6K0<>
M< %G"S=YE1DJ%U#*Q1E\=*5)26IODJ( 8-@:7ZA\":=C:"U%V$>R<SS'OT!4
M1A(X!51IV(%=61ZW2BO(YYJ#<Q.FN[01]7%9Y!O>DE!@8&QS.IE5;6OMZM?=
M5H+1'4!#WEA, >C.(ZQ>8Z:W9V9"A91K2F5$E3&NZK"@JB"U;4NU2'?AZF2%
M<UU=/6!"(Y$TQBAE#2/!MF=W5?[IA"=A'E,)F_.68_Q?<]ZSROX/4AYEOE!T
MLT+]SC5V&(7'"]5-#7(VK7!MH6NWAQP6G,-L0+[-B[H3T-*L&9\..^Y:I=Q/
ML&KS:+[;P.UE1)T.UACO*/ECA_YXTL!YIV$?5)9^@!^+TT%_C%Y[.NJCX[.0
MTW%_-A);Y2#M=\*9[OS.&,(=V)8 $'46/>M'@W:KHY*.?=<]VNHPZ ^"=F5?
M_)$;FCU=#;)&T"V5=T599L6U]>@GB._!B5UF<(P.>10/$?:0V-A14,K82,2-
M*BX*I/1!Q>,3(!,0DLF_J[+3^M4=$H0T!_XM7/5WSD<D?+E-M<'/_<+>E@0V
M@.F?+"C%C>XE.K69P'++OA?WQ7MLSF+"<T$E#CSKLBKLJ+^"+D3AI] %+U=K
MK\/UPYG?30[*9%74%$_"U3'$&'+W=57$:(=*S%>%4ANRJ,M0^(#;ZWE-3-SL
MH^[9 /4-647J:#BR-#D2:,D%0,@5Q*VHNKK*!C?9LGN*H0M#TO[@X2H($!J.
M_!&X+]<0.Q"YW&N.H,%M.O&GTTE-(_<F(,?DQ%FFC.6[6-B4_S@O@4$$D <
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M$0L2GY"3LD_CSVW=YJ4EN<T\,Q!$>I558Y":J%8-UY9Y'Z74SWL$7W?H&*S
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M8U;?L]^7UZ^5CTSMN-"0X99,>]WSO@.J?@'4 R.+ZM;=2$-W>-7=TZ,)E5U
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M>X)79_.7SR[T;RC+8\*^Z^\=ZG<O7T9W0/5=O9*$D&1D76P4=Z!VO*Q-%W7
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M)E!:<TCIHV'<O;TP%4MQ&M#%-*@W&#BQL%RA=H+UG&"DVF#<Z\*F;H+/8?O
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M&DI-SC[2F)EA$ ?'Z2Y<_E([&J5@MO1VH?$!M-]H[?:.)QA?P\4?4$L#!!0
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M6.'W RAK@/=W4IK3Q 88OT@6/P!02P,$%     @ -X!E4F3CA8_*!@  *Q(
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MBD="+H&-"9)!SZ10&(Q-*AF1L ^"-1%$$BMW;J#+XD,5MRE .,^HR<T] =A
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M1'6=MEL8V;CNMI$&>Z6;[O'C!)0]@,^W4IK3PCH8/G>6_P!02P,$%     @
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M:V#>KX70QX%U4%\#I_\#4$L#!!0    ( #> 95+\9T2(K0(  &P'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)U546_:,!#^*U:TAU9JFY  +15$
M:F'3]C )E75[F/9@DDMBU;&I[4#W[W=V0@8TL*XOR=F^[^[[SF=[O)'J21<
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M&JGZ;J\'1J[<];B4!B];9Q;X'(*R#KB>26FV WOCM@]L_ =02P,$%     @
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M)E3E\/H^KB>2E>9*6S.I+D@SS-0G#+@.4.\WC,G#1-^2[4<Q_@=02P,$%
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M6SX3;NPW1ME39G$FGRM[@Y1Y BHJN+SO6&MG:@[AN[UQ^P4:RK@^@$]P>U/
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MS)GHI='S[L'<PQ:&=B.PN+NT^M_?+J64MLC51'V!79AOYIMOEF'Z2\:?Q!Q
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MJE=VM,CM36,E-+FSS9ANQRC- /J^%D+O.^;R4M^W9_\"4$L#!!0    ( #>
M95+>+:_R>@(  ,L&   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;*65
M76^;,!2&_XJ%>M%*6P%#OBJ"U"::-FF5JJ;=+J9=..$0K/J#V:9I__UL0U&V
MD&;2;H*_WO.\Y\0<LIU43[H",.B%,Z'G065,?16&>E,!)_I2UB#L3BD5)\9.
MU3;4M0)2>!%G(8ZB<<@)%4&>^;4[E6>R,8P*N%-(-YP3]7H#3.[F01R\+=S3
M;67<0IAG-=G""LQC?:?L+.RC%)2#T%0*I*"<!]?QU<W,G?<'OE'8Z;TQ<IFL
MI7QRDR_%/(B<(6"P,2X"L8]G6 !C+I"U\:N+&?1()]P?OT7_Y'.WN:R)AH5D
MWVEAJGDP#5 !)6F8N9>[S]#E,W+Q-I)I_XMVW=DH0)M&&\D[L77 J6B?Y*6K
MPYX QT<$N!-@[[L%>9=+8DB>*;E#RIVVT=S I^K5UAP5[D]9&65WJ=69?"$Y
MI\96V6A$1($64A@JMG:.OE*RIHP:"AJ=+\$0RO0%^HA6]F(4#0,D2U0VIE'@
MC%'><,3 %@C5Y+4-V(@"%+(72!$7M-W6Z Q1@1XJV6A+U%EH;![.3;CI/-^T
MGO$1STO87*(D_H!PA*/'U1*=GUW\&26T5>A+@?M28!\V.1+VO_/Z<;W61ME[
M]O,=-TGO)O%NTB-N7&Y#I6E58Z]R;]QS'N-DG(7/ ZRT9Z6G6/$0JU6-]EGQ
M-!YFC7K6Z!0+#[%&!ZS9;#2,&O>H\2E4,H0:'Z#P-!E&37K4Y!0J'4)-_ATU
M[5'3=U$/%=CN6QI00\#I 3#%1\HXZX&S]X'2$#;$FAU<Q32-_LXNW.M-KLW?
M$K6E0MMWIK2RZ')BO:JV=;83(VO?KM;2V.;GAY7]VH!R!^Q^*:5YF[@.V'^_
M\M]02P,$%     @ -X!E4@OE=6N=!P  -#   !D   !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&ULO9M;;]LV%,>_"N%U0PJTLD12E-TE >(XQ3HL:-"L[4.Q
M!\6F8R&Z>!2="[ //^H2'=F62,E)_9+8"L_AX1'Y^Q]*S/%#(N[2)><2/49A
MG)X,EE*N/@R'Z6S)(S^UDA6/U5\6B8A\J;Z*VV&Z$MR?YT91.,2VS8:1'\2#
MT^/\VI4X/4[6,@QB?B50NHXB7SQ->)@\G R<P?.%+\'M4F87AJ?'*_^67W/Y
M=74EU+=AY64>1#Q.@R1&@B].!F?.APMOE!GD+;X%_"&M?4;94&Z2Y"[[\FE^
M,K"SB'C(9S)SX:M?]_R<AV'F2<7Q;^ET4/69&=8_/WO_F ]>#>;&3_EY$GX/
MYG)Y,A@-T)PO_'4HOR0/?_!R0&[F;Y:$:?X3/11M/7N 9NM4)E%IK"*(@KCX
M[3^6B:@9$*_% )<&>,L .RT&I#0@VSVT&=#2@&[W0%L,W-(@'_JP&'N>N*DO
M_=-CD3P@D;56WK(/>?9S:Y6O(,XFRK44ZJ^!LI.G'_U H&]^N.;HDOOI6G U
M"V2*CJ9<^D&8OD5OT!"E2U_P% 4Q^AH',GVG+JK/?R^3=>K'\_1X*%4HF</A
MK.QV4G2+6[IUT&42RV6*+N(YGS?8GQOLL<;!4.6@2@1^3L0$:SW^N8XM1.QW
M"-O8_GH]14=OWL+0BY]-<>J]3OE,>74VO#9XF7;VXHQW8FOP=]%CK+_],B(,
M_][B;B.7I)I4)/=/]IY4/_Y2)NB3Y%'ZCZ9#6G5(\PYI2X??<Q[P.?+ON5!\
M0XLL@OL\@F2!Y)*C!U\(/\[F[HJ+F0I'-6NZG_J.7-NR[5\U$;M5Q*[6T32X
M#^8\GJ.G@(>-"T!O;XJ#57$PK9^/D*@CM:2G21CZ0MV@_]";IJ *9RQWEFG0
M_>D8,W(\O*]/YMU&A-JL:K01IU?%Z76-4]W0E(M \>@,72E9X4*H.Y]/WNHN
M=QG,Q-N)<^2TA#FJPAQIP_QT]1G]N.31#1>Z>3VNW(T/LY <&_3 UH[@LY@'
ML2H9GIF?)?(Z_YCEL94XD]*M6\NF2SS/;<ZG4],G1QO/>1*K-2V#FY#7[O:U
M3&9W73+M8.@('RC7@$F':,=V\:A0%*0<K40P:Z+1M'3@U;+JN-:X+:O 2T?/
ML2Y95;?[,HB#:!UU2C20SW$/E&B G*.G7#Z!BRS7R9!)03&E&T6Y=#JN)Y]8
MN"WY@#)'S[*NR?<?.R<?^.2,#I1\8)@S_AG)'^_.?&+1YMQCP!O6XZU4CHOW
M3KMV=$@X!GYAYS )QT RC U86:EMF!K7?1+Z,@@#^=18<^J]L+'E.+H2 P/G
ML)YS7X+T#BT$YVK7(+D2$(F$+QMU9&IPY5@CK T*$(CU"#168%.# U,)AH&(
M6%_,53=,)2=JC$1OC]$3SU8405&^*=(%!<S$KUD93O!NU>>,V&BK-&QHY=;J
MQ\U0 :A8#]0^BUK%W[%(PP!5?""H8H JUD.UZQK7>V'4LHEN#A, *]&#M<\:
M-[A2:]S3!@7P)?KBT;S&#0Y,:YP E$E'*+>M<8.]XQ(T]Y^TV_/:_EQ/T>8*
M)%L_1:F_QVHA %Y"#[-:" "6Z &Y7PE2.MTH0;#EC)IQ18"L1$_6S;(?@N@3
M6D-IVKXO($!2LD]I.GV/MR>&[K8 -\F!N$F F^0G%*.3TNF&N+$M:2O;;-P2
MV\+CYEM" :Q43T/C)G%2.FC?)!8!-C0;6[BEHJ; 6*I'9#<EFAB\>"/+WH9^
M&;;>T%BF4D TU2.VAX1-#*YLRV/-HS%0WE#>4D \U2/>*'T3@X,&Z2N'T-MN
M<PBUA[KZ MLDF1.#/2W+8H8;E+,<B]Y#C\*:@AA1O1CU+*Q+;W7V8'M,[.W5
MO=O,<7#;\S<*8D7U8G7NI\N0IRE*]GPP6/JO/QBDGFO3-C""5M%7TJKN10P%
MZ:('DBX*TD5_AG31#M)%&YZUM!<Z+DB7^U+I<@V:5,1G:K49'BB7^RK*9? R
MPA8=-8+28&C<?+F@7.[K*9?!E6W19N4RV)DV;2XHE_M2Y3(X:%6N_G:;0P#E
M<E^H7 9[[(Q;)<M@VF&?Z-9>4NJEJAFQ9\\2T(&H+@B-RPY#5!<4Q-4KR'[;
MPM)IG4;4(BU"ZX*BN/I7AQUSW5W,7% 6]T"O&1E( ]-+PWYB5CIM$;/-4$ &
MF)[#U[LODXOHOO=X(<" U>Q [QD9$)7IP;;?/&>[[Q[M5M5EP$;6D8WZ)Y<&
M+\9M'P/(,3WD^CRY-+@R;=]8[5B&ONPV/[DT.# >$ %*,CTEC4\N#?8]-E$,
M:,GTM.RWB9J6WNK@H';+>P<&W&3ZBKP"!"\+W7G?S5'90<=3$Q[@U3/@M3/3
MNNN)!T3U#O3.TP.J>OKR<S_$E4Z[(<X#WGI]SG6H#!_I9<UK).W6L:J+LE5V
MT*;6;-06+0#9>Q4@&[P8=S,> -E[/2 ;7)EV)1X V7LAD"<&!ZV[DOYVFT.H
M':%[(<@-]AVV%AX W-,#_!5>@I0]F!Y;#&NGHR,N;O-CZ2F:)>M8%N>#JZO5
MT?>S_,#WUO5SY\.T., .;HKS])>^N WB%(5\H5S:5C8K17%$O?@BDU5^!OLF
MD3*)\H]+[L^YR!JHOR^21#Y_R3JH_E'@]']02P,$%     @ -X!E4EUO("4(
M P  F @  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULK59-;^(P$/TK
M5M1#*VT;DD"@%2 5V&I[J%25;7M8[<$D$V(UL:GM0/OO=^R$E$+(=J6]@#_F
MO;PWXW@RW CYHE( 3=[RC*N1DVJ]NG)=%:604W4A5L!Q)Q$RIQJG<NFJE00:
M6U">N7ZG$[HY9=P9#^W:O1P/1:$SQN%>$E7D.97O$\C$9N1XSG;A@2U3;1;<
M\7!%ES '_;BZESAS:Y:8Y< 5$YQ(2$;.M7<U'9AX&_#$8*-VQL0X60CQ8B:W
M\<CI&$&00:0- \6_-4PARPP1RGBM.)WZD0:X.]ZRWUCOZ&5!%4Q%]LQBG8Z<
M@4-B2&B1Z0>Q^0&5GY[ABT2F["_95+$=AT2%TB*OP*@@9[S\IV]5'G8 7G@$
MX%< ?Q_0/0((*D!@C9;*K*T9U70\E&)#I(E&-C.PN;%H=,.XJ>)<2]QEB-/C
M&\HD>:)9 >0.J"HD8(FT(J<ST)1EZHR<DSD>G;C(@(B$1"GE2R",$YT"20QZ
M;=&X9U;P*"4@)<1$I50"V5 IJ2',&%VPC.EW)'R<S\CIR1DY,3P_4U$HRF,U
M=#4:,K+<J!(_*<7[1\1[/KD37*>*?.<QQ)\)7,Q$G0Y_FXZ)W\HX@^B"!-XW
MXG?\3H.@Z9?AWF6+G*"N3F#Y@B-\_SGSOZX72DM\<WZW:.O6VKI66_>(M@DL
M&>>,+XV =Z"RJ7XE16@IS(6RQIKY76_HKG>3>ACE^Y=^6$=]TM>K]?5:]=TJ
M55 >V?QL<]$DL97%7*)7:D4C&#F88 5R#<Z8-)V,DJ>W8R(<=)HMA+6%L-7"
MM"[Y1[F;+(0'C_:\H!_L9?DPZAS#PEZSQGZML=^J\0&BC"K%$A91>S%CNI^W
M1X]Q+0B\%GCXFG3W#Q7Y0>AU]X2W"OA2A3XY&]3.!JW.\$XQ9E8@F8B;Y+?"
M_^'D#/[RDI3JW9U+/@>YM+U/D4@47)<77+U:M]=KVU7VUB?8=LLN^4%3]NP[
M*O&=QAL#$J3L7/2Q-++L@^5$BY5M)0NAL3'988J?#B!- .XG0NCMQ#R@_A@9
M_P%02P,$%     @ -X!E4GTJ3_/= @  ;0@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&ULE59M;]HP$/XKIVB36HF1D/#6"I" ;%JG5:K*NGV8]L$D
M%[#JV)EM"OS[V4Z:005I^R7QRSW/W7,Y^S+:"OFHUH@:=CGC:NRMM2ZN?5\E
M:\R):HL"N=G)A,R)-E.Y\E4AD:0.E#,_#(*^GQ/*O<G(K=W)R4AL-*,<[R2H
M39X3N9\A$]NQU_&>%^[I:JWM@C\9%62%"]0/Q9TT,[]F26F.7%'!06(V]J:=
MZWAH[9W!3XI;=3 &JV0IQ*.=W*1C+[ !(<-$6P9B7D\X1\8LD0GC;\7IU2XM
M\'#\S/[%:3=:ED3A7+!?--7KL3?T(,6,;)B^%]NO6.GI6;Y$,.6>L*UL P^2
MC=(BK\ F@ISR\DUV51X. )W^&4!8 <*7@.X90%0!HK<"NA6@ZS)32G%YB(DF
MDY$46Y#6VK#9@4NF0QOYE-O/OM#2[%*#TY,;GH@<X0?9H8*+&#6A3%W")WA8
MQ'#QX7+D:^/%VOI)Q3@K&<,SC)T0;@77:P6?>8KI,8%OPJMC#)]CG(6-C#$F
M;8@Z+0B#SM6)@.9OAP]/P.,WP\.@04U49SQR?-&K&8>8JH0)M9$(OZ=+I:4Y
M!7\:7'1K%UWGHGO&Q5S(0DBB$;3Q8@?JU'=L)@FC=A!\/)7N]^..5/1J%;U&
MHFDN-ER#R( 4A10[:DXYLCU<4 ZQ8(Q(=:H\XY*U[UCMK?<TN>I'PUX0F*_W
M="*>?AU/OS&>A29ZHX7<UUD]E=1FCO-)?3_N2,2@%C%H)/J<9>BNVD81S1S!
M.0WOAAU)&-82AHT\]N3,-UH!X2E\$TL%TT2W8+XF?(5@BL,:W!ME+8@Q0RDQ
M=4O?*5E21O6^!0=G<(8<,ZI?JZIY&=/@H*J"=AB]J"C_X"+.4:Y<0U.0V$(N
M[[MZM>Z94]<J7JS/.M?SLO7]IRD;\2V1*\H5,,P,9= >F'*797,K)UH4[KI?
M"FV:AQNNS?\ 2FM@]C,A]//$.JC_,";_ %!+ P04    "  W@&522Z%3(RT#
M   6#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6S%5U%OFS 0_BL6
MZD,KK04#@:1*D-9$TR*U4]6TV\.T!P<N"2I@9ILD_?>U@0)-",JT5GE);+C[
M_-U]OK,9;BA[YBL @;9QE/"1MA(BO=9U[J\@)OR*II#(-PO*8B+DE"UUGC(@
M0>X41[II&(X>DS#1O&'^[)YY0YJ)*$S@GB&>Q3%A+S<0T<U(P]K;@X=PN1+J
M@>X-4[*$&8BG])[)F5ZA!&$,"0]I@A@L1MI7?#W&KG+(+7Z&L.&-,5*AS"E]
M5I-I,-(,Q0@B\(6"(/)O#6.((H4D>?PM0;5J3>78'+^A?\N#E\',"8<QC7Z%
M@5B-M+Z& EB0+!(/=/,=RH!Z"L^G$<]_T::T-33D9US0N'26#.(P*?[)MDQ$
MPP';!QS,TL$\UL$J':P\T()9'M:$".(-&=T@IJPEFAKDN<F]931AHF2<"2;?
MAM)/>-/$IS&@1[(%CLXG($@8\0MTB69RPP19!(@N5%J ,0B0(%M$. ?!I<73
M;(+.SR[0&0H3]+BB&2=)P(>ZD+04N.Z7%&X*"N8!"A/PKY"%OR#3,(T6]_'1
M[GCPWEV7R:@R8E89,7,\ZZ,S\OM6(J&I@)C_Z>!A53RLG(=],*[])>8@"Q?0
MFD09*:H@DG5($A_:TE[@.SF^*N>U9SJ#GLS1NIG=?2OLNGVKLGI'WJ[(VYWD
M;X'SRR-I%DB]!H'+-IXM9AU$>Q717B?1'[)3MHC9QK,32+7;:YX2'T::[*<<
MV!HT#[5MY__'>1>I4T7J=$;Z4(!Q)*NT%D1NVSN(Y\"ZMJQ;+>&>M'3Z%8_^
M)Y=.?V^SX8&QLR%;;-P#NW%0$1]T$G^$.*5,'J<H"!<R!CA6(6S4_=XXJ4:X
M<?+@3U:I7* I@>78]HY.+5:F:=CM2N'ZF,!F)_TIYYDBAGS*Q7$BU:T?6Z<5
MJ>[CN+N1?X!(^XU[T'-W->ID\>]-$=?]'W<? +>4<^03QEYD4!O"@J.4K)LN
M=DZK9-V;L?O92KK[%PH3._U=+??-<,\VG)V"TQN75O7%<$?8,DPXBF A_8PK
M5^K&BDMX,1$TS>^Q<RKDK3@?KN2'"S!E(-\O*!5O$W4UKCZ%O%=02P,$%
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M?ODCP.5$L&.QE_["A&!I<7B@T99R=8'\?L>8>#M1V_/5WS&6_P%02P,$%
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MX^(%^_M82O-T4S30G,D-_P=02P,$%     @ -X!E4D?YW2=( @  W 4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULE91=;YLP%(;_BL7-5FF+^2Q)
M19#:9--ZL2UJM.W:@4.P:C"U3=+NU\\V!"4+D5(NP,<^[\MS#MC)GHMG60(H
M]%JQ6LZ=4JGF#F.9E5 1.>$-U'JEX*(B2H=BBV4C@.165#'LN^XMK@BMG32Q
M<RN1)KQ5C-:P$DBV547$VP,POI\[GG.8>*+;4ID)G"8-V<(:U*]F)72$!Y><
M5E!+RFLDH)@[]][=(C+Y-N$WA;T\&B-3R8;S9Q,\YG/'-4# (%/&@>C'#A;
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M?48]=[SYHGOL5E)')]: QTTGALZINT3RQPV)5?SE201"=> FR80]X_1WPS*
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M_$+S^4-1U-T;&>#T<)Z;_P%02P,$%     @ -X!E4FNDUUW-!0  (B@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-34N>&ULS9IK;Z-&%(;_RLBJU(W4&N:*
M63F6DDVJ;M5MHXW:?ECU \%C&RT7+XR37:D_OL/%'%1@(#)IG \.V#YS#C/G
M?3Q^S?(I23]G.RD5^AJ%<78YVRFU?VM9F;^3D9?-D[V,]2N;)(T\I4_3K97M
M4^FMBZ HM(AM"ROR@GBV6A;/W:6K97)081#+NQ1EARCRTF_7,DR>+F=X=GSB
M8[#=J?P):[7<>UMY+]4?^[M4GUGU*.L@DG$6)#%*Y>9R=H7?7CMV'E"\X\]
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MN1JH3X*7$[_<2):;D;9F4@U(LTS4+0FX-E#O-XS)PT8+U/>NR6]02P,$%
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MZJ-B;5M6<R\M!^W8\X*XYRZWTWYHUHFCKK]KE?R3;">T=AU:NS&T7[M1(/@
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M7EDH($EI!W'F3<;CN<<)%3@*1,5ON"Y1+"NA0WS>AI!K/B4A]N?G&#FY:YE
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M/OFR:W6E>;W_:FS_Q=N'OP!02P,$%     @ -X!E4EEV ?CU 0  .",  !H
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:NT[K0!2%X5>)_ !,]BW
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M^J]_LNCO>6OJ[CV?#7^R7+T"4$L! A0#%     @ -X!E4@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  W@&52*?B27.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  W@&52F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #> 95*B
MBB4;+@0  ,,0   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  W@&52G%NU<LX%  !J%P  &
M    @(%R#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M-X!E4II-06D- P  N0H  !@              ("!=A(  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #> 95+Z7RIE9 0  - /   8
M          " @;D5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  W@&52)2M@B* '  #G+   &               @(%3&@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -X!E4KOZG/!Z @  =P4
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M965T,3 N>&UL4$L! A0#%     @ -X!E4@G@'#KS @   P8  !D
M     ("!S%P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #> 95).AKT.VPP  %DC   9              "
M@1!U  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ -X!E
M4FFB/VN0#0  RB,  !D              ("!(H(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  W@&52Z60*- P#  !Y!@  &0
M        @('ICP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( #> 95(LLC^( P0  )()   9              " @2R3  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ -X!E4EE$=3J( P  ;P<
M !D              ("!9I<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  W@&52R%]9;6,#  !Z!P  &0              @($EFP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #> 95(/1X)%
MPR,  "%U   9              " @;^>  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ -X!E4NBRVO$7 P  5 <  !D
M ("!N<(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  W
M@&52;RQ%\V@"   O!0  &0              @($'Q@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #> 95+3U(P3L (  (@%   9
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M970R.2YX;6Q02P$"% ,4    "  W@&52_31%?"D#  "="   &0
M    @(%_U@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M #> 95)DXX6/R@8  "L2   9              " @=_9  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ -X!E4E309L?_ @  :P8  !D
M             ("!X.   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  W@&52Y6_.H;$#  #Z"   &0              @($6Y   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #> 95++<-< E 0
M  8.   9              " @?[G  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ -X!E4B?-.VB' P  $@X  !D              ("!
MR>P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  W@&52
M_&=$B*T"  !L!P  &0              @(&'\   >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( #> 95(/4#<B @,  "D*   9
M      " @6OS  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ -X!E4I'5&8F- @  ( <  !D              ("!I/8  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  W@&52T9@@0%,"  "P!0
M&0              @(%H^0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( #> 95*JX:/?/@,  .@+   9              " @?+[  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ -X!E4BDZJ5"?
M @  3@<  !D              ("!9_\  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  W@&52M'"Y1O$#  !["P  &0
M@($] @$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #>
M95+>+:_R>@(  ,L&   9              " @64& 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ -X!E4@OE=6N=!P  -#   !D
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M=#0X+GAM;%!+ 0(4 Q0    ( #> 95+%OI/-Y 0  )HA   9
M  " @0PF 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M-X!E4I<'81I4!0  GQL  !D              ("!)RL! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  W@&521_G=)T@"  #<!0  &0
M            @(&R, $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( #> 95('F:L%5 4  .L7   9              " @3$S 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ -X!E4C_@98LY P
M\ L  !D              ("!O#@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  W@&52&,1B \\*  "H9P  &0              @($L
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( #> 95)K
MI-==S04  "(H   9              " @3)' 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ -X!E4OI697*[ P  ) X  !D
M     ("!-DT! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M  " "P  #0              @ &*7 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( #> 95*7BKL<P    !,"   +              "  0A? 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( #> 95(7@N9SG 0  '4G   /              "
M ?%? 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  W@&52678!^/4!   X
M(P  &@              @ &Z9 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  W@&52%\C,&]L!  #1(@  $P              @ 'G
L9@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0P!# $P2  #S: $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>375</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders??? Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders??? Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Prepaid Expenses and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PrepaidExpensesandOtherReceivables</Role>
      <ShortName>Prepaid Expenses and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Other Payables and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/OtherPayablesandAccruedExpenses</Role>
      <ShortName>Other Payables and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Convertible Preferred Shares and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConvertiblePreferredSharesandWarrants</Role>
      <ShortName>Convertible Preferred Shares and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityDeficit</Role>
      <ShortName>Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Financial Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FinancialExpensesNet</Role>
      <ShortName>Financial Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare</Role>
      <ShortName>Basic and Diluted Net Loss (Profit) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Prepaid Expenses and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables</Role>
      <ShortName>Prepaid Expenses and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/PrepaidExpensesandOtherReceivables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Payables and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/OtherPayablesandAccruedExpensesTables</Role>
      <ShortName>Other Payables and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/OtherPayablesandAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Commitments and Contingent Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables</Role>
      <ShortName>Commitments and Contingent Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Convertible Preferred Shares and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables</Role>
      <ShortName>Convertible Preferred Shares and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/ConvertiblePreferredSharesandWarrants</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Shareholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityDeficitTables</Role>
      <ShortName>Shareholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Financial Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FinancialExpensesNetTables</Role>
      <ShortName>Financial Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/FinancialExpensesNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables</Role>
      <ShortName>Basic and Diluted Net Loss (Profit) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossProfitPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/General</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Significant Accounting Policies (Details) - Schedule of Restrictions on Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofRestrictionsonCashandCashEquivalentsTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Restrictions on Cash and Cash Equivalents</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Significant Accounting Policies (Details) - Schedule of Property and equipment useful life</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofPropertyandequipmentusefullifeTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Property and equipment useful life</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Prepaid Expenses and Other Receivables (Details) - Schedule of prepaid expenses and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofprepaidexpensesandotherreceivablesTable</Role>
      <ShortName>Prepaid Expenses and Other Receivables (Details) - Schedule of prepaid expenses and other receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PrepaidExpensesandOtherReceivablesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Other Payables and Accrued Expenses (Details) - Schedule of other payables and accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofotherpayablesandaccruedexpensesTable</Role>
      <ShortName>Other Payables and Accrued Expenses (Details) - Schedule of other payables and accrued expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/OtherPayablesandAccruedExpensesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Commitments and Contingent Liabilities (Details) - Schedule of future minimum lease payments under operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable</Role>
      <ShortName>Commitments and Contingent Liabilities (Details) - Schedule of future minimum lease payments under operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/CommitmentsandContingentLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of the preferred share warrants liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofchangeinthefairvalueofthepreferredsharewarrantsliabilityTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of change in the fair value of the preferred share warrants liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofdeferredtaxassetsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Convertible Preferred Shares and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsDetails</Role>
      <ShortName>Convertible Preferred Shares and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofconvertiblepreferredsharesTable</Role>
      <ShortName>Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ConvertiblePreferredSharesandWarrantsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Shareholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityDeficitDetails</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of ordinary share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofordinarysharecapitalTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of ordinary share capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of status of options to employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of status of options to employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofequitybasedawardsrecognizedTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofoptionsoutstandingTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Financial Expenses, Net (Details) - Schedule of financial expenses net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleoffinancialexpensesnetTable</Role>
      <ShortName>Financial Expenses, Net (Details) - Schedule of financial expenses net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/FinancialExpensesNetTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Basic and Diluted Net Loss (Profit) Per Share (Details) - Schedule of basic and diluted net loss per ordinary share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofbasicanddilutednetlossperordinaryshareTable</Role>
      <ShortName>Basic and Diluted Net Loss (Profit) Per Share (Details) - Schedule of basic and diluted net loss per ordinary share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossProfitPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/RelatedParties</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="pypd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pypd-20201231.xml</File>
    <File>pypd-20201231.xsd</File>
    <File>pypd-20201231_cal.xml</File>
    <File>pypd-20201231_def.xml</File>
    <File>pypd-20201231_lab.xml</File>
    <File>pypd-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001213900-21-013722-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-013722-xbrl.zip
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M7H<7JE>>^@)?^-[X%[SUD^D;C;;1:K]O]-ZW>L;YS:W1:K2:_,C>S]_O?,<
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MM.7R2(R9EQFP.%HX@9#BF<WGF-<EW%X\XY9,(MQNFX>Q)OZXG6W8;S-W+)Q
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MF95KX:M[E7:_5(RH%)^TWAP?[.N>;>YZQQ6!5(KX+:S6VS_LS82I(J!*416
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M+![IJV"6?%H9_TXS67*@6_71JAYU[4**EQ#R!VW0CB7\K!1(\YB2Y9!<D8
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M?RX04GQJ<XS/27 B'B')C93P@).$7 *P6UERU8RS.O)/;:ZS>V_W[_73B]B
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MM>!.1C79E2G;0-/(H4BJ_-,,Z=*[:JI%%87?Y146V821;Q,C)KC1$E>+4LV
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MUWG"Z4Q.NT8UJOOC9+L.Y0B/Z&(V:3_EX@?<H)9BCBQ!4R76>,G#$C1!&]Y
M^"Z$%Y,^',S$(=ENW4^1+4.TRQ/CT\FOG\]O<:OP[8BCK/A]--K[%-O$!0&L
MGA1O-Y0>O#<NX#'QZ/G?C&M^APRG($VBD/[;B^NC'Q,$J![[><@W(E9="P$B
M]&^(!WUCJQ**/6G.XL:9+5"GV1R@ $S?D5:(?!_)*1+SLHY"1[;E"7Z6BT$
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MT4$J[R,1<(L/34_NP*.)=,F^>B&5&O9]^TZ+S<?%';'4E]>D'C$CC+?9E+H
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MM0!3L#0N(]EY4TX774TNN)L\!L^@_R1)PU:1UIH=;W^ ".2R8NUB7@(U";3
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MF0=YRUPW*+;7%I8=M7/VE)$IL4@YZ*2*,R*L].UD=08<9BX+".10V,A#YA$
ME!L%OKE/M5+0T^'1F*E(7>%9V4LVM:'D*^J,ONG*I&K@N?#"I[B68-_X%^Y
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M4O6"]=2TF7WCPO,'@BI,I);IJY Z,CB;B$"4/NA,6#T(,5@3CXU2S"%-%ND
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M#0(4FR7B\GI)P4WAN*\Z76)<IS$H!]86VV%Z=LJ\PYJ/,)6S6H (>PDJY%"
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MEV /[%3?9@S41,E7[EHK17H[09=3D=8?Z#M"MXKIW7$&-G>Z3"Y[C8RZM_+
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MM6@Y?EMRA:[M9%JN3%$SA^,"D,>./0:<V8^ ?S+?F#\DG7F^Z2\I)81)P/"
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M;U+\%+QYZ980A?0"9G<O4R_W>_>BDC:A.E3%%V]+#F@$UI5+YF CH8."^X4
MN?#Q XE?BTA^^ UNC27P#XHCX!7O<8I)9^&X<;W9#CN]IGTD3V06*+KSM7<^
M<^2EE%4F)SA.I;.5?GP)6X0><GX3!UCZK=KIP6/PGT$?_J-W^F#SONUUE#XC
MO+?]CM&++AHY1F*S5ZXH<GH.+&$F+,]U]GZCH^GQB\H._:*1K<P T3NZ$GVS
M+?02:B6_.3Y23*"-Q'21<R8=&7%$E\FZP\GU &\X-(JJ^'WCV"1:Y]E!%9-P
M:<T>""C.\J7WZPBN-69+B&R& B_4 "-L<V0O,O 25\FR/)1 T3Y]6Z1E):U,
M9X%<+%.'<<+S2;TTIH276^"R!(T:>'.Q? #C$LX<@$'J>!\W%O]O^/7KVYN$
MF9B2C;@@70*]HZ[E^V!_3$!&V9/0-P4[\\#LE;Z:_P7!X+]*[ZGI/+7LR+6S
MXI-IS;E>1?28[SY)>D_B,B+O@/'RPG-2ST%E@6>H[X-)TW%$4%P+!C;)(B)X
M*]P#Y@3W$*$V-"W@,F4WG_4WO> !,]YB9OGPW[2!%NDZ=!/4[8Y>#!/8]WQB
MS=BU2M^\02,^:O=VS?[M\2[^[2]PF#:B5:(9*P?@V+Y<4ADT6C["7S D. 3:
M!> ?GRBJ8_%#U4A:OK27?1"),0&*,;P*)[=)MTMW_&1Z1!H]NFA& Q>L.,7H
M2G>WHZ2(8YGFL$,D?O(7*%8(G,4%&0U&3:DZ*IF/\.Y'-#RXQ@]\QBR2MWH/
MTU>3D4VNSX)NHO;DWF# -%H6<N4*6+2**JO#@3P<#@)'?C+$2A$3./MLXK-8
M%7P[-(_&.  3Q0 -)<)_<;<?\"8Q8Y(DE&U,C>E((X_Z?0+Y': HB?;H&C[3
M!EVYJW=#*#/F?-$H6=8F^!?@SS'7P?H7O3PE?%+,RW46AQ*N-1>W[P?XC$E/
M[HM)[:LM%PUG 1K#625SD/<+9CX"5JQGI+C;F3EF9/V5S!T72&DY1YK((G)#
MNKW]FB)R&H.V[/%L.>&1]A")U$;%B >9)*! D\RT@*4XC?<4I'%FH:_P2]SL
MZ#!RQ2&&;(?P=,3LJ;U&7*(K\D#=S"6:W#/Z<K_?VT1@LL09!(%XJ\MJ5UO'
M)KC6"Q_&2"-4C*_?]H=*G',B?CG-ZZ_>VV^RR^T7C-*D#NS@#DC)3:GH/XQ^
MVG^!7MN@7\->:88-=:N X+/1VL58%=YG9NP+TA?J9'.]T'5#!Y%F7)E)SGQ$
MQ#(NA,LO8,*(7[(Q/EH;DQJ%CZ[$8,\8T*!E_D7<L>7%W C?KN^ 8(9=Z?U;
M!4ST#^R.C=Y%$VL>2.R.0L9%\06(EH";+>87(:8[LYC9^U[]@%_WEO.Y&;B,
M6 QGK;V$R2P\8@U(&/\)@,+&[4="AUIZ(&] 1_"? C6< P>GZ,XQ1X6I&.@B
M=,:$3+Q LH5VU929?&<S8H*41(4!1>U[DSD:S^=@/K_2+)408/@^__* ?AGP
M^%[[(,V)BQE&<$ZX0ZP#,3-&?'(BL;G/GGTH!_0!MXK^@3F3S!D]!&_Y@&8!
MH@:L3'0U;1H9RIU5U-&VYKE(%0B P)N^-<ZWZU6.HHD!E@L(GR85;N8K=<:@
MBKI<20$U25'[:[DIH*3H7LOD*7;M:O( #E@WAA)VR%E1DA*&/'XCD\<8>:]3
M!='UU1;,(W-[2_<9M!Y*+/$M84;<S)I;@5#";5@.*"$T32SP3# 5,6+WC])[
MBU$S'?.*+^U)K_!WCZDRXYGCP>,_(KV^M^"K9E8@CIJ_;4)2 C$O%G,+!^*3
MLW'2.611UGNEF8OP0F3&*,DN"-9,J2MW8H91OD"4<5RO>G-"("B%@U#R_2@H
M/N&K2E/3<G&W?X(4#+/MS/#MC!CA?$&WQ2B3R=T9R>L@3(!HE>=UE,)D[&YB
M'N;80>$N8QF%%$GPJ31S[,=SO"V Z-@X\E>FE[L8)3^?@Z1?NNQNHVY%,!#0
ME0^K82!,QF-!?-%[?O8:*N3A[0C/,IIF'D).S]PL8$E0B6Q3?K8\J;2E(9(;
MG@2G#65N6&1H0H$]E)3&W!*:<&D19GPA(@-[V*(2)VXW,%&R25@K"EHHV7;O
MBD+$W(79XGJ]M%9[&.DP'^$&@<LHGBG%\F0CIEGU4L@ (*4K+NBH$30E],6J
M\BZ(G:%U1_/B\'ZBKZ=W'(WF64@1D^68)4)],WG"1N2*80I:7(;']UE$AG>Y
M>$;/2TQ"MX7L1M2KL#)N6DZ<?K!?6>IWAW(/:# A!ZAHQ.(/K2?])RX<XH($
MO[.BW6;YDT_3+*W7*B6[6*673-@&CO7V6Y0Q-V 4]=\<E>6RR75\+FZ17U<=
M<$'B<"J1>;VME1+4S!.D8K5Z?Y /7,Q/BNSCDC&F": G[8'8M"X$5IP2TU]R
M<:K)JMKE%R'&5<SQ&*4F/$*]OEZD#H:I'\QKY,5>#O<L^?MOTP:]:&,=P#]_
M6+PN)A]CH(>04YO<&]F30!S<PWE]FH&M><&=&/]<>N>/IKGX>$D>_"CP^#D0
M#==P'[A+%-?L76R:KPI*@>5_)]-_O6%X>4-O=7@Y_6RL_(%^.O5GTT8A=N_H
M*D@V_/$-9K%8<W/F_>O-];<O;RY4K:<IQF#PSQ^V ^2BW"9&]/:*@;_T)MO
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M?7F';SY:"ZQ?_L5,7H\1 WP))!-+&J+Y;? T")"IXTZ)A:]Z(/ S8>"87-X
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M&I"R;!Z&:<IR>D/3,=3]#X@1HZM/]$P+\7FN1Z^AF,6VAOZJM=4Z T U!O)
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MV5WF$;](%#E"[]&_6,^(]3:"'GUV\;@>\[F(OM0VH'8@>-.&08G^E0>FEIZ
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MOD/VZ+#9.CQNOEP0-[EW:TT4C'1T\==Z*))\FZ"0WT\HP,$Q9'..;7O&,S:
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MW=*XG>A_ R22.PN LR#4 +%'F5BHS'*1K94_';=^+]W?M@+$,2L-^;)S%9?
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M@O0"M/&$L(^T:TD4YCEL)]AD:&+A0&]2[Z4Z..2X]%?7Z(\[9FP'V9] 1 A
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M@*;=9G:ESW6,7)TW7TN^0F> EXW98LS,154U)JFL]V1-[9@->:I1T\XD:^%
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MY9MS0P1_EG1>8K!#VCYCZ?]02P,$%     @ -X!E4J]1#_M-0P  _CD$ !4
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M$VY^LC?CN4,WUCRFF(7+P/N+S-5G(!W,_*+/P0K3A+VKLP $C14C&,/@E>%
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MIRG!5*5J'%B/*>JV"BIJ5A%[M#!*(".7P>PA_)TX$4[@F#(3]H,L>U\+91$
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MMR(W (86!8A3=PXH0JN]R U+$=B.7"O>Y^:ZJ0B H2B?_> V&\*!%4TEM.>
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MP0D'M6A+Y(H<V,I7[2IO5:"-OI_S*:S#(%GYN^( G"238Y$*C 7!I^/;?:U
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M#%B,8C6W=43@RG.K^_%P3T.7MR*;!//L2?8R6(31FK_4JKJYY\3[HQBO-(S
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M]HNT("3HQU>,$JLXR7[M_P-02P,$%     @ -X!E4C(\IM\=H   QUT( !4
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M(-ITTDX/"6J&SVVBW?Y -KP/')^C G?[XHX%-&MAJ8YQ=5%;N"RKS"3-4G4
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MXV[$ [R*@L")$[!'?B(Y4K:<(?-O"- S]>#W(.[M=11OH(]K)I#RH_@R0Q!
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MV;]@*/E2,;.SV>L7+#88^BZ;YVF;^[*#O;BU2 WEI\^=J^:E'7+"B#WNLF;
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M#-.HD-%,"0SAO(T7\B'_[P>8X"+ *QC[T3@;_4'Y,QUW&I)Y9NH4VO_D+\F
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M90]&IOC=49N($BFK$5OB3;%'7O-E1#S;."\WF_Q\B6RHG^*?1LJ[8@YG(;&
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MTYJ.N/$;NZDB'=Z[VF%,;W#O0BSH\@E/Z%$>["3)G,]K^)1>(-?K9Z82:E3
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M2[C=.FF'77*,-X/(,;\ A-@@\[+KS>DTC'*&O_J3Q$&KO%Z66=MV%0INFSN
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M4"\7R-^-M.5OY#_ 4@<L_1]02P,$%     @ -X!E4@G\Q@:(0P  EV4$ !4
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M&8'I^Z"<T,J\48C3=%B?C,"FB/K=BZFW\Q;TXB?DN%0^&<O3H^S%H;IR(W4
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MB'#1NE.GGKIWND_^M%<U%=O31+^P4HES$GD;NC%J*8FL8#!Z0Y'+^:SR!O9
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MW=Z\?*GH<D\A-R4!8/8HMPAG,N5^/_RF-(7<E 2 620W\4WI'P;D]@Y2;MW
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M]D  *,I&\%8Y]#P6Y=*#"7$TISC^](H1Q'IRLK_]?U!+ 0(4 Q0    ( #>
M95(:;'TJT L! .DI#@ 1              "  0    !P>7!D+3(P,C Q,C,Q
M+GAM;%!+ 0(4 Q0    ( #> 95*MZ&R#3AD  )XT 0 1              "
M ?\+ 0!P>7!D+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( #> 95+63%(*Y L
M 'J#   5              "  7PE 0!P>7!D+3(P,C Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  W@&52KU$/^TU#  #^.00 %0              @ &3,0$
M<'EP9"TR,#(P,3(S,5]D968N>&UL4$L! A0#%     @ -X!E4C(\IM\=H
MQUT( !4              ( !$W4! '!Y<&0M,C R,#$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( #> 95()_,8&B$,  )=E!  5              "  6,5 @!P
J>7!D+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  'ED"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
